

Grants and Contracts Office

Funding Opportunities Monthly Edition Oct 2024 Due Dates

Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in Oct 2024. The opportunities are organized in the following order:

- 1. National Institutes of Health (NIH)
- 2. National Science Foundation (NSF)
- 3. Other Federal
- 4. Non Federal

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
121794 Comprehensive Partnerships to A (U54 Clinical Trial Optional)	dvance Cancer Health Equity (CPACHE)	National Cancer Institute/NIH/DHHS	PAR-23- 09- 308 [Op	Sep-2024 otional][LOI/Pre-App	Not] Specified
Contact Name	Sandra L. San Miguel-Majors, DrPH, M.S.				
Contact Telephone	240-276-5977				
Contact Email	sandra.sanmiguel@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Sep-2024 [Optional][LOI/Pre-App], 09-	Oct-2024 , 09-Sep-2025 [Optior	nal][LOI/Pre-App], 0	9-Oct-2025	
Synopsis	This funding opportunity seeks to support Program. The CPACHE Program develops a between institutions serving underserved designated Cancer Centers (CCs). The prog cancer and cancer disparities research, ed institutions in each partnership are expect education capacity of the ISUPSs; 2) prome CCs in developing and sustaining research investigators and students conducting can outreach and education initiatives that be	and maintains comprehensive, health disparity populations a gram aims to achieve a stronger ucation, and outreach, as well a ted to work collaboratively to: 1 ote the diversity of the cancer n programs focused on cancer he cer health disparities research;	long-term, and mut nd underrepresente r national cancer pro as cancer's impact o 1) increase the cancer research workforce; ealth disparities and and 4) develop and	ually beneficial part ed students (ISUPSs) ogram and address on underserved pop er research and can (3) improve the effe d increase the numb	nerships and NCI- challenges in ulations. The cer research ectiveness of er of
RFA-CA-24-011 Advanced Deve122679Biospecimen Science Technologie(R33 Clinical Trial Not Allowed)	lopment and Validation of Emerging s for Basic and Clinical Cancer Research	National Cancer Institute/NIH/DHHS	RFA-CA- 01- 24-011 [Op	Sep-2024 otional][LOI/Pre-App	900,000] USD
Contact Name	Kelly Crotty, Ph.D.				
Contact Telephone	240-255-0917				
Contact Email	kelly.crotty@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Sep-2024 [Optional][LOI/Pre-App], 01-	Oct-2024			
Synopsis	This Notice of Funding Opportunity (NOFC further development and validation of em	 solicits grant applications pro erging technologies that impro 	pposing exploratory we the quality of the	research projects fo e samples used for c	ocused on cancer

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
		research or clinical care. This includes new analytes during the collection, processing, applications where major feasibility gaps for supportive preliminary data, but still requin research community. The overall goal is to or otherwise interrogating the quality and the development of tools, devices, instrum establish verification criteria for quality ass technologies are expected to accelerate an diagnosis, treatment, or epidemiology, or a variations that affect biospecimen sample in the application of the technology or the being developed, are not appropriate for the NCI-sponsored Innovative Molecular Analy	handling, and/or storage of car or the technology or methodol re further development and rig support the development of h utility of biological samples use tentation, and associated metho sessment/quality control and h ind/or enhance research in cance address issues associated with quality. Projects proposing to u biological or clinical question b his NOFO and will not be revie	ncer-relevant bio ogy have been o gorous validation ighly innovative ed for downstrea nods to preserve andling under di cer biology, early cancer health dis use existing tech being pursued, ar wed. This fundin	ospecimens. This NOFO vercome, as demonstr to encourage adoptic technologies capable or protect sample interverse conditions. These detection and screen sparities, by reducing p nologies where the no and not the technical ca	D solicits R33 rated with on by the of maximizing D will support egrity, or se ng, clinical ore-analytical velty resides spabilities
1//n/x	RFA-CA-24-010 Innovative Biosp and Clinical Cancer Research (R61	Decimen Science Technologies for Basic Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS		01-Sep-2024 Optional][LOI/Pre-Ap	450,000 o] USD
		Kelly Crotty, Ph.D.				
	Contact Telephone					
		<u>kelly.crotty@nih.gov</u>				
	Sponsor Website					
	-	Link to program URL 01-Sep-2024 [Optional][LOI/Pre-App], 01-C)ct 2024			
		This Notice of Funding Opportunity (NOFO early-stage development of highly innovati or clinical care. This includes new capabiliti during the collection, processing, handling, development of highly innovative technolo biological samples used for downstream ar instrumentation, and associated methods to assessment/quality control and handling un enhance research in cancer biology, early o) solicits grant applications pro ive technologies that improve to ies to address issues related to , and/or storage of cancer-rele ogies capable of maximizing or nalyses. This NOFO will support to preserve or protect sample in nder diverse conditions. These	the quality of the pre-analytical de vant biospecime otherwise interre t the developme integrity, or esta technologies are	e samples used for can egradation of targeted ns. The overall goal is ogating the quality an nt of tools, devices, blish verification criter e expected to accelera	cer research l analytes to support the d utility of ia for quality te and/or

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	issues associated with cancer health dispar Projects proposing the application of existi target/question being pursued are not resp part of a broader NCI-sponsored Innovative	ng technologies where the nov consive to this solicitation and	velty resides in the b will not be reviewe	piological or clinical d. This funding oppo	
	ecular and Cellular Analysis Technologies arch (R61 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA- 01- 24-008 [Op	Sep-2024 tional][LOI/Pre-App	450,000] USD
Contact Telephone Contact Email Sponsor Website Program URL	<u>kelly.crotty@nih.gov</u>	Dct-2024			
Synopsis	This Notice of Funding Opportunity (NOFO early-stage development of highly innovati clinical, or epidemiological cancer research capabilities involving a high degree of tech of cancer biology. Well-suited applications cancer biology, early detection and screen associated with cancer health disparities. T applicability but must be focused on impro proposing the application of existing techn pursued are not responsive to this solicitat sponsored Innovative Molecular Analysis T	ive technologies offering novel a. The emphasis of this NOFO is nical innovation for targeting, p must offer the potential to acc ing, clinical diagnosis, treatmer echnologies proposed for deve ving molecular and/or cellular ologies where the novelty resid ion and will not be reviewed. T	molecular or cellul on supporting the probing, or assessin celerate and/or enh nt, control, epidemi clopment may be in characterizations o des in the biological	ar analysis capabilities development of now g molecular and cell ance research in the ology, and/or addres tended to have wid f cancer biology. Pro- or clinical target/q	es for basic, vel lular features e areas of ss issues espread ojects uestion being
RFA-CA-24-014 Revision Applica122688Supported Technology to Acceler Optional)	ations for Incorporation of Novel NCI- ate Cancer Research (P50 Clinical Trial	National Cancer Institute/NIH/DHHS	RFA-CA- 01- 24-014 [Op	Sep-2024 tional][LOI/Pre-App	150,000] USD
Contact Telephone	Kelly Crotty, Ph.D. :240-255-0917 <u>kelly.crotty@nih.gov</u>				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Sep-2024 [Optional][LOI/Pre-App], 01-	Oct-2024			
	Synopsis	The purpose of this Notice of Funding Opp P50 specialized centers proposing to expa progress for the parent study by incorpora NCI Innovative Molecular Analysis Techno independent validation and accelerate the As a component of the NCI IMAT program innovative tools and methods that enable	nd upon original research quest ating a new technical approach logies (IMAT) program. Awards e suitability of these emerging t , this NOFO aims to promote in	tion(s) from specif or instrument dev from this NOFO au echnologies for ap terdisciplinary coll	ic projects or otherw eloped through supp re meant to incentivi propriate research co aboration in the deve	ise accelerate ort from the ze ommunities.
		ations for Incorporation of Novel NCI- ate Cancer Research (U01 Clinical Trial	National Cancer	RFA-CA- 01	•	150,000
	<u>Optional)</u>	<u> </u>	Institute/NIH/DHHS	24-013 [O	ptional][LOI/Pre-App] USD
	Contact Name	Kelly Crotty, Ph.D.				
	Contact Telephone	:240-255-0917				
	Contact Email	kelly.crotty@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Sep-2024 [Optional][LOI/Pre-App], 01-	Oct-2024			
	Synopsis	The purpose of this Notice of Funding Opp U01 research projects. The applicants sho accelerate progress for the parent study b from the NCI Innovative Molecular Analys independent validation and accelerate the As a component of the NCI IMAT program innovative tools and methods that enable	uld propose to expand upon the y incorporating a new technica is Technologies (IMAT) program e suitability of these emerging t , this NOFO aims to promote in	e original research l approach or instr n. Awards from this echnologies for ap terdisciplinary coll	question(s) or other ument developed th s NOFO are meant to propriate research co aboration in the deve	wise rough suppor incentivize ommunities.
122683		ations for Incorporation of Novel NCI- ate Cancer Research (R01 Clinical Trial	National Cancer Institute/NIH/DHHS	RFA-CA- 01 24-012 [O	-Sep-2024 ptional][LOI/Pre-App	150,000)] USD

SPIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
Contact Name	Kally Crothy Dh D				
Contact Name Contact Telephone	Kelly Crotty, Ph.D.				
	kelly.crotty@nih.gov				
Sponsor Website					
-	_ <u>Link to program URL</u> 01-Sep-2024 [Optional][LOI/Pre-App], 01-0	Det 2024			
Deaume Dates (ALL)	The purpose of this Notice of Funding Opp		e revision appli	cations from currently f	funded NCI
Synopsis	R01 research projects. The applicants shou accelerate progress for the parent study by from the NCI Innovative Molecular Analysis independent validation and accelerate the a component of the NCI IMAT program, the innovative tools and methods that enable	Ild propose to expand upon the y incorporating a new technica s Technologies (IMAT) program adoption of these emerging te is NOFO aims to promote inter	e original resear I approach or in n. Awards from t echnologies by a disciplinary colla	ch question(s) or other strument developed th his NOFO are meant to ppropriate research co aboration in the develo	wise rough support o incentivize mmunities. As
RFA-CA-24-009 Advanced Deve122738Molecular and Cellular Analysis TellResearch (R33 Clinical Trial Not All		National Cancer Institute/NIH/DHHS		01-Sep-2024 [Optional][LOI/Pre-App	900,000 o] USD
Contact Name	Kelly Crotty, Ph.D.				
Contact Telephone	240-255-0917				
Contact Email	kelly.crotty@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Sep-2024 [Optional][LOI/Pre-App], 01-0	Dct-2024			
Synopsis	This Notice of Funding Opportunity Annou focused on further development and valida assessing molecular and cellular features of NOFO solicits R33 applications where majo demonstrated with supportive preliminary adoption by the research community. Well research in the areas of cancer biology, ear	ation of emerging technologies of cancer biology for basic, clini or feasibility gaps for the techno data, but still requires further I-suited applications must offer	offering novel of cal, or epidemio ology or method development a the potential to	capabilities for targetin logical cancer research dology have been overc nd rigorous validation t o accelerate and/or enh	g, probing, or h. This come, as to encourage hance

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
and/or address issues associated with ca have widespread applicability but must b Projects proposing the application of exist target/question being pursued are not re part of a broader NCI-sponsored Innovat	be focused on improving molect sting technologies where the no esponsive to this solicitation and	ular and/or cellular cl ovelty resides in the k d will not be reviewe	haracterizations of o piological or clinical d. This funding oppo	ancer.
 <u>RFA-CA-24-015 Revision Applications for Incorporation of Novel NCI-</u> <u>Supported Technology to Accelerate Cancer Research (P30 Clinical Trial</u> <u>Optional</u>) 	National Cancer Institute/NIH/DHHS	RFA-CA- 01- 24-015 [Op	Sep-2024 otional][LOI/Pre-App	150,000] USD
Contact Name Kelly Crotty, Ph.D.				
Contact Telephone :240-255-0917				
Contact Email <u>kelly.crotty@nih.gov</u>				
Sponsor Website				
Program URL <u>Link to program URL</u>				
Deadline Dates (ALL) 01-Sep-2024 [Optional][LOI/Pre-App], 01	l-Oct-2024			
The purpose of this Notice of Funding Op Center Support Grants (CCSG) to support new technical approach or instrument de Synopsis (IMAT) program into a pilot cancer resea promote interdisciplinary collaboration i independent validation and accelerate th accelerate scientific discovery.	t an expansion of cancer resear eveloped through support from irch project. As a component of n the development of innovativ	ch conducted in a car the NCI Innovative N f the NCI IMAT progra re tools and methods	ncer center by incor Molecular Analysis T am, this NOFO is me as well as incentiviz	porating a echnologies eant to e
120726 Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-23- 259	Oct-2024	2,499,995 USD
		233		030
Contact Name Darrell Tata, Ph.D.				
Contact Telephone 240-276-5894				
Contact Email <u>Darrell.Tata@nih.gov</u>				
Sponsor Website				
Program URL Link to program URL				
Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Oct-2025	o , US-Feb-2026 , US-Oct-2026			

Sponsor Number	Deadline Date	Funding Amount
ncer Institute (NCI) inter science and/or spectros undamental biology, pot oplication to this NOFO w investigators who work other disease-related) pro in imaging than for a spec- prations or establish new is NOFO defines innovati t clinical trials that test for ded to support commerc- ion.	scopic technologie tential risk of deve will be formation of together as partn roblem. In this sens ecific scientific or of v ones that would tion as the likelihoo functionality or val	es into methods elopment, of an academic- iers to identify se, the NOFO clinical research drive the field od to deliver a lidate
PAR-23- 051	Oct-2024	2,500,000 USD
t applications that propo pression. It is anticipated nechanisms through whi ole lipids play in linking d bolism; and stimulate res complexity of lipid bioch	I that this program ich lipid metabolis diet with the biolog esearch and tool de	n will support om mediates gy of cancer;
PAR-23- 052	Oct-2024	275,000 USD
	/3-	23-UCT-2024

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Kristine.Willis@nih.gov				
	Sponsor Website					
	-	Link to program URL 23-Oct-2024 , 14-Feb-2025 , 23-Oct-2025				
	Synopsis	The purpose of this funding opportunity and the links between diet, lipid metabolism and fundamental studies designed to identify a tumor growth and progression, focusing sp bridge the historically divided fields of nutri this emerging area, which faces particular of unpublished preliminary data are limited to qualified new investigators to the field.	nd tumor growth and progressi and define the molecular mech becifically on the central role lip rition and molecular metabolis challenges because of the com	ion. It is anticipated anisms through whi pids play in linking d m; and stimulate re plexity of lipid bioch	that this program ch lipid metabolis iet with the biolog search and tool de nemistry. For this a	will support m mediates gy of cancer; evelopment in announcement
1/1/4/	tervention Research to Improve ational)	Native American Health (R01 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR-23- 298 21-0	Oct-2024	Not Specified
	Contact Name	Alexa Romberg Ph.D.				
	Contact Telephone	301-435-0264				
	Contact Email	alexa.romberg@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	21-Oct-2024 , 07-Jan-2025 , 21-Oct-2025 ,				
	Synopsis	The purpose of this notice of funding oppo American populations. This includes 1) etic 2) research that develops, adapts, or tests where a sufficient body of knowledge on in develops and tests strategies to overcome interventions. Through this initiative, interv resources, and resilience to identify and rig mortality. Interventions should be designed tested, and have the flexibility to be readily	blogic research that will directly interventions for health promo- ntervention efficacy exists, rese barriers to the adoption, integ vention and related research is gorously test culturally appropriate d with a consideration for sust	y inform interventio otion, prevention, tr earch on disseminat ration, scale-up, and s sought to build upo riate solutions to rec ainability within the	n development or eatment, or recov ion and implemen d sustainability of on community kno duce morbidity an communities whe	adaptations, ery, and 3) tation that effective wledge, d ere they are

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		includes NOFOs using the R21 Exploratory Planning Grant mechanism (PAR-23-285). Alaska Natives, American Indians (whose a Hawaiians. The term 'Native Hawaiian' me which now comprises the State of Hawaii.	For the purposes of this NOFO, ancestral lands fall at least part eans any individual any of whos	Native Americans in ially within the U.S. m	clude the followi nainland border),	ng population , and Native
121293	Intervention Research to Improve Trials Optional)	e Native American Health (R21 Clinical	National Cancer Institute/NIH/DHHS	PAR-23- 299 21-0	oct-2024	275,000 USD
	Contact Telephone Contact Emai Sponsor Website Program URI Deadline Dates (ALL	l <u>alexa.romberg@nih.gov</u>	ortunity (NOFO) is to support dans is includes 1) etiologic research adapts, or tests interventions for f knowledge on intervention effec- loratory/developmental research rovide foundational knowledge earch to Improve Native Americ earch Project Grant (R01) mecha purposes of this NOFO, Native A ral lands fall at least partially with eans any individual any of whos	evelopmental/explor o that will directly info- for health promotion, ficacy exists, research tive interventions. Th ch is sought that build that will inform effect an Health (IRINAH) in anism and PAR-23-28 Americans include the thin the U.S. mainland	orm intervention , prevention, trea h on strategies to rough this initiat ds upon Native co ctive and scalable nitiative, which al 5, which uses the e following popu d border), and Na	developmen atment, or o overcome ive, culturally ommunity e interventior so e Clinical Trial lations: Alask ative
106546		r Therapy-induced Adverse Sequelae and Strategies (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21- 329 05-0	oct-2024	Not Specifie
	Contact Name Contact Telephone	e Kelly Filipski PhD, MPH 240-276-6841				
			inities Due: Oct 2024			11

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Email	Filipskikk@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024				
Synopsis	The purpose of this Funding Opportunity A address adverse sequelae of cancer therap posttreatment effects. This FOA supports b mechanisms of therapy-induced adverse so understanding into therapeutic approache projects should focus on 1) mechanistic stu identify and validate clinical endpoints (bic use in clinical trials that will evaluate the e	bies that persist and become ch basic, translational, and/or clin equelae, clinically characterize es to prevent or minimize the d udies with translational endpoi pmarkers, imaging, patient-rep	nronic comorbidities ical research project the adverse sequela evelopment of long- nts; and/or 2) longit orted outcomes, or o	or develop as del s that seek to iden ae, or translate the term sequelae. Re udinal clinical phe combined elemen	ayed ntify the e mechanistic esearch enotyping to its) for future
08548 Epidemiologic Research on Emerge Susceptibility (R01 Clinical Trial No		National Cancer Institute/NIH/DHHS	PAR-22- 083	Dct-2024	Not Specified
Contact Name	Tram Kim Lam, Ph.D., MPH				
Contact Telephone	240-276-6967				
Contact Email	Tram.Lam@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025				
Synopsis	The purpose of this Funding Opportunity A innovative hypotheses on emerging risk fa- risk factors (e.g., viral hepatitis) associated histological subtypes) in the United States.	ctors (biological, environmenta I with the development of liver	al, and social) and th	eir interplay with	established
	orative: Enabling Biomimetic Tissue- cer Research (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22- 099	Dct-2024	2,000,00 USD
Contact Name Contact Telephone	Steven Becker, Ph.D. 240-276-6210				

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Email <u>steven.becker@nih.gov</u>				
Sponsor Website				
Program URL Link to program URL				
Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025				
This Funding Opportunity Announceme biomimetic tissue-engineered technolo fields of regenerative medicine, tissue e generating novel experimental models hypothesis. The projects supported by t (TEC) Research Program. The Cancer TE and ex vivo systems available for cancer promote the exploration of cancer pher	gies for cancer research. Collabo engineering, biomaterials, and bio that mimic cancer pathophysiolo this FOA will collectively participa C Program will (1) catalyze the ac r research, (2) expand the breadt	rative, multidisciplinar oengineering with can ogy in the context of a ate in the Cancer Tissu dvancement of innova ch of these systems to	ry projects that e acer biology will b testable cancer r le Engineering Co ative, well charact	ngage the be essential fo research Illaborative terized in vitro
L09909 Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (Re Clinical Trial Not Allowed)	01 National Cancer Institute/NIH/DHHS	PAR-22- 139 05-0	Oct-2024	2,500,00 USD
Contact Name Michael Graham Espey, Ph.D.				
Contact Telephone 240-276-7619				
Contact Email <u>SP@nih.gov</u>				
Sponsor Website				
Program URL Link to program URL				
Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025				
The purpose of this Funding Opportunit Synopsis cancer biology methods and model syst therapeutics (e.g., radiopharmaceutical	ems to study effects of different	types of radiation use	ed in radionuclide	e-based
Innovative Approaches to Studying Cancer Communication in the New	National Cancer	PAR-22-)ct-2024	2,500,00
III847 Information Ecosystem (R01 Clinical Trial Optional)	Institute/NIH/DHHS	164 05-0	101-2024	USD
Contact Name Kelly D. Blake, ScD				
Contact Name Kelly D. Blake, ScD Contact Telephone 240-281-5934				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Sponsor Website	2				
Program URI	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025				
Synopsis	Through this Funding Opportunity Announ supporting meritorious research projects application of new cancer communication communication interventions using innov communication models emphasizing bidir communication science approaches to the prevention and control. Applications show	in three distinct domains relate a surveillance approaches; 2) the ative methods and designs; and ectional influence between leve e investigation of behavioral tar	ed to cancer commu e development and d 3) the developmen els. For such project gets and health out	nication: 1) the ut testing of rapid ca It and testing of m s, applicants shou comes related to o	ility and ncer ultilevel cance ld apply cancer
111859 Precision Approaches in Radiation Clinical Trial Optional)	n Synthetic Combinations (PAIRS, R01	National Cancer Institute/NIH/DHHS	PAR-22- 198	Oct-2024	Not Specified
Contact Name	Michael Graham Espey, Ph.D.				
Contact Telephone	240-276-5609				
Contact Emai	I <u>SP@nih.gov</u>				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025				
Synopsis	Through this Funding Opportunity Announ that seek to investigate actionable synthe therapy. The goal of the Precision Approa synthetic combination strategies and facil effective anticancer treatments.	tic vulnerabilities that can be co ches in Radiation Synthetic Con	onditionally paired v nbinations (PAIRS) p	vith tumor respon rogram is to deve	ses to radiatio lop radiation-
117334 Impacts of Climate Change Across Clinical Trial Optional)	s the Cancer Control Continuum (R01	National Cancer Institute/NIH/DHHS	PAR-23- 153 05-	Oct-2024	Not Specified
Contact Name	Curt DellaValle, Ph.D., MPH				
Contact Telephone	240-276-7225				
Contact Emai	l <u>curt.dellavalle@nih.gov</u>				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 ,	, 05-Oct-2025 , 05-Feb-2026			
Synopsis	This notice of funding opportunity (NOFO) the effects of climate change across the ca survivorship, and ways to prevent or mitig knowledge of the impact of climate chang	ancer control continuum, from gate negative health effects. Thi	cancer etiology and is includes, but is no	cancer risks throut t limited to, studie	gh es to improve
107221 Modulating Human Microbiome F Against Cancer (R01 Clinical Trial	Function to Enhance Immune Responses Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22- 061	Oct-2024	Not Specified
Contact Name	Phillip J. Daschner, M.Sc.				
Contact Telephone	240-276-6227				
Contact Email	PD93u@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024				
Synopsis	The purpose of this Funding Opportunity a which the human microbiome inhibits or e targets for cancer prevention strategies. A microbes (or consortia) or their metabolit sporadic tumor formation. Concentration, effectiveness and thus those parameters s	enhances anti-tumor immune r Applications should be focused es target immune responses th , timing, and duration of admin	esponses, and to ide on delineating how at enhance or preve istered beneficial m	entify potential no host interactions v ent inflammation-a	vel molecular vith specific issociated or
Imaging, Biomarkers and Digital P 110471 Premetastatic Cancer and Precan Phenotypes (R01 Clinical Trial Opt		National Cancer Institute/NIH/DHHS	PAR-22- 131 05-	Oct-2024	Not Specified
Contact Name	Sudhir Srivastava, Ph.D., MPH				
Contact Telephone	240-276-7028				
•	srivasts@mail.nih.gov				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025				
	Synopsis	This Funding Opportunity Announcement imaging, biomarkers, digital pathomic and earliest detection of premetastatic aggress demonstrate an aggressive phenotype. Th clinical decisions in a technology agnostic registered, cross-correlated imaging result strategies such as artificial intelligence and supported by this FOA will collectively part Program. The goals of the CIB are to: (1) in identification of lethal cancer versus non-li- positives and false negatives.	other -omic integration strates sive cancer as well as identifyin is FOA specifically attempts to manner by improving sensitivit s integrated with multiplexed b l virtual reality visualization for ticipate in the existing Consorti nprove diagnostic performance	gies for improving cu og precancerous lesio address and improve y and specificity of a biomarker data and improving discover fum for Imaging and by developing metl	urrent approaches ons that will subse e diagnostic uncer opplied tests. N-dir digital pathomics of y are encouraged. Biomarkers (CIB) I nodology for the e	for the quently tainty in nensional co- using analytic The projects Research arly
112619 <u>B</u>	Biology of Bladder Cancer (RO1 Cl	inical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22- 218	Dct-2024	Not Specified
	Contact Name	Ron Johnson, Ph. D.				
	Contact Telephone	240-276-6250				
	Contact Email	rjohnso2@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025				
	Synopsis	This Funding Opportunity Announcement mechanisms of bladder cancer. Bladder ca of the high incidence and frequent tumor progress has been made in the molecular known regarding the molecular mechanism our understanding of the biological process Fundamental knowledge of how molecular understanding of bladder cancer biology a	ncer is a significant health prob recurrence, bladder cancer exa profiling of bladder cancers and ns driving initiation, progressio ses of the normal bladder at th r and cellular functions of the b	olem both in the Uni lots an outsized med d identification of m on and malignancy of he molecular, cell an oladder are altered in	ted States and glo ical burden. While utated genes, rela f bladder cancer. F d organ levels is lin n cancer will aid on	bally. Because recent tively little is urthermore, mited.
114678 C	Co-infection and Cancer (R01 Clin	ical Trial Not Allowed)	National Cancer	PAR-23- 05-0	Oct-2024	Not



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Institute/NIH/DHHS	055		Specified
Contact Name	Tram Kim Lam, Ph.D., MPH				
Contact Telephone	240-276-6967				
Contact Email	lamt@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 ,	05-Oct-2025			
Synopsis	The purpose of this Funding Opportunity A addressing the roles of co-infection and ca inform prevention and treatment strategies infections by two or more infectious (path includes both acute and chronic infections given to investigations of co-infections wit co-infections that engender novel opportu-	ncer to shed light on presently es for infection-related cancers ogenic or non-pathogenic) age by viruses, bacteria, parasites, h known oncogenic agents (ex	unestablished path . Co-infection is defi nts – either concurr and/or other micro cluding human imm	ways in carcinoge ned as the occurre ently or sequentia organisms. Prefer	nesis that may ence of lly – and ence will be
120755 Assay Development and Screenin or Immunomodulators (R01 Clinic	g for Discovery of Chemical Probes, Drugs cal Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-23- 264	Oct-2024	Not Specified
Contact Name	Suzanne Forry, Ph.D.				
Contact Telephone	240-276-5922				
Contact Email	forryscs@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 ,	05-Oct-2025,05-Feb-2026,0	5-Jun-2026		
Synopsis	Through this Notice of Funding Opportunit discovery and development of novel, smal probe cancer biology, to validate cancer ta this NOFO include: 1) development of the implementation to identify initial screening	I molecules for cancer. Molecu argets, or as the basis for optim primary screen assay(s) and te	les discovered throu ized drugs. Stages o sting in an initial pilo	ugh this NOFO may if discovery resear ot screen; 2) prima	y be used to ch covered by ry screen
	3) hit validation using a series of assays an			-	put screens);

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	unding Mount
<u>I</u>	<u>Frial Required)</u>		Institute/NIH/DHHS	273		Specified
	Contact Name	Rebecca Ferrer				
	Contact Telephone	240-276-6914				
	Contact Email	ferrerra@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 ,	05-Oct-2025 , 05-Feb-2026			
	Synopsis	This Notice of Funding Opportunity (NOFO effects occur in a cancer context, elucidate cancer sites, and contexts in which expecta defined in this context as beliefs about futu Expectancies can be evoked by social, psyc cognitive, behavioral, and biological outcon held by patients, clinicians, family member applications that enroll individuals and gro and behavioral research.	their role in cancer symptom ancy effects can be leveraged t ure outcomes, including one's hological, environmental, and mes caused by expectancies. Es s, caregivers, and/or dyadic/so	management, and i o improve cancer o response to cancer systemic factors. Ex xpectancy effects c ocial networks. Prog	identify patients, sym outcomes. Expectanci or cancer treatment of cancy effects are an be generated by e gram is particularly in	ptoms, es are the xpectancies terested in
		iers to Healthcare Transitions for Survivors		RFA-CA- 12-	•	2,495,000
<u>C</u>	of Childhood and Adolescent Can		Institute/NIH/DHHS	24-027 [Op	otional][LOI/Pre-App]	USD
		Lynn S. Adams, PhD				
	Contact Telephone					
	Contact Email	adamsls@nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	12-Sep-2024 [Optional][LOI/Pre-App], 11-C	Dct-2024			
	Synopsis	Through this notice of funding opportunity intervention studies that address individua childhood and adolescent cancers. The goa and strategies that promote high-quality tr adolescent cancers to ensure these survivo	I and system level barriers to t al of this opportunity is to supp ransitional care and continued	ransition from pedi ort the development engagement of sur	iatric to adult care fo nt and testing of inte vivors of childhood a	r survivors of rventions nd

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	anticipated that this research will provide widely disseminated and adopted.	e critical evidence for establishir	ng best practices and	l standards of care	e that can be
120897 Research Projects to Enhance App Translational Research (R01 Clinic	plicability of Mammalian Models for cal Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-23- 281	Oct-2024	2,495,000 USD
Contact Name	Joanna Watson, Ph.D.				
Contact Telephone	240-276-6206				
Contact Email	Joanna.Watson@nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025	, 05-Oct-2025 , 05-Feb-2026 , 0	5-Jun-2026		
Synopsis	Through this Notice of Funding Opportun expand, improve, or transform the utility through this NOFO encourages submissio organoids, tumoroids and cell models, use appropriate to test questions of clinical in contrast with the goals of many mechanis cancer models, transplantation tumor mo testing, non-clinical research. Among man demonstrations of how to overcome tran mammalian models or their genetics for u translational models, test approaches to v used translationally.	of mammalian cancer and tumo n of projects devoted to demon ed for translational research are nportance, and provide reliable stic, NCI-supported R01 projects odels, or models derived from m ny other possible endeavors, ap slational deficiencies of mamma unexplored translational challen	or models for transla istrating that mamme robust representat information for pati is that use mammals, nammalian or humar plicants in response alian oncology mode iges, advance standa	ational research. T nalian models, incl ions of human bic ent benefit. These or develop and u n tissues or cells fo to this NOFO cou els, define new use and practices for u	he NCI, uding blogy, are e practical goals se mammalian or hypothesis- ld propose es of se of
120973 <u>Mechanisms that Impact Cancer F</u> <u>Clinical Trial Optional</u>)	Risk with Use of Incretin Mimetics (R01	National Cancer Institute/NIH/DHHS	PAR-23- 279	Oct-2024	Not Specified
Contact Name	Edward R. Sauter, MD, PhD				
Contact Telephone	240-276-7657				
Contact Email	edward.sauter@nih.gov				
Sponsor Website					
Program URL	Link to program URL				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	05-Oct-2024, 05-Feb-2025, 05-Jun-2025, Through this notice of funding opportunity initiated studies addressing mechanisms b glucose?dependent insulinotropic polypep is due to their reported effects on thyroid, effect profile compared to other classes of cancer biology field who may study increti incretin mimetics other than GLP-1 RAs or the agent(s) they propose to study are mo 1/GIP-1 RAs. Route of agent administration	y (NOFO), the National Cancer I y which incretin mimetics, spec ide (GIP)-1 receptor agonists (I prostate and other cancer risk incretin mimetics. In addition, n mimetic effects on diseases of GLP-1/GIP-1 RAs, such as diper re effective and/or have a mor	nstitute (NCI) invite cifically glucagon-lik RAs), impact cancer s, and the generally this NOFO seeks to other than cancer. In otidyl peptidase (DP e favorable side effe	s applications for i e peptide (GLP)-1 risk. The focus on more favorable e draw in talented s nvestigators wishir P)-4 inhibitors, mu	or dual GLP-1/ or these agents fficacy and side scientists to the ong to study ust justify why
123579 Modular R01s in Cancer Control a Optional)	nd Population Sciences (R01 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR-24- 122	Oct-2024	1,250,000 USD
Contact Name	Scott Rogers, MPH				
Contact Telephone	240-276-6932				
Contact Email	rogerssc@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024				
Synopsis	This notice of funding opportunity (NOFO) The overarching goal is to provide support substantially advance cancer research in st behaviors and behavioral interventions, he	to promote research efforts of tatistical and analytic methods,	n novel scientific ide epidemiology, cano	eas that have the p cer survivorship, ca	ootential to ancer-related
123053 National Cancer Institute's Investi for Cancer Treatment and Diagno	igator-Initiated Early Phase Clinical Trials sis (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-24- 085	Sep-2024	2,499,995 USD
Contact Name	Lori A. Henderson, Ph.D.				
Contact Telephone	240-276-5930				
Contact Email	hendersonlori@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 2026 , 05-Feb-2026 , 07-May-2026 , 05-Ju		-	-2025 , 05-Oct-20	25 , 07-Jan-
Synopsi	Through this Notice of Funding Opportuni implement early phase (Phase 0, I, and II) therapeutic interventions of direct relevar at least 1 clinical trial related to the scient Evaluation Program, Cancer Imaging Progr Alternative Medicine Program and/or the an early phase trial by itself, or in combina III clinical trials.	investigator-initiated clinical tri ace to the research mission of D ific interests of one or more of t am, Cancer Diagnosis Program, HIV and AIDS Malignancies Res	als focused on cance CTD and OHAM. The the following resear Radiation Research earch Programs. App	er-targeted diagno e proposed projec ch programs: Can Program, Comple plicants may prop	ostic and ct must involve cer Therapy ementary and ose to conduct
123051 Cancer Prevention and Control C Trial Required)	linical Trials Grant Program (R01 Clinical	National Cancer Institute/NIH/DHHS	PAR-24- 072	Sep-2024	Not Specified
Contact Name	Brandy Heckman-Stoddard, Ph.D., M.P.H.				
Contact Telephon	e 240-276-7048				
Contact Ema	il <u>heckmanbm@mail.nih.gov</u>				
Sponsor Website	2				
Program UR	L <u>Link to program URL</u>				
Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 2026 , 05-Feb-2026 , 07-May-2026 , 05-Jui	· · ·		-2025 <i>,</i> 05-Oct-20	25 , 07-Jan-
Synopsi	Through this notice of funding opportunity investigator-initiated clinical trials related NCI Division of Cancer Control and Popular improvements in early detection, screenin s survivorship related to cancer; with such a practice and/or public health. Applications Health (NIH) definition of a clinical trial (se described in this NOFO and the application cancer diagnosis and/or oncologic therapy	to the programmatic interests of tion Sciences that have the pote g, prevention and interception, ttributes, the proposed studies submitted to this NOFO must e NOT-OD-15-015 for details) a n instructions. This NOFO does	of the NCI Division o ential to reduce the healthcare delivery should also have th include studies that nd provide specific	f Cancer Prevention burden of cancer of quality of life, ar the potential to imp meet the Nationa clinical trial inform	on and/or the through nd/or prove clinical I Institutes of nation as
112622 Biology of Bladder Cancer (R21 C	linical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22- 219	Dct-2024	275,000 USD



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name	Ron Johnson, Ph. D.				
	Contact Telephone	240-276-6250				
	Contact Email	rjohnso2@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025				
	Synopsis	This Funding Opportunity Announcement mechanisms of bladder cancer. Bladder ca of the high incidence and frequent tumor progress has been made in the molecular known regarding the molecular mechanism our understanding of the biological proces Fundamental knowledge of how molecula understanding of bladder cancer biology a	ncer is a significant health prob recurrence, bladder cancer exa profiling of bladder cancers and ms driving initiation, progressio sses of the normal bladder at th r and cellular functions of the b	olem both in the Uni cts an outsized med d identification of me n and malignancy of ne molecular, cell an ladder are altered ir	ted States and glo ical burden. While utated genes, rela f bladder cancer. F d organ levels is li n cancer will aid o	bally. Because recent tively little is urthermore, mited.
114679 <mark>Co</mark>	p-infection and Cancer (R21 Clin	ical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-23- 056 16-0	Oct-2024	275,000 USD
	Contact Name					
		Tram Kim Lam, Ph.D., MPH				
	Contact Telephone					
	•					
	•	240-276-6967 lamt@mail.nih.gov				
	Contact Email Sponsor Website	240-276-6967 lamt@mail.nih.gov				
	Contact Email Sponsor Website Program URL	240-276-6967 lamt@mail.nih.gov	16-Oct-2025			

		Sponsor Name	Sponsor Number Deadline Date	Funding Amount
21014 Mechanisms that Impact Cancer Clinical Trial Not Allowed)	Risk with Use of Incretin Mimetics (R21	National Cancer Institute/NIH/DHHS	PAR-23- 280 16-Oct-2024	275,000 USD
Contact Name	e Edward R. Sauter, MD, PhD			
Contact Telephone	240-276-7657			
Contact Emai	l <u>edward.sauter@nih.gov</u>			
Sponsor Website				
Program UR	Link to program URL			
Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025	, 16-Oct-2025 , 16-Feb-2026 , 1	16-Jun-2026 , 16-Oct-2026	
Synopsis	Through this notice of funding opportunit initiated studies addressing mechanisms b 1/glucose-dependent insulinotropic polyp agents is due to their reported effects on and side effect profile compared to other scientists to the cancer biology field who	by which incretin mimetics, spo peptide (GIP)-1 receptor agonis thyroid, prostate and other ca classes of incretin mimetics. In	ecifically glucagon-like peptide (GLP)-1 sts (RAs), impact cancer risk. The focus incer risks, and the generally more fav n addition, this NOFO seeks to draw in	1 or dual GLP- s on these vorable efficacy
14360 Pragmatic Trials across the Cance Trial Required)	er Control Continuum (UG3/UH3 Clinical	National Cancer Institute/NIH/DHHS	PAR-22- 256 17-Oct-2024	Not Specified
Contact Name	Wynne E. Norton, PhD			
Contact Telephone				
Contact Emai	l wynne.norton@nih.gov			
Sponsor Website				
Program UR	Link to program URL			
Deadline Dates (ALL) 17-Oct-2024 , 14-Feb-2025 , 14-Jun-2025	, 17-Oct-2025		
Synopsis	Through this funding opportunity announ development of evidence-based cancer-re settings in the United States. Specifically, on cancer-related outcomes across the ca UG3/UH3 phased cooperative agreement and finalizing study-related activities in pr	elated interventions that reflect this FOA will support research ncer control continuum using mechanism. The UG3 phase w	ct the diversity of people, places, cont that tests the impact of cancer-relate a pragmatic trial study design. This FC vill support refining the cancer-related	exts, and ed interventions DA will use the
06892 Exploratory Grants in Cancer Con	trol (R21 Clinical Trial Optional)	National Cancer	PAR-21- 08-Oct-2024	275,000

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Institute/NIH/DHHS	341		USD
Contact Name	Mukesh Verma, Ph.D.				
Contact Telephone	240-276-6889				
Contact Email	vermam@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	08-Oct-2024 , 08-Nov-2024				
Synopsis	Through this funding opportunity announ exploratory/developmental research gran behavior, screening, and understanding e control cancer. The overarching goal is to novel scientific ideas that have the potent development of novel techniques, agents	t (R21) applications that focus tiologic factors contributing to t provide support to promote th ial to substantially advance pop	on different aspects the development of e early and conceptu pulation-based cance	of cancer control cancer, and devel ual stages of resea er research, such a	by modifying oping ways to rch efforts or as the
	impact on a field of cancer research (e.g.				•
22281 Assay Validation of High Quality N (UH2/UH3 Clinical Trial Not Allow	impact on a field of cancer research (e.g. on <i>Markers for Clinical Studies in Cancer</i>		avioral, health care o		•
(UH2/UH3 Clinical Trial Not Allow	impact on a field of cancer research (e.g. on <i>Markers for Clinical Studies in Cancer</i>	epidemiologic, biomedical, beha National Cancer	PAR-23- 08-0	delivery or clinical). Not
(UH2/UH3 Clinical Trial Not Allow	impact on a field of cancer research (e.g. o <u>Markers for Clinical Studies in Cancer</u> ed) Tracy G. Lively, Ph.D.	epidemiologic, biomedical, beha National Cancer	PAR-23- 08-0	delivery or clinical). Not
(UH2/UH3 Clinical Trial Not Allow Contact Name Contact Telephone	impact on a field of cancer research (e.g. o <u>Markers for Clinical Studies in Cancer</u> ed) Tracy G. Lively, Ph.D.	epidemiologic, biomedical, beha National Cancer	PAR-23- 08-0	delivery or clinical). Not
(UH2/UH3 Clinical Trial Not Allow Contact Name Contact Telephone	impact on a field of cancer research (e.g. o <u>Markers for Clinical Studies in Cancer</u> ed) Tracy G. Lively, Ph.D. 240-276-5944 <u>livelyt@mail.nih.gov</u>	epidemiologic, biomedical, beha National Cancer	PAR-23- 08-0	delivery or clinical). Not
(UH2/UH3 Clinical Trial Not Allow Contact Name Contact Telephone Contact Email Sponsor Website	impact on a field of cancer research (e.g. o <u>Markers for Clinical Studies in Cancer</u> ed) Tracy G. Lively, Ph.D. 240-276-5944 <u>livelyt@mail.nih.gov</u>	epidemiologic, biomedical, beha National Cancer	PAR-23- 08-0	delivery or clinical). Not
UH2/UH3 Clinical Trial Not Allow Contact Name Contact Telephone Contact Email Sponsor Website Program URL	impact on a field of cancer research (e.g. o <u>Markers for Clinical Studies in Cancer</u> ed) Tracy G. Lively, Ph.D. 240-276-5944 <u>livelyt@mail.nih.gov</u>	epidemiologic, biomedical, beh National Cancer Institute/NIH/DHHS	PAR-23- 313 08-0	delivery or clinical). Not

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	increasingly combined with immunotherap markers, including immune markers, can b analytical validation of assays for these mo assays may undergo clinical validation. The assays for up to 3 years using well-annotat NOFO may be used to validate existing assi- studies. Efforts to harmonize clinical labora- assays across multiple clinical laboratories, will require multi-disciplinary interaction a clinical laboratory scientists. This NOFO is n clinical trials but is intended for validation investigational assays. Investigators respor accomplished in the UH2 phase for transiti	be developed and validated simple cular/cellular/imaging marke e UH3 phase of this NOFO supple ad biospecimens from retrosp ays for use in other cancer clin atory tests, including investigat , are also appropriate for this f and collaboration among scient not intended to support early-so of assays to the point where the nding to this NOFO must address	nultaneously. The UF ers, which must be a ports clinical validation ective or prospective ical trials, observation tion into the perform unding opportunity. ific investigators, on stage development of ney could be integration so both UH2 and UH	12 phase of this Ne chieved within 2 on of analytically v e clinical trials or so nal studies, or po nance and reprodu Projects propose cologists, statistic of technology or the ted into clinical tr 3 phases. Milesto	OFO supports years before validated studies. This pulation ucibility of d for this NOFO ians, and he conduct of ials/studies as
122288 Assay Validation of High Quality M Clinical Trials Not Allowed)	Markers for Clinical Studies in Cancer (UH3	National Cancer Institute/NIH/DHHS	PAR-23- 314	Dct-2024	750,000 USD
Contact Name	Tracy G. Lively, Ph.D.				
Contact Telephone	240-276-5944				
Contact Email	livelyt@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	08-Oct-2024 , 14-Feb-2025 , 11-Jun-2025 ,	15-Oct-2025 , 13-Feb-2026 , 1	0-Jun-2026 , 14-Oct-	2026	
Synopsis	Through this Notice of Funding Opportunit and validation of molecular/cellular/imagin detection, diagnosis, prognosis, monitoring cancer prevention and control. This NOFO toxicity. Applicants to this NOFO must have similar to those for the intended clinical us increasingly combined with immunotherap multiple markers, including immune market support the clinical validation of established clinical trials or studies. This NOFO may be	ng markers (referred to as "ma g, and prediction of response of will also support the validation e an assay(s) whose performan se of the marker(s) and assay(s bies to enhance the durability of ers, can be developed and valid ed assays for up to 3 years usin	rkers" or "biomarke or resistance to treat n of pharmacodynam nce has been analytic). As chemotherapie of anti-cancer respon dated simultaneously g specimens from re	rs") and assays fo ment, as well as r nic markers and m cally validated in s s and/or radiatior nses, assays for m y. The UH3 mecha trospective or pro	r cancer narkers for arkers of pecimens therapies are easuring nism will ospective

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	population studies. Efforts to harmonize cl reproducibility of assays across multiple cl proposed for this NOFO will require multic statisticians, and clinical laboratory scienti the conduct of clinical trials but is intended trials/studies as investigational assays.	inical laboratories, are also app lisciplinary interaction and colla sts. This NOFO is not intended	propriate for this fur aboration among sc to support early-sta	nding opportunity. ientific investigato ige development o	Projects ors, oncologists, f technology or
106230 NCI Mentored Research Scientist (K01 Clinical Trial Required)	Development Award to Promote Diversity	National Cancer Institute/NIH/DHHS	PAR-21- 296 12-	Oct-2024	Not Specified
Contact Name	Mulualem E. Tilahun, D.V.M., Ph.D				
Contact Telephone	240-276-7360				
Contact Email	mulualem.tilahun@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	12-Oct-2024				
Synopsis	This Funding Opportunity Announcement Award to Promote Diversity (K01) to enhan- eligible individuals from diverse backgroun- the biomedical, behavioral, social and clini of "protected time" for intensive research Opportunity Announcement (FOA) is desig independent clinical trial, a clinical trial fea- career development. Applicants not planni- clinical trial led by another investigator, m	nce the diversity in the NCI-fun ads, including groups that have cal sciences. This FOA provides career development under the ned specifically for applicants p isibility study, or a separate and ing an independent clinical trial	ded cancer research been shown to be salary and research guidance of an exp proposing to serve a cillary clinical trial, a l, or proposing to ga	h workforce by sup nationally underre n support for a sus perienced mentor. as the lead investig as part of their rese	porting presented in tained period This Funding ator of an earch and
108550 Epidemiologic Research on Emerge Susceptibility (R21 Clinical Trial No.		National Cancer Institute/NIH/DHHS	PAR-22- 084 16-	Oct-2024	275,000 USD
Contact Name	Tram Kim Lam, Ph.D., MPH				
Contact Telephone	240-276-6967				
Contact Email	Tram.Lam@nih.gov				
Sponsor Website					

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
•	Link to program URL 16-Oct-2024 , 16-Feb-2025				
Synopsis	The purpose of this Funding Opportunity A innovative hypotheses on emerging risk fa risk factors (e.g., viral hepatitis) associated histological subtypes) in the United States	ctors (biological, environmenta I with the development of liver	al, and social) and	their interplay with e	stablished
108359 Exploratory/Developmental Bioer Clinical Trial Optional)	ngineering Research Grants (EBRG) (R21	National Cancer Institute/NIH/DHHS	PAR-22- 091	5-Oct-2024	275,000 USD
Contact Name	Miguel R. Ossandon, Ph.D.				
Contact Telephone	240-276-5714				
Contact Email	ossandom@mail.nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Oct-2024				
Synopsis	The purpose of this engineering-oriented to exploratory/developmental Bioengineering utility of new capabilities or improvement problems in basic biomedical, pre-clinical, clinical trials that test functionality or valid trials in any area of cancer research are no	g Research Grant (EBRG) applic s in quality, speed, efficacy, op or clinical research, clinical car late performance in the choser	cations to demons erability, costs, an e delivery, or acce n setting. Applicati	trate feasibility and p d/or accessibility of so ssibility. This FOA wil ons that propose pha	otential plutions to I support
	k (MetNet): MetNet Research Projects (U01		PAR-22- 23	•	2,500,000
<u>Clinical Trial Not Allowed</u>	1	Institute/NIH/DHHS	234 [C	ptional][LOI/Pre-App] USD
	Joanna M. Watson, Ph.D.				
Contact Telephone					
	watsonjo@mail.nih.gov				
Sponsor Website					
•	Link to program URL				
Deadline Dates (ALL)	23-Sep-2024 [Optional][LOI/Pre-App], 23-	Oct-2024 , 20-May-2025 [Optio	nal][LOI/Pre-App]	, 20-Jun-2025	

SPIN ID Program Title		Sponsor Name	Sponsor Number Deadline Dat	e Funding Amount
Synopsi	The National Cancer Institute's (NCI) Me support using systems-level approaches t advance our understanding of metastasis picture of the processes involved. Throug MetNet Research Projects. These Researc to address gaps and opportunities in met across the Network.	to understand pressing questio s as a whole body, systems-leve gh this Funding Opportunity An ch Projects should be defined a	ns in metastasis. The overall goal of el problem to develop a comprehen nouncement (FOA), the NCI invites is discrete entities that use systems	the MetNet is to sive and cohesive applications for -level approaches
114550 NCI Small Grants Program for Car 2025 (NCI Omnibus) (R03 Clinical	ncer Research for Years 2023, 2024, and Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-23- 058 07-Sep-2024	100,000 USD
Contact Name				
Contact Telephone				
Contact Emai				
Sponsor Website				
Program UR	Link to program URL	24 F.L. 2025 07 M. 2025	20 1 2025 07 6 2025 47 0	2025 07 1
Deadline Dates (ALL	07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 2026	, 24-Feb-2025, 07-Way-2025,	20-Jun-2025, 07-Sep-2025, 17-Oc	-2025 , 07-Jan-
Synopsi	This funding opportunity announcement period of time with limited resources. Th feasibility studies; secondary analysis of e methodology; and development of new r	e RO3 grant mechanism suppor existing data; small, self-contain	ts different types of projects includ	ing pilot and
NCI Pathway to Independence Av 122437 Researchers (K99/R00 - Independence Humans Required)	ward for Early-Stage Postdoctoral lent Basic Experimental Studies with	National Cancer Institute/NIH/DHHS	PAR-23- 288 15-Oct-2024	Not Specified
Contact Name	Sergey Radaev, PhD			
Contact Telephone	240-276-5630			
Contact Emai	l <u>sradaev@mail.nih.gov</u>			
Sponsor Website				
Program UR	Link to program URL			
Deadline Dates (ALL) 15-Oct-2024 , 14-Feb-2025 , 16-Jun-2025	, 14-Oct-2025 , 17-Feb-2026 ,	15-Jun-2026 , 14-Oct-2026	
A	NIH Funding Opport			

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of the NCI Pathway to Indeper increase and maintain a strong cohort of m designed for postdoctoral fellows with rese mentored research training beyond their d these fellows from their mentored, postdo positions. The program will provide indeper competitive, independent research careers cancer data sciences are especially encoura (NOFO) is designed specifically for candidat clinical trial feasibility study, or a separate planning an independent clinical trial, or pr must apply to companion NOFO (PAR-23-2 involving humans, referred to in NOT-OD-1 studies fall within the NIH definition of a cl should be submitted under this NOFO inclu experimentally manipulate independent va purpose of understanding the fundamenta products in mind. Applicants not planning a to gain research experience in a clinical triat to the 'Independent Clinical Trial Not Allow interests of one or more of the participatin	ew and talented, NCI-supporter earch and/or clinical doctoral d loctoral degrees. The objective ctoral research positions to ind endent NCI research support du s. Researchers in the scientific a aged to work with their institut tes proposing to serve as the le ancillary clinical trial, as part of roposing to gain research expe 86). This Notice of Funding Op .8-212 as "prospective basic sc inical trial and also meet the d ude studies that prospectively a ariables) and that assess biome I aspects of phenomena witho an independent clinical trial or al or basic experimental study y yed' companion NOFO. The pro-	d, independent inve- legrees who do not in of this award is to find dependent tenure-transition the areas of cancer conti- cions to apply. This New and investigator of a fitheir research and rience in a clinical transition finition of basic research assign human partici- dical or behavioral of ut specific application basic experimental with humans led by posed project must	estigators. This pro- require an extend acilitate a timely to rack (or equivalent to help awardees rol, cancer prever Notice of Funding on independent clin career development ial led by another c science experime ing human particip search. Types of st ipants to condition outcomes in human on towards proces study with human another investigat	bgram is ed period of ransition of c) faculty aunch tion and Dpportunity nical trial, a ent. Those not investigator, ental studies bants." These udies that ns (i.e., ins for the ses or s, or proposing cor, must apply
	NCI Pathway to Independence Av Researchers (K99/R00 - Independ		National Cancer Institute/NIH/DHHS	PAR-23- 287 15-0	Oct-2024	Not Specified
	Contact Name	Sergey Radaev, PhD				
	Contact Telephone	240-276-5630				
	Contact Email	sradaev@mail.nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	15-Oct-2024 , 14-Feb-2025 , 16-Jun-2025 ,				
	Synopsis	The purpose of the NCI Pathway to Independent increase and maintain a strong cohort of neuronal				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		designed for postdoctoral fellows with rese mentored research training beyond their of these fellows from their mentored, postdo positions. The program will provide indeper competitive, independent research careers cancer data sciences are especially encours (NOFO) is designed specifically for candida clinical trial feasibility study, or a separate planning an independent clinical trial, or pu must apply to companion NOFO (PAR-23-2	loctoral degrees. The objective octoral research positions to inc endent NCI research support du s. Researchers in the scientific aged to work with their institut tes proposing to serve as the le ancillary clinical trial, as part of roposing to gain research expe	of this award is to f dependent tenure-tr uring this transition areas of cancer cont tions to apply. This r ead investigator of a f their research and	acilitate a timely t rack (or equivalent to help awardees l rol, cancer preven notice of funding o n independent clin career developme	ransition of c) faculty aunch ntion and pportunity nical trial, a ent. Those not
	NCI Pathway to Independence Aw Researchers (K99/R00 - Independ	vard for Early-Stage Postdoctoral lent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-23- 286 15-0	Oct-2024	Not Specified
	Contact Name	Sergey Radaev, PhD				
	Contact Telephone	240-276-5630				
	Contact Email	<u>sradaev@mail.nih.gov</u>				
	Sponsor Website	2				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Oct-2024 , 14-Feb-2025 , 16-Jun-2025 ,	14-Oct-2025 , 17-Feb-2026 , 1	5-Jun-2026 , 14-Oct-	2026	
	Synopsis	The purpose of the NCI Pathway to Indeper increase and maintain a strong cohort of n designed for postdoctoral fellows with rest mentored research training beyond their of these fellows from their mentored, postdo positions. The program will provide indeper competitive, independent research careers cancer data sciences are especially encours (NOFO) is designed specifically for candida clinical trial feasibility study, or an ancillary experience in a clinical trial led by a mento investigator, should apply to the companio	ew and talented, NCI-supporte earch and/or clinical doctoral d loctoral degrees. The objective endent NCI research support du s. Researchers in the scientific a aged to work with their institut tes proposing research that do y clinical trial. Under this NOFO or or co-mentor. Those proposing	ed, independent inve legrees who do not of this award is to f dependent tenure-tr uring this transition f areas of cancer cont tions to apply. This N es not involve leadin candidates are perr ng a clinical trial or a	estigators. This pro require an extend acilitate a timely t rack (or equivalent to help awardees trol, cancer preven Notice of Funding on ng an independent mitted to propose	ogram is ed period of ransition of t) faculty to launch tion and Opportunity t clinical trial, a a research

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
109910 Systematic Testing of Radionuclic Clinical Trial Not Allowed)	les in Preclinical Experiments (STRIPE) (R21	National Cancer Institute/NIH/DHHS	PAR-22- 140	6-Oct-2024	275,000 USD
Contact Name Contact Telephone	Michael Graham Espey, Ph.D. 240-276-7619				
Contact Emai Sponsor Website	I <u>SP@nih.gov</u>				
Program URL	Link to program URL 16-Oct-2024 , 16-Feb-2025				
	The purpose of this Funding Opportunity A cancer biology methods and model system therapeutics (e.g., radiopharmaceutical th	ns to study effects of different t	ypes of radiation	used in radionuclide	-based
110931 Notice of Special Interest (NOSI): Cannabinoid Action in Cancer	Basic Mechanisms of Cannabis and	National Cancer Institute/NIH/DHHS	NOT- CA-22- 07 085	7-Sep-2024	Not Specified
	Ron Johnson, Ph.D.				
Contact Telephone					
Contact Emai	rjohnso2@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 05-Oct-2024 , 2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 16 05-Oct-2026 , 12-Oct-2026 , 16-Oct-2026 ,	n-2025 , 16-Jun-2025 , 07-Sep-2 -Feb-2026 , 07-May-2026 , 05-J	025 , 05-Oct-2025 un-2026 , 12-Jun-	5 , 12-Oct-2025 , 16- 2026 , 16-Jun-2026 ,	Oct-2025 , 07- 07-Sep-2026 ,
Synopsis	The purpose of this Notice of Special Inter- cannabis and cannabinoids affect cancer b cancer symptoms.			-	•
106319 Utilizing the PLCO Biospecimens I and Early Detection Research (UC	Resource to Bridge Gaps in Cancer Etiology 01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21- 330	1-Oct-2024	Not Specified



SPIN ID Prog	gram Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Claire Zhu, Ph.D.				
	Contact Telephone	zhucla@mail.nih.gov				
	Sponsor Website					
	·	Link to program URL				
	Deadline Dates (ALL)					
		Trial. The PLCO Biorepository offers high-or screened arm participants, and a onetime	collection of buccal cells from	both the screened a	nd the control arn	
	Synopsis	Available data associated with the biospec clinical data. This FOA supports a wide ran analyses of cancer risk, as well as discover involve use of PLCO biospecimens and ma characteristics of the PLCO biospecimens. Alzheimer's, depression, hip fracture, oste do not involve the use of PLCO biospecime	nge of cancer research includin ry and validation of early dete ny include other resources; ad Research on non-cancer outc eoporosis and rheumatoid art	ng, but not limited to, ction biomarkers. The ditionally, it should als omes, especially thos nritis) may also be sup	biochemical and p proposed researces so take advantage e related to aging	genetic ch project mu of the uniqu (e.g.,
		clinical data. This FOA supports a wide ran analyses of cancer risk, as well as discover involve use of PLCO biospecimens and ma characteristics of the PLCO biospecimens. Alzheimer's, depression, hip fracture, oste do not involve the use of PLCO biospecime Research on the Etiology, Early Detection,	nge of cancer research includin ry and validation of early deten ny include other resources; ad Research on non-cancer out coporosis and rheumatoid art ens will not be supported und	ng, but not limited to, ction biomarkers. The ditionally, it should als omes, especially thos nritis) may also be sup er this FOA. NOT-	biochemical and p proposed researces so take advantage e related to aging	genetic ch project mu of the uniqu (e.g.,
	e of Special Interest (NOSI): ning and Prevention of Early	clinical data. This FOA supports a wide ran analyses of cancer risk, as well as discover involve use of PLCO biospecimens and ma characteristics of the PLCO biospecimens. Alzheimer's, depression, hip fracture, oste do not involve the use of PLCO biospecime Research on the Etiology, Early Detection,	nge of cancer research includin ry and validation of early deter ny include other resources; add Research on non-cancer outco eoporosis and rheumatoid arth ens will not be supported und National Cancer	ng, but not limited to, ction biomarkers. The ditionally, it should als omes, especially thos nritis) may also be sup er this FOA. NOT- CA-23- 07-5	biochemical and g proposed researce so take advantage related to aging oported. Research	genetic ch project mu of the uniqu (e.g., projects that Not
	e of Special Interest (NOSI): ning and Prevention of Early	clinical data. This FOA supports a wide ran analyses of cancer risk, as well as discover involve use of PLCO biospecimens and ma characteristics of the PLCO biospecimens. Alzheimer's, depression, hip fracture, oste do not involve the use of PLCO biospecime Research on the Etiology, Early Detection, (-Onset Colorectal Cancer Gary Della'Zanna	nge of cancer research includin ry and validation of early deter ny include other resources; add Research on non-cancer outco eoporosis and rheumatoid arth ens will not be supported und National Cancer	ng, but not limited to, ction biomarkers. The ditionally, it should als omes, especially thos nritis) may also be sup er this FOA. NOT- CA-23- 07-5	biochemical and g proposed researce so take advantage related to aging oported. Research	genetic ch project mu of the uniqu (e.g., projects tha Not
	e of Special Interest (NOSI): ning and Prevention of Early Contact Name Contact Telephone	clinical data. This FOA supports a wide ran analyses of cancer risk, as well as discover involve use of PLCO biospecimens and ma characteristics of the PLCO biospecimens. Alzheimer's, depression, hip fracture, oste do not involve the use of PLCO biospecime Research on the Etiology, Early Detection, (-Onset Colorectal Cancer Gary Della'Zanna	nge of cancer research includin ry and validation of early deter ny include other resources; add Research on non-cancer outco eoporosis and rheumatoid arth ens will not be supported und National Cancer	ng, but not limited to, ction biomarkers. The ditionally, it should als omes, especially thos nritis) may also be sup er this FOA. NOT- CA-23- 07-5	biochemical and g proposed researce so take advantage related to aging oported. Research	genetic ch project mu of the uniqu (e.g., projects tha Not
	e of Special Interest (NOSI): ning and Prevention of Early Contact Name Contact Telephone	clinical data. This FOA supports a wide ran analyses of cancer risk, as well as discover involve use of PLCO biospecimens and ma characteristics of the PLCO biospecimens. Alzheimer's, depression, hip fracture, oste do not involve the use of PLCO biospecime Research on the Etiology, Early Detection, <i>r</i> -Onset Colorectal Cancer Gary Della'Zanna 240-276-7042 <u>Gary.DellaZanna@nih.gov</u>	nge of cancer research includin ry and validation of early deter ny include other resources; add Research on non-cancer outco eoporosis and rheumatoid arth ens will not be supported und National Cancer	ng, but not limited to, ction biomarkers. The ditionally, it should als omes, especially thos nritis) may also be sup er this FOA. NOT- CA-23- 07-5	biochemical and g proposed researce so take advantage related to aging oported. Research	genetic ch project mu of the uniqu (e.g., projects tha Not
	<u>e of Special Interest (NOSI):</u> ning and Prevention of Early Contact Name Contact Telephone Contact Emai Sponsor Website	clinical data. This FOA supports a wide ran analyses of cancer risk, as well as discover involve use of PLCO biospecimens and ma characteristics of the PLCO biospecimens. Alzheimer's, depression, hip fracture, oste do not involve the use of PLCO biospecime Research on the Etiology, Early Detection, <i>r</i> -Onset Colorectal Cancer Gary Della'Zanna 240-276-7042 <u>Gary.DellaZanna@nih.gov</u>	nge of cancer research includin ry and validation of early deter ny include other resources; add Research on non-cancer outco eoporosis and rheumatoid arth ens will not be supported und National Cancer	ng, but not limited to, ction biomarkers. The ditionally, it should als omes, especially thos nritis) may also be sup er this FOA. NOT- CA-23- 07-5	biochemical and g proposed researce so take advantage related to aging oported. Research	genetic ch project mi of the uniqu (e.g., projects tha Not
	<u>e of Special Interest (NOSI):</u> ning and Prevention of Early Contact Name Contact Telephone Contact Emai Sponsor Website	 clinical data. This FOA supports a wide ran analyses of cancer risk, as well as discover involve use of PLCO biospecimens and ma characteristics of the PLCO biospecimens. Alzheimer's, depression, hip fracture, oste do not involve the use of PLCO biospecime Research on the Etiology, Early Detection, r-Onset Colorectal Cancer Gary Della'Zanna 240-276-7042 Gary.DellaZanna@nih.gov Link to program URL 	nge of cancer research includin ry and validation of early deten ny include other resources; add Research on non-cancer outco eoporosis and rheumatoid art ens will not be supported und National Cancer Institute/NIH/DHHS	ng, but not limited to, ction biomarkers. The ditionally, it should als omes, especially thos nritis) may also be sup er this FOA. NOT- CA-23- 07-5 018	biochemical and g proposed research so take advantage e related to aging oported. Research Sep-2024	genetic ch project me of the uniqu (e.g., projects tha Not Specifie

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date I	Funding Amount
	mitigating risk factors, identifying biomark early-onset colorectal cancer (EOCRC), def	-	-	s, and preventive inter	ventions for
Notice of Special Interest (NOSI):115286Research Within the Mission of the National Cancer Institute	Career Development Opportunities for the Division of Cancer Prevention at the	National Cancer Institute/NIH/DHHS	NOT- CA-23- 0 035	7-Sep-2024	Not Specified
Contact Telephone Contact Email Sponsor Website Program URL	<u>Jessica.Faupel-Badger@nih.gov</u> <u>Link to program URL</u> 07-Sep-2024 , 12-Oct-2024 This NOSI from the NCI expresses continue			rd applications from e	arly career
	scientists conducting research within the r f Innovative Informatics Methods and nd Management (R21 Clinical Trial	National Cancer Institute/NIH/DHHS	RFA-CA- 1	6-Oct-2024 Optional][LOI/Pre-App	275,000 USD
Contact Name Contact Telephone	Juli Klemm, Ph.D. 202-853-7889				

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
	to accelerate or enhance research. To be s method or algorithm is novel and how it w generation and/or data analysis will not be	ill benefit the cancer research	field. Projects wit	h a significant level of	
123041 RFA-CA-24-019 Sustained Support	ort for Informatics Technologies for Cancer Clinical Trial Optional)	National Cancer Institute/NIH/DHHS		6-Oct-2024 Optional][LOI/Pre-App	Not Specified
Contact Telephone	juli.klemm@nih.gov				
_	Link to program URL 16-Oct-2024 [Optional][LOI/Pre-App], 15-N	Nov-2024			
Synopsis	The purpose of this Notice of Funding Opp continued development and sustainment of management, analysis, and dissemination biology, cancer treatment and diagnosis, e epidemiology, and/or cancer health dispar (ITCR) Program, this NOFO focuses on sustain widely-adopted informatics tools and reson generate these tools and resources that an research-driven informatics technology act order to be successful, the proposed sustain be maintained and how it has benefited an assessing and maximizing the value of the between the resource and the targeted resources and the targeted resource and the targeted resources and the targeted resources and the targeted resources and the targeted resource and the targeted resources and the targeted resources and targeted resources	of high value informatics resea of data and knowledge across arly cancer detection, risk asse ities. As a component of the N aining operations and improvin urces. This is in contrast to ear re supported by companion ITC ross the development lifecycle inment plan must provide clea and will continue to benefit the o resource to researchers and su	rch resources to i the cancer resear essment and prev CI's Informatics T ng the user exper ly-stage and adva R NOFOs. The ce to address priori r justification for cancer research f ipporting collabo	mprove the acquisition ch continuum includin ention, cancer control echnology for Cancer F ience and availability of nced development eff ntral mission of ITCR is ty needs in cancer rese why the research reso ield. In addition, mecha	n, g cancer and cesearch f existing, orts to to promote arch. In urce should anisms for
123034 RFA-CA-24-018 Advanced Devel Cancer Research and Managemen	lopment of Informatics Technologies for nt (U24 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS		6-Oct-2024 Optional][LOI/Pre-App	3,000,000 USD
Contact Telephone	Juli Klemm, Ph.D. 202-853-7889 juli.klemm@nih.gov				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Sponsor Website					
-	Link to program URL				
Deadline Dates (ALL)	16-Oct-2024 [Optional][LOI/Pre-App], 15-N			<i></i>	
Synopsis	The purpose of this Notice of Funding Opp for advanced development and enhancem visualization, and interpretation of data ac diagnosis, early cancer detection, risk asse disparities. As a component of the NCI's In on emerging informatics technology, defin demonstrated potential to have a significa enhancement, and has not been widely ad must have a clear rationale on why the pro addition, mechanisms to solicit feedback for included. Potential applicants who are inter consult the companion NOFOs listed above	ent of emerging informatics te ross the cancer research contin ssment and prevention, cancer formatics Technology for Cancer ed as one that has passed the nt and broader impact, has cor opted in the cancer research fi posed technology is needed a rom users and collaborators th erested in early-stage developm	chnologies to impro- nuum including canor control and epiden er Research (ITCR) F initial prototyping a mpelling reasons for eld. To be successfund how it will benef roughout the develo	we the acquisition, a cer biology, cancer t niology, and cancer program, this NOFO nd pilot developme further improveme il, proposed develop it the cancer resear opment process mu	analysis, creatment and health focuses nt stage, has ent and oment plans ch field. In st be
123030 RFA-CA-24-017 Early-Stage Dev Cancer Research and Management	elopment of Informatics Technologies for nt (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA- 16- 24-017 [Op	Oct-2024 tional][LOI/Pre-App	900,000 JUSD
Contact Name	Juli Klemm, Ph.D.				
Contact Telephone	202-853-7889				
Contact Email	juli.klemm@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Oct-2024 [Optional][LOI/Pre-App], 15-N	lov-2024			
Synopsis	The purpose of this Notice of Funding Opp development of enabling informatics techn data and knowledge across the cancer rese cancer detection, risk assessment and prev component of the NCI's Informatics Techno development from prototyping to hardenin NOFO as initial tool development or the sig	nologies to improve the acquis earch continuum including can vention, cancer control and epi ology for Cancer Research (ITC ng and adaptation. Early-stage	ition, management, cer biology, cancer t demiology, and/or R) Program, this NO development is def	analysis, and disser reatment and diagr cancer health dispar FO focuses on early ined for the purpose	nination of nosis, early rities. As a -stage e of this

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	ITCR is to promote research-driven inform cancer research. In order to be successful, technology is needed and how it will bene and collaborators throughout the develop	proposed development plans i fit the cancer research field. In	must have a clear ra addition, mechanis	tionale on why th	e proposed
108323 Notice of Special Interest (NOSI): and Health Outcomes Among Chi	Disparities Affecting Healthcare Utilization Idhood Cancer Survivors	National Cancer Institute/NIH/DHHS	NOT- CA-22- 25- 029	Sep-2024	Not Specified
Contact Name	Veronica Chollette, RN, MS				
Contact Telephone	240-276-6969				
Contact Email	<u>cholletv@mail.nih.gov</u>				
Sponsor Website	2				
-	Link to program URL				
Deadline Dates (ALL)	25-Sep-2024 , 08-Oct-2024				
Synopsis	The purpose of this Notice is to highlight the Population Sciences (DCCPS) in receiving a to disparities in survivorship care, healthcat focus on factors that extend beyond the in intervention that involves healthcare team to disparities in health outcomes and resu	pplications to understand and are utilization, and health outco adividual (e.g., survivor, caregiv as, healthcare system, commur	address the full spe omes among childho rer, clinician) to inclu nity, payer, and/or p	ctrum of factors th ood cancer survive ude an examinatio olicy-level factors	nat contribute ors. Studies that n or
107760 Notice of Special Interest (NOSI): and Coordination During Cancer I	Research on Interprofessional Teamwork Diagnosis and Treatment	National Cancer Institute/NIH/DHHS	NOT- CA-22- 07- 014	Sep-2024	Not Specified
Contact Name	Sallie J. Weaver, PhD, MHS				
Contact Telephone	240-276-6254				
Contact Email	sallie.weaver@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 25-Sep-2024 , 05-Oct-2024 ,	08-Oct-2024			

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis appli	Notice of Special Interest (NOSI) highli lications focused on understanding and treatment.				
107222 Modulating Human Microbiome Functi Against Cancer (R21 Clinical Trial Not A		National Cancer Institute/NIH/DHHS	PAR-22- 062 16-0	Dct-2024	275,000 USD
Contact Name Philli	lip J. Daschner, M.Sc.				
Contact Telephone 240-	-276-6227				
Contact Email PD93	<u>3u@nih.gov</u>				
Sponsor Website					
Program URL <u>Link</u>	to program URL				
Deadline Dates (ALL) 16-0	Oct-2024				
Synopsis micro sport	ch the human microbiome inhibits or e ets for cancer prevention strategies. A robes (or consortia) or their metabolite radic tumor formation. Concentration, ctiveness and thus those parameters sl	pplications should be focused or es target immune responses that timing, and duration of admini	on delineating how h at enhance or preve stered beneficial mi	nost interactions v nt inflammation-a	vith specific
	•				
Innovative Approaches to Studying Can	ncer Communication in the New	National Cancer	PAR-22-	Dct-2024	heir 275,000
111848 Innovative Approaches to Studying Can Information Ecosystem (R21 Clinical Tri	ncer Communication in the New ial Optional)	National Cancer Institute/NIH/DHHS		Oct-2024	heir
11848 Innovative Approaches to Studying Can Information Ecosystem (R21 Clinical Tri Contact Name Kelly	ncer Communication in the New ial Optional) y D. Blake, ScD		PAR-22-	Oct-2024	heir 275,000
11848 Innovative Approaches to Studying Can Information Ecosystem (R21 Clinical Tri Contact Name Kelly Contact Telephone 240-	ncer Communication in the New ial Optional) y D. Blake, ScD -281-5934		PAR-22-	Oct-2024	heir 275,000
11848 Innovative Approaches to Studying Can Information Ecosystem (R21 Clinical Tri Contact Name Kelly Contact Telephone 240- Contact Email kelly	ncer Communication in the New ial Optional) y D. Blake, ScD -281-5934		PAR-22-	Oct-2024	heir 275,000
11848 Innovative Approaches to Studying Can Information Ecosystem (R21 Clinical Tri Contact Name Contact Telephone Contact Email Sponsor Website	ncer Communication in the New ial Optional) y D. Blake, ScD -281-5934 y.blake@nih.gov		PAR-22-	Dct-2024	heir 275,000
Innovative Approaches to Studying Can Information Ecosystem (R21 Clinical Tri Contact Name Kelly Contact Telephone 240- Contact Email kelly Sponsor Website Program URL	ncer Communication in the New ial Optional) y D. Blake, ScD -281-5934 y.blake@nih.gov		PAR-22-	Dct-2024	heir 275,000

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	communication pilot interventions using i cancer communication models emphasizin communication science approaches to the prevention and control. Applications shou	ng bidirectional influence betwe e investigation of behavioral tar	een levels. For such gets and health out	projects, applican comes related to c	ts should apply cancer
111860 Precision Approaches in Radiation Clinical Trial Optional)	Synthetic Combinations (PAIRS, R21	National Cancer Institute/NIH/DHHS	PAR-22- 199	Oct-2024	275,000 USD
Contact Name	Michael Graham Espey, Ph.D.				
Contact Telephone	240-276-5609				
Contact Emai	<u>SP@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025				
Synopsis	Through this Funding Opportunity Annour that seek to investigate actionable synthe therapy. The goal of the Precision Approa synthetic combination strategies and facil effective anticancer treatments.	tic vulnerabilities that can be co ches in Radiation Synthetic Con	onditionally paired v nbinations (PAIRS) p	vith tumor respon rogram is to deve	ses to radiation op radiation-
115117 Notice of Special Interest (NOSI):	Adaptive Biomaterials for Cancer Biology	National Cancer Institute/NIH/DHHS	NOT- CA-23- 07- 030	Sep-2024	Not Specified
Contact Name	Eric M. Johnson Chavarria, Ph.D.				
Contact Telephone	240-276-7416				
Contact Emai	eric.johnsonchavarria@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 2025	, 16-Oct-2024 , 07-Jan-2025 , 0	5-Feb-2025 , 12-Feb	-2025 , 16-Feb-20	25 , 07-May-
Synonsis	The purpose of this Notice of Special Inter	est (NOSI) is to promote resear	ch focused on the d	levelopment, adag	tation, or

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		integration of innovative biomaterials for o insights into basic cancer research.	cancer biology. The application	s of these new mate	erials are expected	l to enable new
11/448	Impacts of climate change across Trial Optional)	the cancer control continuum (R21 Clinical	National Cancer Institute/NIH/DHHS	PAR-23- 152 16-	Oct-2024	275,000 USD
	Contact Name	Curt DellaValle, Ph.D., MPH				
	Contact Telephone	240-276-7225				
	Contact Email	curt.dellavalle@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 ,	16-Oct-2025 , 16-Feb-2026			
	Synopsis	This Notice of Funding Opportunity (NOFC the effects of climate change across the ca survivorship, and ways to prevent or mitig knowledge of the impact of climate change	ncer control continuum, from ate negative health effects. Th	cancer etiology and is includes, but is no	l cancer risks throu ot limited to, studie	igh es to improve
117714	Notice of Special Interest (NOSI):	RNA Modifications in Cancer Biology	National Cancer Institute/NIH/DHHS	NOT- CA-23- 07- 060	Sep-2024	Not Specified
	Contact Name	Stefan Maas, Ph.D.				
	Contact Telephone	240-276-6230				
	Contact Email	<u>stefan.maas@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 05-Oct-2024 , 2025 , 07-May-2025 , 05-Jun-2025 , 12-Jur Jan-2026				
	Synopsis	Through this Notice of Scientific Interest (I RNA modifications in the area of cancer bi substantial impact on gene expression and	ology. Despite the recognition	that RNA modificati	ions and editing e>	ert a

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	modifications and their de-regulation as de crosstalk between different types of RNA r the modification code are needed to revea cancer phenotype.	modification, and the elucidation	on of the molecular	players that read	and interpret
106228 NCI Mentored Research Scientist (K01 Independent Clinical Trial No	Development Award to Promote Diversity	National Cancer Institute/NIH/DHHS	PAR-21- 295	Oct-2024	Not Specified
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Mulualem E. Tilahun, D.V.M., Ph.D 240-276-7360 <u>mulualem.tilahun@nih.gov</u> <u>Link to program URL</u>	(FOA) is a continuation of the N nce the diversity in the NCI-fun nds, including groups that have ical sciences. This FOA provides career development under the ing research that does not invo	ICI Mentored Resea ded cancer researcl been shown to be i salary and researcl guidance of an exp live leading an inde	h workforce by sup nationally underre n support for a sus perienced mentor. pendent clinical tri	lopment oporting presented in tained period This FOA is al, a clinical
Cancer Prevention and Control Cli	in a clinical trial led by a mentor or co-mer investigator, should apply to the companic inical Trials Planning Grant Program (U34	ntor. Applicants proposing a cli	nical trial or a separ	ate ancillary clinica	•
112021 Clinical Trials Optional)		Institute/NIH/DHHS	174 07-	Sep-2024	Specified
Contact Telephone Contact Email Sponsor Website Program URL	heckmanbm@mail.nih.gov	25-Feb-2025 , 07-May-2025 , 2	25-Jun-2025		

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	Through this Funding Opportunity Announ clinical trials across the cancer prevention health behaviors, screening, early detectio care, and the long-term outcomes of cancer rationale for conducting a clinical trial, inve- challenges, intervention, outcome/ endpoin protocol completely. These information gas the need for additional time and expenses trial designs, which minimize infrastructure intervention, at-risk group, symptom or ve- include a pilot/feasibility clinical trial if neo	and control spectrum aimed at on, healthcare delivery, manage er survivors. Although the scier estigators often lack critical info ints, data/statistical challenges ups can result in multiple protoc that may prevent study compl e and reduce costs may need to mue. Preparatory studies may f	t improving preventi ement of treatment- ntific literature or pro- ormation about the or operational risks col changes before a etion. Further, the s o be tested in the co fill information gaps	on/ interception, or related symptoms eliminary data mar study population, necessary to final and after trial start uitability and feas ntext of a particul	cancer-related , supportive y provide the accrual ize the trial -up, leading to bility of new ar
112019 Cancer Prevention and Control Cli Clinical Trials Optional)	nical Trials Planning Grant Program (R34	National Cancer Institute/NIH/DHHS	PAR-22- 173	Sep-2024	Not Specified
Contact Name	Brandy Heckman-Stoddard, Ph.D., M.P.H.				
Contact Telephone	240-276-7048				
Contact Email	heckmanbm@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025 ,	25-Feb-2025 , 07-May-2025 , 2	25-Jun-2025		
Synopsis	Through this Funding Opportunity Announ clinical trials across the cancer prevention health behaviors, screening, early detectio care, and the long-term outcomes of cance rationale for conducting a clinical trial, inve challenges, intervention, outcome/ endpoin protocol completely. These information gas the need for additional time and expenses trial designs, which minimize infrastructure intervention, at-risk group, symptom or ve include a pilot/feasibility clinical trial if neo	and control spectrum aimed at on, healthcare delivery, manage er survivors. Although the scien estigators often lack critical info ints, data/statistical challenges ups can result in multiple proto- that may prevent study compl e and reduce costs may need to nue. Preparatory studies may f	t improving preventi ement of treatment- ntific literature or pro- ormation about the or operational risks col changes before a etion. Further, the s o be tested in the co fill information gaps	on/ interception, or related symptoms eliminary data mar study population, necessary to final and after trial start uitability and feas ntext of a particul	cancer-related , supportive y provide the accrual ize the trial -up, leading to ibility of new ar

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
103024 Academic-Industrial Partnerships Diagnosis and Treatment (R01 - C	for Translation of Technologies for Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21- 206	Oct-2024	2,495,000 USD
Contact Name	Miguel Ossandon MS				
Contact Telephone	240-276-5714				
Contact Emai	l <u>ossandom@mail.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)) 05-Oct-2024 , 05-Nov-2024				
Synopsis	engineering developments into methods research to assess risk, detect, prevent, d meet evolving requirements for technolo clinical, clinical and non-clinical settings, d institutes. This FOA specifies a partnershi engaging the strengths of academic, indu inter-disciplinary, multi-institutional resea and translate a solution to their chosen p suitable for end users. Each partnership s partnership should plan to transition a te to a status useful in the chosen setting. For translate technologies that address probl of disease status. This FOA defines "innow clinical trials that test functionality or vali clinical trials that lack translation as the p cancer research are not sought by and wi commercial production or basic research	liagnose, treat, and/or manage gies and methods relevant to the domestic or foreign, for condition p structure that is expected to strial, and other investigators. arch team to work in strategic a roblem. They are expected to p hould include at least one acade chnology, method, assay, device unding may be requested to en ems in biology, pathology, risk vation" as likelihood to deliver a date performance in the chose primary motivation. Application Il not be supported through thi	disease. The rationale he advance of researc ons and diseases with help bridge gaps in kr The partners on each alliance to implement olan, design, and valid lemic and one industr e, and/or system from hance, adapt, optimiz assessment, diagnosis a new capability to en n setting. This FOA is s that propose phase	e is to deliver new ch and delivery of nin the missions of nowledge and exp application shou a coherent strate late that the solutrial organization. m a demonstration ze, validate, and of s, treatment, and d users. This FOA not intended to so III clinical trials in	w capabilities to f care in pre- of participating berience by ld establish an egy to develop tion will be Each on of possibility otherwise //or monitoring will support support straight n any area of
112442 NCI Clinical and Translational Exp Clinical Trial Optional)	loratory/Developmental Studies (R21	National Cancer Institute/NIH/DHHS	PAR-22- 216 10-C	Oct-2024	275,000 USD
Contact Name	e William C. Timmer, Ph.D				

Contact Telephone 240-276-6130



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Sponsor Website Program URL	Link to program URL 10-Oct-2024, 01-Nov-2024, 13-Feb-2025 This Funding Opportunity Announcement studies, directly related to advancements management, or reduction of cancer dispa- following: new molecular agents or biolog treatment-related toxicity; cancer screenin approaches; predictive and prognostic bio vitro tumor models (including genetically e lines); and strategies to address therapeut new treatment strategies may involve rep on established mechanisms of action. Com	(FOA) supports preclinical and in cancer treatment, diagnosis, arities. This includes (but is not ics for cancer treatment; mana ng or diagnostic tools, such as i markers for patient selection o engineered mouse models, pat tic outcome disparities among u urposed agents or novel combin parative correlative studies in ore mechanisms underlying the pomparative oncology studies in a swell. This FOA does not sup ys, molecular mechanisms, or n tudies, or studies of behavioral reviewed (see below for a mor ism is intended to encourage en- ptional stages of these projects. T or to the development of nove	early phase clinical prevention, compa limited to) developr gement strategies for maging techniques; r stratification; clinic ient-derived xenogra underserved popula nations of intervent cancer patients with ir differential resport dogs investigating so port research that for hechanisms of meta interventions. Thes re detailed description xploratory and develop- hese studies may in l techniques, agents	rative oncology, sy ment and testing of or cancer-related a cancer preventive cally relevant in vi aft models, organi- tions. In addition f tions (including rac n age, gender, raci strategies for treat ocuses on basic ca stasis), late-stage e applications will on of studies that lopmental research wolve considerabl	ymptom of the symptoms or agents or vo or in oids, and cell to novel agents, diation), based al/ethnic, or toxicity) and ment and incer biology clinical trials, be deemed are not th projects by e risk but may
Notice of Special Interest (NOSI):113746Study Designs for Liquid Biopsy A Cancers	Utilization of Cohorts and Prospective ssay Validation for Early Detection of	National Cancer Institute/NIH/DHHS	NOT- CA-23- 05-: 004	Sep-2024	Not Specified
Contact Telephone	matthew.young@nih.gov				

Icahn School of Medicine at Mount Sinai

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 01-Oct-2024 2025 , 13-Feb-2025 , 01-Mar-2025 , 05-A				25 , 05-Feb-
Synopsis	The purpose of this Notice of Special Interbiomarker technology developers with as and biorepository researchers. Proposals and validation utilizing statistically power populations with a sound study design and	ssays for early cancer detection that facilitate early cancer bior ed retrospective cohorts and/c	, and population-bas narker assay develop	ed researchers, in oment, verification	cluding cohor n, qualification
13232 Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22- 242	Sep-2024	Not Specified
Contact Name	Rao Divi, Ph.D.				
Contact Telephone	240-276-6913				
Contact Email	<u>divir@mail.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 2025 , 07-Sep-2025	4 , 07-Jan-2025 , 05-Feb-2025 , (05-Mar-2025 , 07-Ma	ay-2025 , 05-Jun-2	025 , 05-Jul-
Synopsis	The purpose of this funding opportunity that: 1) apply a multidisciplinary bioengir optimize, validate, translate or accelerate and address specific research or clinical p enhancing our understanding of health a design-directed, developmental, discover applying an integrative approach to incre- science.	neering approach to the solution e adoption of promising tools, n problem in basic, translational, a nd disease, and/or c) improve p ry-driven, or hypothesis-driven	n of a biomedical pro nethods and technique and/or clinical science practice of medicine. research, and this FC	blem; and 2) deve ues: a) that fulfill a e and practice, b) Applications may A is appropriate f	elop, integrate an unmet nee capable of propose or small team
113233 Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22- 243	Sep-2024	Not Specified
Contact Name Contact Telephone	Rao Divi, Ph.D. 240-276-6913				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Email	divir@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 2025 , 07-Sep-2025	07-Jan-2025 , 05-Feb-2025 , 0	5-Mar-2025 , 07-Ma	y-2025 , 05-Jun-2	025 <i>,</i> 05-Jul-
Synopsis	The purpose of this funding opportunity and that: 1) apply a multidisciplinary bioengine validate, translate or otherwise accelerate or clinical problem in basic, translational, o developmental, discovery-driven, or hypot approach to increase our understanding of support clinical trials that test functionality conventional clinical trials that lack translational any area of research are not sought by and commercial production.	ering approach to the solution the adoption of promising too r clinical science and practice. hesis-driven research and is ap and solve problems in biologic or validate performance in the tion as the primary motivation	of a biomedical pro ls, methods, and tec An application may propriate for small t cal, clinical, or transl e chosen setting. Th . Applications that p	blem; and 2) inter hniques for a spe propose design-d teams applying ar ational science. is FOA is not inter ropose phase III c	grate, optimize cific research irected, integrative This FOA will inded to suppor linical trials in
105645 Integration of Imaging and Fluid-E (R01 Clinical Trial Optional)	Based Tumor Monitoring in Cancer Therapy	National Cancer Institute/NIH/DHHS	PAR-21- 290	Sep-2024	499,999 USD
Contact Name	Shane Woodward				
Contact Telephone	240-276-6624				
Contact Email	woodwars@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025				
Synopsis	National Cancer Institute (NCI) invites app monitoring (liquid biopsy) assays during ca characterization of therapy response and/o mechanism.	ncer therapy in patients to det	ermine the optimal	use of those mod	alities in the
121826 Revision Applications for Validation NIH-Supported Research Grants (on of Biomarker Assays Developed Through R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-24- 047 08-0	Dct-2024	450,000 USD

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Name Sumana Dey, Ph.D. Contact Telephone 240-276-5748 Contact Email <u>sumana.dey@nih.gov</u> Sponsor Website				
Program URL <u>Link to program URL</u> Deadline Dates (ALL) 08-Oct-2024 , 14-Feb-2025 , 11-Jul-2025 ,	14-Oct-2025 , 13-Feb-2026 , 10)-Jul-2026 , 13-Oct-	2026	
Through this Notice of Funding Opportuni (formerly called "competing revisions") fre projects that are expected to accelerate to as "assays") to the clinic. Specifically, the and clinical validation of molecular/cellula diagnosis, prognosis, monitoring, and pre- Synopsis control. Applications may support the acq observational cohorts/consortia for the pr this NOFO encourage multidisciplinary int and clinical laboratory staff. Clinical laboratory parts of the application. This NOFO is not clinical trials, but rather the adaption and as investigational assays/tools/devices.	om currently funded NCI R01 re he pace of translation of NCI-su focus of applications submitted ar/imaging markers (referred to diction of response in treatmer juisition of well-annotated spec urpose of clinical validation of t eraction among scientific inves atory scientist(s) and statistical intended to support early-stage	esearch projects. The ported methods/ in response to this as "markers" or "b at, as well as market timens from NCI-su he assay. Research tigators, assay dev experts are highly e development of t	ne applicants should p assays/technologies NOFO should be on biomarkers") for cancers for cancer prevent pported or other clin projects proposed in elopers, clinicians, sta encouraged to compre echnology or the con	propose referred to the adaption or detection on and cal trials or response to tisticians, ise integral duct of
127223 <u>RFA-CA-24-029 RNA Modifications Driving Oncogenesis (RNAMoDO; U01</u> <u>Clinical Trial Not Allowed)</u>	National Cancer Institute/NIH/DHHS	RFA-CA- 05 24-029 [O	-Oct-2024 ptional][LOI/Pre-App	3,250,000 USD
Contact Name Stefan Maas, Ph.D. Contact Telephone Contact Email <u>stefan.maas@nih.gov</u>				
Sponsor Website Program URL <u>Link to program URL</u> Deadline Dates (ALL) 05-Oct-2024 [Optional][LOI/Pre-App], 04-				
Synopsis Through this Notice of Funding Opportuni Modifications Driving Oncogenesis (RNAN	ity (NOFO), the National Cancer 10DO) initiative. This NCI initiat	⁻ Institute (NCI) soli ive aims to promot	cits applications for t e fundamental studie	he RNA s in the

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	emerging area of RNA modifications that u translational reprogramming of cancer cell expression and function and their de-regul to a crucial role for mRNA, tRNA, and rRNA and adaptation to therapy. However, the n dynamic changes in RNA modifications, as RNA molecules during translation, are not composed of up to five U01 grants that wil	s. RNA modifications have been ation has been linked to the ca modifications in translational nolecular mechanisms underlyi well as the interplay between o understood and represent the	n recognized to exe ncer phenotype. In reprogramming dui ng this reshaping o different RNA modif	rt a substantial im particular, recent ring tumor initiatic f the translatome fications within an	pact on gene insights point on, progression, caused by d/or across
123791 NCCIH Natural Product Mid Phase Clinical Trial Required)	e Clinical Trial Cooperative Agreement (U01	National Center for Complementary and Integrativ Health/NIH/DHHS	ve PAR-24- 115 21-	Oct-2024	1,750,000 USD
Contact Name	Sekai Chideya, M.D., MPH				
Contact Telephone	301-827-1916				
Contact Email	<u>sekai.chideya@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	21-Oct-2024 , 13-Nov-2024 , 23-Jun-2025 ,	17-Jul-2025 , 23-Feb-2026 , 17	-Mar-2026 , 20-Oct	-2026 , 13-Nov-20	26
Synopsis	This Funding Opportunity Announcement phase clinical trials of natural products. All data of bioavailability and documentation biological signature (i.e., measure of the m biological signature in the patient populati mechanism of action will this preliminary of mid-phase clinical trial to do the following: future multi-site clinical trial; or determine natural product to inform inclusion/exclusi expected to be hypothesis based, mileston FOA will not support single-site or multi-site for the treatment or prevention of cancer. contact for the area of science for which the	applications submitted under t that the natural product produc echanism of action). Only in ca on of interest or when there is lata requirement be waived. Ap determine the optimal dose on which patient phenotypes will on criteria of a future efficacy s e-driven, and directly related to the efficacy or effectiveness trials Applicants are encouraged to c	this FOA must be succes a replicable and ses when it is not p a fundamental und oplications submitter formulation of a g be responders vers study. Clinical trials o the research prior s, nor will it suppor	apported by suffici I measurable impa ossible/practical to erstanding of the ed to this FOA show iven natural produ- sus non-responder submitted under to rities and mission t trials to test natu- riate NCCIH Scienti	ent preliminary oct on a o measure a product's uld propose a uct for use in a rs to the this FOA are of NCCIH. This ural products fic/Research

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
1 165 //	Enhancing Mechanistic Research (Clinical Trial Optional)	on Precision Probiotic Therapies (R61/R33	National Center for Complementary and Integrativ Health/NIH/DHHS	e PAR-24- 238 01-0	Oct-2024	1,750,000 USD
	Contact Name	Hye-Sook Kim, Ph.D.				
	Contact Telephone	301-827-6910				
	Contact Email	hye-sook.kim@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Oct-2024 , 02-Jun-2025 , 02-Feb-2026 ,	01-Oct-2026 , 02-Jun-2027			
	Synopsis	The purpose of this notice of funding opport the development of effective precision pro- to identify, understand, and develop strate heterogenicity in humans that often cause applications that will characterize person- responders, which may then help enhance provide 1 or 2 years of support to identify gender, diet, age, genetic background, life effects using observational or secondary d support studies to assess the causality of t rigorous mechanistic study designs in anin clinical trials. The combined R61/R33 shou	obiotic interventions using a mil- egies to address barriers in prec- es inconsistent probiotic therape specific features affecting probio e probiotic clinical outcomes. The host biological patterns (e.g., na style, or health history) that are lata analysis studies. The second the factors identified in the R61 nal models or human subjects. T	estone-driven, biph ision probiotic inte sutic responses. Spe otic responses to id e first phase, funde ative microbiome, i correlated with dif phase, funded und phase that impact p this NOFO will not s	hasic award mecha rventions to accou ecifically, this NOF lentify subgroups ed by the R61 mec mmune system, so ferences in probio der the R33 mecha probiotic responsi support efficacy or	anism. It aims unt for the O solicits of probiotic hanism, will ex and/or otic clinical anism, will veness through

Contact Name Hye-Sook Kim, Ph.D.



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Telephone	301-827-6910				
	hye-sook.kim@nih.gov				
Sponsor Website					
	Link to program URL				
-	01-Oct-2024 , 02-Jun-2025 , 02-Feb-2026 ,	. 01-Oct-2026 . 02-Jun-2027			
Synopsis	The purpose of this notice of funding opport the development of effective precision pro- strategies to address barriers in precision in inconsistent responses to probiotic trea causality of person-specific features or pat in order to enhance therapeutic outcomes native microbiome, immune system, sex a correlated with clinical probiotic effects ca must offer rigorously designed mechanisti intended to support projects where poten interventions have been identified, as dem studies to test for causality. This NOFO wil research to identify host biological pattern (R61/R33) PAR-24-238. This Notice of Fund	obiotic interventions. The NOFO probiotic interventions' develop atments. Specifically, this NOFO tterns affecting probiotic respon s. This NOFO will support studies and/or gender, diet, age, genetic an modulate responsiveness to p ic studies using relevant/innovation tial host biological patterns that nonstrated with supportive prel Il not support efficacy or effective as that may affect probiotic head ding Opportunity (NOFO) requir	aims to identify, up oment to account for solicits R33 applican hses and identify su s that assess wheth background, lifest probiotic intervent tive animal models t are correlated with iminary data, which veness clinical trials lth outcomes shoul	inderstand, and dev or human heterogen ations that will assess ubgroups of probiot her host biological p cyle, or health histor ions. Well-suited ap or human subjects. th probiotic usage o h require further mo s. Applicants pursuin Id consider the com	elop nicity resulting the ic responder atterns (e.g. y) that are plications This NOFO r echanistic ng early-stag panion
126608 RFA-AT-24-010 Whole Person R Person RCC) (U24 Clinical Trial No	Research and Coordination Center (Whole at Allowed)	National Center for Complementary and Integrativ Health/NIH/DHHS	ve RFA-AT- 01- 24-010 [Op	Oct-2024 otional][LOI/Pre-App	7,500,00] USD
Contact Name	Elizabeth Ginexi, Ph.D.				
Contact Telephone	301-827-0160				
Contact Email	elizabeth.ginexi@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Oct-2024 [Optional][LOI/Pre-App], 01-I	Nov-2024			
Synopsis	The purpose of this Notice of Funding Opp Research and Coordination Center (Whole	portunity (NOFO) is to solicit app Person RCC) under the NIH Wh	blications for the es nole Person Initiativ	stablishment of the ve. This center will b	Whole Pers e integral in

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		coordinating the initial and future research seamlessly integrate current and emerging multi-scale human knowledge network. Th highest priority. The first objective is to bui physiological organ system functions and ic function. It is expected that the conceptua intelligence/machine learning (AI/ML)], bui knowledge of healthy human physiology, li test existing datasets for the conceptual m Whole Person RCC's role will additionally in infrastructure for the entire NIH Whole Per	g biomedical knowledge about his NOFO aims to accomplish tw ild a healthy human whole per- dentify Common Data Element I map will not be built from dat t will be mapped by a team of inking all physiological systems hap and CDEs and build at least nclude fostering multidisciplina	human health, there to major objectives v son physiome conce s (CDEs) appropriate ta using computation content experts usin into a whole. The se one prototype in sili	by forming a com with the first object ptual map to repr for each major p nal methods [e.g., g existing establis econd objective is ico model of who	prehensive, ctive of the resent all hysiological artificial shed to select and le person. The
123153	Interventions Delivered Remotely	s of Complementary and Integrative or via mHealth (R01 Clinical Trial	National Center for Complementary and Integrati	ve PAR-24- 086 21-0	Oct-2024	Not Specified
	<u>Required)</u>		Health/NIH/DHHS			
		Beda Jean-Francois, Ph.D.				
	Contact Telephone					
		<u>beda.jean-francois@nih.govr01</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	21-Oct-2024 , 13-Nov-2024 , 20-Feb-2025 , 2026 , 17-Mar-2026 , 22-Jun-2026 , 13-Jul-			2025 , 17-Nov-20	25 , 20-Feb-
	Synopsis	This Notice of Funding Opportunity (NOFO conducted clinical trials to assess the effica NCCIH- designated areas of high research p remotely delivered and conducted fully po participants and may utilize mHealth tools approach and provide preliminary data on intervention has promise of clinical benefit Scientific/Research contact for the area of to this NOFO. This NOFO requires a Plan f scientific and technical peer review evaluation	acy or effectiveness of complete priority. Applications submitted wered clinical trial with no in-p or technologies. Applicants mu the feasibility and safety of the t. Applicants are encouraged science for which they are plan for Enhancing Diverse Perspect	nentary and integrat d under this NOFO are person contact betwo ust provide justificat e approach, along wi to contact the appro- nning to develop an ives (PEDP), which w	tive health interve re expected to pro- een research staff ion for the remote th evidence that to priate NCCIH application prior to vill be assessed as	entions in opose a and study ely delivered the to submitting part of the

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		be withdrawn. Applicants are strongly enc guidance material.	couraged to read the NOFO instr	ructions carefully ar	nd view the availa	ble PEDP
1/3////	NCCIH Multi-Site Feasibility Clinic (R01 Clinical Trial Required)	al Trials of Mind and Body Interventions	National Center for Complementary and Integrativ Health/NIH/DHHS	ve PAR-24- 083 21-	Oct-2024	Not Specified
	Contact Name	Pete Murray, Ph.D.				
	Contact Telephone	301-496-4054				
	Contact Email	peter.murray@nih.gov				
	Sponsor Website	2				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	21-Oct-2024 , 13-Nov-2024 , 20-Feb-2025 2026 , 22-Jun-2026 , 14-Jul-2026 , 20-Oct-		-Oct-2025 , 18-Nov	-2025 , 20-Feb-202	26 , 17-Mar-
	Synopsis	This notice of funding opportunity (NOFO) integrative health approaches with physic interventions) in NCCIH-designated areas propose a multisite feasibility clinical trial and conduct of a subsequent clinical effica- trial within NCCIH's mission. NCCIH expects so doing demonstrate that the proposed (powered, full-scale clinical trial. Under this including, but not limited to the following: demonstrating feasibility of recruitment, a adherence to the intervention, as well as r the feasibility of protocolized multimodal preparation for a future fully powered, mul- expected to be justified by sufficient prelin- published literature. The data collected sh competitive fully powered multisite clinical submitting to this NOFO, applicants are er the science area of the planned applicatio be assessed as part of the scientific and te	al and/or psychological therape of high research priority. Application that will provide new information acy or effectiveness study, pragments that applications to this NOFC R01) research is scientifically new s R01, the data collected should assessing whether the interver accrual, and randomization of par- retention of participants through interventions, and/or demonstru- ultisite efficacy or effectiveness minary data from previous single could be used to fill gaps in scient al trial that has the potential to pro- ncouraged to contact the approp- n. This NOFO requires a Plan for	utic inputs (often ca ations submitted un on that is scientifica matic trial, or disser will describe the p ecessary to design o be used to fill gaps ntion can be deliver articipants across si hout the study acro rating feasibility of o trial. The need for n e site feasibility or a ntific knowledge an make a significant in oriate NCCIH Scient r Enhancing Diverse	alled mind and bo nder this NOFO an ally necessary for t mination and impl- olanned future clin or plan the subseque in scientific know ed with fidelity ac tes; demonstratin as sites; refining a data collection acr multisite feasibility acceptability trial(d be necessary to mpact on public h ific/Research cont e Perspectives (PE	dy e expected to the planning ementation ical trial and in uent fully fledge, ross sites; g participant nd assessing oss sites in y trials is s) or the develop a ealth. Prior to cact person for DP), which will

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	considered incomplete and will be withdra and view the available PEDP guidance mat		ouraged to read th	ne NOFO instructio	ons carefully	
123152 Feasibility Clinical Trials of Mind a Priority Research Topics (R34 Clin	and Body Interventions for NCCIH High ical Trial Required)	National Center for Complementary and Integrativ Health/NIH/DHHS	e PAR-24- 084 21-	Oct-2024	450,000 USD	
Contact Name	Jennifer N. Baumgartner, Ph.D.					
Contact Telephone	301-402-4084					
Contact Emai	jennifer.baumgartner@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	21-Oct-2024 , 13-Nov-2024 , 20-Feb-2025 , 10-Mar-2025 , 20-Jun-2025 , 14-Jul-2025 , 20-Oct-2025 , 17-Nov-2025 , 20-Feb- 2026 , 17-Mar-2026 , 22-Jun-2026 , 13-Jul-2026 , 20-Oct-2026 , 13-Nov-2026					
Synopsis	The goal of this notice of funding opportunapproaches with physical and/or psycholo that have been identified by NCCIH as high clinical trials that provide new information clinical efficacy or effectiveness study, prance NCCIH expects that applications to this NC the proposed (R34) research is scientificall Under this R34, the data collected should scale clinical trial, including, but not limite published data; tailoring or adapting the crefining the intervention to determine the retention, and data collection procedures; interventions; or examining acceptability a have the potential to make a significant imencouraged to contact the appropriate NC application. This NOFO requires a Plan for scientific and technical peer review evaluate be withdrawn. Applicants are strongly encouraged to contact the appropriate NC application. This NOFO requires a Plan for scientific and technical peer review evaluates be withdrawn. Applicants are strongly encouraged to contact the strongly encourage	gical therapeutic inputs (often c n-priority research topics. This function is that are scientifically necessary gmatic trial, or dissemination are DFO will describe the planned func- ly necessary to design or plan the be used to fill gaps in scientific k d to the following: examining fer ontent or structure of an interver most appropriate frequency or a refining and assessing the feasi and adherence of control condition pact on public health. Prior to CCIH Scientific/Research contact Enhancing Diverse Perspectives ation. Applications that fail to in	alled mind and bounding opportunity of for the planning and implementation ture clinical trial ar e subsequent com nowledge necessa asibility and acceptention to a specific duration; determining bility of protocolizations. The subseque submitting to this person for the sciest (PEDP), which will clude a PEDP will the	dy interventions) f v is intended to sup and conduct of a su trial within NCCIH ad in so doing dem petitive full-scale of ry to develop a co tability of interven population, moda ning feasibility of r ed multi-compone ent full-scale clinica NOFO, applicants ence area of the pl l be assessed as pa- be considered inco	or conditions oport feasibility ubsequent 's mission. onstrate that clinical trial. mpetitive full- tions lacking lity, or setting; recruitment, nt al trial should are anned art of the mplete and will	

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Development of Innovative Informatics ools, and Methods for Vision Research	National Eye Institute/NIH/DH	HS NOT-EY- 23-005 05-5	Sep-2024	Not Specified
Contact Name	James Gao, Ph.D.				
Contact Telephone	301-594-6074				
Contact Email	james.gao@nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 16-Oct-2024 2025 , 05-Sep-2025 , 07-Sep-2025 , 16-Oct			2025 , 07-May-20	25 , 16-Jun-
Synopsis	The purpose of this Notice of Special Inter interested in supporting research to devel improve data acquisition, analysis, visualiz innovation and its potential impact on visi translational research.	op innovative informatics and d ation, annotation, integration, a	ata science method and interpretation.	ds, algorithms, and The emphasis will	tools to be on
109678 <u>NEI Regenerative Medicine Clinica</u> Not Allowed)	al Trial Planning Grant (R34 - Clinical Trials	National Eye Institute/NIH/DH	HS PAR-22- 135 07-5	Sep-2024	300,000 USD
Contact Name	Donald Everett, MA				
Contact Telephone	301-435-8181				
Contact Email	everettd@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 ,	. 16-Feb-2025 , 07-May-2025			
Synopsis	The National Eye Institute (NEI) supports r trial, it is critical to have clear delineation and procedures in a Manual of Procedures such as obtaining regulatory authorization manufacturing and production facilities, a often costly and time-consuming, and the Medicine Clinical Trial Planning Grant may	and documentation of the trial's s (MOP). Additionally, there are ns or approvals and establishing ssay or cell analysis centers, and y may involve collection of prelin	rationale, design, other elements es agreements with re data coordinating minary data to asse	analytic technique sential to the laun equisite partners i centers. These ac ess feasibility. The	es, protocols, ching of a trial, ncluding cell tivities are

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	MOP and procedures necessary for implen vision in humans through regeneration of the second s		te interventions (or	new treatments)	that restore
109530 <u>NEI Clinical Research Study Plann</u> <u>Allowed)</u>	ing Grant Program (R34 Clinical Trial Not	National Eye Institute/NIH/DH	HS PAR-22- 128 07-5	Sep-2024	300,000 USD
Contact Name	Donald Everett, MA				
Contact Telephone	301-435-8181				
Contact Email	everettd@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 ,	16-Feb-2025 , 07-May-2025			
Synopsis	eye/vision conditions. At the time of subm detailed information regarding the study ra environment, organizational structure, and Procedures (MOP), the development of wh grant funding opportunity supports applica may be used to support the development of document recruitment potential. The gran NEI FOA is applicable to both epidemiologi	ationale, design, analytic techni d collaborative arrangements. T hich represents a costly and tim ants in their planning efforts to of a MOP, as well as to conduct t must not be used to generate	ques, protocols and his information is b e-consuming activit conduct collaboration preliminary studies data on the effects	d procedures, faci lest conveyed in a ty. This clinical res ive clinical researc s to refine study p	lities and Manual of earch planning ch. The grant rocedures or
109824 NEI Research Grant for Vision-Rel Trial Not Allowed)	lated Secondary Data Analysis (R21 Clinical	National Eye Institute/NIH/DH	HS PAR-22- 141 07-9	Sep-2024	275,000 USD
Contact Name	Donald Everett, M.A.				
Contact Telephone	301-435-8181				
Contact Email	everettd@mail.nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 ,	16-Feb-2025 , 07-May-2025			
Synopsis	This FOA encourages applications from ins	titutions/organizations that pro	pose to conduct vis	sion-related secor	dary data

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	analyses utilizing existing database resource the original data collection. The NEI suppor projects wherein numerous data collection of data generated by these studies often pe questions or develop new analytical appro- those collected under NEI support, but suc secondary data analysis using existing data studies. This FOA may be used to develop r must not be used to support the collection	rts an extensive portfolio of clir activities are required to meet rovides unique, cost-effective of aches secondary to a project's h data are of the highest progra sets from vision-related clinica new statistical methodologies of	nical trials and large t each project's spe opportunities to inv originally-intended ammatic interest. T al trials, epidemiolo	-scale epidemiolo cific aims. The res estigate additiona purpose. Data are he purpose of this gic, and other clini	gic research ultant wealth I research not limited to FOA is for ical research
111645 <u>NHLBI TOPMed: Omics Phenotype</u> - <u>Clinical Trial Not Allowed</u>)	es of Heart, Lung, and Blood Disorders (X01	National Heart, Lung, and Bloc Institute/NIH/DHHS	od PAR-22- 194 17-	Oct-2024	Not Specified
	Pankaj Qasba, Ph.D.				
Contact Telephone					
	<u>qasbap@nhlbi.nih.gov</u>				
Sponsor Website					
-	Link to program URL				
Deadline Dates (ALL)	17-Oct-2024 , 07-Jan-2025				
Synopsis	This Funding Opportunity Announcement ((TOPMed) program to generate a large vol- molecular mechanisms of Heart, Lung, Bloc omics data and related phenotypic data wi database for Genotypes and Phenotypes (o program from genetic Map to Mechanism TOPMed datasets, enabling functional gene	ume of integrated genetic and od, and Sleep (HLBS) disorders. Il be deposited in a public NIH- IbGaP) and NHLBI's BioData Ca (M2) and to fill knowledge gaps	multi-omics data to No funding will be designated controll talyst (BDC).The ov s that have not bee	facilitate discove provided under th ed-access databas erall goal is to trar n sufficiently cove	ry of the iis FOA. The se such as the nsition the red by existing
RFA-HL-25-009 Mentored Caree125805Diversity in Biomedical Research (Allowed)	er Development Award to Promote Faculty K01 Independent Clinical Trial Not	National Heart, Lung, and Bloc Institute/NIH/DHHS	od RFA-HL- 25-009 17-	Oct-2024	Not Specified
Contact Name	Karin F. Lidman, Ph.D.				
Contact Telephone					



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Email	karin.fredriksson@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	17-Oct-2024 , 07-Jan-2025 , 11-Feb-2025 , 2026 , 07-Jan-2027 , 11-Feb-2027 , 07-May		7-Jan-2026 , 11-Feb	-2026 , 07-May-20)26 , 14-Oct-
Synopsis	This Notice of Funding Opportunity (NOFO highly trained investigators in research ar guidance of an experienced mentor in the targeted toward individuals whose basic, of and experimental approaches needed to se sleep disorders in the general and health of proposing research that does not involve le ancillary clinical trial. Applicants to this NO or co-mentor. Applicants proposing a clinic investigator should apply to the companio	eas of interest to the NHLBI. Th biomedical, behavioral or clinical clinical, and translational researce olve problems related to cardior lisparities populations. This NOF eading an independent clinical to FO are permitted to propose re cal trial or an ancillary study to a	e career developme al sciences leading ch interests are gro vascular, pulmonar O is designed speci rial, a clinical trial f search experience	ent will take place to research indepo unded in the adva y, and hematologi ifically to support easibility study, or in a clinical trial le	under the endence. It is nced methods c diseases and candidates a separate d by a mentor
114386 Secondary Analysis of Existing Data	tasets in Heart, Lung, and Blood Diseases Trial Not Allowed)	National Heart, Lung, and Bloo Institute/NIH/DHHS	od PAR-23- 036 28-0	Oct-2024	150,000 USD
Contact Name	Ruth Kirby, RN, BS				
Contact Telephone	301-435-0401				
Contact Email	kirbyr@nhlbi.nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	28-Oct-2024 , 07-Jan-2025 , 28-Feb-2025 ,	07-May-2025 , 28-Oct-2025 , 07	7-Jan-2026		
Synopsis	This Funding Opportunity Announcement using existing human datasets in areas rele (NHLBI) scientific mission. The FOA aims to and/or generate new models, systems, too biobehavioral research. Generation of new	evant to the National Heart, Lun o stimulate the use of existing hi ols, or technologies that have th	g, Blood Diseases a uman datasets to in	and Sleep Disorder avestigate novel so	s Institute ientific ideas,
125802 RFA-HL-25-008 Mentored Caree	er Development Award to Promote Faculty	National Heart, Lung, and Bloo	d RFA-HL- 17-0	Oct-2024	Not

Icahn School of Medicine at Mount Sinai

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	unding Mount
Diversity in Biomedical Research ((K01 Independent Clinical Trial Required)	Institute/NIH/DHHS	25-008		Specified
Contact Name	Karin F. Lidman, Ph.D.				
Contact Telephone	301-435-0535				
Contact Email	karin.fredriksson@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
	17-Oct-2024 , 07-Jan-2025 , 11-Feb-2025 , 2026 , 07-Jan-2027 , 11-Feb-2027 , 07-May		7-Jan-2026 , 11-F	eb-2026 , 07-May-202	5 , 14-Oct-
Synopsis	pool of highly trained investigators by pro- supervised research under an accomplishe will take place under the guidance of an ex- research independence. It is targeted towa grounded in the advanced methods and ex- pulmonary, and hematologic diseases and designed to support candidates proposing feasibility study, or a separate ancillary clin independent clinical trial, or proposing to with their institutes to apply to companion	ed investigator in research areas sperienced mentor in the biome ard individuals whose basic, clir sperimental approaches needed sleep disorders in the general a to serve as the lead investigato nical trial, as part of their resear gain research experience in a cl	s of interest to th edical, behavioral nical, and translat d to solve probler and health dispar or of an independ rch and career de	e NHLBI. The career de l or clinical sciences lea ional research interest ms related to cardiovas ities populations. This ent clinical trial, a clinic evelopment. Those not	velopment ding to s are cular, NOFO is cal trial planning an
125098 NHLBI Early Phase Clinical Trials for (R61/R33 Clinical Trial Required)	or Therapeutics and/or Diagnostics	National Heart, Lung, and Bloc Institute/NIH/DHHS		3-Sep-2024 Optional][LOI/Pre-App]	Not Specified
Contact Name	Sumita Khatri, MD				
Contact Telephone	301-402-9673				
Contact Email	sumita.khatri@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	03-Sep-2024 [Optional][LOI/Pre-App], 07-5 Feb-2025 , 05-May-2025 [Optional][LOI/Pr 2025 , 02-Oct-2025 , 04-Jan-2026 [Optiona	e-App], 07-May-2025 , 04-Jun-2	2025 , 03-Sep-202	25 [Optional][LOI/Pre-A	

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	App], 07-May-2026, 04-Jun-2026, 03-Sep The objective of this funding opportunity is therapeutic interventions for heart, lung, l clinical trial start-up and implementation a for the implementation of the proposed to therapeutic/diagnostic in preparation for t bi-phasic, milestone-driven mechanism of as stability, shipping studies, and site train	is to support investigator-initiate blood, and sleep (HLBS) disorder activities, this FOA will provide su rial. All the activities proposed in the clinical trial. The proposed tr award where the first phase can	d, Phase I clinical s in adults and chi upport for final sta the R61 phase m ial can be single o	trials for diagnostic Idren. In addition to age preclinical activit ust be directly relat r multisite. This FOA	and supporting ies needed ed to the will utilize a
125065 NHLBI Early Phase Clinical Trials for HLBS Disorders (R33 CT Required)	or Therapeutics and/or Diagnostics for)	National Heart, Lung, and Bloo Institute/NIH/DHHS		Sep-2024 ptional][LOI/Pre-App	4,545,000] USD
Contact Name Contact Telephone	Sumita Khatri, MD 301-402-9673				
Contact Email	sumita.khatri@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	03-Sep-2024 [Optional][LOI/Pre-App], 07-5 May-2025 [Optional][LOI/Pre-App], 07-Ma 2025 , 04-Jan-2026 [Optional][LOI/Pre-App , 04-Jun-2026 , 03-Sep-2026 [Optional][LO	ay-2025 , 04-Jun-2025 , 03-Sep-2 o], 07-Jan-2026 , 03-Feb-2026 , 0	025 [Optional][LO 5-May-2026 [Opt	I/Pre-App], 07-Sep-2 onal][LOI/Pre-App],	2025 , 02-Oct
Synopsis	The objective of this Notice of Funding Op diagnostic and therapeutic interventions f proposed trial can be single or multi-site. clinical trial within the first quarter of the (FDA, DSMB, IRB) approvals, and establish agreements should be established by the t readiness activities are desired, applicants phased approach.	or heart, lung, blood, and sleep (Applicants applying for funding or project period. Discussion, subm ment of drug (and placebo, if ap time of award. If time and suppo	(HLBS) disorders in under this NOFO s nission, and attain plicable) supplies, rt for these and o	n adults and childrer hould be ready to ir ment of applicable r and any necessary t ther pre-clinical and	n. The iitiate the egulatory chird-party /or trial

113286 Notice of Special Interest (NOSI): Basic and Translational Research on	National Heart, Lung, and Blood		Not
Circadian Regulation of Heart, Lung, Blood, and Sleep Disorders (R01)	Institute/NIH/DHHS	HL-22- 07-Sep-2024 043	Specified
		015	



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Name	Ravi Balijepalli, Ph.D.				
Contact Telephone					
	ravi.balijepalli@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL) 2026, 05-Feb-2026, 07-May-2026, 05-Jun-2026, 07-Sep-2027, 05-Feb-2026, 07-Sep-2026, 07-May-2026, 07-Sep-2026, 07-May-2026, 07-Sep-2026, 07-Sep-2027, 07-May-2026, 07-Sep-2026, 05-Oct-2026, 07-Jan-2027, 05-Feb-2027, 07-Ma					
Synopsis	This NOSI aims to stimulate research on ur peripheral tissues, and to find new avenue diagnosis, treatment, and prevention. Basi mechanisms contributing to the pathophys multiple investigator teams of experts in h and sleep researchers to provide a compre purpose is to facilitate translational resear prevention and treatment of HLBS condition clinical markers, and/or therapeutic target molecular, and genomic studies aimed at ea are appropriate. Studies to delineate circan to assess therapeutic safety, efficacy, effect	es for the investigation of heart, c, translational, and clinical res- siology of HLBS disorders are in eart, lung, and blood research f chensive understanding of the c ch to identify potential applicat ons. Mechanism-based studies is s of HLBS conditions are encour- elucidating the relationship betw dian-based mechanisms, therap	lung, and blood dis earch applications to vited. This NOSI en fields to synergistic circadian biology in cions of circadian so investigating the cir raged. Behavioral, p ween circadian-dep peutic targets, epide	sease risk, pathoge to elucidate circad courages multidisc ally work with circ relation to HLBS co cience to the diagn rcadian rhythm dy ohysiological, phar pendent mechanisr	enesis, ian-dependent ciplinary and adian biologists onditions. The osis, sregulation, macological, ns and disease
Notice of Special Interest (NOSI): 114141 Cardiovascular Disease (R01 Clinic Trials Allowed)	Advancing Research in Lipoprotein(a) and cal Trials Allowed) and (R01 No Clinical	National Heart, Lung, and Bloc Institute/NIH/DHHS	od NOT- HL-22- 07- 052	Sep-2024	Not Specified
Contact Name	Lijuan Liu, PhD				
Contact Telephone	301-435-0582				
Contact Email	lliu@nhlbi.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 2026	05-Feb-2025 , 07-May-2025 , 0	5-Jun-2025 , 07-Seț	o-2025 , 05-Oct-20	25 , 07-Jan-

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
Synopsis	The purpose of this NOSI is to stimulate re encourage multidisciplinary collaborations	search on lipoprotein(a) [Lp(a)] to conduct basic, preclinical, ar	and its role in ca nd mechanistic cl	rdiovascular disease inical studies on Lp((CVD). We a) and CVD.
Notice of Special Interest (NOSI):106202Cardiometabolic Health in Early S Through Adolescence to Young Adoles	tages of the Lifecourse: Pre-adolescence	National Heart, Lung, and Bloc Institute/NIH/DHHS	od NOT- HL-21- 0 015	7-Sep-2024	Not Specified
Contact Name	Alison G.M. Brown, PhD, MS, RDN				
Contact Telephone	301-435-0583				
Contact Email	<u>Alison.brown@nih.gov</u>				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 2026 , 05-Feb-2026 , 07-May-2026 , 05-Jur	-	5-Jun-2025 , 07-S	ep-2025 , 05-Oct-20	25 , 07-Jan-
	This Notice of Special Interest (NOSI) calls during transitionary phases across the life	course, from pre-adolescence (6	5-10 years) throu	gh adolescence (11-	
Synopsis	young adulthood (19-39 years). This initiat pathogenesis of cardiometabolic health an phases from pre-adolescence into adolesc interventions (at the individual and popula transitionary phases.	nd cardiovascular disease (CVD) ence and adolescence into your	risk in vulnerable ng adulthood, and	e groups throughout d 2) develop precisio	he transitionary on prevention
Synopsis Notice of Special Interest (NOSI): 112260 Pathobiological Mechanisms of Lu Cellular Systems (R01)	pathogenesis of cardiometabolic health an phases from pre-adolescence into adolesc interventions (at the individual and popula transitionary phases. <u>Studies of Cellular/Molecular</u>	nd cardiovascular disease (CVD) ence and adolescence into your	risk in vulnerable ng adulthood, and ascular and cardi	e groups throughout d 2) develop precisio	he transitionary on prevention
Notice of Special Interest (NOSI):112260Pathobiological Mechanisms of Lu Cellular Systems (R01)	pathogenesis of cardiometabolic health an phases from pre-adolescence into adolesc interventions (at the individual and popula transitionary phases. <u>Studies of Cellular/Molecular</u>	nd cardiovascular disease (CVD) ence and adolescence into your ations levels) to address cardiov National Heart, Lung, and Bloc	risk in vulnerable ng adulthood, and ascular and cardi od NOT- HL-22- 0	e groups throughout d 2) develop precisic ometabolic risk acro	he transitionary on prevention oss these Not
Notice of Special Interest (NOSI):112260Pathobiological Mechanisms of Lu Cellular Systems (R01)	pathogenesis of cardiometabolic health an phases from pre-adolescence into adolesc interventions (at the individual and popula transitionary phases. <u>Studies of Cellular/Molecular</u> ung Diseases Using Human 3-Dimensional	nd cardiovascular disease (CVD) ence and adolescence into your ations levels) to address cardiov National Heart, Lung, and Bloc	risk in vulnerable ng adulthood, and ascular and cardi od NOT- HL-22- 0	e groups throughout d 2) develop precisic ometabolic risk acro	he transitionary on prevention oss these Not
Notice of Special Interest (NOSI): 112260 Pathobiological Mechanisms of Lu Cellular Systems (R01) Contact Name Contact Telephone	pathogenesis of cardiometabolic health an phases from pre-adolescence into adolesc interventions (at the individual and popula transitionary phases. <u>Studies of Cellular/Molecular</u> ung Diseases Using Human 3-Dimensional	nd cardiovascular disease (CVD) ence and adolescence into your ations levels) to address cardiov National Heart, Lung, and Bloc	risk in vulnerable ng adulthood, and ascular and cardi od NOT- HL-22- 0	e groups throughout d 2) develop precisic ometabolic risk acro	he transitionary on prevention oss these Not
Notice of Special Interest (NOSI): 112260 Pathobiological Mechanisms of Lu Cellular Systems (R01) Contact Name Contact Telephone	pathogenesis of cardiometabolic health an phases from pre-adolescence into adolesc interventions (at the individual and popula transitionary phases. <u>Studies of Cellular/Molecular</u> ung Diseases Using Human 3-Dimensional Qing Lu, Ph.D. 301-480-9158 <u>qing.lu@nih.gov</u>	nd cardiovascular disease (CVD) ence and adolescence into your ations levels) to address cardiov National Heart, Lung, and Bloc	risk in vulnerable ng adulthood, and ascular and cardi od NOT- HL-22- 0	e groups throughout d 2) develop precisic ometabolic risk acro	he transitionary on prevention oss these Not
Notice of Special Interest (NOSI): 112260 Pathobiological Mechanisms of Luccellular Systems (R01) Contact Name Contact Telephone Contact Email Sponsor Website	pathogenesis of cardiometabolic health an phases from pre-adolescence into adolesc interventions (at the individual and popula transitionary phases. <u>Studies of Cellular/Molecular</u> ung Diseases Using Human 3-Dimensional Qing Lu, Ph.D. 301-480-9158 <u>qing.lu@nih.gov</u>	nd cardiovascular disease (CVD) ence and adolescence into your ations levels) to address cardiov National Heart, Lung, and Bloc	risk in vulnerable ng adulthood, and ascular and cardi od NOT- HL-22- 0	e groups throughout d 2) develop precisic ometabolic risk acro	he transitionary on prevention oss these Not

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	The purpose of this NOSI is to promote resonset and progression of lung diseases at a experimental systems with cellular heteroge will utilize ex vivo preparations (e.g., thin heronomic cells and will employ state-of-art mult specific pathobiological processes in systemed to the systemed systemed specific pathobiological processes in systemed	a molecular/cellular level, provid geneity and 3-D architecture. It numan lung slices) or 3-D multi- ti-omics measures (e.g., spatial o	ding a systems-leve is expected that pr cellular in vitro sys	el understanding b ojects supported l tems (e.g., organo	y studying by this NOSI ds) of human
Notice of Special Interest (NOSI): 115585 Evaluate Candidate -Omics Varian Sleep Disease (R01, R41, R42, R43		National Heart, Lung, and Bloo Institute/NIH/DHHS	d NOT- HL-23- 05- 066	Sep-2024	Not Specified
	Charlene Schramm, Ph.D.				
Contact Telephone					
	schrammc@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 2025 , 07-May-2025 , 05-Jun-2025 , 05-Sep Feb-2026 , 05-Apr-2026 , 07-May-2026 , 05	o-2025 , 07-Sep-2025 , 07-Sep-20	025,05-Oct-2025	•	
Synopsis	The NHLBI is issuing this Notice of Special I disorders in the following area(s): Develop provide biological validation of candidate I between genotypes and phenotypes Deve	ment and/or application of moc numan variants associated with	lerate- or high-thr HLBS disorders De	oughput functiona fining causal relati	l assays to
116586 Notice of Special Interest (NOSI): TOPMed Data (Parent R01 Clinica	Integrative Omics Analysis of NHLBI I Trial Not Allowed)	National Heart, Lung, and Bloo Institute/NIH/DHHS	d NOT- HL-23- 07- 067	Sep-2024	Not Specified
Contact Name	James Luo, Ph.D.				
Contact Telephone	301-435-0533				
Contact Email	luoja@nih.gov				
Sponsor Website					
Brogram LIPI	Link to program URL				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 2026 , 05-Feb-2026 , 07-May-2026	05-Feb-2025 , 07-May-2025 , 05	5-Jun-2025 , 07-Sej	o-2025 , 05-Oct-20	25 , 07-Jan-
	The symptom-based diagnosis and treatm years, yet an understanding of the molecul Furthermore, in most cases the impact of Therefore, the NHLBI has created the Tran data to characterize a variety of HLBS dise over 194,270 well-phenotyped individuals over 44,342 DNA methylation profiles, and whole genome sequence information. Hay seeks to turn its attention to effectively let through novel systems biology analyses ar lower costs and technological improvement volumes of omics data, the ability to analy challenging. Systems level models incorpoo biological networks and the gene-gene and Thus, advanced analyses that incorporate individuals are essential to move TOPMed	lar mechanisms underlying man genetic variation on severity of o s-omics for Precision Medicine (ases. TOPMed is well on its way and is currently generating mult d 26,124 metabolomics profiles) ring produced an unprecedented veraging this resource to uncove ad the power of artificial intelligents in sequencing technology have ze such large datasets to extract rating trans-omics analyses will b gene-environment interactions genotype and phenotype dataset	y of these diseases disease and treatm TOPMed) program to collecting whole ti-omics data (e.g., from many of these d volume of high-th er biological function ence (AI) and Mach ve vastly expanded biologically mean be an important st s influencing disease	s has remained elu- ient outcomes rem n, which aims to ut e genome sequence over 31,852 RNA se individuals to co- nroughput data, T(on and disease pat nine Learning (ML) d our ability to gen ingful insights rem ep in uncovering t se and treatment	sive. nains unknown. ilize genomics ce (WGS) from sequences, omplement OPMed now hobiology . Although erate large nains he underlying putcomes.
107287 Notice of Special Interest (NOSI): I Ancillary Studies to Large Ongoing	Heart, Lung, Blood and Sleep Focused g Clinical Studies (Revised)	National Heart, Lung, and Bloo Institute/NIH/DHHS	d NOT- HL-21- 07- 030	Sep-2024	Not Specified
Contact Name	Jue Chen, Ph.D.				
Contact Telephone	301-435-0550				
Contact Email	jue.chen@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 ,	05-Feb-2025 , 07-May-2025			
Synopsis	This Notice of Special Interest (NOSI) seek treatment of diseases within the mission of clinical research studies through ancillary conduct focused ancillary studies to large	of the National Heart, Lung, and studies. The purpose of this NOS	Blood Institute (NH I is to invite reseau	HLBI) by leveraging rch project applica	; ongoing tions to

	SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
--	---------	---------------	--------------	----------------	---------------	-------------------

observational studies, and registries. This NOSI also serves as a replacement for NOT-HL-20-755 (expired as of November 6, 2021).

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
10/043	Notice of Special Interest (NOSI): Evaluation and Analysis to Health		National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 22-001	07-Sep-2024	Not Specified
	Contact Name	Lucy L. Hsu, M.P.H.				
	Contact Telephone	301-402-3276				
	Contact Email	lucy.hsu@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-20	25			
	Synopsis	The purpose of this Notice of Special Ir science in heart, lung, blood, or sleep (to improve health.				
IIIXIIIIIXI	Notice of Special Interest (NOSI): Tools for Use in Underserved Pop	Diagnostics and Disease Management ulations	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 22-024	07-Sep-2024	Not Specified
	Contact Name	Bishow Adhikari, Ph.D.				
	Contact Telephone	301-594-2791				
	Contact Email	adhikarb@nhlbi.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 05-Feb-20	25 , 05-Jun-2025			
	Synopsis	The purpose of this NOSI is to stimulate management tools for heart, lung, bloc populations. Underserved populations, homeless, low-income individuals, the	od, or sleep (HLBS) disorders that are do for the purpose of this NOSI, can inclu	esigned to r de racial an	meet the needs of the ur ad ethnic minorities, imm	iderserved iigrants, the

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
		disadvantaged, rural or have few healt will be given to technology solutions th partners is required throughout the pr	nat are accessible and feasible in the	ese communities	. Working with com	
108064	Notice of Special Interest (NOSI): Mitochondrial Involvement in Lur	Promoting Fundamental Research on ng Diseases and Sleep Disorders	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 22-003	07-Sep-2024	Not Specified
	Contact Name	Jining Lu				
	Contact Telephone	301-827-2807				
	Contact Email	jining.lu@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-20	25 , 05-Feb-2025			
	Synopsis	and diseased lungs. Multidisciplinary c lung progenitor/organoid culture syste We encourage investigators to Utilizat and/or well-defined congenital mitoch	ems, advanced single cell-and "-omic ion oflung cells from human donors	" technologies, and animal moc	and lung cell biology	is encourage
122332	NHLBI Clinical Trial Pilot Studies (I	R34 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24- 049	07-Sep-2024	450,000 USD
	Contact Name	Patrice Desvigne-Nickens, MD				
	Contact Telephone	301-435-0504				
	Contact Email	desvignp@mail.nih.gov				
	Sponsor Website					
	•	Link to program URL				
	•)25 , 07-Jan-

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		subsequent trial. Furthermore, this NOFO w sufficient to inform the future trial without test the efficacy, safety, clinical managemen heart, lung, blood, or sleep disorders. In con for clinical trials (as described at Clinical Tria provide new information that answers a sci therefore, informs the final development of proposed future clinical trial will require a re diverse teams working together and capital teams. There are many benefits that flow fr enhancing global competitiveness, contribu- advancing the likelihood that underserved p To support the best science, the NIH encour- perspectives include but are not limited to: researchers from fields such as computation well as bioethics Engagement from differe- undergraduate-focused, minority-serving, c geographic and regional heterogeneity Im Participation of individuals from diverse bac behavioral, and clinical research workforce with disabilities, those from disadvantaged to benefit early- and mid-career investigato will be assessed as part of the scientific and considered incomplete and will be withdraw and view the available PEDP guidance mate	further studies. The planned F int, or implementation of inter- ntrast to the study start up or al Development Continuum ientific or operational question f a Phase II-IV clinical trial. Reg- new application. Plan for Enha lizing on innovative ideas and rom a diverse scientific workfor uting to robust learning environ populations participate in, and irages inclusivity in research. E - Transdisciplinary research pr and biology, physics, engineeri rent types of institutions and o community-based) Individua ivestigators and teams composi- ckgrounds, including groups hi (see NOT-OD-20-031), such as backgrounds, and women Cors. This NOFO requires a Plan d technical peer review evaluation. Applicants are strongly en	Phase II, III, or IV tria vention(s) in the pre preparation phase of NHLBI, NIH), the R34 n(s) which may be p gardless of the result ncing Diverse Persp distinct perspectives orce, including: foster nments, improving to benefit from resea xamples of structure ojects and collabora ng, mathematics, co rganizations (e.g., re l applications and pass sed of researchers a storically underrept s underrepresented opportunities to enh for Enhancing Dive tion. Applications th	al must be primari evention and/or tr of NHLBI funding of 4 mechanism is int ragmatic in nature ts of the R34, supp ectives The NIH re s outperform hom ering scientific inne the quality of the rch, and enhancin es that promote d ations among neu- omputer and data esearch-intensive, artnerships that e t different career resented in the bio racial and ethnic g ance the research rse Perspectives (I nat fail to include	ly intended to reatment of opportunities tended to e and, oort of the ecognizes that nogeneous ovation, research, g public trust. iverse roscientists an sciences, as nhance stages omedical, groups, those nenvironment PEDP), which a PEDP will be

106072	Notice of Special Interest (NOSI): Bold New Bioengineering Research for	National Heart, Lung, and Blood	NOT-HL-	07-Sep-2024	Not
100072	Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue)	Institute/NIH/DHHS	21-024	07-360-2024	Specified

Contact Name Narasimhan Danthi, Ph.D. Contact Telephone 301-435-5170

Contact Email ndanthi@mail.nih.gov

Sponsor Website



PIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Program UR	L Link to program URL				
) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-20	25			
Synopsi	This Notice of Special Interest is a reiss National Heart, Lung and Blood Institu bioengineering projects which are exp s commercial products. Please note that research into future follow-on funding overlap with the NHLBI Catalyze Progra	te (NHLBI) of an area of special inte ected to transition their research in this R21 program does not overlap , technologies, or commercial produ	rest to support ea to future follow-o with projects wh ucts. Please note	arly phases of innov on funding, technolo ich are expected to that this R21 progra	vative ogies, or o transition the am does not
09308 <u>RFA-HL-23-018 Maximizing the</u> <u>Biospecimen Repository: Scientif</u> <u>Research (R21)</u>	Scientific Value of the NHLBI Biologic Control Content of the NHLBI Biologic	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 23-018	9-Aug-2024	150,000 USD
Contact Nam	e Margaret Ochocinska, PhD				
Contact Telephon	e 301-827-8285				
Contact Ema	il <u>ochocinm@mail.nih.gov</u>				
Sponsor Websit	e				
Program UR	L Link to program URL				
Deadline Dates (ALI) 09-Aug-2024 , 21-Oct-2024 , 10-Dec-20	024			
Synopsi	This Funding Opportunity Announcem (http://www.nhlbi.nih.gov/about/org/ Biologic Specimen Repository (Biorepo researchers with an opportunity to gen	mission) using the existing biospeci ository), thereby maximizing the scie	men collections t entific value of the	hat are stored in th e stored collections	e NHLBI
12358 Data Coordinating Center for Mu Trials (Collaborative U24 Clinical	Ilti-Site Investigator-Initiated Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22- 193	.1-Sep-2024	Not Specified
Contact Nam	e Nancy DiFronzo, PhD				
Contact Telephon	e 301-435-0065				
Contact Ema	il difronzon@nhlbi.nih.gov				
	<u>v</u>				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Sep-2024 , 11-Oct-2024 , 10-Jan-20	25 , 11-Feb-2025 , 12-May-2025 , 12	1-Jun-2025 , 11-Sep	p-2025	
	Synopsis	This Funding Opportunity Announceme investigator-initiated multi-site clinical research clinical trials. Trials using inno These trials may include ones that test FOA applies must be relevant to the re 15-015). For additional information ab encouraged to consult the NHLBI webs award and runs in parallel with a comp Coordinating Center (CCC). The objecti coordination, administration, data mar CCC application. The application should clinical trial community engagement an	trials including efficacy, comparative vative designs such as platform trial different therapeutic, behavioral, a search mission of the NHLBI and me out the mission, strategic vision, an ite. This FOA will utilize a milestone anion FOA PAR-22-192() that encou- ve of the DCC application is to presen agement, and biostatistical support d also describe its approaches to co	ve effectiveness, pr ils, adaptive, and B and/or prevention s eet the NIH definiti d research prioritie e-driven cooperation urages applications ent a comprehension t for the clinical tri- llaborate with the s	ragmatic and/or im ayesian designs ar strategies. Trials fo ion of a clinical tria es of the NHLBI, ap we agreement med is for a collaborating we plan to provide al proposed in the CCC on implement	plementation e encouraged or which this I (see NOT-OI plicants are hanism of g Clinical overall project collaborating ation of the
		submitted on the same application due appropriate Scientific/Research contact	-	• •	ngly encouraged to	
117357 -	Clinical Coordinating Center for N Trials (Collaborative UG3/UH3 Clin	appropriate Scientific/Research contaction appropriate Scientific/Research contaction appropriate Scientific and Science and S	-	ΡΔΒ-22-	ngly encouraged to -Sep-2024	
117357	Trials (Collaborative UG3/UH3 Clin	appropriate Scientific/Research contaction appropriate Scientific/Research contaction appropriate Scientific and Science and S	t prior to submitting an application National Heart, Lung, and Blood	PAR-22- 11		o contact the Not
17357	Trials (Collaborative UG3/UH3 Clin	appropriate Scientific/Research contact <u>Aulti-Site Investigator-Initiated Clinical</u> <u>nical Trial Required)</u> Nancy DiFronzo, PhD	t prior to submitting an application National Heart, Lung, and Blood	PAR-22- 11		o contact the Not
17357	Trials (Collaborative UG3/UH3 Clin Contact Name Contact Telephone	appropriate Scientific/Research contact <u>Aulti-Site Investigator-Initiated Clinical</u> <u>nical Trial Required)</u> Nancy DiFronzo, PhD	t prior to submitting an application National Heart, Lung, and Blood	PAR-22- 11		o contact the Not
17357	Trials (Collaborative UG3/UH3 Clin Contact Name Contact Telephone	appropriate Scientific/Research contact Aulti-Site Investigator-Initiated Clinical nical Trial Required) Nancy DiFronzo, PhD 301-435-0065 difronzon@nhlbi.nih.gov	t prior to submitting an application National Heart, Lung, and Blood	PAR-22- 11		o contact the Not
17357	Trials (Collaborative UG3/UH3 Clin Contact Name Contact Telephone Contact Email Sponsor Website	appropriate Scientific/Research contact Aulti-Site Investigator-Initiated Clinical nical Trial Required) Nancy DiFronzo, PhD 301-435-0065 difronzon@nhlbi.nih.gov	t prior to submitting an application National Heart, Lung, and Blood	PAR-22- 11		o contact the Not
117357 -	Trials (Collaborative UG3/UH3 Clin Contact Name Contact Telephone Contact Email Sponsor Website Program URL	appropriate Scientific/Research contact <u>Aulti-Site Investigator-Initiated Clinical</u> <u>nical Trial Required</u>) Nancy DiFronzo, PhD 301-435-0065 <u>difronzon@nhlbi.nih.gov</u>	t prior to submitting an application National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22- 11 192 11	-Sep-2024	o contact the Not

SPIN ID Program Title		Sponsor Name S	ponsor Number	Deadline Date	Funding Amount
	driven cooperative agreement mechan for a collaborating Data Coordinating of rationale for the clinical trial and a cor address project management, subject dissemination of results. The applicati diversity as well as reducing health ine Center (DCC) application must be subr strongly encouraged to contact the ap	Center (PAR-22-193). The objective on mprehensive scientific and operational recruitment and retention, performation on should also describe its approache equities and disparities. Both a CCC apprint mitted on the same application due d	f the CCC applica al plan that desc ance milestones, es to increasing o pplication and a late for consider	ation is to present t ribes it. The applica scientific conduct o community engage collaborating Data ation by NHLBI. App	he scientific ation should of the trial, and ment and Coordinating plicants are
111425 Single-Site Investigator-Initiated C Required)	Clinical Trials (R61/R33 Clinical Trial	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22- 189 1	1-Sep-2024	Not Specified
Contact Name	Nahed El Kassar, MD				
Contact Telephone	301-435-0065				
Contact Email	nahed.elkassar@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	11-Sep-2024 , 11-Oct-2024 , 11-Jan-20	025 , 11-Feb-2025 , 11-May-2025 , 11	-Jun-2025 , 11-Se	ep-2025	
Synopsis	This Funding Opportunity Announcem site clinical trials including efficacy, co using innovative designs such as platfor ones that test different therapeutic, b relevant to the research mission of the additional information about the miss consult the NHLBI website. This FOA wa application is to present the scientific describes it. The application should ad milestones, scientific conduct of the tr not required. Applicants are encourag coordination. The application should ad inequties and disparities, and include	mparative effectiveness, pragmatic a orm trials, adaptive, and Bayesian des ehavioral, and/or prevention strategi e NHLBI and meet the NIH definition ion, strategic vision, and research pri will utilize a bi-phasic, milestone-drive rationale for the clinical trial and a co ldress project management, subject r rial, and dissemination of results. The ed to include a PD/PI with expertise i also describe its approaches to increa	nd/or implemen signs are encoura es. Trials for whi of a clinical trial orities of the NH en mechanism of mprehensive sci recruitment and multiple PD/PI r n biostatistics, cl sing community	tation research clir aged. These trials n ich this FOA applies (see NOT-OD-15-01 LBI, applicants are f award. The object ientific and operati retention, perform model is strongly er linical trial design, a	nical trials. Trial may include must be 15). For encouraged to vive of the onal plan that ance ncouraged but

112356 Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial National Heart, Lung, and Blood PAR-22- 11-Sep-2024 Not



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Required)		Institute/NIH/DHHS	189		Specified
Contact Name	Nahed El Kassar, MD				
Contact Telephone	301-435-0065				
Contact Email	nahed.elkassar@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	11-Sep-2024 , 11-Oct-2024 , 11-Jan-202	25 , 11-Feb-2025 , 11-May-2025 ,	11-Jun-2025 , 11-Sep	o-2025	
Synopsis	site clinical trials including efficacy, com using innovative designs such as platfor ones that test different therapeutic, be relevant to the research mission of the additional information about the mission consult the NHLBI website. This FOA w application is to present the scientific ra describes it. The application should add milestones, scientific conduct of the tria not required. Applicants are encourage coordination. The application should also inequties and disparities, and include a	rm trials, adaptive, and Bayesian of havioral, and/or prevention strate NHLBI and meet the NIH definition on, strategic vision, and research ill utilize a bi-phasic, milestone-dr ationale for the clinical trial and a lress project management, subject al, and dissemination of results. T d to include a PD/PI with expertis so describe its approaches to incr	designs are encourage egies. Trials for which on of a clinical trial (so priorities of the NHLI viven mechanism of a comprehensive scient recruitment and re he multiple PD/PI m e in biostatistics, clir easing community e	ged. These trials m h this FOA applies ee NOT-OD-15-01 BI, applicants are award. The object ntific and operatio etention, performa odel is strongly er nical trial design, a	hay include must be (5). For encouraged to ive of the onal plan that ance incouraged but and
113729 <u>RFA-HL-24-005 Limited Compet</u> K01/K08/K23/K25 Recipients (R03	tition: Small Grant Program for NHLBI 3 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 24-005	-Sep-2024	150,000 USD
Contact Name	Qing Lu, Ph.D.				
Contact Telephone	301-480-9158				
Contact Email	Qing.Lu@nih.gov				
Sponsor Website	3				
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 17-Oct-2024 , 07-Jan-202 2026	25 , 13-Feb-2025 , 07-May-2025 ,	13-Jun-2025 , 07-Sep	o-2025 , 13-Oct-20)25 , 07-Jan-

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
Synopsis	The purpose of this funding opportunity and K25 recipients for small grant suppor resulted from the research conducted un support after the notice of award (NoA) K23, and K25 recipients are eligible to ap NHLBI K award Project Period end date. recipients to conduct research as they conduct intended to support research projects the years) with limited resources and that m These studies include, but are not limite existing data; small, self-contained research development of novel experimental mode the proposed R03 project, is required from application may or may not include pation	rt to expand their current resear nder the K award. Active NHLBI K for their first type-5 K awards ha oply for the R03 if the earliest pos This FOA is intended to enhance omplete their transition to fully in nat can be carried out and comple ay generate preliminary data to d to, pilot or feasibility studies; p arch projects; development of ne dels. A minimum of 40% protecte om applicants. For current and pr	ch objectives or t 01, K08, K23, and s been issued. Re ssible R03 start da the capability of I ndependent inves eted within a shor support a subseq roof of concept si w research metho	o branch out to a net K25 recipients may cently completed NI Ite falls within 2 yea NHLBI K01, K08, K23 tigator status. This F t period of time (no uent R01-equivalent cudies; secondary ar pdologies or technol n effort, not necessa	ew study that apply for R03 HLBI K01, K08, rs of their prior , and K25 R03 program is more than two application. halysis of logies, or arily limited to
127015 <u>NHLBI Career Transition Award fo</u> <u>Research Trainees (K22 Independ</u>		National Heart, Lung, and Blood nstitute/NIH/DHHS	PAR-24- 209	12-Oct-2024	Not Specified
	Kristen Z. Morgan, Ph.D.				
Contact Telephone					
	direducation@nhlbi.nih.gov				
Sponsor Website					
Program URL Deadline Dates (ALL)	Link to program URL 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 2027	5 , 12-Oct-2025 , 12-Feb-2026 , 1	2-Jun-2026 , 12-O	ct-2026 , 12-Feb-20	27 , 12-Jun-
Synopsis	The purpose of the NHLBI Career Transit doctoral-level researchers currently in tr their research programs to extramural in Transition Award will support two phase phase (three years), for a total of five ye extramural phase is not automatic. Appr during the mentored phase as determin- be carried out at the extramural instituti	aining in the NHLBI Division of In Institutions as junior investigators as of research: a mentored intram ars of combined support. Transit roval of the transition will be base ed by an NHLBI progress review,	tramural Researc . To achieve these nural phase (up to ion from the intra ed on the success which will include	h with the opportur objectives, the NH two years) and an mural phase of sup of the awardee's re an evaluation of a	hity to transition LBI Career extramural port to the search program research plan to

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
RI	FA-HL-25-010Phased Multi-Site	candidates proposing research that doe ancillary study to a clinical trial. Applicar mentor or co-mentor. Those proposing companion FOA, PAR-24-211 "NHLBI Co (K22- Clinical Trial Required)".	nts to this FOA are permitted to p a clinical trial or an ancillary clinic	ropose research ex al trial as lead inves	perience in a clinic tigator, should ap	al trial led by a ply to the
126957 <mark><u>Ca</u> <u>St</u></mark>		Adults With High Lifetime Risk Using	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 09 25-010	-Sep-2024	Not Specified
	Contact Name	David Schopfer, M.D., M.A.S.				
	Contact Telephone	301-402-3833				
		david.schopfer@nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	09-Sep-2024 , 28-Oct-2024				
	Synopsis	The goal of this Notice of Funding Oppo progression of coronary atherosclerosis atherosclerotic cardiovascular disease (<i>i</i> the purpose of this NOFO, "young adults coronary atherosclerosis before menops criteria to include women older than ag first efficiently screen the appropriate p intervention(s) are most efficacious at re Trial participants who are identified as r screening component will be immediate until the trial is completely enrolled. It is arm. The control arm is expected to be of two active arms is expected to involve a primary prevention in older high-risk ad with less definite evidence of primary pre- earlier treatment of subclinical ASCVD w	among young adults who are at I ASCVD) event, yet at high lifetime s" is defined as less than or equal ause for women compared to me e 50. This opportunity will suppor opulation eligible for the interver educing the onset or slowing the neeting the subclinical coronary a ely enrolled in the intervention, events expected that the trial will have current guideline-based behaviora n additional pharmacological inter ults, such as LDL lowering therapy revention efficacy in older adults.	ow or borderline 10 risk of developing to 50 years for mer n, it may be reasona t a two component ntion, and second, to progression of subco therosclerosis crite yen though compon three arms. One wi al and pharmacolog ervention(s) with de y. The other active a The goal of this res	o-year risk (<7.5%) cardiovascular dise and given the lo- able to use an expe- prevention clinica o determine which linical coronary at ria for enrollment ent one recruitme II be a control or c ical interventions. finite evidence of arm may involve in earch strategy is to	for their first ease (CVD). For wer rate of anded inclusion I trial that will herosclerosis. in the ent continues omparison One of the efficacy for tervention(s) o determine if

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		recommend treatment. This NOFO will sup for a multi-site clinical trial among young a agreement mechanism of award and runs i Data Coordinating Center (RFA-HL-25-007) clinical trial and a comprehensive scientific management, subject recruitment and rete of results for each stage (screening and tria approaches to increasing community engaged designs such as platform trials, adaptive, and Data Coordinating Center (DCC) application Applicants are strongly encouraged to conto Funding Opportunity (NOFO) requires a Pla	dults without clinical ASCVD. It in parallel with a companion N . The objective of this CCC apple and operational plan that design ention, performance milestone al) and each phase (UG3 and U gement and reducing health in nd Bayesian designs are welcom n must be submitted on the sam tact the appropriate Scientific/	will utilize a milest OFO that encourage lication is to present cribes it. The applica s, scientific conduct H3). The application nequities. Clinical tri med. Both a CCC app me application due Research contacts p	one-driven cooper is applications for the scientific rati ation should addre of the trial, and d should also descr al designs using in plication and a col date for considera	ative a collaborating onale for the ess project issemination ibe its novative laborating tion by NHLBI.
126956	Cardiovascular Disease in Young A		tional Heart, Lung, and Blood stitute/NIH/DHHS	RFA-HL- 09- 25-007	Sep-2024	Not Specified
	Contact Name	David Schopfer, M.D., M.A.S.				
	Contact Telephone	301-402-3833				
	Contact Email	david.schopfer@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Sep-2024 , 28-Oct-2024				
	Synopsis	The goal of this Notice of Funding Opportu progression of coronary atherosclerosis an atherosclerotic cardiovascular disease (ASC the purpose of this NOFO, "young adults" i coronary atherosclerosis before menopaus criteria to include women older than age 5 that will first, efficiently screen the approp intervention(s) are most efficacious at redu Trial participants who are identified as mee	nong young adults who are at le CVD) event, yet at high lifetime is defined as less than or equal se for women compared to me 0. This opportunity will suppor priate population eligible for the ucing the onset or slowing the	ow or borderline 10 risk of developing o to 50 years for men n, it may be reasona t a two component e intervention, and s progression of subcl	-year risk (<7.5%) ardiovascular dise , and given the lov ble to use an expa primary preventic second, determine inical coronary at	for their first ease (CVD). Fo wer rate of anded inclusio on clinical trial e which nerosclerosis.

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	screening component will be immediate until the trial is completely enrolled. It is arm. The control arm is expected to be of two active arms is expected to involve a primary prevention in older high-risk add with less definitive evidence of primary if earlier treatment of subclinical ASCVD recommend treatment. This NOFO will s a multi-site clinical trial among young ad mechanism of award and runs in paralle Coordinating Center (RFA-HL-25-010). Th overall project coordination, administratic collaborating CCC application. The applie 010) on implementation of the clinical tri inequities. Clinical trials using innovative a CCC application and a collaborating Da due date for consideration by NHLBI. Ap contacts prior to applying. This Notice of (PEDP).	s expected that the trial will have current guideline-based behaviora n additional pharmacological inter- ults, such as LDL-lowering therapy prevention efficacy in older adults will reduce adverse clinical events support applications to develop an dults without clinical ASCVD. It will I with a companion NOFO that en- he objective of the DCC application tion, data management, and biost cation should also describe its app rial community engagement and d e designs such as platform trials, a ta Coordinating Center (DCC) app oplicants are strongly encouraged t	three arms. One will and pharmacolo rvention(s) with d or. The other active at the goal of this s to a greater deg d implement a Da utilize a mileston courages applicat n is to present a c atistical support f proaches to collab liversity plans, as daptive, and Baye lication must be s to contact the app	will be a control or gical interventions. efinite evidence of arm may involve in research strategy is ree than current gu ata Coordinating Ce e-driven cooperativ ions for a collabora omprehensive plan or the clinical trial p orate with the CCC well as reducing he sian designs are we ubmitted on the sa propriate Scientific/	comparison One of the efficacy for itervention(s) to determine ideline- nter (DCC) for ve agreement ting Clinical to provide proposed in th (RFA-HL-25- alth elcomed. Both me applicatio Research
127019 NHLBI Career Transition Award for Research Trainees (K22 Clinical T		National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24- 211 1	2-Oct-2024	Not Specified
Contact Name	e Kristen Z. Morgan, Ph.D.				
Contact Telephone	301-827-5163				
Contact Emai	il <u>direducation@nhlbi.nih.gov</u>				
Sponsor Website	2				
Program UR	L <u>Link to program URL</u>				
Ŭ					
Deadline Dates (ALL) 12-Oct-2024 , 12-Feb-2025 , 12-Jun-202 2027	5 , 12-Oct-2025 , 12-Feb-2026 , 12	-Jun-2026 , 12-Oc	t-2026 , 12-Feb-20	27 , 12-Jun-

SPIN ID Program Title		Sponsor Name	ponsor Numb	per Deadline Date	Funding Amount
	Transition Award will support two pha phase (three years), for a total of five extramural phase is not automatic. Ap during the mentored phase as determ be carried out at the extramural instit specifically for applicants proposing to study, or a separate ancillary study to proposing to serve as lead investigato	years of combined support. Transitio pproval of the transition will be based ined by an NHLBI progress review, w ution. This Notice of Funding Opport o serve as the lead investigator of an an existing trial, as part of their resea	n from the int l on the succes hich will inclu- unity Annound independent of arch and caree	ramural phase of suppose so of the awardee's read de an evaluation of a read cement (NOFO) is desi clinical trial, a clinical t er development. Appli	port to the search program research plan to gned rial feasibility cants not
107786 Notice of Special Interest (NOSI Studies of Genetic Variation, Fu	: Methods Development for Genomic nction, and Disease	National Human Genome Research Institute/NIH/DHHS	NOT-HG- 22-007	05-Sep-2024	Not Specified
Contact Nam	e Lisa D. Brooks, Ph.D.				
Contact Telephor	ne 301-547-1387				
Contact Ema	ail <u>lisa.brooks@nih.gov</u>				
Sponsor Websi	te				
Program UI	RL Link to program URL				
Deadline Dates (AL	L) 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2	024			
Synops	The National Human Genome Research is applications that develop novel comp relate to genomic function, phenotype	utational or experimental approache	•		-
126962 Broadening Perspectives to Adv	etition: Building Partnerships and ance Ethical, Legal, and Social AER) Program (UM1), Clinical Trial	National Human Genome Research Institute/NIH/DHHS	n RFA-HG- 24-026	16-Oct-2024 [Optional][LOI/Pre- App]	3,250,000 USD
Contact Nam	e Rene Sterling, Ph.D., M.H.A.				
Contact Telephor	ne 301-435-1275				
Contact Ema	ail <u>rene.sterling@nih.gov</u>				
Sponsor Websi	te				
5001301 WC031					
	RL Link to program URL				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	The National Human Genome Research experience, and perspectives brought t advances in human genetics or genomic and Social Implications (ELSI) Research complex, and understudied topics assoc research teams that include partnership research, 3) research capacity building to opportunities for early career scholars, Opportunity (NOFO) is for a limited con United States and its territories that reconstructions are underrepresent	o bear in research addressing the cs. The Building Partnerships and E (BBAER) Program will support: 1) t ciated with advances in human gen os with relevant communities affect to develop, conduct, and sustain E research team members, and other petition that solicits UM1 applica ceived less than \$30 million per ye	ethical, legal, and s Broadening Perspect transdisciplinary EL netics and genomic cted by and with an LSI research, and 4 er BBAER project st tions from domest ar in total NIH func	social implications (ctives to Advance E SI research addres cs, 2) the establish n interest in the pro- workforce develo taff. This Notice of ic organizations loo ling for the past th	(ELSI) of Ethical, Legal, sing timely, ment of ELSI oposed opment Funding cated in the
19016 NIAID New Innovators Awards (DF	P2 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23- 198 12	1-Oct-2024	1,500,000 USD
Contact Name	Diane Lawrence, Ph.D.				
Contact Telephone	240-627-3202				
Contact Email	NIAIDDP2@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	11-Oct-2024 , 10-Oct-2025				
Synopsis	The NIAID New Innovator Award suppo independent Early Stage Investigators of with the potential to produce a major in problems in biomedical research of price scientific directions, or the use of novel backgrounds and in any topic relevant t	of exceptional creativity who proper mpact, test scientific paradigms, o prity to NIAID. Applications propos methodologies are encouraged. A	ose novel, original r advance key conc ing unexpected co opplications from ir	and insightful resea cepts on broad, imp nvergence of discip	arch concepts portant plines, new
20004 Notice of Special Interest (NOSI): A Collaborative Projects Supported		National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI- 23-044 02	2-Oct-2024	100,000 USD
Contact Name	Andrea L. DiCarlo-Cohen, Ph.D.				

SPIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	hena@niaid.nih.gov				
Sponsor Website					
	<u>k to program URL</u>				
Deadline Dates (ALL) 02-					
coll gra safe Synopsis itse gro inst	e purpose of this Notice of Special In laborations between researchers the ant and cooperative agreement portf e and effective medical countermea st-exposure in a radiological or nucle elf to the establishment of formal pa pups to achieve outcomes that would titutions. The goal of NOSI is to foste w funding that will enhance the state	oughout the NIAID/Radiation and olio (e.g., U01, U19, R21, R01, P02 sures (MCMs) and biodosimetry to ar public health emergency. The r rtnerships across projects with sin I likely be impossible without the er collaborations that will allow aw	l Nuclear Counte 1). The NIAID/RN ools for civilians multidisciplinary nilar goals, which expertise, mode	rmeasures Program (CP has been tasked w that can be used at le nature of radiation re n enables collaboratir s, and facilities availa op data that can be le	RNCP)-funded vith developing ast 24 hours search lends og research ble at other
125560 RFA-AI-24-025 Engineering Durable (R01 Clinical Trial Not Allowed)	e HIV Vaccine Responses (ENDURE)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 24-025	10-Sep-2024 [Optional][LOI/Pre- App]	750,000 USD
Contact Name Am	ny Palin, Ph.D.				
Contact Telephone 240	0-627-3342				
Contact Email <u>am</u>	ıy.palin@nih.gov				
Sponsor Website					
Program URL Lini					
	-Sep-2024 [Optional][LOI/Pre-App], (
	e purpose of this Notice of Funding C prove durable immune responses to		basic and applied	l research to underst	and and
107638 Notice of Special Interest (NOSI): Acce	elerating Malaria Vaccine Discovery	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI- 22-014	07-Sep-2024	Not Specified
Contact Name Anr Contact Telephone 240					



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Email	moa@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-20	25			
Synopsis	The purpose of this Notice of Special I NIAID on early phase translational reso suitable for further downstream devel of new vaccine candidates that prever malaria parasites, especially Plasmodi	earch that will generate new malari lopment and clinical evaluation. Thi nt infection, ameliorate disease, and	a vaccine candidat s NOSI encourages d/or interrupt trans	es with desirable f studies that will le	eatures ead to discover
123681 Understanding Mechanisms and C Clinical Trial Not Allowed)	Dutcomes of Trained Immunity (R01	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-24- 112	5-Oct-2024	Not Specified
Contact Name	Ari Joffe, Ph.D.				
Contact Telephone	240-669-5084				
Contact Email	ari.joffe@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-20	025 , 05-Oct-2025 , 05-Feb-2026 , 05	5-Jun-2026 , 05-Oc	t-2026	
Synopsis	The purpose of this Notice of Funding mechanisms and biomarkers of traine immunity, related to 1) immune system allergic diseases, autoimmunity, or rej	d immunity (i.e., innate immune me m development and function, 2) im	emory), plus the fu munity to vaccines	nctional implicatio	ns of trained
114374 Notice of Special Interest (NOSI): (Complement in Fundamental	National Institute of Allergy and	NOT-AI-	7-Sep-2024	Not
Immunology		Infectious Diseases/NIH/DHHS	23-012	7-3ep-2024	Specified
Contact Name	Ari Joffe, PhD				
Contact Telephone	240-669-5084				
Contact Email	ari.joffe@nih.gov				
Sponsor Website					
Program URL	Link to program URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	2025, 07-Sep-2025, 05-Oct-2025, 16	-Oct-2025 , 07-Jan-2026			
	Synopsis	The main objective of this program is t components and/or receptors in the ir pathogenic infections, vaccination, po- studies will inform the development o	nitiation, magnitude, maintenance, st-infection sequelae, autoimmunit	and quality of imr y, allergy, or trans	nune responses inv plantation. The res	olved in
115066	NAID Physician-Scientist Pathway ndependent Clinical Trial Not Allo	<u>/ to Independence Award (K99/R00</u> owed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23- 071	7-Sep-2024	Not Specified
	Contact Name					
	Contact Telephone	301-594-5945				
	Contact Email	AITrainingHelpDesk@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-20 2026	25 , 12-Feb-2025 , 07-May-2025 , 1	2-Jun-2025 , 07-Se	ep-2025 , 12-Oct-20	125 , 07-Jan-
	Synopsis	The purpose of the NIAID Physician-Sc a strong cohort of new and talented in transition of outstanding postdoctoral positions to independent, tenure-track support during this transition to help a thereby help to address the national p is designed specifically for candidates trial feasibility study, or an ancillary cli in a clinical trial led by a mentor or co- should apply to the companion FOA (P	dependent physician-scientists. The researchers with a clinical doctoration or equivalent faculty positions. The wardees launch competitive, indep hysician-scientist workforce shorta proposing research that does not in nical trial. Under this FOA candidate mentor. Those proposing a clinical	his program is designed te degree from me be program will pro- bendent research of ge. This Funding O hvolve leading an it es are permitted t	gned to facilitate a entored, postdocto ovide independent careers in biomedic opportunity Annour ndependent clinica o propose a resear	timely ral research NIAID research cal fields and ncement (FOA) I trial, a clinical ch experience
115065 -	NAID Physician-Scientist Pathway Clinical Trial Required)	/ to Independence Award (K99/R00	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23- 070 1	2-Oct-2024	Not Specified
	Contact Name Contact Telephone					

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		AITrainingHelpDesk@niaid.nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	12-Oct-2024 , 07-Jan-2025 , 12-Feb-202 The purpose of the NIAID Physician-Scie				
	Synopsis	a strong cohort of new and talented inde transition of outstanding postdoctoral re positions to independent, tenure-track of support during this transition to help aw thereby help to address the national phy is designed specifically for candidates pr feasibility study, or a separate ancillary of independent clinical trial, or proposing to companion FOA (PAR-23-071)	ependent physician-scientists. The esearchers with a clinical doctora or equivalent faculty positions. The vardees launch competitive, indep visician-scientist workforce shorta oposing to serve as the lead inver- clinical trial, as part of their resea	nis program is designed te degree from me ne program will pro- pendent research o ge. This Funding O stigator of an inde rch and career dev	gned to facilitate a entored, postdocto ovide independent careers in biomedic pportunity Annour pendent clinical tria relopment. Those n	timely ral research NIAID research cal fields and ncement (FOA) al, a clinical trial not planning an
107851	Notice of Special Interest (NOSI): . Develop a Universal Influenza Vac		National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI- 22-013 0	7-Sep-2024	Not Specified
	Contact Name	Jennifer L. Gordon, Ph.D.				
	Contact Telephone	301-761-6805				
	Contact Email	Jennifer.gordon2@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-202	4 , 07-Jan-2025			
	Synopsis	The purpose of this Notice of Special Int in "A Universal Influenza Vaccine: The St	erest (NOSI) is to support researc rategic Plan for the National Inst	th that contributes that contributes itute of Allergy and	to the areas of inte Infectious Disease	erest outlined es."
108513	NIAID Career Transition Award (Ka Allowed)		National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22- 075	7-Sep-2024	Not Specified
	Contact Name Contact Telephone					



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Emai	AITrainingHelpDesk@niaid.nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL	07-Sep-2024 , 12-Oct-2024 , 07-Jan-20	25			
Synopsis	The purpose of the NIAID Career Trans assistant professor or equivalent and i Funding Opportunity Announcement (leading an independent clinical trial, a candidates are permitted to propose a	nitiate a successful biomedical care FOA) is designed specifically for car clinical trial feasibility study, or an	eer as an independ ndidates proposing ancillary study to	lent research scient g research that doe a clinical trial. Unde	tist. This s not involve
106991 <u>Notice of Special Interest (NOSI):</u> Improving Mouse Models of Hun	Leveraging Microbial Exposure for nan Immunity	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI- 21-072 C	17-Sep-2024	Not Specified
Contact Name	Qian "Joy" Liu, M.D., M.Sc.				
Contact Telephone	301-761-6621				
Contact Emai	l <u>niaidmousemodelnosi@nih.gov</u>				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL	07-Sep-2024 , 05-Oct-2024 , 16-Oct-20	024 , 07-Jan-2025			
Synopsis	This Notice of Special Interest (NOSI) s exposures (commonly referred to as "o of human immune function in homeos	dirty mice") to determine their use	fulness as researcl	n tools to advance u	
	argeting the Pathogen within the	National Institute of Allergy and	NOT-AI-	17-Sep-2024	Not
Arthropod Vector		Infectious Diseases/NIH/DHHS	22-074	7 500 2024	Specified
Contact Name	Adriana Costero-Saint Denis, Ph.D.				
Contact Telephone	240-292-4184				
Contact Emai	l <u>acostero@niaid.nih.gov</u>				
Sponsor Website	2				
Program URI	Link to program URL				
5					

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
	Synopsis	2025, 07-Sep-2025, 05-Oct-2025, 16 This Notice of Special Interest (NOSI) in pathogen/vector interactions to identi	nvites applications to stimulate mu	ltidisciplinary res n transmission to	earch to better unde the vertebrate host	erstand
16360	Notice of Special Interest (NOSI): Develop a Coccidioidomycosis (Va		National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI- 23-031	05-Sep-2024	Not Specified
	Contact Name	Dona C. Love, Ph.D.				
	Contact Telephone	301-761-7788				
	Contact Email	Dona.Love@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 05-Oct-20 2025 , 07-May-2025 , 05-Jun-2025 , 16 Jan-2026				•
	Synopsis	The purpose of this Notice of Special In outlined in the NIAID Strategic Plan For clear relevance to the strategic prioriti address gaps in Coccidioides basic rese support vaccine development; 3) deve	or Research To Develop A Valley Fe ies defined in the strategic plan, wh earch to support the development	ver Vaccine. The hich encompasses of a vaccine; 2) de	proposed research s s three major resear evelop tools and res	hould have ch areas: 1)
	Understanding Mechanisms and (Outcomes of Trained Immunity (D21	National Institute of Allergy and			
23682	<u>Clinical Trial Not Allowed</u>	<u>Juccomes of Trained Immunity (R21</u>	Infectious Diseases/NIH/DHHS	PAR-24- 111	16-Oct-2024	275,000 USD
23682	Clinical Trial Not Allowed)	Ari Joffe, Ph.D.			16-Oct-2024	-
23682	Clinical Trial Not Allowed)	Ari Joffe, Ph.D.			16-Oct-2024	-
23682	Clinical Trial Not Allowed) Contact Name Contact Telephone	Ari Joffe, Ph.D.			16-Oct-2024	-
23682	Clinical Trial Not Allowed) Contact Name Contact Telephone	Ari Joffe, Ph.D. 240-669-5084 <u>ari.joffe@nih.gov</u>			16-Oct-2024	-
23682	Clinical Trial Not Allowed) Contact Name Contact Telephone Contact Email Sponsor Website	Ari Joffe, Ph.D. 240-669-5084 <u>ari.joffe@nih.gov</u>			16-Oct-2024	-
.23682	Clinical Trial Not Allowed) Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Ari Joffe, Ph.D. 240-669-5084 <u>ari.joffe@nih.gov</u>	Infectious Diseases/NIH/DHHS	111		-

SPIN ID Prog	ram Title		Sponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
		immunity, related to 1) immune syste allergic diseases, autoimmunity, or re	•	•	es or natural infectio	ns, or 3)
	of Special Interest (NOSI): aft Survival	Optimizing Vascularized Composite	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-Al- 22-023	07-Sep-2024	Not Specified
	Contact Name	Patricia Kehn, Ph.D.				·
	Contact Telephone					
		pkehn@NIAID.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2 2025 , 07-Sep-2025 , 05-Oct-2025 , 16				25 , 16-Jun-
	Synopsis	The National Institute of Allergy and I models or human tissue specimens th rejection and maximize graft survival immunosuppression required for long	nat focus on 1) optimizing treatment after vascularized composite allotra	and graft monit	oring to reduce incide	ence of acute
	-24-029 Mechanisms of I (U01 Clinical Trial Not Allo	nducing HIV Immunity in Early Life wed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 24-029	10-Sep-2024 [Optional][LOI/Pre- App]	3,750,000 USD
	Contact Name	Anjali Singh, Ph.D.				
	Contact Telephone	240-507-4924				
	Contact Email	anjalisingh@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Sep-2024 [Optional][LOI/Pre-App]	, 09-Oct-2024			
	Synopsis	The purpose of this notice of funding for establishing, developing and main the impact of prophylactic vaccination infection.	taining immunity to HIV in early life	(from birth to lea	ss than 12 years of ag	ge), including

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
127123	Notice of Special Interest (NOSI): of DEAD/H-box Helicases	Understanding the Immune Functions	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-Al- 24-058	05-Oct-2024	Not Specified
	Contact Name	Qian "Joy" Liu, M.D., M.Sc.				
	Contact Telephone	301-761-6621				
	Contact Email	liujoy@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Oct-2024				
	Synopsis	This Notice of Special Interest (NOSI) so function, and regulation of DEAD/H-bo from such studies may be applied to th or treat/prevent immune-mediated dis	x helicases in immune homeostasi he design of improved vaccines and	s, activation, and/	or function. Know	edge obtained
113395	NIAID Research Opportunities for Promote Workforce Diversity (RO	<u>New and "At-Risk" Investigators to</u> <u>1 Clinical Trial Optional)</u>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22- 241	07-Sep-2024	Not Specified
	Contact Name	Diane Adger-Johnson, MPH				
	Contact Telephone					
	Contact Email	AITrainingHelpDesk@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 05-Nov-20 2025 , 07-Sep-2025	024 , 07-Jan-2025 , 05-Feb-2025 , 0	5-Mar-2025 , 07-I	May-2025 , 05-Jun-2	025 , 05-Jul-
	Synopsis	The purpose of this funding opportuni mission. This FOA seeks to support eith successfully for substantial, independe support as a PD/PI on a substantial ind award in the current fiscal year, will ha backgrounds, including those from gro	ner (a) a New Investigator (NI), an i nt funding from NIH, or (b) are an ependent research award and unle ve no substantial research grant fu	ndividual who has 'At-Risk' investiga ess successful in se unding in the follo	s not previously com tor, an individual wh ecuring a substantia wing fiscal year, fro	npeted no had prior I research grant
109790	NIAID Research Education Program	m (R25 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22- 134	09-Oct-2024	1,755,000 USD

		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
Contact Name					
Contact Telephone					
	AlTrainingHelpDesk@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Oct-2024				
Synopsis	The NIH Research Education Program (R2 overarching goal of this R25 program is to workforce to meet the nation's biomedica goal, this FOA will support creative educat Experiences Mentoring Activities	support educational activities t I, behavioral and clinical resear	that complemer ch needs. To ac	it and/or enhance the complish the stated ov	training of a /er-arching
7233 RFA-AI-24-041 Novel Approache Medical Countermeasure Develop		ational Institute of Allergy and fectious Diseases/NIH/DHHS	RFA-AI- 24-041	02-Oct-2024 [Optional][LOI/Pre- App]	200,000 USD
Contact Name	Lanyn P. Taliaferro, Ph.D.				
Contact Telephone	240-669-5479				
Contact Email	lanyn.taliaferro@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
-	Link to program URL 02-Oct-2024 [Optional][LOI/Pre-App], 01-N	Nov-2024			
Deadline Dates (ALL) Synopsis		portunity (NOFO) is to support e intermeasures, biodosimetry, a om radiation exposure sustaine t of preliminary data to help ad	nd animal mode d during a radia vance high-risk,	el development to tion mass casualty inci high-reward projects	dent. This needed for a

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Name	Leah R. Vincent, PhD				
Contact Name Contact Telephone					
	leah.vincent@nih.gov				
Sponsor Website					
	Link to program URL				
Ŭ	05-Oct-2024 [Optional][LOI/Pre-App], 04	-Nov-2024			
Synopsis	The nurnose of this notice of funding on	portunity (NOFO) is to support ba	asic and exploratory	research projects	to advance
120360 Notice of Special Interest (NOSI): Accelerating Research in Underst	Administrative Supplement for	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR- 24-008 02	-Oct-2024	300,000 USD
Contact Name	Alexey Belkin, Ph.D.				
Contact Telephone	240-755-3031				
Contact Email	alexey.belkin@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	02-Oct-2024				
Synopsis	The purpose of this announcement is to Musculoskeletal and Skin Diseases (NIAM research uncovering the basis for inferio response in Black Americans and African Asian Americans, and Native Hawaiians a	IS) is interested in receiving adm r diagnosis, increased prevalence Americans, Hispanics and Latino	inistrative supplem , elevated clinical so s, American Indians	ents to grants focu everity, and altere	used on skin d treatment
109528 Limited Competition: Small Grant K25 Recipients (R03) (Clinical Tria	Program for NIAMS K01, K08, K23, and Is Not Allowed	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-22- 119 21	-Oct-2024	100,000 USD
Contact Name	Su-Yau Mao, Ph.D.				
Contact Telephone	301-594-5032				
Contact Email	maos2@mail.nih.gov				
·					

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	21-Oct-2024 , 19-Feb-2025				
Synopsis	The National Institute of Arthritis and I supported K01, K08, K23, and K25 recip during the second to fourth year of the costs for the entire project period of up conduct research as they complete the supports different types of projects, in contained research projects; developm is, therefore, intended to support research and that provide support, in addition to Clinical trials of any phase will not be s	pients the opportunity to apply for eir K award. Through the use of this p to two years, the NIAMS is seekin eir transition to fully independent in cluding pilot and feasibility studies, nent of research methodology; and arch projects that can be carried ou o the career development award, f	Small Grant (R03) s mechanism, which ny to enhance the ca nvestigator status. T ; secondary analysis development of ne ut in a short period	upport at an appr allows up to \$100 apability of its scie he R03 grant med of existing data; w research techno of time with limite	opriate point),000 direct entists to chanism small, self- plogy. The RO ed resources
14290 <u>Notice of Special Interest (NOSI):</u> <u>HIV/AIDS in NIAMS</u>	Promoting Research Opportunities on	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-	-Aug-2024	Not Specified
Contact Name	Heiyoung Park, Ph.D.				
Contact Telephone	301-594-5032				
Contact Email	parkh1@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
. ,	06-Aug-2024, 07-Sep-2024, 05-Oct-20 2025, 07-May-2025, 05-Jun-2025, 16 Jan-2026, 05-Feb-2026, 16-Feb-2026, 07-Jan-2027, 05-Feb-2027, 16-Feb-20 2027, 07-Jan-2028	-Jun-2025 , 06-Aug-2025 , 07-Sep-2 , 07-May-2026 , 05-Jun-2026 , 16-Ju	2025 , 05-Oct-2025 , un-2026 , 07-Sep-20	16-Oct-2025 , 05 26 , 05-Oct-2026	-Dec-2025 , 0 , 16-Oct-2026
Synopsis	The purpose of this announcement is t and Skin Diseases (NIAMS) of an area c mission.				

117716 Notice of Special Interest (NOSI): Supporting Exploratory/Developmental National Institute of Arthritis and NOT-AR- 06-Aug-2024 Not

SPIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
Research Focused on NIAMS Core	e Mission Areas	Musculoskeletal and Skin Diseases/NIH/DHHS	23-006		Specified
Contact Name	Jana Eisenstein				
Contact Telephone	301-594-5032				
Contact Email	jana.eisenstein@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	06-Aug-2024, 07-Sep-2024, 05-Oct-20 2025, 07-May-2025, 05-Jun-2025, 16 Jan-2026, 05-Feb-2026, 16-Feb-2026 07-Jan-2027	5-Jun-2025 , 06-Aug-2025 , 07-Sep-	2025 , 05-Oct-20	25 , 16-Oct-2025 , 05	-Dec-2025 , 07
Synopsis	The purpose of this announcement is Musculoskeletal and Skin Diseases (NI on NIAMS core mission areas. Awards systems, tools, agents, targets, and ter research within the NIAMS mission. T considerable risk, but have the potent	AMS) is interested in receiving Exp will provide support for innovative chnologies that have the potential hese studies often assess the feasi	loratory/Develo projects that in for significant in bility of a novel a	omental grant applica troduce novel scienti npact, and to substan avenue of investigatic	tions focused fic ideas, mode tially advance on and involve
127122 RFA-AR-25-005HEAL Initiative: I Longitudinal Cohort Teams (UC2)		National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	RFA-AR- 25-005	11-Sep-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Rebecca Lenzi, Ph.D.				
Contact Telephone	2				
Contact Email	rebecca.lenzi@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	11-Sep-2024 [Optional][LOI/Pre-App],	11-Oct-2024			
Synopsis	The purpose of this Notice of Funding interdisciplinary teams to enhance lon (cLBP) cohort studies. This Notice of F	ngitudinal data collection and analy	sis with existing	large scale chronic lo	w back pain

SPIN ID Program Title		Sponsor Name	Sponsor Numb	per Deadline Date	Funding Amount
	Research teams will build upon the inf (BACPAC) Research Program to contin comprehensive understanding of chro the originally funded BACPAC awarded existing HEAL projects. Funded teams, that will facilitate interactions, synergi accelerate the knowledge transfer acr	ue to advance the diagnosis and tre nic pain across musculoskeletal dise es. Teams are encouraged, but not li through this NOFO, will inform the ies, and integration of methodologie	atment of low l ases. New app mited to, colla structure and k es, data elemer	back pain to accelerate licant teams are encou borative arrangements key elements of future	e Iraged, beyonc s across HEAL efforts
127031 RFA-AR-24-007HEAL KIDS (Know Studies): Chronic Pain Program (L	vledge, Innovation and Discovery JC2 Clinical Trial Optional)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	RFA-AR- 24-007	21-Oct-2024 [Optional][LOI/Pre- App]	6,500,000 USD
Contact Name	Robert Walker, Jr Ph.D.				
Contact Telephone	2				
Contact Emai	I <u>robert.walker2@nih.gov</u>				
Sponsor Website	2				
-	Link to program URL				
Deadline Dates (ALL	21-Oct-2024 [Optional][LOI/Pre-App],				
Synopsis	As part of the NIH's Helping to End Ad Musculoskeletal and Skin Diseases and Chronic Pain Collaborating Research T projects that combine clinical research understanding of primary and seconda enhance and expand our capacity to p management of pediatric pain condition challenge in the biopsychosocial mode interactions. Teams are encouraged to innovative, and improved strategies to may include testing of powerful tools, condition-specific, age-appropriate the Opportunity (NOFO) complements the clinical trials of acute pain in infants, c respectively. This Notice of Fuding Op	d other participating NIH Institutes a eams (HEAL KIDS CPT) Program to co any chronic pain conditions in childre ursue challenging biological problem ons. The HEAL KIDS CPT projects are el of pain that requires collaboration o consider transformative objectives o enhance understanding of chronic models, and approaches to accelerate erapeutics, and next-generation clin e previously issued NOFO (RFA-HD-2 hildren, and adolescents and the est	nd Centers inv onduct interdis and measureme en and adolesce ns, therapeutic expected to ac , synergy, know and design pro pain mechanis ate the develop ical manageme 4-011) and NOI tablishment of	ite applications for the sciplinary team-based i ent science, which will ents. The results are ex- ts development, and ef- ddress a significant scie wledge integration and ojects that would lead ms at the individual lead oment and translation ent of pain. This Notice FO (RFA-HD-24-012) for a HEAL KIDS Resource	HEAL KIDS research improve our opected to fective entific team to new, vel. Research of pain of Funding ocused on Center,

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
17677 Notice of Special Interest (NOSI): Applications	Synthetic Biology for Biomedical	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	NOT-EB- 23-002 06	5-Sep-2024	Not Specified
Contact Name	Hye-Sook Kim, Ph.D.				
Contact Telephone	301-827-6910				
Contact Emai	l <u>hye-sook.kim@nih.gov</u>				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	06-Sep-2024 , 05-Oct-2024 , 16-Oct-20 2025 , 16-Oct-2025	024 , 08-Jan-2025 , 05-Feb-2025 , 16	-Feb-2025 , 05-Ma	y-2025 , 05-Jun-20	25 , 16-Jun-
Synopsis	The purpose of this Notice is to announ National Cancer Institute (NCI), the Na the National Institute of Allergy and In Bioengineering (NIBIB), the Eunice Ken	tional Heart, Lung and Blood Institu fectious Diseases (NIAID), the Natio	ite (NHLBI), the Na nal Institute of Bio	tional Institute on a medical Imaging a	Aging (NIA), nd
	the National Institute of General Medi- relevant to synthetic biology.	•			
	the National Institute of General Medi relevant to synthetic biology.	•	ng new application		
13425 Placenta Development and Funct Not Allowed)	the National Institute of General Medi relevant to synthetic biology.	cal Sciences (NIGMS) are encouragin National Institute of Child Health a	ng new application	is to advance resea	Not
13425 Placenta Development and Funct Not Allowed)	the National Institute of General Medi relevant to synthetic biology. <u>hinvasive, Real Time Assessment of</u> <u>tion Across Pregnancy (R01 Clinical Trial</u> David Weinberg, PhD	cal Sciences (NIGMS) are encouragin National Institute of Child Health a	ng new application	is to advance resea	Not
13425 <u>Placenta Development and Funct</u> <u>Not Allowed)</u> Contact Name Contact Telephone	the National Institute of General Medi relevant to synthetic biology. <u>hinvasive, Real Time Assessment of</u> <u>tion Across Pregnancy (R01 Clinical Trial</u> David Weinberg, PhD	cal Sciences (NIGMS) are encouragin National Institute of Child Health a	ng new application	is to advance resea	Not
13425 <u>Placenta Development and Funct</u> <u>Not Allowed)</u> Contact Name Contact Telephone	the National Institute of General Media relevant to synthetic biology. <u>hinvasive, Real Time Assessment of</u> tion Across Pregnancy (R01 Clinical Trial David Weinberg, PhD 301-435-6973 <u>weinbergd@mail.nih.gov</u>	cal Sciences (NIGMS) are encouragin National Institute of Child Health a	ng new application	is to advance resea	Not
13425 <u>Placenta Development and Funct</u> <u>Not Allowed)</u> Contact Name Contact Telephone Contact Emai Sponsor Website	the National Institute of General Media relevant to synthetic biology. <u>hinvasive, Real Time Assessment of</u> tion Across Pregnancy (R01 Clinical Trial David Weinberg, PhD 301-435-6973 <u>weinbergd@mail.nih.gov</u>	cal Sciences (NIGMS) are encouragin National Institute of Child Health a	ng new application	is to advance resea	Not
13425 <u>Placenta Development and Funct</u> <u>Not Allowed</u>) Contact Name Contact Telephone Contact Emai Sponsor Website Program URI	the National Institute of General Medi relevant to synthetic biology. <u>hinvasive, Real Time Assessment of</u> <u>tion Across Pregnancy (R01 Clinical Trial</u> David Weinberg, PhD 301-435-6973 <u>weinbergd@mail.nih.gov</u>	cal Sciences (NIGMS) are encouragin National Institute of Child Health a	ng new application	is to advance resea	nrch activities
13425 <u>Placenta Development and Funct</u> <u>Not Allowed</u>) Contact Name Contact Telephone Contact Emai Sponsor Website Program URI Deadline Dates (ALL)	the National Institute of General Media relevant to synthetic biology. hinvasive, Real Time Assessment of tion Across Pregnancy (R01 Clinical Trial David Weinberg, PhD 301-435-6973 weinbergd@mail.nih.gov Link to program URL	cal Sciences (NIGMS) are encouragin National Institute of Child Health a Human Development/NIH/DHHS nent (FOA) invites grant application velopment of safe, real-time, non-ir	ng new application and PAR-22- 237 05	is to advance resea	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Placenta Development and Functi Not Allowed)	on Across Pregnancy (R21 Clinical Trial	Human Development/NIH/DHHS	236		USD
	Contact Name	David Weinberg, PhD				
	Contact Telephone	301-435-6973				
	Contact Email	weinbergd@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Oct-2024 , 16-Nov-2024				
	Synopsis	This Funding Opportunity Announcem emerging novel approaches for the dev the development and function of the h	elopment of safe, real-time, non-ir			
11267/1	Chemical Screening and Optimiza Allowed)	tion Facility (X01 Clinical Trial Not	National Institute of Child Health a Human Development/NIH/DHHS	and PAR-23- 193)3-Oct-2024	Not Specified
	Contact Name	Christopher C. Lindsey, PhD				
	Contact Telephone	301-538-9761				
	Contact Email	<u>chris.lindsey@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-Oct-2024 , 03-Apr-2025 , 03-Oct-202	25 , 03-Apr-2026			
	Synopsis	The NICHD has a state-of-the-art Chem contraceptive and reproductive health preclinical services including Investigati protein generation, X-ray crystallograph drug metabolism). The long-term object therapeutic option in the field of contra availability and available funding).	related product development. This onal Device Exemption (IDE) or Inv ny, high throughput screening, stru tive is to enable a preclinical candi	facility has the ca estigational New cture activity rela date for IND/IDE	apabilities and capa Drug (IND)-enabling ationships, hit-to-lea study(ies) that offer	city for g studies (e.g., nd generation, s a safe
I I /X	Advancing Research to Understan Clinical Trial Not Allowed)	d Congenital Malformations (R01	National Institute of Child Health a Human Development/NIH/DHHS	and PAR-22- 215	05-Oct-2024	2,499,995 USD

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Reiko Toyama, Ph.D.				
Contact Telephone					
	toyamar@nih.gov				
Sponsor Website					
-	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025			anala that in the f	
Synopsis	The purpose of this funding opportunity a understanding of the mechanisms under with human translational/clinical approac methods (genomics, proteomics, metabo developmental biology research to identi associated with the formation of, suscept	lying the formation of structural l ches. Applicants are encouraged plomics, etc.), and synthetic biolo ify specific genetic, epigenetic, er	birth defects using to take advantage gy, biochemical ar wironmental, or g	g animal models in e of advances in ger nd other approache gene/environment i	conjunction letics, 'omics s to nteractions
107317 Innovative Screening Approaches Disorders in Newborns (R01 - Clin		lational Institute of Child Health a luman Development/NIH/DHHS	and PAR-21- 353 0	5-Oct-2024	Not Specified
Contact Name	Mollie Minear, Ph.D.				
Contact Telephone	301-827-9442				
Contact Email	mollie.minear@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024				
Synopsis	This FOA encourages research relevant to for potentially fatal or disabling condition genetic conditions where screening may demonstrating the benefits of early inter- screening panel. This FOA defines a "high infants with the condition would significa	ns that have been identified throu be possible in the near future. Ha vention or treatment, are import priority" condition as one where	ugh newborn scre aving an accurate ant criteria for inc screening is not o	ening, as well as for screening test, as w cluding a condition currently recomme	^r "high priority' vell as on a newborn
103657 NICHD Small Research Grant Prog with Humans Required)		Jational Institute of Child Health a Juman Development/NIH/DHHS	and PA-21- 231 0	7-Sep-2024	50,000 USE

PIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Constant Norma					
	Contact Name					
	Contact Telephone					
		NICHDReferral@mail.nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-202 The NICHD Small Research Grant Progra				
	Synopsis	mission. This funding opportunity annou in NOT-OD-18-212 as "prospective basic definition of a clinical trial and also meet include studies that prospectively assign variables) and that assess biomedical or aspects of phenomena without specific a applications toward processes or produc	science studies involving human t the definition of basic research. human participants to conditions behavioral outcomes in humans f application towards processes or p	participants." Thes Types of studies th (i.e., experimenta or the purpose of products in mind. S	se studies fall within hat should submit u nlly manipulate inde understanding the Studies conducted	n the NIH inder this FO ependent fundamenta with specific
)3656 <u>N</u>	NICHD Small Research Grant Prog	ram (R()3 (linical Trial Required)	National Institute of Child Health a Human Development/NIH/DHHS	and PA-21- 07 221 07	7-Sep-2024	100,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	NICHDReferral@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-202	5			
	Synopsis	The NICHD Small Research Grant Progra mission. The R03 activity code supports resources. The R03 program may be use analysis of existing data; small, self-cont new research technology.	small research projects that can b d for different types of projects in	e carried out in a s cluding pilot and f	short period of time easibility studies; s	e with limite econdary
	Advancement and Innovation in N Development and Predictors (R01		National Institute of Child Health a Human Development/NIH/DHHS	and PAR-24- 243	5-Oct-2024	Not Specified
Icahn S Mount	School of Medicine at	NIH Funding Oppor	tunities Due: Oct 2024			92

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Name	-				
Contact Telephone					
	virginia.salo@nih.gov				
•	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Nov-2024 , 05-Feb-2025 , 2026 , 05-Mar-2026 , 05-Jun-2026 , 05-Jul- Jul-2027				
Synopsis	The purpose of this notice of funding opport conceptualization of qualities of the enviro development of novel measures of childre focused, culturally and linguistically respon development and/or impairment, and prece will be assessed as part of the scientific and be considered incomplete and will be with Diverse Perspectives (PEDP).	onment that can support langua n's language development. The nsive, and generalizable tools to dictors thereof. This NOFO requi nd technical peer review evaluat	ge development in overall goal is to be further our unders ires a Community E ion. Applications th	children and that uild the number of tanding of children ingagement (CE) P nat fail to include a	focuses on the strengths- n's language lan, which CE Plan will
126760 Advancement and Innovation in M Development and Predictors (R21		tional Institute of Child Health a man Development/NIH/DHHS	nd PAR-24- 244 16-	-Oct-2024	275,000 USD
Contact Name	Virginia Salo				
Contact Telephone	301-402-3682				
Contact Email	virginia.salo@nih.gov				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
	16-Oct-2024 , 16-Nov-2024 , 16-Feb-2025 , 2026 , 16-Mar-2026 , 16-Jun-2026 , 16-Jul- Jul-2027				
Synopsis	The purpose of this notice of funding oppo conceptualization of qualities of the enviro development of novel measures of childre	onment that can support langua	ge development in	children and that	focuses on the

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
		focused, culturally and linguistically res development and/or impairment, and p Enhancing Diverse Perspectives (PEDP).	predictors thereof. This Notice of Fu		-	
107310 -	nnovative Screening Approaches Disorders in Newborns (R21 - Clin		National Institute of Child Health a Human Development/NIH/DHHS	and PAR-21- 355	16-Oct-2024	275,000 USD
	Contact Name	Mollie Minear, Ph.D.				
	Contact Telephone	301-827-9442				
	Contact Email	mollie.minear@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Oct-2024				
	Synopsis	This FOA encourages research relevant for potentially fatal or disabling condition genetic conditions where screening man demonstrating the benefits of early inter screening panel. This FOA defines a "hig infants with the condition would signific	ons that have been identified throu y be possible in the near future. Ha ervention or treatment, are importa gh priority" condition as one where	igh newborn sc ving an accurat ant criteria for screening is no	reening, as well as fo te screening test, as v including a condition ot currently recomme	r "high priority' vell as on a newborn
	nnovative Screening Approaches Disorders in Newborns (R03 - Clin		National Institute of Child Health a Human Development/NIH/DHHS	ind PAR-21- 354	16-Oct-2024	100,000 USD
	Contact Name	Mollie Minear, Ph.D.				
	Contact Telephone					
	Contact Telephone	301-827-9442 mollie.minear@nih.gov				
	Contact Telephone Contact Email Sponsor Website	301-827-9442 mollie.minear@nih.gov				
	Contact Telephone Contact Email Sponsor Website	301-827-9442 mollie.minear@nih.gov Link to program URL				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	demonstrating the benefits of early interv screening panel. This FOA defines a "high infants with the condition would significan	priority" condition as one where	screening is not cu	urrently recomme	
113756 NCMRR Early Career Research Aw	uard (RO3 (Tinical Trial (Intional)	ational Institute of Child Health a uman Development/NIH/DHHS	and PAR-23- 029 16-	-Oct-2024	200,000 USD
Contact Name	Maria Nurminskaya, PhD				
Contact Telephone	240-591-9986				
Contact Email	Maria.nurminskaya@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025	, 16-Oct-2025 , 16-Feb-2026			
		ation Docoarch (NICN/DD) Larly (a	proor Bocopreh (EC)	D) Award (DO2) is i	ntandad ta
Synopsis	support both basic and clinical research fr research must be focused on one or more the NIH Research Plan on Rehabilitation for rehab-plan). The NCMRR ECR Award R03 g existing data; small, self-contained resear outcomes research; and development of r Award R03 is for the Program Director(s)/ subsequent R01 application.	of the areas within the mission or strategic priorities (https://ww grant mechanism supports variou ch projects; development of rese new technology. Irrespective of t	are establishing in of NCMRR: Applica vw.nichd.nih.gov/n us types of projects earch methodology he type of project,	dependent resear nts are encourage ewsroom/news/1 including second ; translational rese the intent of the l	ch careers. The d to refer to 10121-NIH- ary analysis of earch; NCMRR ECR
113468 Notice of Special Interest (NOSI): Research for Healthy Pregnancies	support both basic and clinical research fr research must be focused on one or more the NIH Research Plan on Rehabilitation fo rehab-plan). The NCMRR ECR Award R03 g existing data; small, self-contained researc outcomes research; and development of r Award R03 is for the Program Director(s)/ subsequent R01 application.	om rehabilitation scientists who of the areas within the mission or strategic priorities (https://ww grant mechanism supports variou ch projects; development of rese new technology. Irrespective of t	are establishing in of NCMRR: Applica vw.nichd.nih.gov/n us types of projects earch methodology he type of project, I(s)) to obtain suffic	dependent resear nts are encourage ewsroom/news/1 including second ; translational rese the intent of the l	ch careers. The d to refer to 10121-NIH- ary analysis of earch; NCMRR ECR
113468 Notice of Special Interest (NOSI): Research for Healthy Pregnancies	support both basic and clinical research fr research must be focused on one or more the NIH Research Plan on Rehabilitation fo rehab-plan). The NCMRR ECR Award R03 g existing data; small, self-contained researc outcomes research; and development of r Award R03 is for the Program Director(s)/ subsequent R01 application.	om rehabilitation scientists who of the areas within the mission or strategic priorities (https://ww grant mechanism supports variou ch projects; development of rese new technology. Irrespective of t Principal Investigator(s) (PD(s)/P	are establishing in of NCMRR: Applica ww.nichd.nih.gov/n us types of projects earch methodology he type of project, I(s)) to obtain suffi	dependent resear nts are encourage ewsroom/news/1 including second ; translational rese the intent of the l cient preliminary o	ch careers. The d to refer to 10121-NIH- ary analysis of earch; NCMRR ECR data for a Not
113468 Notice of Special Interest (NOSI): Research for Healthy Pregnancies	support both basic and clinical research fr research must be focused on one or more the NIH Research Plan on Rehabilitation for rehab-plan). The NCMRR ECR Award R03 g existing data; small, self-contained research outcomes research; and development of r Award R03 is for the Program Director(s)/ subsequent R01 application. High Priority Areas in Placental s (Reissue) High Placental Na	om rehabilitation scientists who of the areas within the mission or strategic priorities (https://ww grant mechanism supports variou ch projects; development of rese new technology. Irrespective of t Principal Investigator(s) (PD(s)/P	are establishing in of NCMRR: Applica ww.nichd.nih.gov/n us types of projects earch methodology he type of project, I(s)) to obtain suffi	dependent resear nts are encourage ewsroom/news/1 including second ; translational rese the intent of the l cient preliminary o	ch careers. The d to refer to 10121-NIH- ary analysis of earch; NCMRR ECR data for a Not
113468 Notice of Special Interest (NOSI): Research for Healthy Pregnancies Contact Name Contact Telephone	support both basic and clinical research fr research must be focused on one or more the NIH Research Plan on Rehabilitation for rehab-plan). The NCMRR ECR Award R03 g existing data; small, self-contained research outcomes research; and development of r Award R03 is for the Program Director(s)/ subsequent R01 application. High Priority Areas in Placental s (Reissue) High Placental Na	om rehabilitation scientists who of the areas within the mission or strategic priorities (https://ww grant mechanism supports variou ch projects; development of rese new technology. Irrespective of t Principal Investigator(s) (PD(s)/P	are establishing in of NCMRR: Applica ww.nichd.nih.gov/n us types of projects earch methodology he type of project, I(s)) to obtain suffi	dependent resear nts are encourage ewsroom/news/1 including second ; translational rese the intent of the l cient preliminary o	ch careers. The d to refer to 10121-NIH- ary analysis of earch; NCMRR ECR data for a Not
113468 Notice of Special Interest (NOSI): Research for Healthy Pregnancies Contact Name Contact Telephone	support both basic and clinical research fr research must be focused on one or more the NIH Research Plan on Rehabilitation fo rehab-plan). The NCMRR ECR Award R03 g existing data; small, self-contained researc outcomes research; and development of r Award R03 is for the Program Director(s)/ subsequent R01 application. High Priority Areas in Placental s (Reissue) John V. Ilekis, PhD 301-435-6895 ilekisj@nih.gov	om rehabilitation scientists who of the areas within the mission or strategic priorities (https://ww grant mechanism supports variou ch projects; development of rese new technology. Irrespective of t Principal Investigator(s) (PD(s)/P	are establishing in of NCMRR: Applica ww.nichd.nih.gov/n us types of projects earch methodology he type of project, I(s)) to obtain suffi	dependent resear nts are encourage ewsroom/news/1 including second ; translational rese the intent of the l cient preliminary o	ch careers. The d to refer to 10121-NIH- ary analysis of earch; NCMRR ECR data for a Not
113468 Notice of Special Interest (NOSI): Research for Healthy Pregnancies Contact Name Contact Telephone Contact Email Sponsor Website	support both basic and clinical research fr research must be focused on one or more the NIH Research Plan on Rehabilitation fo rehab-plan). The NCMRR ECR Award R03 g existing data; small, self-contained researc outcomes research; and development of r Award R03 is for the Program Director(s)/ subsequent R01 application. High Priority Areas in Placental s (Reissue) John V. Ilekis, PhD 301-435-6895 ilekisj@nih.gov	om rehabilitation scientists who of the areas within the mission or strategic priorities (https://ww grant mechanism supports variou ch projects; development of rese new technology. Irrespective of t Principal Investigator(s) (PD(s)/P	are establishing in of NCMRR: Applica ww.nichd.nih.gov/n us types of projects earch methodology he type of project, I(s)) to obtain suffi	dependent resear nts are encourage ewsroom/news/1 including second ; translational rese the intent of the l cient preliminary o	ch careers. The d to refer to 10121-NIH- ary analysis of earch; NCMRR ECR data for a Not

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	Although the placenta is a short-lived or organ for the propagation of our species may result in many common adverse pre- restriction, stillbirth, and preterm birth. fetus that can impact the health of the ir as obesity, cardiovascular disease, and d help address a number of major gaps in	and future health of our progeny gnancy outcomes. These include In addition, a poorly functioning p ndividual later in adult life. This inc iabetes. Thus, a more comprehen	. Perturbations ir early pregnancy l lacenta can lead cludes an increas	any one of its many oss, preeclampsia, f to aberrant program ed incidence of adul	r functions etal growth nming of the t diseases such
127099 RFA-HD-25-011 The Road to Pre Coordinating Center (UM2 Clinica		National Institute of Child Health a Human Development/NIH/DHHS		1-Oct-2024 [LOI/Pre .pp]	e- Not Specified
Contact Name	Monica Longo, MD, PhD				
Contact Telephone					
Contact Email	Monica.Longo@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Oct-2024 [LOI/Pre-App], 01-Nov-2024	1			
Synopsis	This Notice of Funding Opportunity (NOF Stillbirth Research Consortium. The DCC (see RFA-HD-25-010) and will provide ma qualifications, including but not limited t epidemiology, and data science. DCC per experience in the statistical analysis of h working with large national datasets. The Stillbirth Research Consortium to suppor knowledge for advancement in stillbirth- approaches that utilize an equity lens to	will assist the work of the researce anagement and support for the Co o, expertise in clinical/health info sonnel must have experience in the igh-volume demographic, clinical, e DCC and Research Centers toget t cutting-edge basic, translational relevant research across the United	h projects funded onsortium. DCC st rmatics, bioinforr he supervision of laboratory, and i her will establish , clinical and/or c ed States, with a	d in the companion a caff must possess str natics, -omics, biost clinical studies, as v maging data, and ex an integrated and c lata sciences researd particular emphasis	announcement ong scientific atistics, vell as perience ollaborative ch to generate on
126985 Archiving and Documenting Child Sets (R03 Clinical Trial Not Allowe	Health and Human Development Data I d)	National Institute of Child Health a Human Development/NIH/DHHS	ind PAR-24- 256 1	6-Oct-2024	100,000 USD
Contact Name Contact Telephone	Susan M. Jekielek, PhD				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<u>susan.jekielek@nih.gov</u>				
Sponsor Website					
	Link to program URL				
Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-202				
Synopsis	The purpose of this funding opportunity sets within the scientific mission of the (NICHD) in order to enable secondary ar original data collected with NICHD fund	Eunice Kennedy Shriver National nalysis of these data by the scient	Institute of Child He	alth and Human De	evelopment
127098 RFA-HD-25-010 The Road to Pre Centers (UG1 Clinical Trial Option	evention of Stillbirth – Clinical Research	National Institute of Child Health Human Development/NIH/DHHS		-Oct-2024 [LOI/Pre	- 860,000 USD
· · · · · · · · · · · · · · · · · · ·	<u> </u>		23-010 Ap	[40	030
Contact Name	Monica Longo, MD, PhD				
	Monica.Longo@nih.gov				
Sponsor Website					
	Link to program URL				
C	01-Oct-2024 [LOI/Pre-App], 01-Nov-202	24			
Synopsis	The purpose of this Notice of Funding O a Research Center in the Stillbirth Resear Coordinating Center (see RFA-HD-25-01 collaborative Stillbirth Research Consort research to generate knowledge for adv emphasis on approaches that utilize an populations. International collaboration	pportunity (NOFO) is to invite ap arch Consortium. This NOFO runs 1). The Research Centers and the tium to support cutting-edge bas vancement in stillbirth-relevant re equity lens to identify ways to de is encouraged and allowable. Av ojectives in their efforts to unders umentation, models, and other to enhancing understanding of the I defects, genetic factors, infection placenta, and maternal tissues; (4 datasets) and database resources	in parallel with the DCC together will e ic, translational, clin esearch across the U crease the incidence varded Research Cen stand and prevent st echnologies that cou mechanisms underl ons, and/or complica 4) leveraging second , with the ultimate a	Stillbirth Research establish an integra ical, and/or data so inited States, with a e of stillbirth in vulu nters, with complex tillbirth including (1 uld have a direct cli ying vulnerability to ations that may con lary data analysis a aim to elucidate stil	Center Data ted and iences a particular nerable mentary .) supporting nical or healt o stillbirth; (3 tribute to nd integration lbirth risk or

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	care. Research Center applications must p Centers may actively collaborate on studi efforts. This will likely include partnership and Pediatric Precision in Therapeutics (N activities with partner Federal health age Research Services Administration, and the foster interdisciplinary approaches, facilit health. To stimulate novel approaches, it biology, nursing, environmental science, p mathematics, computer science, nutrition addition, Research Centers must include a	es and projects with other NICH os with the Maternal Fetal Medic (IPRINT) initiative; NIH Institutes ncies, including the Centers for I e Office of the Assistant Secretar ate data sharing, and enhance the is anticipated that key personne public health, biology, behaviora and engineering) will collabora	D Networks and in cine Units (MFMU) or Offices such as Disease Control and ry on Women's Hea he impact of their i el in complementar and social science ate to address stillb	itiatives to strength Network and the N All of Us; and mate d Prevention, the H alth. These collabor research on matern y disciplines (e.g., n e, biostatistics/stati pirth-relevant resea	en research ICHD Materna rnal health ealth and ations will al and fetal nedicine, stics,
127100 RFA-HD-25-005Women's Repro- Development Program (K12 Clinic	ductive Health Research (WRHR) Career N cal Trial Optional) H	ational Institute of Child Health uman Development/NIH/DHHS		5-Oct-2024 [LOI/Pre pp]	e- Not Specified
Contact Name	Donna Mazloomdoost, MD				
Contact Telephone					
Contact Email	donna.mazloomdoost@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Oct-2024 [LOI/Pre-App], 15-Nov-2024				
Synopsis	The purpose of this Notice of Funding Op Institute of Child Health and Human Deve Health Research (WRHR) Career Develope programs trains junior faculty who have r are committed to an independent researc build the national capacity of outstanding gynecology and contribute to the improve appointment of [Scholars (K12)] proposin separate ancillary clinical trial; or proposin of their research and career development	lopment (NICHD) is to announce ment Program. This nationwide g ecently completed postgraduate ch career in women's reproducti g junior clinician-investigators whe ement of women's health. This g to serve as the lead investigate ng to gain research experience in	e the re-competitic group of mentored e clinical training in ve health. The goa no will strengthen t Notice of Funding (or of an independe	on of the Women's l institutional caree obstetrics and gyn l of this program is the field of obstetri Opportunity (NOFO ent clinical trial; or p	Reproductive r development ecology and to continue to cs and) allows proposing a
117230 NIDCR Research Grants for Analys	ses of Existing Genomics Data (R01) N	ational Institute of Dental and	PAR-23- 07	7-Sep-2024	Not



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
(Clinical Trial Not Allowed)	C	raniofacial Research/NIH/DHHS	133		Specified
Contact Name	Noffisat Oki				
Contact Telephone	301-402-6778				
Contact Email	noffisat.oki@nih.gov				
Sponsor Website					
	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 2026 , 05-Feb-2026 , 07-May-2026	, 05-Feb-2025 , 07-May-2025 , 0)5-Jun-2025 <i>,</i> 07-Se	p-2025 , 05-Oct-20	025 , 07-Jan-
Synopsis	The purpose of this NOFO is to announce to human dental, oral, or craniofacial (DO available genomic data, with or without of Data analysis for each project can be perf proposed project(s), including methods f (AI)/Machine Learning (ML)/Deep Learning silico work is required to validate the resu Projects aimed at understanding oral hea priority. Projects focused on investigating intervention targets or defining the patho	C) biology, and diseases and co ther types of complementary d ormed using existing and/or no or data and metadata mining, d og (DL) methods. In addition to a lts of the proposed analysis, or th disparities to inform strategi and/or characterizing human b	nditions, through a ata, using statistica vel methods to be o ata integration, and analysis of existing o to validate a newly es for improving he iological pathways	nalysis of existing a l and computation developed in the d Artificial Intellige data, experimental developed analyti ealth for all individu to inform identifica	and publicly al approaches. nce or in c method. uals are a
117461 NIDCR Prospective Observational Cooperative Agreement (U01 Clir		ational Institute of Dental and raniofacial Research/NIH/DHHS	PAR-23- 162 07	7-Sep-2024	Not Specified
·	Lorena Baccaglini, DDS, MS, PhD	· ·			
Contact Telephone					
Contact Email	lorena.baccaglini@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 2026 , 05-Feb-2026 , 07-May-2026	, 05-Feb-2025 , 07-May-2025 , 0)5-Jun-2025 , 07-Se	p-2025 <i>,</i> 05-Oct-20	25 , 07-Jan-
Synopsis	This NOEO will support through the coop	erative agreement mechanism,	investigator-initiat	ed observational s	tudies or

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		data/biospecimens.				
107546	IDCR Clinical Trial Planning and I greement (UG3/UH3 Clinical Tria		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21- 160	6-Sep-2024	Not Specified
	Contact Telephone Contact Email Sponsor Website	dena.fischer@nih.gov				
	Deadline Dates (ALL)	06-Sep-2024 , 03-Oct-2024 , 08-Jan-202				
	Synopsis	This Funding Opportunity Announcement to plan and implement clinical trials with (NIDCR). Studies appropriate for this FC biologic, device, or procedure for denta for a Food and Drug Administration (FD milestone-driven UG3 planning phase, The UH3 phase of the award will suppor permits both operational and scientific protocol and preparing other document Procedures, data management plan). A feasibility and/or acceptability of a plar intervention delivery; feasibility of prop fidelity monitoring procedures) and ass trial. The UG3 phase cannot be used to an investigational drug, biologic or devit to the FDA prior to the UH3 phase.	thin the mission of the National Ins DA are those testing diagnostic, pro- al, oral, or craniofacial diseases or o DA)-regulated product. Awards mad with possible transition to a UH3 co ort the conduct of one investigator planning activities. Operational pl its to implement the clinical trial (e illowable scientific planning activition ned intervention and associated so posed data collection procedures; sessment of the subject population test for intervention safety or efficient	stitute of Dental ar evention or treatm conditions, includin de under this FOA linical trial implem -initiated clinical tri anning activities in e.g., data collection ies include small-so tudy procedures (e preliminary testing to determine recr cacy. If the applica	nd Craniofacial Rese ent approaches to ng trials for any pha will initially suppor entation phase of u ial. The UG3 planni clude, at minimum instruments, Man cale data collection e.g., acceptability o g of intervention tra- tuitment potential f	earch test a drug, use of testing a one-year up to five years, ng phase , finalizing the ual of to assess the f mode of ining and or the future ical trial with
	otice of Special Interest (NOSI): / arnessing Immune System Plasti	Achieving Tissue Robustness Through city	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE- 22-005	7-Sep-2024	Not Specified
	Contact Name Contact Telephone	Preethi Chander, PhD 301-827-4620				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	preethi.chander@nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-202 2025 , 07-Sep-2025	24 , 07-Jan-2025 , 05-Feb-2025 , 1	6-Feb-2025 , 07-Ma	y-2025 , 05-Jun-20)25 , 16-Jun-
	Synopsis	NIDCR announces its interest in encour underlying the ability or inability of the external perturbations, and to examine response to infectious and autoimmune knowledge derived from this research w that shift the balance between degener preventative disease management in a	immune system to dynamically maintenance immune mechanisms of protections of dental, oral, and crark will facilitate development of nove trative and regenerative processes	naintain its function on against recurren niofacial (DOC) tissu el, personalized imm toward protection	al role against inte ce of chronic infla les. The expectatic nunomodulatory-k	ernal and mmation in on is that new oased therapies
	NIDCR Dual Degree Dentist Scient (K99/R00 Clinical Trial Not Allowe	ist Pathway to Independence Award d)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22- 041 07	7-Sep-2024	Not Specified
	Contact Name	Leslie A. Frieden, PhD				
	Contact Telephone	301-496-4263				
	Contact Email	leslie.frieden@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-202	25			
		The purpose of the NIDCR Dual Degree and maintain a strong cohort of indepe health. This program is designed to faci postdoctoral research positions to inde years of mentored training and three to support is available to accommodate cl full-time professional effort) in any year specifically for applicants proposing res feasibility study, or an ancillary study to	ndently funded dentist scientists of litate a timely transition of outsta pendent, tenure-track or equivale of five years of independent resear inical training in a dental specialty r of the R00 phase. This Funding C earch that does not involve leadir	dedicated to improvending dual degree of ent faculty positions ch. An option for five program at no more opportunity Annount of an independent of	ving dental, oral and dentist scientists from by providing supp ve years of indepe re than 3 person-n deement (FOA) is d clinical trial, a clini	nd craniofacial rom mentored, port for two ndent (R00) nonths (25% lesigned cal trial

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	trial as lead investigator, should apply in humans referred to in NOT-OD-18-2 the companion Basic Experimental Stu	212 as "prospective basic science st	udies involving hu		
Short-term Mentored Career End110993Craniofacial Research for Mid-CaIndependent Clinical Trial Not Al		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22- 0 121 0	7-Sep-2024	Not Specified
Contact Name Contact Telephone	e Leslie A. Frieden, PhD e 301-496-4263				
	il <u>leslie.frieden@nih.gov</u>				
•	L Link to program URL				
-) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-20	025 , 12-Feb-2025 , 07-May-2025			
Synopsi	The goal of the NIDCR Career Enhance investigators who either wish to expan their research by incorporating DOC ro oral, and craniofacial health and disea candidates proposing research that do ancillary study to a clinical trial. Applic mentor or co-mentor.	nd or augment their dental, oral, or esearch into their research program se. This Funding Opportunity Anno bes not involve leading an independ	[•] craniofacial (DOC) n to advance funda uncement (FOA) is dent clinical trial, a	research program mental knowledge designed specifica clinical trial feasibi	, or to redirect about dental, lly for lity study, or an
117231 NIDCR Small Research Grants for (R03 Clinical Trial Not Allowed)	Analyses of Existing Genomics Data	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-23- 132 0	7-Sep-2024	200,000 USD
Contact Name	e Noffisat Oki				
Contact Telephone	e 301-402-6778				
Contact Ema	il <u>noffisat.oki@nih.gov</u>				
Sponsor Website	e				
Program UR	L Link to program URL				
Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-20 2026 , 16-Feb-2026 , 07-May-2026	025 , 16-Feb-2025 , 07-May-2025 , 1	Լ6-Jun-2025 , 07-Տգ	p-2025 , 16-Oct-20)25 , 07-Jan-

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	Synopsis	The purpose of this NOFO is to annour to human dental, oral, or craniofacial (available genomic data, with or withou Data analysis for each project can be p proposed project(s), including method (AI)/Machine Learning (ML)/Deep Lear biological pathways to inform identific are encouraged.	DOC) biology, and diseases and co at other types of complementary d performed using existing and/or no ds for data and metadata mining, d rning (DL) methods. Projects focuse	nditions, throug ata, using statist vel methods to k ata integration, ed on investigatio	h analysis of existing ical and computation be developed in the and Artificial Intellige ng and/or characteriz	and publicly nal approaches. ence zing human
116699 P		NIDCR Support for Research on the Cavity in Coronavirus Disease 2019	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE- 23-004	07-Sep-2024	Not Specified
	Contact Name	Amanda Melillo, Ph.D.				
	Contact Telephone	301-529-7217				
	Contact Email	<u>amanda.melillo@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-20 2025 , 07-Sep-2025 , 05-Oct-2025 , 16-				025 , 16-Jun-
	Synopsis	The National Institute of Dental and Cr encourage research studies focused or CoV-2 and/or Coronavirus Disease 201	n the physiological involvement of	-	•	-
106245 <u>In</u>	IDCR Behavioral and Social Inter nplementation Cooperative Agre equired)	vention Clinical Trial Planning and eement (UG3/UH3 Clinical Trial	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21- 317	06-Sep-2024	Not Specified
	Contact Name	Melissa W. Riddle, PhD				
	Contact Telephone	301-451-3888				
	Contact Email	riddleme@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				

SPIN ID Program Title		Sponsor Name S	ponsor Numbe	er Deadline Date	Funding Amount
Deadline Dates (ALL) Synopsis	research applications to plan and im include clinical trials to develop and Applications for NIDCR support of cl Model framework, described in deta FOA will initially support a milestone trial implementation phase (UH3) of permit both scientific and operation assess the feasibility and/or accepta (e.g., acceptability of study content	2025 sunity Announcement (FOA) is to encour applement behavioral and social interven l test behavior change interventions rela- linical trials research are expected to ide ail here and incorporate an experimenta e-driven UG3 planning phase for up to 2 f up to five years. The UG3 phase for be nal planning activities. Scientific planning ability of a planned behavioral or social i or mode of delivery; feasibility of propo fidelity monitoring procedures). Operat	tion clinical tri- ated to dental, entify research al medicine app years, with po- ehavioral and s g activities inclu- ntervention ar osed data colled	als. Studies appropr oral, or craniofacial proposals using the proach. Awards mad possible transition to social intervention c ude small-scale data and associated study ction procedures; pr	iate for this FOA conditions. NIH Stage le under this a UH3 clinical linical trials will collection to procedures eliminary
108402 <u>NIDCR Dentist Scientist Career Tr</u>	development of: the final clinical pro tools for data and quality managem other essential documents. The UH3 stages, from early mechanistic resea services research (Stages IV/V). This considered clinical trials based on th and Contracts for guidance).	otocol; the intervention manual or equivent, safety and operational oversight plase will support the conduct of inversion development (e.g. FOA may also support basic behavioral ne NIH's revised clinical trial definition (provide the second stress of the second	valent; the dat ans; recruitme stigator-initiat ., Stages 0/ I) t experimental please see Clini	a management systent nt and retention stra ed intervention rese hrough implementa studies with human	em and other ategies; and earch at all tion and health s that are nts for Grants Not
Investigators (K22 Clinical Trial No.	ot Allowed)	Craniofacial Research/NIH/DHHS	044	12-001-2024	Specified
	e Leslie A. Frieden, PhD				
Contact Telephone					
	l leslie.frieden@nih.gov				
Sponsor Website					
-	L Link to program URL				
Deadline Dates (ALL) Synopsis	transition of highly qualified dentist track or equivalent faculty positions	cientist Career Transition Award for Intr is from NIH Intramural postdoctoral rese at eligible institutions. The award will p e NIH Intramural Research Program, and	earch positions provide suppor	to extramural acad t for two years of m	emic tenure- entored
					j.

SPIN ID Program Title		Sponsor Name S	ponsor Numb	er Deadline Date	Funding Amount
	the extramural institution. This Fundin research that does not involve leading clinical trial. Applicants to this FOA are mentor. Applicants proposing a clinica to the companion FOA (PAR-22-045).	an independent clinical trial, a clinical permitted to propose research expe	al trial feasibili rience in a clir	ty study, or an ancilla lical trial led by a men	ry study to a tor or co-
123308 NIDDK High Risk Multi-Center Clir Cooperative Agreements (U34 Cli	nical Study Implementation Planning nical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-24- 094	09-Oct-2024	450,000 USD
Contact Name	Tracy Rankin, Ph.D., M.P.H.				
Contact Telephone	301-594-4748				
Contact Email	<u>rankint@mail.nih.gov</u>				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Oct-2024 , 10-Jun-2025 , 11-Feb-20	026 , 08-Oct-2026 , 10-Jun-2027			
Synopsis	NIDDK supports investigator-initiated, process that may include an implement peer review of the rationale for the pre- study; 3) Provide support for the develor operations; and 4) Support the develor proposed clinical study should be hyper- scientific staff is strongly encouraged pro- Diverse Perspectives (PEDP), which will evaluation. Applications that fail to im- strongly encouraged to read the FOA in-	ntation planning cooperative agreeme oposed clinical study; 2) Permit asses lopment of documents needed for th pment of other essential elements re othesis-driven and focus on a disease prior to the submission of the U34 ap II be assessed as part of the scientific clude a PEDP will be considered incor	ent (U34). The sment of the of e conduct of t quired for the in the mission plication. This and technical nplete and wil	U34 is designed to: 1 design and protocol of he study, including a r conduct of the clinica of NIDDK. Consultation NOFO requires a Plan peer review I be withdrawn. Appli) Permit early f the proposed manual of al study. The on with NIDDI for Enhancing
125668 RFA-DK-25-005Type 1 Diabetes Clinical Trial Not Allowed)	TrialNet Clinical Network Hub (U01	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 25-005	16-Sep-2024 [Optional][LOI/Pre- App]	3,750,000 USD
Contact Name	Ellen Leschek, M.D.				
	301-402-8291				



SPIN ID	Program Title		Sponsor Name	Sponsor Numb	per Deadline Date	Funding Amount
	Contact Email	LeschekE@extra.niddk.nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	16-Sep-2024 [Optional][LOI/Pre-App], 1				
	Synopsis	The purpose of this Notice of Funding (Network Hub (HUB), a screening and cl early intervention in type 1 diabetes (T TrialNet network by providing coordina increase screening, recruitment and re will be assessed as part of the scientific considered incomplete and will be with and view the available PEDP guidance r	inical activities coordination unit for 1D). The main objective of the HUE ation of communications and outre tention. This NOFO requires a Plan and technical peer review evaluat adrawn. Applicants are strongly end	or clinical trials 3 is to increase ach and develo for Enhancing I ion. Applicatior	focusing on the preve the efficiency and pro- ping new tools and ap Diverse Perspectives (Ins that fail to include a	ntion of and ductivity of the proaches to PEDP), which a PEDP will be
	RFA-DK-25-004 Coordinating Ce Clinical Trial Required)	enter for Type 1 Diabetes TrialNet (U01	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 25-004	16-Sep-2024 [Optional][LOI/Pre- App]	29,500,000 USD
	Contact Name	Ellen Leschek, MD				
	Contact Telephone	301-402-8291				
	Contact Email	LeschekE@extra.niddk.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Sep-2024 [Optional][LOI/Pre-App], :				
	Synopsis	The purpose of this Notice of Funding ((TNCC). The TrialNet network identifies symptoms and enrolls them in trials an insulin production. The TNCC participat studies and intervention trials. The TNC implementation and completion, and (control, dissemination and public access including the evaluation, selection, and	s people with type 1 diabetes (T1D) d studies aimed at prevention of p tes in ongoing studies and interven CC will: (1) support a wide range of 2) provide data and sample managessibility. The TNCC will be responsib	at stages befor rogression to cl tion trials as we research projec ement, includin ole for network	re and after onset of c inical disease and pre- ell as the design and co cts in varying stages o ng standardized acquis administration and op	linical servation of onduct of new f development ition, quality perations,

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
	Executive and Steering Committees, co Perspectives (PEDP), which will be asse fail to include a PEDP will be considere NOFO instructions carefully and view t	essed as part of the scientific and te d incomplete and will be withdrawi	chnical peer rev n. Applicants are	view evaluation. Appli	cations that
125933 <u>RFA-DK-25-007 Nutrition Obesi</u> <u>Optional)</u>	ty Research Centers (P30 Clinical Trial	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 25-007	09-Sep-2024 [Optional][LOI/Pre- App]	3,750,000 USD
Contact Name	Mary E. Evans, Ph.D.				
Contact Telephone	301-594-4578				
Contact Email	evansmary@niddk.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Sep-2024 [Optional][LOI/Pre-App], (09-Oct-2024 , 10-Jun-2025			
Synopsis	This Funding Opportunity Announceme core centers that are part of an integra Research Centers (NORC) program is do obesity. NORCs support three primary program, and an Enrichment program. the efficiency, productivity, effectivene	nted and existing program of nutrition esigned to support and enhance the research-related activities: Researc All activities pursued by Nutrition (on and/or obesi e national resea h Core services, Dbesity Research	ty research. The Nutri rch effort in nutrition a Pilot and Feasibility h Centers are designe	tion Obesity and (P and F)
125935 RFA-DK-25-011 Nutrition Obesir Center (RRC) (P2C- Clinical Trial O	ty Research Centers Research Resource ptional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 25-011	09-Sep-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Mary E. Evans, Ph.D.				
Contact Telephone	301-594-4578				
Contact Email	evansmary@niddk.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Sep-2024 [Optional][LOI/Pre-App], (09-Oct-2024			

SPIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
Synops	This Notice of Funding Opportunity (N Research Resource Center (RRC) for the consists of eleven Centers across the r through cutting-edge basic, clinical, tra collaboration with the existing NORC p (2) establish and curate a NORC Progra pronged approach to support and grow outreach and impact, (4) administer ar and (5) manage a Pilot and Feasibility I will be assessed as part of the scientifi considered incomplete and will be with and view the available PEDP guidance	te NIDDK Nutrition Obesity Research nation that support and enhance the anslational, and health disparities re- program, the RRC will (1) provide adr am website and centralized reposito w a diverse early-to-midcareer resear and manage a NORC Opportunity Prog Program. This NOFO requires a Plan c and technical peer review evaluation hdrawn. Applicants are strongly enco	Centers (NOR national resea search in nutrit ministrative sup ry of research o rch workforce gram to addres for Enhancing on. Application	C) Program. The NORC rch effort in nutrition tion science and obesi oport for the entire No resources, (3) implement with a goal of maximi as gaps and promote of Diverse Perspectives (as that fail to include a	C Program and obesity ty. In ORC Program, ent a multi- zing national ollaboration, PEDP), which PEDP will be
122000 RFA-DK-25-003 Silvio O. Conte Centers (P30 Clinical Trial Optio	e Digestive Diseases Research Core nal)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 25-003	23-Sep-2024 [Optional][LOI/Pre- App]	3,750,000 USD
Contact Nam	e Peter J. Perrin, Ph.D.				
Contact Telephor	ne 301-451-3759				
Contact Ema	nil <u>Peter.Perrin@nih.gov</u>				
Sponsor Websi	:e				
Program UI	RL Link to program URL				
Deadline Dates (AL	L) 23-Sep-2024 [Optional][LOI/Pre-App],	23-Oct-2024			
Synops	This Notice of Funding Opportunity (N (DDRCCs). The DDRCCs are part of an i NIDDK. The purpose of this Centers pr communication, collaboration, and eff NIDDK's mission. DDRCCs are based o and new research ideas among the fur must be organized around a central th members. The central theme must be Institutes or Centers are considered th Perspectives (PEDP), which will be asse	ntegrated program of digestive and rogram is to bring together basic and ectiveness of ongoing research relat n the core concept, whereby shared nded investigators are supported in a eme that reflects the focus of the di within the primary mission of the NI ne primary source of NIH funding. Th	liver diseases r d clinical invest red to digestive resources aim a cost-effective gestive or liver DDK, and not t his NOFO requi	esearch support prov igators as a means to and/or liver diseases ed at fostering produc manner. Each propo diseases research of hematic areas for whi res a Plan for Enhanci	ided by the enhance within the ctivity, synergy, sed DDRCC the Center ch other NIH ng Diverse



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	fail to include a PEDP will be considere NOFO instructions carefully and view t	•	••	rongly encouraged	d to read the
107685 <u>Stimulating Urology Interdisciplin</u> (SUITOR) (R01 Clinical Trial Optio		National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-22-	-Oct-2024	Not Specified
Contact Name	Julie Barthold, MD				
Contact Telephone	301-594-9655				
Contact Emai	l julia.barthold@nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025				
Synopsis	The Stimulating Urology Interdisciplina high quality, interdisciplinary research Diseases (NIDDK). The NIDDK invites in translational, or clinical research in spe progress are particularly timely. As suc opportunities. The research topic area to neurourology, as described below.	relevant to the mission of the Nati vestigator-initiated research projectific benign urologic conditions an h, research topics of interest will cl	onal Institute of Dia ct grant application d diseases where no hange over time to	abetes and Digesti s (R01s) in specific eeds and opportur take advantage of	ve and Kidney areas of basic, nities for emerging
108051 <u>Stimulating Hematology Investiga</u> <u>Clinical Trial Not Allowed</u>)	ation: New Endeavors (SHINE) (RO1	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	ΡΔς-22-	-Oct-2024	Not Specified
Contact Name	Shilpa Hattangadi, M.D.				
Contact Telephone	301-594-7726				
Contact Emai	l <u>shilpam.hattangadi@nih.gov</u>				
Sponsor Website	2				
Program URI	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024				
Synopsis	The Stimulating Hematology Investigat	ion: New Endeavors (SHINE) progr	ram is intended to p	promote innovativ	e, high-quality

SPIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	nonmalignant hematology research re Diseases (NIDDK), National Institute o initiated research project grant applic invited to this program that supports that are at the leading edge of the fiel and Contracts and hyperlinked to this	f Aging (NIA), and the National Hear ations (R01s) in specific areas of bas growth in the nonmalignant hemato d will change over time and will be u	t, Lung, and Blo ic and early trar logy research d	od Institute (NHLBI). slational hematolog omain. Specific eme	Investigator- research are rging topics
16589 Small R01s for Clinical Trials Targe NIDDK (R01 Clinical Trial Required	eting Diseases within the Mission of I)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-23- 086	07-Sep-2024	600,000 USD
Contact Name	Aynur Unalp-Arida, M.D., M.Sc., Ph.D.				
Contact Telephone	301-594-8879				
Contact Email	aynur.unalp-arida@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2(2026 , 05-Feb-2026 , 07-May-2026	025 , 05-Feb-2025 , 07-May-2025 , 0	5-Jun-2025 <i>,</i> 07-	Sep-2025 , 05-Oct-20)25 , 07-Jan-
Synopsis	This Funding Opportunity Announcem humans that will lay the foundation for conditions within the mission of NIDD to acquire preliminary data regarding retention, and study conduct. Applica objectives, and have a high likelihood understanding, diagnosis, prevention and/or public health. Preliminary data	or larger clinical trials related to the K. The program will support small, s the effects of the intervention, as w tions for clinical trials submitted und that the trial findings will lead to mo or treatment of the diseases studied	prevention and/ hort-term proof ell as feasibility ler this FOA sho pre definitive, hy l and have the p	or treatment of dise -of-concept clinical t data related to recru uld have clearly desc pothesis-driven tria	ases and rials in humar itment and ribed aims an s to improve
23312 NIDDK High Risk Multi-Center Clir (U01 Clinical Trial Required)	iical Study Cooperative Agreement	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-24- 103	05-Oct-2024	Not Specified
Contact Name Contact Telephone	Tracy Rankin, Ph.D., M.P.H. 301-594-4748				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Email	rankint@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-20	25 , 05-Oct-2025 , 05-Feb-2026 , 05	5-Jun-2026 <i>,</i> 05-Oc	t-2026	
Synopsis	This NOFO invites applications for invecenter. Proposed trials should be hypo focus on a disease relevant to the miss permitted under this NOFO. Applicants cooperative agreement (U34; see PAR- to the submission of either a U34 or U0 which will be assessed as part of the sc will be considered incomplete and will carefully and view the available PEDP g diverse-perspectives-pedp attached to	thesis-driven, have the potential to ion of NIDDK. Planning activities m who require a planning phase may 24-094). Consultation with NIDDK D1 application. This NOFO requires cientific and technical peer review of be withdrawn. Applicants are stror guidance material located at: https:	o change clinical pr ust be completed y first apply for an Scientific/Researc a Plan for Enhanci evaluation. Applic ngly encouraged to	ractice and/or publ prior to submissior implementation pl n staff is strongly e ng Diverse Perspec ations that fail to in p read the FOA inst	ic health, and n and are not anning ncouraged prio ctives (PEDP), nclude a PEDP ructions
123309 NIDDK High Risk Multi-Center Clin (U01 Clinical Trial Not Allowed)	nical Study Cooperative Agreement	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-74-	5-Oct-2024	Not Specified
Contact Name	Tracy Rankin, Ph.D., M.P.H.				
Contact Telephone	301-594-4748				
Contact Email	rankint@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-20	25 , 05-Oct-2025 , 05-Feb-2026 , 05	5-Jun-2026 <i>,</i> 05-Oc	t-2026	
Synopsis	This NOFO invites applications for invectinical center. Proposed studies should Planning activities must be completed planning phase may first apply for an inwith NIDDK Scientific/Research Staff st NOFO requires a Plan for Enhancing Dippeer review evaluation. Applications t	d be hypothesis-driven and focus o prior to submission and are not per mplementation planning cooperation rongly encouraged prior to the sub verse Perspectives (PEDP), which w	n a disease releval rmitted under this ve agreement (U3- omission of either a vill be assessed as	nt to the mission o NOFO. Applicants 4; see PAR-24-094) a U34 or U01 applic part of the scientifi	f NIDDK. who require a . Consultation cation. This c and technical

SPIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	Applicants are strongly encouraged to (with link to https://braininitiative.nih.			_	
112160 NIDDK Central Repository Non-re Trial Not Allowed)	newable Sample Access (X01 Clinical	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22- 171	29-Oct-2024	Not Specified
Contact Name	Rebecca M. Rodriguez, Ph.D				
Contact Telephone	301-451-0323				
Contact Emai	rebecca.rodriguez2@nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	29-Oct-2024 , 04-Mar-2025 , 25-Jun-20)25			
					C3. 11113
Synopsis	initiative allows investigators to apply about the samples available can be fou assessment report from the NIDDK Cer	ind at the Repository's website. App	es from one or r plicants must inc	nore of these studies clude a volume and ir	. Information npact
High Impact Interdisciplinary Sci	about the samples available can be fou	for access to non-renewable sample and at the Repository's website. App	es from one or r plicants must inc	nore of these studies clude a volume and ir	. Information npact
07664 High Impact, Interdisciplinary Science Clinical Trial Optional)	about the samples available can be fou assessment report from the NIDDK Cer	for access to non-renewable sample and at the Repository's website. App ntral Repository with the X01 Applic National Institute of Diabetes and Digestive and Kidney	es from one or r olicants must ind ation to docum PAR-22-	nore of these studies clude a volume and ir ent sample availabilit	. Information npact ty. Not
07664 High Impact, Interdisciplinary Science Clinical Trial Optional)	about the samples available can be fou assessment report from the NIDDK Cer ence in NIDDK Research Areas (RC2 Norann Zaghloul, Ph.D.	for access to non-renewable sample and at the Repository's website. App ntral Repository with the X01 Applic National Institute of Diabetes and Digestive and Kidney	es from one or r olicants must ind ation to docum PAR-22-	nore of these studies clude a volume and ir ent sample availabilit	. Information npact ty. Not
07664 High Impact, Interdisciplinary Science Clinical Trial Optional) Contact Name Contact Telephone	about the samples available can be fou assessment report from the NIDDK Cer ence in NIDDK Research Areas (RC2 Norann Zaghloul, Ph.D.	for access to non-renewable sample and at the Repository's website. App ntral Repository with the X01 Applic National Institute of Diabetes and Digestive and Kidney	es from one or r olicants must ind ation to docum PAR-22-	nore of these studies clude a volume and ir ent sample availabilit	. Information npact ty. Not
07664 High Impact, Interdisciplinary Science Clinical Trial Optional) Contact Name Contact Telephone	about the samples available can be fou assessment report from the NIDDK Cer ence in NIDDK Research Areas (RC2 Norann Zaghloul, Ph.D. 301-435-6677 norann.zaghloul@nih.gov	for access to non-renewable sample and at the Repository's website. App ntral Repository with the X01 Applic National Institute of Diabetes and Digestive and Kidney	es from one or r olicants must ind ation to docum PAR-22-	nore of these studies clude a volume and ir ent sample availabilit	. Information npact ty. Not
07664 High Impact, Interdisciplinary Scie Clinical Trial Optional) Contact Name Contact Telephone Contact Emai Sponsor Website	about the samples available can be fou assessment report from the NIDDK Cer ence in NIDDK Research Areas (RC2 Norann Zaghloul, Ph.D. 301-435-6677 norann.zaghloul@nih.gov	for access to non-renewable sample and at the Repository's website. App ntral Repository with the X01 Applic National Institute of Diabetes and Digestive and Kidney	es from one or r olicants must ind ation to docum PAR-22-	nore of these studies clude a volume and ir ent sample availabilit	. Information npact ty. Not
107664 High Impact, Interdisciplinary Scie Clinical Trial Optional) Contact Name Contact Telephone Contact Emai Sponsor Website	about the samples available can be fou assessment report from the NIDDK Cer ence in NIDDK Research Areas (RC2 Norann Zaghloul, Ph.D. 301-435-6677 norann.zaghloul@nih.gov	for access to non-renewable sample and at the Repository's website. App ntral Repository with the X01 Applic National Institute of Diabetes and Digestive and Kidney	es from one or r olicants must ind ation to docum PAR-22-	nore of these studies clude a volume and ir ent sample availabilit	. Information npact ty. Not

SPIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	knowledge gaps, scientific opportunitie in significant ways designed to accelera within the mission of the NIDDK.				
127247 RFA-DK-25-019The Chronic Pane (CPCRC)- Clinical Centers (CPCRC-	creatitis Clinical Research Consortium CCs) (U01 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 25-019	18-Sep-2024 [Optional][LOI/Pre- App]	2,000,000 USD
Contact Name	Aynur Unalp-Arida, M.D., Ph.D.				
Contact Telephone	301-594-8879				
Contact Email	aynur.unalp-arida@nih.gov				
Sponsor Website	2				
-	Link to program URL				
Deadline Dates (ALL)	18-Sep-2024 [Optional][LOI/Pre-App],	18-Oct-2024			
Synopsis	This Notice of Funding Opportunity (Ne Clinical Research Consortium (CPCRC) is adults. The consortium will continue t (CPDPC). The consortium has been rer establishment in Fall 2015 has conduct characterization of patients with CP (in pathophysiology of chronic pancreatiti cancer association. The CPDPC is comp continuation of the CPDPC, the CPCRC, objectives of the former consortium in DK-25-020 "Single Source for the NIDD (CPCRC- DCC) (U01 Clinical Trial Option with collaborative projects that make u Consortium member institutions. In ad annotated repository of bio-specimens administered by the DCC, to allow for the progression. To effectively contribute the and clinicians with multi-disciplinary ex (see https://cpdpc.mdanderson.org/cli	to contribute to ongoing and new s he work of the current Study of Chr named to reflect the revised resear- ted longitudinal clinical studies with ocluding those with Acute Recurren s and its sequela: chronic pain, pan posed of multiple Clinical Centers (C will focus on chronic pancreatitis, these areas. Applications for the d K Chronic Pancreatitis Clinical Rese hal)." The DCC along with CCs share use of the combined expertise and dition, a major collaborative effort s (blood, pancreatic and duodenal j the identification and validation of to the ongoing CPDPC clinical studie expertise to match the objectives of	tudies on chron ronic Pancreatit ch focus as desc comprehensive t Pancreatitis, A creatic insufficie C) and one Data both adults and ata coordinating arch Consortium results freely w technological ca within the Cons uice, stools and biomarkers for r es, each CC appl the ongoing cor	ic pancreatitis, both in is, Diabetes and Pancre cribed below. The CPD e epidemiological and RP) to gain insight inte- ency, diabetes, and pa- a Coordinating Center children, to pursue and g center are being invi- n (CPCRC) Data Coord within Consortium and apabilities present in a sortium is the establis when feasible pancre- risk stratification and ication should include nsortium CPDPC	n children and reatic Cancer PC since its biological o the increatic (DCC). The nd expand the ted via RFA- inating Center will continue II the hment of an atic tissue), disease researchers

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	and to develop Consortium-wide collal capabilities present in all the CCs. Appl cancer will not be considered responsi	ications focused on basic and anima			-
113279 Limited Competition: Small Grant Recipients (R03 Clinical Trial Opti	t Program for NIDDK K01/K08/K23/K25 onal)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22- 129 01	7-Sep-2024	150,000 USD
Contact Name	e Lisa M. Spain, Ph.D.				
Contact Telephone	301-451-9871				
Contact Emai	I <u>SpainL@niddk.nih.gov</u>				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL	07-Sep-2024 , 16-Oct-2024 , 16-Nov-20 2025 , 07-Sep-2025	024 , 07-Jan-2025 , 25-Feb-2025 , 16	-Mar-2025 , 07-N	lay-2025 , 16-Jun-2	025 <i>,</i> 16-Jul-
Synopsis	The National Institute of Diabetes and supported K01, K08, K23, and K25 recip the award period of their K award. Thr K01, K08, K23, and K25 award recipien investigator status. The R03 grant mec secondary analysis of existing data; sm development of new research technolo out in a short period of time with limite equivalent, application.	pients the opportunity to apply for S ough the use of this mechanism, the ts to conduct research as they comp hanism supports different types of p all, self-contained research projects ogy. The R03 is, therefore, intended	Small Grant (R03) e NIDDK is seeking blete their transiti projects, including s; development of to support resear	support during the g to enhance the ca on to fully indepen g pilot and feasibilit research methodo ch projects that ca	latter years of pability of its dent y studies; logy; and n be carried
113566 Notice of Special Interest (NOSI): Effects of Micro and/or Nanoplas	Understanding Exposure and Health stics	National Institute of Environmenta Health Sciences/NIH/DHHS	al NOT-ES- 23-002 01	7-Sep-2024	Not Specified
Contact Name	Lingamanaidu V. Ravichandran, Ph.D				
Contact Telephone	984-287-3309				
Contact Emai	l lingamanaidu.ravichandran@nih.gov				
Sponsor Website					

SPIN ID Program Title		Sponsor Name	Sponsor Num	per Deadline Date	Funding Amount
Deadline Dates (ALL	07-Sep-2024 , 05-Oct-2024 , 16-Oct-20 2025 , 07-Sep-2025 , 05-Oct-2025 , 16- Jun-2026 , 07-Sep-2026 , 05-Oct-2026 16-Jun-2027 , 07-Sep-2027 , 05-Oct-20	-Oct-2025 , 07-Jan-2026 , 05-Feb-202 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb	26 , 16-Feb-20	26 , 07-May-2026 , 05-	Jun-2026 , 16-
Synopsi	The purpose of this Notice of Special In s Environmental Health Sciences (NIEHS microplastics (MPs) and nanoplastics (), has special interest in applications	• •		
127197 RFA-ES-24-004 Revolutionizing Health Research (RIVER) (R35 Cli	Innovative, Visionary Environmental nical Trial Optional)	National Institute of Environmenta Health Sciences/NIH/DHHS	l RFA-ES- 24-004	02-Oct-2024 [Optional][LOI/Pre- App]	6,000,000 USD
Contact Nam	e Jennifer B. Collins				
Contact Telephon	e 984-287-3247				
Contact Ema	il <u>collins6@niehs.nih.gov</u>				
Sponsor Websit	e				
Program UR	L <u>Link to program URL</u>				
Deadline Dates (ALL) 02-Oct-2024 [Optional][LOI/Pre-App],	01-Nov-2024			
Synopsi	The NIEHS Revolutionizing Innovative, support for outstanding investigators i freedom, as well as sustained support program seeks to identify individuals v existing investigator-initiated research sciences research program.	in the Environmental Health Science to pursue their research in novel dir with a potential for continued innova	s, giving them ections in orde tive and impa	intellectual and admir er to achieve greater in ctful research and con	nistrative mpacts. The nbine their
119809 RFA-ES-23-011 Time-Sensitive Environmental Health Sciences (National Institute of Environmenta Health Sciences/NIH/DHHS	l RFA-ES- 23-011	01-Oct-2024	275,000 USD
Contact Nam	e Toccara Chamberlain, M.A.				
Contact Telephon	e 984-287-4482				
Contact Ema	Il toccara.chamberlain@nih.gov				
Sponsor Websit	e				
Program UR	L Link to program URL				

SPIN ID Program Title		Sponsor Name	ponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL) Synopsis	01-Oct-2024, 02-Dec-2024, 03-Mar-2025, This Notice of Funding Opportunity (NOFO unpredictable event or policy change provi environmental exposure data. The primary human-made disasters, emerging environn distinguishing feature of an appropriate stu NIH grant review/award cycle, for the rese will be achieved by more frequent applicat issuance. The entire cycle, from submission) is intended to support novel er des a limited window of opporte motivation of the NOFO is to u nental public health threats, and udy is the need for rapid review arch question to be addressed a ion due dates and expediting pe	nvironmental heal unity to collect hu nderstand the cor l policy changes in and funding, subs nd swiftly implem er review, council	th research in whith man biological sar isequences of nation the U.S. and abro tantially shorter the ented. The shorte	nples or ural and ad. A nan the typical ned timeframe
110572 Limited Competition: NIGMS Mat Structural Biology (P30 - Clinical T		tional Institute of General Medio ences/NIH/DHHS	cal PAR-22- 166 10	-Oct-2024	Not Specified
Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	maryann.wu@nih.gov Link to program URL	amlines for structural biology re nust be well-established, requiri they serve or to maintain them ently have been or currently are aded to current best practices, m	search. "Mature" ng no significant r at the state of the being supported l nake its capability	refers to the techn lovel technology d e art. This funding by NIGMS funding. and availability kn	niques made evelopment in opportunity is . It is expected
121233 IDeA Clinical & Translational Rese Clinical Trial Optional)	earch Development (CTR-D) Award (P20- Sci	tional Institute of General Medio ences/NIH/DHHS	cal PAR-23- 257 09	-Oct-2024	7,500,000 USD
Contact Telephone	Michele McGuirl, Ph.D. michele.mcguirl@nih.gov				

SPIN ID Program Title			Sponsor Name S	ponsor Numbe	r Deadline Date	Funding Amount
S	ponsor Website					
	Program URL	Link to program URL				
Dead	lline Dates (ALL)	09-Oct-2024 , 09-Oct-2025				
	Synopsis	The purpose of the Institutional Develor is to support clinical and translational r organizations in IDeA-eligible states that to build a foundation of clinical and translation research on diseases and health challe	esearch, workforce development, a at have limited clinical and translatic nslational research expertise and in	nd infrastructur nal research ca rastructure tha	e enhancement at h pacity. CTR-D award	ealth research s are intended
121232 IDeA Clinical & Tra Clinical Trial Optic		arch Network (CTR-N) Award (P50 -	National Institute of General Medio Sciences/NIH/DHHS	cal PAR-23- 241	09-Oct-2024	16,500,000 USD
	Contact Name	Michele McGuirl, Ph.D.				
Cor	ntact Telephone					
	Contact Email	michele.mcguirl@nih.gov				
S	ponsor Website					
	Program URL	Link to program URL				
Dead	lline Dates (ALL)	09-Oct-2024 , 09-Oct-2025				
	Synopsis	The purpose of the Institutional Develor to support biomedical research capacit translational research to further enhan populations served by the CTR-N. The infrastructure for clinical and translatic abilities to design and implement clinic across one or more IDeA states.	y in IDeA states that have been conc ce their capacity to enable and stree program supports statewide or mult nal research; develop the research	ducting significa ngthen research i-state regional workforce and e	nt levels of clinical a on health challenge networks to: expand nhance the networl	nd es faced by the d existing < organizations
		<u>mic Career Development Awards</u> ical Trial Not Allowed)	National Institute of General Medie Sciences/NIH/DHHS	cal PAR-22- 212	03-Oct-2024	Not Specified
	Contact Name	Shakira Nelson, Ph.D.				
Cor	ntact Telephone					

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-Oct-2024				
	Synopsis	The Institutional Research and Academic C postdoctoral research experience at a rese teaching and mentoring skills at a teaching IRACDA program requires effective partner institution that has a historical mission or in the biomedical research workforce. One biomedical scientists who have the necess careers. An additional goal of the IRACDA research-oriented, early career teachers, r providing research opportunities for the fa methods and technologies. This Funding C	earch-intensive institution combi g-intensive partner institution wi erships between a research-inten a demonstrated commitment to e goal of the IRACDA program is t sary knowledge and skills to purst program is to benefit the teachin mentors, and role models for the aculty and students; and/or bring Opportunity Announcement (FOA	ned with an oppo th a diverse stude sive institution an educating studen to develop a diver ue independent a ng-intensive partn students; enhand ging expertise with a) does not allow a	ertunity to develop ent population. Acc ad a teaching-intens ts from groups und se pool of well-trai cademic teaching a er institutions, e.g. cing science educat h state-of-the-art re appointed scholars	critical cordingly, the sive partner errepresente ned nd research , by providing ional offering esearch to lead an
11/X/4	aximizing Investigators' Researc vestigators (R35 - Clinical Trial C		ational Institute of General Medio iences/NIH/DHHS	cal PAR-23- 145 03	3-Oct-2024	1,250,000 USD
	Contact Name	Sailaja Koduri, Ph.D.				
	Contact Telephone					
	Contact Email	sailaja.koduri@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-Oct-2024 , 03-Feb-2025 , 03-Oct-2025 ,	02 5 4 2020			
			, U3-Feb-2U26			

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	could enhance their ability to take on a for investigators to follow important ne proposed in advance of the studies. Mo investigators to increase overall scienti- by researchers writing and reviewing gr investigators to devote more time and	ew research directions as opportun ore widely distribute funding amon fic productivity and the chances for rant applications, allowing them to	ities arise, rather tl g the nation's highl important breaktl spend more time c	nan being bound t y talented and pro nroughs. Reduce th conducting researc	o specific aims omising ne time spent
	al Interventions that Promote Careers in se (R01 - Clinical Trial Not Allowed)	National Institute of General Med Sciences/NIH/DHHS	ical PAR-24- 230 17	-Oct-2024	Not Specified
Contact Telephone Contact Email Sponsor Website Program URL	Mercedes Rubio <u>mercedes.rubio@nih.gov</u> <u>Link to sponsor website</u> <u>Link to program URL</u> 17-Oct-2024 , 15-Oct-2025 , 14-Oct-202 The B-INSPIRE: Research on Behavioral Funding Opportunity (NOFO) encourage interventions to enhance research-orie biomedical research workforce. Application	INterventionS that Promote Caree es applications that propose resear nted individuals' interest, motivation	ch designed to con on, persistence and	duct studies of be preparedness for	havioral careers in the
Synopsis	leveraging existing intervention cohorts general novel combinations and integra projects are expected to produce resea of academic settings and career levels t Plan for Enhancing Diverse Perspective	s, using new or advanced methods ation of rigorous intervention datas irch findings that will guide the imp to enhance the diversity of the bior	of analysis of rigoro ets for analysis, are lementation of bel	ous intervention d e also encouraged navioral interventi	atasets, or . Funded ons in a variety
108741 Notice of Special Interest (NOSI): Outcomes in Infectious Disease M	Inclusion of Economic Factors and Iodeling Studies	National Institute of General Med Sciences/NIH/DHHS	ical NOT-GM- 22-021 08	-Aug-2024	Not Specified
Contact Telephone	Veerasamy.ravichandra@nih.gov				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Program URL	Link to program URL				
Deadline Dates (ALL)	08-Aug-2024 , 07-Sep-2024 , 05-Oct-20	024 , 12-Oct-2024 , 08-Dec-2024 , 0	7-Jan-2025		
Synopsis	The National Institute of General Medi applications focused on infectious dise interested in mathematical and compu of possible intervention strategies, tha	ase modeling research that incorpo itational modeling studies of infect	orates economic fa ious disease sprea	ctors. The Institute d and evolution, ar	is particularly
125765 Academic Research Enhancement	: Award for Undergraduate-Focused Allowed)	National Institute of General Mec Sciences/NIH/DHHS	lical PAR-24- 152 01	7-Sep-2024	375,000 USD
Contact Name	Charles Ansong, Ph.D.				
Contact Telephone					
Contact Email	charles.ansong@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 25-Oct-2024 , 07-Jan-20 2026 , 25-Feb-2026 , 07-May-2026 , 25				
Synopsis	The purpose of this Academic Research small scale research grants at institution providing biomedical research experie applicant institutions. Eligible institution million dollars per year of NIH support composed of multiple schools and colle the non-health professional schools ar Organizations for more information.	ons that do not receive substantial nces primarily for undergraduate st ons must award baccalaureate scien (in both direct and F&A/indirect co eges, the \$6 million funding limit is	funding from the N tudents, and enhar nce degrees and ha osts) in 4 of the last based on the amo	IIH, with an emphancing the research ave received no mo t 7 fiscal years. For unt of NIH funding	sis on environment a re than \$6 institutions received by a
125769 Academic Research Enhancement Focused Institutions (R15 Clinical	: Award (AREA) for Undergraduate- Trial Required)	National Institute of General Mec Sciences/NIH/DHHS	lical PAR-24- 214	7-Sep-2024	375,000 USD
Contact Name	Mahua Mukhopadhyay, PhD				
Contact Telephone					
Contact Email	mukhopam@mail.nih.gov				
Sponsor Website					
Icahn School of Medicine at	NIH Funding Opp	ortunities Due: Oct 2024			120

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 25-Oct-2024 , 07-Jan-202 2026 , 25-Feb-2026 , 07-May-2026 , 25-				
Synopsis	The purpose of this Academic Research small scale research grants at institution providing biomedical research experien applicant institutions. Eligible institution million dollars per year of NIH support (composed of multiple schools and collect the non-health professional schools and Organizations for more information. This and/or minimal risk clinical trials such as and have low risks to potentially cause p of the participating NIH institutes.	ns that do not receive substantial f ces primarily for undergraduate st ns must award baccalaureate scien in both direct and F&A/indirect co ges, the \$6 million funding limit is I colleges within the institution as s Notice of Funding Opportunity (s those that do not require FDA ov	Funding from the N sudents and enhar nee degrees and has osts) in 4 of the las based on the amo a whole. See Part NOFO) supports in rersight, do not int	NIH, with an empha acing the research e ave received no mo t 7 fiscal years. For bunt of NIH funding II. Section 3.1 Eligit avestigator-initiated cend to formally est	sis on environment at the than \$6 institutions received by all ble mechanistic tablish efficacy,
Maximizing Opportunities for Science127138Careers (MOSAIC) Postdoctoral CareDiversity (K99/R00 Independent Care	areer Transition Award to Promote	National Institute of General Med Sciences/NIH/DHHS	ical PAR-24- 225 0	7-Sep-2024	Not Specified
Contact Name	Kenneth D. Gibbs, Jr., Ph.D.				
Contact Telephone					
	kenneth.gibbs@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-202 2026 , 12-Feb-2026 , 07-May-2026 , 12- Jun-2027 , 07-Sep-2027	· · · · · · · · · · · · · · · · · · ·		•	
Synopsis	The purpose of the Maximizing Opportu support a cohort of early career, indeper from underrepresented groups) conduc career transition award for postdoctora to organizations to provide these schola	ndent investigators from diverse l ting research in NIH mission areas l scholars (K99/R00) and a researc	backgrounds (for e . The program has h education coop	example, individual s two components: erative agreement	s an individual (UE5) awarded

	SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
--	---------	---------------	--------------	----------------	---------------	-------------------

support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Candidates seeking support through this NOFO are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Candidates proposing a clinical trial or an ancillary clinical trial as lead investigator, should work with their institutions to apply to the companion NOFO PAR-24-226.

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
127080 Innovative Programs to Enhance Clinical Trial Not Allowed)	Research Training (IPERT) (R25 Independent	National Institute of General Medical Sciences/NIH/DHHS	PAR-24- 252	17-Oct-2024	500,000 USD
Contact Name	Sydella Blatch Alexander, Ph.D.				
Contact Telephone					
Contact Emai	l <u>sydella.blatch@nih.gov</u>				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	17-Oct-2024 , 15-Oct-2025 , 14-Oct-2026				
Synopsis	The NIH Research Education Program (R25) su overarching goal of this R25 program is to sup workforce to meet the nation's biomedical, bu goal, this Notice of Funding Opportunity (NOF Development Mentoring Activities Curriculum	port educational activities that ehavioral and clinical research n O) will support educational acti	complemer eeds. To ac vities with a	nt and/or enhance the tra complish the stated over a primary focus on: Cours	aining of a r-arching ses for Skills

SPIN ID Program Title	2	Sponsor Name S	ponsor Numb	er Deadline Date	Funding Amount
	designed to equip participants with technica research workforce. Activities must be open one or more career stages from undergradu have a robust program leadership structure, NOFO requires a Plan for Enhancing Diverse	to the broader biomedical reso ates to professionals (for exam participant recruitment plan, a	earch commu ple faculty, sta	nity and may focus on aff scientists). Funded	participants programs wi
108588 RFA-MH-22-155 NIMH Instrum Allowed)	entation Program (S10 Clinical Trial Not	National Institute of Mental Health/NIH/DHHS	RFA-MH- 22-155	09-Sep-2024 [Optional][LOI/Pre- App]	600,000 USD
Contact Nam	e Yvonne Bennett <i>,</i> Ph.D.				
Contact Telephone	301-222-7094				
Contact Ema	l <u>yvonne.bennett@nih.gov</u>				
Sponsor Website	2				
Program UR	L Link to program URL				
•	L <u>Link to program URL</u>) 09-Sep-2024 [Optional][LOI/Pre-App], 09-Oc	t-2024			
•) 09-Sep-2024 [Optional][LOI/Pre-App], 09-Oc The NIMH Instrumentation Program encoura commercially available instrument or to pure available. The goal of the NIMH Instrumenta	ages applications from NIH fun- chase a group of components t ition Program is to make such i pental health-related research.	o create an in nstruments av Examples of ir	strument that is not co ailable to either indivi astruments that might	ommercially dual be submitte
Deadline Dates (ALL Synopsis) 09-Sep-2024 [Optional][LOI/Pre-App], 09-Oc The NIMH Instrumentation Program encoura commercially available instrument or to pure available. The goal of the NIMH Instrumenta laboratories or core facilities that conduct m under this Funding Opportunity Announcem and biomedical imagers.	ages applications from NIH fun- chase a group of components t ition Program is to make such i nental health-related research. ent (FOA) include light microso	o create an in nstruments av Examples of ir copes, electror	strument that is not co ailable to either indivi astruments that might	ommercially dual be submitte
Deadline Dates (ALL Synopsis 119014 <u>RFA-MH-25-190 Precision Men</u> <u>Selection in Depression (UG3/UH</u>) 09-Sep-2024 [Optional][LOI/Pre-App], 09-Oc The NIMH Instrumentation Program encoura commercially available instrument or to pure available. The goal of the NIMH Instrumenta laboratories or core facilities that conduct m under this Funding Opportunity Announcem and biomedical imagers.	ages applications from NIH fun- chase a group of components t ition Program is to make such i eental health-related research. ent (FOA) include light microsc <u>t</u> National Institute of Mental	o create an in nstruments av Examples of ir copes, electror RFA-MH-	strument that is not co ailable to either indivi astruments that might microscopes, spectro 18-Sep-2024 [Optional][LOI/Pre-	ommercially dual be submitte ophotometer Not
Deadline Dates (ALL Synopsis 119014 <u>RFA-MH-25-190 Precision Men</u> <u>Selection in Depression (UG3/UH</u>	 O9-Sep-2024 [Optional][LOI/Pre-App], 09-Oc The NIMH Instrumentation Program encoura commercially available instrument or to pure available. The goal of the NIMH Instrumenta laboratories or core facilities that conduct munder this Funding Opportunity Announcem and biomedical imagers. Ital Health: Develop Tools to Inform Treatmenta I Clinical Trial Optional) Michele Ferrante, PhD 	ages applications from NIH fun- chase a group of components t ition Program is to make such i eental health-related research. ent (FOA) include light microsc <u>t</u> National Institute of Mental	o create an in nstruments av Examples of ir copes, electror RFA-MH-	strument that is not co ailable to either indivi astruments that might microscopes, spectro 18-Sep-2024 [Optional][LOI/Pre-	ommercially dual be submitte ophotometer Not
Deadline Dates (ALL Synopsis 119014 RFA-MH-25-190 Precision Men Selection in Depression (UG3/UH Contact Name Contact Telephone	 O9-Sep-2024 [Optional][LOI/Pre-App], 09-Oc The NIMH Instrumentation Program encoura commercially available instrument or to pure available. The goal of the NIMH Instrumenta laboratories or core facilities that conduct munder this Funding Opportunity Announcem and biomedical imagers. Ital Health: Develop Tools to Inform Treatmenta I Clinical Trial Optional) Michele Ferrante, PhD 	ages applications from NIH fun- chase a group of components t ition Program is to make such i eental health-related research. ent (FOA) include light microsc <u>t</u> National Institute of Mental	o create an in nstruments av Examples of ir copes, electror RFA-MH-	strument that is not co ailable to either indivi astruments that might microscopes, spectro 18-Sep-2024 [Optional][LOI/Pre-	ommercially dual be submitte ophotomete Not
Deadline Dates (ALL Synopsis 119014 RFA-MH-25-190 Precision Men Selection in Depression (UG3/UH Contact Name Contact Telephone	 O9-Sep-2024 [Optional][LOI/Pre-App], 09-Oc The NIMH Instrumentation Program encoura commercially available instrument or to pure available. The goal of the NIMH Instrumenta laboratories or core facilities that conduct m under this Funding Opportunity Announcem and biomedical imagers. Ital Health: Develop Tools to Inform Treatmen I3 Clinical Trial Optional) Michele Ferrante, PhD 301-793-2634 michele.ferrante@nih.gov 	ages applications from NIH fun- chase a group of components t ition Program is to make such i eental health-related research. ent (FOA) include light microsc <u>t</u> National Institute of Mental	o create an in nstruments av Examples of ir copes, electror RFA-MH-	strument that is not co ailable to either indivi astruments that might microscopes, spectro 18-Sep-2024 [Optional][LOI/Pre-	ommercially dual be submitte ophotomete Not
Deadline Dates (ALL Synopsis 119014 RFA-MH-25-190 Precision Men Selection in Depression (UG3/UF Contact Name Contact Telephone Contact Emai Sponsor Website	 O9-Sep-2024 [Optional][LOI/Pre-App], 09-Oc The NIMH Instrumentation Program encoura commercially available instrument or to pure available. The goal of the NIMH Instrumenta laboratories or core facilities that conduct m under this Funding Opportunity Announcem and biomedical imagers. Ital Health: Develop Tools to Inform Treatmen I3 Clinical Trial Optional) Michele Ferrante, PhD 301-793-2634 michele.ferrante@nih.gov 	ages applications from NIH fun- chase a group of components t ition Program is to make such i eental health-related research. ent (FOA) include light microsc <u>t</u> National Institute of Mental	o create an in nstruments av Examples of ir copes, electror RFA-MH-	strument that is not co ailable to either indivi astruments that might microscopes, spectro 18-Sep-2024 [Optional][LOI/Pre-	ommercially dual be submitto photomete Not

SPIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
Synopsis	The purpose of this phased Notice of Fund early validation of predictive tools and/or l existing therapeutics for depression. This p multi-disciplinary teams to address scientif phase (UG3), investigators are expected to differentially respond to one well-establish secondary analysis of data from completed pilot feasibility studies to assess promising therapeutic for depression. In the second p initially validate the utility of the tool/biom The overall goal of this NOFO is to support established depression treatments and hal characteristics to justify further testing. Ult for future use in decision-making in clinical	biomarkers to inform individual shased inter-agency program will fic, technical, clinical, regulatory identify potential tools and/or hed depression treatment versu clinical trials or using real-wor new tools or biomarkers to pre- bhase (UH3), investigators will of harker for predicting differentia the testing of various tools/bio t the development of those too timately, tools that are successf	-level treatmer ill be milestone y, and commerce biomarker(s) the s another. This ld clinical data, edict individual conduct independent l response to en- markers as pre- ols that do not r	It selection among two -based and provide su- cialization requirement nat can predict wheth could be accomplished or by conducting smattreatment response to ndent, prospective clinistablished treatments dictors of response to neet sufficient performance	o or more upport from ts. In the first er a patient will ed using II, efficient o a specific nical trials to for depression. well- mance
125379 RFA-MH-25-130Optimizing Beha Young Adults (R34 Clinical Trial Re	avioral Sleep Interventions for Adolescents a equired)	and National Institute of Menta Health/NIH/DHHS	al RFA-MH- 25-130	30-Sep-2024 [Optional][LOI/Pre- App]	450,000 USD
Contact Name	Mary Rooney, Ph.D.				
Contact Telephone					
	mary.rooney@nih.gov				
Sponsor Website					
-	Link to program URL				
Deadline Dates (ALL) Synopsis	30-Sep-2024 [Optional][LOI/Pre-App], 30-C NIMH seeks applications for pilot research address common sleep problems in adoles should be designed to evaluate the feasibil real world settings, and to conduct a prelin mental health outcomes, and to obtain pre emphasis is placed on studies that address	h to adapt, optimize, and test end cents and young adults with or lity, tolerability, acceptability, sa ninary test of the intervention's eliminary data needed as a prer	mpirically supp at risk for a me afety, and pote s impact on targ equisite a large	orted behavioral inter ental health disorder. In ntial effectiveness of get mechanisms and s r-scale effectiveness t	Pilot trials the approach in leep and rrial. An
124037 RFA-MH-25-170 BRAIN Initiativ	e: Research on the Ethical Implications of	National Institute of Menta	al RFA-MH-	12-Sep-2024	1,200,000



SPIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
Advancements in Neurotechnolog	gy and Brain Science (R01 Clinical Trial	Health/NIH/DHHS	25-170	[Optional][LOI/Pre- App]	USD
Contact Name	James Churchill, Ph.D.				
Contact Telephone	301-326-8800				
Contact Email	James.Churchill@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	12-Sep-2024 [Optional][LOI/Pre-App], 11-0 [Optional][LOI/Pre-App], 09-Oct-2026	Oct-2024 , 11-Sep-2025 [Optior	nal][LOI/Pre-App], 10-Oct-2025 , 10-Se	p-2026
Synopsis	Guided by the goals established in BRAIN 2 Working Group on BRAIN 2.0 Neuroethics Research through Advancing Innovative Ne ethical issues associated with research foc advancements supported by the BRAIN Ini disciplinary teams focused on key ethical i under this FOA are intended to be both co discoveries supported through the BRAIN	Subgroup, this Funding Opport eurotechnologies® (BRAIN) Init used on the human brain and r itiative. This FOA encourages re ssues associated with BRAIN In mplementary and integrative v	unity Announce iative is intender esulting from er search project g itiative supporte	ment (FOA) from the d to support efforts ac merging technologies grant applications from ed research areas. Effo	NIH Brain Idressing core and n multi- rts supported
124039 <u>RFA-MH-25-171 BRAIN Initiativ</u> Advancements in Neurotechnolog <u>Optional</u>)	e: Research on the Ethical Implications of gy and Brain Science (R21 Clinical Trial	National Institute of Ment Health/NIH/DHHS	al RFA-MH- 25-171	12-Sep-2024 [Optional][LOI/Pre- App]	400,000 USD
Contact Name	James Churchill, Ph.D.				
Contact Telephone	301-326-8800				
Contact Email	James.Churchill@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	12-Sep-2024 [Optional][LOI/Pre-App], 11-0 [Optional][LOI/Pre-App], 09-Oct-2026	Oct-2024 , 11-Sep-2025 [Optior	nal][LOI/Pre-App], 10-Oct-2025 , 10-Se	p-2026
Synopsis	Guided by the goals established in BRAIN 2 Working Group on BRAIN 2.0 Neuroethics				

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
		through Advancing Innovative Neurotechno applications that propose to study core eth from emerging technologies and advancem grant applications from multi-disciplinary te research areas. Efforts supported under this transformative, breakthrough neuroscience higher-risk R21 grant applications, whereas proposing longer term projects with suppor Perspectives (PEDP), which will be assessed fail to include a PEDP will be considered inc NOFO instructions carefully and view the av	ical issues associated with rese ents supported by the BRAIN I eams focused on key ethical iss s NOFO are intended to be bot e discoveries supported throug its companion funding opport ting preliminary data. This NO as part of the scientific and te omplete and will be withdraw	earch focused or nitiative. This N sues associated th complementa h the BRAIN Init unity RFA-MH-2 FO requires a Pl chnical peer rev n. Applicants are	n the human brain and OFO encourages rese with BRAIN Initiative s ary and integrative wit tiative. This NOFO see 25-170 seeks R01 gran lan for Enhancing Dive view evaluation. Appli	d resulting arch project supported th the ks shorter, t applications erse cations that
113136		e: Engineering and Optimization of Molecula ction of Neural Circuits (UM1 Clinical Trial No	– National Institute of Menta	al RFA-MH- 22-245	18-Sep-2024 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Douglas S. Kim, Ph.D.				
	Contact Telephone	301-827-6463				
		douglas.kim@nih.gov				
	Sponsor Website					
	-	Link to program URL 18-Sep-2024 [Optional][LOI/Pre-App], 17-O				
		This funding opportunity announcement (For optimization of high-impact, molecular tech The Centers will produce high-impact molecular state variables (e.g., intracellular calcium, m integrators of neural activity, optogenetic, of molecular switches. This FOA is part of the Armamentarium project, whose goal is to g across multiple species. In this FOA, techno manipulation that are beyond the proof-of- newly developed brain cell access reagents. molecular engineering, (2) in vivo validation	OA) is intended to support the mologies to monitor and/or m cular probes such as, but not li nembrane voltage, released ne chemogenetic, sonogenetic, m Brain Research through Advan enerate tools to specifically ac logy optimization is sought for concept stage and that can be . Each Molecular Payloads Cen	anipulate brain mited to, fluore eurotransmitters agnetogenetic a cing Innovative cess, manipulat existing tools fo delivered selec ter is expected	cell activity in experin escent protein indicate s/neuromodulators, e actuators, and activity Neurotechnologies (B e, and monitor brain or brain cell monitorin tively as payloads to c to integrate: (1) suffic	nental animals ors of neurona tc.), molecular -dependent RAIN Initiative cell types og or cell types using iently scaled

SPIN ID Program Title	s	ponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	animals, (3) benchmarking throughout the ter tools into easily produced and applied forma demonstration experiments that establish gr foster close interaction between technologis by other Armamentarium FOAs for brain cell technology design, benchmarking, validation cell access reagents.	ts for neuroscience users. Mo oundbreaking capabilities of i ts and neurobiologists in a res access reagents. The Armame	lecular Payload mproved molec search consortio entarium conso	s Centers may also ir cular tools in vivo. Th um including tool dev rtium will promote ri	nclude optional is FOA will relopers funded gorous
102908 Understanding and Modifying Ter Activity (R01 Clinical Trial Optional	mporal Dynamics of Coordinated Neural al)	National Institute of Menta Health/NIH/DHHS	l PAR-21- 175	05-Oct-2024	Not Specified
Contact Telephone Contact Email Sponsor Website	andrew.rossi@nih.gov Link to program URL 05-Oct-2024 A growing body of evidence suggests that op	<u> </u>	•		
Synopsis	coordinated neural activity. These findings in spike-phase correlations, spike population dy for the treatment of cognitive, social, or affect Announcement (FOA) supports projects that improve cognitive, affective, or social process manipulations to address at least one, and id parameters of neural coordination, when man processing; (2) in animals or humans, determ affect the systems-level coordination of elect systems-level electrophysiological changes in improvements in healthy persons or clinical p systems-level aspects to understand the func- patterns unfold across the brain to impact co- whereas its companion FOA, PAR-21-176, see	ynamics, and other patterns m ctive symptoms in neuropsych test whether modifying elect sing. Applications must use ex- leally more, of the following to anipulated in isolation, improv- nine how particular abnormali trophysiological patterns during behaving animals predict and populations; and (4) use biological stion and mechanisms by which ognitive, affective, or social pre-	hight be useful of hiatric disorders rophysiological sperimental des opics: (1) in anin re particular asp ties at the gence ng behavior; (3) alogous electro gically-realistic ch oscillatory ar pocessing. This F	drivers of therapeutic s. This Funding Oppor patterns during beha- igns that incorporate mals or humans, dete bects of cognitive, aff mic, molecular, or ce determine whether physiological and cog computational mode do ther electrophysi OA uses the R01 gran	c development tunity avior can e active ermine which ective, or social ellular levels in vivo, gnitive Is that include ological

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106895 <u>Applications (R01 Clinical Trial N</u>	ation Device Development for Mental Health ot Allowed)	National Institute of Ment Health/NIH/DHHS	al PAR-22- 039	-Oct-2024	Not Specified
Contact Nam	e David McMullen, M.D.				
Contact Telephon	e 301-451-0180				
Contact Ema	il <u>david.mcmullen@nih.gov</u>				
Sponsor Websit	re				
Program UR	RL Link to program URL				
Deadline Dates (AL	L) 05-Oct-2024				
Synops	Applications should be submitted by multi- engineering, clinical, and regulatory affairs, or significant enhancement of novel tools (should focus on the engineering developm to demonstrate initial proof of concept is a should propose design-directed, developm	treating mental health disorde 2) significantly enhance, by me hat are currently U.S. Food and g electrical/magnetic stimulation ell as multi-focal, closed-loop a ancement of the spatial resolu- vices (e.g., software updates) a disciplinary teams with diverse Applications submitting in reso hardware/software) for brain ent and bench top testing of th llowable. Applications to this F ental, or discovery-driven tech	ers. Applications are eans of hardware/so d Drug Administration and develop new approaches. Applica- tion, depth of delive are not within the so expertise including ponse to this FOA s stimulation in huma- te tool, animal and l GOA are not expected anology research usi	e encouraged that oftware improvem on (FDA)-approved stimulation techr tions seeking to de ery, and/or precision ope of this announ g systems neurosci hould promote the ins.Although the a limited human test d to be hypothesis	will either 1) ents, the d or cleared. iques capable evelop new on of the ncement. ence, e development pplication ting necessary s-driven, but
106926 <u>Neuromodulation/Neurostimula</u> Applications (R01 Clinical Trial N	ation Device Development for Mental Health	National Institute of Ment Health/NIH/DHHS	al PAR-22- 039 05-	-Oct-2024	Not Specified
	e David McMullen, M.D.				
Contact Telephon					
	ill david.mcmullen@nih.gov				
Sponsor Websit					
· ·	RL Link to program URL				



SPIN ID Pro	gram Title		Sponsor Name	Sponsor Numbe	Deadline Date	Funding Amount
	Deadline Dates (ALL)	05-Oct-2024				
	Synopsis	The purpose of this funding opportunity and generation of brain stimulation devices for t develop novel brain stimulation devices or 2 effectiveness of brain stimulation devices th Novel devices should move beyond existing of increased spatiotemporal precision as we capabilities should focus on significant enha device. Incremental changes to existing devi Applications should be submitted by multi-d engineering, clinical, and regulatory affairs. or significant enhancement of novel tools (h should focus on the engineering developme to demonstrate initial proof of concept is all should propose design-directed, developme	treating mental health disorder 2) significantly enhance, by mental are currently U.S. Food and electrical/magnetic stimulation ell as multi-focal, closed-loop a uncement of the spatial resolution ices (e.g., software updates) a disciplinary teams with diverse Applications submitting in response ardware/software) for brain set and bench top testing of the lowable. Applications to this F	ers. Applications a cans of hardware, d Drug Administra on and develop ne opproaches. Appli tion, depth of del re not within the expertise includi ponse to this FOA stimulation in hur te tool, animal an OA are not expect	re encouraged that /software improven- ition (FDA)-approve- ew stimulation tech- cations seeking to d ivery, and/or precis- scope of this annou- ng systems neuroso should promote the nans.Although the a- d limited human test- ted to be hypothesi-	will either 1) nents, the d or cleared. niques capable levelop new ion of the incement. ience, e development application sting necessary s-driven, but
		· · · · · · · · · · · · · · · · · · ·	and, of allocovery and the teen	noiogy rescurent		nouciics.
115061	l and Psychosis Symptoms D Dptional)	uring the Menopause Transition (R01 Clinical	· · · · · · · · · · · · · · · · · · ·)5-Oct-2024	Not Specified
115061	<u> Optional)</u>		National Institute of Menta	al PAR-23-		Not
15061	<u> Optional)</u>	uring the Menopause Transition (R01 Clinical Laura M. Rowland, Ph.D.	National Institute of Menta	al PAR-23-		Not
15061	<u>Dptional)</u> Contact Name Contact Telephone	uring the Menopause Transition (R01 Clinical Laura M. Rowland, Ph.D.	National Institute of Menta	al PAR-23-		Not
15061	<u>Dptional)</u> Contact Name Contact Telephone	uring the Menopause Transition (R01 Clinical Laura M. Rowland, Ph.D. 301-480-8335 laura.rowland@nih.gov	National Institute of Menta	al PAR-23-		Not
15061	<u>Optional)</u> Contact Name Contact Telephone Contact Email Sponsor Website	uring the Menopause Transition (R01 Clinical Laura M. Rowland, Ph.D. 301-480-8335 laura.rowland@nih.gov	National Institute of Menta	al PAR-23-		Not
115061	<u>Optional)</u> Contact Name Contact Telephone Contact Email Sponsor Website	uring the Menopause Transition (R01 Clinical Laura M. Rowland, Ph.D. 301-480-8335 <u>laura.rowland@nih.gov</u> <u>Link to program URL</u>	National Institute of Menta	al PAR-23-		Not

SPIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
115060 Laboratories to Optimize Digital H	ealth (R01 Clinical Trial Required)	National Institute of Menta Health/NIH/DHHS	N PAR-23- 096	05-Oct-2024	Not Specified
Contact Name	Adam Haim, Ph.D.				
Contact Telephone	301-435-3593				
Contact Email	<u>Haima@mail.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025				
	and quality of digital mental health interverse serious mental illness. This Funding Opport health test beds that leverage well-establis	unity Announcement (FOA) is i	ntended to sup	port the developmen	t of digital
	optimize existing evidence-based digital he interventions that are statistically powered particularly in populations who experience	alth interventions and to cond to provide a definitive answer	uct clinical resea regarding the ir	irch testing digital me	ental health
	optimize existing evidence-based digital he interventions that are statistically powered	alth interventions and to cond to provide a definitive answer	uct clinical resea regarding the ir ole populations.	irch testing digital me	ental health
119702 <u>Cellular and Molecular Biology of</u> Not Allowed)	optimize existing evidence-based digital he interventions that are statistically powered particularly in populations who experience	alth interventions and to conduct to provide a definitive answer health disparities and vulnerat National Institute of Menta	uct clinical resea regarding the ir ole populations. nl PAR-24-	arch testing digital mo ntervention's effectiv	ental health eness Not
119702 <u>Cellular and Molecular Biology of</u> Not Allowed)	optimize existing evidence-based digital he interventions that are statistically powered particularly in populations who experience <u>Complex Brain Disorders (R01 Clinical Trial</u> David Panchision	alth interventions and to conduct to provide a definitive answer health disparities and vulnerat National Institute of Menta	uct clinical resea regarding the ir ole populations. nl PAR-24-	arch testing digital mo ntervention's effectiv	ental health eness Not
119702 Cellular and Molecular Biology of Not Allowed) Contact Name Contact Telephone	optimize existing evidence-based digital he interventions that are statistically powered particularly in populations who experience <u>Complex Brain Disorders (R01 Clinical Trial</u> David Panchision	alth interventions and to conduct to provide a definitive answer health disparities and vulnerat National Institute of Menta	uct clinical resea regarding the ir ole populations. nl PAR-24-	arch testing digital mo ntervention's effectiv	ental health eness Not
119702 Cellular and Molecular Biology of Not Allowed) Contact Name Contact Telephone	optimize existing evidence-based digital he interventions that are statistically powered particularly in populations who experience <u>Complex Brain Disorders (R01 Clinical Trial</u> David Panchision 301-402-3969	alth interventions and to conduct to provide a definitive answer health disparities and vulnerat National Institute of Menta	uct clinical resea regarding the ir ole populations. nl PAR-24-	arch testing digital mo ntervention's effectiv	ental health eness Not
119702 Cellular and Molecular Biology of Not Allowed) Contact Name Contact Telephone Contact Email Sponsor Website	optimize existing evidence-based digital he interventions that are statistically powered particularly in populations who experience <u>Complex Brain Disorders (R01 Clinical Trial</u> David Panchision 301-402-3969	alth interventions and to conduct to provide a definitive answer health disparities and vulnerat National Institute of Menta	uct clinical resea regarding the ir ole populations. nl PAR-24-	arch testing digital mo ntervention's effectiv	ental health eness Not
119702 Cellular and Molecular Biology of Not Allowed) Contact Name Contact Telephone Contact Email Sponsor Website Program URL	optimize existing evidence-based digital he interventions that are statistically powered particularly in populations who experience <u>Complex Brain Disorders (R01 Clinical Trial</u> David Panchision 301-402-3969 <u>panchisiond@mail.nih.gov</u>	alth interventions and to condu to provide a definitive answer health disparities and vulnerat National Institute of Menta Health/NIH/DHHS	uct clinical resea regarding the ir ole populations. al PAR-24- 024	arch testing digital mo ntervention's effectiv	ental health eness Not

SPIN ID Program Title	S	ponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
	incorporated into the research design to facil these are neither required nor expected. Stue elucidate the neurobiological impact of indivi components and their relationships within de factors, components, and processes. The rese disseminated with sufficient detail to enrich of Ontology, Synaptic Gene Ontology, FAIR Data mechanism and therapeutic target identificat further develop lines of inquiry where feasibil research at the early and conceptual stages of	dies should not attempt to "r idual or combined risk factor efined biological process(es). ulting paradigms, component common and/or federated da a Informatics) in order to brid tion. The present NOFO (R01 ility or proof-of-concept has b	nodel" disorders (s), such as the a This can include pathways, and b ata resources (e. ge the gap betwo activity code) ca peen established	but instead should ffected molecular ar the fundamental bio piological processes g., those contributin een disease risk fact n be used for applica Applicants proposi	aim to ad cellular blogy of these should be g to the Gene ors, biological ations to ng exploratory
117750 Assay Development and Screening Brain Disorders (R01 Clinical Trial	g for Discovery of Validated Chemical Hits for Not Allowed)	National Institute of Menta Health/NIH/DHHS	II PAR-23- 168	07-Sep-2024	Not Specified
Contact Telephone Contact Email Sponsor Website	michelottiel@mail.nih.gov				
Deadline Dates (ALL)	Link to program URL 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05 2026 , 05-Feb-2026 , 07-May-2026	-Feb-2025 , 07-May-2025 , 0	5-Jun-2025 , 07-S	ep-2025 , 05-Oct-20)25 , 07-Jan-
Synopsis	The overarching goal of this Notice of Fundin assays for the discovery of validated hits that potential drug candidates for the treatment of that has the desired activity in a compound s Stages of discovery research covered by this identify initial screening hits (high throughput using a series of assays and initial medicinal of	t can be used in future drug d of mental illness. For purpose creen and whose activity is c NOFO include 1) assay develo It target-focused screens, or r	iscovery/develop s of this initiative onfirmed upon re opment; 2) prima noderate throug	oment efforts for ide e, a "hit" is defined a etesting in orthogon ry screen implemen	entifying as a compound al assays. tation to
119663 Schizophrenia and Related Disorde	ers During mid- to Late-Life (R01 Clinical Trial	National Institute of Menta Health/NIH/DHHS	II PAR-24- 023	05-Oct-2024	Not Specified
Contact Name Contact Telephone	Laura M. Rowland, Ph.D. 301-480-8335				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Email	laura.rowland@nih.gov				
Sponsor Website					
Ŭ	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , (
Synopsis	The purpose of this Notice of Funding Oppores research to better understand the emerger mid- to late-life, and to identify targets for the R01 grant mechanism, while the compa risk/high reward projects that lack prelimin	nce, trajectory, and outcomes of future development of prevent mion NOFO (PAR-24-026), uses	of schizophrenia an tion and treatment s the R21 mechanis	d related psychoti interventions. Thi m. Investigators p	c disorders in s NOFO uses
118003 Notice of Special Interest (NOSI): Studies of Rare Genetic Neurodev	NIMH Planning Grants for Natural History /elopmental Disorders	National Institute of Menta Health/NIH/DHHS	al NOT-MH- 23-235 07-	-Sep-2024	Not Specified
Contact Name	Margaret Grabb, Ph.D.				
Contact Telephone	301-443-3563				
Contact Email	mgrabb@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , (2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-	•	5-Jun-2025 , 07-Sep	o-2025 , 05-Oct-20	25 , 07-Jan-
Synopsis	The National Institute of Mental Health (NII conduct retrospective natural history studie in function in patients (birth to 25 years of a these studies is to assess the time of onset establish potential timepoints for intervent quantitative clinical functional measures or future clinical trials. These retrospective na (see Food and Drug Administration's (FDA's	es that explore the prevalence age) with rare genetic neurode and severity of these symptom ion. Additionally, the planning biomarkers that could be used tural history studies are expect	of disabling psychia evelopmental disorce ns, identify appropr grants should focus d as prognostics and ted to enable future	atric symptoms an ders (NDD). The pr iate outcome mea s on identifying pc d/or measures of o e prospective long	d disruptions incipal goal of sures, and tential change in
118004 Notice of Special Interest (NOSI): Rare Genetic Neurodevelopmenta	Pre-Clinical Research on Gene Therapies for al Disorders	National Institute of Menta Health/NIH/DHHS	al NOT-MH- 23-236 07-	-Sep-2024	Not Specified
Contact Name					

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Telephone	301-443-3563				
Contact Email	NIMHgenetherapies@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , (2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun)5-Jun-2025 <i>,</i> 07-Se	p-2025 , 05-Oct-20	25 , 07-Jan-
Synopsis	The National Institute of Mental Health (NI clinical research aimed at developing novel disorders with prominent cognitive, social a	approaches for somatic cell g	-		•
112309 Building in vivo Preclinical Assays Therapeutic Development (R01 C	of Circuit Engagement for Application in	National Institute of Ment Health/NIH/DHHS	al PAR-22- 170 07	7-Sep-2024	Not Specified
Contact Name	Jamie Driscoll				
Contact Telephone	301-443-5288				
Contact Email	jdrisco1@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , (05-Feb-2025 , 07-May-2025 , 0)5-Jun-2025 <i>,</i> 07-Se	p-2025	
Deadline Dates (ALL) 07-Sep-2024, 05-Oct-2024, 07-Jan-2025, 05-Feb-2025, 07-May-2025, 05-Jun-2025, 07-Sep-2025 The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and beh measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to opti and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowled the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therap Synopsis development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment developm The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay mea that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a p					

SPIN ID Program Title	s	ponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	to build a suite of assays that are evaluated i species and healthy humans. In summary, th phase testing of novel therapeutic agents by	is FOA will support efforts to	improve the to	ol kit of assays availab	le for early
114657 <u>Clinical Studies of Mental Illness (</u>	Collaborative R01) (Clinical Trial Optional)	National Institute of Menta Health/NIH/DHHS	al PAR-23- 050	07-Sep-2024	Not Specified
Contact Name	Jonathan Pevsner, Ph.D				
Contact Telephone	301-728-5618				
Contact Email	jonathan.pevsner@nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05 2026	5-Feb-2025 , 07-May-2025 , 0	5-Jun-2025 , 07	-Sep-2025 , 05-Oct-20	25 , 07-Jan-
Synopsis	This Funding Opportunity Announcement (FC health genetics, biomarker studies, and studie of psychopathology). Applicants should apply Accordingly, the collaborating studies share a sample size, accelerate recruitment, or increa- health disparity populations. (see https://ww parameters.html). It is expected that one site centralized administration. For a linked set of Investigator (PD/PI). The collaborative R01 pe database management, statistical analysis, a	ies of mental illnesses (e.g., p y to this FOA when two or mo a specific protocol across the ase the inclusion of women a ww.nimhd.nih.gov/about/stra e will be submitted as a coord f collaborative R01s, each app rogram provides a mechanism	sychopathology ore sites are nee sites and are or nd minorities (N tegic-plan/nih-s linating R01 for plication has its	y, neurodevelopmenta eded to complete the ganized as such in ord NOT-OD-18-014) and I strategic-plan-definition data management an own Program Directo	Il trajectories study. Ier to increase VIH-defined ons-and- d/or other r/Principal
126283 RFA-MH-25-160 Suicide Preven Income Countries (R34 Clinical Tr	tion Across the Life Span in Low- and Middle- ial Optional)	National Institute of Menta Health/NIH/DHHS	al RFA-MH- 25-160	24-Sep-2024 [Optional][LOI/Pre- App]	450,000 USD
Contact Telephone	vidya.vedham@nih.gov				

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
Program URL	Link to program URL				
Deadline Dates (ALL)	24-Sep-2024 [Optional][LOI/Pre-App], 24-C	oct-2024			
Synopsis	The purpose of this Notice of Funding Oppo sensitive, innovative interventions to ident self-injury (NSSI) in Low- and Middle-Incom strengthen research capacity within the LN	ify and mitigate the risk of suic e Countries (LMICs). The prope	dal ideation and osed research ini	behavior (SIB), and, tiatives must incorp	/or non-suicida
103213 Effectiveness Trials for Post-Acute Longer-term Outcomes (R01 Clinic	e Interventions and Services to Optimize cal Trial Required)	National Institute of Menta Health/NIH/DHHS	II PAR-21- 210	05-Oct-2024	Not Specified
Contact Name	Adam Haim, Ph.D.				
Contact Telephone	301-435-3593				
Contact Email	haima@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024				
Synopsis	NIMH seeks applications for research proje for the post-acute management of mental Opportunity Announcement (FOA) encoura moderators, mediators, and mechanisms o matched to the stage of illness in terms of managing residual symptoms/impairment, intensity/burden for promoting optimal lor powered to provide a definitive answer reg effectiveness trials designed to evaluate the post-acute phase intervention approaches	health conditions affecting you ges clinical trials to establish the faction of post-acute phase the poth their focus (e.g., consolidate preventing relapse, promoting ager-term outcomes. This FOA parding the effectiveness of the e initial feasibility, tolerability,	th, adults, and o ne effectiveness erapeutic and se iting and mainta adherence and a s intended to su post-acute phas acceptability, saf	lder adults. This Fun and test hypotheses rvices interventions ining gains from init appropriate service pport trials that are e intervention. Supp	ding regarding that are ial treatment, use) and statistically port for pilot
115030 Building in vivo Preclinical Assays Therapeutic Development (R01 Cl	of Circuit Engagement for Application in inical Trial Not Allowed)	National Institute of Menta Health/NIH/DHHS	II PAR-23- 091	07-Sep-2024	Not Specified
Contact Name Contact Telephone Contact Email					

SPIN ID	Program Title	S	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05	-Feb-2025 , 07-May-2025 , 0)5-Jun-2025 , 07-Sep	-2025	
	Synopsis	The goal of this Funding Opportunity Announ measures for use as assays in the early screen and evaluate measures of neurophysiologica pharmacokinetic/pharmacodynamic (PK/PD) the neurobiology of mental illnesses. The screen neurobiology and clinical neuroscience to end development pipeline in which treatment can neurobiological mechanisms of potential clin accomplished by supporting basic neuroscience development pipeline by advancing the disco engagement as tools for early phase target van The efforts supported by this initiative focus that are adaptable across early therapeutic set to build a suite of assays that are evaluated in species and healthy humans. In summary, this phase testing of novel therapeutic agents by	ning phase of treatment dev l and behavioral processes the markers of neural processes eening assays developed fro- hance the scientific value of indidates and therapeutic tar- ical relevance to mental illnes and at improving the e- overy of in vivo physiological alidation and therapeutic scr on measures in animals as a creens in animals to evaluati in future projects for coherer is FOA will support efforts to	elopment. This FOA hat may serve as s of clinical interest l m this FOA are expe preclinical animal d gets can be evaluate esses. The objectives efficiency and scient and behavioral mea reening for mental il first step in generat ion in humans. The f nee of assay perform improve the tool ki	will support effor based on available ected to build upor ata contributing to ed for their ability s of this FOA will b ific value of the th sures reflecting ci lness treatment d ing translational a FOA may be consid- nance between the t of assays availab	ts to optimize knowledge of n systems o a therapeutic to impact erapeutic frcuit evelopment. assay measures dered a preque e preclinical ole for early
11/15/19	Notice of Special Interest (NOSI): Emotional and Social Representat	The Neural Mechanisms of Multi-Dimensional ion	National Institute of Ment Health/NIH/DHHS	al NOT-MH- 23-120	-Sep-2024	Not Specified
	Contact Name	Andrew Breeden, Ph.D.				
	Contact Telephone					
	Contact Email	andrew.breeden@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	-	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07	7-Jan-2025			
		NIMH is issuing this Notice of Special Interest perspective into studies of the neural mecha integrate a broad array of emotional and soc	t (NOSI) to outline priorities nisms underlying emotional	and/or social repres	entations. The ab	ility to

SPIN ID Program Title	5	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	underlying these processes are not well und diverse multi-dimensional emotional and/or health relevant cognitive, social, and affectiv of multiple modalities (e.g., social, emotiona dynamic processes that unfold over a variety	social cues are represented a ve behavioral functions. The te I, visual, and auditory), the ef	cross brain circuit erm "multi-dimens	s that are importan sional" refers to th	nt for mental e consideratior
115209 Innovative Pilot Mental Health Se (R34 Clinical Trial Not Allowed)	rvices Research Not Involving Clinical Trials	National Institute of Menta Health/NIH/DHHS	I PAR-23- 16 105 16	5-Oct-2024	450,000 USD
Contact Name	Susan T. Azrin, Ph.D.				
Contact Telephone	301-443-3267				
Contact Email	azrinst@mail.nih.gov				
Sponsor Website					
	Link to program URL				
Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025				
	The purpose of this Funding Opportunity An support the delivery of high-quality, continu individuals with, or at risk for developing, an projects that address NIMH strategic prioriti described in Goal 4 of the NIMH Strategic Pla access, continuity, utilization, quality, value, services, which may serve as targets in futur tools, technologies, measures, or methods a and analyzing large data sets to understand and predictive analytic approaches; Whereve goals.	ously improving mental health mental illness. This announcer es to strengthen the public he an. Proposed research should and outcomes, including disp e service delivery interventior nd statistical approaches to st factors affecting mental healt	n services to bener nent invites applic alth impact of NIN seek to: Identify n arities in outcome development; De udy these issues; h services outcom	fit the greatest nur cations for non-clin AH-supported rese nutable factors that s, or scalability of evelop and test new Test the feasibility es using advanced	nber of ical trial pilot earch as it impact mental health w research of integrating computational
119705 Cellular and Molecular Biology of <u>Not Allowed</u>)	Complex Brain Disorders (R21 Clinical Trial	National Institute of Menta Health/NIH/DHHS	I PAR-24- 025 16	5-Oct-2024	275,000 USD
Contact Name	David Panchision				
Contact Telephone	301-402-3969				
	panchisiond@mail.nih.gov				



SPIN ID Program Title		Sponsor Name	Sponsor Numbe	Deadline Date	Funding Amount	
Sponsor Website						
Program URL	nk to program URL					
Deadline Dates (ALL)	6-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026					
This Notice of Funding Opportunity (NOFO) encourages research on the biology of high confidence risk factor with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural purposes of this NOFO, the term "complex" can refer to a multifactorial contribution to risk (e.g., polygenic environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hy generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro exp paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome me incorporated into the research design to facilitate the characterization of intracellular, transcellular and circu these are neither required nor expected. Studies should not attempt to "model" disorders but instead shoul synopsis elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular components and their relationships within defined biological process(es). This can include the fundamental factors, components and processes. The resulting paradigms, component pathways and biological processes disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributi Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk fa mechanism and therapeutic target identification. The present NOFO (R21 activity code) can be used for app develop early stage, high-risk, exploratory approaches or establish proof-of-concept where there is little or data. Applicants proposing to develop lines of inquiry where feasibility or proof of concept has been establist to the companion R01 NOFO (PAR-24-024).						
102513 Development of Psychosocial The Mental Disorders (R61/R33 Clinic	erapeutic and Preventive Interventions for al Trial Required)	National Institute of Menta Health/NIH/DHHS	I PAR-21- 135	.5-Oct-2024	Not Specified	
Contact Name	Alexander Talkovsky, Ph.D.					
Contact Telephone	301-827-7614					
Contact Email	alexander.talkovsky@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	15-Oct-2024					
Synopsis	NIMH solicits clinical trial applications throu intervention development pipeline, from fi					

SPIN ID Program Title	9		Sponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
		through to effectiveness trials. The purpose psychosocial intervention approaches in whe experimental therapeutics approach, this For processes underlying mental disorders into may include, but are not limited to, potenti processes, neural circuits or neural activity mechanisms. Novel psychosocial intervention interventions for which there is an empirical substantially enhance outcomes. Support we testing of a novel intervention's impact on a maintenance (target engagement). Up to 3 that meet the "go/no-go" milestones embe target engagement and to test whether enge Ultimately, trials must be designed so that me utility and will support "go/no-go" decisions pursuing other stages of the clinical trial pip	the target and/or intervent DA is intended to speed the tra- promising novel psychosocial p ally modifiable behavioral, cogn subserving specific behaviors of ons may be standalone interven al rationale by which the augment will be provided for up to two yes a target process or mechanism years of additional support (R3 dded in the R61 phase. The R33 gaging the intervention target/r results, whether positive or neg s about further development and	tion strategy is in nslation of eme preventative or nitive, affective r cognitive proc ntions or augme entation (and co ears (R61 phase) associated men 3 phase) will be 3 phase is inter- nechanism meo pative, will provind/or testing of	novel. Consistent wit rgent research on m therapeutic interven and/or interpersona esses, and/or other entations to efficacio rresponding target) of preliminary mile tal disorder risk, cau provided for studies ded to support the re- liates changes in clin de information of his the intervention. Ap	h NIMH's echanisms and tions. Targets l factors or neurobiologica us s expected to stone-driven sation, or with findings eplication of ical outcomes gh scientific
		pgic or Device-based Interventions for the R61/R33 Clinical Trial Required)	National Institute of Menta Health/NIH/DHHS	Ι ΡΔΒ-21-	15-Oct-2024	Not Specified
	Contact Name	Margaret Grabb, Ph.D.				
C	Contact Telephone	301-443-3563				
	Contact Email	mgrabb@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
De	adline Dates (ALL)	15-Oct-2024				
		NIMH solicits clinical trial applications throu intervention development pipeline, from fir		-		

SPIN ID Program Title	5	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	testing of pharmacologic or device-based int the intervention is adequately tested, to pro controlled, dose-dependent neurophysiolog biphasic high-risk applications. Support for a available in the companion R33, PAR-21-136 one of the companion FOAs.	vide meaningful information vice meaningful information vical/clinical/behavioral effect. single phased award that doe	where target mod The R61/R33 FO es not need the de	ulation yields a we As are intended to evelopmental (R61)	ll- support phase is
102528 Early Stage Testing of Pharmacolo Treatment of Mental Disorders (R	ogic or Device-based Interventions for the 133- Clinical Trial Required)	National Institute of Menta Health/NIH/DHHS	I PAR-21- 136	5-Oct-2024	Not Specified
Contact Name	Margaret Grabb, Ph.D.				
Contact Telephone	301-443-3563				
Contact Email	mgrabb@mail.nih.gov				
Sponsor Website					
-	Link to program URL				
Deadline Dates (ALL)	15-Oct-2024				
Synopsis	NIMH solicits clinical trial applications throu intervention development pipeline, from first through to effectiveness trials. The purpose with novel mechanisms of action or device-te functions in individuals with mental illness (a bipolar disorder). Early intervention studies subjects (a prodromal phase), prior to full di stage testing of pharmacologic or device-bas action of the intervention is adequately test controlled, dose-dependent neurophysiolog are appropriate for this FOA. This R33 FOA s are encouraged to apply to the companion F	st-in human, early testing of n of this FOA is to support the e based interventions, for the tro e.g., schizophrenia, depression are also encouraged where sy agnostic criteria being met. Ul sed interventions using a prote ed, to provide meaningful info ical/clinical/behavioral effect. upports single-phased clinical	ew interventions, arly stage testing eatment of sympt n, autism, obsessiv mptoms of a diso timately, this FOA ocol design where prmation where ta Pediatric, adult an trial awards. Appl	confirmatory effica of pharmacologic i oms or domains of re compulsive disor rder have been ide is intended to sup the presumed me inget modulation yi nd geriatric focused	acy trials, nterventions altered rder, anxiety, ntified in port early chanism of elds a well- d interventions
102910 Understanding and Modifying Ter Activity (R21 Clinical Trial Optional	mporal Dynamics of Coordinated Neural al)	National Institute of Menta Health/NIH/DHHS	I PAR-21- 176 10	5-Oct-2024	275,000 USD
Contact Name Contact Telephone	Andrew Rossi, Ph.D. 301-443-1576				

SPIN ID Program Title	S	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Sponsor Website	Link to program URL 16-Oct-2024 A growing body of evidence suggests that op coordinated neural activity. These findings in spike-phase correlations, spike population dy for treatment of cognitive, social, or affective Announcement (FOA) supports projects that improve cognitive, affective, or social process manipulations to address at least one, and ic parameters of neural coordination, when ma	ndicate that oscillatory rhythm ynamics, and other patterns n e symptoms in neuropsychiati test whether modifying elect sing. Applications must use es deally more, of the following t anipulated in isolation, improv- nine how particular abnormali trophysiological patterns duri n behaving animals predict an populations; and (4) use biolo	ns, their co-modula night be useful driv ric disorders. This F rophysiological pat kperimental design opics: (1) in animal ve particular aspect ities at the genomic ng behavior; (3) de alogous electrophy gically-realistic con	tion across freque ers of therapeutic funding Opportuni sterns during beha s that incorporate s or humans, dete s of cognitive, affe c, molecular, or ce termine whether vsiological and cog nputational mode	highly ncy bands, development ty vior can active rmine which ective, or socia llular levels in vivo, nitive s that include
103214 Pilot Effectiveness Trials for Post- Longer-term Outcomes (R34 Clini	patterns unfold across the brain to impact co mechanism, whereas its companion FOA, PA an established premise. Acute Interventions and Services to Optimize	R-21-175, seeks R01 grant ap	plications for larger		
	Adam Haim, Ph.D.		211		030
Contact Telephone	301-435-3593				
Contact Email	haima@mail.nih.gov				
Sponsor Website					
	Link to program URL				
Deadline Dates (ALL)					
Synopsis	NIMH seeks applications for pilot projects to interventions for the post-acute managemer				

SPIN ID	Program Title	2	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		both their focus (e.g., consolidating and mai preventing relapse, promoting adherence ar effectiveness research, the trial should be de effectiveness of the approach; to address wh presumed to underlie the intervention effect effectiveness trial (e.g., comparative effective interventions to improve post-acute outcom acceptability, safety and preliminary indicati design of definitive effectiveness trials. Supp phase interventions is provided via the R01,	nd appropriate service use) an esigned to evaluate the feasib hether the intervention engag ts; and to obtain preliminary of reness study, practical trial) de nes. This FOA supports pilot re ons of effectiveness of post-ap port for fully-powered, definiti	d intensity/burder ility, tolerability, ac es the target(s)/m lata needed as a p signed to definitel search to evaluate cute phase interve	 In this pilot phas cceptability, safety echanisms(s) that re-requisite to a la ly test the effective the feasibility, tolention approaches 	e of , and potentia is/are rger-scale eness of erability, and inform the
$111\times \times /14$	Notice of Special Interest (NOSI): and Violence Against Others	NIMH Priorities on Research on Aggression	National Institute of Menta Health/NIH/DHHS	I NOT-MH- 22-095	-Aug-2024	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	NIMHResearchOnAggres@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
		08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 1				
	Synopsis	NIMH is issuing this Notice of Special Interes prevention of interpersonal aggression and		or research on the	etiology, risks for,	and
	Notice of Special Interest (NOSI): Behaviors (R01 Clinical Trial Optic	Neuro-Glia Mechanisms Governing Complex onal)	National Institute of Menta Health/NIH/DHHS	II NOT-MH- 22-090 07	-Sep-2024	Not Specified
	Contact Name	Michele Ferrante, Ph.D.				
	Contact Telephone	301-435-6782				
	Contact Email	michele.ferrante@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
		07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 0	7 1. 2025 05 5. 2025 40		2025	

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
Synopsis	This Notice of Special Interest (NOSI) encou neuro-glia activity coupling in modulating co		Illy test mechani	stic hypotheses on th	e role of
115199 Novel Assays to Address Translati (UG3/UH3 Clinical Trial Optional)	ional Gaps in Treatment Development	National Institute of Ment Health/NIH/DHHS	al PAR-23- 087	21-Oct-2024	Not Specified
Contact Name	Jamie Driscoll				
Contact Telephone	301-443-5288				
Contact Email	jdrisco1@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	21-Oct-2024 , 21-Feb-2025 , 20-Jun-2025				
Synopsis	The Funding Opportunity Announcement (F measures of neurophysiological processes t another species relevant to the therapeutic aimed at identifying measures for potential therapies and their targets. Data may also r species and humans, thus establishing a firr humans. The ultimate goal of this FOA is to congruent measures as well as inconsistence treatment candidates. The objectives of the translational neuroscientists who are comm target validation and therapeutic developm processes in both animals and in healthy hu pharmacologic manipulations. In this way, p	hat are disrupted within or ac development pipeline. The in development as preclinical as eveal assay measures where p n basis for limiting speculative improve the efficiency of the ies between the preclinical sc FOA will be accomplished by itted to advancing the discove ent. Groups will be tasked wit mans. Groups will evaluate as projects will reveal the potenti	ross mental diso itiative will supp says for evaluati performance is d e extrapolations of therapeutic deve reening pipeline supporting parti ery of in vivo phy ch developing and say performance al of specific ass	rders in both healthy ort initial proof of co- ng potential new dru issimilar between pro- of preclinical animal elopment process by and clinical evaluation rerships among basic visiological measures d optimizing in vivo a e across both species ays to translate from	humans and in ncept studies g and device eclinical animal findings to identifying on of new and as tools for ssays of brain in response to
RFA-MH-25-180 Mechanisms or126545Associated Neuroinflammation and Neuropathogenesis and Cure (RO)	· · · · · · · · · · · · · · · · · · ·	National Institute of Ment Health/NIH/DHHS	al RFA-MH- 25-180	08-Oct-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Name Contact Telephone	Jeymohan Joseph, Ph.D. 240-627-3869				

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
	Contact Email	jjeymoha@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	· · ·	08-Oct-2024 [Optional][LOI/Pre-App]				
	Synopsis	The goal of this Notice of Funding Opportun associated neuroinflammation and central r research focused on defining the role and m inflammation, immune activation and CNS of dynamics is also an area of interest. Novel t associated neuroinflammation in the CNS of cell systems, organoid models, post-morten to address this research area. Basic and Tra Multidisciplinary research teams and collabor preliminary data may be most appropriate f data may wish to apply using this R01 mech	nervous system (CNS) HIV per- nechanisms of defective provi co-morbidities. The impact of herapeutic strategies targetin ompartment is also an area of in tissue, animal models and si inslational research in domest orations are encouraged but r or the companion R21 NOFO,	sistence. In parti ruses, HIV protei neuroinflammati g the reciprocal i high priority for ngle-cell technol ic and internatio not required. Hig	cular this NOFO enco ns and/or nucleic acid ion in regulating CNS impact of persistent v this initiative. State- ogies can be used as onal settings are also h risk/high payoff pro	urages ds in inducing reservoir virus and of-the-art CNS potential tools of interest. ojects that lack
1 16 / 35		sured Phenotypes to Advance Computation ACT-MH) (U01 Clinical Trial Optional)	al National Institute of Ment Health/NIH/DHHS	al RFA-MH- 25-195	18-Sep-2024 [Optional][LOI/Pre- App]	12,500,000 USD
	Contact Name	Jenni Pacheco, Ph.D.				
	Contact Telephone	301-443-3645				
	Contact Email	jenni.pacheco@nih.gov				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	18-Sep-2024 [Optional][LOI/Pre-App], 18-O	ct-2024			
	Synopsis	This Notice of Funding Opportunity (NOFO) and computational methods to define nove decision making in mental disorders. A mult develop behavioral tasks (and other types o differences in individuals with or at risk of d identify existing datasets that include behav	l clinical signatures that can b i-component approach is pro f measures, as appropriate) tl eveloping mental disorders; (e used for individ posed in which g nat are optimized 2) collect the dat	dual-level prediction a rantees will (1) ident d for measurement o ta from novel clinical	and clinical ify and/or f individual cohorts and/o

SPIN ID Program Title	s	ponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
	derive novel clinical signatures that incorpor are informative for clinical purposes; and (4) previous RFA-MH-23-106), which is responsil of combined data, and creation of a data infr propose new cohorts from one or more popu disorders of behavior regulation, psychosis) a cohorts that have appropriate data structure Notice of Fuding Opportunity (NOFO) require	partner with the existing Dat ble for coordinating the harm rastructure to support data sh ulations targeted to specific c and/or care delivery settings, es, or may use a combination	a Coordinating C onization of met aring with the so inical groupings may leverage da of approaches w	Center (DCC) (funded thods, aggregation o cientific community. (e.g., mood/anxiety ata from existing clin vith new and existing	l under f data, analysis Applicants may disorders, ical research
117822 Mentored Career Transition Awar Required)	d for Intramural Fellows (K22 Clinical Trials	National Institute of Menta Health/NIH/DHHS	l PA-23- 150	12-Oct-2024	Not Specified
Contact Name	Ashlee Van't Veer				
Contact Telephone	301-443-3107				
Contact Email	dnbbstrainingbranch@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12	2-Oct-2025 , 12-Feb-2026			
Synopsis	The Mentored Career Transition Award for N award program that is intended to facilitate a Intramural Programs (DIRP) from intramural equivalent faculty positions at eligible U.S. in award will provide research support during t research programs. This Funding Opportunit as the lead investigator of an independent cl part of their research and career developme research experience in a clinical trial led by a	a timely transition of qualified postdoctoral research position istitutions. Both the intramur he extramural phase to help y Announcement (FOA) is des inical trial, a clinical trial feasi nt. Applicants not planning ar	l postdoctoral fe ns to extramura al and extramur wardees launch igned specificall bility study, or a independent cl	ellows in the NIMH D II, academic tenure-t al phases will be me competitive, indepo y for applicants prop separate ancillary c inical trial, or propos	ivision of rack or ntored, and the endent oosing to serve inical trial, as
117821 Mentored Career Transition Awar Not Allowed)	d for Intramural Fellows (K22 Clinical Trials	National Institute of Menta Health/NIH/DHHS	l PA-23- 149	12-Oct-2024	Not Specified
Contact Name Contact Telephone	Ashlee Van't Veer 301-443-3107				



SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
	Contact Email	dnbbstrainingbranch@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 1	12-Oct-2025 , 12-Feb-2026			
	Synopsis	The Mentored Career Transition Award for award program that is intended to facilitate Intramural Programs (DIRP) from intramura equivalent faculty positions at eligible U.S. is award will provide research support during research programs. This Funding Opportuni that does not involve leading an independe Applicants to this FOA are permitted to pro Applicants proposing a clinical trial or an an 23-150.	e a timely transition of qualifie al postdoctoral research position institutions. Both the intramu the extramural phase to help ity Announcement (FOA) is de ent clinical trial, a clinical trial f pose research experience in a	d postdoctoral fe ons to extramura ral and extramura awardees launch signed specifical easibility study, o clinical trial led	ellows in the NIMH D al, academic tenure-t ral phases will be men n competitive, indepen y for applicants prop or an ancillary clinical by a mentor or co-me	ivision of rack or ntored, and the endent osing research trial. entor.
	RFA-MH-25-136 Pilot Research Suicide Prevention (R34 Clinical Tr	Opportunities in Crisis Response Services for rial Optional)	r National Institute of Ment Health/NIH/DHHS	al RFA-MH- 25-136	02-Sep-2024 [Optional][LOI/Pre- App]	675,000 USD
	Contact Name	Jennifer Humensky, Ph.D.				
	Contact Telephone	301-480-1265				
	Contact Email	jennifer.humensky@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	02-Sep-2024 [Optional][LOI/Pre-App], 01-O	oct-2024 , 03-May-2025 [Optio	nal][LOI/Pre-App), 02-Jun-2025	
	Synopsis	This NOFO seeks to promote pilot explorate crisis response services, approaches to imp on implementation and outcomes. Researc presentations, psychosocial factors, age-rel (rural/remote settings), racial/ethnic and cu provided. Studies are encouraged that addu powered studies is provided through a com	rove the quality and outcomes h is sought that is conducted i lated characteristics (e.g., yout ultural considerations, and hea ress the continuum of crisis se	s of services, and n real-world sett th; adult; older a alth disparities in rvice systems. So	the impact of state a ings, where a wide ra dult), geographic con fluence the types of upport for larger-scal	and local policy inge of clinical text care that are e or fully-

SPIN ID Program Title		Sponsor Name Sp	oonsor Numb	er Deadline Date	Funding Amount
	Opportunities in Crisis Response Service	es for Suicide Prevention (R01 Clinica	l Trial Option	al).	
L26537 RFA-MH-25-135 Resear Suicide Prevention (R01 C	ch Opportunities in Crisis Response Services for linical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH- 25-135	02-Sep-2024 [Optional][LOI/Pre- App]	Not Specified
Contac	t Name Jennifer Humensky, Ph.D.				
Contact Tel	ephone 301-480-1265				
Conta	ct Email <u>jennifer.humensky@nih.gov</u>				
Sponsor	Vebsite				
Progr	am URL Link to program URL				
Deadline Dat	es (ALL) 02-Sep-2024 [Optional][LOI/Pre-App], 0	1-Oct-2024 , 03-May-2025 [Optional][LOI/Pre-Ap	p], 02-Jun-2025	
	response services, approaches to impro		ices, and the	impact of state and loc	cal policy on
S	• • • • • • •	we the quality and outcomes of services of is sought that is conducted in real- e-related characteristics (e.g., youth; and cultural considerations, and health address the continuum of crisis services s the R34 mechanism (RFA-MH-25-12)	ices, and the -world setting adult; older a n disparities in ce systems. S	impact of state and loc gs, where a wide range adult), geographic cont nfluence the types of c upport for pilot studies	cal policy on of clinical cext care that are s is provided
RFA-MH-25-181 Mecha 26543 <u>Associated Neuroinflamm</u>	response services, approaches to impro implementation and outcomes. Research presentations, psychosocial factors, age (rural/remote settings), racial/ethnic ar provided. Studies are encouraged that through a companion NOFO that utilize	we the quality and outcomes of services of is sought that is conducted in real- e-related characteristics (e.g., youth; and cultural considerations, and health address the continuum of crisis services s the R34 mechanism (RFA-MH-25-12)	ices, and the -world setting adult; older a n disparities in ce systems. S	impact of state and loc gs, where a wide range adult), geographic cont nfluence the types of c upport for pilot studies	cal policy on of clinical cext care that are s is providec
RFA-MH-25-181 Mecha26543Associated NeuroinflammNeuropathogenesis and C	ynopsis ynopsis nesentations, psychosocial factors, age (rural/remote settings), racial/ethnic ar provided. Studies are encouraged that through a companion NOFO that utilize Response Services for Suicide Prevention nisms of Reciprocal Interactions between HIV ation and CNS Persistence: Implications in HIV	ove the quality and outcomes of services of is sought that is conducted in real- e-related characteristics (e.g., youth; address the considerations, and health address the continuum of crisis services of the R34 mechanism (RFA-MH-25-13 on (R34 Clinical Trial Optional)). National Institute of Mental	ices, and the -world setting adult; older a n disparities in ce systems. S 36); Pilot Res RFA-MH-	impact of state and loc gs, where a wide range adult), geographic cont influence the types of c upport for pilot studies earch Opportunities in 08-Oct-2024 [Optional][LOI/Pre-	cal policy on of clinical cext are that are s is provided Crisis 275,000
26543 <u>Associated Neuroinflamm</u> Neuropathogenesis and C Contac	response services, approaches to impro implementation and outcomes. Research presentations, psychosocial factors, age (rural/remote settings), racial/ethnic ar provided. Studies are encouraged that a through a companion NOFO that utilize Response Services for Suicide Prevention hisms of Reciprocal Interactions between HIV ation and CNS Persistence: Implications in HIV ure (R21 Clinical Trial Not Allowed)	ove the quality and outcomes of services of is sought that is conducted in real- e-related characteristics (e.g., youth; address the considerations, and health address the continuum of crisis services of the R34 mechanism (RFA-MH-25-13 on (R34 Clinical Trial Optional)). National Institute of Mental	ices, and the -world setting adult; older a n disparities in ce systems. S 36); Pilot Res RFA-MH-	impact of state and loc gs, where a wide range adult), geographic cont influence the types of c upport for pilot studies earch Opportunities in 08-Oct-2024 [Optional][LOI/Pre-	cal policy on of clinical cext are that are s is provided Crisis 275,000
RFA-MH-25-181 Mecha 26543 <u>Associated Neuroinflamm</u> <u>Neuropathogenesis and C</u> Contact Tel	ynopsis ynopsis nesentations, psychosocial factors, age (rural/remote settings), racial/ethnic ar provided. Studies are encouraged that through a companion NOFO that utilize Response Services for Suicide Prevention <u>nisms of Reciprocal Interactions between HIV</u> <u>ation and CNS Persistence: Implications in HIV</u> <u>ure (R21 Clinical Trial Not Allowed)</u> tt Name Jeymohan Joseph, Ph.D.	ove the quality and outcomes of services of is sought that is conducted in real- e-related characteristics (e.g., youth; address the considerations, and health address the continuum of crisis services of the R34 mechanism (RFA-MH-25-13 on (R34 Clinical Trial Optional)). National Institute of Mental	ices, and the -world setting adult; older a n disparities in ce systems. S 36); Pilot Res RFA-MH-	impact of state and loc gs, where a wide range adult), geographic cont influence the types of c upport for pilot studies earch Opportunities in 08-Oct-2024 [Optional][LOI/Pre-	cal policy on e of clinical cext care that are s is provided Crisis 275,000
26543 <u>Associated Neuroinflamm</u> Neuropathogenesis and C Contac Contact Tel	response services, approaches to impro implementation and outcomes. Researd presentations, psychosocial factors, age (rural/remote settings), racial/ethnic ar provided. Studies are encouraged that a through a companion NOFO that utilize Response Services for Suicide Preventionnisms of Reciprocal Interactions between HIV ation and CNS Persistence: Implications in HIV ure (R21 Clinical Trial Not Allowed)tt Name ephone 240-627-3869ct Email ijjeymoha@mail.nih.gov	ove the quality and outcomes of services of is sought that is conducted in real- e-related characteristics (e.g., youth; address the considerations, and health address the continuum of crisis services of the R34 mechanism (RFA-MH-25-13 on (R34 Clinical Trial Optional)). National Institute of Mental	ices, and the -world setting adult; older a n disparities in ce systems. S 36); Pilot Res RFA-MH-	impact of state and loc gs, where a wide range adult), geographic cont influence the types of c upport for pilot studies earch Opportunities in 08-Oct-2024 [Optional][LOI/Pre-	cal policy on e of clinical cext care that are s is provided Crisis 275,000
26543 <u>Associated Neuroinflamm</u> Neuropathogenesis and C Contac Contac Sponsor N Progr	vnopsisresponse services, approaches to impro implementation and outcomes. Researd presentations, psychosocial factors, age (rural/remote settings), racial/ethnic ar provided. Studies are encouraged that a through a companion NOFO that utilize Response Services for Suicide Preventionmisms of Reciprocal Interactions between HIV ation and CNS Persistence: Implications in HIV ure (R21 Clinical Trial Not Allowed)tt Name ephoneJeymohan Joseph, Ph.D. 240-627-3869 ct Email jjeymoha@mail.nih.govWebsite am URLLink to program URL	ove the quality and outcomes of services of is sought that is conducted in real- e-related characteristics (e.g., youth; address the considerations, and health address the continuum of crisis services of the R34 mechanism (RFA-MH-25-13 on (R34 Clinical Trial Optional)). National Institute of Mental	ices, and the -world setting adult; older a n disparities in ce systems. S 36); Pilot Res RFA-MH-	impact of state and loc gs, where a wide range adult), geographic cont influence the types of c upport for pilot studies earch Opportunities in 08-Oct-2024 [Optional][LOI/Pre-	cal policy on e of clinical cext care that are s is provided Crisis 275,000
26543 <u>RFA-MH-25-181 Mecha</u> 26543 <u>Associated Neuroinflamm</u> <u>Neuropathogenesis and C</u> Contac Contac Conta Sponsor V Progr Deadline Dat	ynopsisresponse services, approaches to impro implementation and outcomes. Researd presentations, psychosocial factors, age (rural/remote settings), racial/ethnic ar provided. Studies are encouraged that a through a companion NOFO that utilize Response Services for Suicide Preventionnisms of Reciprocal Interactions between HIV ation and CNS Persistence: Implications in HIV ure (R21 Clinical Trial Not Allowed)tt Name ephoneJeymohan Joseph, Ph.D. 240-627-3869 ct Email jjeymoha@mail.nih.govWebsite	ove the quality and outcomes of servi ch is sought that is conducted in real- e-related characteristics (e.g., youth; address the continuum of crisis servic s the R34 mechanism (RFA-MH-25-13 on (R34 Clinical Trial Optional)). National Institute of Mental Health/NIH/DHHS	ices, and the -world setting adult; older a n disparities in ce systems. S 36); Pilot Res RFA-MH- 25-181	impact of state and loc gs, where a wide range adult), geographic cont offluence the types of c upport for pilot studies earch Opportunities in 08-Oct-2024 [Optional][LOI/Pre- App]	cal policy on e of clinical cext are that are s is provided Crisis 275,000 USD

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	associated neuroinflammation and central in research focused on defining the role and m inflammation, immune activation and CNS of dynamics is also an area of interest. Novel to associated neuroinflammation in the CNS of cell systems, organoid models, post-morten to address this research area. Basic and tran Multidisciplinary research teams and collab preliminary data are most appropriate for the apply to the R01 mechanism, RFA-MH-25-14	nechanisms of defective provi co-morbidities. The impact of herapeutic strategies targetin ompartment is also an area of n tissue, animal models and si nslational research in domesti orations are encouraged but r he RFA-MH-25-181 R21 mecha	ruses, HIV protein neuroinflammation g the reciprocal im high priority for th ngle-cell technolog c and international not required. High	s and/or nucleic aci n in regulating CNS pact of persistent v is initiative. State of ies can be used as settings are of inte risk/high payoff pro	ids in inducing reservoir virus and of the art CNS potential tools erest. bjects that lack
102507 Pilot Effectiveness Trials for Treat (R34 Clinical Trial Required)	ment, Preventive and Services Interventions	National Institute of Ment Health/NIH/DHHS	al PAR-21- 131	5-Oct-2024	450,000 USD
Contact Name	Joel Sherrill, Ph.D.				
Contact Telephone	301-443-2477				
Contact Email	jsherril@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Oct-2024				
Synopsis	NIMH solicits clinical trial applications throu intervention development pipeline, from fir through to effectiveness trials. The purpose effectiveness research on preventive and th broader target populations or for use in cor testing of innovative services interventions. intended to support pilot studies of intervent the intervention engages the target(s)/mec that accounts for changes in clinical/functio services, etc.). In this pilot effectiveness ph approaches that can be justified in terms of FOA supports pilot studies and provides res preliminary effectiveness of approaches to	rst-inhuman, early testing of n e of this FOA is to encourage p nerapeutic interventions with mmunity practice settings, and . Consistent with the NIMH ex ntion effectiveness or service hanism(s) presumed to under onal outcomes, changes in pro- tase of research, NIMH places f their potential to substantiall cources for evaluating the feas	ew interventions, o ilot research consis- previously demons (2) research on the perimental therape delivery approache lie the intervention vider behavior, imp highest priority on y impact practice a ibility, tolerability,	confirmatory effica stent with NIMH's p trated efficacy, for e development and eutics approach, th es that explicitly ad effects (i.e., the m proved access or co intervention and so ind public health. T acceptability and s	cy trials, priorities for: 1) use with preliminary is FOA is dress whether techanism(s) ontinuity of ervice delivery this afety and

SPIN ID Program Title	s	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	service delivery, and for obtaining the prelim comparative effectiveness study, pragmatic separate FOAs that utilize the R01 mechanise Effectiveness of Treatment, Preventive, and effectiveness trials (PAR-21-129;"Clinical Tria (Collaborative R01 Clinical Trial Required)").	trial). Support for fully-power m for single-site effectiveness Services Interventions (R01)." als to Test the Effectiveness of	ed effectiveness trials (PAR-21-13) and collaborativ Treatment, Preve	studies is provided 0; "Clinical Trials to e R01 mechanism f ention, and Service	through Test the or multi-site s Interventions
102506 Clinical Trials to Test the Effective Interventions (R01 Clinical Trial Re	ness of Treatment, Preventive, and Services equired)	National Institute of Menta Health/NIH/DHHS	II PAR-21- 130 1	5-Oct-2024	Not Specified
Contact Name	Joel Sherrill, Ph.D.				
Contact Telephone	301-443-2477				
Contact Email	jsherril@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Oct-2024				
Synopsis	NIMH solicits clinical trial applications throug intervention development pipeline, from firs through to effectiveness trials. This FOA seek test hypotheses regarding moderators, medi clinical trials designed to test the therapeutid evidence of efficacy, for use in community ar effectiveness or increase the clinical impact of device-based, rehabilitative and combination trials to test patient-, provider-, organization equity, and/or value of services. The interver practice-relevant questions. This FOA uses t sufficient scope to test effectiveness and exa require participation of two or more collabor accelerate recruitment, or increase sample d 129 "Clinical Trials to Test the Effectiveness of FOA is designed for applicants seeking fundir	st-inhuman, early testing of ne ks to support clinical trials to e iators, and mechanisms of act c value of treatment and prev nd practice settings. Application of pharmacologic, somatic, ps in interventions to prevent or the nal-, or systems-level services intion research covered under the R01 grant mechanism to se amine mediators and moderate rative sites for completion of liversity and representation) i of Treatment, Preventive, and	ew interventions, establish the effec- ion of these inter- entive intervention ons might include ychosocial (e.g., p creat mental illnes interventions to in this announceme upport trials that cors of response. S the study (e.g., in s provided throug Services Interven	confirmatory effica tiveness of interve ventions. This FOA ons for which there research to evalua sychotherapeutic, s. This FOA also su mprove access, con ent is explicitly focu are adequately pow Support for multi-si order to increase s h a separate FOA, I tions (Collaborative	cy trials, ntions and to supports is already te the behavioral), pports clinical tinuity, quality, sed on wered and of te trials that ample size, PAR-21- e RO1)." This

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
		Applicants pursuing other stages of the clin	ical trial pipeline should consic	der one of the co	mpanion FOAs.	
102511	Development of Psychosocial The Mental Disorders (R33 Clinical Tria	rapeutic and Preventive Interventions for al Required)	National Institute of Menta Health/NIH/DHHS	al PAR-21- 134	15-Oct-2024	Not Specified
	Contact Telephone	alexander.talkovsky@nih.gov				
	Program URL Deadline Dates (ALL)	Link to program URL 15-Oct-2024 NIMH solicits clinical trial applications throu	igh a series of Funding Opport	unity Announcer	nents (FOAs) that co	wer the
	Synopsis	intervention development pipeline, from fin through to effectiveness trials. The purpose psychosocial intervention approaches in wh experimental therapeutics approach, this Fe processes underlying mental disorders into may include, but are not limited to, potenti processes, neural circuits or neural activity mechanisms. Novel psychosocial intervention target and/or the intervention strategy is me interventions for which there is an empirical substantially enhance outcomes. Support we engagement findings, and to relate change designed so that results, whether positive of "go/no-go" decisions about further develop seeking to fund pilot stages of research. Ap the companion FOAs.	e of this FOA is to encourage pinich the target and/or interven OA is intended to speed the tra- promising novel psychosocial ally modifiable behavioral, cog subserving specific behaviors of on strategies might include in- ovel. They may also be standal al rationale by which the augm vill be provided for up to 3 year in the intervention target/med or negative, will provide inform oment and/or testing of the intervention	lot research deve tion strategy is n anslation of eme preventative or t gnitive, affective a person or techno one intervention entation (and co rs for studies to r chanism to clinica nation of high scie cervention. This F	eloping and testing i lovel. Consistent wit rgent research on m herapeutic interven and/or interpersona esses, and/or other blogy-assisted delive is or augmentations rresponding target) replicate previous ta al benefit. Ultimately entific utility and wil GOA is designed for a	nnovative h NIMH's echanisms and tions. Targets I factors or neurobiological ry, provided the of efficacious is expected to rget r, trials must be I support pplicants
102509	First in Human and Early Stage Cli Devices for Psychiatric Disorders (nical Trials of Novel Investigational Drugs or (U01 Clinical Trial Required)	National Institute of Menta Health/NIH/DHHS	al PAR-21- 133	15-Oct-2024	Not Specified
	Contact Name Contact Telephone	Margaret Grabb, Ph.D. 301-443-3563				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Sponsor Website Program URL Deadline Dates (ALL) Synopsis	mgrabb@mail.nih.gov Link to program URL 15-Oct-2024 NIMH solicits clinical trial applications throu intervention development pipeline, from find through to effectiveness trials. The purposed stage clinical trials of novel mechanism of a psychiatric disorders in areas of unmet mechanism of adult populations. First in human (FIH) and pharmacological effects, safety, and tolerated disorders. Phase II/PoC studies must evaluated measures) and clinical indicators of effect. evaluate target engagement, safety, tolerated "de-risk" novel mechanism of action investic disorders, and devices or combination treated further clinical development as FDA-approved partnerships between the biomedical reseated device development. This FOA is designed for clinical trials as outlined above. Applicants proved the second	rst-inhuman, early testing of ne e of this FOA is to encourage co action investigational drugs or r dical need. The FOA will suppor Phase Ib studies of novel agen bility to assess feasibility for Ph ate the drug's impact on clinica The FOA also supports FIH and bility, and efficacy. The overall igational drugs, novel drugs for tments in order to attract priva- ved treatments. A key aspect of archers and biotechnology or in for applicants seeking funding f	ew interventions, o operative agreem novel neuromodula t milestone-driver ts must assess targ ase II/proof of con Ily relevant physio early feasibility stu objective is to facil use in pediatric po te or other public this FOA is the for dustry researchers or cooperative agr	confirmatory effica- ent applications to atory devices for the early stage trials get engagement (b cept (PoC) studies logical systems (fu udies (EFS) of nove litate rapid collection opulations with pso funding (when appreciation of collabo is to facilitate psych eements supporting	cy trials, o support early ne treatment of in pediatric an rain exposure in psychiatric nctional I devices to on of data to ychiatric propriate) for rative niatric drug or ng early stage
	not involving cooperative agreements shou <u>Is of Non-Pharmacological Interventions for</u> al Required)	•	D PAR-21-	-Oct-2024	Not Specified
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Adam Haim, Ph.D. 301-435-3593 <u>haima@mail.nih.gov</u> Link to program URL				· · ·

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
	intervention development pipeline, from fir through to effectiveness trials. The purpose therapeutic and preventive interventions for approach. Under this FOA, trials must be de high scientific utility and will support "go/nd dissemination of the intervention. Intervent interpersonal, and device-based (both invas combination thereof. Interventions appropri- previous demonstration that the intervention efficacy signal, and must address an unmet that includes measurement of the hypothes and change in functional or clinical effects. In determine the intervention's potential for si- pipeline should consider one of the compan-	of this FOA is to support confi r mental disorders in adults ar signed so that results, whether o-go" decisions about further of tions to be studied include, but ive/surgically implanted as we tate for efficacy testing must k on engages and alters the hypo therapeutic need. Support will sized mechanism of action and Ultimately, this FOA is intende ignificant clinical benefit. Appl	rmatory efficacy nd children throu r positive or nega levelopment, eff t are not limited ell as noninvasive be based on a cor othesized mechan be provided for the relationship d to support a su	testing of non-phar gh an experimental ative, will provide in ectiveness testing, o to behavioral, cognit /transcranial) appro npelling scientific ra hism of action, a pre a trial of the interve between change in fficiently-powered e	macological therapeutics formation of tr tive, aches, or a tionale, liminary ention's efficacy the mechanism efficacy trial to
106896 <u>Neuromodulation/Neurostimulation</u> Applications (R21 Clinical Trial No	ion Device Development for Mental Health t Allowed)	National Institute of Menta Health/NIH/DHHS	al PAR-22- 038	l6-Oct-2024	275,000 USD
	David McMullen, M.D.				
Contact Telephone					
	david.mcmullen@nih.gov				
Sponsor Website					
	Link to program URL				
Deadline Dates (ALL) Synopsis	16-Oct-2024 The purpose of this funding opportunity and generation of brain stimulation devices for t develop novel brain stimulation devices or 2 effectiveness of brain stimulation devices th Novel devices should move beyond existing of increased spatiotemporal precision as we capabilities should focus on significant enha device. Incremental changes to existing dev Applications should be submitted by multi-	treating mental health disorde 2) significantly enhance, by me hat are currently U.S. Food and electrical/magnetic stimulation ell as multi-focal, closed-loop a incement of the spatial resolut ices (e.g., software updates) a	rs. Applications a ans of hardware, Drug Administra in and develop no pproaches. Appli tion, depth of del re not within the	re sought that will e /software improven ation (FDA)-approve ew stimulation techn cations seeking to d ivery, and/or precisi scope of this annou	either 1) nents, the d or cleared. niques capable evelop new fon of the ncement.

SPIN ID Program T	itle	s	Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
		engineering, clinical, and regulatory affairs. A or significant enhancement of novel tools (ha should focus on the engineering developmen to demonstrate initial proof of concept is allo should propose design-directed, developmen Applications that seek to study scientific or c This FOA uses the R21 grant mechanism, enco opportunity, PAR-22-039, seeks R01 grant ap	ardware/software) for brain st nt and bench top testing of the owable. Applications to this FC ntal, or discovery-driven techr clinical hypotheses that simply couraging shorter, higher-risk a	imulation in h tool, animals A are not expo ology research utilize devices	umans. Although the and limited human to ected to be hypothes n using integrative ap are outside the scop	application esting necessary is-driven, but proaches. e of this FOA.
106477	ation/Neurostimulat (R21 Clinical Trial No	ion Device Development for Mental Health at Allowed)	National Institute of Menta Health/NIH/DHHS	PAR-22- 038	16-Oct-2024	275,000 USD
	Contact Name	David McMullen, M.D.				
	Contact Telephone	301-451-0180				
	Contact Emai	david.mcmullen@nih.gov				
	Sponsor Website	2				
	Program URI	Link to program URL				
	Deadline Dates (ALL)	16-Oct-2024				
	Synopsis	The purpose of this funding opportunity ann generation of brain stimulation devices for the develop novel brain stimulation devices or 22 effectiveness of brain stimulation devices that Novel devices should move beyond existing effective of increased spatiotemporal precision as well capabilities should focus on significant enhant device. Incremental changes to existing device Applications should be submitted by multi-di- engineering, clinical, and regulatory affairs. A or significant enhancement of novel tools (has should focus on the engineering development to demonstrate initial proof of concept is allow should propose design-directed, development Applications that seek to study scientific or concepting.	reating mental health disorder) significantly enhance, by mea at are currently U.S. Food and electrical/magnetic stimulatio II as multi-focal, closed-loop ap ncement of the spatial resolut ces (e.g., software updates) ar isciplinary teams with diverse Applications submitted in resp ardware/software) for brain st nt and bench top testing of the owable. Applications to this FC ntal, or discovery-driven techr	s. Applications ans of hardwar Drug Administ n and develop oproaches. App on, depth of d e not within th expertise inclu onse to this FC imulation in he tool, animals DA are not expe ology research	s are sought that will re/software improver ration (FDA)-approver new stimulation tech plications seeking to c elivery, and/or precis the scope of this annou ding systems neuroso OA should promote the umans. Although the and limited human te ected to be hypothes in using integrative ap	either 1) nents, the ed or cleared. niques capable develop new ion of the uncement. cience, e development application esting necessary is-driven, but proaches.

SPIN ID	Program Title	s	ponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
		This FOA uses the R21 grant mechanism, enc opportunity, PAR-22-039, seeks R01 grant ap		applications, wh	ereas its companion	funding
11/11/58	NIMH Exploratory/Developmenta Allowed)	Il Research Grant (R21 Clinical Trial Not	National Institute of Menta Health/NIH/DHHS	al PA-21- 235	07-Sep-2024	275,000 USD
	Contact Name	Susan Koester, Ph.D.				
	Contact Telephone	301-443-3563				
	Contact Email	koesters@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025				
	Synopsis	The NIMH Exploratory/Developmental Grant NIMH mission by providing support for the ex considerable risk but may lead to a breakthro	arly and conceptual stages of	f these projects.	These studies may in	volve
		NIMH mission by providing support for the exconsiderable risk but may lead to a breakthromodels, or strategies, or to the generation of major impact on biomedical, behavioral, or c	arly and conceptual stages of ough or to the development f pilot or feasibility data. The linical mental health research	f these projects. of novel techniqu preliminary worl h, or on the deliv	These studies may ir ues, agents, methods k from these studies	ivolve 5, measures, could lead to care.
15/111		NIMH mission by providing support for the exconsiderable risk but may lead to a breakthromodels, or strategies, or to the generation of	arly and conceptual stages of ough or to the development of pilot or feasibility data. The	f these projects. of novel techniqu preliminary worl h, or on the deliv	These studies may ir ues, agents, methods k from these studies	ivolve s, measures, could lead to
15/111	Mood and Psychosis Symptoms d Trial Optional)	NIMH mission by providing support for the exconsiderable risk but may lead to a breakthromodels, or strategies, or to the generation of major impact on biomedical, behavioral, or c	arly and conceptual stages of ough or to the development pilot or feasibility data. The linical mental health research National Institute of Menta	f these projects. of novel techniqu preliminary worl h, or on the deliv al PAR-23-	These studies may ir ues, agents, methods k from these studies very of mental health	ovolve s, measures, could lead to care. 275,000
15/111	Mood and Psychosis Symptoms d Trial Optional)	NIMH mission by providing support for the exconsiderable risk but may lead to a breakthromodels, or strategies, or to the generation of major impact on biomedical, behavioral, or curing the Menopause Transition (R21 Clinical Laura M. Rowland, Ph.D.	arly and conceptual stages of ough or to the development pilot or feasibility data. The linical mental health research National Institute of Menta	f these projects. of novel techniqu preliminary worl h, or on the deliv al PAR-23-	These studies may ir ues, agents, methods k from these studies very of mental health	ovolve s, measures, could lead to care. 275,000
15/111	Mood and Psychosis Symptoms d Trial Optional) Contact Name Contact Telephone	NIMH mission by providing support for the exconsiderable risk but may lead to a breakthromodels, or strategies, or to the generation of major impact on biomedical, behavioral, or curing the Menopause Transition (R21 Clinical Laura M. Rowland, Ph.D.	arly and conceptual stages of ough or to the development pilot or feasibility data. The linical mental health research National Institute of Menta	f these projects. of novel techniqu preliminary worl h, or on the deliv al PAR-23-	These studies may ir ues, agents, methods k from these studies very of mental health	ovolve s, measures, could lead to care. 275,000
15/111	Mood and Psychosis Symptoms d Trial Optional) Contact Name Contact Telephone	NIMH mission by providing support for the eaconsiderable risk but may lead to a breakthrown odels, or strategies, or to the generation of major impact on biomedical, behavioral, or considerable the Menopause Transition (R21 Clinical Laura M. Rowland, Ph.D. 301-480-8335 laura.rowland@nih.gov	arly and conceptual stages of ough or to the development pilot or feasibility data. The linical mental health research National Institute of Menta	f these projects. of novel techniqu preliminary worl h, or on the deliv al PAR-23-	These studies may ir ues, agents, methods k from these studies very of mental health	ovolve s, measures, could lead to care. 275,000
15/111	Mood and Psychosis Symptoms d Trial Optional) Contact Name Contact Telephone Contact Email Sponsor Website	NIMH mission by providing support for the eaconsiderable risk but may lead to a breakthrown odels, or strategies, or to the generation of major impact on biomedical, behavioral, or considerable the Menopause Transition (R21 Clinical Laura M. Rowland, Ph.D. 301-480-8335 laura.rowland@nih.gov	arly and conceptual stages of ough or to the development pilot or feasibility data. The linical mental health research National Institute of Menta	f these projects. of novel techniqu preliminary worl h, or on the deliv al PAR-23-	These studies may ir ues, agents, methods k from these studies very of mental health	ovolve s, measures, could lead to care. 275,000
15/111	Mood and Psychosis Symptoms d Trial Optional) Contact Name Contact Telephone Contact Email Sponsor Website	NIMH mission by providing support for the eaconsiderable risk but may lead to a breakthrown models, or strategies, or to the generation of major impact on biomedical, behavioral, or considerable methods and the methods and the methods and the methods are stransition (R21 Clinical Laura M. Rowland, Ph.D. 301-480-8335 laura.rowland@nih.gov	arly and conceptual stages of ough or to the development pilot or feasibility data. The linical mental health research National Institute of Menta	f these projects. of novel techniqu preliminary worl h, or on the deliv al PAR-23-	These studies may ir ues, agents, methods k from these studies very of mental health	ovolve s, measures, could lead to care. 275,000

SPIN ID Program Title	s	ponsor Name	ponsor Numb	er Deadline Date	Funding Amount
	FOA (PAR-23-097) uses the R01 grant mecha preliminary data, or studies that utilize existi preliminary data who seek longer-term fund	ng data may wish to apply usi	ng the R21 me	chanism, while applica	
119664 Schizophrenia and Related Disor Optional)	ders During mid- to Late-Life (R21 Clinical Trial	National Institute of Mental Health/NIH/DHHS	PAR-24- 026	16-Oct-2024	275,000 USD
Contact Nam	e Laura M. Rowland, Ph.D.				
Contact Telephon	e 301-480-8335				
Contact Ema	il laura.rowland@nih.gov				
Sponsor Websit	e				
Program UR	L Link to program URL				
Deadline Dates (ALI) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16	5-Oct-2025 , 16-Feb-2026 , 16-	Jun-2026		
	The purpose of this Notice of Funding Oppor research to better understand the emergence				
Synopsi	research to better understand the emergenc	e, trajectory, and outcomes of iture development of preventi ion NOFO (PAR-24-023) uses t ry data may be more appropri	f schizophrenia on and treatm he R01 mecha ate for the R22	and related psychoti ent interventions. Thi nism. Investigators pr	c disorders i s NOFO use oposing higl
Advancing Learning Health Care	research to better understand the emergence mid- to late-life, and to identify targets for fur the R21 grant mechanism, while the compan risk/high reward projects that lack preliminate preliminary data who seek longer-term fundion Research in Outpatient Mental Health	e, trajectory, and outcomes of iture development of preventi ion NOFO (PAR-24-023) uses t ry data may be more appropri	f schizophrenia on and treatm he R01 mecha ate for the R2: mechanism.	and related psychoti ent interventions. Thi nism. Investigators pr	c disorders i s NOFO uses oposing higl
23916 Advancing Learning Health Care Treatment Settings (R34 Clinical	research to better understand the emergence mid- to late-life, and to identify targets for fur the R21 grant mechanism, while the compan risk/high reward projects that lack preliminate preliminary data who seek longer-term fundion Research in Outpatient Mental Health	e, trajectory, and outcomes of iture development of preventi ion NOFO (PAR-24-023) uses t ry data may be more appropri ing should apply using the R01 National Institute of Mental	f schizophrenia on and treatm he R01 mecha ate for the R22 mechanism. PAR-24-	and related psychoti ent interventions. Thi nism. Investigators pr mechanism, while ap 17-Sep-2024 [Optional][LOI/Pre-	c disorders i s NOFO uses oposing hig oplicants wit 450,000
23916 Advancing Learning Health Care Treatment Settings (R34 Clinical	research to better understand the emergence mid- to late-life, and to identify targets for fur the R21 grant mechanism, while the compan risk/high reward projects that lack preliminate preliminary data who seek longer-term fundi Research in Outpatient Mental Health Trial Optional) e Michael Freed, Ph.D.	e, trajectory, and outcomes of iture development of preventi ion NOFO (PAR-24-023) uses t ry data may be more appropri ing should apply using the R01 National Institute of Mental	f schizophrenia on and treatm he R01 mecha ate for the R22 mechanism. PAR-24-	and related psychoti ent interventions. Thi nism. Investigators pr mechanism, while ap 17-Sep-2024 [Optional][LOI/Pre-	c disorders i s NOFO uses oposing higl oplicants wit 450,000
23916 Advancing Learning Health Care Treatment Settings (R34 Clinical Contact Nam Contact Telephon	research to better understand the emergence mid- to late-life, and to identify targets for fur the R21 grant mechanism, while the compan risk/high reward projects that lack preliminate preliminary data who seek longer-term fundi Research in Outpatient Mental Health Trial Optional) e Michael Freed, Ph.D.	e, trajectory, and outcomes of iture development of preventi ion NOFO (PAR-24-023) uses t ry data may be more appropri ing should apply using the R01 National Institute of Mental	f schizophrenia on and treatm he R01 mecha ate for the R22 mechanism. PAR-24-	and related psychoti ent interventions. Thi nism. Investigators pr mechanism, while ap 17-Sep-2024 [Optional][LOI/Pre-	c disorders i s NOFO use: oposing hig oplicants wit 450,000
23916 Advancing Learning Health Care Treatment Settings (R34 Clinical Contact Nam Contact Telephon	research to better understand the emergence mid- to late-life, and to identify targets for fur the R21 grant mechanism, while the compan risk/high reward projects that lack preliminate preliminary data who seek longer-term fundi Research in Outpatient Mental Health Trial Optional) e Michael Freed, Ph.D. e 301-443-3747 il michael.freed@nih.gov	e, trajectory, and outcomes of iture development of preventi ion NOFO (PAR-24-023) uses t ry data may be more appropri ing should apply using the R01 National Institute of Mental	f schizophrenia on and treatm he R01 mecha ate for the R22 mechanism. PAR-24-	and related psychoti ent interventions. Thi nism. Investigators pr mechanism, while ap 17-Sep-2024 [Optional][LOI/Pre-	c disorders i s NOFO use: oposing hig oplicants wit 450,000
23916 Advancing Learning Health Care Treatment Settings (R34 Clinical Contact Nam Contact Telephon Contact Ema Sponsor Websit	research to better understand the emergence mid- to late-life, and to identify targets for fur the R21 grant mechanism, while the compan risk/high reward projects that lack preliminate preliminary data who seek longer-term fundi Research in Outpatient Mental Health Trial Optional) e Michael Freed, Ph.D. e 301-443-3747 il michael.freed@nih.gov	e, trajectory, and outcomes of iture development of preventi ion NOFO (PAR-24-023) uses t ry data may be more appropri ing should apply using the R01 National Institute of Mental	f schizophrenia on and treatm he R01 mecha ate for the R22 mechanism. PAR-24-	and related psychoti ent interventions. Thi nism. Investigators pr mechanism, while ap 17-Sep-2024 [Optional][LOI/Pre-	c disorders s NOFO use oposing hig oplicants wit 450,000
23916 Advancing Learning Health Care Treatment Settings (R34 Clinical Contact Nam Contact Telephon Contact Ema Sponsor Websit	research to better understand the emergence mid- to late-life, and to identify targets for fur the R21 grant mechanism, while the compan risk/high reward projects that lack preliminal preliminary data who seek longer-term fundi Research in Outpatient Mental Health Trial Optional) e Michael Freed, Ph.D. e 301-443-3747 il michael.freed@nih.gov e L Link to program URL 17 Son 2024 [Optional][LOJ/Bro. Appl. 16. Optional]	e, trajectory, and outcomes of iture development of preventi ion NOFO (PAR-24-023) uses t ry data may be more appropri ing should apply using the R01 National Institute of Mental Health/NIH/DHHS	f schizophrenia on and treatm he R01 mecha ate for the R22 mechanism. PAR-24- 118	and related psychoti ent interventions. Thi nism. Investigators pr mechanism, while ap 17-Sep-2024 [Optional][LOI/Pre- App]], 16-Feb-2025 , 17-M	c disorders s NOFO use oposing hig oplicants wir 450,000 USD

SPIN ID	Program Title	S	Sponsor Name	Sponsor Numl	per Deadline Date	Funding Amount
		health care framework to support adoption, practices in outpatient mental health and su to, Certified Community Behavioral Health C Administration (SAMHSA) expansion grant p demonstration program, or as a part of inde certification criteria. This NOFO requires acti behavioral health partners across all phases staff/service users and health services resea served by CCBHCs with unique needs, includ groups or underserved communities; (2) wo vary in terms of prior experience, expertise a treatment; (4) hybrid effectiveness-implement treatment, or services delivery approaches in response services within CCBHC settings.	bstance use treatment system linics (CCBHCs) funded throug rogram and CCBHCs participat pendent state programs when ive collaboration between beh of the research process. Studi rchers may focus on (1) identii ing health disparities experier rkforce development strategie and skills; (3) developing and t entation trials aimed at implen	ns. These setting the Substan- ting in their sta- te the CCBHCs havioral health es that are co- fying subgroup need by people es, including ne testing tools to nenting and im	ngs could include, but a ce Abuse and Mental H ates' Section 223 CCBH are meeting the federa researchers and comm designed between com s within the population from racial and ethnic w approaches to train promote measuremen proving evidence-base	re not limited ealth Services C Medicaid I CCBHC munity munity clinic n of individua minority providers wh it-based d prevention,
126959	Genetic Architecture of Mental D (U01 Clinical Trial Not Allowed)	isorders in Ancestrally Diverse Populations II	National Institute of Menta Health/NIH/DHHS	il PAR-24- 240	15-Sep-2024 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Miri Gitik, Ph.D.				
	Contact Telephone	301-827-3523				
	Contact Email	<u>miri.gitik@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Sep-2024 [Optional][LOI/Pre-App], 11-Oc	t-2024 , 13-Jun-2025 , 13-Feb	-2026		
	Synopsis	The following Notice of Funding Opportunity accelerate gene discovery for psychiatric disc genetic architecture of mental illnesses acro NOFO instructions and review the accompar	orders in cohorts of non-Euro ss ancestrally diverse global p	pean ancestry	to advance our unders	tanding of th
126961	<u>Genetic Architecture of Mental D</u> (U24 Clinical Trial Not Allowed)	isorders in Ancestrally Diverse Populations II	National Institute of Menta Health/NIH/DHHS	II PAR-24- 241	15-Sep-2024 [Optional][LOI/Pre- App]	Not Specified

App]

SPIN ID Program Tit	le		Sponsor Name	Sponsor Numb	per Deadline Date	Funding Amount
	Contact Telephone	<u>miri.gitik@nih.gov</u>				
D	Program URL	Link to program URL 15-Sep-2024 [Optional][LOI/Pre-App], 11-C	Oct-2024			
	Synopsis	This Notice of Funding Opportunity (NOFO collaborative, work between PAR-24-240U0 initiative described in the companion anno- psychiatric genetic studies by supporting la globe, currently significantly underrepreser harmonization and joint analyses across ne the network and develop best practices gui Develop and disseminate ethical best pract psychiatric genetic studies in different setti working groups and the network steering c steering committee as needed. Applicants of NOFO, PAR-24-240	01 research projects funded un uncement. The APN-2 initiative irge scale genomic studies in po- nted in the field. The APN Coor twork projects, (b) Plan, coord idance for individual member p cices for APN members and the ings around the world, (d) Serv committee, and (e) Provide adm	nder the Ancest e has an overall opulations of no rdinating Center inate and facilit projects and the e scientific comr re as a liaison be ninistrative sup	ral Populations Netwo goal of enhancing div on-European Ancestry (APN-2 CC) will: (a) C rate research training wider scientific comm nunities, with a specif etween the different n port for the network v	rk 2 (APN-2) ersity in around the oordinate dat activities acro nunity, (c) ic focus on etwork vorkgroups ar
111257 <u>RFA-NS-22-036</u> <u>Optional)</u>	6 NINDS Interdisc	iplinary Team Science Grant (RM1 Clinical Tr	rial National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 22-036	08-Sep-2024 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	David Owens, Ph.D.				
	Contact Telephone	301-496-9248				
	Contact Email	NINDSteamscience@nih.gov				
	Sponsor Website					
	e e	Link to program URL				
D	eadline Dates (ALL) Synopsis	08-Sep-2024 [Optional][LOI/Pre-App], 08-C This funding opportunity announcement (F to pursue bold, impactful, and challenging i	OA) is designed to support inte			

SPIN ID Program Title	S	ponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	should be interdisciplinary in nature, and the collaboration, synergy, and managed team in efforts or parallel projects. This program is dis integrated research plan with a singular focus consider transformative objectives with defin	teractions. Proposed researd stinct from the NINDS P01 in s, one set of aims, and a bud	ch should not re that it will supp	present a collection o port a cohesive, single	f individual , well-
118525 RFA-NS-23-027 Collaborative O Innovative Neuroscience (COMBI	pportunities for Multidisciplinary, Bold, and NE) (RM1 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 23-027	08-Sep-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Name					
Contact Telephone	301-496-9248				
Contact Email	NINDSteamscience@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	08-Sep-2024 [Optional][LOI/Pre-App], 08-Oct	-2024			
Synopsis	The Collaborative Opportunities for Multidisc support integrated efforts of three to six PDs, outcomes within the scope of this program an interdisciplinary team approach involving inn synergy in expertise and approaches, and we collection of individual efforts or parallel proj transformative research goal. This program is focused goal instead of multiple aims.	/PIs to pursue a bold, impact nd the NINDS mission. This d ovative combination of disti II-managed team interaction ects, but rather an integrate	ful, and challen lefined research nct disciplines a s. Proposed res d effort from all	ging goal with defined goal must only be acl nd/or intellectual viev earch must not repres I PIs to achieve a single	l 5-year nievable by an vpoints, ent a e,
118126 RFA-NS-24-020 NINDS Sustaina Rigor (STIRR) Program (RC2 - Clini	ble Transformation of Institutional Research cal Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 24-020	17-Sep-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Devon Crawford				
Contact Telephone	301-827-7758				
Contact Email	devon.crawford@nih.gov				
Sponsor Website					

PIN ID Program Title S	Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
Program URL Link to program URL				
Deadline Dates (ALL) 17-Sep-2024 [Optional][LOI/Pre-App], 17-Oc	t-2024 , 17-Sep-2025 [Optiona	al][LOI/Pre-App], 17-Oct-2025	
Synopsis Synopsis This Notice of Funding Opportunity (NOFO) a transparency practices within academic and Attention to principles of rigorous study desi community, as well as the biomedical comm scientific findings. Awards are intended to su the departmental, inter-departmental, or eq	research institutions to promo ign and transparent reporting unity at large, to design and p upport the implementation of	ote a culture of are essential to erform valid ex innovative prog	high-quality neuroso enable the neuroso periments and to as	cience research ientific sess the value c
25193 Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01 - Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 196	04-Oct-2024	500,000 USD
Contact Name Roderick A. Corriveau, Ph.D.				
Contact Telephone 301-496-5680				
Contact Email roderick.corriveau@nih.gov				
Sponsor Website				
Program URL Link to program URL				
Deadline Dates (ALL) 04-Oct-2024				
The purpose of this Notice of Funding Oppor Synopsis cellular and hemodynamic mechanisms that how they may contribute to cognitive decline	underlie diffuse white matter	•	-	
17726 RFA-NS-23-026 BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 23-026	11-Oct-2024	Not Specified
Contact Name Natalie Trzcinski, Ph.D				
Contact Telephone 301-469-1779				
Contact Email natalie.trzcinski@nih.gov				
Sponsor Website				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	11-Oct-2024				
	Synopsis	This funding opportunity announcement (FC research practice. The resource(s) should be Scientific Vision" and "The BRAIN Initiative 2 community. The resource(s) should address impractical in their current form. Activities r	e relevant to the goals of the l 2.0: From Cells to Circuits, Tow compelling needs of neurosc must include dissemination of ols and reagents; user training forms and/or specialized facil delivery; minor adaptations t	BRAIN Initiative as o vard Cures" and sha ience researchers th an existing resourc g on the usage of ne ities; minor improve o meet the needs o	utlined in the "BR red broadly to the nat are otherwise e, and may include w technologies or ements to increase f a user communit	AIN 2025: A e neuroscience unavailable or e one or more techniques; e the y.Applications
121162		nd Validation of Remote or Patient Wearable atures or Functional Assessments to Monitor	•	d RFA-NS- 04	-Oct-2024	Not
121102		al Trials (UG3/UH3 - Clinical Trial Optional)	Stroke/NIH/DHHS	^u 24-023 ⁰⁴	-001-2024	Specified
	Contact Name	Ram Arudchandran, PhD				
	Contact Telephone	301-402-5257				
	Contact Email	ramachandran.arudchandran@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	04-Oct-2024				
	Synopsis	The purpose of this Notice of Funding Oppo world digital endpoints derived from data ge monitoring the experience of pain, its progr endpoints refer to biosignatures obtained fr devices. Development of digital endpoints w specific focus on selecting and validating no proposed digital endpoints may focus on a se to identify digital endpoints across various per represent each relevant pain condition and develop, and validate digital endpoints that appropriate pain-related functional measure	enerated by existing remote of ression, response to intervent rom functional and physiologi vill involve clinical research us vel measurements as approp specific pain condition or enco pain conditions should involve associated clinical networks. accurately measure pain and	or wearable devices ions, and impact on cal assessments cap sing existing wearab riate digital endpoin ompass multiple pai e Multiple Principal I These teams should related outcomes,	These endpoints quality of life. In t otured by remote of le or remote devic ts for pain assess n conditions. Appl nvestigator (MPI)- collaborate to dis such as quality of	will be used for his NOFO, or wearable ces, with a nent. The ications aiming led teams that cover, ife or

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	analysis, and advanced statistical methods to responsible for coordinating clinical trials, statistical analysis, and algorithm development developing digital endpoints for a single pair along with centralized resource groups resp methods, technology development, and statisticam is required to incorporate patient perso of digital measurements in the study. The find data from existing remote or wearable technology as digital endpoints, and assessments, serving as digital endpoints, and	tandardizing sample or data co ent across all pain conditions n condition, MPI-led teams wi onsible for coordinating clinic tistical analysis. Furthermore, spectives, concerns, and valua nal products of this effort wou nologies. The goal is to demor	ollection methods, under investigatior ith cross-functional al trials, standardiz the inclusion of pe ble input regarding uld be algorithms a nstrate that digital	technology develo n. For applications f l expertise should b zing sample or data cople with lived exp g the relevance and nd software design biosignatures or dig	pment, focused on be included, collection berience in the l acceptability led to analyze
	and BRAIN Initiative Diversity Specialized vancement in Neuroscience (D-SPAN) Award ved)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	d RFA-NS- 08 24-030	3-Oct-2024	Not Specified
Contact Nan	ne Michelle Jones-London, PhD				
Contact Telephor	ne 301-451-7966				
Contact Ema	ail jonesmiche@ninds.nih.gov				
Sponsor Websi	te				
Program UI	RL Link to program URL				
Deadline Dates (AL	L) 08-Oct-2024 , 20-Mar-2025 , 07-Oct-2025 , 2	20-Mar-2026 , 06-Oct-2026			
Synops	The purpose of the NIH Blueprint Diversity S Award is to support a defined pathway acro including those from groups underrepresent completion of the doctoral dissertation and postdoctoral positions, and will provide care becoming independent neuroscience resear to propose to lead an independent clinical to by a sponsor or co-sponsor	iss career stages for outstandin ted in biomedical and behavio transition of talented graduat eer development opportunitie rchers. This Funding Opportun	ng graduate studer oral sciences. This t te students to stror es relevant to their ity Announcement	nts from diverse ba wo-phase award w ng neuroscience res long-term career g t (FOA) does not allo	ckgrounds, ill facilitate search oal of ow applicants
111360 Notice of Special Interest (NOSI Hydrocephalus): Disease Mechanisms of Prenatal and Pediatri	National Institute of Neurological Disorders and Stroke/NIH/DHHS	d NOT-NS- 23-004 07	7-Sep-2024	Not Specified

Stroke/NIH/DHHS

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Name	Jill Morris, Ph.D.				
Contact Telephone	301-496-5754				
Contact Email	jill.morris@nih.gov				
Sponsor Website					
•	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 0	· · ·	•		
Synopsis	The purpose of this Notice is to inform pote research projects that focus on deciphering pathogenesis of prenatal and/or pediatric h	the molecular, cellular and d	evelopmental mech	anisms involved in	
126126 RFA-NS-24-041 NIH HEAL Initiat Health Care Systems (UG3/UH3 -	ive: Coordinated Approaches to Pain Care in Clinical Trial Optional)	National Institute of Neurological Disorders an Stroke/NIH/DHHS	d RFA-NS- 08- 24-041	-Oct-2024	Not Specified
Contact Name	Linda Porter, PhD				
Contact Telephone	301-451-4460				
Contact Email	porterl@ninds.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	08-Oct-2024 , 07-Nov-2024				
Synopsis	This Notice of Funding Opportunity (NOFO) to embed existing evidence-based coordina where this type of care does not exist. This health care delivery system of applicant inst include interventions from multiple disciplin biopsychosocial model of pain. Emphasis sh coordinated care proposed by the study tea should be informed through engagement of policymakers, and payors. The study teams implementation scientists. Trials will be sup Implementation Studies to Improve the Ma	ted pain care models into a v NOFO is intended to embed titutions. Coordinated pain content and be on reaching population should be aligned with hear of stakeholders including patie are expected to include healt ported by the Coordinating C	ariety of public and the coordinated care are approaches prop hould aim to improve ons of patients with alth care resources o nts, providers, healt h care providers fro enter (CC) of the HE	private health care e model under stu- posed for study are greatest need. Mo of the participating hcare system exec m multiple discipli AL Pragmatic and	e systems (HC dy into the e expected to nt based on th odels of HCS and cutives,

SPIN ID Program Title	s	ponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
	(https://rethinkingclinicaltrials.org/.) The Co coordination across studies awarded through refinement of proposed studies in partnersh	n this NOFO. Recipients will	work with the C	•	
126258 RFA-NS-25-011 Functional Targ Dementias (R61/R33 Clinical Trial	et Validation for Alzheimer's Disease-Related Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-	09-Oct-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Pascal Laeng, PhD				
Contact Telephone	301-496-7416				
Contact Email	pascal.laeng@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Oct-2024 [Optional][LOI/Pre-App], 08-No	v-2024			
Synopsis	This NOFO invites applications that propose is candidates for Alzheimer's Disease-Related D approaches to help de-risk subsequent trans Target(s) or molecular pathway(s) to be cons or genetic data generated in human samples for the development of customized technolo candidate(s) in cells and/or tissues and moni Upon demonstration of technical feasibilities validate the impact of the target modulation reproducibility guidelines. This NOFO will sup are expected to have a substantial collaborat anyone or group within the ADRD spectrum of degeneration (FTD), Lewy body dementias (L (PDD), vascular contributions to cognitive im etiology dementias (MED).	Dementias (ADRD). This NOFC lational research and acceler sidered for validation must ha . In its initial phase, this NOF gies, models, and protocols t tor their functional biological s, a second phase (R33 stage) in different modalities across oport applications that addre- tive effort between independ of disorders. Disorders covere BD) (including dementia with	D seeks to promo ate the advanced we been already O provides suppo o modulate the consequences i will carefully an s collaborating la ss objectives for ent laboratories ed in these appli o Lewy bodies (D	ote critical target valid ment of novel therap identified using tissu ort for up to two year expression or activity n vitro or in vivo disea d reproducibly measu aboratories using the both the R61 and R3 . This NOFO is not spe cations are frontoten LB)), Parkinson diseas	lation ies for ADRD. e expression s (R61 stage) of target ase models. ire and cross NIH rigor and B phases and ecific for aporal se dementia
107186 Clinical Trial Readiness for Function Optional)	onal Neurological Disorders (U01 Clinical Trial	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22- 053	05-Oct-2024	Not Specified

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Codrin Lungu, MD				
Contact Telephone					
	lunguci@ninds.nih.gov				
Sponsor Website					
_	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024				
Synopsis	Functional Neurological Disorders (FNDs) a clinical findings providing evidence of inco- conditions. FNDs are highly prevalent and some respects, this group of conditions sits come to the attention of neurologists. Mar caused by the symptoms, and the high cos missed opportunity for therapeutic interver remain very challenging. Diagnostic criteria on positive clinical findings, and can be sup more difficult to correctly diagnose than of biomarkers can be developed, but significa FNDs. Therapies exist and have been studio hampered by limitations in available outco prediction of aggregate treatment respons projects that address critical needs for clin of biomarkers, endpoints and clinical outco for clinical trials. Projects involving biomar 315, PAR-21-056, PAR-21-057, PAR-21-058 investigators, industry, and patient groups	mpatibility between the sympt associated with significant mor s at the intersection of neurolo nagement is complex and requ t in healthcare utilization and I ention and therefore, a healthc a have been proposed but they oported by laboratory or ancilla thers. More importantly, labor antly more research is needed i ed in select populations but ga ome measures. Differential resp ical trial readiness in FNDs. Pro ome assessments (COA) that ar ker discovery or early validatio 8, PAR-21-059). The initiative w	oms and recognized bidity, health care of gy and psychiatry, b ires interdisciplinary oss of productivity, are crisis. Diagnosis are not universally ary investigation find atory-supported dia in these areas to adv thering high-level evo conses to treatment nvites researchers to jects appropriate for re fit-for-purpose an n should apply to the ill promote partners	I neurological or mosts, and even mosts, and even mo out the majority of approaches. Give FNDs amount to a and management agreed upon. Diag dings. Certain FND gnosis is possible, vance clinical man vidence through cl s have been recor o submit prospect r this FOA include d have a defined o e relevant FOAs (F hips among acade	nedical prtality. In cases first in the disability significant of FNDs gnosis is based subtypes are and agement of inical trials is ded, and thus, ive clinical the validation context of use PAR-19- emic
104258 NINDS Efficacy Clinical Trials (UG3	3/UH3 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	d PAR-21- 237 10-	-Sep-2024	Not Specified
Contact Name	Jaramy Brown MD				

Contact Name Jeremy Brown, MD Contact Telephone 301-496-9135



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Email	Jeremy.brown@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	10-Sep-2024 , 09-Oct-2024 , 08-Jan-2025				
Synopsis	The purpose of this Funding Opportunity A efficacy clinical trials to the National Institu within the mission and research interests o behavioral and rehabilitation therapies. Inf the NINDS website (https://www.ninds.nih	te of Neurological Disorders a f the NINDS and may evaluate ormation about the mission ar	nd Stroke (NINDS) drugs, biologics, a). The trials must ad and devices, as well	dress questior as surgical,
10549 NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	d PAR-22- 142 C	08-Oct-2024	Not Specified
Contact Name	Jeremy Brown MD				
Contact Telephone					
Contact Email	jeremy.brown@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	08-Oct-2024 , 10-Feb-2025				
Synopsis	The purpose of this Funding Opportunity A exploratory Phase 1 and Phase 2 clinical tria trials must address questions within the mi biologics, feasibility or preliminary efficacy therapies. All Phase 1 exploratory trials mu inform a future Phase 2 trial that may also Phase 1 studies be encouraging. This FOA u	als to the National Institute of ssion and research interests or studies of devices, and early s st contribute to the justification be performed as part of the cu	Neurological Diso f the NINDS. They tudies of surgical, on for and provide urrent grant applic	rders and Stroke (N may include studie behavioral or rehat some of the data r	IINDS). These s of drugs and pilitation equired to
15920 NIH SIREN Neurologic Clinical Tria	ls (UG3/UH3 - Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	d PAR-23- 090 C	08-Oct-2024	Not Specified
Contact Name	Jeremy Brown, MD				

Icahn School of Medicine at Mount Sinai

SPIN ID Program Title		Sponsor Name	Sponsor Numb	per Deadline Date	Funding Amount
Contact Telephone	301-594-4481				
	jeremy.brown@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	08-Oct-2024 , 07-Feb-2025 , 06-Jun-2025 , (07-Oct-2025 , 06-Feb-2026			
Synopsis	This funding opportunity announcement (F emergencies. Successful applicants will col Clinical Coordinating Center (CCC) will work SIREN Data Coordinating Center (DCC) will affiliated clinical sites will provide on-site in existing SIREN infrastructure to apply under other U.S. and international consortia nece emergencies. Multi-center clinical trials in s the NIH StrokeNet, and not within SIREN.	laborate and conduct the trial with the successful applicant provide statistical and data man plementation of the clinical p r this FOA. The NIH SIREN Net ssary to conduct larger, defini	within the NIH s to implement anagement supp protocols. Applic work will also be tive trials of pro	SIREN Network. The N the proposed trial effi port. The NIH SIREN h cants do not need to b e uniquely poised to c mising interventions f	IIH SIREN ciently and the ubs and their e part of the ollaborate with or neurological
	diness to Understand and Develop Solutions tions and Barriers to Health Equity in ADRD	to National Institute of Neurological Disorders an Stroke/NIH/DHHS	d RFA-NS- 25-013	04-Sep-2024 [Optional][LOI/Pre- App]	2,000,000 USD
Contact Name	Kristina Mclinden, Ph.D.				
Contact Telephone	301-827-2563				
Contact Email	kristina.mclinden@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	04-Sep-2024 [Optional][LOI/Pre-App], 04-O	0ct-2024			
Synopsis	This Notice of Funding Opportunity invites a implications (SEBI) and barriers for health e NOFO will propose research to establish cli develop solutions addressing barriers to eq health disparities and communities that int data to support or inform future clinical tria (SEBI) related to assessing risk for, identific	equity research in Alzheimer's nical trial readiness for comm juity in ADRD outcomes amon ersect with them. These resea als that address either the soc	Disease Related unity-driven inte g populations de urch projects are ial ethical and/o	Dementias. Application erventions to understand efined by the NIH to expected to produce or behavioral implication	ons to this and and kperience preliminary ons

SPIN ID Program Title	s	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	health disparities and how these factors may a Community Engaged Research Inclusion (C assessed as part of the scientific and technic be considered incomplete and will be withdr and view the available PEDP and CERI guidar	ERI) Plan and Plan for Enhanc al peer review evaluation. Ap rawn. Applicants are strongly	ing Diverse Perspect plications that fail t	ctives (PEDP), which to include a PEDP of	h will be or a CERI will
100306 <u>NINDS Ruth L. Kirschstein Nationa</u> of Postdoctoral Fellows (F32 Clinic	al Research Service Award (NRSA) for Training cal Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	9 PAR-21- 032 07-	-Sep-2024	Not Specified
Contact Name	Stephen Korn, Ph.D.				
Contact Telephone	301-496-4188				
Contact Email	korns@ninds.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 10-Oct-2024 , 07-Jan-2026				
Synopsis	The purpose of this award is to support outst outstanding mentors. Candidates are eligible proposed postdoctoral position to within 12 seeks to foster early, goal-directed planning candidate that have the potential for signific seeks innovative research ideas and thought postdoctoral fellow into an outstanding scien reasoning and the quantitative principles of years of a candidate's activity in a specific lab planning and timely completion of "mentore Announcement (FOA) does not allow applicat to propose research experience in a clinical to (FOA) does not allow applicants to propose to research experience in a clinical trial led by a	e to apply for support from the months after starting in the p and to encourage application ant impact. Inclusion of prelin ful plans for training and mer ntist. Applications are expected experimental design and analy boratory or research environre ed training" within a particula ants to propose to lead an ind trial led by a sponsor or co-sp to lead an independent clinications	is program from ~1 proposed postdocto is for bold and/or in minary data is stron ntorship that will fa- ed to incorporate st lysis. Support by thi ment, so as to furth r lab or environmer ependent clinical tr onsor. This Funding	2 months prior to oral position. This inovative projects agly discouraged; r cilitate the develo crong training in qu s program is limite er encourage early nt. This Funding Op rial, but does allow g Opportunity Anne	the start of the NINDS F32 by the ather, this F32 oment of the uantitative ed to the first 4 y, thoughtful oportunity applicants ouncement
111323 Notice of Special Interest (NOSI): Pediatric Hydrocephalus	Tools to Enhance the Study of Prenatal and	National Institute of Neurological Disorders and	NOT-NS- 23-003 07-	-Sep-2024	Not Specified



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Stroke/NIH/DHHS			
Contact Name	Jill Morris, Ph.D.				
Contact Telephone	301-496-5754				
Contact Email	jill.morris@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-		5-Feb-2025 , 07-M	ay-2025 , 05-Jun-20)25 , 16-Jun-
Synopsis	The purpose of this Notice is to inform pot or substantially modify existing cutting-edg Applications should aim to transform the f including animal and cell models, novel me neuroscience community to understand di	ge tools that will advance prena ield of prenatal and/or pediatri ethods and innovative technolo	atal and/or pediat c hydrocephalus gies that will be v	ric hydrocephalus r research by generat videly used through	esearch. ing tools
	Gene-based Therapies for Ultra-Rare Disorders (U01 - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22- 030 1	0-Oct-2024	Not Specified
Contact Name	Ann-Marie Broome, PhD, MBA				
Contact Telephone	301-496-1779				
Contact Email	ann-marie.broome@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	10-Oct-2024				
Synopsis	The Ultra-Rare Gene-Based Therapy (URGe planning activities for First-in-Human (FIH) oligonucleotides and viral-based gene ther funding opportunity announcement (FOA) biological rationale and demonstrated pro- specified patient population towards an IN	clinical testing of gene-based or apies, for ultra-rare neurologic is to accelerate the developme of of concept (POC) data for the	or transcript-direct al or neuromuscu ant of a promising e intended approa	ted therapeutics, su lar disorders. The g clinical candidate v	ich as oal of this vith robust
06250 Carpor Transition Award for NIND	S Intramural Clinician-Scientists (K22 Clinica	National Institute of	PAR-21- 1	.2-Oct-2024	Not

SPIN ID Program Title	Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
Trial Required)	Neurological Disorders and Stroke/NIH/DHHS	327		Specified
Contact Name Stephen Korn, Ph.D. Contact Telephone Contact Email korns@ninds.nih.gov				
Sponsor Website				
Program URL Link to program URL				
Deadline Dates (ALL) 12-Oct-2024				
This NINDS K22 is specifically designed to fac scientists to independent, academic faculty scientific research as well as clinical activitie Synopsis applicants proposing to serve as the lead inv separate ancillary study to an existing trial, a independent clinical trial, or proposing to ga companion FOA PAR-21-328.	positions that support clinicia s. This Funding Opportunity A vestigator of an independent of as part of their research and c	n-scientists to en nnouncement (F clinical trial, a clir areer developme	ngage in independen OA) is designed spec nical trial feasibility s ent. Applicants not p	tly funded cifically for tudy, or a lanning an
106361 Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	9 PAR-21- 328	12-Oct-2024	Not Specified
Contact Name Stephen Korn, Ph.D.				
Contact Telephone				
Contact Email <u>korns@ninds.nih.gov</u>				
Sponsor Website				
Program URL Link to program URL				
Deadline Dates (ALL) 12-Oct-2024				
This NINDS K22 is specifically designed to fac scientists to independent, academic faculty Synopsis scientific research as well as clinical activitie applicants proposing research that does not ancillary study to a clinical trial. Applicants t	positions that support clinicia s. This Funding Opportunity A involve leading an independe	n-scientists to en nnouncement (F ent clinical trial, a	ngage in independen OA) is designed spec clinical trial feasibil	tly funded cifically for ity study, or an

PIN ID Program Title			Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
		mentor or co-mentor. Applicants proposing should apply to the companion FOA PAR-21		udy to an ongc	ing clinical trial as lead	d investigato
09940 Prospective Observ Neurosciences (UG		arative Effectiveness Research in Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22- 076	07-Sep-2024	Not Specified
	Contact Name	Adam L. Hartman, MD				
Cont	tact Telephone	301-496-9135				
	Contact Email	adam.hartman@nih.gov				
Sp	oonsor Website					
	Program URL	Link to program URL				
Deadli	line Dates (ALL)	07-Sep-2024, 18-Oct-2024, 07-Jan-2025, 1 The purpose of this Funding Opportunity Ar	nnouncement (FOA) is to encou		-	
Deadli		•	nnouncement (FOA) is to encou ectiveness research (CER) to the ervational studies will be consid INDS and may evaluate prevent d devices, or surgical, behaviora	e National Instit dered). The stud tive strategies, al, and rehabilit	ute of Neurological Di dy must address quest diagnostic approaches ation therapies. NIND	isorders and tions within s, or S is particula
	Synopsis	The purpose of this Funding Opportunity An prospective observational comparative effe Stroke (NINDS) (note: only prospective obse the mission and research interests of the N interventions including drugs, biologics, and interested in pragmatic study designs that u	nnouncement (FOA) is to encou ectiveness research (CER) to the ervational studies will be consid INDS and may evaluate prevent d devices, or surgical, behaviora	e National Instit dered). The stud tive strategies, al, and rehabilit f prospectively	ute of Neurological Di dy must address quest diagnostic approaches ation therapies. NIND	sorders and tions within s, or S is particula
26697 <u>RFA-NS-24-040 T</u> <u>Trial Not Allowed)</u>	Synopsis The NINDS Hum	The purpose of this Funding Opportunity An prospective observational comparative effect Stroke (NINDS) (note: only prospective obset the mission and research interests of the N interventions including drugs, biologics, and interested in pragmatic study designs that the important to current clinical practice.	nnouncement (FOA) is to encou ectiveness research (CER) to the ervational studies will be consid INDS and may evaluate prevent d devices, or surgical, behaviora utilize a cost-effective means of National Institute of Neurological Disorders and	e National Instit dered). The stud tive strategies, al, and rehabilit f prospectively RFA-NS-	tute of Neurological Di dy must address quest diagnostic approaches ration therapies. NIND collecting observation 17-Sep-2024 [Optional][LOI/Pre-	isorders and cions within s, or S is particular al data 4,575,000
26697 <u>RFA-NS-24-040 T</u> <u>Trial Not Allowed)</u>	Synopsis The NINDS Hum	The purpose of this Funding Opportunity Ar prospective observational comparative effe Stroke (NINDS) (note: only prospective obse the mission and research interests of the Ni interventions including drugs, biologics, and interested in pragmatic study designs that u important to current clinical practice.	nnouncement (FOA) is to encou ectiveness research (CER) to the ervational studies will be consid INDS and may evaluate prevent d devices, or surgical, behaviora utilize a cost-effective means of National Institute of Neurological Disorders and	e National Instit dered). The stud tive strategies, al, and rehabilit f prospectively RFA-NS-	tute of Neurological Di dy must address quest diagnostic approaches ration therapies. NIND collecting observation 17-Sep-2024 [Optional][LOI/Pre-	isorders and cions within s, or S is particula al data 4,575,000
26697 <u>RFA-NS-24-040 T</u> <u>Trial Not Allowed)</u> Cont	Synopsis The NINDS Hum Contact Name Itact Telephone	The purpose of this Funding Opportunity Ar prospective observational comparative effe Stroke (NINDS) (note: only prospective obse the mission and research interests of the Ni interventions including drugs, biologics, and interested in pragmatic study designs that u important to current clinical practice.	nnouncement (FOA) is to encou ectiveness research (CER) to the ervational studies will be consid INDS and may evaluate prevent d devices, or surgical, behaviora utilize a cost-effective means of National Institute of Neurological Disorders and	e National Instit dered). The stud tive strategies, al, and rehabilit f prospectively RFA-NS-	tute of Neurological Di dy must address quest diagnostic approaches ration therapies. NIND collecting observation 17-Sep-2024 [Optional][LOI/Pre-	isorders and cions within s, or S is particula al data 4,575,000
26697 <u>RFA-NS-24-040 T</u> <u>Trial Not Allowed)</u> Cont	Synopsis The NINDS Hum Contact Name Itact Telephone	The purpose of this Funding Opportunity Ar prospective observational comparative effects Stroke (NINDS) (note: only prospective obset the mission and research interests of the Ni interventions including drugs, biologics, and interested in pragmatic study designs that to important to current clinical practice.	nnouncement (FOA) is to encou ectiveness research (CER) to the ervational studies will be consid INDS and may evaluate prevent d devices, or surgical, behaviora utilize a cost-effective means of National Institute of Neurological Disorders and	e National Instit dered). The stud tive strategies, al, and rehabilit f prospectively RFA-NS-	tute of Neurological Di dy must address quest diagnostic approaches ration therapies. NIND collecting observation 17-Sep-2024 [Optional][LOI/Pre-	isorders and cions within s, or S is particula al data 4,575,000
26697 <u>RFA-NS-24-040 T</u> <u>Trial Not Allowed)</u> Cont	Synopsis The NINDS Hum Contact Name Itact Telephone Contact Email consor Website	The purpose of this Funding Opportunity Ar prospective observational comparative effects Stroke (NINDS) (note: only prospective obset the mission and research interests of the Ni interventions including drugs, biologics, and interested in pragmatic study designs that to important to current clinical practice.	nnouncement (FOA) is to encou ectiveness research (CER) to the ervational studies will be consid INDS and may evaluate prevent d devices, or surgical, behaviora utilize a cost-effective means of National Institute of Neurological Disorders and	e National Instit dered). The stud tive strategies, al, and rehabilit f prospectively RFA-NS-	tute of Neurological Di dy must address quest diagnostic approaches ration therapies. NIND collecting observation 17-Sep-2024 [Optional][LOI/Pre-	isorders and cions within s, or S is particula al data 4,575,000
26697 <u>RFA-NS-24-040 T</u> <u>Trial Not Allowed)</u> Cont Spe	Synopsis The NINDS Hum Contact Name tact Telephone Contact Email consor Website Program URL	The purpose of this Funding Opportunity Ar prospective observational comparative effects Stroke (NINDS) (note: only prospective obset the mission and research interests of the Ni interventions including drugs, biologics, and interested in pragmatic study designs that us important to current clinical practice.	nnouncement (FOA) is to encou ectiveness research (CER) to the ervational studies will be consid INDS and may evaluate prevent d devices, or surgical, behaviora utilize a cost-effective means of National Institute of Neurological Disorders and Stroke/NIH/DHHS	e National Instit dered). The stud tive strategies, al, and rehabilit f prospectively RFA-NS-	tute of Neurological Di dy must address quest diagnostic approaches ration therapies. NIND collecting observation 17-Sep-2024 [Optional][LOI/Pre-	isorders and cions within s, or S is particula al data 4,575,00

PIN ID Program Title	S	ponsor Name S	ponsor Numb	er Deadline Date	Funding Amount
	Disorders and Stroke (NINDS) Human Cell and fibroblast and induced pluripotent stem cell (where appropriate, genetically modify new h Cell and Data Repository will distribute huma advance basic and translational research in m	iPSC) lines as well as develop, igh-quality iPSC lines in accord n cell resources broadly to qua	characterize, ance with the	expand source cells a NINDS mission. The	nd iPSCs, and NINDS Human
NINDS Alzheimer's Disease and A 26698 (AD/ADRD) Advanced Postdoctor Diversity (K99/R00 Independent C		National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 212	12-Oct-2024	Not Specified
Contact Name	Amelie Gubitz, Ph.D.				
Contact Telephone	301-451-7966				
Contact Email	ADRDK99@ninds.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12 2027	-Oct-2025 , 12-Feb-2026 , 12-J	lun-2026 , 12-	Oct-2026 , 12-Feb-20	27 , 12-Jun-
Synopsis	The purpose of the NINDS Alzheimer's Diseas Promote Diversity (K99/R00) program is to su backgrounds, including those from groups un Notice of NIH's Interest in Diversity), conduct eligible postdoctoral researchers from their n equivalent faculty positions. The program wil help recipients establish independent resear designed specifically for applicants proposing trial feasibility study, or an ancillary study to a experiences in a clinical trial led by a mentor	apport a cohort of new and tal derrepresented in biomedical ing ADRD research. The progra- nentored, postdoctoral research I provide independent NIH res ch programs in the ADRD field research that does not involv a clinical trial. Applicants to th	ented, indepe and behavior am is designed ch positions to earch support . This Notice o e leading an in	ndent investigators findent investigators find al sciences (e.g. see N d to facilitate a timely o independent, tenuro during this transition of Funding Opportuni adependent clinical tr	om diverse OT-OD-20-03 transition of e-track or in order to y (NOFO) is ial, a clinical
	ed Dementias (ADRD) Advanced Postdoctoral D Independent Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 213	12-Oct-2024	Not Specified
Cantast Nama	Amber McCartney, Ph.D.				
Contact Name Contact Telephone					

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	Contact Email	amber.mccartney@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 2 2027	12-Oct-2025 , 12-Feb-2026 , 12	2-Jun-2026 , 12-	Oct-2026 , 12-Feb-20	27 , 12-Jun-
	Synopsis	The purpose of the NINDS Alzheimer's Dise Award (K99/R00) program is to support a c The program is designed to facilitate a time postdoctoral research positions to indepen independent NIH research support during t in the ADRD field. This Notice of Funding O does not involve leading an independent cli Candidatesto this NOFO are permitted to p	cohort of new and talented, in ely transition of eligible postdo dent, tenure-track or equivale his transition in order to help pportunity (NOFO) is designed inical trial, a clinical trial feasib	dependent inve- ctoral researchent nt faculty positi recipients estat specifically for bility study, or a	stigators conducting A ers from their mentor ons. The program will olish independent reso candidates proposing n ancillary study to a d	ADRD research. ed, provide earch programs research that clinical trial.
1/6/10	PAR-24-249 Interaction Betwee Dementia (R01 - Clinical Trial Not	n Environmental Factors and Lewy Body Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	d PAR-24- 249	04-Sep-2024 [Optional][LOI/Pre- App]	2,500,000 USD
	Contact Name	David A. Jett				
	Contact Telephone	301-496-6035				
	Contact Email	jettd@nih.gov				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	04-Sep-2024 [Optional][LOI/Pre-App], 04-O	Oct-2024			
	Synopsis	Many avenues of research are focused on in underlying biology and genetic risk factors. of Funding Opportunity (NOFO) is to suppo and Lewy body formation. These factors in external exposures. This NOFO will support relationship between environmental factor related to the cause of LBD and its progress	Environmental risk factors are rt research that establishes ca iclude exposures to environme t mechanistic, translational, ar s and LBD. It is expected that t	e also considere usal links betwe ental toxicants, l nd human subje chese studies wi	d but are understudie en a range of environ ight and noise, climat ct studies to understa Il identify environmer	d. This Notice mental factors e, and other nd the ntal risk factors

SPIN ID Program Title		Sponsor Name	Sponsor Number	r Deadline Date	Funding Amount
	interventions and quality of life.				
NIH HEAL Initiative PainCare Clinic126781Patient-Oriented Research Career Required)	cian Training Program (PCTP): Mentored r Development award (K23 - Clinical Trial	National Institute of Neurological Disorders and Stroke/NIH/DHHS	d PAR-24- 220 1	.2-Oct-2024	Not Specified
Contact Name	Laura D. Wandner				
Contact Telephone					
Contact Email	Laura.Wandner@nih.gov				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	12-Oct-2024 , 12-Nov-2024 , 12-Feb-2025 , 2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2 Jul-2027				
Synopsis	The purpose of the NIH HEAL Initiative Pain Career Development award (K23) (Clinical T doctoral degrees to create a group of new a program will provide independent NIH rese independent research programs in areas su program. This Notice of Funding Opportur investigator of an independent clinical trial, part of their research and career developm research experience in a clinical trial led by	Trial Required) is to support th and well-trained, independent earch support during the early- apported by the NIH HEAL Initi- nity (NOFO) is designed specifie , a clinical trial feasibility study ent. Applicants not planning a	e career developm investigators. Thi career phase to h ative's Clinical Res cally for applicant r, or a separate an n independent cli	nent of individuals v is supervised career elp recipients estal search in Pain Mana s proposing to serve cillary study to an e nical trial, or propos	with clinical development blish gement e as the lead xisting trial, as
	cian Training Program (PCTP): Mentored vards (K08 - Clinical Trials Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	d PAR-24- 219 1	2-Oct-2024	Not Specified
Contact Name	Laura D. Wandner				
Contact Telephone					
Contact Email	Laura.Wandner@nih.gov				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				

SPIN ID Program Title	5	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL)	12-Oct-2024 , 12-Nov-2024 , 12-Feb-2025 , 1 2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-20 Jul-2027				
Synopsis	The purpose of this NIH HEAL Initiative Paine Awards (K08 - Clinical Trials Not Allowed) is a create a group of new and well-trained, inde independent NIH research support during the in areas supported by the NIH HEAL Initiative Opportunity (NOFO) is designed specifically clinical trial, a clinical trial feasibility study, or research experience in a clinical trial led by a as lead investigator should apply to the com- studies involving humans, referred to in NOT These studies fall within the NIH definition of that should be submitted under this NOFO in experimentally manipulate independent var purpose of understanding the fundamental a products in mind. Applicants not planning ar to gain research experience in a clinical trial to the 'Independent Clinical Trial Not Allowed programmatic interests of one or more of the	to support the career develop ependent investigators. This su ne early-career phase to help r e's Clinical Research in Pain M for applicants proposing resea or an ancillary clinical trial. Unc a mentor or co-mentor. Those panion NOFO. This Parent Ar T-OD-18-212 as "prospective k of a clinical trial and also meet nclude studies that prospective iables) and that assess biomed aspects of phenomena withou n independent clinical trial or l or basic experimental study w ed' companion NOFO. The pa	ment of individuals upervised career de recipients establish anagement progra arch that does not der this NOFO appl proposing a clinica nouncement is for basic science studie the definition of b ely assign human p dical or behavioral it specific application basic experimental vith humans led by roposed project mo	s with clinical doct evelopment progra- independent rese m. This Notice of involve leading an icants are permitte al trial or an ancilla r basic science exp es involving humar asic research. Type participants to con outcomes in huma on towards proces study with humar another investiga ust be related to th	oral degrees to am will provide arch programs Funding independent ed to propose a ry clinical trial erimental participants." es of studies ditions (i.e., ans for the ses or ns, or proposing tor, must apply ne
	cian Training Program (PCTP): Mentored vards (K08 - Clinical Trials Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 217 12	-Oct-2024	Not Specified
	Laura D. Wandner				
Contact Telephone					
	Laura.Wandner@nih.gov				
·	Link to sponsor website				
Program URL	Link to program URL			2025 42 11 22	
Deadline Dates (ALL)	12-Oct-2024 , 12-Nov-2024 , 12-Feb-2025 , 1 2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-20				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Jul-2027 The purpose of this NIH HEAL Initiative Pain Awards (K08) (Clinical Trials Required) is to s create a group of new and well-trained, inde independent NIH research support during th in areas supported by the NIH HEAL Initiativ Opportunity (NOFO) is designed specifically clinical trial, a clinical trial feasibility study, o career development. Applicants not plannin clinical trial led by another investigator, mus	support the career developme ependent investigators. This s ne early-career phase to help e's Clinical Research in Pain M for applicants proposing to se or a separate ancillary study to g an independent clinical trial	ent of individuals w upervised career d recipients establis Aanagement progra erve as the lead inv o an existing trial, a l, or proposing to g	vith clinical doctora levelopment progra h independent rese am. This Notice of I vestigator of an ind as part of their rese	l degrees to am will provide earch programs Funding ependent arch and
Innovation Grants to Nurture Initi102747Neurotherapeutic Agent CharacteClinical Trial Not Allowed)	al Translational Efforts (IGNITE): rization and In vivo Efficacy Studies (R61/R3	National Institute of Neurological Disorders and Stroke/NIH/DHHS	d PAR-21- 122 2:	1-Oct-2024	750,000 USD
Contact Name	Becky Roof, PhD				
Contact Telephone	301-496-1779				
	rebecca.roof@nih.gov				
Sponsor Website					
-	Link to program URL				
Deadline Dates (ALL)					
Synopsis	This funding opportunity announcement (FC efficacy studies to demonstrate that propos development to treat neurological or neuro small molecules, biologics or biotechnology- Initial Translational Efforts (IGNITE) to advar Neurotherapeutics Network or other transla	ed therapeutic agent(s) have muscular disorders that fall un derived products. This FOA is nee projects to the point when	sufficient biologicander the NINDS mi part of a suite of I	al activity to warrar ssion. Therapeutic nnovation Grants t	t further agents include o Nurture
Innovation Grants to Nurture Initi 102739 and Validation of Model Systems (R61/R33 Clinical Trial Not Allowe		nt National Institute of Neurological Disorders and Stroke/NIH/DHHS	d PAR-21- 123 22	1-Oct-2024	750,000 USD
Contact Name	Becky Roof, PhD				

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title	5	Sponsor Name	Sponsor Num	per Deadline Date	Funding Amount
	Contact Telephone	301-496-1779				
	•	rebecca.roof@nih.gov				
	Sponsor Website					
	•	Link to program URL				
	Deadline Dates (ALL)	21-Oct-2024				
	Synopsis	This funding opportunity announcement (FC human/animal tissue ex vivo systems that re neurological or neuromuscular disorder. The relevance of animal models or ex vivo syster Ideally, models proposed for this FOA would following therapeutic intervention that wou of Innovation Grants to Nurture Initial Trans stages of drug discovery.	ecapitulate the phenotypic ar e goal of this FOA is to promo ms that will be utilized to faci I have the potential to provid Id be applicable in both precl	nd physiologic c te a significant litate future de e feasible and r inical and clinic	haracteristics of a defi improvement in the tr velopment of neurothe neaningful assessmen al settings. This FOA is	ned anslational erapeutics. ts of efficacy part of a suite
		ures Against Chemical Threats (CounterACT)	National Institute of	. PAR-24-	18-Sep-2024	300,000
	Basic Research on Chemical Threa Clinical Trial Not Allowed)	ats that Affect the Nervous System (R01	Neurological Disorders an Stroke/NIH/DHHS	d 030	[Optional][LOI/Pre- App]	USD
	Contact Name	Shardell Spriggs, Ph.D.				
	Contact Telephone	301-443-8189				
	Contact Email	shardell.spriggs@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	18-Sep-2024 [Optional][LOI/Pre-App], 17-Oc [Optional][LOI/Pre-App], 16-Oct-2026	ct-2024 , 18-Sep-2025 [Option	nal][LOI/Pre-Ap	p], 17-Oct-2025 , 17-Se	ep-2026
	Synopsis	This Funding Opportunity Announcement (F toxic industrial chemicals, and pesticides tha threats are toxic compounds that have been that could be deliberately or accidentally rel to generate results that further elucidate me	at have primary or secondary n identified by the United Stat leased into the civilian popula	effects on the interview of the set of the s	nervous system. These t (USG) as Chemicals o supported by this NOF	chemical f Concern (CoC O is expected

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
123196 NIH StrokeNet Clinical Trials and Recovery, and Prevention (UG3/L	Biomarker Studies for Stroke Treatment, IH3 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	d PAR-24- 101 18	3-Oct-2024	Not Specified
Contact Name	Scott Janis, Ph.D.				
Contact Telephone	301-496-9135				
Contact Email	moyc@ninds.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	18-Oct-2024 , 19-Feb-2025 , 20-Jun-2025 ,	20-Oct-2025 , 19-Feb-2026 , 18	3-Jun-2026 , 19-Oc	t-2026	
Synopsis	This NOFO encourages applications for mu interventions; biomarker or outcome meas prevention, treatment, and recovery; and a within StrokeNet. Successful applicants wil review, NINDS will prioritize studies among StrokeNet National Coordinating Center (N efficiently and the National Data Manager StrokeNet Regional Coordinating Centers (I well as on-site implementation of the clinic with other US and international consortia r treatment, prevention, and recovery. It is N treatment, recovery, or prevention will be consider funding multi-site stroke clinical to UG3/UH3 cooperative agreement activity of driven planning and start-up phase, with po Only UG3 projects that meet the scientific phase. Applications submitted in response include plans for project management and existing NIH StrokeNet infrastructure to ap	sure validation studies that are ancillary studies designed to ac I collaborate and conduct the s the highest scoring to be cond CC) will work with the success and their affiliated clinica and their affiliated clinica cal protocol. The NIH StrokeNe necessary to conduct larger, de NINDS's intent that all NINDS-su conducted within the NIH Stro rials outside of this network. T code. Awards made under this possible transition to an implem milestones and award requirer to this FOA must address both performance milestones for ea	immediately prep Id scientific aims to study within the NI ducted in the NIH S ful applicant to imp e statistical and da al sites will provide t network will also finitive trials of pro upported multi-cer keNet. Only in exco his NOFO uses the NOFO will initially entation (UH3) ph nents of the UG3 p the UG3 and UH3	aratory to trials in s o active studies bein H StrokeNet. Follow StrokeNet infrastructor be an an agement su e recruitment/reten be uniquely poised omising intervention ter clinical trials in eptional circumstan bi-phasic, mileston support a one-year ase of up to 6 addit ohase may transition phases and are exp	troke ag conducted ving peer ture. The NIH ed study pport. The NIH tion support as to collaborate ns for stroke stroke ces will NINDS e driven milestone- ional years. n to the UH3 ected to
	nd Validation of Human Cellular Models for entias (ADRD) (R01 - Clinical Trial Not Allow	National Institute of Neurological Disorders and Stroke/NIH/DHHS	d RFA-NS- 24-032 [C	D-Sep-2024 Dptional][LOI/Pre- pp]	2,500,000 USD

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Name	Linda McGavern, PhD				
Contact Telephone					
Contact Email	mcgavernlm@ninds.nih.gov				
Sponsor Website					
C	Link to program URL				
Deadline Dates (ALL)	20-Sep-2024 [Optional][LOI/Pre-App], 21-C				
Synopsis	This Notice of Funding Opportunity (NOFO) pathophysiologically relevant human cellul system needs to reflect multiple aspects of pathologies and brain cell types observed i cellular models could be developed and val understanding of human disease mechanis	ar models of Alzheimer's Disea the human condition as much n ADRD. Validation is required lidated with the goal of suppor	ase Related Demer as possible, such , including face an ting therapeutic d	tias (ADRD). The ce as capturing the mu d construct validity evelopment or bett	ultiple Human er
26685 NINDS Faculty Development Awa Research (K01 Independent Clinic	rd to Promote Diversity in Neuroscience al Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	d PAR-24- 228 1	2-Oct-2024	Not Specified
Contact Name	Michelle Jones-London, Ph.D.				
Contact Telephone	301-451-7966				
Contact Email	NINDSDiversityTraining@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep Sep-2027	· · · · · · · · · · · · · · · · · · ·	•		
Synopsis	The purpose of the NINDS Faculty Develops participation in the independent neuroscie including those from groups underrepreser and career stage-appropriate mentorship a support under this award if they are in the application. This notice of funding opportu-	nce research workforce by pro nted in biomedical research, w nd professional development first 3 years of a faculty tenure	viding junior facul ith research cost s in neuroscience re track or equivale	ty from diverse bac upport, protected r search. Individuals nt position at the ti	kgrounds, esearch time are eligible fo me of

SPIN ID Program Title	5	Sponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
	not involve leading an independent clinical t this NOFO candidates are permitted to prop proposing a clinical trial or an ancillary study NOFO (PAR-24-229).	ose a research experience in a	a clinical trial led	by a mentor or co-n	nentor. Those
126690 NINDS Faculty Development Awa Research (K01 Independent Clinic	rd to Promote Diversity in Neuroscience al Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 229	12-Oct-2024	Not Specified
Contact Name	Michelle Jones-London				
Contact Telephone	301-451-7966				
Contact Email	NINDSDiversityTraining@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 0 2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2 Sep-2027	•		•	-
Synopsis	The purpose of the NINDS Faculty Developm participation in the independent neuroscier including those from groups underrepresent and career stage-appropriate mentorship an support under this award if they are in the fi application. This notice of funding opportun investigator of an independent clinical trial, research and career development. Those no in a clinical trial led by another investigator,	nce research workforce by pro ed in biomedical research, wi nd professional development i irst 3 years of a faculty tenure nity (NOFO) is designed specif a clinical trial feasibility study t planning an independent cli	byiding junior fac th research cost n neuroscience track or equival fically for candid , or a separate a nical trial, or pro	ulty from diverse ba support, protected research. Individuals ent position at the ti ates proposing to sen ncillary clinical trial, posing to gain resea	ckgrounds, research time are eligible fo me of rve as the lead as part of the
126342 Mechanistic Investigations into A Settings (R01 - Clinical Trial Not A	DRD Associated Protein Structures in Biologic Ilowed)	al National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 234	04-Oct-2024	500,000 USD
Contact Name Contact Telephone	George Umanah, PhD				

SPIN ID Program Title	5	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Email	umanahgk@ninds.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	04-Oct-2024				
Synopsis	This Notice of Funding Opportunity (NOFO) to address the mechanistic insights and caus Alzheimer's disease-related dementias (ADR determining structures of ADRD-linked macr methodology is expected to provide high-res macromolecular species associated with AD conformations. Studies in response to this N further characterize and validate the structu studies in the native cellular environment to the accumulation of dysfunctional proteins i development and other related applications	sal cellular and molecular rela D) clinical phenotypic outcor comolecular in native (health solution information on the in RD and how pathological env NOFO can also include the de- tral findings. The long-term ge inform efficient tools develo n patients, as well as for othe	tionships between nes. The application y and pathological) s dentity, dynamics an ironments influence velopment of in situ cal of this funding o pment and designs	molecular patholo ns are expected to settings. The prop- nd relative abunda e dynamics and str research tools an pportunity is for th that better identif	gy and focus on osed ince of uctural d resources to hese structural fy and monitor
108301 RFA-NS-22-034 HEAL Initiative: Safe and Effective Pain Treatmen	Discovery and Validation of Novel Targets for t (R01 Clinical Trial Not Allowed)	National Institute of Neurological Disorders an Stroke/NIH/DHHS	d RFA-NS- 07 22-034 07	-Aug-2024	Not Specified
Contact Name	Michael L. Oshinsky, PhD				
Contact Telephone	301-496-9964				
Contact Email	michael.oshinsky@nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Aug-2024 , 02-Oct-2024 , 06-Dec-2024				
Synopsis	The purpose of this Funding Opportunity An therapeutic targets to facilitate the develop science discovery of targets in the periphera body that can be used to develop treatment Research supported by this FOA must includ pain treatment target. This will lower the ris	ment of pain therapeutics. S I nervous system, central ner is that have minimal side effe e rigorous validation studies	pecifically, the focus yous system, immu cts and little to no a to demonstrate the	s of this FOA is on ne system or othe abuse/addiction lia robustness of the	the basic r tissues in the Ibility. target as a

SPIN ID Program Title	S	ponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	biologics, natural substances, or devices that develop new medical devices is not the focus responsive to this FOA and are encouraged in for any one or group of pain conditions. Proje headache disorders, osteoarthritis, diabetic n pain, orofacial pain, etc. will be considered. P conditions or for specific pathological condition populations such as women, children, older a	of this FOA. Basic science stu the context of novel pain th ects to identify novel targets europathy, chemotherapy-ir rojects to identify novel targons will be considered. Proje	idies of pain an erapeutic targe or acute pain, o duced neuropa ets for a combin cts that seek to	d related systems in t t discovery. This FOA chronic pain, migraine thy, sickle-cell pain, p nation of chronic over identify novel targets	he body are is not specific other oost stroke lapping pain s in specific
.27154 RFA-NS-25-002 Materials to En (UE5 Clinical Trial Not Allowed)	hance Training in Experimental Rigor (METER)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 25-002	10-Sep-2024 [Optional][LOI/Pre- App]	250,000 USD
Contact Name	Devon Crawford				
Contact Telephone	301-496-1917				
Contact Emai	l <u>devon.crawford@nih.gov</u>				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL	10-Sep-2024 [Optional][LOI/Pre-App], 10-Oct	-2024			
Synopsis	The NIH Research Education Program (UE5) s overarching goal of this UE5 program is to su workforce to meet the nation's biomedical, b goal, this FOA will support creative education NINDS Materials to Enhance Training in Exper innovative educational materials that will be awareness, understanding, and practice of fu scientists in various career stages and learnin	pport educational activities t ehavioral and clinical researc al activities with a primary for rimental Rigor (METER) UE5 v incorporated into a new cutt ndamental principles of rigor	nat complemen h needs. To acc ocus on: Curricu vill support cur ing-edge online	t and/or enhance the complish the stated ov lum or Methods Deve riculum development resource that aims to	e training of a ver-arching elopment Th in the form o promote
27141 (MOSAIC) Postdoctoral Career Tr	entific and Academic Independent Careers ansition Award to Promote Diversity (K99/R00 I Studies with Humans Required (BESH))	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 227	07-Sep-2024	Not Specified
Contact Name	Lanay M. Mudd, Ph.D., FACSM				
Contact Telephone	301-594-9346				
	NIH Funding Opportuniti	Dues Oct 0004			

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Email Sponsor Website	lanay.mudd@nih.gov				
-	Link to program URL 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun Jun-2027 , 07-Sep-2027	· · · · · · · · · · · · · · · · · · ·			
Synopsis	The purpose of the Maximizing Opportunit support a cohort of early career, independent from underrepresented groups) conducting career transition award for postdoctoral so to organizations to provide these scholars of support their transition to and success in in MOSAIC program supports NIH's efforts to perspectives, experiences and backgrounds Transition Award to Promote Diversity (K99 researchers from diverse backgrounds from equivalent research-intensive faculty positi demonstrated meaningful contributions and biomedical research workforce, such as act environments that support the success of t underrepresented groups. This Notice of H referred to in NOT-OD-18-212 as "prospect the NIH definition of a clinical trial and also under this NOFO include studies that prosp independent variables) and that assess bio fundamental aspects of phenomena without planning an independent clinical trial or ba clinical trial or basic experimental study wit Trial Not Allowed' companion NOFO. The p the participating NIH Institutes and Centers	ent investigators from diverse g research in NIH mission areas cholars (K99/R00) and a research with additional mentoring, net dependent, tenure-track or ec develop a biomedical research s needed to advance discovery 9/R00) program is to facilitate a n their mentored postdoctoral ions. The program is designed d proposed compelling future civities that promote inclusive, trainees and scientists from all Funding Opportunity is for basic tive basic science studies involve o meet the definition of basic re- pectively assign human particip medical or behavioral outcome ut specific application towards sic experimental study with hu th humans led by another inve- proposed project must be related	backgrounds (for ex s. The program has ch education cooper working and profes quivalent research-in n workforce that will . The goal of the MG a timely transition of research positions to support postdoc plans to promote b supportive, and acc backgrounds, include ic science experiment ving human particip esearch. Types of st pants to conditions (es in humans for the processes or produ- umans, or proposing stigator, must apply ed to the programm	kample, individuals two components: rative agreement (sional development ntensive faculty ca l benefit from the OSAIC Postdoctora of promising postd to independent, te toral researchers road participation cessible biomedica ding individuals fro ntal studies involv pants." These studi udies that should i.e., experimentall e purpose of unde to gain research e y to the 'Independ	an individual (UE5) awarded int activities to areers.The full range of al Career octoral enure-track or who have in the I research om ing humans, es fall within be submitted y manipulate rstanding the cants not experience in a ent Clinical
113257 NINR Areas of Emphasis for Research Equity (R01 Clinical Trial Optional	arch to Optimize Health and Advance Health)	National Institute of Nursi Research/NIH/DHHS	ng PAR-22- 230 07-	-Sep-2024	Not Specified

PIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
Contact Nam	e David L. Tilley, MPH, MS, CPH				
Contact Telephon					
Contact Ema	il <u>david.tilley@nih.gov</u>				
Sponsor Websit	e				
Program UR	L Link to program URL				
Deadline Dates (AL	_) 07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 ,	07-Jan-2025, 05-Feb-2025, 05	-Mar-2025 , 07	-May-2025	
Synops	This funding announcement solicits R01 go with the scientific framework detailed in the research will be rooted in nursing's holistic, nation's most pressing and persistent healt study designs to inform practice and policy	ne 2022-2026 National Institute , contextualized approach to ur th challenges with a solutions o	of Nursing Res derstanding pe	earch (NINR) Strategie ople and their health	c Plan. This , address the
13258 NINR Areas of Emphasis for Rese Equity (R21 Clinical Trial Optional	earch to Optimize Health and Advance Health	National Institute of Nursin Research/NIH/DHHS	eg PAR-22- 231	07-Sep-2024	200,000 USD
Contact Nam	e David L. Tilley, MPH, MS, CPH				
Contact Telephon	e 301-827-6014				
Contact Ema	il <u>david.tilley@nih.gov</u>				
Sponsor Websit	e				
Program UR	L Link to program URL				
Deadline Dates (ALI	_) 07-Sep-2024 , 16-Oct-2024 , 16-Nov-2024 ,	07-Jan-2025 , 16-Feb-2025 , 16	5-Mar-2025 , 07	-May-2025	
Synops	This funding announcement solicits R21 g are consistent with the research framewor is Plan. This research will be rooted in nursing address the nation's most pressing and per rigorous study designs to inform practice a	k detailed in the 2022-2026 Na g's holistic, contextualized appr sistent health challenges with a	tional Institute oach to unders	of Nursing Research (tanding people and th	NINR) Strateg neir health,
	al Development Immersion (REDI): Award (R25 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-22- 226	17-Sep-2024 [Optional][LOI/Pre- App]	1,250,000 USD
Contact Nam	e Saroj Regmi, Ph.D.				

SPIN ID Program Title	5	Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
Contact Telephone	301-402-7700				
•	saroj.regmi@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	17-Sep-2024 [Optional][LOI/Pre-App], 17-Oc	ct-2024			
Synopsis	The NIH Research Education Program (R25) soverarching goal of this R25 program is to su workforce to meet the nation's biomedical, goal, this FOA will support creative educatio invites applications to the Research and Entry program promotes the development of entry graduate students and postdoctoral research relevant to the mission of NIA, including agin trainees for a wide-range of career paths, including the students and post of career paths, including the students and post of career paths, including the students of the students of career paths, including the students of the career paths of the students of th	upport educational activities to behavioral and clinical resear nal activities with a primary for repreneurial Development Im- epreneurial education progra- hers, as well as early-career no ng and Alzheimer's disease (A	that complement och needs. To acc ocus on: Course omersion (REDI) oms that are des naster's, Ph.D., a D) research. The	it and/or enhance the complish the stated or s for Skills Developme Award program. The igned to broaden the and Dr.P.H. scientists, e goal of the program	training of a ver-arching ent This FOA skillset of in fields is to prepare
	l Development Immersion (REDI): Mentored ent Award (K01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-22- 227	17-Sep-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Saroj Regmi, Ph.D.				
Contact Telephone	301-480-8964				
Contact Email	saroj.regmi@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	17-Sep-2024 [Optional][LOI/Pre-App], 17-Oc	ct-2024			
	This Funding Opportunity Announcement (F Entrepreneurial Development Immersion (RI purpose of the program is to provide suppor development experience in the biomedical, designed to support participants' transition is and teaching faculty, as well as entrepreneu candidates for this opportunity are experien	EDI): Mentored Entrepreneur rt and protected time (three t behavioral, or clinical science to research independence in rial, industry, science policy,	rial Career Devel to five years) for to leading to rese a multitude of c and research ad	opment Award progra an intensive, supervi earch independence. areer options, includi ministration positions	am. The sed career The program ng research 5. Optimal

SPIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	junior faculty members (usually with Ph.D. entrepreneurial training and are pursuing c training and career development opportun supervised career development activities. T involve leading an independent clinical trial FOA, candidates are permitted to propose a	areers in research areas suppo ities for early-career academic This FOA is designed specificall I, a clinical trial feasibility study	orted by NIA. Th scientists as pa y for candidates y, or an ancillary	is K01 FOA includes er rt of its translational r proposing research tl clinical trial. Under th	ntrepreneurial esearch and nat does not nis
116492 RFA-AG-24-015 Paul B. Beeson in Aging (K76 Clinical Trial Require	Emerging Leaders Career Development Awa ed)	rd National Institute on Aging/NIH/DHHS	RFA-AG- 24-015	18-Sep-2024 [Optional][LOI/Pre- App]	1,125,000 USD
Contact Name					
Contact Telephone					
	NIAtraining@nih.gov				
Sponsor Website					
•	Link to program URL				
Deadline Dates (ALL)	18-Sep-2024 [Optional][LOI/Pre-App], 18-O				
Synopsis	The overall goal of the NIH Research Career scientists is available in appropriate scientif needs. NIH Institutes and Centers (ICs) supp programs designed to foster the transition investigators in achieving specific objective to determine the best program to support to Extramural Training Mechanisms website. The help develop a cadre of scientists prepared improved research or healthcare outcomes additional research, professional career and biomedical workforce. NIH Emerging Leader leadership and who will use this award to for leaders in their field of expertise. These skill careers in an emerging discipline within the increasing the visibility and overall research research community. It is anticipated that	fic disciplines to address the N port a variety of mentored and of new investigators to resear s. Candidates should review the their goals. More information The objective of the NIH Emerge to take an active leadership re s. This program supports basic d leadership skills essential for ers are early-stage investigators urther develop the tools, skills lls will prepare them to assume eir professional specialty. Emerge n support and academic capacit	ation's biomedia I non-mentored ch independenc about Career program ging Leaders Car or clinically train assuming a lead s conducting res and resources t e academic lead rging leaders de ity within their e	cal, behavioral, and cli career development a e and to support estal er development (K) av ograms may be found eer Development Awa ative change that will ned faculty members w dership role in an incre earch who have show to have a significant in ership roles and indep monstrate a commitmed ducational, medical/h	nical research award blished ward programs at the NIH ard (K76) is to lead to who seek easingly global in early signs of npact as bendent hent to realth, and/or

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
-----------------------	--------------	----------------	---------------	-------------------

policymakers. Within the field of aging research, the small numbers of individuals skilled in geriatrics, and the smaller numbers pursuing research on aging, are inadequate to address the burgeoning needs of the rapidly growing older population. A key goal of this initiative, therefore, is to foster the careers of emerging clinical investigators who possess the skills necessary for academic leadership in aging and geriatrics. Unlike other mentored K award programs, this initiative aims to recruit investigators who have had competitively awarded research support at the faculty level and who have shown early signs of leadership in their field of expertise. Although early-stage investigators, through their efforts, these individuals are well poised to change theory, practice, and outcomes related to the health of older individuals. Through this announcement and the companion FOA, emerging leaders will aim to capitalize on current opportunities in clinical, translational, or groundbreaking basic research in aging and geriatrics to advance an emerging discipline or effect changes in practice within their professional specialty. Through the NIH Emerging Leaders Career Development Award, investigators are provided salary and research support for a sustained period of "protected time" (3-5 years) for career development and to advance the leadership skills of physician-investigators and other investigators trained in health professions. These investigators conduct research in basic, translational or clinical, and Patient-Oriented Research (POR) in disciplines relevant to aging and geriatrics. The award is intended to prepare early-stage investigators for academic research leadership, as well as provide mentoring in their scientific research area of interest. The focus is on building a cadre of investigators and leaders to advance knowledge and skills in a new field, a new methodology, or a new approach, both through their own research and through their leadership, in the broader community of their specialty. The Beeson Program Through this FOA, NIA uses the NIH Emerging Leaders Career Development Award to administer the Paul B. Beeson Emerging Leaders Career Development Award in Aging program. The program is named after Dr. Paul B. Beeson, who profoundly influenced the career paths of many physicians, including several who now form the core leadership in geriatric medicine. Dr. Beeson was Chairman of Medicine at Emory and Yale Medical Schools, Nuffield Professor at Oxford University, and Professor and Distinguished VA Physician at the University of Washington. He chaired the first Institute of Medicine study on "Aging and Medical Education" in 1978. His leadership as an editor of the Cecil Textbook of Medicine greatly influenced medical education. From his research and patient care base, he grew increasingly interested in the process of aging, and this interest led to a commitment that included his editorship of the Journal of the American Geriatrics Society. The aims of the program are as follows: To provide support for career development and to advance the leadership skills of medical and surgical specialists conducting clinically relevant basic, translational or clinical, and POR in disciplines relevant to aging and geriatrics. To deepen the commitment of research institutions to promote transformative academic research and leadership in aging and geriatric medicine by linking mentors to emerging scientists with a commitment to future leadership in aging research and policy. Research Objectives This FOA provides an opportunity for candidates to expand their research area of interest and pursue activities consistent with the expectation of future leadership in the candidate's chosen field. NIA welcomes applications in all fields of aging research, including basic, translational, genetic, biological, neuroscientific, clinical, behavioral, and social sciences research on aging. A particular priority of NIA at the moment is research on Alzheimer's disease (AD) and Alzheimer's disease-related dementias

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		(ADRD). This initiative is targeted primarily and resources related to aging, and who has NIH, similar support from other federal age awarded to the candidate at the faculty leve advance and develop an independent line committed and skilled leaders in their resp either clinical duties or research activities to forward. Examples include organizing semi or other activities where the candidates has research accomplishments and visibility. The adults. For this FOA, the candidate's project areas relevant to aging. The full range of re- encouraged, including basic and translation clear the eventual clinical relevance of the research and scientific literature associated must identify mentors who are senior rese commit time to supervise and guide the ca advance the candidate both as a researche award is an annual meeting for Beeson sch	ave received initial funding for encies, or foundation funding. vel. Individuals who have lever of research and who can provi pective fields are also welcome that illustrate keen engagemer inar series, conferences or sym ave played a leading role in enh he proposed career development of may be in any of a broad ran esearch methods appropriate t nal research and cell or compu proposed work. We expect that d with the field of aging resear earchers in aging and/or age-re andidate during the period of the er and as an emerging leader in	research, such as the The award(s) should aged faculty-level re- de evidence that the to apply. Prior evident and commitment posia at a national re- nancing their fields' a ent and research sho ge of basic, translati o completing the pro- tational models, pro- at scholars will contre ch. Required Element lated diseases and che award. A part of the the field. Annual m	rough small grant I have been comp search developme ey possess the attr ence of leadership to moving the app neeting; organizin academic medical, build focus on aging ional, behavioral, o oposed investigation ovided that the ap ribute significantly nts Mentorship - Conditions, and wh that commitment eetings - A centra	support from etitively ent support to ributes of o can be in olicant's field g workshops; /health and g or older clinical, or PO ion is plication mak r to the Candidates to agree to is the intent t al part of this

Annual meetings are a valuable forum for scientific and professional networking opportunities for current Beeson awardees, Beeson alumni, and mentors. The meetings are intended to spark collaboration and expose scholars to a wide range of exciting science on aging. Clinical Trials This FOA is designed specifically for candidates proposing to serve as the lead

investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA, RFA-AG-24-014. NIH defines a clinical trial as "A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes." (NOT-OD-15-015). NIH not only supports trials of safety and efficacy, it also supports mechanistic exploratory studies that meet the definition of a clinical trial and are designed to explore or understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. These studies may focus on basic and/or translational discovery research in healthy human subjects and in human subjects who are affected by the pathophysiology of diseases and disorders. By addressing basic questions and concepts in biology, behavior, and pathophysiology, these studies may provide insight into understanding human diseases and disorders along with potential treatments or preventive

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
		strategies. NIH also supports biomarker stu about physiological function, target engage response. NIH thus supports studies that m safety, clinical efficacy, effectiveness, clinic interventions. Investigators proposing NIH- information about developing statistical me supports a central resource to NIA staff and clinical research. This resource, the Clinical management system to support the busine support the conduct of clinical research wit interface, integrate, or adapt their information the CROMS as necessary, including the use	ement of novel therapeutics, a neet the definition of clinical tr al management, and/or imple defined clinical trials may refe ethods and study designs. Clin d extramural investigators to f Research Operations Manage ess functions, management, ar th human subjects. It is the ex tion system(s) and processes t	and/or the impact rials (as noted abo ementation of prevent of the Research facilitate/support f ement System (CR and oversight respo pectation by NIA to to interact with ex	of therapeutics on t ve) but do not seek ventive, therapeutic, Methods Resources rations Managemer the conduct and man OMS), is a comprehe nsibilities of NIA gra hat all successful ap	reatment to establish and services website for t System NIA nagement of ensive data nts that plicants will
I I M/IUI I	RFA-AG-24-014 Paul B. Beeson in Aging (K76 Independent Clinica	Emerging Leaders Career Development Awa Il Trial Not Allowed)	ard National Institute on Aging/NIH/DHHS	8FA-AG- 24-014	18-Sep-2024 Optional][LOI/Pre- App]	1,125,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	NIAtraining@nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	18-Sep-2024 [Optional][LOI/Pre-App], 18-C				
	Synopsis	This Funding Opportunity Announcement (a commitment to aging and/or aging-relate leadership skills in their specialty and in the (NIA) is pursuing this initiative to recruit ea begun to establish research programs and expertise and be poised to change theory, other mentored K awards, candidates for the Program Director/Primary Investigator (PD) to develop an independent line of research FOA is designed specifically for applicants p	ed diseases to apply for this av e broader field of aging and ge rly-stage investigators who ha who, through this award, will practice, and health outcomes his award must have received /PI) at the faculty level or have n. They must show evidence of	ward with the goal eriatrics research. ave successfully co be ready to assum s related to the he competitively awa e otherwise levera f leadership in the	of advancing their r The National Institut mpeted for a resear le leadership roles ir alth of older individu arded research supp ged faculty-level res clinical or research	esearch and te on Aging ch grant and their field of uals. Unlike ort as a search support domain. This

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
	clinical trial feasibility study, or a separate a experience in a clinical trial led by a mentor lead investigator should apply to the compa	or co-mentor. Applicants pro			
110477 RFA-AG-23-016 Transition to Age (F99/K00 Clinical Trial Not Allowe	ging Research for Predoctoral Students d)	National Institute on Aging/NIH/DHHS	RFA-AG- 23-016	18-Oct-2024	Not Specified
Contact Name					
Contact Telephone					
Contact Email	NIAtraining@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	18-Oct-2024				
Synopsis	The National Institute on Aging (NIA) invites are interested in receiving aging-related pos This FOA seeks to foster the development or clinical, epidemiological, neuroscientific, bel Successful applicants will be awarded the Tr recruit and retain emerging investigators in dissertation projects and provide a variety of competitive, aging-focused postdoctoral post to propose to lead an independent clinical to by a sponsor or co-sponsor.	stdoctoral training to apply to f research and clinician scient havioral, social, and economic ransition to Aging Research Av aging research. This two-phas of training supports to facilitat sitions. This Funding Opportu	this Funding Opp ists in the followi c research on agir ward for Predocto se award will allow te the smooth tra nity Announceme	portunity Announcering areas: genetic, bing, both basic and tra oral Students, whose w awardees to comp nsition of doctoral great (FOA) does not all	nent (FOA). blogical, anslational. purpose is to lete doctoral raduates into low applicants
125974 RFA-AG-25-024 Access and Mar Aging and AD/ADRD (R61/R33 Clin	nipulation of Brain Cell Subtypes Implicated in nical Trial Not allowed)	n National Institute on Aging/NIH/DHHS	RFA-AG- 25-024	06-Sep-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Erin E. Gray, Ph.D.				
Contact Telephone	301-451-3968				
Contact Email	erin.gray@nih.gov				
Sponsor Website					
Program URL	Link to program URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		06-Sep-2024 [Optional][LOI/Pre-App], 07-C This Notice of Funding Opportunity (NOFO brain cell subtypes that are altered in aging frontotemporal disorders (FTD), Lewy body (VCID), and multiple etiology dementias (N utilization of sophisticated tools that pair b element identification to do the following: degenerating mammalian brains. Monitor to brain aging and AD/ADRD in animal mod Exploratory/Developmental Phased Award to demonstrate proof-of-principle. The R33 hypothesis testing.) invites applications proposing g, Alzheimer's Disease (AD), an y dementia (LBD), vascular con MED). Specifically, the goal of t preakthroughs in adeno-associa Optimize precise targeting of c and/or manipulate these cells dels. To achieve the goal, this f activity code. The R61 phase p	d AD-Related Deme tributions to cogniti his NOFO is to encou ated virus (AAV) cap disease-relevant cell in vivo to address m NOFO utilizes the R6 provides up to 2 yea	ntias (ADRDs). ADI ve impairment and urage the develop sid engineering wi subtypes in aged nechanistic hypoth 1/R33 rs of support for p	RDs include d dementia ment and th enhancer and beses related ilot activities

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125539		y Efficacy Studies of Psychedelic-Assisted Adults (UG3/UH3 Clinical Trial	National Institute on Aging/NIH/DHHS	RFA-AG- 25-004	11-Sep-2024 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Sekai Chideya-Chihota, MD, MPH				
	Contact Telephone	240-552-2994				
	Contact Email	<u>sekai.chideya@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Sep-2024 [Optional][LOI/Pre-App], 10	0-Oct-2024			
	Synopsis	This NOFO invites applications to suppor efficacy data of psychedelic-assisted the conditions. This NOFO uses the UG3 / UF code. Applications must include a resear last up to two years, and should involve safety, pharmacokinetic, and pharmacoc	rapy (PAT) in defined groups of olde H3 Exploratory/Developmental Phas rch plan describing both UG3 and UH preliminary studies in healthy older	r adults livin ed Award Co 13 phases. Tl adults acros	g with specific chronic pa poperative Agreement act ne first phase, the UG3 ph s a broad age range to ev	in tivity nase, may aluate

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
		Activities in the UG3 phase will inform f may last up to 3 years and should includ conditions and must include participant older adults. In both phases, participant the upper age range (i.e., 75-80 years, a "classic" psychedelics, typically understo acid diethylamide (LSD), and mescaline, (MDMA). Synthetic analogs of these age considered psychedelic agents in this No	le expanded safety and prelimina s living with non-contraindicated s across a broad range of ages mind nd 80+ years old). For the purpos bod to be 5-HT2 agonists such as as well as entactogens or empatients are also included. Cannabis, I	ry efficacy studie co-occurring con ust be included, ses of this NOFO, psilocybin, N,N-I hogens such as n	es in older adults with nditions representativ with particular attent the term psychedelic Dimethyltryptamine (nethylenedioxymetha	chronic pain ve of real-worl ion to strata a cincludes DMT), lysergic imphetamine
108299	NIA Renewal and Competing Rev Research (U01 Clinical Trial Optio	ision Cooperative Agreements in Aging nal)	National Institute on Aging/NIH/DHHS	PAR-22- 362	01-Oct-2024	Not Specified
	Contact Name	Ramesh Vemuri, Ph.D.				
	Contact Telephone	301-402-7700				
	Contact Email	ramesh.vemuri@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Oct-2024				
	Synopsis	This Funding Opportunity Announcemer resubmissions, for awarded U01 researc				heir
120843		of Biomarkers for Alzheimer's Disease ADRD)?(U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-23- 258	05-Oct-2024	Not Specified
	Contact Name	Yuan Luo, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	Yuan.Luo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Oct-202	5 , 05-Feb-2026			
	Synopsis	This notice of funding opportunity (NOF	O) invites applications to accelerations	ate the establish	ment of effective and	l reliable

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
		biomarkers of Alzheimer's disease (AD) a development, clinical trials, and/or clinic a biomarker, composite biomarker, or bi and Drug Administration (FDA's) Biomar pathways.	cal practice. Specifically, this NOF iomarker signature, with rigor co	O will support a mparable to the	nalytical and/or clinic expectations describ	al validation of ed in the Food
115099	-	nd the Impact of Sex Differences on the sk and Responsiveness to Treatment	National Institute on Aging/NIH/DHHS	PAR-23- 082	25-Oct-2024	Not Specified
	Contact Name	Nandini Arunkumar, Ph.D.				
	Contact Telephone	301-451-2313				
	Contact Email	nandini.arunkumar@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	25-Oct-2024 , 21-Feb-2025				
	Synopsis	This Funding Opportunity Announcemer to gain a comprehensive mechanistic un aging on the phenotypes of risk and resi molecular determinants underlying resp	derstanding of the impact of sex lience to Alzheimer's disease (AD	differences on t and AD-related	he molecular trajecto d dementias (ADRD), a	ries of brain
112937		nd the Impact of Sex Differences on the sk and Responsiveness to Treatment	National Institute on Aging/NIH/DHHS	PAR-22- 228	25-Oct-2024	Not Specified
	Contact Name	Nandini Arunkumar, Ph.D.				
	Contact Telephone	301-451-2313				
	Contact Email	nandini.arunkumar@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deedline Detec (ALL)	25 0 1 2024 24 5 1 2025				
	Deadline Dates (ALL)	25-Oct-2024 , 21-Feb-2025				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		to gain a comprehensive mechanistic un aging on the phenotypes of risk and resi molecular determinants underlying resp	lience to Alzheimer's disease (AD) and AD-related o	dementias (ADRD), a	
114469	NIA Multi-site Clinical Trial Imple Required)	mentation Grant (R01 Clinical Trial	National Institute on Aging/NIH/DHHS	PAR-23- 057 0	5-Oct-2024	Not Specified
	Contact Name	Sergei Romashkan, M.D., Ph.D.				
	Contact Telephone	301-435-3047				
	Contact Email	romashks@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-202	5 , 05-Oct-2025			
108328	Early and Late Stage Clinical Trial	This Funding Opportunity Announcement interventional clinical trials (all phases). research mission. Information about NIA s for the Spectrum of Alzheimer's mentias and Age-Related Cognitive	The trials should be hypothesis-	Viven, milestone-o	-	
	Decline (R01 Clinical Trial Option	<u>al)</u>	Aging/Nih/DHHS	878		specified
	Contact Name	Laurie Ryan				
	Contact Telephone	301-496-9350				
	Contact Email	ryanl@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Oct-2024				
	Synopsis	The purpose of this Funding Opportunit implement early to late stage clinical tria and neuropsychiatric changes associated disease-related Dementias (ADRD) acros	als of promising pharmacological d with age-related cognitive decl	and non-pharmac ine and Alzheimer	cological interventio 's disease (AD) and a	ns for cognitive Alzheimer's

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
124752	New Approaches for Measuring B (R01 Clinical Trial Optional)	Brain Changes Across Longer Timespans	National Institute on Aging/NIH/DHHS	PAR-24- 160 05-	-Oct-2024	Not Specified
	Contact Name	Elizabeth Newman, Ph.D.				
	Contact Telephone	301-480-7937				
	Contact Email	elizabeth.newman@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-202	5 , 05-Oct-2025 , 05-Feb-2026 , 0	5-Jun-2026 , 05-Oct	-2026 , 05-Feb-202	27
	Synopsis	opportunity is intended to encourage te epochs of the lifespan, to better predict (PEDP), which will be assessed as part of PEDP will be considered incomplete and carefully and view the available PEDP gu	easure brain activity, connectivity goal is to extend our understand ter health and disease. Research h cognitive, motor, or affective re- can focus on longitudinal neuroar s, connectomics, neural population chnological and conceptual innov outcomes at later ages. This NOF f the scientific and technical peer will be withdrawn. Applicants ar	, genomics, or other ing of brain develop can include healthy egulation challenges natomical or functio on activity patterns, vation to improve re O requires a Plan for review evaluation.	r aspects across th ment and aging, ir human participan s; and/or animal re nal changes at any and others. This fu epeated measures or Enhancing Diver Applications that f	e age spectrum including studies ts of any age; esearch on r level, inding across longer se Perspectives fail to include a
114865	Pilot Studies for the Spectrum of Disease-Related Dementias and A Clinical Trial Optional)	Alzheimer's Disease/Alzheimer's Age-Related Cognitive Decline (R61	National Institute on Aging/NIH/DHHS	PAR-23- 18- 083 18-	-Oct-2024	650,000 USD
	Contact Name	Laurie Ryan				
	Contact Telephone	301-496-9350				
	Contact Email	ryanl@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	18-Oct-2024				



SPIN ID Program Title	Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
The purpose of this Funding Opportuce collection of pilot data to support ea Synopsis for cognitive and neuropsychiatric of Alzheimer's disease-related dementic and 2) stimulate studies to enhance	arly stage testing of promising ph hanges associated with age-relat ias (ADRD) across the spectrum f	narmacological and ne ed cognitive decline	on-pharmacological i and Alzheimer's dise	nterventions ase (AD) and
Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's108329Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-21- 360	18-Oct-2024	650,000 USD
Contact Name Laurie Ryan				
Contact Telephone 301-496-9350				
Contact Email ryanl@mail.nih.gov				
Sponsor Website				
Program URL Link to program URL				
Deadline Dates (ALL) 18-Oct-2024				
The purpose of this Funding Opportu collection of pilot data to support ea Synopsis for cognitive and neuropsychiatric cl Alzheimer's disease-related dementi and 2) stimulate studies to enhance	arly stage testing of promising ph hanges associated with age-relat ias (ADRD) across the spectrum f	narmacological and ne ed cognitive decline	on-pharmacological i and Alzheimer's dise	nterventions ase (AD) and
collection of pilot data to support ea Synopsis for cognitive and neuropsychiatric cl Alzheimer's disease-related dementi	arly stage testing of promising ph hanges associated with age-relat ias (ADRD) across the spectrum to trial design and methods.	harmacological and no red cognitive decline from pre-symptomat	on-pharmacological i and Alzheimer's dise	nterventions ase (AD) and
Collection of pilot data to support ea Synopsis for cognitive and neuropsychiatric cl Alzheimer's disease-related dementi and 2) stimulate studies to enhance Notice of Special Interest (NOSI): Research on Pain, Pain Management	arly stage testing of promising ph hanges associated with age-relat ias (ADRD) across the spectrum f trial design and methods.	harmacological and no red cognitive decline from pre-symptomat NOT-AG-	on-pharmacological i and Alzheimer's dise c to more severe sta	nterventions ase (AD) and ges of disease Not
08054 Notice of Special Interest (NOSI): Research on Pain, Pain Management and Opioids in Aging	arly stage testing of promising ph hanges associated with age-relat ias (ADRD) across the spectrum f trial design and methods.	harmacological and no red cognitive decline from pre-symptomat NOT-AG-	on-pharmacological i and Alzheimer's dise c to more severe sta	nterventions ase (AD) and ges of diseas Not
collection of pilot data to support early for cognitive and neuropsychiatric of Alzheimer's disease-related dementiand 2) stimulate studies to enhance Notice of Special Interest (NOSI): Research on Pain, Pain Management and Opioids in Aging Contact Name Devon Oskvig, Ph.D.	arly stage testing of promising ph hanges associated with age-relat ias (ADRD) across the spectrum f trial design and methods.	harmacological and no red cognitive decline from pre-symptomat NOT-AG-	on-pharmacological i and Alzheimer's dise c to more severe sta	nterventions ase (AD) and ges of diseas Not
collection of pilot data to support ea Synopsis for cognitive and neuropsychiatric of Alzheimer's disease-related dementi and 2) stimulate studies to enhance 08054 Notice of Special Interest (NOSI): Research on Pain, Pain Management and Opioids in Aging Contact Name Devon Oskvig, Ph.D. Contact Telephone 301-827-5899	arly stage testing of promising ph hanges associated with age-relat ias (ADRD) across the spectrum f trial design and methods.	harmacological and no red cognitive decline from pre-symptomat NOT-AG-	on-pharmacological i and Alzheimer's dise c to more severe sta	nterventions ase (AD) and ges of diseas Not
collection of pilot data to support ea for cognitive and neuropsychiatric cl Alzheimer's disease-related dementi and 2) stimulate studies to enhance 08054 Notice of Special Interest (NOSI): Research on Pain, Pain Management and Opioids in Aging Contact Name Devon Oskvig, Ph.D. Contact Telephone 301-827-5899 Contact Email devon.oskvig@nih.gov	arly stage testing of promising ph hanges associated with age-relat ias (ADRD) across the spectrum f trial design and methods.	harmacological and no red cognitive decline from pre-symptomat NOT-AG-	on-pharmacological i and Alzheimer's dise c to more severe sta	nterventions ase (AD) and ges of diseas Not
collection of pilot data to support ea for cognitive and neuropsychiatric of Alzheimer's disease-related dementi and 2) stimulate studies to enhance Notice of Special Interest (NOSI): Research on Pain, Pain Management and Opioids in Aging Contact Name Contact Telephone Contact Telephone Contact Email Sponsor Website	arly stage testing of promising ph hanges associated with age-relat ias (ADRD) across the spectrum f trial design and methods. National Institute on Aging/NIH/DHHS	harmacological and no red cognitive decline from pre-symptomat NOT-AG- 22-004	on-pharmacological i and Alzheimer's dise c to more severe sta 08-Aug-2024	nterventions ase (AD) and ges of diseas Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Num	per Deadline Date	Funding Amount
		receiving grant applications focused on mission areas. This NOSI invites research pain experience with aging; enhancing a improving health equity of aging popula competing revisions to existing awards a pain, pain management, and opioids rel 005.	n applications that focus on impro ssessment, prevention, and man tions suffering with pain. New ap are all encouraged through this N	oving the under agement strate plications, resu OSI. For admini	standing of mechanisr gies for pain in older a bmissions, competing strative supplements f	ns underlying dults; and renewals, and ocused on
120970		g Development (Phase 1 to 2a) for Novel rum of Alzheimer's Disease (AD) and AD- 'UH3 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-23- 274	21-Oct-2024	Not Specified
	Contact Name	Akanni Clarke				
	Contact Telephone	301-496-9350				
	Contact Email	akanni.clarke@nih.gov				
	Sponsor Website	2				
	-	Link to program URL				
	Deadline Dates (ALL)	21-Oct-2024 , 21-Feb-2025 , 23-Jun-202	5 , 20-Oct-2025 , 20-Feb-2026 , 22	2-Jun-2026 , 19	-Oct-2026	
	Synopsis	The purpose of this notice of funding op phase 1 clinical trials with phase 1b/pha pharmacological interventions for Alzhe evaluated through this program, which tau mechanisms and aim to address cog pre-symptomatic to more severe stages prespecified, go/no-go safety and tolera development.	se 2a clinical trials to streamline t imer's disease (AD) and AD-relate can include small molecules or bio nitive and/or neuropsychiatric sy of disease. This NOFO uses a pha	the early-stage ed dementias (A ologics for exan mptoms in indivised award activ	evaluation of promisin DRD). Candidate inter pple, must engage non viduals across the spec vity code. Applications	ng ventions -amyloid/non ctrum, from must include
	RFA-AG-25-003 Research Collal Measurement and Modeling (U2-	boration Network in Structural Racism 4 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	RFA-AG- 25-003	17-Sep-2024 [Optional][LOI/Pre- App]	5,000,000 USD
	Contact Name Contact Telephone	Frank Bandiera, PhD 301-402-7629				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	frank.bandiera@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	17-Sep-2024 [Optional][LOI/Pre-App], 17	-Oct-2024			
	Synopsis	This Notice of Funding Opportunity (NOF of disciplines to collaborate with each ot life course health and aging. Applicants measures and methods through input fro repository for use by researchers, comm course health and aging. Support of activ political science, and the public health sc life course health and aging research. En advances in measurement and methods measurement and methods of structural approaches from the behavioral/social sc Collaboration with NIA Centers and othe racism. Serving as a central resource for institutes, series of workshops, advanced and methods of structural racism for agin	her in the measurement and mo should propose activities that in om the broader research commu- unity members, and policy make ities that bring together scholar iences to improve measuremen gagement with national and inte- of structural racism in research racism in life course health and ciences, humanities, education, r NIA research networks on mea- the organization of meetings an I seminars on methodology, or s	odeling of structura include the following unity and developm ers through a data p is in the behavioral/ t and methods for t ernational scientific on life course healt aging research, incl and political science surement and method d other educationa	I racism to facilitat g: Expansion of stru- ent of a publicly av- portal to facilitate r disciences, humanit the study of structu organizations to p h and aging. Pilot p orporating interdis e with the public h- hods for the study I activities (e.g., int	e research on uctural racism vailable data research on life ies, education, ural racism in romote further projects on sciplinary ealth sciences. of structural censive summer
11/2/2	Small Research Grant Program fo AD/ADRD Research (R03 Clinical	r the Next Generation of Researchers in Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-23- 179 16	-Oct-2024	200,000 USD
	Contact Name	Luci Roberts, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	<u>roberlu@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025	, 16-Oct-2025 , 16-Feb-2026			
	Synopsis	This Small Research Grant Program (R03) prevention, diagnosis, treatment, and/or dementias (AD/ADRD). Specifically, this N	care for individuals with Alzhei	mer's disease and A	lzheimer's disease	-related

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		overall goal of this NOFO is (i) to encour AD/ADRD research; and (ii) to stimulate perform pilot studies to develop new, in expertise. Individuals from diverse backs apply for NIH support. Investigators who announcement are specifically encourag	established researchers who hav novative AD/ADRD research prog grounds, including those from un have not successfully competed	ve not had a major a grams that leverage derrepresented gro	ward in AD/ADRD and build upon th ups are always end	research to eir existing couraged to
124754	New Approaches for Measuring E (R21 Clinical Trial Optional)	Brain Changes Across Longer Timespans	National Institute on Aging/NIH/DHHS	PAR-24- 161 16-	Oct-2024	400,000 USD
	Contact Name	Elizabeth Newman, Ph.D.				
	Contact Telephone	301-480-7937				
	Contact Email	elizabeth.newman@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-202	5 , 16-Oct-2025 , 16-Feb-2026 , 1	6-Jun-2026 , 16-Oct	-2026 , 16-Feb-202	27
	Synopsis	The purpose of this funding opportunity new approaches, or innovative application other aspects across the age spectrum of development and aging, including studies repeated measures across longer epochs healthy human participants of any age; so challenges; and/or animal research on the functional changes at any level, including and others. This funding opportunity is in high reward funding mechanism to devel preliminary data. This NOFO requires a scientific and technical peer review evalu- be withdrawn. Applicants are strongly en- guidance material.	ons of existing approaches, to m f neurodevelopment. The overar es of the neurodevelopmental ori s of the lifespan to better predict specific clinical groups such those nese domains of function. The stu g genetics/genomics, single cells, ntended to encourage technolog lop highly innovative ideas that e Plan for Enhancing Diverse Persp uation. Applications that fail to ir	easure brain activit ching goal is to extend gins of later health coutcomes at later a with cognitive, mo udies can focus on lo connectomics, neu ical and conceptual either lack prelimina ectives (PEDP), which colude a PEDP will b	y, connectivity, ger end our understand and disease, by im ages. Research can tor, or affective re ongitudinal neuroa ral population activi innovation throug ary data or need ac ch will be assessed e considered incon	nomics, or ding of brain proving include gulation natomical or vity patterns, h this high risk, lditional as part of the nplete and will
126831		tage Clinical Trials for the Spectrum of Related Dementias and Age-Related	National Institute on Aging/NIH/DHHS	RFA-AG- 25-011 17-	Oct-2024	Not Specified



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Cognitive Decline (R01 Clinical T	rial Optional)				
Contact Nam	e Laurie Ryan				
Contact Telephor	e 301-496-9350				
Contact Ema	il <u>ryanl@mail.nih.gov</u>				
Sponsor Websit	e				
Program UF	L Link to program URL				
Deadline Dates (AL	_) 17-Oct-2024				
Synops	The purpose of this Notice of Funding Op early- to late-stage clinical trials of prom the cognitive, behavioral, and neuropsyc (AD) and Alzheimer's disease-related dep	ising pharmacological and non-p hiatric changes associated with	harmacological int age-related cogniti	erventions to preve ve decline and Alzh	ent and/or treat eimer's disease
126832 RFA-AG-25-010Alzheimer's Cli	nical Trials Consortium (ACTC) Clinical	National Institute on	RFA-AG-	7-Oct-2024	Not
Trials (R01 Clinical Trial Require	<u>d)</u>	Aging/NIH/DHHS	25-010	7-001-2024	Specified
Contact Nam	e Laurie Ryan, Ph.D.				
Contact Telephor	e 301-496-9350				
Contact Ema	il <u>ryanl@mail.nih.gov</u>				
Sponsor Websit	e				
Program UF	L Link to program URL				
Deadline Dates (AL	_) 17-Oct-2024				
Synops	This Funding Opportunity Announcemen promising pharmacological and non-pha Alzheimer's disease (AD) and other age-r coordination and management infrastru	rmacological interventions that i elated dementias using the Alzh	may prevent, delay	v, or treat the symp	toms of
	: Development of Radiotracers for Alzheimer's Disease (AD) and AD-Related	National Institute on Aging/NIH/DHHS	NOT-AG- 22-032	5-Sep-2024	Not Specified
Contact Nam	e Lorenzo M. Refolo, Ph.D.				
Contact Telephor	e 301-594-7576				

SPIN ID	Program Title		Sponsor Name	Sponsor Numbo	er Deadline Date	Funding Amount
	Contact Email	refolol@nia.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 05-Oct-202 2025 , 05-Sep-2025	4 , 12-Nov-2024 , 07-Jan-2025 , 0	5-Feb-2025 , 05-	Apr-2025 , 07-May-2	025 <i>,</i> 05-Jun-
	Synopsis	This Notice of Special Interest (NOSI) inv Emission Tomography (PET) for use in Al and/or emerging biological process or m pathophysiology of neurodegeneration.	zheimer's disease (AD) and AD-re	elated dementias	(ADRD) research tar	geting new
126974	<u>RFA-AG-25-020 Claude D. Pepp</u> <u>Centers (P30 Clinical Trial Option</u>	er Older Americans Independence al)	National Institute on Aging/NIH/DHHS	RFA-AG- 25-020	11-Sep-2024 [Optional][LOI/Pre- App]	4,625,000 USD
	Contact Name	Basil Eldadah, MD, PhD				
	Contact Telephone	301-496-6761				
	Contact Email	<u>eldadahb@nia.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Sep-2024 [Optional][LOI/Pre-App], 1	L-Oct-2024			
	Synopsis	This Funding Opportunity Announcement Centers (OAICs) award. The goal of the C education to increase scientific knowled awards are designed to develop or strent related to the mission of the OAIC progr	DAIC program is to establish centre ge leading to better ways to main gthen programs that focus on, an	ers of excellence ntain or restore i	in geriatrics research ndependence in olde	and research r persons. OAIC
108048	NIA Renewal and Revision Coope (U54 Clinical Trial Optional)	rative Agreements in AD/ADRD Research	National Institute on Aging/NIH/DHHS	PAR-22- 077	17-Oct-2024	Not Specified
	Contact Name	Suzana Petanceska, Ph.D.				
	Contact Telephone	301-594-7754				
	Contact Email	petanceskas@nia.nih.gov				

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	Sponsor Website					
	•	Link to program URL				
	-	17-Oct-2024 , 14-Feb-2025				
	Synopsis	This Funding Opportunity Announcement resubmissions, for funded U54 Specializ projects with multiple highly integrated (AD) and Alzheimer's disease-related de multidisciplinary team of investigators w more AD/ADRD implementation research Alzheimer's and Related Dementias.	ed Center cooperative agreement components focused on a commu- mentias (ADRD). It is anticipated within a single institution or a cons	ts that support la on research que that such projec sortium of instit	arge-scale, complex restion relevant to Alzh ts will likely involve a utions, and will addre	esearch eimer's disease n integrated ss one or
127244	RFA-AG-25-023 Deciphering the Aging and AD/ADRD (R21 Clinical	e Impact of RNA Modifications on Brain Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG- 25-023	01-Oct-2024 [Optional][LOI/Pre- App]	400,000 USD
	Contact Name	Alison Yao, Ph.D.				
	Contact Telephone	301-827-7264				
	Contact Email	<u>yaoal@nia.nih.gov</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Oct-2024 [Optional][LOI/Pre-App], 0	1-Nov-2024			
	Synopsis	The purpose of this Notice of Funding O landscape and functional implications of dementias (ADRD). AD-related dementia cognitive impairment/dementia (VCI/D) (R21) applications focused on uncoverin impact on brain aging and the pathogen mechanistic investigation of previously i	f RNA modifications in brain aging as include Lewy body dementia (L , and mixed dementias. This NOF g novel mechanisms underlying F esis of AD/ADRD. Proposed studi	g and Alzheimer' BD), frontotemp O supports explo RNA modificatior	s disease (AD) and AD poral dementia (FTD), pratory and developm n-mediated processes	D-related vascular nental grant and their
127243	RFA-AG-25-021 Grants for Early to Aging Research (GEMSSTAR) (F	y Medical/Surgical Specialists' Transition R03 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	RFA-AG- 25-021	01-Oct-2024 [Optional][LOI/Pre- App]	250,000 USD

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Name					
Contact Telephone					
	niagemsstar@mail.nih.gov				
Sponsor Website	Link to sponsor website				
	Link to program URL				
Deadline Dates (ALL)	01-Oct-2024 [Optional][LOI/Pre-App], 0	1-Nov-2024			
Synopsis	support for early-career physician-scient launch careers as future leaders in aging notice of funding opportunity (NOFO) in yield pilot data and experience for subse	g- or geriatric-focused research. I vites applications that propose t equent aging research projects. T	n support of the pr o conduct transdise The GEMSSTAR pro	ogram's goal, this G ciplinary aging rese gram encourages ca	GEMSSTAR arch that will
, , , , , , , , , , , , , , , , , , , ,	seek out a supportive research environn physician- and dentist-scientists in aging specialty/discipline. Toward this end, GE supportive research environment. In sel extent to which a candidate's environme	g- or geriatric-focused research, p EMSSTAR candidates should inclu ecting GEMSSTAR awardees, the	particularly as it app ude a Professional I National Institute	olies to their clinica Development Plan t on Aging (NIA) will	l hat reflects thi
	physician- and dentist-scientists in aging specialty/discipline. Toward this end, GE supportive research environment. In sel	g- or geriatric-focused research, p EMSSTAR candidates should inclu ecting GEMSSTAR awardees, the	particularly as it app ade a Professional I National Institute iatric-focused resea	olies to their clinica Development Plan t on Aging (NIA) will	l hat reflects thi
122532 Aging Research Dissertation Awa Trial Not Allowed)	physician- and dentist-scientists in aging specialty/discipline. Toward this end, GE supportive research environment. In sel extent to which a candidate's environment rds to Promote Diversity (R36 Clinical	g- or geriatric-focused research, p EMSSTAR candidates should inclu ecting GEMSSTAR awardees, the ent is supportive of aging- or ger National Institute on	particularly as it app ide a Professional I National Institute iatric-focused resea PAR-24-	olies to their clinica Development Plan t on Aging (NIA) will arch.	hat reflects thi consider the Not
122532 Aging Research Dissertation Awa Trial Not Allowed)	physician- and dentist-scientists in aging specialty/discipline. Toward this end, GE supportive research environment. In sel extent to which a candidate's environment rds to Promote Diversity (R36 Clinical Jamie Lahvic, Ph.D.	g- or geriatric-focused research, p EMSSTAR candidates should inclu ecting GEMSSTAR awardees, the ent is supportive of aging- or ger National Institute on	particularly as it app ide a Professional I National Institute iatric-focused resea PAR-24-	olies to their clinica Development Plan t on Aging (NIA) will arch.	hat reflects thi consider the Not
122532 Aging Research Dissertation Awa Trial Not Allowed) Contact Name Contact Telephone	physician- and dentist-scientists in aging specialty/discipline. Toward this end, GE supportive research environment. In sel extent to which a candidate's environment rds to Promote Diversity (R36 Clinical	g- or geriatric-focused research, p EMSSTAR candidates should inclu ecting GEMSSTAR awardees, the ent is supportive of aging- or ger National Institute on	particularly as it app ide a Professional I National Institute iatric-focused resea PAR-24-	olies to their clinica Development Plan t on Aging (NIA) will arch.	hat reflects thi consider the Not
122532 Aging Research Dissertation Awa Trial Not Allowed) Contact Name Contact Telephone Contact Email	physician- and dentist-scientists in aging specialty/discipline. Toward this end, GE supportive research environment. In sel extent to which a candidate's environment rds to Promote Diversity (R36 Clinical Jamie Lahvic, Ph.D.	g- or geriatric-focused research, p EMSSTAR candidates should inclu ecting GEMSSTAR awardees, the ent is supportive of aging- or ger National Institute on	particularly as it app ide a Professional I National Institute iatric-focused resea PAR-24-	olies to their clinica Development Plan t on Aging (NIA) will arch.	hat reflects thi consider the Not
122532 Aging Research Dissertation Awa Trial Not Allowed) Contact Name Contact Telephone Contact Email Sponsor Website	physician- and dentist-scientists in aging specialty/discipline. Toward this end, GE supportive research environment. In sel extent to which a candidate's environment rds to Promote Diversity (R36 Clinical Jamie Lahvic, Ph.D.	g- or geriatric-focused research, p EMSSTAR candidates should inclu ecting GEMSSTAR awardees, the ent is supportive of aging- or ger National Institute on	particularly as it app ide a Professional I National Institute iatric-focused resea PAR-24-	olies to their clinica Development Plan t on Aging (NIA) will arch.	hat reflects thi consider the Not
122532 Aging Research Dissertation Awa Trial Not Allowed) Contact Name Contact Telephone Contact Email Sponsor Website	physician- and dentist-scientists in aging specialty/discipline. Toward this end, GE supportive research environment. In sel extent to which a candidate's environment rds to Promote Diversity (R36 Clinical Jamie Lahvic, Ph.D.	g- or geriatric-focused research, p EMSSTAR candidates should inclu ecting GEMSSTAR awardees, the ent is supportive of aging- or ger National Institute on Aging/NIH/DHHS	particularly as it app ide a Professional I National Institute iatric-focused resea PAR-24- 052 16-Jul-2025 , 16-Od	olies to their clinica Development Plan t on Aging (NIA) will arch. 5-Oct-2024	hat reflects thi consider the Not Specified
122532 Aging Research Dissertation Awa Trial Not Allowed) Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	physician- and dentist-scientists in aging specialty/discipline. Toward this end, GE supportive research environment. In sel extent to which a candidate's environment rds to Promote Diversity (R36 Clinical Jamie Lahvic, Ph.D. <u>NIATraining@mail.nih.gov</u> <u>Link to program URL</u> 16-Oct-2024 , 16-Nov-2024 , 16-Feb-202	g- or geriatric-focused research, p EMSSTAR candidates should inclue ecting GEMSSTAR awardees, the ent is supportive of aging- or ger National Institute on Aging/NIH/DHHS 25 , 16-Mar-2025 , 16-Jun-2025 , ul-2026 , 16-Oct-2026 , 16-Nov-2 FO) invites R36 applications to p	particularly as it app ide a Professional I National Institute iatric-focused resea PAR-24- 052 16-Jul-2025 , 16-Oc 2026 romote diversity in	olies to their clinica Development Plan t on Aging (NIA) will arch. 5-Oct-2024 ct-2025 , 16-Nov-20 the scientific resea	hat reflects thi consider the Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber Deadline Date	Funding Amount
			Aging/NIH/DHHS	120		Specified
	Contact Name	Jamie Lahvic, Ph.D.				
	Contact Telephone					
	Contact Email	NIATraining@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Oct-2024 , 12-Nov-2024 , 12-Feb-202	25 , 12-Mar-2025 , 12-Jun-2025 ,	12-Jul-2025 , 12	2-Oct-2025 , 12-Nov-20	25
	Synopsis	The purpose of the NIA Career Transition tenure-track or equivalent faculty position provide postdoctoral phase funding; the faculty positions within 12 months after position at an extramural institution/org salary and research support. This Notice research that does not involve leading a	ons conducting research that adv refore, candidates should be pre- confirmation of a positive fundir ganization, the award will provide of Funding Opportunity (NOFO)	vances the miss pared to transing decision. Aft three years of is designed spe	ion of NIA. This award tion to tenure-track or er transition to an appr protected research tin cifically for candidates	does not equivalent oved faculty ne through proposing
127251	RFA-AG-25-022 Deciphering the Aging and AD/ADRD (R01 Clinical	e Impact of RNA Modifications on Brain Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG- 25-022	01-Oct-2024 [Optional][LOI/Pre- App]	2,500,000 USD
	Contact Name	Alison Yao, Ph.D.				
	Contact Telephone	301-827-7264				
	Contact Email	<u>yaoal@nia.nih.gov</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Oct-2024 [Optional][LOI/Pre-App], 02	1-Nov-2024			
	Synopsis	The purpose of this Notice of Funding O landscape and functional implications of dementias (ADRD). AD-related dementia cognitive impairment/dementia (VCI/D), mechanisms underlying RNA modification progression of AD/ADRD. The ultimate g	RNA modifications in brain agin as include Lewy body dementia (I , and mixed dementias. This NOF on-mediated processes and their	g and Alzheime LBD), frontoten O supports app impact on brai	r's disease (AD) and AD poral dementia (FTD), ilications focused on ur n aging and the pathog	p-related vascular acovering nove enesis and

SPIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	AD/ADRD.				
RFA-AG-25-029 Short Courses127271Develop Behavioral InterventionIndependent Clinical Trial Not A		National Institute on Aging/NIH/DHHS	RFA-AG- 25-029	06-Sep-2024 [Optional][LOI/Pre- App]	1,750,000 USD
Contact Telephon	il <u>NIATraining@mail.nih.gov</u>				
•	e L <u>Link to program URL</u>				
Deadline Dates (ALI	.) 06-Sep-2024 [Optional][LOI/Pre-App], 08 The NIH Research Education Program (R overarching goal of this R25 program is behavioral and clinical research and its i Opportunity (NOFO) will support educa of this NOFO is to invite applications that behavioral interventions to promote hea end of life decision-making and care, and intervention is used broadly here, to inc	25) supports research education to support educational activities mplications. To accomplish the si tional activities with a primary fo it propose the creation of short c althy aging and prevent illness, in d support the needs of the growi	that foster a bet tated over-archi cus on: Courses ourses on utilizin nprove care, fos ng older adult p	ter understanding of b ng goal, this Notice of for Skills Developmen ng the NIH Stage Mode ter disease manageme opulation. The term b	biomedical, Funding t The purpose el to develop ent, assist wit ehavioral

175753	RFA-AA-24-008 Comprehensive Alcohol Research Centers (P60 Clinical	National Institute on Alcohol	RFA-AA-	15-Oct-2024	6,250,000
125752	trial Optional)	Abuse and Alcoholism/NIH/DHHS	24-008	[Optional][LOI/Pre-	USD

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
					App]	
	Contact Name	Gregory Bloss, M.A.				
	Contact Telephone	301-443-3865				
	Contact Email	Gregory.Bloss@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Oct-2024 [Optional][LOI/Pre-App], 15	-Nov-2024			
	Synopsis	This Notice of Funding Opportunity (NOF mechanism which requires a disseminati center. The overall purpose of the NIAAA fostering interdisciplinary, collaborative include, but are not limited to: the natur prevention of alcohol misuse, alcohol use behavioral, psychosocial, and economic of and other NIH-designated populations th contribute to the development of new re- research.	on core to initiate and expand co A Alcohol Research Center progra research on a wide variety of top e, etiology, genetics, epigenetics, e disorder, alcohol-related end or consequences across the lifespan nat experience health disparities.	mmunity educat m is to provide lo ics relevant to th diagnosis, epide gan diseases and and impacting lo Centers also are	ion related to the ac eadership in conduct e Institute's mission emiology, treatment, d their biomedical, n racial and ethnic min regional or national	tivities of the ing and . These topics and eurochemical, ority groups resources that
	RFA-AA-24-007 Specialized Alco Optional)	ohol Research Centers (P50 Clinical trial	National Institute on Alcohol Abuse and Alcoholism/NIH/DHH	RFA-AA-	15-Oct-2024 [Optional][LOI/Pre- App]	5,750,000 USD
	Contact Name	Gregory Bloss, M.A.				
	Contact Telephone	301-443-3865				
	Contact Email	Gregory.Bloss@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Oct-2024 [Optional][LOI/Pre-App], 15	-Nov-2024			
	Synopsis	The National Institute on Alcohol Abuse to foster and conduct interdisciplinary, c related problems, and other health relat	ollaborative research on Alcohol	Use Disorder (Al	JD), alcohol misuse a	and alcohol

SPIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	leadership in research, and research meth Topics include, but are not limited to, the related end organ diseases and their biom health and NIH-designated populations the development of research methods, techno	nature, etiology, genetics, diagnetical, psychosocial, and econor at experience health disparities.	osis, treatment nic consequend Centers are als	, and prevention of A ces across the lifespar o major contributors	UD, alcohol- n and minority to the
120716 Alcohol Treatment, Pharmacothe Clinical Trial Required)	······································	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23- 5 250	05-Oct-2024	2,500,000 USD
Contact Name	Brett T. Hagman, Ph.D.				
Contact Telephone	301-443-0638				
Contact Emai	<u>brett.hagman@nih.gov</u>				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 ,	05-Oct-2025 , 05-Feb-2026 , 05-	Jun-2026		
Synopsis	The National Institute on Alcohol Abuse ar focusing on alcohol treatment and recover recovery from alcohol use disorder (AUD), mechanisms of behavioral change (MOBC) AUD treatment and recovery.	ry research. This NOFO will focus including: medications develop	s broadly on top ment, precisior	pics relevant for treat medicine, behaviora	ment of and I therapies an
	AUD treatment and recovery.				nologies for
20720 Alcohol Health Services Research	(R01 Clinical Trial Ontional)	Vational Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23- 5 251	05-Oct-2024	Not Specified
	(R01 Clinical Trial Ontional)			05-Oct-2024	Not
	Laura E. Kwako, Ph.D.			05-Oct-2024	Not
Contact Name Contact Telephone	Laura E. Kwako, Ph.D.			05-Oct-2024	Not
Contact Name Contact Telephone	Laura E. Kwako, Ph.D. 301-451-8507 <u>laura.kwako@nih.gov</u>			05-Oct-2024	Not
Contact Name Contact Telephone Contact Email Sponsor Website	Laura E. Kwako, Ph.D. 301-451-8507 <u>laura.kwako@nih.gov</u>			05-Oct-2024	Not
Contact Telephone Contact Email Sponsor Website Program URL	Laura E. Kwako, Ph.D. 301-451-8507	Abuse and Alcoholism/NIH/DHHS	5 251	05-Oct-2024	Not

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		disorder (AUD); within this focus, there making treatment for AUD more appea dissemination and implementation of e as a means of addressing the treatment	ling, (3) examining cost structures a xisting evidence-based approaches	and insurance syst to treating AUD, a	ems, (4) conductin	g studies on
	Alcohol Treatment, Pharmacothe Clinical Trial required)	erapy, and Recovery Research (R34	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23- 5 249 16-	-Oct-2024	450,000 USD
	Contact Name	Brett T. Hagman, Ph.D.				
	Contact Telephone	301-443-0638				
	Contact Email	brett.hagman@nih.gov				
	Sponsor Website					
	Program LIBI	Link to program LIDI				
		Link to program URL				
	-	16-Oct-2024 , 16-Feb-2025 , 16-Jun-202				
	Deadline Dates (ALL)		and Alcoholism solicits application very research. This NOFO will focus D), including: medications develop	ns for an R34 Clinic s broadly on topics ment, precision m	relevant for treat edicine, behaviora	ment of and I therapies and
.20721	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-202 The National Institute on Alcohol Abuse focusing on alcohol treatment and reco recovery from alcohol use disorder (AU mechanisms of behavioral change (MO AUD treatment and recovery.	and Alcoholism solicits application very research. This NOFO will focus D), including: medications develop	ns for an R34 Clinic s broadly on topics ment, precision m h, and innovative PAR-23-	relevant for treat edicine, behaviora	ment of and I therapies and
20721	Deadline Dates (ALL) Synopsis <u>Alcohol Health Services Research</u>	16-Oct-2024 , 16-Feb-2025 , 16-Jun-202 The National Institute on Alcohol Abuse focusing on alcohol treatment and reco recovery from alcohol use disorder (AU mechanisms of behavioral change (MO AUD treatment and recovery.	and Alcoholism solicits application very research. This NOFO will focus D), including: medications develop 3C), recovery, translational researc National Institute on Alcohol	ns for an R34 Clinic s broadly on topics ment, precision m h, and innovative PAR-23-	s relevant for treat edicine, behaviora methods and techr	ment of and I therapies and nologies for 450,000
20721	Deadline Dates (ALL) Synopsis <u>Alcohol Health Services Research</u>	16-Oct-2024 , 16-Feb-2025 , 16-Jun-202 The National Institute on Alcohol Abuse focusing on alcohol treatment and reco recovery from alcohol use disorder (AU mechanisms of behavioral change (MO AUD treatment and recovery.	and Alcoholism solicits application very research. This NOFO will focus D), including: medications develop 3C), recovery, translational researc National Institute on Alcohol	ns for an R34 Clinic s broadly on topics ment, precision m h, and innovative PAR-23-	s relevant for treat edicine, behaviora methods and techr	ment of and I therapies and nologies for 450,000
20721	Deadline Dates (ALL) Synopsis <u>Alcohol Health Services Research</u> Contact Name Contact Telephone	16-Oct-2024 , 16-Feb-2025 , 16-Jun-202 The National Institute on Alcohol Abuse focusing on alcohol treatment and reco recovery from alcohol use disorder (AU mechanisms of behavioral change (MO AUD treatment and recovery.	and Alcoholism solicits application very research. This NOFO will focus D), including: medications develop 3C), recovery, translational researc National Institute on Alcohol	ns for an R34 Clinic s broadly on topics ment, precision m h, and innovative PAR-23-	s relevant for treat edicine, behaviora methods and techr	ment of and I therapies and nologies for 450,000
20721	Deadline Dates (ALL) Synopsis <u>Alcohol Health Services Research</u> Contact Name Contact Telephone	16-Oct-2024 , 16-Feb-2025 , 16-Jun-202 The National Institute on Alcohol Abuse focusing on alcohol treatment and reco recovery from alcohol use disorder (AU mechanisms of behavioral change (MO AUD treatment and recovery. (R01 Clinical Trial Optional) Laura E. Kwako, Ph.D. 301-451-8507 laura.kwako@nih.gov	and Alcoholism solicits application very research. This NOFO will focus D), including: medications develop 3C), recovery, translational researc National Institute on Alcohol	ns for an R34 Clinic s broadly on topics ment, precision m h, and innovative PAR-23-	s relevant for treat edicine, behaviora methods and techr	ment of and I therapies and nologies for 450,000
20721	Deadline Dates (ALL) Synopsis Alcohol Health Services Research Contact Name Contact Telephone Contact Email Sponsor Website	16-Oct-2024 , 16-Feb-2025 , 16-Jun-202 The National Institute on Alcohol Abuse focusing on alcohol treatment and reco recovery from alcohol use disorder (AU mechanisms of behavioral change (MO AUD treatment and recovery. (R01 Clinical Trial Optional) Laura E. Kwako, Ph.D. 301-451-8507 laura.kwako@nih.gov	and Alcoholism solicits application very research. This NOFO will focus D), including: medications develop 3C), recovery, translational researc National Institute on Alcohol	ns for an R34 Clinic s broadly on topics ment, precision m h, and innovative PAR-23-	s relevant for treat edicine, behaviora methods and techr	ment of and I therapies and nologies for 450,000
.20721	Deadline Dates (ALL) Synopsis Alcohol Health Services Research Contact Name Contact Telephone Contact Email Sponsor Website Program URL	16-Oct-2024 , 16-Feb-2025 , 16-Jun-202 The National Institute on Alcohol Abuse focusing on alcohol treatment and reco recovery from alcohol use disorder (AU mechanisms of behavioral change (MO AUD treatment and recovery. (R01 Clinical Trial Optional) Laura E. Kwako, Ph.D. 301-451-8507 laura.kwako@nih.gov	and Alcoholism solicits application very research. This NOFO will focus D), including: medications develop BC), recovery, translational researc National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	ns for an R34 Clinic s broadly on topics ment, precision m h, and innovative PAR-23- 5 252 16-	s relevant for treat edicine, behaviora methods and techr	ment of and I therapies an nologies for 450,000

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
		making treatment for AUD more appeali dissemination and implementation of ex as a means of addressing the treatment	isting evidence-based approache	s to treating AU	•	-
122636	Prevention and Intervention App Disorders (R61/R33 Clinical Trial (roaches for Fetal Alcohol Spectrum Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHH	PAR-24- IS 068	16-Oct-2024	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	<u>duntyw@mail.nih.gov</u>	FO) focuses on prevention and int a. The intent of this NOFO is to su xposure and the incidence of FAS ry/Developmental Phased Award econdary data analysis for hypoth in the R33 phase. The transition lievement of specific milestones s ants interested in planning clinica	tervention strat pport research D and (2) interv (R61/R33) mec nesis developme to the R33 phas set for the R61 p	egies for fetal alcohol that advances (1) pre ventions for FASD. The hanism, clinical trial o ent and feasibility, and se will be determined phase. Highest priority	vention ese objectives ptional. The d research by NIAAA y will be given
124492	Health Equity and End Health Dis	ms of Care Initiative (MCCI) to Advance parities Among Women and Girls in Underserved Communities (U34 Clinical	National Institute on Alcohol Abuse and Alcoholism/NIH/DHH	RFA-AA-	19-Sep-2024 [Optional][LOI/Pre- App]	600,000 USD
	Contact Telephone Contact Email Sponsor Website	<u>droach@nih.gov</u>				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	19-Sep-2024 [Optional][LOI/Pre-App], 18 The purpose of this NOFO is to support the Health Equity and End Health Disparities ICO dissemination and implementation science among racial/ethnic minority women and use disorders, chronic stress, cardiopulme HIV/AIDS. This concept proposes a contribe behavioral health, integrative care, and contribe of these domains, and to have maximum underserved women and girls. While Me because it is during the early reproductive progresses, setting the stage for multiple stakeholder partnerships, provider training minority women and girls who currently and girls living in low resource settings). Institutions and other institutions with ex- requires a Plan for Enhancing Diverse Per- review evaluation. Applications that fail are strongly encouraged to read the NOF	he planning phase of the Model (Among Women and Girls in Raci cience initiative to advance racia e age. Specifically, the Model Co ce approaches to significantly red d girls of reproductive age at risk onary diseases, common metabo nuum of care approach that inter- ardiopulmonary and endocrine s impact on the overall health and CCI is not a maternal health initia e period, i.e., adolescence, that re- chronic debilitating conditions in ng, and infrastructure changes to have the least access to high qua Applications that include a partra stensive programs in women's here to include a PEDP will be consider	Continuums of Care al/Ethnic Minority (l equity and end he ontinuums of Care In duce the prevalence and living with mer olic disorders (e.g., o grates preventive h specialties to fully and d well-being of racia ative, women and gi multimorbidity typic n later life. Special o improve access for ality health care (e.g hership between Res ealth research are st assessed as part of t ered incomplete and	Initiative (MCCI) Communities. MC alth disparities in itiative will apply and impact of m ital health disorded diabetes), cancer, ealth services, pri- ddress health care I and ethnic mino rls ages 15-44 yrs cally begins and ra- emphasis will be p r subgroups of rac c., racial/ethnic mi- search Centers in trongly encourage he scientific and t I will be withdraw	Cl is a multi- racial/ethnic the latest ulti-morbidity ers, substance and mary care, needs in each rity and other are centered pidly placed on using ial/ethnic nority women Minority d. This NOFO echnical peer n. Applicants
107782		dult Populations: Military Worktorce	National Institute on Alcohol Abuse and Alcoholism/NIH/DHH	NOT-AA- 05- IS 22-001	Sep-2024	Not Specified
		Bradley Kerridge, Ph.D.				
	Contact Telephone					
		bradley.kerridge@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 2025 , 07-May-2025 , 05-Jun-2025 , 16-Ju	1 , 16-Oct-2024 , 05-Jan-2025 , 07 In-2025 , 05-Sep-2025 , 07-Sep-2	7-Jan-2025 , 05-Feb- 025	2025 , 16-Feb-202	25 , 05-Apr-

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	The purpose of this future grant applicat alcohol misuse among persons aged 18 t commonly in the military, workforce, or four-year colleges. Research on epidemic encouraged.	o 29 who are not enrolled in four community college populations, v	-year colleges or ur vhich are understue	niversities. These p died relative to the	persons are eir age peers in
11658/	Advancing mHealth Interventions for Icohol-Related Domestic Violence	National Institute on Alcohol Abuse and Alcoholism/NIH/DHH	NOT-AA- S 23-003 07-:	Sep-2024	Not Specified
Contact Name	Robert Freeman, Ph.D.				
Contact Telephone					
	rfreeman@mail.nih.gov				
Sponsor Website					
-	Link to program URL 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Ju Feb-2026 , 12-Feb-2026 , 16-Feb-2026 , 0	n-2025 , 07-Sep-2025 , 05-Oct-20	25 , 12-Oct-2025 , 1	.6-Oct-2025 , 07-Ja	•
Synopsis	In light of the documented increases in the of the global COVID-19 pandemic and an grant application solicitation is to annound eveloping, testing, and intervening provalcohol consumption at levels sufficient evictimization. In particular, this solicitation potential efficacy, and implementation of (mHealth) that rely on communication the term "domestic violence" will extend partner violence (IPV).	ray of mandated restrictions enac nce NIAAA's interest in addressin kimal to drinking occasions, when to trigger DV and to provide skills on seeks to advance the developm of scalable, low resource, and rem echnologies for reducing and prev	ted to mitigate COV g the critical need for risk of DV is elevate shown to reduce ri nent, feasibility, acc otely delivered inter enting alcohol cons	VID spread, the pu or research relate ed, to decrease th sk of DV perpetrat eptability, pilot te rventions via mot sumption and DV.	rpose of this d to e likelihood of ion and sting, bile devices For this FOA,
122632 Prevention and Intervention App Disorders (R34 Clinical Trial Option	roaches for Fetal Alcohol Spectrum onal)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHH	PAR-24- S 067 16-0	Oct-2024	450,000 USD
Contact Name Contact Telephone	William Dunty, PhD 301-443-7351				



SPIN ID	Program Title		Sponsor Name S	ponsor Number	Deadline Date	Funding Amount
	Contact Email	duntyw@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025	5 , 16-Oct-2025 , 16-Feb-2026 , 16-	Jun-2026 <i>,</i> 16-00	ct-2026	
	Synopsis	This Notice of Funding Opportunity (NOF strategies for fetal alcohol spectrum disc that advances (1) prevention approaches FASD. It is expected that research condu and submitting subsequent applications exploratory phased projects may conside	orders (FASD) throughout the lifesp s to reduce prenatal alcohol expose cted via this mechanism will consis for larger scale FASD prevention o	oan. The intent o ure and incidenc at of studies that r intervention st	f this NOFO is to su e of FASD and (2) in are a pre-requisite	oport research terventions fo for preparing
126230	RFA-DC-24-008 Early-Stage Diss Research in Communication Disor		National Institute on Deafness an Other Communication Disorders/NIH/DHHS	RFA-DC- 24-008 [C	1-Sep-2024 Dptional][LOI/Pre- pp]	400,000 USD
	Contact Name	Holly L. Storkel, Ph.D.				
	Contact Telephone	301-496-5061				
	Contact Email	holly.storkel@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
		11-Sep-2024 [Optional][LOI/Pre-App], 11				
		NIDCD invites applications for early-stag areas of hearing, balance, taste, smell, ve		on (D&I) researc	h projects in the NI	OCD mission
122439	RFA-DC-24-004 In Vivo High-Res Visualization (R01 Clinical Trial op		National Institute on Deafness an Other Communication Disorders/NIH/DHHS	RFA-DC-	1-Oct-2024	2,499,995 USD
	Contact Name	Amy Poremba, Ph.D.				
	Contact Telephone	301-997-3152				
	Contact Email	amy.poremba@nih.gov				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
·	Link to program URL 01-Oct-2024 , 03-Feb-2025 This funding opportunity aims to suppor technologies for the living human inner e techniques or developing new imaging to detail and accuracy than currently possis important to the development of new ar or contrast agents that can enhance visu opportunity is expected to significantly a otoliths, membranes, ions, and vasculatu achieve this goal, a multidisciplinary tear encouraged. Studies in humans and inte advance the needed technology. Any intr application in awake humans or define th opportunity announcement (NOFO) also improvement of human in vivo structura criteria: meet the budget limits of this NO low risks to subjects, and intend to gather low-risk trials determined to be Basic Exp of a clinical trial and meet the definition application. High-risk clinical trials not m Agreement for In Vivo High-Resolution Ir	ear. Proposed projects should focu echniques that can visualize inner ole. Both structural and functional and improved techniques. Projects alization of the inner ear structure dvance the ability to visualize auc ure, in detail in awake patients in a mapproach that takes advantage rmediate studies in mammalian a ermediate studies must articulate he limitations and the usefulness i supports investigator initiated low I and functional imaging technolo DFO, not require FDA oversight, n er scientific data/evidence to infor perimental Studies with Humans (of basic research. It is advisable th eeting all the criteria above are re	us on improving the ear structures in v aspects, including may also focus on es. Research suppo litory and vestibula a clinical setting us of the expertise of nimal models may a clear path of the in anesthetized hur w-risk clinical trials gies. Clinical trials gies. Clinical trials ot be an NIH-define m subsequent stud BESH). These studi nat only one clinica	e resolution of cur ivo with significan visualizing dynam developing new in orted in response t in components, su- ing non-invasive te each team memb be proposed to de proposed method mans. This notice addressing the de must meet ALL the ed Phase III Clinica dies. This NOFO als es fall within the N I trial be proposed panion U01 Coope	rent imaging cly greater ic elements are haging probes to this funding ch as hair cells, echniques. To er is highly evelop or dology to of funding velopment or following I Trial, have so supports IIH definition I in each rative
122441 RFA-DC-24-005 Cooperative Age Imaging for Inner Ear Visualization	greement for In Vivo High-Resolution on (U01 Clinical Trial Required)	National Institute on Deafness ar Other Communication Disorders/NIH/DHHS	BEA-DC-	Oct-2024	2,499,995 USD
Contact Name	Amy Poremba, Ph.D.				
Contact Telephone					
	amy.poremba@nih.gov				
Sponsor Website					
-	Link to program URL				
Deadline Dates (ALL)	01-Oct-2024 , 03-Feb-2025				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	This funding opportunity aims to support functional imaging technologies for the liv current imaging techniques or developing significantly greater detail and accuracy th dynamic elements, are important to deve imaging probes or contrast agents that ca to this funding opportunity is expected to such as hair cells, otoliths, membranes, io invasive techniques. To achieve this goal, team member is highly encouraged. Stud technology. Any intermediate studies mus humans or define the limitations and the cooperative agreement between an NIDC the following criteria: requires FDA oversis participants. These investigator-initiated guidance resulting from a cooperative agr funding opportunity. Low risk clinical trials Resolution Imaging for Inner Ear Visualizar encouraged to contact the scientific/resea proposed research.	ring human inner ear. Proposed new imaging techniques that ca han currently possible. Structural loping new and improved techni- n enhance visualization of the in- significantly advance the ability ns, and vasculature, in detail in a a multidisciplinary team approa- ies in humans must be proposed at articulate a clear path of the p usefulness in anesthetized huma D Project Scientist and an Invest ght, is intended to formally esta clinical trials are perceived to be eement. Only one clinical trial m s not meeting any of the criteria tion (R01 - Clinical Trial Optional	projects should foc an visualize inner ea l and functional asp iques. Projects may iner ear structures. to visualize audito awake patients in a ch that takes advar to develop, advan proposed methodol ans. This funding o igator to support a blish efficacy, or ha enefit from close in nay be proposed per above are referred) RFA-DC-24-004. In	cus on improving t ar structures in viv pects, including vis valso focus on dev Research support ry and vestibular of clinical setting us tage of the exper- ice, or test the nee ogy to application pportunity suppor clinical trial that r as potentially high teraction, oversighter application subr d to the companion nvestigators are st	he resolution of ro with sualizing reloping new red in response components, ing non- tise of each eded in awake ts a neets ANY of er risks to nt, and nitted to this n In Vivo High- crongly
	ment Award for Established Investigators ontal Studies with Humans Required)	National Institute on Deafness a Other Communication Disorders/NIH/DHHS	PAR_{JA}	Sep-2024	Not Specified
Contact Name	Alberto L. Rivera-Rentas, Ph.D.				
Contact Telephone	301-496-1804				
	riverara@nidcd.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 , 2026 , 09-Feb-2026 , 07-May-2026 , 08-Ju				
Synopsis	The purpose of the NIDCD Research Caree	er Enhancement Award for Estab	olished Investigator	rs (K18) program is	to enable

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		established, proven investigators to augm skills to answer questions relevant to the Opportunity Announcement is for basic so "prospective basic science studies involvin and also meet the definition of basic resea prospectively assign human participants to biomedical or behavioral outcomes in hur without specific application towards proce basic experimental study with humans, or with humans led by another investigator, proposed project must be related to the p Centers (ICs) based on their scientific miss applicants proposing to serve as the lead is separate ancillary study to an existing trial independent clinical trial, or proposing to companion NOFOS PAR-24-140 and PAR-2	hearing, balance, smell, taste, v sience experimental studies inve- ing human participants." These s arch. Types of studies that show o conditions (i.e., experimental nans for the purpose of underst esses or products in mind. Appli- proposing to gain research exp must apply to the 'Independent programmatic interests of one o sions. This Notice of Funding O nvestigator of an independent I, as part of their research and o gain research experience in a cl	poice, speech and la plving humans, refe studies fall within th uld submit under th ly manipulate indep tanding the fundam icants not planning perience in a clinical t Clinical Trial Not A or more of the partic pportunity (NOFO) clinical trial, a clinic career development	nguage sciences. T rred to in NOT-OD ne NIH definition of is FOA include stud bendent variables) nental aspects of pl an independent cl trial or basic expe illowed' companion cipating NIH Institu- is designed specifi- cal trial feasibility s t. Applicants not pl	his Funding -18-212 as f a clinical tria dies that and that asses henomena inical trial or rimental study n NOFO. The utes and cally for tudy, or a anning an
1 72078	NIDCD Research Career Enhancer (K18 Independent Clinical Trial No	nent Award for Established Investigators (National Institute on Deafness a Other Communication Disorders/NIH/DHHS	PAR_{JA}	-Sep-2024	Not Specified
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.				
	Contact Telephone	301-496-1804				
	Contact Email	riverara@nidcd.nih.gov				
	Sponsor Website					
	_	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 , 2026 , 09-Feb-2026 , 07-May-2026 , 08-Ju	, 10-Feb-2025 , 07-May-2025 , 0 n-2026 , 07-Sep-2026 , 08-Oct-2)9-Jun-2025 , 07-Se 2026 , 07-Jan-2027 ,	p-2025 , 08-Oct-20 , 08-Feb-2027 , 07-	25 , 07-Jan- May-2027
		The purpose of the NIDCD Research Caree established, proven investigators to augm skills to answer questions relevant to the Funding Opportunity (NOFO) is designed s independent clinical trial, a clinical trial fe	ent or redirect their research p hearing, balance, smell, taste, v specifically for applicants propo	rograms through th oice, speech and la sing research that c	ne acquisition of ne nguage sciences. T does not involve le	ew research his Notice of ading an

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
		permitted to propose research experien ancillary clinical trial as lead investigator				
123922	NIDCD Research Career Enhancer (K18 Clinical Trial Required)	ment Award for Established Investigators	National Institute on Deafness ar Other Communication Disorders/NIH/DHHS	PAR-1/1-	07-Sep-2024	Not Specified
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.				
	Contact Telephone	301-496-1804				
	Contact Email	riverara@nidcd.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 2026 , 09-Feb-2026 , 07-May-2026 , 08-J				
	Synopsis	The purpose of the NIDCD Research Care established, proven investigators to aug skills to answer questions relevant to the Opportunity Announcement (FOA) is des independent clinical trial, a clinical trial f research and career development. Appli experience in a clinical trial led by anoth	ment or redirect their research pro- e hearing, balance, smell, taste, vo signed specifically for applicants p easibility study, or a separate anc cants not planning an independen	ograms through bice, speech and roposing to serv illary study to a bt clinical trial, o	the acquisition of ne l language sciences. T ve as the lead investion existing trial, as par r proposing to gain r	ew research This Funding gator of an t of their esearch
	NIDCD Low Risk Clinical Trials in C Trial Required)	Communication Disorders (R01 Clinical	National Institute on Deafness ar Other Communication Disorders/NIH/DHHS	PAR_{JA}	07-Sep-2024	2,499,995 USD
	Contact Name	Trinh T. Ly, M.D.				
	Contact Telephone	301-435-4085				
	Contact Email	trinh.ly@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 2026 , 05-Feb-2026 , 07-May-2026 , 05-J	5 , 05-Feb-2025 , 07-May-2025 , 09 un-2026 , 07-Sep-2026 , 05-Oct-20	5-Jun-2025 , 07- 026 , 07-Jan-202	Sep-2025 , 05-Oct-20 27)25 , 07-Jan-

SPIN ID	Program Title		Sponsor Name	ponsor Numbe	er Deadline Date	Funding Amount	
	Synopsis	The NIDCD is committed to identifying edisorders by supporting well-designed a (NOFO) supports investigator initiated lot trials must meet ALL the following criter defined Phase III Clinical Trial, have low studies. This NOFO also supports low ris (BESH). These studies fall within the NIH that only one clinical trial be proposed in clinical trials not meeting all the criteria Agreement for Clinical Trials in Commun	nd well-executed clinical trials. This ow risk clinical trials addressing the ia: meet the budget limits of this N risks to subjects, and intends to gat k trials determined to be Basic Scie definition of a clinical trial and me n each NIDCD Clinical Trials in Comp above are referred to companion L	s notice of func mission and re OFO, not requi ther scientific c nce Experimen et the definitio munication Dis	ling opportunity anno search interests of N re FDA oversight, no lata/evidence to info tal Studies involving n of basic research. I orders R01 applicatic	ouncement IDCD. Clinical t an NIH rm subsequen Humans t is advisable on. High risk	
117406	Notice of Special Interest (NOSI): Communication in Minimally Ver Autism	Promoting Language and bal/Non-Speaking Individuals with	National Institute on Deafness an Other Communication Disorders/NIH/DHHS	N() -)(-	05-Sep-2024	Not Specified	
	Contact Name	Holly L. Storkel, Ph.D.					
	Contact Telephone	301-496-5061					
	Contact Email	holly.storkel@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 05-Oct-202 2025 , 05-Apr-2025 , 07-May-2025 , 05-J Jan-2026 , 07-Jan-2026 , 05-Feb-2026 , 1	un-2025 , 16-Jun-2025 , 05-Sep-20	25 , 07-Sep-202	25 , 05-Oct-2025 , 16		
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to encourage applications for research to promote language and communication in autistic individuals who are minimally verbal/non-speaking. Further research is needed to evaluate and tailor existing interventions, develop novel interventions, develop and apply new research designs and methods to intervention efforts, and identify meaningful outcome measures.					
114999	Notice of Special Interest (NOSI): Neural Circuits Underlying Sensor	Fundamental Science Research on the ry Processing	National Institute on Deafness an Other Communication Disorders/NIH/DHHS	NUT-DC-	07-Sep-2024	Not Specified	
	Contact Name	Merav Sabri, Ph.D.					
	Contact Telephone	301-827-0908					
	School of Medicine at	NIH Funding Oppor	tunities Due: Oct 2024			216	

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	merav.sabri@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 2025 , 16-Jun-2025 , 07-Sep-2025 , 05-O			2025 , 07-May-20	25 , 05-Jun-
	Synopsis	The National Institute on Deafness and C from its new strategic plan, in basic and balance, taste and smell. NIDCD encoura mechanistic understanding of the behav cutting-edge technologies and approach imaging, optogenetics, chemogenetics, s expected to integrate appropriate doma sciences, engineering, computational mo and comparative, cross-species projects	mechanistic research on neural ci ges multidisciplinary and innovat ior of neural circuits at cellular an es for recording and modulation of conogenetics, magnetogenetics, p ins of expertise, including but not odeling, statistical analysis, and bi	rcuits underlying se ive projects, from d d sub-second temp of cells and circuits harmacologic modu i limited to biologica	ensory processing iverse teams, to a oral resolution by (e.g., electrophysi ulation). Applicational, chemical and pl	in hearing, dvance a integrating ology, optical ons are hysical
117259	Notice of Special Interest (NOSI): within the NIDCD Mission Areas	Encouraging Women's Health Research	National Institute on Deafness an Other Communication Disorders/NIH/DHHS	N() -) (-	Sep-2024	Not Specified
	Contact Name	Christopher Myers				
	Contact Telephone	301-435-0713				
	Contact Email	myersc@nidcd.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 2025 , 05-Jun-2025 , 16-Jun-2025 , 25-Ju Feb-2026 , 16-Feb-2026 , 25-Feb-2026 ,	n-2025 , 07-Sep-2025 , 05-Oct-20	•		•
	Synopsis	The National Institute on Deafness and C (NOSI) to stimulate research in areas reg to conduct and support research and res smell, voice, speech, and language. As no Strategic Plan NIDCD), research project	arding the health of women with search training in the normal and oted in the recently issued 2023–2	in the scope of NID disordered process 2027 NIDCD Strateg	CD's mission. NID es of hearing, bala ic Plan (2023-202	OCD's mission is nce, taste, 7 NIDCD

PIN ID Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
	the NIDCD mission areas. These projects hormonal, or genetic aspects, behaviora quality of life.				
22020 NIDCD Cooperative Agreement for Disorders (U01 - Clinical Trial Rec	or Clinical Trials in Communication quired)	National Institute on Deafness an Other Communication Disorders/NIH/DHHS	PAR_{JA}	28-Oct-2024	Not Specified
Contact Name	Trinh T. Ly, M.D.				
Contact Telephone	301-435-4085				
Contact Emai	l <u>trinh.ly@nih.gov</u>				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	28-Oct-2024 , 27-Feb-2025 , 27-Jun-2025	5 , 28-Oct-2025 , 27-Feb-2026 , 29-	Jun-2026 , 27-C	oct-2026	
Synopsis	The NIDCD is committed to identifying e supporting well-designed and well-exect between an NIDCD Project Scientist and requires FDA oversight, is intended to fo applications exceeding the annual direct opportunity. These investigator-initiated resulting from a cooperative agreement, opportunity. Low risk clinical trials not m Clinical Trials in Communication Disorde contact Dr. Trinh Ly, prior to submission,	ated clinical trials. This funding opp an Investigator to support a clinica rmally establish efficacy, or has po costs of \$700,000 or more, in cert clinical trials are perceived to ber Only one clinical trial may be prop eeting any of the criteria above ar rs (R01-Clinical Trial Required) PA	portunity suppo al trial that mee otentially higher ain cases, may hefit from close posed per applic re referred to th R-24-051. Inves	rts a cooperative agr ts ANY of the followi risks to participants. also be a criterion fo interaction, oversigh cation submitted to t e companion NIDCD tigators are strongly	eement ng criteria: Clinical trial r this funding t, and guidance his funding Low Risk
23134 RFA-DC-24-007 NIDCD Researc	<u>h Opportunities for New Investigators to</u> 01 Clinical Trial Optional)	National Institute on Deafness an Other Communication Disorders/NIH/DHHS	RFA-DC-	28-Oct-2024	2,495,000 USD
Contact Name	Kelly King, Au.D., Ph.D.				
Contact Telephone	301-402-3458				
	kingke@nidcd.nih.gov				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	28-Oct-2024 , 06-Feb-2025				
		This Notice of Funding Opportunity (NOI are within the scientific mission areas of This program is intended to support Earl groups underrepresented in the health- underrepresented groups (e.g., see NOT institutions to apply. Preliminary data a	the National Institute on Deafnes y Stage and New Investigators fro related sciences. Investigators from -OD-20-031, Notice of NIH's Intere	s and Other Comm m diverse backgrou n diverse backgrou	unication Disorde unds, including the nds, including tho	rs (NIDCD). ose from se from
124315	NIDCD Early Career Research(ECF	() Award (R21 Clinical Trial Optional)	National Institute on Deafness ar Other Communication Disorders/NIH/DHHS	PAR-74-	Oct-2024	375,000 USD
	Contact Name	Bracie Watson, Jr.				
	Contact Telephone	301-402-3458				
	Contact Email	watsonb@nidcd.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	17-Oct-2024 , 19-Feb-2025 , 17-Jun-202	5 , 17-Oct-2025 , 18-Feb-2026 , 17	-Jun-2026 , 19-Oct-	2026 , 17-Feb-202	27
	Synopsis	The NIDCD Early Career Research (ECR) / who are beginning to establish an indep- research must be focused on one or mor- hearing, balance, smell, taste, voice, spe- types of projects including secondary an research methodology; translational rese Irrespective of the type of project, the in Investigator(s) (PD(s)/PI(s)) to obtain suf-	endent research career. It cannot re of the areas within the biomedi ech, or language. The NIDCD ECR alysis of existing data; small, self- earch; outcomes research; and de itent of the NIDCD ECR Award R21	be used for thesis of cal and behavioral Award R21 grant m contained research velopment of new . is for the Program	or dissertation res- scientific mission of echanism support projects; develop research technolo Director(s)/Princi	earch. The of the NIDCD s different ment of gy.
124298	NIDCD Mentored Career Develop Au.D./Ph.D. Audiologists (K01 Ind with Humans Required)	ment Award for Postdoctorate ependent Basic Experimental Studies	National Institute on Deafness ar Other Communication Disorders/NIH/DHHS	PAR-14-	Sep-2024	315,000 USD
	Contact Name	Alberto L Rivera-Rentas Ph D				

Contact Name Alberto L. Rivera-Rentas, Ph.D.



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Telephone	301-496-1804				
Contact Emai	riverara@nidcd.nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 , 2026 , 13-Feb-2026 , 07-May-2026 , 15-Ju				
Synopsis	The purpose of the NIDCD Mentored Care support comprehensive and rigorous post behavioral, or clinical sciences of promisin independent investigators in scientific hea Opportunity (NOFO) is designed specifical clinical trial, a clinical trial feasibility study career development. Applicants not plann clinical trial led by another investigator, m	doctoral research and career do by Au.D./Ph.D. audiologists who alth-related research fields relev ly for applicants proposing to se , or a separate ancillary study to ing an independent clinical tria	evelopment experie have the potential vant to NIDCD's mis erve as the lead inv o an existing trial, a l, or proposing to g	ences in the biome I to become produc ssion. This Notice o restigator of an ind as part of their rese	dical, ctive, f Funding ependent arch and
124297 NIDCD Mentored Career Develop Au.D./Ph.D. Audiologists (K01 Cli	picel Trial Required)	National Institute on Deafness a Other Communication Disorders/NIH/DHHS	PAR-14-	-Sep-2024	315,000 USD
Contact Name	Alberto L. Rivera-Rentas, Ph.D.				
Contact Telephone	301-496-1804				
Contact Emai	riverara@nidcd.nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 , 2026 , 13-Feb-2026 , 07-May-2026 , 15-Ju		-	•	
Synopsis	The purpose of the NIDCD Mentored Care support comprehensive and rigorous post behavioral, or clinical sciences of promisin independent investigators in scientific hea Announcement (FOA) is designed specifica clinical trial, a clinical trial feasibility study	doctoral research and career do ng Au.D./Ph.D. audiologists who alth-related research fields relev ally for candidates proposing re	evelopment experie have the potential vant to NIDCD's mis search that does no	ences in the biome I to become produc ssion. This Funding ot involve leading a	dical, ctive, Opportunity in independen

SPIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	propose a research experience in a clini study to an ongoing clinical trial as lead Required or for PAR-21-087 for Indeper	investigator, should apply to the c	ompanion FOA	PAR-21-085 for Clinica	
124299 NIDCD Mentored Career Develop Au.D./Ph.D. Audiologists (K01 Inc	oment Award for Postdoctorate dependent Clinical Trial Not Allowed)	National Institute on Deafness ar Other Communication Disorders/NIH/DHHS		07-Sep-2024	315,000 USD
Contact Name	e Alberto L. Rivera-Rentas, Ph.D.				
Contact Telephone	301-496-1804				
Contact Emai	l <u>riverara@nidcd.nih.gov</u>				
Sponsor Website					
Program UI	Link to program URL				
Deadline Dates (ALL	07-Sep-2024 , 17-Oct-2024 , 07-Jan-202 2026 , 13-Feb-2026 , 07-May-2026 , 15-				
Synopsis	The purpose of the NIDCD Mentored C support comprehensive and rigorous po- behavioral, or clinical sciences of promi- independent investigators in scientific h Opportunity (NOFO) is designed specific clinical trial, a clinical trial feasibility stu propose research experience in a clinical clinical trial as lead investigator, should	ostdoctoral research and career de sing Au.D./Ph.D. audiologists who health-related research fields releva cally for applicants proposing resea dy, or an ancillary study to a clinica al trial led by a mentor or co-mento	velopment expe have the potent ant to NIDCD's r arch that does n al trial. Applican or. Those propos	eriences in the biomed ial to become produc nission. This Notice of ot involve leading an i ts to this NOFO are pe sing a clinical trial or a	lical, tive, Funding ndependent ermitted to
27101 Dissemination and Implementati Conference (U13 Clinical Trial No	ion Research in Communication Disorders ot Allowed)	National Institute on Deafness ar Other Communication Disorders/NIH/DHHS	RFA-DC-	25-Oct-2024 [LOI/Pre App]	- 100,000 USD
Contact Name	Holly L. Storkel, Ph.D.				
Contact Telephone	301-496-5061				
Contact Emai	l <u>holly.storkel@nih.gov</u>				
Sponsor Website					
•					

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	25-Oct-2024 [LOI/Pre-App], 25-Nov-2024 NIDCD invites applications to organize and research skills applicable to all NIDCD miss conference or scientific meeting is defined meeting where persons assemble in perso explore or clarify a defined subject, proble mechanism to support recipient sponsored an assistance mechanism used when there involvement means that, before and after project activities.	ion areas, specifically hearing, b l as a gathering, symposium, ser n or meet virtually to coordinat m, or area of knowledge. This is d and directed meetings, confer will be substantial Federal scie	palance, taste, sm minar, workshop e, exchange, and s a U13 cooperativ rences, and works entific or program	ell, voice, speech, ar or any other organiz disseminate informa ve agreement confer hops. Cooperative a matic involvement.	nd language. A ed and formal ation or to rence grant greements are Substantial
106846 NIDCD Clinical Research Center G	irant (P50 Clinical Trial Optional) C	lational Institute on Deafness a Other Communication Disorders/NIH/DHHS	$P \Delta R_{-} / f_{-}$	9-Oct-2024	7,500,000 USD
Contact Name	Lana Shekim, Ph.D.				
Contact Telephone	301-496-5061				
Contact Email	shekiml@nidcd.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Oct-2024 , 06-Feb-2025				
Synopsis	The National Institute on Deafness and Otl Center Grants designed to advance the dia disorders. For this announcement, Clinical or data/tissues from individuals with a con studies of the prevention, pathogenesis, p disorder of hearing, balance, smell, taste, y not required to (optional).	agnosis, prevention, treatment, Research is defined as research nmunication disorder. Examples athophysiology, diagnosis, treat	and amelioration involving individ s of such research tment, manageme	of human communi uals with communic include but are not ent or epidemiology	cation ation disorders limited to, of a disease or
RFA-DA-25-022 Advancing Tech122290Pharmacological, Gene Editing, a Mechanistic or Therapeutic Reservation	nd other Cargoes for HIV and SUD	lational Institute on Drug buse/NIH/DHHS	RFA-DA- 25-022 [(5-Oct-2024 Optional][LOI/Pre- pp]	Not Specified
Contact Name	Kathleen Borgmann, Ph.D.				

SPIN ID Program Title			Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
Contact	Telephone	301-594-6561				
Cor	ntact Email	Kahtleen.Borgmann@nih.gov				
Spons	or Website					
Pro	ogram URL	Link to program URL				
Deadline I	Dates (ALL)	15-Oct-2024 [Optional][LOI/Pre-App], 15	-Nov-2024			
Synopsis or other cargoes for HIV and SUD mechanistic research.						gene editing,
			National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 25-021	15-Oct-2024 [Optional][LOI/Pre- App]	Not Specified
Con	tact Name	Sunila Nair, PhD				
Contact	Telephone	301-827-6832				
Cor	ntact Email	sunila.nair@nih.gov				
Sponse	or Website					
Pro	ogram URL	Link to program URL				
Deadline I	Dates (ALL)	15-Oct-2024 [Optional][LOI/Pre-App], 15	-Nov-2024			
	Synopsis i	The purpose of this notice of funding opp effect of HIV and/or anti-retroviral thera individuals with substance use/misuse, the mechanisms.	py on the growth, development	and functioning	of the placenta in pre	gnant
111212 RFA-DA-23-008 Stim Recurring Epidemics (F			National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 23-008	13-Oct-2024 [Optional][LOI/Pre- App]	Not Specified
Con	tact Name	Richard A. Jenkins PhD				
Contact	Telephone	301-443-1923				
Cor	ntact Email	enkinsri@mail.nih.gov				
Sponse	or Website					
Pro	ogram URL <mark>I</mark>	Link to program URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	13-Oct-2024 [Optional][LOI/Pre-App], 12- The primary goal of this Funding Opportu care outcomes among people who use st methamphetamine and cocaine derivativ Applications responding to this FOA shou stimulant use and HIV or (2) develop and episodic users, while also reducing HIV ris to meet the unique needs of target popu orientation, and co-occurring conditions.	inity Announcement (FOA) is to s imulants, encompassing a range res), including stimulant use co-o ld: (1) implement evidence-base test new intervention approache sk and/or improving HIV care out	of stimulant use ccurring with the d approaches tha es that can reduc tcomes. Interven	(from episodic to pe use of opioids and/o at address the interso e stimulant use, part tion approaches sho	rsistent, or other drugs. ection of ticularly among uld be tailored
112875		n Community-Engaged Research at	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 23-032 [.5-Oct-2024 Optional][LOI/Pre- App]	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	<u>ketz@nih.gov</u>	t (FOA) is a part of NIDA's Racial have a major impact in identifyi e misuse, with a goal of preventi use, addiction, and related healt ances in this scientific area by en be submitted by collaborative cor sues prioritized by the relevant of trate, based on the strength of the	ng, developing, i ing, reducing, or h consequences isuring relevant r mmunity partner communities. No e logic, a compel	mplementing, or test eliminating disparitie including HIV. Comr esearch questions w ed investigative tean preliminary data are ing potential to prod	ting strategies es in racial and nunity ith immediate ns who will required.
112854		1 (Ommunity-Engaged Research (RU)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 23-013	.4-Oct-2024 Optional][LOI/Pre- App]	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber Deadline Date	Funding Amount
	Contact Name	Kathy Etz, PhD				
	Contact Telephone	301-402-1749				
	Contact Email	<u>ketz@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	14-Oct-2024 [Optional][LOI/Pre-App], 14	I-Nov-2024			
	Synopsis	This Funding Opportunity Announcemen applications to conduct research that wi to improve outcomes related to substan and/or ethnic communities insubstance research can facilitate rapid advances in applicability. As such, applications must conduct research projects that address is However, projects must clearly demonst outcomes	Il have a major impact in identify ce misuse, with a goal of preven use, addiction, and related healt this scientific area by ensuring r be submitted by collaborative co ssues prioritized by the relevant	ving, developing ting, reducing, o ch consequence elevant researc ommunity partn communities. N	g, implementing, or test or eliminating dispariti s, including HIV. Comm h questions with imme ered investigative tea lo preliminary data are	sting strategies ies in racial nunity engage ediate ms who will e required.
112855	and Substance Use: Novel Approa	hing Equity at the Intersection of HIV aches to Address HIV Related Health and/or Ethnic Populations (R01 Clinical	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 23-061	15-Oct-2024 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Sheba K. Dunston, EdD				
	Contact Telephone	301-402-1526				
	Contact Email	Sheba.Dunston@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Oct-2024 [Optional][LOI/Pre-App], 14	I-Nov-2024			
	Synopsis	This Funding Opportunity Announcemen promoting racial equity in NIDA's researce intervention research on structural facto influences that lead to inequities at the i	ch portfolio. The purpose of this ors, organizational practices, poli	FOA is to stimu cies, and other	late new observationa social, cultural, and co	al and ontextual

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
		minority populations affected by persist identity (e.g., race, ethnicity, gender, sea another is encouraged.				
113590	Substance Use: Novel Approache	ing Equity at the Intersection of HIV and s to Address HIV Related Health and/or Ethnic Populations (R34 Clinical	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 23-062	.5-Oct-2024 Optional][LOI/Pre- App]	450,000 USD
	Contact Name	Sheba K. Dunston, EdD				
	Contact Telephone	301-402-1526				
	Contact Email	<u>Sheba.Dunston@nih.gov</u>				
	Sponsor Website					
	•	Link to program URL				
	Deadline Dates (ALL)	15-Oct-2024 [Optional][LOI/Pre-App], 14	1-Nov-2024			
	Synopsis	This Funding Opportunity Announcemer promoting racial equity in NIDA's resear structural factors, organizational practic inequities at the intersection of HIV and by persistent HIV disparities. Research the gender, sexual orientation, gender ident	ch portfolio. The purpose of this f es, policies, and other social, cult substance use among underserve nat addresses the multiple dimen	FOA is to support ural, and context ed racial and/or e sions of individua	pilot or feasibility re ual influences that le thnic minority popul ils' identity (e.g., rac	search on ad to ations affected e, ethnicity,
112861		arch at Minority Serving Institutions on erlying the Impact of Structural Racism (R61/R33 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 23-029 [.5-Oct-2024 Optional][LOI/Pre- App]	2,000,000 USD
	Contact Name	Vani Pariyadath, Ph.D.				
	Contact Telephone					
	Contact Email	vani.pariyadath@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Oct-2024 [Optional][LOI/Pre-App], 14	1-Nov-2024			

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	Synopsis	This Funding Opportunity Announcemer applications that are exploratory/develo investigate their impact on neurocogniti This FOA solicits applications from mino	pmental in nature and seek to pa on, with an emphasis on reducin	arse the complex g SUD risk and ir	effects of structural forming preventative	racism and
112859	RFA-DA-23-028 NIDA REI: Resea Underlying the Impact of Structur Trajectory (R61/R33 Clinical Trial		National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 23-028	15-Oct-2024 [Optional][LOI/Pre- App]	2,000,000 USD
		Vani Pariyadath, Ph.D.				
	Contact Telephone					
		vani.pariyadath@nih.gov				
	Sponsor Website					
	-	Link to program URL 15-Oct-2024 [Optional][LOI/Pre-App], 14				
	Synopsis	This Funding Opportunity Announcemer applications that are exploratory/develo investigate their impact on neurocogniti	pmental in nature and seek to pa	arse the complex	effects of structural	racism and
112862		l Equity Visionary Award Program for itutions on Substance Use and Racial)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 23-031	15-Oct-2024 [Optional][LOI/Pre- App]	3,500,000 USD
	Contact Name	Vani Pariyadath, Ph.D.				
	Contact Telephone	301-443-3209				
	Contact Email	vani.pariyadath@nih.gov				
	Sponsor Website					
	•	Link to program URL				
	Deadline Dates (ALL)	15-Oct-2024 [Optional][LOI/Pre-App], 14				
	Synopsis	This Funding Opportunity Announcemer promoting racial equity in NIDA's resear career or established scholars who self-i	ch portfolio. This announcement	invites application	ons supporting indep	endent, early

SPIN ID Program Title		Sponsor Name	Sponsor Num	ber Deadline Date	Funding Amount
	experts with the skills to make exception ethnic minority groups that experience supports transformative, boundary-push peer review process. This FOA is a limite Section III (below). All institutions are el	poorer outcomes related to sub ning applications that may be ri d-competition annoucement, c	ostance use and s sky or at a stage open to institutio	ubstance use disorders too early to fare well ir ns meeting the eligibili	s. This award the traditiona
	EI: Racial Equity Visionary Award Program for Jse and Racial Equity (DP1 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 23-026	15-Oct-2024 [Optional][LOI/Pre- App]	3,500,000 USD
Conta	ct Name Aria Davis Crump, Sc.D.				
Contact Te	lephone 301-435-0881				
Conta	act Email aria.crump@nih.gov				
Sponsor	Website				
Prog	ram URL Link to program URL				
Deadline Da	tes (ALL) 15-Oct-2024 [Optional][LOI/Pre-App], 14	4-Nov-2024			
	This Funding Opportunity Announcement promoting racial equity in NIDA's resear career or established scholars who self-it Synopsis with the skills to make exceptionally cre minority groups that experience poorer transformative, boundary-pushing applit review process.	ch portfolio This announceme dentify as health equity, health ative contributions to the study outcomes related to substance	ent invites applica disparities, or so of equity for un use and substan	tions supporting indep ocial determinants of h derserved U.S. racial ar ce use disorders. This a	endent, early ealth experts nd/or ethnic award support
	ay of Autophagy Regulated Cell Death and HIV ce Use Disorders (R21 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 25-010	14-Oct-2024 [Optional][LOI/Pre- App]	Not Specified
Conta	ct Name Shang-Yi Anne Tsai, PhD				
Contact Te	lephone 301-827-5842				
.	act Email <u>stsai@nih.gov</u>				
Conta					
Conta Sponsor					

PIN ID Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
) 14-Oct-2024 [Optional][LOI/Pre-App], 1 The notice of funding opportunity (NOF autophagy and to identify autophagy pa s comorbities in the context of addictive s effects of compounds known to interfer clearly address the intersection between	O) aims to support studies to exp othways that can be exploited to o substance use. The NOFO invites e with autophagy pathways on H	control HIV infec mechanistic stuc	tion and pathogenesis lies and preclinical stu	s of Idies testing
	utophagy Regulated Cell Death and HIV Disorders (R01 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 25-009	14-Oct-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Nam	e Shang-Yi Anne Tsai, PhD				
Contact Telephon	e 301-827-5842				
Contact Ema	il <u>stsai@nih.gov</u>				
Sponsor Websit	e				
Program UR	L Link to program URL				
Deadline Dates (ALL) 14-Oct-2024 [Optional][LOI/Pre-App], 14	4-Nov-2024			
Synopsi	The notice of funding opportunity (NOF autophagy and to identify autophagy pa s comorbities in the context of addictive s effects of compounds known to interfer clearly address the intersection between	thways that can be exploited to o substance use. The NOFO invites in e with autophagy pathways on H	control HIV infec mechanistic stuc	tion and pathogenesis lies and preclinical stu	s of Idies testing
21015 Population Assessment of Tobac Access (X01)	co and Health (PATH) Study Biospecimen	National Institute on Drug Abuse/NIH/DHHS	PAR-24- 027	31-Oct-2024	Not Specified
Contact Nam	e Heather L. Kimmel, Ph.D.				
Contact Telephon	e 301-443-6504				
Contact Ema	ll <u>heather.kimmel@nih.gov</u>				
Sponsor Websit	2				
Program UR	L <u>Link to program URL</u>				

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	per Deadline Date	Funding Amount
	Synopsis	The Population Assessment of Tobacco biospecimens (urine, plasma, serum, an and health outcomes associated with to allows investigators to apply for access Study and this resource may be found o (NAHDAP) website, part of the Inter-Un (https://nida.nih.gov/research/nida-reso access).	d genomic DNA) and related reservance of the biospecimens from the PAT n the at the University of Michiga iversity Consortium for Political and	arch data on be of funding oppo IH Study Inforn n's National Ad nd Social Reseau	haviors, attitudes, bio ortunity (NOFO) nation about the PATH diction & HIV Data Arc rch's (ICPSR) website	hive Program
124661	RFA-DA-25-005Research on the HIV and Substance Use (R21 Clini	e Neuro-Immune Axis in the context of cal Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 25-005	13-Oct-2024 [Optional][LOI/Pre- App]	400,000 USD
	Contact Name	Kiran Vemuri, Ph.D.				
	Contact Telephone	301-435-4446				
	Contact Email	<u>kiran.vemuri@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	13-Oct-2024 [Optional][LOI/Pre-App], 1	3-Nov-2024			
	Synopsis	The purpose of this notice of funding op neuroimmune networks, communicatio and substance use. This NOFO will also our knowledge of the regulatory mecha disorder comorbidity. Exploratory proje conceptualized premise founded with a announcement RFA-DA-25-004.	n pathways, and targets that reside support research on the discovery nisms by which neuroimmune int cts are appropriate for this NOFO	de within neuro / of novel modu eractions contr . Applicants wit	immune axes, in the c latory probes/tools th ibute to HIV and subst h projects testing a ful	ontext of HIV at can advance ance use ly
124658	RFA-DA-25-004Research on the HIV and Substance Use (R01 Clini	e Neuro-Immune Axis in the context of cal Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 25-004	13-Oct-2024 [Optional][LOI/Pre- App]	Not Specified
	Contact Name Contact Telephone	Kiran Vemuri, Ph.D. 301-435-4446				

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber Deadline Date	Funding Amount
	Contact Email	kiran.vemuri@nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	13-Oct-2024 [Optional][LOI/Pre-App], 13				
	Synopsis	The purpose of this notice of funding op neuroimmune networks, communication and substance use. This NOFO will also s our knowledge of the regulatory mechar disorder comorbidity. Applications testin appropriate for this NOFO. Exploratory r DA-25-005.	n pathways, and targets that residupport research on the discovery nisms by which neuroimmune int ng a fully conceptualized premise	de within neuro y of novel modu eractions contr founded with a	oimmune axes, in the c ilatory probes/tools the ibute to HIV and substand adequate preliminary of	ontext of HIV at can advance ance use data are
	RFA-DA-25-056 Establishing a C	Center for the Advancement of	National Institute on Dour		13-Oct-2024	0 500 000
126229	Substance Use Disorder (SUD) Ph Not Allowed)	armacotherapeutics (U54 Clinical Trials	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 25-056	[Optional][LOI/Pre- App]	9,500,000 USD
	Contact Name	Tam Nguyen, Ph.D.				
	Contact Telephone					
	•	tam.nguyen@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	13-Oct-2024 [Optional][LOI/Pre-App], 13	3-Nov-2024			
	Synopsis	The purpose of this notice of funding op formal product development for new su through initial experiments via technical	bstance use disorder (SUD) pharr			
		e: Brain-Behavior Quantification and e and Integrative Models of Behavior at al Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 24-040	10-Sep-2024 [Optional][LOI/Pre- App]	8,000,000 USD
	Contact Name	Holly Moore, PhD				

SPIN ID Program Title		Sponsor Name	Sponsor Numb	per Deadline Date	Funding Amount
	I <u>holly.moore@nih.gov</u>				
Sponsor Website					
Deadline Dates (ALL	L <u>Link to program URL</u> 10-Sep-2024 [Optional][LOI/Pre-App], 09- [Optional][LOI/Pre-App], 09-Oct-2026	Oct-2024 , 10-Sep-2025 [Optior	nal][LOI/Pre-App	o], 09-Oct-2025 , 10-So	ep-2026
Synopsi	This Brain-Behavior Quantification and Sy together transdisciplinary teams and aim a invasive, multi-dimensional, high-resolution capture of dynamic environmental data; 2 neural and environmental data; and 3) dev understanding of behavior as a complex d integrate synchronously recorded neural of developed with the support of the NIH BR proposing basic research involving human reveal and understand fundamental princi- research focused on specific diseases or di- proposing research exclusively in non-hum NOFO requires a Plan for Enhancing Divers peer review evaluation. Applications that Applicants are strongly encouraged to rea	to 1) develop, validate, and app on objective measurement of be 2) develop advanced analytic ap velop and test new theoretical a ynamic system. Proposed proje data and/or inform existing mod AIN Initiative. This BRAIN Initiat subjects, including observation iples underlying behavioral func- isorders, nor research limited to nan animal models should apply se Perspectives (PEDP), which w fail to include a PEDP will be co	ly cutting-edge ehavior at the o proaches to inte- and computatio cts are expected dels of neurobe- tive NOFO is spe- nal studies and s ction. This NOFC of the use of non- y under the com- y under the com- vill be assessed nsidered incom	tools and methods fo rganismal level, with s egrate multidimension nal models aiming to d to be designed with havioral function, such ecifically soliciting app econdary data analys D is not intended to st human animal mode spanion NOFO, RFA-D as part of the scientifi plete and will be with	r minimally synchronous hal behavioral, advance the capacity to h as those lications is, that aims to imulate s. Applications A-24-041. This c and technica drawn.
RFA-DA-24-041 BRAIN Initiativ126211Synchronization - Transformativthe Organismal Level (U01 Clinic)	e and Integrative Models of Behavior at	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 24-041	10-Sep-2024 [Optional][LOI/Pre- App]	8,000,000 USD
Contact Name	e Holly Moore, PhD				
Contact Telephone	e 301-827-7376				
Contact Emai	I <u>holly.moore@nih.gov</u>				
Sponsor Website	2				
Program URI	L Link to program URL				
Deadline Dates (ALL	10-Sep-2024 [Optional][LOI/Pre-App], 09- [Optional][LOI/Pre-App], 09-Oct-2026	Oct-2024 , 10-Sep-2025 [Optior	nal][LOI/Pre-App	o], 09-Oct-2025 , 10-So	ep-2026

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Brain-Behavior Quantification and human animal models that bring togethe tools and methods for minimally invasive level, with synchronous capture of data f approaches to integrate multidimensional theoretical and computational models ain projects are expected to be designed with existing models of neurobehavioral funct NOFO is intended for applications using r of human subjects data as a significant co requires a Plan for Enhancing Diverse Per review evaluation. Applications that fail t are strongly encouraged to read the NOF	r transdisciplinary teams and air , multi-dimensional, high-resolu- rom the dynamic environment o al behavioral, neural and environ ming to advance understanding h the capacity to integrate synch ion, such as those developed wir ion-human animal models. Appl omponent should submit under t spectives (PEDP), which will be a o include a PEDP will be conside	n to 1) develop, val tion measurement of the organism; 2) of mental data; and 3 of behavior as a con pronously recorded th the support of the licants proposing re- the companion NOI assessed as part of red incomplete and	idate, and apply cu of behavior at the develop advanced) develop and test nplex dynamic sys neural data and/o e NIH BRAIN Initia search involving h O RFA-DA-24-040 the scientific and t I will be withdrawn	utting-edge organismal analytic new tem. Proposed r inform tive. This umans or use . This NOFO echnical peer n. Applicants
111673			National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 22-058 07	Sep-2024	Not Specified
		Olivier Berton, Ph.D.				
	Contact Telephone	301-827-7771 Olivier.berton@nih.gov				
	Sponsor Website					
	•	Link to program URL				
	-	07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 2025 , 07-May-2025 , 05-Jun-2025 , 12-Ju Jan-2026				
	Synopsis	The mission of the Division of Neuroscier human research aimed at identifying the across the lifespan and to guide treatmer on the cellular mechanisms and circuitry the regulation and plasticity of neurotran to, and/or withdrawal from, addictive sul interactions and their modification by sul substance use and SUD, and 5) neuroimr	causes and consequences of sub at strategies. The Integrative New that underlie substance use and smitter and neuromoduatory sy ostances, 2) the study of substar ostance use and SUD 4) neuroen	ostance use and sub uroscience (IN) Brain SUD. Research sup stems induced by co ince-induced neurot docrine modulation	ostance use disord nch within DNB sup ported by the Bran hronic or intermite pxicity, 3) neuron-p n of neural systems	ers (SUD) oports research nch covers: 1) tent exposure glia s in relation to

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		induced neuroinflammation.				
115450		Pharmacogenomic Approaches to e Disorder (SUD) Treatment Strategies, A	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-001 07	7-Sep-2024	Not Specified
	Contact Name	Guifang Lao, Ph.D.				
	Contact Telephone	301-827-5931				
	Contact Email	laog@nih.gov				
	Sponsor Website					
	Program URL					
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-202 2025 , 07-Sep-2025 , 05-Oct-2025 , 16-C		-)25 , 16-Jun-
		2020,0,000 2020,00 000 2020,20 0		,	, ,	
	Synopsis	NIDA is interested in receiving research	proposals focusing on studying p	harmacogenomics	in PLWH with SUD	as a crucial
104862	Notice of Special Interest (NOSI):	NIDA is interested in receiving research	proposals focusing on studying p e, in the path of personalized car National Institute on Drug	harmacogenomics e for HIV and drug NOT-DA-	in PLWH with SUD	Not
104862	Notice of Special Interest (NOSI): Computational Neuroscience	NIDA is interested in receiving research step in the science of Precision Medicine Advancing HIV/AIDS Research through	proposals focusing on studying p e, in the path of personalized car	harmacogenomics e for HIV and drug	in PLWH with SUD abuse	
104862	Notice of Special Interest (NOSI): Computational Neuroscience Contact Name	NIDA is interested in receiving research step in the science of Precision Medicine Advancing HIV/AIDS Research through Yu (Woody) Lin	proposals focusing on studying p e, in the path of personalized car National Institute on Drug	harmacogenomics e for HIV and drug NOT-DA-	in PLWH with SUD abuse	Not
104862	Notice of Special Interest (NOSI): Computational Neuroscience Contact Name Contact Telephone	NIDA is interested in receiving research step in the science of Precision Medicine Advancing HIV/AIDS Research through Yu (Woody) Lin 301-435-1318	proposals focusing on studying p e, in the path of personalized car National Institute on Drug	harmacogenomics e for HIV and drug NOT-DA-	in PLWH with SUD abuse	Not
104862	Notice of Special Interest (NOSI): Computational Neuroscience Contact Name Contact Telephone Contact Email	NIDA is interested in receiving research step in the science of Precision Medicine Advancing HIV/AIDS Research through Yu (Woody) Lin 301-435-1318 ylin1@mail.nih.gov	proposals focusing on studying p e, in the path of personalized car National Institute on Drug	harmacogenomics e for HIV and drug NOT-DA-	in PLWH with SUD abuse	Not
104862	Notice of Special Interest (NOSI): Computational Neuroscience Contact Name Contact Telephone Contact Email Sponsor Website	NIDA is interested in receiving research step in the science of Precision Medicine Advancing HIV/AIDS Research through Yu (Woody) Lin 301-435-1318 <u>ylin1@mail.nih.gov</u>	proposals focusing on studying p e, in the path of personalized car National Institute on Drug	harmacogenomics e for HIV and drug NOT-DA-	in PLWH with SUD abuse	Not
104862	Notice of Special Interest (NOSI): Computational Neuroscience Contact Name Contact Telephone Contact Email Sponsor Website Program URL	NIDA is interested in receiving research step in the science of Precision Medicine Advancing HIV/AIDS Research through Yu (Woody) Lin 301-435-1318 ylin1@mail.nih.gov	proposals focusing on studying p e, in the path of personalized car National Institute on Drug Abuse/NIH/DHHS	harmacogenomics e for HIV and drug NOT-DA-	in PLWH with SUD abuse	Not

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
126763	Combined Neuromodulation and Development for Stimulant Use D Phenotype (U01 Clinical Trial Req	isorder (StUD) Enriched for Vulnerable	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 25-057	27-Oct-2024 [Optional][LOI/Pre- App]	2,500,000 USD
	Contact Name	Tanya Ramey				
	Contact Telephone	301-827-5944				
	Contact Email	tanya.ramey@nih.gov				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	27-Oct-2024 [Optional][LOI/Pre-App], 27	7-Nov-2024			
	Synopsis	behavioral treatment as a component for outcomes in StUD, the objective is to tar high levels of impulsivity, compulsivity, a treatment modalities combinations: pair magnetic stimulation, transcranial direct focused ultrasound, and others) with eit cognitive behavioral therapy) or novel tr and Drug Administration (FDA) approval treatments and/or combination product	rget patients with vulnerable phe and cognitive dysfunction. Moreo ring non-invasive neuromodulatio t current stimulation, vagal stimu ther known efficacious behavioral reatments. Applications should p process, with the ultimate goal of	notype including wer, this NOFO o on (including, bu lation, alternatin l interventions (olan to move dev	g those with reported concentrates on advar t not limited to transc ng current stimulation e.g., contingency man vices to their next step	qualitatively ncing cranial n, low-intensity agement, o in the Food
126634		udies to Investigate the Interrelationship Rhythms and Substance Use Disorders vith Humans Required)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 25-044	29-Sep-2024 [Optional][LOI/Pre- App]	1,500,000 USD
	Contact Name	Sunila Nair, PhD				
	Contact Telephone	301-827-6832				
	Contact Email	<u>sunila.nair@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	29-Sep-2024 [Optional][LOI/Pre-App], 29	9-Oct-2024			
	Synopsis	The purpose of this FOA is to support ba	sic science experimental studies	involving humar	ns to expand our know	/ledge of

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	per Deadline Date	Funding Amount
		the interrelationships between sleep/cir offer insights into the fundamental proce implications for managing risks associate therapeutics. This Notice of Funding Opp this is a PEDP opportunity to include the experimental studies involving humans, science studies involving human particip definition of basic research. Types of stu assign human participants to conditions or behavioral outcomes in humans for th application towards processes or product	esses that link SUDs to sleep/circa ed with developing SUDs and/or ic portunity (NOFO) requires a Plan f mandatory PEDP language throu referred to in the NIH Grants Poli ants. "These studies fall within th dies that should be submitted un (i.e., experimentally manipulate i he purpose of understanding the f cts in mind. Studies conducted with	adian rhythms a dentifying new for Enhancing D gh out the cont cy Statement S de NIH definition der this NOFO i ndependent va fundamental as th specific appli	and vice-versa, and ma targets for prevention Diverse Perspectives (P cent. This NOFO is for P ection 4.1.3.1 as "proson of a clinical trial and nclude studies that pr riables) and that assess pects of phenomena v cations toward process	y also have and EDP).Check if basic science pective basic also meet the ospectively is biomedical vithout specific ises or
126635		udies to Investigate the Interrelationship Rhythms and Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 25-045	29-Sep-2024 [Optional][LOI/Pre- App]	1,500,000 USD
	Contact Name	Sunila Nair, PhD				
	Contact Telephone	301-827-6832				
	Contact Email	<u>sunila.nair@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	29-Sep-2024 [Optional][LOI/Pre-App], 29	9-Oct-2024			
	Synopsis	The purpose of this FOA is to support resinterrelationship between sleep/circadia insights into the fundamental processes have implications for managing risks assorble therapeutics. This Notice of Funding Op	in rhythms and substance use dis that link SUDs to disorders of slee ociated with developing SUDs and	orders (SUDs). ep/circadian rh d/or identifying	These mechanistic stury ythms and vice-versa, new targets for preve	dies will offer and may also ntion and
117589		e Research on Substance Use Disorders dies with Humans (BESH) Required)	National Institute on Drug Abuse/NIH/DHHS	PAR-23- 158	09-Oct-2024	Not Specified
	Contact Name Contact Telephone	Vani Pariyadath, Ph.D. 301-443-3209				
		NIH Eunding Oppor	tunities Due: Oct 2024			226

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Emai	l vani.pariyadath@nih.gov				
Sponsor Website	2				
Program URI	Link to program URL				
Deadline Dates (ALL)) 09-Oct-2024 , 13-Mar-2025 , 20-Jun-202	5 , 09-Oct-2025 , 13-Mar-2026			
Synopsis	This Notice of Funding Opportunity (NOI research applications that are explorator mechanisms underlying substance use d use. This NOFO is for basic science exper basic science studies involving human pa- meet the definition of basic research. Ty prospectively assign human participants that assess biomedical or behavioral out phenomena without specific application toward processes or products in mind sh Research on Substance Use Disorders (Re research approach, applicants are encour Grant (Parent R01 Basic Experimental St	ry and developmental in nature lisorders (SUD), including fundan rimental studies involving humar articipants." These studies fall wi pes of studies that should be sul to conditions (i.e., experimental comes in humans for the purpos towards processes or products in nould submit under the compani 61/R33 Clinical Trial Optional) P/ uraged to apply under a different	and focus on unders nental circuitry and h ns, referred to in NO ithin the NIH definiti bmitted under this N Ily manipulate indep se of understanding in mind. Studies con on NOFO - Explorato AR-23-157. For proje	standing the neuro behavior relevant T-OD-18-212 as "p ion of a clinical tria IOFO include stud bendent variables) the fundamental a ducted with speci- pry Clinical Neuros ects not requiring a	biological to substance prospective al and also ies that and studies aspects of fic application cience a phased
117587 Exploratory Clinical Neuroscience (R61/R33 Clinical Trial Optional)	e Research on Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	PAR-23- 157 09-	-Oct-2024	Not Specified
Contact Name	Vani Pariyadath, Ph.D.				
Contact Telephone	301-443-3209				
Contact Emai	l <u>vani.pariyadath@nih.gov</u>				
Sponsor Website	٤				
Program URI	Link to program URL				
Deadline Dates (ALL) 09-Oct-2024 , 13-Mar-2025 , 20-Jun-202	5 , 09-Oct-2025 , 13-Mar-2026			
Synopsis	This Notice of Funding Opportunity (NOI research applications that are explorato mechanisms underlying substance use d	ry and developmental in nature	and focus on unders	tanding the neuro	biological

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	per Deadline Date	Funding Amount
		on Substance Use Disorders (R61/R33 B a phased research approach, applicants 183 "Research Project Grant (Parent R0	are encouraged to apply under a			•
104182	Notice of Special Interest (NOSI): Elucidate Disease Pathology and Addiction	Advanced Computational Approaches to Identify Novel Therapeutics for	² National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-004	07-Sep-2024	Not Specified
	Contact Name	Susan Wright, Ph.D.				
	Contact Telephone	301-402-6683				
	Contact Email	<u>susan.wright@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-202	4 , 07-Jan-2025			
	Synopsis	The purpose of this Notice is to inform p in grant applications that will develop o relationships in ways that will rapidly ac use disorder (SUD) drug discovery and in approaches in one or more of the follow 2) supercomputing/parallel computing,	r utilize advanced computational dvance the development of new t mprove health care. NIDA has a p ving categories: 1) artificial intellig	approaches to c reatments, allow varticular interes	describe complex drug v for targeted funding t in applications that	g-disease g of substance include
14003	Notice of Special Interest (NOSI): Treating Addiction and Substance	Targeting Epigenetic Regulators for e Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-004	08-Aug-2024	Not Specified
	Contact Name	Sam Ananthan, Ph.D.				
	Contact Telephone	301-435-2199				
	Contact Email	<u>sam.ananthan@nih.gov</u>				
	Contact Email Sponsor Website					
	Sponsor Website					

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Institute on Drug Abuse (NI special interest in innovative research th regulators and mechanisms for the treat	at uses chemical and pharmacolo	ogical approaches to	• •	
114150	Notice of Special Interest (NOSI): Medical/Psychosocial Consequen		National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-002 07-	Sep-2024	Not Specified
	Contact Name	Raul Mandler, MD				
	Contact Telephone	240-281-0569				
	Contact Email	mandlerr@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 2025 , 07-Sep-2025 , 05-Oct-2025 , 16-O		5-Feb-2025 , 07-Ma	y-2025 , 05-Jun-20	25 , 16-Jun-
	Synopsis	The purpose of this notice is to support r therapeutic measures for chemsex in per lesbian, gay, bisexual.				
113995		Health Services and Economic Research bl, and Tobacco Use Disorders (R01, R21,	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 23-012 07-	Sep-2024	Not Specified
	Contact Name	Tisha Wiley, Ph.D.				
	Contact Telephone	301-594-4381				
	Contact Email	tisha.wiley@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 2025 , 07-Sep-2025 , 05-Oct-2025 , 16-O		5-Feb-2025 , 07-Ma	y-2025 , 05-Jun-20	25 , 16-Jun-
	Synopsis	The purpose of this Notice is to inform p interest in grant applications to conduct delivery of efficient, effective drug, alcob	rigorous health services and eco	nomic research to n	naximize the availa	bility and

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		include: (1) clinical quality improvement implementation science; (4) availability, improvement of research methodology,	demand, access, and financing;	(5) effectiveness; an	nd (6) development	-
114048		Chemoproteomic Approaches for eutics to Treat Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-005 08	-Aug-2024	Not Specified
	Contact Name	Sam Ananthan, Ph.D.				
	Contact Telephone	301-435-2199				
	Contact Email	<u>sam.ananthan@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Aug-2024 , 07-Sep-2024 , 05-Oct-202 2025 , 16-Feb-2025 , 08-Apr-2025 , 07-N Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 0	lay-2025 , 05-Jun-2025 , 12-Jun-2			
	Synopsis	The purpose of this Notice is to inform p interest in supporting basic research on development of drugs to treat addiction	the application of chemoproteo	-		•
114151	Notice of Special Interest (NOSI): Medical/Psychosocial Consequer		National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-002 07-	-Sep-2024	Not Specified
	Contact Name	Raul Mandler, MD				
	Contact Telephone	240-281-0569				
	Contact Email	mandlerr@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 2025 , 07-May-2025 , 05-Jun-2025 , 12-Ju Jan-2026				· ·
	Synopsis	The purpose of this notice is to support in the rapeutic measures for chemsex in pe				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		lesbian, gay, bisexual.				
117405	Notice of Special Interest (NOSI):	Liveraging Glial Cells to Treat Addiction	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-006 07	-Sep-2024	Not Specified
	Contact Name	Shang-Yi Anne Tsai, Ph.D.				
	Contact Telephone	301-827-5842				
	Contact Email	<u>stsai@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Ju Feb-2026 , 12-Feb-2026 [LOI/Pre-App], 1	in-2025 , 07-Sep-2025 , 05-Oct-20	025, 12-Oct-2025,	16-Oct-2025 , 07-J	an-2026 , 05-
		This Notice of Special Interest (NOSI) en	courages studies to exploit the u	nique properties an	d functions of glial	امت ما ا
	Synopsis	develop strategies to mitigate Central N substances or therapeutic avenues for a	ervous System (CNS) damage due			
119295		develop strategies to mitigate Central N	ervous System (CNS) damage due discrimination de la construcción de la	e to acute or chroni		
119295	Substance Use/Substance Use Di Clinical Trials Not Allowed)	develop strategies to mitigate Central N substances or therapeutic avenues for a	ervous System (CNS) damage du ddiction treatments.	PAR-23-	c exposure to addi	tive 100,000
119295	Substance Use/Substance Use Di Clinical Trials Not Allowed)	develop strategies to mitigate Central N substances or therapeutic avenues for a <u>sorder Dissertation Research Award (R36</u> Marsha F. Lopez, Ph.D., M.H.S.	ervous System (CNS) damage du ddiction treatments.	PAR-23-	c exposure to addi	tive 100,000
119295	Substance Use/Substance Use Dis Clinical Trials Not Allowed) Contact Name Contact Telephone	develop strategies to mitigate Central N substances or therapeutic avenues for a <u>sorder Dissertation Research Award (R36</u> Marsha F. Lopez, Ph.D., M.H.S.	ervous System (CNS) damage du ddiction treatments.	PAR-23-	c exposure to addi	tive 100,000
119295	Substance Use/Substance Use Dis Clinical Trials Not Allowed) Contact Name Contact Telephone	develop strategies to mitigate Central N substances or therapeutic avenues for a <u>sorder Dissertation Research Award (R36</u> Marsha F. Lopez, Ph.D., M.H.S. 301-443-6504 <u>marsha.lopez@nih.gov</u>	ervous System (CNS) damage du ddiction treatments.	PAR-23-	c exposure to addi	ctive 100,000
119295	Substance Use/Substance Use Dis Clinical Trials Not Allowed) Contact Name Contact Telephone Contact Email Sponsor Website	develop strategies to mitigate Central N substances or therapeutic avenues for a <u>sorder Dissertation Research Award (R36</u> Marsha F. Lopez, Ph.D., M.H.S. 301-443-6504 <u>marsha.lopez@nih.gov</u>	ervous System (CNS) damage du ddiction treatments.	PAR-23-	c exposure to addi	ctive 100,000
119295	Substance Use/Substance Use Dis Clinical Trials Not Allowed) Contact Name Contact Telephone Contact Email Sponsor Website	 develop strategies to mitigate Central Ne substances or therapeutic avenues for a sorder Dissertation Research Award (R36 Marsha F. Lopez, Ph.D., M.H.S. 301-443-6504 marsha.lopez@nih.gov Link to program URL 07-Sep-2024 16-Oct-2024 07-Jap-2021 	ervous System (CNS) damage du ddiction treatments. National Institute on Drug Abuse/NIH/DHHS 5 , 16-Feb-2025 , 07-May-2025 , 2	e to acute or chroni PAR-23- 194 07	c exposure to addi -Sep-2024	tive 100,000 USD

SPIN ID Program Title		Sponsor Name	Sponsor Num	ber Deadline Date	Funding Amount
	from individuals from diverse backgrou Interest in Diversity (NOT-OD-20-031). involve leading an independent clinical NOFO are permitted to propose resear	This NOFO is designed specificall trial, a clinical trial feasibility stu	y for applicants dy, or an ancilla	proposing research the ry clinical trial. Applica	at does not
105778 Imaging - Science Track Award f Basic Experimental Studies with	or Research Transition (I/START) (R03- Humans Required)	National Institute on Drug Abuse/NIH/DHHS	PAR-21- 309	07-Sep-2024	150,000 USD
Contact Telephor	ill <u>john.fedota@mail.nih.gov</u>				
-	RL Link to program URL L) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-202				
Synops	This Funding Opportunity Announceme investigators to the area of neuroimagi is seeking to adopt neuroimaging method studies. The R03 is intended to support resources.	ng, including both newly indepen dologies in their research program	ndent investigate ms, to enable the	ors and established inv e conduct of small "pro	vestigators oof of concept
.05780 Imaging - Science Track Award f	or Research Transition (I/START) (R03-	National Institute on Drug Abuse/NIH/DHHS	PAR-21- 310	07-Sep-2024	150,000 USD
Contact Nam	e John Fedota, PhD				
Contact Telephor	e 301-402-0812				
Contact Ema	il john.fedota@mail.nih.gov				
Contact Ema Sponsor Websit					
Sponsor Websit					
Sponsor Websit Program UF	e				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		of concept" studies. The R03 is intended limited resources.	d to support research projects that	at can be carried out	in a short period	of time with
109484	Notice of Special Interest (NOSI): Actionable Insights for Substance	Leveraging Data Science to Bring use Prevention and Treatment	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 23-006 07-	Sep-2024	Not Specified
	Contact Name	Janet Kuramoto-Crawford, PhD				
	Contact Telephone	301-443-8856				
	Contact Email	janet.kuramoto-crawford@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-202 2025 , 07-Sep-2025	24 , 07-Jan-2025 , 05-Feb-2025 , 1	6-Feb-2025 , 07-May	y-2025 , 05-Jun-20	25 , 16-Jun-
	Synopsis	This Notice encourages research project prevention and treatment 2) shorten th or near real-time, and 3) explore methor treatment and prevention. Priority will health records, syndromic surveillance,	e time between data capture and ods and tools that may allow for fa be given to projects that emphasi	data availability so aster or better locali ze the use of existin	that data are avai zed responses for g data streams (e.	lable real-time substance use g., electronic
109268	Notice of Special Interest (NOSI):	Epidemiology of Drug Abuse	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 22-004 07-	Sep-2024	Not Specified
	Contact Name	Marsha Lopez, PhD, MHS				
	Contact Telephone	301-443-6504				
	Contact Email	Marsha.Lopez@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-202 2025 , 07-Sep-2025	24 , 07-Jan-2025 , 05-Feb-2025 , 1	6-Feb-2025 , 07-May	y-2025 , 05-Jun-20	25 , 16-Jun-
	Synopsis	The purpose of this Notice is to encoura the nature, extent, distribution, etiolog individuals, families, communities, and	y, comorbidities, and consequence	es of drug use, misu	se, and addiction	across

SPIN ID	Program Title		Sponsor Name	Sponsor Num	per Deadline Date	Funding Amount
		risk, resilience, and causation across scienterplay among genetic, environmenta outcomes. Priority will be given to resear addition to novel data collection, appro- agencies to harness existing data on the treatment programs. The research areas disparities or inequities, familial/genetic interactions.	l, neurobiological, and developme arch with a well described path to aches are encouraged that build o epidemiology and etiology of dru s noted below should be consider	ental factors an wards translation on the research ug misuse to im ed in the conte	d associated health an on and/or public healt investments of NIH ar prove public health pr xt of topics such as he	d disease n impact. In d sister HHS evention and alth
127083	RFA-DA-25-037 Translating Soc Neurocognitive Development and Clinical Trial Not Allowed)	ioenvironmental Influences on d Addiction Risk (TranSINDA) (U01	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 25-037	07-Oct-2024 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Holly Moore, PhD				
	Contact Telephone					
	Contact Email	holly.moore@nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	07-Oct-2024 [Optional][LOI/Pre-App], 0				
	Synopsis	The goal of this Notice of Funding Oppo aimed at longitudinal research designs i mechanisms mediating the impact of th substance use disorders (SUD) and their (NOFO) requires a Plan for Enhancing Di	n animal models and advanced ne e early-life social environment on comorbidities in adolescence and	euroscience and neurobehavior	d theoretical tools to e ral development and th	lucidate ne risk for
126437	RFA-DA-25-085 Translational R Between Substance Use Epidemi Intervention Research (U24 Clinic	ology/Etiology and Prevention	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 25-085	13-Oct-2024 [Optional][LOI/Pre- App]	1,400,000 USD
	Contact Name	Alexa Romberg, PhD				
	Contact Telephone	301-435-0264				
	Contact Email	alexa.romberg@nih.gov				
	Sponsor Website					

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber Deadline Date	Funding Amount			
	•	Link to program URL							
	Deadline Dates (ALL)	13-Oct-2024 [Optional][LOI/Pre-App], 13							
	Synopsis	Effective translation and cross-fertilization between research disciplines are long-standing and challenging problems. The purpose of this notice of funding opportunity (NOFO) is to seek innovative applications for Translational Resource Centers that will establish and support multidisciplinary research teams to conduct translational research between the fields of 1) substance use epidemiology and etiology and 2) substance use prevention intervention. Resource centers are expected to conduct activities that bring investigators in these fields together for active collaboration to develop research questions, design study approaches (with either collection of new data or analysis of existing data), and to develop strategies for application of findings from one field into research in the other field. Collaborative activities supported by the Center should have specific goals that lead to concrete products (e.g., publications, grant applications, intervention development or adaptation) and must include a plan for evaluating center success.							
25421	Interventions to Reduce Sleep He Optional)	ealth Disparities (R01 - Clinical Trials	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-24- 110	05-Oct-2024	Not Specified			
	Contact Name	Arielle S. Gillman, PhD, MPH							
	Contact Telephone	301-435-0060							
	Contact Email	arielle.gillman@nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	05-Oct-2024 , 07-Jan-2025 , 05-Feb-202 2026 , 07-May-2026 , 05-Jun-2026 , 07-S Sep-2027	· · · · · · · · · · · · · · · · · · ·	•					
	Synopsis	The purpose of this initiative is to suppo disparities, and examine sleep as a mod experience health disparities.			-	-			
.26432	Community Level Interventions to Health Disparities (R01 - Clinical 1	o Improve Minority Health and Reduce Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-24- 231	06-Sep-2024 [Optional][LOI/Pre- App]	1,000,000 USD			
	Contact Name	Crystal L. Barksdale, PhD, MPH							

PIN ID Program	ı Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	301-827-4288				
	Contact Email	crystal.barksdale@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-Sep-2024 [Optional][LOI/Pre-App], (Jan-2026 , 06-Sep-2026 [Optional][LOI/	05-Oct-2024 , 07-Jan-2025 , 06-Sep /Pre-App], 05-Oct-2026 , 07-Jan-202	-2025 [Optional][L 27	OI/Pre-App], 05-00	ct-2025 , 07-
	Synopsis	The purpose of this initiative is to supp health and reduce health disparities.	ort research to develop and test co	mmunity-level inte	erventions to impro	ove minority
156/0	ploratory/Developmen al Optional)	<u>tal Research Grant Program (R21 -</u>	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-23- 111 07-	-Sep-2024	275,000 USD
	Contact Name					
	Contact Telephone	301-402-1366				
	Contact Email	GrantsInfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-202 2026 , 16-Feb-2026 , 07-May-2026	25 , 16-Feb-2025 , 07-May-2025 , 10	6-Jun-2025 , 07-Se	p-2025 , 16-Oct-20	025 , 07-Jan-
	Synopsis	NIMHD invites applications to support break new ground in the fields of mino directions or applications that can dire U.S.	rity health and/or health disparities	s or extend previou	us discoveries towa	ard new
10201	Special Interest (NOSI): on Women's Health in t	Administrative Supplements for the IDeA States	National Institutes of Health/DH	HS NOT-GM- 22-005 17-	-Oct-2024	200,000 USD
	Contact Name	Crina Frincu, Ph.D.				
	Contact Telephone					
	Contact Email	crina.frincu@nih.gov				
	Sponsor Website					

Program URL Link to program URL Deadline Dates (ALL) 17-Oct-2024 The Office of Research on Women's Health (ORWH) and the National Institute of General Medical Sciences (NIGMS), a with the other participating NIH Institutes, Centers, and Offices (ICOs) announce the availability of administrative supplements to IDeA awards to expand research and research capacity in the IDeA states to address important issues women's health across the lifespan. The proposed research must be within the scope of the parent grant and must ad least one of the strategic goals of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing S	SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
The Office of Research on Women's Health (ORWH) and the National Institute of General Medical Sciences (NIGMS), with the other participating NIH Institutes, Centers, and Offices (ICOs) announce the availability of administrative supplements to IDeA awards to expand research and research capacity in the IDeA states to address important issues women's health across the lifespan. The proposed research must be within the scope of the parent grant and must ad least one of the strategic goals of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing S	Program URL	Link to program URL				
with the other participating NIH Institutes, Centers, and Offices (ICOs) announce the availability of administrative supplements to IDeA awards to expand research and research capacity in the IDeA states to address important issues women's health across the lifespan. The proposed research must be within the scope of the parent grant and must across the lifespan. The 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing S	Deadline Dates (ALL)	17-Oct-2024				
for the Health of Women."	Synopsis	with the other participating NIH Institutes, supplements to IDeA awards to expand res women's health across the lifespan. The pr	Centers, and Offices (ICOs) an earch and research capacity ir oposed research must be with	nounce the availabil In the IDeA states to a In the scope of the p	lity of administrati address important parent grant and r	ve issues of nust address a

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
112311		Against Chemical Threats (CounterACT) Therapeutics pment (UG3/UH3 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22- 209	17-Oct-2024	Not Specified
	Contact Name	Shardell Spriggs, PhD				
	Contact Telephone	301-443-8189				
	Contact Email	shardell.spriggs@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	17-Oct-2024				
	Synopsis	This Funding Opportunity Announcement (FOA) solicit mitigate the adverse health effects resulting from toxi be used in a terrorist attack or accidentally released fr chemical warfare agents, toxic industrial chemicals, per solicitation includes validation of therapeutic targets a this FOA supports target validation and characterization optimization and in vivo demonstration of activity and overall UG3/UH3 funding period, projects are expected	c chemical exposure. om industrial produce esticides, and pharma and preclinical charac on of initial lead comp efficacy in relevant p	Chemical th tion, storage aceutical-bas terization of bound(s); UH bost-exposur	reats are toxic compound or shipping. They include ed agents. The overall sco lead compounds. The UG B phase activities include re models. At the conclusio	s that could specific pe of this 3 phase of candidate on of the
118192	RFA-OD-23-017 Tobacco Regula	National Institutes of Health/DHHS	RFA-OD- 23-017	04-Oct-2024	2,500,000 USD	

SPIN ID	Program Title		Sponsor Nam	ne	Sponsor Number	Deadline Date	Funding Amount
	Contact Name	Rachel Grana Mayne, PhD					
	Contact Telephone						
	Contact Email	Rachel.Mayne@nih.gov					
	Sponsor Website						
	•	Link to program URL					
	-	04-Oct-2024 , 02-May-2025					
	Synopsis	The purpose of this Notice of Funding Opporesearch that will provide scientific data to must address the research priorities related Tobacco Products (CTP). The awards under through FDA CTP and the Family Smoking P are expected to generate findings and data distribution, and marketing of tobacco products products of tobacco products of tobacco products distribution.	inform regula d to the regula this NOFO wil Prevention and that are direct	tion of tobacco p atory authority of Il be administerec Tobacco Control ctly relevant in inf	roducts to protec the Food and Dru by NIH using fur Act (P.L. 111-31)	t public health. Rese Ig Administration (F ds that have been n . Research results fro	arch Projects DA) Center for nade available om this NOFO
112989		termeasures Research Program (CCRP) Initia cts of Acute Exposure to Ultra-Potent Synth owed)	otic (LIPS) IN	ational Institutes f Health/DHHS	-	Oct-2024 otional][LOI/Pre-App	900,000] USD
	Contact Name	Kiran Vemuri, Ph.D.					
	Contact Telephone	301-435-4446					
	Contact Email	kiran.vemuri@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	20-Oct-2024 [Optional][LOI/Pre-App], 19-N	lov-2024				
	Synopsis	This Funding Opportunity Announcement (signaling pathways, and therapeutic targets toxicities caused by acute Ultra-Potent Syn persistent or delayed pathophysiological ef	s, for understa thetic (UPS) o	anding and revers pioid exposure. Tl	ing the effects of his FOA will also s	an overdose and the	e observed
109762	RFA-HL-23-007 Limited Compet Transition Scholar (StARRTS) (K38	tition: Stimulating Access to Research in Res Clinical Trial Not Allowed)		ational Institutes f Health/DHHS	RFA-HL- 23-007	Oct-2024	Not Specified

SPIN ID	Program Title		Sponsor Name		Sponsor Numb	er Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	david.schopfer@nih.gov Link to program URL 11-Oct-2024 , 10-Jan-2025 The purpose of the Stimulating Access to R program is to retain and support clinician in in Residency (StARR) R38 Program (RFA-HL K38 grants described in this FOA will be ref Scholars with opportunities for additional r career faculty appointments (as defined in StARRTS K38 program will provide a pathw the StARR R38 program. Transition Scholar	esearch in Resider nvestigators who l -18-023 or RFA-HL erred to as Transif research and caree Section III. 3. Add ay to retain the ne grantees will rece	ncy Transition have successf 23-006) as re tion Scholars. er developme itional Inform ewly-created eive support fo	Scholar (StARR ully completed esident-investig The intent of th nt during subse ation on Eligibil pool of clinician or continued res	TS) K38 Career Develo the Stimulating Access ators. Individuals who is FOA is to provide Tr quent clinical fellowshi ty). It is anticipated th investigators generate earch and career deve	oment to Research are awarded ansition p or early at the ed through lopment
		opportunities in basic, clinical and/or trans to independent research careers. This Func proposing research that does not involve le study to a clinical trial. Applicants to this FC or co-mentor.	ling Opportunity A eading an indepen	Announcemer dent clinical t	nt (FOA) is designation of the second s	ned specifically for app al feasibility study, or a	olicants an ancillary
121524	RFA-DA-24-067 HEAL Initiative: Use Preventive Services (R01 Clin	Research to Increase Implementation of Su ical Trial Optional)		nal Institutes alth/DHHS		7-Sep-2024 Dptional][LOI/Pre-App]	Not Specified
	Contact Name	Amy B. Goldstein, PhD					
	Contact Telephone	301-827-4124					
		amy.goldstein@nih.gov					
	Sponsor Website						
	-	Link to program URL					2025
		17-Sep-2024 [Optional][LOI/Pre-App], 17-C [Optional][LOI/Pre-App], 16-Jan-2026					
	Synopsis	Despite an evidence base of effective progr	rams to prevent th	ne initiation o	f substance use	misuse and disorder,	a substantia

SPIN ID	Program Title	Spon	sor Name	Sponsor Num	per Deadline Date	Funding Amount
		research to practice gap exists. The goal of this in public health and responding to the opioid crisis This notice of funding opportunity (NOFO) solicit researched, could create the foundation needed of interventions to prevent opioid and other sub preliminary or feasibility data is available. This N pilot data is unavailable.	by increasing knowledge s applications to address to inform a prevention i stance misuse and use di	pertaining to t understudied a nfrastructure fo sorders. This N	he delivery of prevent areas of opportunity th or ongoing delivery and OFO invites projects fo	on services. aat, if I sustainment r which
121525	RFA-DA-24-066 HEAL Initiative: Use Preventive Services (R61/R33	Research to Increase Implementation of Substan	<u>ce</u> National Institutes of Health/DHHS		17-Sep-2024 [Optional][LOI/Pre-Ap	Not o] Specified
	Contact Name	Amy B. Goldstein, PhD				
	Contact Telephone					
	Contact Email	amy.goldstein@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	17-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-20 [Optional][LOI/Pre-App], 16-Jan-2026	24 , 18-May-2025 [Optio	nal][LOI/Pre-Ap	p], 17-Jun-2025 , 17-D	ec-2025
	Synopsis	Despite an evidence base of effective programs to research to practice gap exists. The goal of this in public health and responding to the opioid crisis services. This notice of funding opportunity (NOF researched, could create the foundation needed of interventions to prevent opioid and other sub preliminary or feasibility data is not available. The which pilot data is available.	nitiative is to support pro by increasing knowledge O) solicits applications to to inform a prevention i stance misuse and use di	jects that fill th pertaining to t address under nfrastructure fo isorders. This N	is research to practice he delivery of prevent rstudied areas of oppo or ongoing delivery and OFO invites projects fo	gap, improving on rtunity that, if I sustainment r which
115551		ral Racism and Discrimination on Minority Health			09-Oct-2024	2,500,000
	Health Disparities (R01 - Clinical 1	<u>rial Optional)</u>	of Health/DHHS	112		USD
	Contact Name	Jennifer Alvidrez, PhD				
	Contact Telephone					
	Contact Email	jennifer.alvidrez@nih.gov				

SPIN ID	Program Title		Sponsor N	lame	Sponsor Number	Deadline Date	Funding Amount				
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	09-Oct-2024 , 07-Jan-2025 , 09-Oct-2025 , 0	07-Jan-202	6							
	Synopsis	This initiative will support intervention rese minority health or reduce health disparities	nitiative will support intervention research that addresses structural racism and discrimination (SRD) in order to improve rity health or reduce health disparities.								
125252	-	myloid Related Imaging Abnormalities (ARI by (R01 - Clinical Trial Not Allowed)	A <u>) After</u>	National Institutes of Health/DHHS	PAR-24- 198 04-	Oct-2024	2,500,000 USD				
	Contact Name	Francesca Bosetti, PhD									
	Contact Telephone	301-496-1431									
	Contact Email	Francesca.Bosetti@nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	04-Oct-2024									
	Synopsis	This notice of funding opportunity (NOFO) molecular mechanisms that underlie brain in amyloid-related imaging abnormalities (be targeted to protect the BBB, and thus th	blood vess ARIA). The	els responses to pas goal is to establish a	sive anti-beta-am n understanding c	yloid immunothera of molecular mecha	oy that result nisms that can				
120775	NIH Brain Development Cohorts (NBDC) Biospecimen Access (X01 Clinical Tria	al Not	National Institutes	PAR-23-	Oct-2024	Not				
120775	Allowed)			of Health/DHHS	229	000-2024	Specified				
	Contact Name	Kimberly LeBlanc, Ph.D									
	Contact Telephone	301-827-4102									
	Contact Email	kimberly.leblanc@nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	06-Oct-2024 , 06-Feb-2025 , 05-May-2025 ,	, 07-Oct-20	25 , 06-Feb-2026 , 0	5-May-2026						
		The Adolescent Brain Cognitive Developme child health in the U.S., collecting data from years old and continuing for a decade. In ad	n more tha	n 11,000 children ac	ross the country b	beginning when the	y were 9-10				

SPIN ID	Program Title	Sp	onsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
		biospecimens, including oral fluids for hormon environmental exposures, and blood for gener investigators to apply for access to biological s found on the NIDA ABCD Study web page. Add opportunities page, under Supplemental Infor Brain Development Cohorts (NBDC) Bioreposit biospecimen access. Visit the NBDC portal to o Availability Inquiry to determine the resource	tic analysis and metabolic samples from the ABCD Str ditional information about mation for NOFOs. ABCD S tory and Analysis Center, v query available samples us	and hematologic udy [®] . More inforn this resource is a Study biospecimen vhich offers a web ing the Biospecim	assays. This initiative nation about the ABC vailable on the NIDA f ns are managed throu portal with services en Explorer, submit a	allows D Study can be unding gh the NIH related to Biospecimen
117936	RFA-NS-23-023 BRAIN Initiative TargetedBCPP (R34 Clinical Trials	e: Targeted BRAIN Circuits Planning Projects – Not Allowed)	National Institute of Health/DHHS		2-Sep-2024 Optional][LOI/Pre-App	450,000 [] USD
	Contact Name	Karen K David, PhD				
	Contact Telephone	301-496-9964				
	Contact Email	BRAINCircuits@NIH.GOV				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	02-Sep-2024 [Optional][LOI/Pre-App], 02-Oct-	2024			
		This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-23-024). Applications should be adventurous, exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.				
122567		Administrative Supplements to Support Addict e Pilot Research Projects at NIMHD-Funded Res		es NOT-MD- 23-019 1	7-Oct-2024	Not Specified
	Contact Name	Arundhati Gogineni, PhD				
	Contact Telephone	301-427-9545				
	Contact Email	arundhati.gogineni@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				

SPIN ID	Program Title	2	Sponsor N	ame	Sponsor Nun	nber I	Deadline Date	Funding Amount		
	Deadline Dates (ALL)	17-Oct-2024 , 17-Jan-2025 , 17-Apr-2025 , 1	7-Oct-202	5 , 17-Jan-2026 , 17-	Apr-2026					
	Synopsis	This Notice of Special Interest (NOSI) invites Minority Institutions (RCMI) U54 awards to s investigators (NIs) focused on research on su funded careers. It is expected that pilot proj- grant or career development applications to	support pi ubstance u ect PIs wil	lot research projects use, addiction, and/c I work with their ins	s led by early or neuroscien titutions to p	-stage ir ce, as a repare a	nvestigators (ESIs) bridge to indeper and submit follow	and new ndently -up researcl		
125296	Neuropathological Interactions B Allowed)	etween COVID-19 and ADRD (R01 - Clinical Tr	<u>rial Not</u>	National Institutes of Health/DHHS	PAR-24- 203	04-Sep [Optio	o-2024 nal][LOI/Pre-App]	2,500,000 USD		
	Contact Name	William Daley, Ph.D.								
	Contact Telephone	301-496-1431								
	Contact Email	william.daley@nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	04-Sep-2024 [Optional][LOI/Pre-App], 04-Oc	ct-2024							
	Synopsis	This Notice of Funding Opportunity (NOFO) is to solicit applications that propose studies in animal, cell culture, and/or human tissue models to elucidate the mechanisms by which COVID-19 interacts with and/or modulates ADBD-relevant phenotypes								
117665	Clinical Trial Readiness for Rare D Not Allowed)	viseases, Disorders, and Syndromes (R21 Clini	ical Trial	National Institutes of Health/DHHS	PAR-23- 159	17-Oct	t-2024	275,000 USD		
	Contact Name	Alice Chen Grady, M.D.								
	Contact Telephone	301-827-2015								
	Contact Email	alice.chen2@nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	17-Oct-2024								
	()									

SPIN ID	Program Title	SI	ponsor N	ame	Sponsor Nun	nber	Deadline Date	Funding Amount
		facilitate rare diseases research by enabling e towards clinical trials, and to increase their lik clinical outcome assessment measures, or by upcoming clinical trials.	kelihood (of success through a	development	and te	sting of rigorous bio	omarkers and
117667	Clinical Trial Readiness for Rare D Not Allowed)	Diseases, Disorders, and Syndromes (RO3 Clinica	al Trial	National Institutes of Health/DHHS	PAR-23- 160	17-0	ct-2024	100,000 USD
	·				100			030
		Alice Chen Grady, M.D.						
	Contact Telephone							
	Sponsor Website	alice.chen2@nih.gov						
	•	Link to program URL						
	Deadline Dates (ALL)							
	Synopsis	This Funding Opportunity Announcement (FC address critical needs for clinical trial readine facilitate rare diseases research by enabling e towards clinical trials, and to increase their lik clinical outcome assessment measures, or by upcoming clinical trials.	ess in rare efficient a kelihood o	diseases. The initia nd effective movem of success through o	tive seeks ap nent of candio development	plicatic date th and te	ons that are intende erapeutics or diagn sting of rigorous bio	d to ostics omarkers and
112756	RFA-DA-23-054 HEAL Initiative Crisis (R33 Clinical Trial Optional)	Translating Research to Practice to End the O	<u>verdose</u>	National Institutes of Health/DHHS	RFA-DA- 23-054		ep-2024 onal][LOI/Pre-App]	3,750,000 USD
	Contact Name	Carrie Mulford, Ph.D.						
	Contact Telephone	301827-6473						
	Contact Email	carrie.mulford@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	16-Sep-2024 [Optional][LOI/Pre-App], 17-Oct				•••		
	Synopsis	The goal of this initiative is to support action- address the overdose crisis. There remains ar	-oriented n urgent r	research that accele need for research th	erates the tra at advances t	inslatio the des	n of research to praising of stigma-free p	actice to patient-

SPIN ID	Program Title		Sponsor N	ame	Sponsor Num	ber Dea	adline Date	Funding Amount
		centered systems of care such that people term. This Funding Opportunity Announcer particularly those that focus on fundament organizational, community, or system level should focus on replicable, scalable, equita promising treatments into routine use. This is a companion to RFA-DA-23-053, which so	ment (FOA) al barriers o ls. Projects ble approad s FOA invite	solicits applications or facilitators to redu should be in alignme ches for accelerating s projects for which	that address ucing overdos ent with the o g the moveme preliminary c	understud e deaths a verall goal nt of movi or feasibilit	ied areas of op It the individua s of the HEAL I ing evidence-ba	portunity, l, provider, nitiative, and ased and
112755	RFA-DA-23-053 HEAL Initiative: Crisis (R61/R33 Clinical Trial Optio	Translating Research to Practice to End the onal)	<u>Overdose</u>	National Institutes of Health/DHHS	RFA-DA- 23-053	16-Sep-20)24][LOI/Pre-App]	Not Specified
	Contact Telephone	carrie.mulford@nih.gov						
	Ŭ	Link to program URL						
		16-Sep-2024 [Optional][LOI/Pre-App], 17-C The goal of this initiative is to support action address the overdose crisis. There remains centered systems of care such that people term. This FOA solicits applications that add fundamental barriers or facilitators to reduce system levels. Projects should be in alignment scalable, equitable approaches for accelerate This FOA invites phased applications to sup submission. This FOA is a companion to RFA	on-oriented an urgent r who experi dress under ucing overdo ent with the ating the mo oport projec	research that accelenced for research the ence addiction can a rstudied areas of op ose deaths at the ind e overall goals of the ovement of evidence its for which prelimin	erates the tran at advances the recover and su portunity, par dividual, provi e HEAL Initiative e-based and p nary or feasib	nslation of the design ustain thei ticularly th der, organ ve, and sho romising t ility data is	research to pr of stigma-free r recovery over nose that focus izational, comr ould focus on r reatments into s not available	oatient- the long- on nunity, or eplicable, routine use. at the time o
113055	RFA-EB-22-002 HEAL Initiative: Therapeutic Devices (R18 Clinical	Translational Development of Diagnostic ar Trial Not Allowed)	<u>nd</u>	National Institutes of Health/DHHS	RFA-EB-22- 002	•)24][LOI/Pre-App]	2,250,000 USD
	Contact Telephone	Moria F. Bittmann 301-496-7699 <u>moria.bittmann@nih.gov</u>						

SPIN ID Program Title		Sponsor N	ame	Sponsor Numb	per Deadline Date	Funding Amount
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	15-Sep-2024 [Optional][LOI/Pre-App], 15-C)ct-2024 , 1	8-May-2025 [Option	nal][LOI/Pre-Ap	p], 17-Jun-2025	
Synopsis	The purpose of this Funding Opportunity A use as safe, effective, and non-addictive dia program is to demonstrate treatment using or OUD, building upon the latest mechanist pathways involved in pain or OUD. Awarde readiness for first in human (FIH) clinical tri studies. The scope of the program includes for human use.	agnostics a g credible r tic knowlec d activities ials by over	nd treatments for pa eural targets for de ge about the anaton will facilitate the tra coming key challeng	ain or opioid us vice-based inte my and physiol anslation of new ges identified d	e disorder (OUD). The rventions and/or diag ogy of central, spinal, w devices up to the st uring preliminary prod	e goal of the mostics for pair and peripheral age of of-of-concept
	oplications of Existing NIH Centers for AIDS R ers for AIDS Research (D-CFAR) Grants (P30 C		National Institutes of Health/DHHS	PAR-24- 080	09-Oct-2024	Not Specified
Contact Name	Eric Refsland, Ph.D.					
Contact Telephone	301-761-7193					
Contact Email	eric.refsland@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	09-Oct-2024 , 09-Oct-2025					
Synopsis	This notice of funding opportunity (NOFO) Research (CFAR) and Developmental CFARs support and infrastructure for training, me United States and globally. Additionally this encouraging collaborations and incorporati Plan for Enhancing Diverse Perspectives (PB evaluation.	s (D-CFAR) ntoring, an s NOFO sup ion of dive	to expand the role of d research related to ports expanding exp se perspectives into	f the CFARs an o HIV and HIV-r perimental app the CFAR and	d D-CFARs to include a elated health disparit roaches while engagin D-CFAR goals. This NC	additional ies in the ng and DFO requires a
123794 NCCIH Natural Product Early Pha Clinical Trial Required)	se Clinical Trial Phased Innovation Award (Re	<u>61/R33</u>	National Institutes of Health/DHHS	PAR-24- 124	21-Oct-2024	1,750,000 USD

IN ID Program Title	5	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Courte at Name					
	Sekai Chideya, M.D., MPH				
Contact Telephone					
Sponsor Website	sekai.chideya@nih.gov				
	Link to program URL				
-	21-Oct-2024 , 13-Nov-2024 , 23-Jun-2025 , 1	5-14-2025 22-Eab-2026 17	-Mar-2026 20-Oct	-2026 12-Nov-20	26
Synopsis	of natural products (i.e., botanicals, dietary s further clinical testing. Under this FOA, trials information of high scientific utility and will This FOA will provide up to three years (R61 bioavailability, and assessment of the natura on a biological signature(s). If milestones in t be awarded to replicate the impact of the na- whether there is an association between the outcomes in a patient population. Application impact of the natural product on the biologic different doses or formulation. In addition, a treatment approach that is known to impact target population that is more responsive. C milestone-driven, and directly related to the intended to accelerate the translation of em testing to determine whether continued clin trials, nor will it support trials to test natural be supported by the two phases of the R61/ Scientific/Research contact for the area of so to this FOA.	must be designed so that re- support decisions about furth phase) of support for milesto al product's effect (i.e., measu the R61 phase are achieved, u atural product on the biologic degree of the impact on the ons are encouraged to design cal signature by optimizing th opplications can be designed to the same biological signatur linical trials submitted under research priorities and missi erging basic science findings ical research is warranted. Th products for the treatment of R33 award. Applicants are en	sults, whether posit per development or one-driven testing or up to 3 years of add al signature(s) when biological signature R33 studies to dete e delivery of the nature combine the nature is FOA are expect on of NCCIH. This Re about natural produ- his FOA will not suppor prevention of can couraged to contact aning to develop an	ive or negative, w testing of the nature f pharmacokinetic f action) when use itional support (Ra- n used by humans and functional or rmine how to option tural product by e ural product by e ural product with a fact of the natural p ed to be hypothes 51/R33 funding m ucts into early-stage port efficacy or efficer. A maximum of the appropriate	ill provide ural products, ed by human 33 phase) m and assess clinical mize the xamining another product in a sis based, echanism is ge clinical ectiveness of 5 years w NCCIH to submittir
3784 NCCIH Natural Product Early Pha	se Clinical Trial Award (R33 Clinical Trial Requ	ired) of Health/DHHS	5 PAR-24- 116 21-C	oct-2024	1,050,00 USD
Contact Name	Sekai Chideya, M.D., MPH				
Contact Telephone	301-827-1916				

SPIN ID	Program Title		Sponsor N	ame	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	sekai.chideya@nih.gov					
		Link to sponsor website					
	Program URL						
	Deadline Dates (ALL)	21-Oct-2024 , 13-Nov-2024 , 23-Jun-2025 , 1	17-Jul-2025	5 , 23-Feb-2026 , 17-	Mar-2026 , 20-Oc	t-2026 , 13-Nov-20	26
	Synopsis	This Funding Opportunity Announcement (F of natural products (i.e., botanicals, dietary s further clinical testing. Under this FOA, trials information of high scientific utility and will This FOA will provide up to 3 years support f signature(s) when used by humans and asse biological signature and functional or clinica to determine how to optimize the impact of natural product by examining different dose natural product with another treatment app of the natural product in a target population be hypothesis based, milestone-driven, and mechanism is intended to accelerate the tra stage clinical testing to determine whether of effectiveness trials, nor will it support trials	supplements s must be of support do for studies ess whethe all outcome f the natur es or formu- proach that n that is mo- directly re- anslation of continued	nts, and probiotics), designed so that res ecisions about furthe to replicate the imp r there is an associa s in a patient popula al product on the bi- ilations. In addition, t is known to impact ore responsive. Clini lated to the researc f emerging basic scie clinical research is v	which have a stro ults, whether posi- er development o bact of the natural tion between the ation. Applications ological signature applications can l t the same biologi- cal trials submitted h priorities and m ence findings abou- varranted. This FC	ng scientific premi tive or negative, w r testing of the nat product on the bio degree of the impa- are encouraged to by optimizing the code designed to com cal signature; or stu d under this FOA a ission of NCCIH. Th ut natural products A will not support	se to justify ill provide ural product. blogical act on the b design studie delivery of the bline the udy the impac re expected to is R33 funding into early efficacy or
121295 <u>In</u>	tervention Research to Improve	Native American Health (R34 Clinical Trial O	<u>)ptional)</u>	National Institutes of Health/DHHS	PAR-23- 285 21-	Oct-2024	450,000 USD
	Contact Name	Alexa Romberg Ph.D.					
	Contact Telephone	301-435-0264					
	Contact Email	alexa.romberg@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	21-Oct-2024 , 07-Jan-2025 , 21-Oct-2025 , 0	7-Jan-2026	5 , 25-Oct-2026 , 07-	Jan-2027		
	Synopsis	The purpose of this notice of funding opport feasibility research, to improve health in Nat disease prevention, treatment, recovery, or	tive Ameri	can populations. Pro	oposed research n	nay address health	promotion,

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Research with Native American population adapt interventions and clinical trial protoc develop scientifically rigorous and culturall gaps, address unknowns, allow for strength and pilot test the feasibility of the interven appropriateness of a future efficacy, effect Improve Native American Health (IRINAH) i Grant mechanism and PAR-23-299, which u purposes of this NOFO, Native Americans in ancestral lands fall at least partially within the means any individual any of whose ancestor Hawaii.	cols, understand intervention f y appropriate study designs an nening of partnerships with Na tion and clinical trial design, th iveness, or implementation tri initiative, which also includes uses the R21 Exploratory/Deven nclude the following population the U.S. mainland border), and	easibility and accepted methods. Preparent ative American compereby improving se al. This NOFO is pa PAR-23-298, which elopmental Researcons: Alaska Natives, d Native Hawaiians.	otability, and ident ratory studies may munity leaders and cientific rigor and c rt of the Interventi uses the R01 Resea h Grant mechanisr American Indians The term 'Native I	ify and/or fill information d organizations cultural on Research to arch Project n. For the (whose Hawaiian'
102069	Natural History of Disorders Scree Optional)	enable in the Newborn Period (R01 Clinical 1	Trial National Institute of Health/DHHS	s PAR-21- 115 05-	Oct-2024	Not Specified
	Contact Name	Melissa Parisi, MD, PhD				
	Contact Telephone					
	Contact Email	parisima@mail.nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)					
	Synopsis	This funding opportunity announcement (F broad understanding of the natural history by newborn screening. A comprehensive un element to facilitate appropriate interventi timing of the onset of symptoms and comp addition, for some disorders, specific genot other disorders, identification of modifying the clinical outcomes for an individual with ability to: 1) accurately diagnose the disord expression of the disorder; 3) identify under treat symptoms and complications of the d	of disorders that already do o nderstanding of the natural hi ions for infants identified by n plications of a disorder, a valua type-phenotype correlations n genetic, epigenetic, or enviro such a condition. Comprehen ler; 2) understand the genetic erlying mechanisms related to	r could potentially story of a disorder ewborn screening. ble resource will be nay allow prediction nmental factors wi sive data on natura and clinical heterop basic defects; 4) po	benefit from early has been identified By defining the sec e developed for the n of the clinical cou Il enhance an unde a history will facilit geneity and pheno otentially prevent,	identification l as a necessary quence and e field. In urse, and for erstanding of ate the field's typic manage, and

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		predictive information about the disorder.				
105617	Effectiveness of School-Based Hea Trial Optional)	alth Centers to Advance Health Equity (R01	Clinical National Institutes of Health/DHHS	PAR-21- 287 07-S	Sep-2024	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	<u>GrantsInfo@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025				
	Synopsis	The purpose of this Funding Opportunity A based health centers (SBHCs) as a health se populations with health disparities (hence, research that investigates the effectiveness chronic illnesses that disproportionately bu health of at-risk populations such as sexual are also a relevant focus for understanding model that describes hypothesized causal p and how SBHCs may complement (or reduce determine whether SBHCs can be adopted youth and if so, whether SBHCs given their disparities in chronic conditions, and behav lack access to health care.	ervices care delivery model to a underserved youth). The goal s of SBHCs as a health services urden underserved youth. The and gender minority youth, im effective models of SBHCs. Ap bathways by which SBHCs enga- ce) the use of other services. Le as a best practice care model t accessibility to students can be	address the needs of s of this FOA are to care delivery mode mechanisms of imp nmigrant youth, and plications are expen- inge underserved yo essons learned thro to address the healt e an effective site o	of school-aged chil support multidisc el to detect, manag pact by which SBHC d youth who reside cted to provide a d uth to improve he ugh this initiative th services needs o f intervention to a	dren from iplinary ge, and prevent Cs improve the e in rural areas conceptual alth outcomes can help of underserved ddress
105618	Molecular Imaging of Inflammatic	on in Cancer (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21- 05-0 294	Dct-2024	Not Specified
	Contact Name					
	Contact Telephone	301-945-7573				
	Contact Email	GrantsInfo@nih.gov				
	Sponsor Website					

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount				
	Deadline Dates (ALL)	05-Oct-2024								
		The purpose of this Funding Opportunity A development and use of current and emerge inflammation in vivo. The motivation for th in cancer is largely based on in vitro and ex significant new insights relevant to dynamic pre-clinical and clinical investigations for pr approaches for identification and character changes in response to treatment. This FOA to interrogate the role of inflammation in c researchers and imaging scientists. These c inflammation interactions.	ging molecular imaging metho is initiative is that much of cu vivo methods with limited uti c cancer and inflammation int ecise temporal resolution at t ization of in vivo inflammator A encourages applications that ancer through strong cross-fie	nds to gain fundam rrent imaging rese ilization of imaging eractions. Utilizati the molecular and ty cellular physiolo t focus on develop eld collaboration b	ental insights into c arch into the role of approaches that co on of molecular ima cellular level are va gy in cancers and of ing integrated imag etween cancer basi	ancer f inflammation ould lead to aging probes in luable f molecular ing approaches c science				
106975	Notice of Special Interest (NOSI): Contributions to Cognitive Impair	Promoting Research To Understand Vascula ment and Dementia (VCID)	r National Institute of Health/DHHS	s NOT-HL- 23-002 07	-Sep-2024	Not Specified				
	Contact Name	Jue Chen, Ph.D.								
	Contact Telephone	301-435-0550								
	Contact Email	jue.chen@nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , (05-Feb-2025 , 07-May-2025							
	Synopsis	The purpose of this Notice is to inform pote research to understand mechanisms of vas new approaches for the treatment of VCID.	cular contributions to cognitiv							
107608	Drug Discovery For Nervous Syste	em Disorders (R01 Clinical Trials Not Allowed	National Institute of Health/DHHS	s PAR-22- 031 05	-Oct-2024	Not Specified				
	Contact Name	Enrique Michelotti, PhD								
	Contact Telephone	301-443-5415								
	Contact Email	michelottiel@mail.nih.gov								
	Sponsor Website									

SPIN ID Program Title	s	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024				
Synopsis	This Funding Opportunity Announcement (FC treatment of nervous system disorders. Thro Identification, design, synthesis, and preclinic Initial hit-to-lead chemistry to improve activi to improve efficacy and pharmacokinetics; an will be placed on projects that provide novel	bugh this FOA, NIMH, NIAAA, cal testing of small molecules ty of compounds against the nd 4) Initial drug metabolism	NIDA and NIA wis for their potentia target of interest and pharmacokin	h to stimulate resea al as candidate ther 3) Later stage lead etic properties (DN	arch in: 1) apeutics ; 2) optimization
.08571 Notice of Special Interest (NOSI): COVID-19-Associated Coagulopat	Enhancing Research on Deciphering Mechani hy	sms of National Institutes of Health/DHHS	5 NOT-HL- 23-003 07	-Sep-2024	Not Specified
	Anthony Agresti	· · · ·			•
Contact Telephone					
•	agrestia@nhlbi.nih.gov				
Sponsor Website					
	Link to program URL				
-		5-Jun-2025			
Synopsis	This Notice of Special Interest (NOSI) aims to Associated Coagulopathy (CAC) which are pro hypercoagulability at genomic, molecular, an future design of early diagnostics and effectiv applied to on-going COVID-19 clinical trials.	ovoked by vascular endothel nd cellular levels. Knowledge	ial cell injury, hype obtained from suc	erimmune response ch studies may be a	es, and pplied to the
11036 Dissemination and Implementation	on Research in Health (R01 Clinical Trial Optio	nal) National Institutes of Health/DHHS	5 PAR-22- 07 105	-Sep-2024	Not Specified
Contact Name	Gila Neta, Ph.D.				
Contact Telephone	240-276-6785				
Contact Email	gila.neta@nih.gov				
Sponsor Website					

SPIN ID	Program Title		Sponsor N	Name	Sponsor Num	ber Deadlin	e Date	Funding Amount
		07-Sep-2024, 05-Oct-2024, 07-Jan-2025, 0 The purpose of this Funding Opportunity A strategies for overcoming barriers to the ac interventions, practices, programs, tools, tr and implementation of evidence-based inter there is a benefit in understanding circums that are ineffective, unproven, low-value, or research methods and measures are encou	nnouncem doption, ac reatments, erventions tances tha or harmful. uraged. App	ent (FOA) is to supp daptation, integration guidelines, and poli- among underrepresent t create a need to stu- In addition, studies polications that focus	n, scale-up, an cies. Studies tl ented commu op or reduce (to advance dis on re-implemo	d sustainabilit nat promote ec nities are enco "de-implemen ssemination an entation of evi	y of evid quitable puraged. t") the u id implei dence-b	ence-based dissemination Conversely, se of practices mentation ased health
111616		services (e.g. cancer screening) that may had applications must be within the scope of the <u>NIH Research Project Grants on Down Synd</u> tion of Co-occurring conditions across the Lip <u>oject</u>	ne mission	-	es/Centers lis		ncourage	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL	<u>schrammc@nih.gov</u>				t (RO1) applicat	tions the	t are feelled
		on Down syndrome and that meet program communication of outputs of appropriate in Applicants responding to this NOSI are stro innovative data analytics approaches (see C	nmatic objenterest to ongly encou Goal 3, NIH	ectives for the INCLU broader communitie iraged to describe pl I Strategic Plan For D	DE Project. Sh s are a high pi ans for rapid s ata Science).	naring of resou riority of the IN	rces and ICLUDE	l effective Project.
11/11/11	Engineering Next-Generation Hur Clinical Trials Not Allowed)	man Nervous System Microphysiological Sys	stems (R01	National Institutes of Health/DHHS	PAR-23- 046	07-Sep-2024		Not Specified
	Contact Telephone	David M. Panchision, Ph.D. 301-443-5288 <u>panchisiond@mail.nih.gov</u>						

SPIN ID	Program Title		Sponsor N	lame	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website						
	-	Link to program URL					
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 2026	05-Feb-202	25 , 07-May-2025 , C	95-Jun-2025 , 07-Se	o-2025 , 05-Oct-20	25 , 07-Jan-
	Synopsis	This Funding Opportunity Announcement (generation human cell-derived microphysic architectures and physiology with improve future studies of complex nervous system of intended to encourage the further develop proposing exploratory research at the early companion R21 FOA (PAR-23-047).	ological sys d fidelity o developme oment of pr	stems (MPS) and relative ver current capabilitient, function, and ag rojects with feasibilitient	ated assays that rep ties. Supported pro ing in healthy and o ty support for the li	olicate complex ner jects will be expect lisease states. This ne of investigation	rvous system ed to enable FOA is . Applicants
115197		rch Using IMPC-Generated Knockout Mouse Lethality or Subviability (R01 Clinical Trial N		National Institutes of Health/DHHS	5 PAR-23- 074 05-0	Oct-2024	2,499,995 USD
	Contact Name	Mahua Mukhopadhyay, PhD					
	Contact Telephone	301-435-6886					
		mukhopam@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Oct-2024 , 05-Jun-2025 , 05-Oct-2025					
	Synopsis	The purpose of this Funding Opportunity A research on embryonic lethal knockout (KC Consortium (IMPC) of which the NIH Knock generate a comprehensive catalogue of ma human genetic variation. The current (July Overall, the IMPC hopes to generate a null genome. About 30% of these strains are ex portion of homozygous lethal mutations ar the unique opportunity to leverage these m mouse phenotyping effort to perform addi	D) mouse si cout Mouse ammalian g 19, 2022) I mutant an cpected to l re expected nouse strai	trains being generat Phenotyping Progr gene function that w MPC data release in d undertake broad- be either embryonic to have viable hete ns while they are be	ed through the Inte am (KOMP2) is a m vill provide the foun icludes phenotypic based phenotyping or perinatal lethal, erozygous phenotyp eing created and br	ernational Mouse P ember. The missio dation for function data for 8260 know for every gene in t or subviable. How pes. The scientific c	Phenotyping n of IMPC is to nal analyses of ckout genes. the mouse vever, a large ommunity has

SPIN ID	Program Title		Sponsor N	lame	Sponsor Numl	ber Deadline Date	Funding Amount
119254	Novel Mechanism Research on Novel Mechanism Research on Novel Dementia (R01 Clinical Trial Optic	europsychiatric Symptoms (NPS) in Alzheim onal)	<u>er's</u>	National Institutes of Health/DHHS	PAR-23- 207	05-Oct-2024	Not Specified
	Contact Name	Laura M. Rowland, Ph.D.					
	Contact Telephone	301-480-8335					
	Contact Email	laura.rowland@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 ,	05-Oct-202	5,05-Feb-2026,05	Jun-2026		
	Synopsis	The goal of this Notice of Funding Opportu of mechanisms associated with neuropsych disease-related dementias (ADRD). The find and neurobiological pathways leading to N advanced into interventions to treat and pu mechanism, while the companion announce lack preliminary data or utilize existing data	niatric symp dings are ex PS. Finding revent the cement PAF	otoms (NPS) in perso expected to advance s may also provide in development of NPS 8-23-208 uses the R2	ons with Alzhei mechanistic un nsight into nov 5 in AD and/or 21 mechanism.	mer's disease (AD) or A Iderstanding of both bi el therapeutic targets ADRD. This NOFO uses High risk/high payoff p	Alzheimer's iobehavioral that can be the R01
117793		creening and Preventive Services to ADVAN ealth Disparities (R01, Clinical Trial Required		National Institutes of Health/DHHS	PAR-23- 170	05-Oct-2024	Not Specified
	Contact Name	JoyAnn Courtney, Ph.D.					
	Contact Telephone	301-402-3911					
	Contact Email	joyann.courtney@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 ,	05-Oct-202	5 , 05-Feb-2026 , 05	-Jun-2026 , 05	-Oct-2026	
	Synopsis	The Office of Disease Prevention (ODP) and (ICs) are issuing this R01 to solicit application screening and preventive services in popula preventive services, or other healthcare pre- care. Projects are encouraged to leverage should address barriers and facilitators at t	ons to addr ations that ocesses, inc collaboration	ess barriers and faci experience health d cluding timely follow ons with community	litators that im lisparities. Inte v-up of abnorm v partners and s	pede use or uptake of rventions should inclu al findings, and referra service providers. Inter	cancer de screening, al to accessible rventions

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	neighborhood/community. Specific researce leverage collaborations with community paradapt new combinations of evidence-based of the following levels: patient, clinician, he	rtners and service providers to I strategies. Interventions sho	promote or enhan uld address barriers	ce existing interve	entions and/or
093897 <u>Research Project Grant (Parent R</u>	01 Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-183 07-S	ep-2024	Not Specified
Contact Name					
Contact Telephone					
Contact Emai	grantsinfo@nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025				
Synopsis	National Institute of Arthritis and Musculos	tor(s). This Parent Funding Op ject must be related to the pros based on their scientific miss definition of a clinical trial. Na keletal and Skin Diseases (NIA	portunity Announce ogrammatic interest sions. NOTE: The fol tional Heart, Lung, MS) National Institu	ement requires th ts of one or more llowing Institutes/ and Blood Institut ite of Neurologica	at at least 1 of the Centers only re (NHLBI)
	(NIMH)	mentary and Integrative Healt			
093907 <u>Research Project Grant (Parent F</u>		National Institutos			
93907 <u>Research Project Grant (Parent R</u> Contact Name	(NIMH) R01 Basic Experimental Studies with Humans	Required) National Institutes			ll Health Not
	(NIMH) CO1 Basic Experimental Studies with Humans	Required) National Institutes			ll Health Not
Contact Name Contact Telephone	(NIMH) CO1 Basic Experimental Studies with Humans	Required) National Institutes			ll Health Not
Contact Name Contact Telephone	(NIMH) RO1 Basic Experimental Studies with Humans 301-496-4000 grantsinfo@od.nih.gov	Required) National Institutes			ll Health Not
Contact Name Contact Telephone Contact Emai Sponsor Website	(NIMH) RO1 Basic Experimental Studies with Humans 301-496-4000 grantsinfo@od.nih.gov	Required) National Institutes			ll Health Not

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The NIH Research Project Grant supports a interests and competencies of the investiga experimental studies involving humans, ref participants." These studies fall within the Types of studies that should submit under t (i.e., experimentally manipulate independe purpose of understanding the fundamental products in mind. Studies conducted with s appropriate 'Clinical Trials Required' or 'Clin programmatic interests of one or more of t Note: Not all NIH Institutes and Centers (IC participate in this announcement and view and Contact website. ICs that do not participate	ator(s). This Parent Funding Op erred to in NOT-OD-18-212 as NIH definition of a clinical trial this FOA include studies that p ent variables) and that assess k I aspects of phenomena witho specific applications toward pr nical Trial Optional' FOA. The p the participating NIH Institutes s) participate in Parent Annou their respective areas of rese	poportunity Announces "prospective basic and also meet the prospectively assign biomedical or behave out specific applicati ocesses or products proposed project m s and Centers (ICs) b ncements. Applicant arch interest at the	ement is for basic science studies inv definition of basic human participant foral outcomes in on towards proces in mind should su ust be related to th pased on their scients should carefully R01 IC-Specific Scie	science volving human research. ts to conditions humans for the ses or bmit under the ne ntific missions. note which ICs entific Interests
1115/55	Investigator Initiated Research in Clinical Trial Not Allowed)	Computational Genomics and Data Science	(R01 National Institutes of Health/DHHS	s PAR-21- 254 05-0	Dct-2024	2,500,000 USD
		Daniel Gilchrist, Ph.D.				
	Contact Telephone					
	Sponsor Website	daniel.gilchrist@nih.gov				
	·	Link to program URL				
	Deadline Dates (ALL)					
	Synopsis	The purpose of this funding opportunity an computational genomics, data science, stat science, and broadly applicable to human h develops innovative analytical methodolog refinement or hardening of software and to this FOA should be enabling for genomics a	tistics, and bioinformatics rele- nealth and disease. This FOA su ies and approaches, early-stag pols of high value to the biome	vant to one or both upports fundaments ge development of t edical genomics con	of basic or clinical al genomics resear ools and software, nmunity. Work sup	genomic ch that and ported under
102001		Epidemiologic studies in Asian Americans, N Parent R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	s NOT-HL- 23-001 07-5	Sep-2024	Not Specified
	Contact Name	Robb Rowley, MD				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	301-827-9126				
		Robb.Rowley@nih.gov				
	Sponsor Website					
	•	Link to program URL				
	-	07-Sep-2024 , 05-Oct-2024				
	Synopsis	The purpose of this Notice of Special Intere- gaps within and between subpopulations of frequently aggregated in research, potentia ancestry, culture, immigration patterns am life, a critical need exists for epidemiologica exposures, lifestyle, behavioral, genomics, American, Native Hawaiian, and Pacific Isla	of Asian Americans, Native Hav ally masking important social long Asian Americans, socioec al research to enhance our un social, neighborhood, and bio	waiians, and Pacific and health difference onomic position, ar derstanding of the	Islanders. These po ces. Given clear het d acculturation int nterplay of enviror	opulations are terogeneity in to American nmental
107841	Risk and Protective Factors of Far Clinical Trial Optional)	mily Health and Family Level Interventions (R01 - National Institute of Health/DHHS	es PAR-21- 358 07-	Sep-2024	Not Specified
	Contact Name	Deborah E. Linares, PhD, MA				
	Contact Telephone	301-402-2516				
	Contact Email	Deborah.Linares@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 ,	05-Feb-2025 , 07-May-2025			
	Synopsis	The purpose of this initiative is to advance family health and well-being and resilience family resilience as critically important area	. The NIMHD Research Frame	work recognizes far	nily health, family w	
109791		ealth Research Using Existing Data from the A SCD) Study (R01-Clinical Trial Not Allowed)	Adolescent National Institute of Health/DHHS	es PAR-22- 137 07-	Sep-2024	1,250,000 USD
	Contact Name	Julia Zehr, Ph.D.				
	Contact Telephone	301-443-1617				
	Contact Email	Zehrj@mail.nih.gov				



SPIN ID	Program Title		Sponsor N	Name	Sponsor Numb	er Deadline Dat	te Funding Amount
	Sponsor Website						
	-	Link to program URL					
		07-Sep-2024, 05-Oct-2024, 07-Jan-2025, The Adolescent Brain Cognitive Developme substance use, cultural and environmental years-old and following them longitudinally through the NIMH Data Archive. The purpo proposing the analysis of this public use da information about the ABCD Study may be grant mechanism, whereas its companion	ent (ABCD) factors, ar y to early a ose of this I itaset to ind found on t	Study is collecting d ad brain structure ar dulthood. These da Funding Opportunity crease knowledge o the ABCD Study web	nd function from ta will be made / Announcemer f adolescent hea page (www.ab	youth starting wh available to the sc t (FOA) is to encou alth and developm cdstudy.org). This	nen they are 9-10 cientific community urage applications ent. More FOA uses the R01
109172	Microbial-based Cancer Imaging a Allowed)	and Therapy - Bugs as Drugs (R01 Clinical Tr	ial Not	National Institutes of Health/DHHS	5 PAR-22- 085)5-Oct-2024	Not Specified
	Contact Name	Avi Rasooly, PhD					
	Contact Telephone	240-276-6196					
	Contact Email	rasoolya@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025					
		This Funding Opportunity Announcement (bacteriophages, or other non-oncolytic viru interactions between microorganisms, tur imaging, therapeutics or diagnostics. Proje tumor immunity, or as delivery vehicles for tools and approaches. This FOA will suppor Applicants are encouraged to address both microbial-based cancer therapy (including funding opportunity is part of a broader NO	uses and th nors, and th cts can foc r treatment rt basic me n the micro therapies f	eir natural products ne immune system, us on using microor t, diagnosis, or imag chanistic and preclir bial and tumor aspe or oral cancer), tum	s to study the ur and to explore t ganisms as anti- ing, complemer nical studies in c cts of microbial or imaging, tum	iderlying mechanis heir clinical potent tumor agents, as a ting or synergizing ell culture and ani tumor interaction or detection, or di	sms of the complex tial for cancer activators of anti- g with existing mal models. s relevant to
109941	Focused Technology Research an	d Development (R01 Clinical Trial Not Allow	<u>ved)</u>	National Institutes of Health/DHHS	5 PAR-22- 127)7-Sep-2024	Not Specified

SPIN ID Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Contact Name Contact Telephone	Fei Wang, Ph.D.					
	wangf@mail.nih.gov					
Sponsor Website						
-	Link to program URL					
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , (05-Feb-2025 , 07	-May-2025			
Synopsis	This Funding Opportunity Announcement (institutes or Centers (ICs) participating in the enable acquisition of biomedical knowledge technical innovation for impacting future be significantly advance the current state of the of biomedical research questions. These our devices, algorithms and software, chemical by human intervention to become research demonstrated proof-of-concept that have of As such, applications should not propose to questions are not responsive to this FOA are optimization, hardening, or obvious extrapo	he FOA that focus e. Projects shoul siomedical resear he art and be suff utcomes may incl I reagents and pro- n tools. The goal remaining signific test specific bio nd will be admini	s solely on the ld be justified i ch. Outcomes ficiently charac ude, but are no ocesses, biolog of this FOA is to cant technical o logical questio stratively with	development of te n terms of technic or products of the terized for applica ot limited to: labor gical molecules or s o support the deve challenges to full ir ns. Applications pr drawn without rev	echnologies with the al innovation and u proposed project tion in addressing atory instruments systems that have elopment of technologies oposing to test spe- iew. Applications w	e potential to utility of such should a broad range and other been modified blogies with d broad utility ecific biologica vith a focus of
	aging Network Infrastructure to Advance Re Lactating Individuals, and Persons with Disal	hilities	onal Institutes ealth/DHHS	PAR-23- 037 07-5	Sep-2024	Not Specified
	Robert Tamburro, MD, MSc					
Contact Telephone						
	NICHD-Network-ClinicalResearch@nih.gov					
Sponsor Website						
Program URL Deadline Dates (ALL)	Link to program URL 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 0 2026	05-Feb-2025 , 07	-May-2025 , 05	5-Jun-2025 , 07-Se	p-2025 , 05-Oct-20	25 , 07-Jan-
	The purpose of this funding opportunity an	nouncement (FC	OA) is to invite a	applications for mu	ultisite clinical trial	s and

SPIN ID	Program Title	Sp	ponsor Na	ame	Sponsor Nun	nber	Deadline Date	Funding Amount
		observational studies developed in conjunction infrastructure. The goal of this FOA is to opera- trials delineated in Notice NOT-HD-19-034: To greater availability of multisite clinical trial inf data sharing and access to biospecimens to ef- involvement of diverse populations in multisite conducted by and within the participating NIC initiated, multi-Principal Investigator (PI) gran (including NICHD Network investigators) in co It is the intent of this initiative to utilize the N funding and support of the best science in a ti	ationalize o enhance frastructu fficiently te clinical CHD-supp nt applicat onjunctior IICHD Clin	the previously report the rigor and report re to support trials expand research ca trials. Consequentl orted Clinical Research tions by any qualifies with the respectivical Research Netw	orted NICHD oducibility of from a wider pacity for all y, multisite cl nrch Network ed investigato e NICHD Netw ork infrastruc	guiding clinical range investig linical t s will b or in the work Da cture in	g principles for mu I trial protocols To of investigators T gators To facilitato rials and observa e submitted as in e extramural com ata Coordinating a manner that w	ultisite clinical o promote o facilitate e greater tional studies vestigator- munity Center (DCC).
116476	Translational Research in Matern Clinical Trial Optional)	al and Pediatric Pharmacology and Therapeuti		National Institutes of Health/DHHS	PAR-23- 130	05-00	ct-2024	Not Specified
	Contact Name	Katie M. Vance, Ph.D.						
	Contact Telephone	301-435-6640						
	Contact Email	Katie.Vance@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-	-Oct-2025	5 , 05-Feb-2026				
	Synopsis	The purpose of this notice of funding opportu precision medicine in pregnant persons, lacta other technologies that could have a direct cli mechanisms of drug action, including the role pregnancy and lactation; and (3) discover and repurposing for safer and more effective med goal is to improve safe and effective precision children, including those with disabilities.	ating perso linical or h e of pedia d develop dications i	ons, and children th ealth impact; (2) er tric ontogeny and th novel therapeutics n pregnant and lact	rough the de nhance the un he dynamic p or enhance t ating person:	velopm ndersta hysiolo he usa s, neon	nent of novel tool anding of the und ogical changes tha ge of existing drug nates, and children	s, models, and erlying It occur during gs or drug n. The overall
115307	Notice of Special Interest (NOSI): Research	Understanding Sudden Death in the Young Th		National Institutes of Health/DHHS	NOT-HL- 22-040	07-Se	ep-2024	Not Specified
	Contact Name	Kristin M. Burns, MD						

SPIN ID Program Title		Sponsor Na	me	Sponsor Number	Deadline Date	Funding Amount
Contact Telephone	301-594-6859					
Contact Email	<u>kristin.burns@nih.gov</u>					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , (2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun- Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-J	-2026 , 07-S	•			
Synopsis	This Notice of Special Interest (NOSI) highlig other studies to evaluate causes and consec- required to use phenotypic data and/or DN the Young (SDY) Case Registry as foundation samples and/or sequence data alone or in o the NIH Data Sharing Policy so that the data about screening and prevention of SDY.	equences of, IA samples a ons for their r combination	and risk factors for nd/or associated s esearch. Studies n with other cohort	r sudden death in equence data fro nay use SDY Case s. Results of such	the young (SDY). St m the NIH/CDC Sud Registry phenotypic studies are require	udies are den Death in c data and/or d to adhere to
116310 Notice of Special Interest (NOSI): COVID-19-Associated Coagulopat	Enhancing Research on Deciphering Mechar hy		National Institutes of Health/DHHS	NOT-HL- 23-003	-Sep-2024	Not Specified
Contact Name	Anthony Agresti					
Contact Telephone	301-827-8014					
Contact Email	agrestia@nhlbi.nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 ,	05-Jun-2025				
Synopsis	This Notice of Special Interest (NOSI) aims t Associated Coagulopathy (CAC) which are p hypercoagulability at genomic, molecular, a future design of early diagnostics and effect applied to on-going COVID-19 clinical trials.	orovoked by and cellular l ctive treatme	vascular endotheli evels. Knowledge	al cell injury, hypobtained from su	erimmune response ch studies may be a	es, and pplied to the
116911 Research With Activities Related	to Diversity (ReWARD) (R01 Clinical Trial Opt	tional)	National Institutes of Health/DHHS	PAR-23- 122 07	-Sep-2024	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name Contact Telephone	Alison Gammie				
	•	alison.gammie@nih.gov				
	Sponsor Website					
	·	Link to program URL				
	Deadline Dates (ALL)	07-Sen-2024 05-Oct-2024 07-Jan-2025 (05-Feb-2025 , 07-May-2025 , 0	5-Jun-2025 , 07-Se	p-2025 <i>,</i> 05-Oct-20	25 , 07-Jan-
	Synopsis	The NIH Research With Activities Related to geographical location of research and resear for the health-related research of scientists Accessibility (DEIA) and who have no curren both the scientific research and the DEIA ac to the programmatic interests of one or more focused on enhancing diversity in the biom	arch-related activities supporte who are making a significant nt NIH research project grant f ctivities of investigators. The g pre of the participating NIH Ins	ed by NIH. The ReW contribution to Div unding. The ReWA rant will support sc titutes and Centers	/ARD program pro ersity, Equity, Inclu RD program provid ientific research in 5 (ICs) and ongoing	vides suppor ision, and es funding fo areas related
16616		Research Project Grants in Valvular Heart D		- 07-9	Sep-2024	Not
	(CAROL Act)		of Health/DHHS	23-079	•	Specified
		Frank Evans, PhD				
	Contact Telephone					
		evansf@nhlbi.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , (2026 , 05-Feb-2026 , 07-May-2026	05-Feb-2025 , 07-May-2025 , 0	5-Jun-2025 , 07-Se	p-2025 , 05-Oct-20	25 , 07-Jan-
		07-Sep-2024, 05-Oct-2024, 07-Jan-2025, 0 2026, 05-Feb-2026, 07-May-2026 As part of the National Heart, Lung, and Blo Opportunities Legacy (CAROL) Act, this Not heart disease.	ood Institute's implementation	of the Cardiovascu	ular Advances in Re	search and

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	<u>sunejas@mail.nih.gov</u>				
	Program URL	Link to program URL 04-Oct-2024 , 02-Jun-2025 , 03-Oct-2025 This Funding Opportunity Announcement (
	Synopsis	that will advance the science of aging in sp utilizes NIH's R61/R33 Exploratory/Develop support for initial developmental activities this award, investigators will endeavor to c interdisciplinary aging research questions.	pmental Phased Award activity . The R33 phase provides up to	code. The R61 phase 3 years of support	se provides up to 2 for expanded activ	years of vities. Through
114328	Advanced-Stage Development an Interdisciplinary Aging Studies (R	d Utilization of Research Infrastructure for 33 Clinical Trial Optional)	National Institutes of Health/DHHS	s PAR-23- 054 04-0)ct-2024	2,499,995 USD
	Contact Telephone	sunejas@mail.nih.gov				
	-	Link to program URL 04-Oct-2024, 02-Jun-2025, 03-Oct-2025 This Funding Opportunity Announcement (and utilization of novel research infrastruct partnerships or collaborations. This FOA ut support for expanded activities. Applicants or non-NIH support. Through this award, in infrastructure to support projects that add	ture to advance the science of tilizes NIH's R33 Exploratory/De are expected to have an exist nvestigators will endeavor to d	aging in specific are evelopmental Grant ing research infrastr evelop a mature and	as requiring interc s Phase II activity o ructure developed d sustainable resea	lisciplinary code to provide with other NIH
093908	NIH Research Project Grant (Pare	nt R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	^s PA-20-185 07-S	ep-2024	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name					
	Contact Telephone					
		grantsinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025				
	Synopsis	The NIH Research Project Grant supports a interests and competencies of the investiga or more of the participating NIH Institutes Announcement does not accept application participate in Parent Announcements. App their respective areas of research interest a participate in this announcement will not c	ator(s). The proposed project r and Centers (ICs) based on the ns proposing clinical trial(s). No licants should carefully note w at the R01 IC-Specific Scientific	must be related to th ir scientific missions ote: Not all NIH Instit hich ICs participate i Interests and Conta	ne programmatic i s. This Funding Op tutes and Centers in this announcem	nterests of one portunity (ICs) nent and view
103168	Research on Autism Spectrum Dis	sorders (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	^S PA-21-201 05-0	ct-2024	Not Specified
	Contact Name	Lisa Gilotty, Ph.D.				
	Contact Telephone	301-443-3825				
	Contact Email	gilottyl@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)					
	Synopsis	The purpose of this Funding Opportunity A research designed to elucidate the etiology Autism Spectrum Disorders (ASD). The Rese based in scientific areas that represent the of the participating NIH Institutes and Cent one or more of the participating NIH Institu generally expected. Applicants pursuing ex project development should consider the c	y, epidemiology, diagnosis, and earch Project Grant (R01) mec investigators' specific interest ters (ICs). The proposed projec utes and Centers (ICs) based or ploratory/developmental rese	d optimal means of s hanism supports disc s and competencies t must be related to n their scientific miss arch to support early	ervice delivery in crete, specified pr , and that fall with the programmatic sions, and prelimin y and conceptual s	relation to ojects hin the mission c interests of hary data are stages of

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	data, and pilot or feasibility studies that car 21-199.	າ be completed with limited bເ	udgets should consi	der the companio	n R03 FOA, PA-
107429 Patient-Clinician Relationship: Im Experience Health Care Disparitie	nproving Health Outcomes in Populations tha es (R01 Clinical Trial Optional)	t National Institutes of Health/DHHS	5 PAR-22- 064 05-C	Oct-2024	Not Specified
Contact Name	Larissa Aviles-Santa, MD, MPH				
Contact Telephone	301-827-6924				
Contact Emai	avilessantal@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024				
Synopsis	(e.g., patient, clinician, interpersonal, health patient-clinician communication and relation disparities. In addition, this initiative will su Relationship (PCR) in the primary care and o populations that experience health disparition leading to better health outcomes and incre-	onship affects health care outcomport research to (1) gain an u chronic disease care settings a ies, and (2) identify best pract	omes in patients fro inderstanding of ho ffects clinical and no	om populations w w the Patient-Clin on-clinical health	ith health care iician outcomes in
110112 <u>Leveraging Health Information To</u> Care Disparities (R01 Clinical Tria	echnology (Health IT) to Address and Reduce Il Optional)	Health National Institutes of Health/DHHS	5 PAR-22- 145 07-S	ep-2024	Not Specified
Contact Name	Yewande A. Oladeinde, Ph.D.				
Contact Telephone					
•	l beda.jean-francois@nih.gov				
Sponsor Website					
•	Link to program URL				
-	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 0)5-Feb-2025 , 07-May-2025			
	This funding opportunity announcement (Fo information technology (health IT) to reduc communication, and health outcomes for p	DA) seeks to support research e disparities in access to and u	itilization of health	care services, pati	-

SPIN ID	Program Title		Sponsor N	ame	Sponsor Num	ber Deadline Date	Funding Amount
110794	Notice of Special Interest (NOSI): Prevention of HIV or Treatment of	Sustained Release of Antivirals for Treatment for Treatment TB/HBV (SRATP)	<u>nt or</u>	National Institutes of Health/DHHS	NOT-AI- 22-042	07-Sep-2024	Not Specified
	Contact Name	Marina Protopopova, Ph.D.					
	Contact Telephone	301-761-7653					
	Contact Email	marina.protopopova@niaid.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , (05-Feb-202	5 , 07-May-2025			
	Synopsis	The purpose of this Notice is to encourage portfolio of SR/LA products for prevention of protection of three (3) months from eith (implant, transdermal patch, etc.) to reflect	and treatm er a single	ent of HIV. SR/LA ar dosing (injection, or	ntiretroviral pr al administrat	oducts will have a mini ion) or continuous dosi	mum window ng regimen
10513		High Priority Areas in Genetics, Epigenetics, anch in the Division of Neuroscience and Beh		National Institutes of Health/DHHS	NOT-DA- 23-004	07-Sep-2024	Not Specified
	Contact Name	Jonathan D. Pollock, Ph.D.					
	Contact Telephone	301-435-1309					
	Contact Email	jpollock@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , (05-Feb-202	5,07-May-2025,0	5-Jun-2025 , 0	7-Sep-2025	
	Synopsis	The mission of the Division of Neuroscience animal and human research aimed at ident guide treatment strategies. The Genetics, E genetics, epigenetics, and developmental n	ifying the c pigenetics,	auses and conseque and Development (ences of drug a GED) Branch v	addiction across the life within DNB supports re	espan and to search on the
.12441	Research to Action: Assessing and Contaminants (R01 Clinical Trial C	d Addressing Community Exposures to Envir Optional)	<u>onmental</u>	National Institutes of Health/DHHS	PAR-22- 210	05-Oct-2024	2,500,000 USD
	Contact Name	Liam O'Fallon					
	Contact Telephone	984-287-3298					
<u>A</u>	School of Medicine at	NIH Funding Opportun	ities Due: ()ct 2024			277

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	ofallon@niehs.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025				
	Synopsis	This Funding Opportunity Announcement (of environmental exposures of concern to plan based on research findings. Projects s to conduct research and to translate resea NIMHD's commitment to environmental he to nurture and sustain trust and bi-directio Research to Action program is part of the N Environmental Public Health" (PEPH) netw (https://www.niehs.nih.gov/research/supp	a community and to develop a upported under this program v rch findings into public health a ealth disparities and environme onal communication between a National Institute of Environme ork	nd implement an er vill employ commun action. This announ ental justice researc cademic researche ntal Health Science	nvironmental publ nity-engaged resea acement reflects N ch. This FOA also a rs and affected cor	ic health action arch methods EHS' and dvances effort: nmunities. The
112472	Notice of Special Interest (NOSI): Dystrophies (R01)	Respiratory Complications of the Muscular	National Institutes of Health/DHHS	NOT-HL- 22-025 07-S	Sep-2024	Not Specified
	Contact Name	Aruna Natarajan, MD, PhD				
	Contact Telephone	• • •				
	Contact Email	aruna.natarajan@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025				
	Synopsis	The purpose of this NOSI is to encourage re dystrophies. This includes further elucidati testing and existing respiratory therapies in animal models, that examines respiratory re muscular dystrophies.	on of respiratory phenotypes in humans; and mechanistic and	n humans; research I translational resea	n to optimize pulm arch, including in v	onary function itro and in
117550		PET and SPECT Imaging Ligands as Biomarke gical Studies of CNS Disorders (R01 Clinical T		5 PAR-23- 164 07-5	5ep-2024	Not Specified

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Enrique Michelotti, Ph.D.						
Contact Telephone							
Sponsor Website	l <u>michelottiel@mail.nih.gov</u>						
•	L Link to program URL						
Deadline Dates (ALL)07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 2026 , 05-Feb-2026 , 07-May-2026SynopsisThis Funding Opportunity Announcement (NOFO) invites research grant applications that propose the developme evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tom (SPECT) imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously coll in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET use in clinical research. Projects proposing only preclinical animal studies should consider the companion NOFO (F 164).							
Contact Name	Enrique Michelotti, Ph.D.						
Contact Telephone	301-443-5415						
Contact Emai	l <u>michelottiel@mail.nih.gov</u>						
Sponsor Website							
Program URI	Link to program URL						
Deadline Dates (ALL	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 2026 , 05-Feb-2026 , 07-May-2026	05-Feb-2025 , 07-May-2025 , 0)5-Jun-2025 , 07-Sep	-2025 , 05-Oct-20	25 , 07-Jan-		
	This Notice of Funding Opportunity (NOFO novel radioligands for positron emission to in rodent and nonhuman primate brain an appropriate model development. Projects 23-164).	pmography (PET) or single phot d incorporation of pilot or clini	on emission comput cal feasibility evalua	ted tomography (S tion in pre-clinical	PECT) imaging studies and		
120387 Secondary Analysis and Integrati	on of Existing Data to Elucidate Cancer Risk	and National Institutes	s PAR-23- 05-0	ct-2024	1,750,000		

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	per Deadline Date	Funding Amount				
	Related Outcomes (R01 Clinical T	rial Not Allowed)	of Health/DHHS	254		USD				
	Contact Name	Melissa Rotunno, Ph.D.								
	Contact Telephone	240-276-7245								
	Contact Email	rotunnom@mail.nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026								
	Synonsis	Through this Notice of Funding Opportunit Institutes encourages submission of applic datasets and database resources, with the reduction, survival, or response to treatme cancer by supporting the analysis of existir	ations proposing to conduct so ultimate aim to elucidate can ent, etc.). The goal of this initia	econdary data ar cer risk and relat tive is to addres	nalysis and integration ed outcomes (e.g., ris s key scientific question	of existing k prediction or ons relevant to				
		lifestyle, genomic, and molecular profiles of existing data. Applications may include new methods of analyses, or novel combination questions in cancer research.	data. Applicants are encourage w research aims that are being	d to leverage an addressed with	d perform innovative existing data, new or	analyses of the advanced				
120821	RFA-HD-24-007 Understanding	lifestyle, genomic, and molecular profiles of existing data. Applications may include new methods of analyses, or novel combination	data. Applicants are encourage w research aims that are being ns and integration of datasets	ed to leverage an gaddressed with that allow the ex	d perform innovative existing data, new or	analyses of the advanced				
120821	RFA-HD-24-007 Understanding People with Disabilities Caused by	lifestyle, genomic, and molecular profiles of existing data. Applications may include new methods of analyses, or novel combination questions in cancer research. and Mitigating Health Disparities Experience	data. Applicants are encourage w research aims that are being ns and integration of datasets <u>ced by</u> National Institute	ed to leverage an g addressed with that allow the ex s RFA-HD-	nd perform innovative existing data, new or oploration of importar	analyses of the advanced it scientific 2,499,995				
120821	<u>RFA-HD-24-007 Understanding</u> <u>People with Disabilities Caused by</u> Contact Name	lifestyle, genomic, and molecular profiles of existing data. Applications may include new methods of analyses, or novel combination questions in cancer research. and Mitigating Health Disparities Experience y Ableism (R01 Clinical Trial Optional) Toyin Ajisafe, PhD	data. Applicants are encourage w research aims that are being ns and integration of datasets <u>ced by</u> National Institute	ed to leverage an g addressed with that allow the ex s RFA-HD-	nd perform innovative existing data, new or oploration of importar	analyses of the advanced it scientific 2,499,995				
120821	RFA-HD-24-007 Understanding People with Disabilities Caused by Contact Name Contact Telephone	lifestyle, genomic, and molecular profiles of existing data. Applications may include new methods of analyses, or novel combination questions in cancer research. and Mitigating Health Disparities Experience y Ableism (R01 Clinical Trial Optional) Toyin Ajisafe, PhD	data. Applicants are encourage w research aims that are being ns and integration of datasets <u>ced by</u> National Institute	ed to leverage an g addressed with that allow the ex s RFA-HD-	nd perform innovative existing data, new or oploration of importar	analyses of the advanced it scientific 2,499,995				
120821	RFA-HD-24-007 Understanding People with Disabilities Caused by Contact Name Contact Telephone	lifestyle, genomic, and molecular profiles of existing data. Applications may include new methods of analyses, or novel combination questions in cancer research. and Mitigating Health Disparities Experience y Ableism (R01 Clinical Trial Optional) Toyin Ajisafe, PhD 301-827-9242 toyin.ajisafe@nih.gov	data. Applicants are encourage w research aims that are being ns and integration of datasets <u>ced by</u> National Institute	ed to leverage an g addressed with that allow the ex s RFA-HD-	nd perform innovative existing data, new or oploration of importar	analyses of the advanced it scientific 2,499,995				
120821	RFA-HD-24-007 Understanding People with Disabilities Caused by Contact Name Contact Telephone Contact Email Sponsor Website	lifestyle, genomic, and molecular profiles of existing data. Applications may include new methods of analyses, or novel combination questions in cancer research. and Mitigating Health Disparities Experience y Ableism (R01 Clinical Trial Optional) Toyin Ajisafe, PhD 301-827-9242 toyin.ajisafe@nih.gov	data. Applicants are encourage w research aims that are being ns and integration of datasets <u>ced by</u> National Institute	ed to leverage an g addressed with that allow the ex s RFA-HD-	nd perform innovative existing data, new or oploration of importar	analyses of the advanced it scientific 2,499,995				
120821	RFA-HD-24-007 Understanding People with Disabilities Caused by Contact Name Contact Telephone Contact Email Sponsor Website Program URL	lifestyle, genomic, and molecular profiles of existing data. Applications may include new methods of analyses, or novel combination questions in cancer research. and Mitigating Health Disparities Experience y Ableism (R01 Clinical Trial Optional) Toyin Ajisafe, PhD 301-827-9242 toyin.ajisafe@nih.gov	data. Applicants are encourage w research aims that are being ns and integration of datasets <u>ced by</u> National Institute of Health/DHHS	ed to leverage an g addressed with that allow the ex s RFA-HD-	nd perform innovative existing data, new or oploration of importar	analyses of the advanced it scientific 2,499,995				
120821	RFA-HD-24-007 Understanding People with Disabilities Caused by Contact Name Contact Telephone Contact Email Sponsor Website Program URL	lifestyle, genomic, and molecular profiles of existing data. Applications may include new methods of analyses, or novel combination questions in cancer research. and Mitigating Health Disparities Experience y Ableism (R01 Clinical Trial Optional) Toyin Ajisafe, PhD 301-827-9242 toyin.ajisafe@nih.gov Link to program URL	data. Applicants are encourage w research aims that are being ns and integration of datasets <u>ced by</u> National Institute of Health/DHHS 05-Feb-2025 , 07-May-2025 earch to understand the impac adversely influences the healt	t of ableism on h	nd perform innovative existing data, new or oploration of importar 07-Sep-2024 nealth outcomes. Rese n disabilities (PWD), as	analyses of the advanced at scientific 2,499,995 USD USD				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
		of Health/DHHS	238		Specified			
Contact Name	Jovier Evans, Ph.D.							
Contact Telephone	301-443-6328							
Contact Email	jevans1@mail.nih.gov							
Sponsor Website								
Program URL	Link to program URL							
Deadline Dates (ALL)	5-Oct-2024 , 02-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026							
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between soo disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R01 applications, while the companion announceme PAR-23-239 solicits R21 applications. High risk/high payoff projects that lack preliminary data may be most appropriate the R21 mechanism.							
20715 Personal Health Informatics for D Clinical Trial Optional)	elivering Actionable Insights to Individuals (R01 National Institute of Health/DHHS	s PAR-23- 245 05-0	Dct-2024	1,000,000 USD			
Contact Name	Allison Dennis, PhD							
Contact Telephone	301-827-9721							
Contact Email	allison.dennis@nih.gov							
Sponsor Website								
Program URL	Link to program URL							
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 ,	05-Oct-2025 , 05-Feb-2026 , 0	5-Jun-2026 <i>,</i> 05-Oct	-2026				
Synopsis	The purpose of this Notice of Funding Oppo science approaches that can help individua participating institutes listed in this NOFO s by providing meaningful and actionable ins analysis, and personalized risk assessments informatics tools, systems, and platforms c assessments for the benefit of individuals a	Is understand and improve th seek applications that further sights to individuals through in and interpretation. Application an best present the results, in	eir health through a the science of perso novative personal h ons seeking to adva terpretation, and lir	ictionable insights. onal health information nealth data collection nce the understand mitations of persor	The NLM and atics on, integratio ding of how nalized			

SPIN ID	Program Title		Sponsor N	ame	Sponsor Num	ber	Deadline Date	Funding Amount
		real-world evaluation to inform the design of and platforms for the benefit of individuals	-				ealth informatics	tools, systems
120817	Population Approaches to Reduci Optional)	ng Alcohol-related Cancer Risk (R01 Clinical	<u>Trial</u>	National Institutes of Health/DHHS	PAR-23- 244	05-0	ct-2024	Not Specified
	Contact Name	David Berrigan						
	Contact Telephone	240-276-6752						
	Contact Email	berrigad@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 0	05-Oct-202	5 , 05-Feb-2026 , 05	-Jun-2026 , 05	5-Oct-2	2026	
	Synopsis	increasing awareness of the relationship be to alcohol consumption, developing and/or implementation of population-level interven levels of consumption, such as moderate an use disorder (AUD) from the perspective of encouraged, as is attention to underreprese disparities such as American Indian, Alaskan	evaluating ntions to re nd heavy dr cancer pre ented mino	alcohol policy appr educe alcohol-relate inking, are of partic vention and contro rity (URM) populati	oaches, and t ed cancer risk. ular interest, l. Proposals ac ons experienc	he dev Appli as wel ddress cing ca	velopment, testing cations that addre II as those focusin ing understudied Incer and alcohol-	g, and ess multiple g on alcohol areas are
111805	Research Opportunities for New a Diversity (R01 Clinical Trial Option	and "At-Risk" Investigators to Promote Work nal)	<u>xforce</u>	National Institutes of Health/DHHS	PAR-22- 181	06-Se	ep-2024	Not Specified
	Contact Name	Albert Avila, Ph.D.						
	Contact Telephone	301-496-8804						
	Contact Email	aavila@nida.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	06-Sep-2024 , 07-Sep-2024 , 08-Oct-2024 , 0 2025 , 07-Sep-2025	07-Jan-202	5 , 08-Jan-2025 , 06	-Feb-2025 , 05	5-May	-2025 , 07-May-20	025 , 06-Jun-
	Synopsis	This Funding Opportunity Announcement (F	FOA) solicit	s R01 grant applicat	ions that prop	oose ir	ndependent resea	irch projects

SPIN ID Program Title	s	ponsor N	lame	Sponsor Numb	er Deadline Date	Funding Amount
	that are within the scientific mission areas of support New Investigators and At-Risk Invest underrepresented in the health-related scier underrepresented groups (e.g., see NOT-OD- institutions to apply for support under this pr work with their institutions to apply.	igators fr nces. Inve 20-031, N	om diverse backgrou stigators from divers Notice of NIH's Intere	unds, including se backgrounds est in Diversity)	those from groups , including those fron , are encouraged to v	n vork with their
105957 <u>Time-Sensitive Obesity Policy an</u>	nd Program Evaluation (R01 Clinical Trial Not Al	lowed)	National Institutes of Health/DHHS	PAR-21- 305)9-Aug-2024	Not Specified
Contact Nam	e Mary Evans, Ph.D.					
Contact Telephon	e 301-594-4578					
Contact Ema	il <u>evansmary@mail.nih.gov</u>					
Sponsor Websit	re la					
Program UF	L Link to program URL					
Deadline Dates (AL	L) 09-Aug-2024 , 10-Sep-2024 , 09-Oct-2024 , 0	7-Nov-20	24 , 10-Dec-2024 , 0	9-Jan-2025		
Synops	This Funding Opportunity Announcement (FC research to evaluate a new policy or program activity, sedentary behavior, and/or sleep) ar intended to support research where opportu expedited review and funding. All application related policy or program offers an uncomme the research is initiated with minimum delay eligible for re-submission. It is intended that application due date; however, administrativ beyond that timeline.	n that is li nd/or we inities for ns submit on and so . For thes eligible a	kely to influence obe ight outcomes in an empirical study are, ted to this FOA must ientifically-compellin se reasons, application pplications selected	esity related be effort to prever by their very n demonstrate t ng research opp ons submitted t for funding will	haviors (e.g., dietary at or reduce obesity. ature, only available hat the evaluation of portunity that will onl o this time-sensitive be awarded within 4	intake, physical This FOA is through an obesity- y be available if FOA are not months of the
121565 Health and Health Care Disparit Trials Optional)	ies Among Persons Living with Disabilities (R01	<u>- Clinical</u>	National Institutes of Health/DHHS	PAR-23- 309	05-Oct-2024	Not Specified
Contact Nam	e Sundania J. W. Wonnum, PhD, LCSW					
Contact Telephon	e					
Contact Ema	il <u>sundania.wonnum@nih.gov</u>					

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount				
Sponsor Website	s								
Program URI	Link to program URL								
Deadline Dates (ALL	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 ,	05-Oct-2025 , 05-Feb-2026 , 0	5-Jun-2026 , 05-Oct	-2026					
The purpose of this Notice of Funding Opportunity (NOFO) is to support novel and innovative research that examines Synopsis intervenes on the underlying and multilevel causes, pathways, and factors adversely impacting the health and well-b persons with disabilities at the intersections of race and ethnicity, and socioeconomic status.									
	Disparities in Non-Communicable and Chron g the Stage for Better Health Outcomes Acro Not Allowed)	National Institute	s PAR-23- 303 07-5	Sep-2024	Not Specified				
Contact Name	Larissa Avilés-Santa, MD, MPH, Director								
Contact Telephone	301-827-6924								
Contact Emai	avilessantal@nih.gov								
Sponsor Website									
Program URI	Link to program URL								
Deadline Dates (ALL	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun	· · · · · · · · · · · · · · · · · · ·		p-2025 , 05-Oct-20	25 , 07-Jan-				
Synopsis	This Notice of Funding Opportunity (NOFO clinical epidemiology, evaluation of public and healthcare disparities related to non-c mortality in Latin America and among U.S.	and/or health care policies, ar ommunicable and chronic disc	nd validation of mea	surements that ad	dress health				
121337 NIAID and NIDDK Research Oppo	ortunities for New and "At-Risk" Investigator	s to National Institute	s PAR-23-	Sep-2024	Not				
Promote Workforce Diversity (RC	01 Clinical Trial Optional)	of Health/DHHS	275	sep-2024	Specified				
Contact Name	Diane Adger-Johnson, MPH								
Contact Telephone	240-669-2924								
Contact Emai	Altraininghelpdesk@niaid.nih.gov								
Sponsor Website									
Program URI	Link to program URL								
Deadline Dates (ALL	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 ,	05-Feb-2025 , 07-May-2025 ,	05-Jun-2025 , 07-Se	p-2025					

SPIN ID	Program Title		Sponsor N	ame	Sponsor Num	ber Deadlir	e Date	Funding Amount
	Synopsis	The purpose of this notice of funding oppor with their institutions to submit application seeks to support either (a) a New Investigat independent funding from NIH, or (b) an 'At research award and unless successful in sec substantial research grant funding in the fol	s for resea or (NI), wh t-Risk' inve turing a sub	rch projects within t o has not previously stigator, who had pr ostantial research gra	he mission of competed su ior support as	either NIAID o ccessfully for a PD/PI on a	or NIDDK. substanti substanti	This NOFO al, al independent
120869 Al		Referral to Treatment or Prevention (SBIRT/ gs (ATOD) Use and Misuse in Adult Populatio 1, Clinical Trial Required)		National Institutes of Health/DHHS	PAR-23- 270	05-Oct-2024		Not Specified
	Contact Name	Denise Stredrick, Ph.D.						
	Contact Telephone	301-402-9749						
	Contact Email	denise.stredrick@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 0	05-Oct-202	5 , 05-Feb-2026 , 05	-Jun-2026 , 05	-Oct-2026 , 0	5-Feb-202	27
	Synopsis	The Office of Disease Prevention (ODP) and (ICOs) are issuing this NOFO seeking applica and other drugs (ATOD) use and misuse in a purposes of this funding announcement), in with a conversation about harmful substand needed. Proposed research should include and community partners Specific research in	ations to te adult popul avolves scre ce use, and prospectiv	st innovative approa ations that experien eening individuals fo referring individuals e tests of SBIRT/P ar	iches to imple ce health disp r risk of ATOD s for treatmer nd should leve	menting SBIR arities. SBIRT use and misu t or preventiv rage collabor	T/P for al /P, (a ter se, briefl ve service	cohol, tobacco, m used for y intervening s, as
1/1//6	nproving Care and Outcomes fo GM) Populations (R01 Clinical T	r Cancer Survivors from Sexual and Gender N rial Optional)	<u> Minority</u>	National Institutes of Health/DHHS	PAR-23- 292	05-Oct-2024		Not Specified
	Contact Telephone Contact Email Sponsor Website	David Dean Jr., Ph.D., M.S. 240-276-8703 <u>bconnole@mail.nih.gov</u> <u>Link to program URL</u>						

SPIN ID Program Title		Sponsor N	ame	Sponsor Numl	per Deadline Date	Funding Amount
	05-Oct-2024, 05-Feb-2025, 05-Jun-2025, Through this notice of funding opportunity assessment of barriers to quality cancer tree This funding opportunity is intended to add survivors. The goal is to address the disease poorer health outcomes. The NCI solicits pr to understand barriers and/or improve care orientation and gender identity (SOGI) data	(NOFO), th eatment and dress a critic e burden in roposals for e and outco	e National Cancer In d follow-up care for cal need for improve an underserved and observational and/o mes for SGM people	stitute (NCI) in sexual and gen d care deliver l understudiec or intervention e with cancer,	ntends to support the r nder minority (SGM) can y and outcomes for SGM population that is at h nal studies of SGM surv using interoperable sex	A cancer d cancer gher risk of ivors designed
121563 Developing Novel Theory and Me Complex Human Traits (R01 Clinic	thods for Understanding the Genetic Archit cal Trial Not Allowed)	ecture of	National Institutes of Health/DHHS	PAR-23- 302	05-Oct-2024	Not Specified
Contact Name	Alexander Arguello, Ph.D.					
Contact Telephone	240-731-3753					
Contact Email	alexander.arguello@mail.nih.gov					
Sponsor Website						
-	Link to program URL					
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 ,	05-Oct-202	5 , 05-Feb-2026 , 05-	-Jun-2026 , 05	-Oct-2026	
	The goal of this NOFO is to support application of how genetic and non-genetic factors cor Approaches should be interdisciplinary dra- scales of biological, social, and ecological of available large-scale datasets.	ntribute to o wing from t	complex trait variation to the natural and social	on across indiv Il sciences, acc	iduals, families, and po ount for interdepender	pulations. ncies across
124219 Long-Term Effects of Disasters on Disparities (R01- Clinical Trial Opt	Healthcare Systems in Populations with He ional)	<u>alth</u>	National Institutes of Health/DHHS		06-Sep-2024 [Optional][LOI/Pre-App	Not] Specified
Contact Name	Carolina Solis-Sanabria, MD, MPH, FACS					
Contact Telephone	301-827-3460					
Contact Email	carolina.solissanabria@nih.gov					
Sponsor Website						
Program URL	Link to program URL					

SPIN ID	Program Title		Sponsor N	lame	Sponsor Num	ber Deadline Date	Funding Amount
	Deadline Dates (ALL)	06-Sep-2024 [Optional][LOI/Pre-App], 07-Sep-2025, 06-May-2025 [Optional][LOI/Pre 2025, 05-Oct-2025, 06-Jan-2026 [Optional App], 07-May-2026, 05-Jun-2026, 06-Sep- [Optional][LOI/Pre-App], 07-Jan-2027, 05-Fe The purpose of this Notice of Funding Oppo	e-App], 07- I][LOI/Pre-, 2026 [Opti Feb-2027 ,	May-2025 , 05-Jun-2 App], 07-Jan-2026 , (onal][LOI/Pre-App], 07-May-2027	025 , 06-Sep-2)5-Feb-2026 , (07-Sep-2026 ,	2025 [Optional][LOI/Pr 06-May-2026 [Optiona 05-Oct-2026 , 06-Jan-2	e-App], 07-Sep- il][LOI/Pre- 2027
	Synopsis	long-term effects of natural and/or human- disparities living in the U.S. and its territorio	-made disa				-
1 /1 /24	RFA-NS-24-021 HEAL Initiative: Conditions (R01 - Clinical Trial Op	Understanding Individual Differences in Huittional)	<u>man Pain</u>	National Institutes of Health/DHHS	RFA-NS- 24-021	08-Oct-2024	3,250,000 USD
	Contact Name	D.P. Mohapatra, Ph.D.					
	Contact Telephone	301-496-9964					
	Contact Email	dp.mohapatra@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	08-Oct-2024 , 06-Feb-2025					
	Synopsis	This notice of funding opportunity (NOFO) is between-person differences in human pain management strategies towards personaliz collection of clinical and/or preclinical data differences and/or heterogeneity of pain or second pain condition, a comorbid health co opioids, alcohol or other substances. Applic approaches, and include investigators with patients and caregivers on the goals of the approaches supported under this NOFO are underpinnings of inter-individual difference would accelerate the development of evide	a condition to enable ccurring w condition, a cants are e compleme project is l e expected es, heterog	s, focusing on 'Who edicine. The goal of t evidence-based mod ith use of pain therap a comorbid mental h ncouraged to develo entary expertise to fu- nighly encouraged. R to provide better ur geneity, and stratifica	e Person Heal his NOFO is to deling and und by/manageme ealth condition p and implement and implement igorous data-co iderstanding o tion of person	th' and enhancing pair support studies that erstanding of inter-inc nt, or with conditions n, or conditions of use ent novel, multidiscipl t and program goals. I lriven and evidence-ba f biological and/or bio s with lived pain expe	n treatment and focus on the lividual such as a / misuse of inary research nput from ased research psychosocial
1738/17		pping Mechanisms in TDP-43 Proteinopathie DRDs (R01 - Clinical Trial Not Allowed)	<u>es,</u>	National Institutes of Health/DHHS	PAR-24- 148	04-Oct-2024	2,500,000 USD



SPIN ID	Program Title		Sponsor N	ame	Sponsor Num	ber Deadline Date	Funding Amount
		Linda McGavern, PhD					
	Contact Telephone						
		mcgavernlm@ninds.nih.gov					
	Sponsor Website						
	-	Link to program URL					
	Deadline Dates (ALL)	04-Oct-2024					
	Synopsis	This Notice of Funding Opportunity (NOFO molecular relationships between TDP-43 p between at least two TDP-43 proteinopath as, but not limited to, Limbic-predominant neuropathological change (AD-NC), or From understand distinct and overlapping mecha	athology ar nies, one of Age-relate ntotempora	nd clinical phenotypi which must be an A d TDP-43 Encephalo I lobar degeneration	c outcomes. A Izheimer's Dise pathy (LATE), v	dditionally, it requires ease-Related Dementia vith or without Alzheir	comparisons a (ADRD), such mer's disease
1738/16		DRD Multiple Etiology Dementias (R01 - Clir	nical Trial	National Institutes		04-Oct-2024	2,500,000
	<u>Not Allowed)</u>			of Health/DHHS	147		USD
		Linda McGavern, PhD					
	Contact Telephone						
		mcgavernlm@ninds.nih.gov					
	Sponsor Website						
	-	Link to program URL					
	Deadline Dates (ALL)	04-Oct-2024					
	Synopsis	This Notice of Funding Opportunity (NOFO Dementias (ADRD) co-pathologies (e.g., tau co-morbidities, in the same model system whether, and when these interactive multi outcomes, such as cognitive, behavioral, or	u, alpha-syr to identify i i-pathology	uclein, TDP-43, TMI nteractions and cell mechanisms drive v	EM106B, vascu ular and molec	lar), with or without ri cular mechanisms to d	isk factors and etermine how,
122945	Multidisciplinary Studies of HIV/A	NDS and Aging (R01 Clinical Trial Optional)		National Institutes of Health/DHHS	PAR-24- 091	07-Sep-2024	Not Specified
	Contact Name	Ann Namkung, MPH					



SPIN ID	Program Title		Sponsor Name	Sponsor Numb	per Deadline Date	Funding Amount
	Contact Telephone	301-496-6838				
	Contact Email	ann.namkung@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun)25 , 07-Jan-
	Synopsis	This NOFO invites applications at the inters objectives: 1) Improve the understanding of infection and its treatment; and 2) Improve related comorbidities, co-infections, and co aging science approaches. Proposed resear Office of AIDS Research (OAR), as described	of biological, clinical, and socie e approaches for testing, prev omplications in different popu rch must be consistent with th	b-behavioral aspe enting, and treat lations and cult	ects of aging through t ing HIV infection, and ural settings by applyin	the lens of HIV I managing HIV- ng current
122756	Addressing Health and Health Cal Populations (R01 - Clinical Trials C	re Disparities among Sexual and Gender Mir Optional)	nority National Institute of Health/DHHS	es PAR-24- 077	07-Sep-2024	2,500,000 USD
	Contact Name	Rada K. Dagher, Ph.D., M.P.H.				
	Contact Telephone	301-451-2187				
	Contact Email	ada.dagher@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 02026 , 05-Feb-2026 , 07-May-2026 , 05-Jun	05-Feb-2025 , 07-May-2025 , -2026 , 07-Sep-2026 , 05-Oct	05-Jun-2025 , 07 2026 , 07-Jan-20	-Sep-2025 , 05-Oct-20 27)25 , 07-Jan-
	Synopsis	The purpose of this Notice of Funding Opporesearch to identify and characterize the particular among sexual and gender minority populat Number: NOT-MH-24-170: Research Priorit trials applications that reflect the mission a Institute of Mental Health Strategic Plan (n trial applications will not be accepted under human research participants will collect a reflect to the mission of the mathematic section of	athways and mechanisms thr tions of minoritized racial/eth ties The National Institute of I and scientific priorities as ider ih.gov) and also NIMH's Appr er this notice. Per NOT-MH-20	ough which healt nic and socio-eco Mental Health (N Itified in the stra oach to Mental H -067, NIMH expe	h and health care disp nomic statuses. Per IMH) will only accept tegic plan NIMH » The lealth Disparities Rese	parities occur Notice nonclinical e National earch. Clinical

SPIN ID	Program Title	Spon	isor Name	Sponsor Number	Deadline Date	Funding Amount
121869		thcare Disparities on Non-Communicable and Chr ing Health Outcomes Across the Hemisphere (RO	National Institutos	PAR-23- 07-S 304	ep-2024	Not Specified
	Contact Name	Larissa Avilés-Santa, MD, MPH, Director				
	Contact Telephone	301-827-6924				
	Contact Email	avilessantal@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Fe 2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026			o-2025 , 05-Oct-20	25 , 07-Jan-
	Synopsis	The purpose of this Notice of Funding Opportuni focused on clinical, health services, and/or comn related to non-communicable and chronic diseas	nunity-based interventior	is that address hea	Ith and healthcare	disparities
		and among U.S. Hispanics/Latinos.	ses (NCDs) with the highe	st disease burden a	and mortality in Lat	in America
123009	Discovery of in vivo Chemical Pro Allowed)			PAR-24-	Dct-2024	Not Specified
123009	Allowed)	and among U.S. Hispanics/Latinos.	t National Institutes	PAR-24- 05-0		Not
123009	Allowed)	and among U.S. Hispanics/Latinos. bes for the Nervous System (R01 Clinical Trial Not Enrique L. Michelotti, Ph.D.	t National Institutes	PAR-24- 05-0		Not
123009	Allowed) Contact Name Contact Telephone	and among U.S. Hispanics/Latinos. bes for the Nervous System (R01 Clinical Trial Not Enrique L. Michelotti, Ph.D.	t National Institutes	PAR-24- 05-0		Not
123009	Allowed) Contact Name Contact Telephone	and among U.S. Hispanics/Latinos. bes for the Nervous System (R01 Clinical Trial Not Enrique L. Michelotti, Ph.D. 301-443 5415 <u>michelottiel@mail.nih.gov</u>	t National Institutes	PAR-24- 05-0		Not
123009	Allowed) Contact Name Contact Telephone Contact Email Sponsor Website	and among U.S. Hispanics/Latinos. bes for the Nervous System (R01 Clinical Trial Not Enrique L. Michelotti, Ph.D. 301-443 5415 <u>michelottiel@mail.nih.gov</u>	t National Institutes	PAR-24- 05-0		Not
123009	Allowed) Contact Name Contact Telephone Contact Email Sponsor Website Program URL	and among U.S. Hispanics/Latinos. <u>bes for the Nervous System (R01 Clinical Trial Not</u> Enrique L. Michelotti, Ph.D. 301-443 5415 <u>michelottiel@mail.nih.gov</u>	t National Institutes of Health/DHHS	PAR-24- 088	Oct-2024	Not

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber Deadline Date	Funding Amount
		placed on projects that provide new insight	into important disease-related	d biological tar	gets and biological p	processes.
122108	RFA-AI-23-061 Long-Acting Dru Living with HIV-1 II (LADDS II) (R6	g Delivery Systems for ART Optimization in C 1/R33 Clinical Trial Not Allowed)	<u>children</u> National Institutes of Health/DHHS	RFA-AI-23- 061	07-Sep-2024	5,450,000 USD
	Contact Name	Tania B. Lombo Rodriguez, Ph.D.				
	Contact Telephone	301-761-7612				
	Contact Email	tania.lombo@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 0	5-Feb-2025 , 07-May-2025			
		The purpose of this Notice of Funding Oppo		•		
	Synopsis	drug delivery systems for improved, simplifind development of existing long-acting platform that enable product optimization and accele with industry are required.	ms at early stages of developm	nent stages to	perform specific pre	clinical activities
.22024	Synopsis	development of existing long-acting platform that enable product optimization and accele with industry are required.	ms at early stages of developm erated translation to HIV-infec	nent stages to ted children. C	perform specific pre	clinical activities
22024	Synopsis Understanding the Impact of Hea Maternal Morbidity and Mortality	development of existing long-acting platform that enable product optimization and accele with industry are required.	ms at early stages of developm erated translation to HIV-infec arities in National Institutes	nent stages to ted children. C PAR-24-	perform specific pre- ollaborative researc	clinical activities h partnerships Not
22024	Synopsis Understanding the Impact of Hea Maternal Morbidity and Mortality	development of existing long-acting platform that enable product optimization and accele with industry are required. Ithcare System and Clinician Factors on Disp y (R01 - Clinical Trial Optional) Rada K. Dagher, PhD, MPH	ms at early stages of developm erated translation to HIV-infec arities in National Institutes	nent stages to ted children. C PAR-24-	perform specific pre- ollaborative researc	clinical activities h partnerships Not
.22024	Synopsis Understanding the Impact of Hea Maternal Morbidity and Mortality Contact Name Contact Telephone	development of existing long-acting platform that enable product optimization and accele with industry are required. Ithcare System and Clinician Factors on Disp y (R01 - Clinical Trial Optional) Rada K. Dagher, PhD, MPH	ms at early stages of developm erated translation to HIV-infec arities in National Institutes	nent stages to ted children. C PAR-24-	perform specific pre- ollaborative researc	clinical activities h partnerships Not
.22024	Synopsis Understanding the Impact of Hea Maternal Morbidity and Mortality Contact Name Contact Telephone	development of existing long-acting platform that enable product optimization and accele with industry are required. Ithcare System and Clinician Factors on Disp y (R01 - Clinical Trial Optional) Rada K. Dagher, PhD, MPH 301-451-2187 rada.dagher@nih.gov	ms at early stages of developm erated translation to HIV-infec arities in National Institutes	nent stages to ted children. C PAR-24-	perform specific pre- ollaborative researc	clinical activities h partnerships Not
122024	Synopsis Understanding the Impact of Hea Maternal Morbidity and Mortality Contact Name Contact Telephone Contact Email Sponsor Website	development of existing long-acting platform that enable product optimization and accele with industry are required. Ithcare System and Clinician Factors on Disp y (R01 - Clinical Trial Optional) Rada K. Dagher, PhD, MPH 301-451-2187 rada.dagher@nih.gov	ms at early stages of developm erated translation to HIV-infec arities in National Institutes	nent stages to ted children. C PAR-24-	perform specific pre- ollaborative researc	clinical activities h partnerships Not
122024	Synopsis Understanding the Impact of Hea Maternal Morbidity and Mortality Contact Name Contact Telephone Contact Email Sponsor Website Program URL	development of existing long-acting platform that enable product optimization and accele with industry are required. <u>Ithcare System and Clinician Factors on Disp</u> <u>y (R01 - Clinical Trial Optional)</u> Rada K. Dagher, PhD, MPH 301-451-2187 <u>rada.dagher@nih.gov</u>	ms at early stages of developm erated translation to HIV-infec arities in National Institutes of Health/DHHS	nent stages to ted children. C PAR-24- 059	perform specific pre- collaborative researc 05-Oct-2024	clinical activities h partnerships Not
122024	Synopsis Understanding the Impact of Hea Maternal Morbidity and Mortality Contact Name Contact Telephone Contact Email Sponsor Website Program URL	development of existing long-acting platform that enable product optimization and accele with industry are required. Ithcare System and Clinician Factors on Disp y (R01 - Clinical Trial Optional) Rada K. Dagher, PhD, MPH 301-451-2187 rada.dagher@nih.gov Link to program URL 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 0	ms at early stages of developm erated translation to HIV-infec arities in National Institutes of Health/DHHS	nent stages to ted children. C PAR-24- 059	perform specific pre- collaborative researc 05-Oct-2024	clinical activities h partnerships Not
	Synopsis Understanding the Impact of Hea Maternal Morbidity and Mortality Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Notice of Special Interest (NOSI):	development of existing long-acting platform that enable product optimization and accele with industry are required. Ithcare System and Clinician Factors on Disp y (R01 - Clinical Trial Optional) Rada K. Dagher, PhD, MPH 301-451-2187 rada.dagher@nih.gov Link to program URL 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 0 Increasing Uptake of Evidence-Based Screen	ms at early stages of developm erated translation to HIV-infec arities in National Institutes of Health/DHHS 05-Oct-2025 , 05-Feb-2026 , 05 ing in National Institutes	PAR-24- 059 -Jun-2026 , 05	perform specific pre- collaborative researc 05-Oct-2024	clinical activities h partnerships Not Specified
122024	Synopsis Understanding the Impact of Hea Maternal Morbidity and Mortality Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Notice of Special Interest (NOSI): Diverse Populations Across the Li	development of existing long-acting platform that enable product optimization and accele with industry are required. Ithcare System and Clinician Factors on Disp y (R01 - Clinical Trial Optional) Rada K. Dagher, PhD, MPH 301-451-2187 rada.dagher@nih.gov Link to program URL 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 0 Increasing Uptake of Evidence-Based Screen fespan	ms at early stages of developm erated translation to HIV-infec arities in National Institutes of Health/DHHS 05-Oct-2025 , 05-Feb-2026 , 05	PAR-24- 059 G-Jun-2026 , 05	perform specific pre- collaborative researc 05-Oct-2024 -Oct-2026	clinical activities h partnerships Not Specified
	Synopsis Understanding the Impact of Hea Maternal Morbidity and Mortality Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Notice of Special Interest (NOSI): Diverse Populations Across the Li	development of existing long-acting platform that enable product optimization and accele with industry are required. Ithcare System and Clinician Factors on Disp y (R01 - Clinical Trial Optional) Rada K. Dagher, PhD, MPH 301-451-2187 rada.dagher@nih.gov Link to program URL 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 0 Increasing Uptake of Evidence-Based Screen fespan Melissa C. Green Parker, PhD	ms at early stages of developm erated translation to HIV-infec arities in National Institutes of Health/DHHS 05-Oct-2025 , 05-Feb-2026 , 05 ing in National Institutes	PAR-24- 059 -Jun-2026 , 05	perform specific pre- collaborative researc 05-Oct-2024 -Oct-2026	clinical activities h partnerships Not Specified

Contact Name Melissa C. Green Parker, PhD Contact Telephone 301-480-1161 Contact Email melissa.greenparker@nih.gov Sponsor Website Program URL Deadline Dates (ALL) 07-Sep-2024, 05-Oct-2024, 08-Oct-2024, 16-Oct-2024, 07-Jan-2025, 05-Feb-2025, 16-Feb-2025, 07-May-2025 The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Office: (ICs) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and har cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approach to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. Notice of Special Interest (NOSI): Community-Based Participatory Research (CBPR) National Institutes NOT-OD- 07-Sep-2024 Not	SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Program URL Link to program URL Deadline Dates (ALL) 07-Sep-2024, 05-Oct-2024, 08-Oct-2024, 16-Oct-2024, 07-Jan-2025, 05-Feb-2025, 16-Feb-2025, 07-May-2025 The Office of Disease Prevention (ODP) and participating National Institutes of Health (NH) Institutes, Centers, and Office (ICs) are issuing this Notice of Special Interest (NOS): to encourage applications proposing to test multiveles! strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in populations including but not limited to, those experiencing health disparities and those that are understand and address barriers is screening are encouraged. 112421 Notice of Special Interest (NOS): Addressing Evidence Gaps in Screening National Institutes NOT-OD of -Sep-2024 Not Specifie 112421 Contact Name Melissa C. Green Parker, PhD 07-Sep-2024, 05-Oct-2024, 06-Oct-2024, 16-Oct-2024, 07-Jan-2025, 05-Feb-2025, 16-Feb-2025, 07-May-2025 Not Specifie Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-Sep-2024, 05-Oct-2024, 06-Oct-2024, 16-Oct-2024, 07-Jan-2025, 05-Feb-2025, 16-Feb-2025, 07-May-2025 Not Specifie Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-Sep-2024, 05-Oct-2024, 06-Oct-2024, 06-Oct-2024, 07-Jan-2025, 05-Feb-2025, 07-May-2025 Specifie Synopsis Spensor Website Program URL Link to program URL Ink to program URL Ink to program URL	Contact Emai	melissa.greenparker@nih.gov				
Deadline Dates (ALL) 07-Sep-2024, 05-Oct-2024, 08-Oct-2024, 16-Oct-2024, 07-Jan-2025, 05-Feb-2025, 16-Feb-2025, 07-May-2025 The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Office (ICS) are issuing this Notice of Special Interest (NOSI) to encourage applications proposing to test multilevel strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in populations including but not limited to, those experiencing health disparities and those that are underserved. Studies addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address barriers is screening are encouraged. 112421 Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening National Institutes of NOT-OD- of Health/DHHS NOT-OD- 22-179 07-Sep-2024 Not Specifie 112421 Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening National Institutes of Health (NIH) Institutes, Centers, and Office in Health (ICS) are issuing this Motice of Special Interest (NOSI): Addressing Evidence Gaps in Screening National Institutes of Health (NIH) Not 112421 Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening National Institutes of Health (NIH) Not 112421 Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening National Institutes of Health (NIH) Not 112421 Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening evice well	Sponsor Website					
12421 Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening National Institutes of Health (NIH) Institutes, Centers, and Office (ICs) are issuing this Notice of Special Interest (NOSI) to encourage applications proposing to test multilevel strategies and but not limited to, those experiencing health disparities and those that are underserved. Studies addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address barriers is screening are encouraged. 12421 Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening National Institutes is addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address barriers is screening are encouraged. 12421 Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening National Institutes is addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address barriers is screening are encouraged. 12421 Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening National Institutes is addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address barriers is screening are encouraged. 12421 Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening National Institutes is in Studies is addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address is gerefie 12421 Contact Name Melissa C. Green Parker, PhD<	Program URI	Link to program URL				
12421 Notice of Special Interest (NOSI): Concourage applications proposing to test multilevel strategies and inprove the uptake of evidence-based screening services across the lifespan and in populations including but not limited to, those experiencing health disparities and those that are underserved. Studies addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address barriers is screening are encouraged. Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening National Institutes of Addressing Evidence Gaps in Screening Notice of Special Interest (NOSI): Contact Name Melissa C. Green Parker, PhD Notice Of Special Interest (NOSI): Contact Telephone Gontact Telephone Contact Telephone Program URL Deadline Dates (ALL) Melissa C. Green Parker, PhD Notice of Special Interest (NOSI): Contact Name Melissa greenparker@nih.gov Notice of Special Interest (NOSI): Contact Name Melissa greenparker@nih.gov Notice of Special Interest (NOSI): Contact Telephone Gontact Telephone Contact Telephone Contact Telephone Sponsor Website Notice of Disease Prevention (ODP) and participating National Institutes of Health (NHI) Institutes, Centers, and Office (ICS) are issuing this Notice of Special Interest (NOSI): cosilicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and han cannot be determined. This NOSI encourages the devicement and use of innovative and rigorous methods and approach to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. Interest (NOSI): Community-Based Participatory Research (CBPR) Diverse Representation in Research On Down Syndrome (R21 Clinical	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 1	6-Oct-2024 , 07-Jan-2025 , 05	-Feb-2025 , 16-Feb	-2025 , 07-May-20	25
112421 Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening of Health/DHHS 22-179 07-Sep-2024 Specifie Specifie Contact Name Melissa C. Green Parker, PhD 301-480-1161 301-480-1161 301-480-1161 Specifie Contact Telephone 301-480-1161 melissa.greenparker@nih.gov Sponsor Website Program URL Ink to program URL Ink to program URL Deadline Dates (ALL) 07-Sep-2024, 05-Oct-2024, 08-Oct-2024, 16-Oct-2024, 07-Jan-2025, 05-Feb-2025, 16-Feb-2025, 07-May-2025 The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Office Synopsis Synopsis Synopsis Synopsis Specifie Synopsis Specifie Notice of Special Interest (NOSI): Community-Based Participatory Research (CBPR) National Institutes NOT-OD- O7-Sep-2024 Not 112791 Notice of Special Interest (NOSI): Community-Based Participatory Research (CBPR) National Institutes NOT-OD- O7-Sep-2024 Specifie Synopsis Linkta Bardhan, Ph.D. Social Array Specifie Specifie Specifie	Synopsis	(ICs) are issuing this Notice of Special Intere interventions to improve the uptake of evid but not limited to, those experiencing healt effectiveness, dissemination and implement	st (NOSI) to encourage applica ence-based screening services h disparities and those that ar	ations proposing to s across the lifespar e underserved. Stu	test multilevel stran n and in population dies addressing eff	ategies and ns including, ficacy,
Contact Telephone 301-480-1161 Contact Email melissa.greenparker@nih.gov Sponsor Website Program URL Deadline Dates (ALL) 07-sep-2024, 05-Oct-2024, 08-Oct-2024, 16-Oct-2024, 07-Jan-2025, 05-Feb-2025, 16-Feb-2025, 07-May-2025 The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Officers (ICS) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and har cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approach to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. 12791 Notice of Special Interest (NOSI): community-Based Participatory Research (CBPR) initiative in Reducing and Eliminating Health Disparities With a Focus on Addressing Diverse Representation in Research on Down Syndrome (R21 Clinical Trial Optional) National Institutes NOT-OD- 22-142 07-Sep-2024 Not Specifie Vontact Name Sujata Bardhan, Ph.D. Sujata Bardhan, Ph.D. National Institutes NOT-OD- 07-Sep-2024 Specifie	12421 Notice of Special Interest (NOSI):	Addressing Evidence Gaps in Screening		07-9	Sep-2024	Not Specified
Contact Email Sponsor Website melissa.greenparker@nih.gov Sponsor Website Program URL Deadline Dates (ALL) 07-Sep-2024, 05-Oct-2024, 08-Oct-2024, 16-Oct-2024, 07-Jan-2025, 05-Feb-2025, 16-Feb-2025, 07-May-2025 The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Office. (ICs) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and har cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approach to close high priority evidence gaps to elevate screen is services to a level suitable for a definitive grade or recommendation. 12791 Notice of Special Interest (NOSI): Community-Based Participatory Research (CBPR) initiative in Reducing and Elimiting Health Disparities With a Focus on Addressing Diverse Representation in Research On Down Syndrome (R21 Clinical Trial Optional) National Institutes NOT-OD- 22-142 07-Sep-2024 Not Specifie Contact Name Sujata Bardhan, Ph.D. Sujata Bardhan, Ph.D. National Institutes NOT-OD- 22-142 07-Sep-2024 Not Specifie	Contact Name	Melissa C. Green Parker, PhD				
Sponsor Website Program URL Deadline Dates (ALL) Deadline Dates (ALL) O7-Sep-2024, 05-Oct-2024, 08-Oct-2024, 16-Oct-2024, 07-Jan-2025, 05-Feb-2025, 16-Feb-2025, 07-May-2025 The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Office. Synopsia The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Office. Synopsia The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Office. Synopsia The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Office. Synopsia The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Office. Synopsia Sprontive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and har cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approach to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. 12791 Notice of Special Interest (NOSI): Community-Based Participatory Research (CBPR) initiative in Reducing and Eliminating Health Disparities With a Focus on Addressing Diverse Representation in Research On Down Syndrome (R21 Clinical Trial Optional) National Institutes of Health/DHHS 07-Sep-2024 Not Specifie <td>Contact Telephone</td> <td>301-480-1161</td> <td></td> <td></td> <td></td> <td></td>	Contact Telephone	301-480-1161				
Program URL Link to program URL Deadline Dates (ALL) 07-Sep-2024, 05-Oct-2024, 08-Oct-2024, 16-Oct-2024, 07-Jan-2025, 05-Feb-2025, 16-Feb-2025, 07-May-2025 The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Office Synopsis (ICs) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and har cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approach to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. 12791 Notice of Special Interest (NOSI): community-Based Participatory Research (CBPR) Initiative in Reducing and Eliminating Health Disparities With a Focus on Addressing Diverse Representation in Research On Down Syndrome (R21 Clinical Trial Optional) National Institutes NOT-OD- 22-142 07-Sep-2024 Not Specifie L2791 Contact Name Sujata Bardhan, Ph.D. Sujata Bardhan, Ph.D. National Institutes NOT-OD- 22-142 07-Sep-2024 Not Specifie	Contact Emai	melissa.greenparker@nih.gov				
Deadline Dates (ALL) 07-Sep-2024, 05-Oct-2024, 08-Oct-2024, 16-Oct-2024, 07-Jan-2025, 05-Feb-2025, 16-Feb-2025, 07-May-2025 The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Office, (ICs) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and har cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approach to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. 12791 Notice of Special Interest (NOSI): Community-Based Participatory Research (CBPR) initiative in Reducing and Eliminating Health Disparities With a Focus on Addressing Diverse Representation in Research On Down Syndrome (R21 Clinical Trial Optional) National Institutes NOT-OD- of Health/DHHS 22-142 07-Sep-2024 Not Specifie Contact Name Sujata Bardhan, Ph.D. Sujata Bardhan, Ph.D. Sujata Bardhan, Ph.D. Sujata Bardhan, Ph.D.	Sponsor Website	2				
The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Office (ICs) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and har cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approach to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or12791Notice of Special Interest (NOSI): Community-Based Participatory Research (CBPR) Initiative in Reducing and Eliminating Health Disparities With a Focus on Addressing Diverse Representation in Research On Down Syndrome (R21 Clinical Trial Optional)National Institutes of Health/DHHSNOT-OD- 22-14207-Sep-2024Not SpecifieContact NameSujata Bardhan, Ph.D.Sujata Bardhan, Ph.D.Sujata Bardhan, Ph.D.Sujata Bardhan, Ph.D.Sujata Bardhan, Ph.D.	Program URI	Link to program URL				
Synopsis (ICs) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and har cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approach to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. 12791 Notice of Special Interest (NOSI): Community-Based Participatory Research (CBPR) initiative in Reducing and Eliminating Health Disparities With a Focus on Addressing Diverse Representation in Research On Down Syndrome (R21 Clinical Trial Optional) National Institutes NOT-OD-of Health/DHHS 07-Sep-2024 Not Specifie Contact Name Sujata Bardhan, Ph.D. Sujata Bardhan, Ph.D. Sujata Bardhan, Ph.D. Sujata Bardhan, Ph.D.	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 1	6-Oct-2024 , 07-Jan-2025 , 05	-Feb-2025 , 16-Feb	-2025 , 07-May-20	25
12791 Initiative in Reducing and Eliminating Health Disparities With a Focus on Addressing Diverse Representation in Research On Down Syndrome (R21 Clinical Trial Optional) National Institutes NO1-OD- of Health/DHHS 07-Sep-2024 Specifie Contact Name Sujata Bardhan, Ph.D. Sujata Bardhan, Ph.D. Sujata Bardhan, Ph.D.	Synopsis	(ICs) are issuing this Notice of Special Intere preventive screening services where the evi cannot be determined. This NOSI encourage to close high priority evidence gaps to eleva	st (NOSI) to solicit application dence is lacking, of poor quali es the development and use o	s proposing to strea ty, conflicting, or th f innovative and rig	ngthen the eviden ne balance of bene porous methods an	ce base for fits and harn
	12791 Initiative in Reducing and Elimina	ating Health Disparities With a Focus on Addr	essing of Health/DHHS	07-5	ep-2024	Not Specified

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Email	sujata.bardhan@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 ,	16-Feb-2025			
Synopsis	The NIH INvestigation of Co-occurring cond to improve health and quality-of-life for ind announces NIH support for exploratory/de participatory research (CBPR) in DS to addr Project.	dividuals with Down syndrome velopmental grant (R21) appli	e (DS). This Notice of cations that are focu	f Special Interest (I used on communit	NOSI) y-based
112471 Notice of Special Interest (NOSI): and Craniofacial Embryogenesis	Single-Cell Level Spatiotemporal Mapping o	of Dental National Institute of Health/DHHS	s NOT-DE- 22-003 07-S	Sep-2024	Not Specified
Contact Name	Kathryn Stein, PhD				
Contact Telephone	301-827-4653				
Contact Email	kathryn.stein@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-		5-Feb-2025 , 12-Feb	-2025 , 16-Feb-202	25 , 07-May-
Synopsis	The National Institute of Dental and Cranio encourage research that applies cutting ed understand the complex spatiotemporal co	ge imaging and high-throughp	ut 'omics approach	es at the single-cel	l level to
112267 Notice of Special Interest (NOSI):	Advancing Research on Early Pregnancy Los	National Institute of Health/DHHS	s NOT-HD- 22-026 07-S	Sep-2024	Not Specified
Contact Name	Clara Cheng, PhD				
Contact Telephone	301-435-6992				
Contact Email	<u>clara.cheng@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				

SPIN ID	Program Title		Sponsor Name	e	Sponsor Numbe	r Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 2025 , 07-Sep-2025	07-Jan-2025 , C)5-Feb-2025 , 16	-Feb-2025 , 07-N	1ay-2025 , 05-Jun-20	025 , 16-Jun-
	Synopsis	Early Pregnancy loss (EPL), defined as a pre complication, occurring in 12-15% of clinical maternal age. The use of highly sensitive ho clinical recognition, and gives an even highe achieve a successful pregnancy, a series of embryos, favorable conditions for embryo i to sustain the conceptus to term. In additio approximately half of all cases of EPL appear and pathophysiologic processes that under underlying causes of recurrent pregnancy lo basic, translational and clinical studies on b includes research to understand implantati and placentation that are important for ear EPL and recurrent pregnancy loss.	ally recognized CG assays allow er estimated lo strict embryon implantation, r on, maternal im ar to be due to lie non-aneuple oss (RPL). This lo iological proce on mechanistic	pregnancies, wit vs the detection ss of 50-70% of ic and maternal eceptive matern mune tolerance embryonic aneu oid EPL. As a resu NOSI seeks to ad sses that may ur cally and identify	th increased pre- of pregnancy ea conceptions price conditions must al endometrium and hormonal f ploidy, very little ult, there is also ldress these criti neover potential r a range of key f	valence associated w rlier in gestation that in to the second trim be met, that include and optimal uterine actors play a critical e is known about the a lack of understand cal knowledge gaps etiologies of EPL and actors, involved in ir	vith increasing n the time of ester. To high quality e environment role. While physiologic ling for the by encouraging d RPL. This mplantation
114596	Development of Animal Models a Research (R21 Clinical Trials Not A	and Related Biological Materials for Down Sy Allowed)		tional Institutes Health/DHHS	PAR-23- 067 16	5-Oct-2024	275,000 USD
	Contact Name	Sige Zou, PhD					
	Contact Telephone	301-435-0749					
	Contact Email	zous@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 1	16-Oct-2025				
	Synopsis	The INvestigation of Co-occurring condition Project encourages exploratory and innova biological materials for Down syndrome (DS animal models for DS research. The animal basic science studies in areas highly relevan encourages, but is not limited to, projects f single cell or subcellular level, advanced inf	tive research to S) related resea models and re nt to DS. With t focusing on dev	o develop, chara arch and to impr lated biological i his funding oppo relopment of var	cterize, or impro ove access to inf naterials develo ortunity annound ious animal mod	ove animal models a formation about or f ped must have utilit cement, the INCLUD lels, genetic resourc	rom the use of y in targeted or E Project es, atlases at a

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
_		(ML), and integration of multiple animal mo preclinical DS research.	odels and technology platform	s for enhancing rigo	r and reproducibi	ity of
11/1520		Research to Address 'Ending the HIV Epider ance Using Populations At-Risk for or Living		5 NOT-DA- 23-013 09-A	ug-2024	Not Specified
	Contact Name	Vasundhara Varthakavi, PhD				
	Contact Telephone	301-443-2146				
	Contact Email	vasundhara.varthakavi@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun- Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16	2025 , 07-Sep-2025 , 05-Oct-2	025, 16-Oct-2025,	07-Jan-2026 , 05-	-
	Synopsis	The purpose of this NOSI is to support a br the four pillars, including Diagnose, Treat, F Projects proposed in response to this NOSI high risk for contracting HIV or living with F	Prevent, and Respond of the 'E are required to meet the need	nding the HIV Epide ds of the substance u	mic in the U.S. (El using populations	IE)' initiative.
11/1/1/1/	Notice of Special Interest (NOSI): Hepatitis C Virus Diagnostics	Advancing Development of Rapid Point-of-C	Care National Institutes of Health/DHHS	5 NOT-AI- 23-001 05-Se	ep-2024	Not Specified
	Contact Name	Julie Dyall, PhD				
	Contact Telephone	301-631-7296				
	Contact Email	dyallj@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun- Jan-2026				•
	Synopsis	The purpose of this Notice of Special Intere (NIAID) and National Institute of Biomedica				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		encouraging applications in the area of tran diagnose active viremic HCV infections.	nslational research and develo	oment of rapid Po	int-of-Care diagnos	tics that will
115289	Notice of Special Interest (NOSI): Services	Priority Research Opportunities in Crisis Res	sponse National Institutes of Health/DHHS	NOT-MH- 23-140 07	-Sep-2024	Not Specified
	Contact Name	Stephen O'Connor, Ph.D.				
	Contact Telephone	301-480-8366				
	Contact Email	stephen.o'connor2@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 ,	07-Jan-2025 , 05-Feb-2025 , 16	5-Feb-2025 <i>,</i> 07-M	ay-2025	
	Synopsis	Research is sought that is conducted in real age-related (e.g., youth; adult; older adult) influence the types of care that are provide well as applications that address crisis servi	, geographic (rural/remote set ed. Studies are encouraged tha	tings), cultural cont t address the cont	nsiderations, and he inuum of crisis serv	alth disparitie
120393	Secondary Analysis and Integration Related Outcomes (R21 Clinical T	on of Existing Data to Elucidate Cancer Risk a Trials Not Allowed)	and National Institutes of Health/DHHS	PAR-23- 255 16	-Oct-2024	275,000 USD
	Contact Name	Melissa Rotunno, Ph.D.				
	Contact Telephone	240-276-7245				
	Contact Email	rotunnom@mail.nih.gov				
	Sponsor Website	2				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 1	16-Oct-2025 , 16-Feb-2026 , 16	5-Jun-2026		
		Through this Notice of Funding Opportunity	y (NOFO), the National Cancer	Institute (NCI) alo	ng with other parti	

SPIN ID Program Title	Spor	nsor Name	Sponsor Number	Deadline Date	Funding Amount
	cancer by supporting the analysis of existing clin lifestyle, genomic, and molecular profiles data. A existing data. Applications may include new rese methods of analyses, or novel combinations and questions in cancer research.	Applicants are encouraged earch aims that are being	d to leverage and po addressed with exis	erform innovative sting data, new or	analyses of the advanced
120102 Social disconnection and Suicide	Risk in Late Life (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23- 239 16-0	Oct-2024	275,000 USD
Contact Name	Jovier Evans, Ph.D.				
Contact Telephone	301-443-6328				
Contact Emai	jevans1@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-O	ct-2025 , 16-Feb-2026 , 16	5-Jun-2026		
Synopsis	The purpose of this Notice of Funding Opportun disconnection in late-life and late-life suicidal th mechanisms by which social disconnection confi- behaviors in late life. Mechanisms to be conside neurobiological, behavioral, and environmental announcement PAR-23-238 solicits R01 applicat appropriate for this R21 mechanism, while appli 238.	oughts and behaviors. Of ers risk for, and social inte red exist at multiple level This NOFO solicits R21 ap ons. High risk/high payof	specific interest is a gration protects ag s of analysis, includ oplications, while th f projects that lack	research that iden gainst, suicidal tho ling but not limited ne companion preliminary data r	tifies ughts and I to nay be most
	ethods for Understanding the Genetic Architectur		16-0	Dct-2024	275,000
Complex Human Traits (R21 Clini	<u>cal Irial Not Allowed)</u>	of Health/DHHS	301		USD
	Alexander Arguello, Ph.D.				
Contact Telephone					
Contact Emai	alexander.arguello@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-O	+-2025 16-Eab-2026 16	S-lun-2026 16-Oct	2026	

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	The goal of this NOFO is to support applica of how genetic and non-genetic factors cor Approaches should account for interdepen extensive use of theory, modeling, and vali from the natural and social sciences.	ntribute to complex trait variat dencies across scales of biolog	on across individua cal, social, and eco	ls, families, and p logical organizatio	opulations. n, make
103180 Research on Autism Spectrum Dis	sorders (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21-200 16-C	0ct-2024	275,000 USD
Contact Name	Lisa Gilotty, Ph.D.				
Contact Telephone	301-443-3825				
Contact Email	gilottyl@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Oct-2024				
Synopsis	The purpose of this Funding Opportunity A research designed to elucidate the etiology Autism Spectrum Disorders (ASD). The R21 by providing support for the early and cond ground or extend previous discoveries tow required but may be included if available. A studies that can be completed with limited larger studies in established scientific areas FOA, PA-21-201.	y, epidemiology, diagnosis, and grant mechanism is intended t ceptual stages of project develo ard new directions are appropu- Applicants pursuing secondary budgets should consider the c	optimal means of s o encourage exploi opment. Explorator iate for this mecha analysis of existing ompanion R03 FOA	ervice delivery in ratory/developme y, novel studies th nism. No prelimin data, and pilot or ,PA-21-199 . Appl	relation to ntal research at break new ary data are feasibility cants pursuing
107609 Drug Discovery For Nervous Syste	em Disorders (R21 Clinical Trials Not Allowed	National Institutes of Health/DHHS	PAR-22- 032 16-0	0ct-2024	275,000 USD
Contact Name	Enrique Michelotti, PhD				
Contact Telephone	301-443-5415				
Contact Email	michelottiel@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				

NIH Funding Opportunities Due: Oct 2024

298

Icahn School of Medicine at Mount Sinai

PIN ID	Program Title	SI	ponsor Nam	e S	ponsor Num	ber Deadline Date	Funding Amount
	Deadline Dates (ALL)	16-Oct-2024					
	Synopsis	This Funding Opportunity Announcement (FO treatment of nervous system disorders. Throu Identification, design, synthesis, and preclinic Initial hit-to-lead chemistry to improve activit to improve efficacy and pharmacokinetics; an will be placed on projects that provide novel a support applications proposing preclinical dis therapeutics including, but not limited to, larg based therapies (i.e., oligonucleotide- and vir- microbiome therapies).	ugh this FOA cal testing of ty of compound 4) Initial d approaches scovery of bio ge biologic m	NIMH, NIA, NIAA small molecules f inds against the t rug metabolism a or identifying po otechnology prod nacromolecules, (A and NIDA v or their pote arget of inter nd pharmaco cential therap ucts and biolo e.g., proteins	vish to stimulate reseantial as candidate the est; 3) Later stage lead kinetic properties (DM eutic agents. This FOA ogics with potential as antibodies, and pept	arch in: 1) rapeutics; 2) d optimizatior APK). Emphas A will also candidate ides), gene-
1//IX-		Mechanistic Studies on the Impact of Substan HIV-Associated Neurocognitive Disorders		tional Institutes Health/DHHS	NOT-DA- 22-047	07-Sep-2024	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website						
	-	Link to program URL					
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07					
	Synopsis	Compared to men, women are often more lik notice is to inform potential applicants of NID gender-specific differences in HIV-associated therapeutics and optimization of treatment o	DA's special in neurocognit	nterest in underst ive disorders. Thi	anding the ness information	eurobiological bases f can be used for targe	or sex or
			Na	tional Institutes	NOT-DE-		Not
)7484 <u>N</u>	Iotice of Special Interest (NOSI):	The Functional Oral Microbiome	of	Health/DHHS	21-015	07-Sep-2024	Specified
7484 <u>N</u>		The Functional Oral Microbiome Tamara McNealy, PhD.	of	Health/DHHS		07-Sep-2024	
7484 <u>N</u>		Tamara McNealy, PhD.	of	Health/DHHS		07-Sep-2024	
)7484 <u>N</u>	Contact Name Contact Telephone	Tamara McNealy, PhD.	of	Health/DHHS		07-Sep-2024	

PIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Program URL	Link to program URL				
Deadline Dates (ALL)	$07_{\text{Sep}} = 2024$ 05_0ct=2024 16_0ct=2024 (07-Jan-2025 , 05-Feb-2025 , 16	-Feb-2025 <i>,</i> 07-May	/-2025 , 05-Jun-20	25 , 16-Jun-
Synopsis	The National Institute of Dental and Cranio encourage research studies that focus beyo			-	-
03183 <u>Research on Autism Spectrum Di</u>	sorders (R03 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21-199 16-C	oct-2024	100,000 USD
Contact Name	Lisa Gilotty, Ph.D.				
Contact Telephone	301-443-3825				
Contact Email	gilottyl@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Oct-2024				
Synopsis	The purpose of this Funding Opportunity Au research designed to elucidate the etiology Autism Spectrum Disorders (ASD). An RO3 g years and that require limited resources. RO technology, secondary analysis of existing of in applications proposing pilot or feasibility and conceptual stages of project developm larger studies in established scientific areas FOA, PA-21-201.	, epidemiology, diagnosis, and grant supports small, discrete, v 03 applications may include dev lata, and pilot or feasibility stud studies. Applicants pursuing ex ent should consider the compa	optimal means of s vell-defined project velopment of new r dies. Preliminary da kploratory/develop nion R21 FOA, PA-2	ervice delivery in ts that can be com research methodo ta are not require mental research t 21-200. Applicants	relation to apleted in tw alogies or ed, particular o support ea s pursuing
04057 <u>Joint NINDS/NIMH Exploratory N</u> Optional)	euroscience Research Grant (R21 Clinical Tri	al National Institutes of Health/DHHS	PA-21-219 07-S	ep-2024	275,000 USD
Contact Name	Karrah Benson				
Contact Telephone	301-496-0838				
Contact Email	Karrah.benson@nih.gov				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
-	Link to program URL 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 The Joint NINDS/NIMH Exploratory Neuros projects, which fall within the missions of t stages of projects. These studies often asse but have the potential to bring about break development of novel techniques, agents, in this funding opportunity also accepts clinica (studying pathophysiology or mechanism o with humans (BESH) will be supported. For within scope of this funding opportunity an Opportunity Description, below, respective	he NINDS and NIMH. Awards we ass the feasibility of a novel ave athroughs in the understanding methodologies, or models, of l al trials, only applications prop f action of an intervention, bu information on NIH clinical tri anouncement refer to the NIH	vill provide support enue of investigatio g of important area high value to the ne posing "mechanistic t not safety or effic al definitions and th	for the early and contained involve consists of neuroscience, euroscience communication of trials or studies of or basic experiment types of clinical trials of the types o	onceptual iderable risk, or to the unity. While udies" mental studies crials that are
SPIN ID Program Title		Sponsor Name	Sponsor Number	eadline Date	Funding Amount
108898 Notice of Special Interest (NOSI): Response Services	Priority Research Opportunities in Crisis	National Institutes of Health/DHHS	NOT-MH- 22-110 07	7-Sep-2024	Not Specified

Contact Name Stephen O'Connor, Ph.D.

Contact Telephone 301-480-8366

Contact Email stephen.o'connor2@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-Sep-2024, 05-Oct-2024, 16-Oct-2024, 07-Jan-2025, 05-Feb-2025, 16-Feb-2025, 07-May-2025

The National Institutes of Health seeks research conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Examples of NIMH and NIDA studies that are encouraged through this Notice address the continuum of crisis service systems. Applications that include crisis services for children and under-resourced populations are encouraged. Topics of research interest span the crisis care continuum, including the effectiveness of these components: call center capabilities to address distress and coordinate care, deployed mobile crisis outreach and support, and crisis services that can diagnose and provide short term stabilization.

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
109173 Microbial-based Cancer Imaging a Not Allowed)	and Therapy - Bugs as Drugs (R21 Clinical Tria	National Institutes of Health/DHHS	PAR-22- 086 1	6-Oct-2024	275,000 USD
Contact Name Contact Telephone	Avi Rasooly, PhD				
Contact Emai	l <u>rasoolya@mail.nih.gov</u>				
-	<u>Link to program URL</u> 16-Oct-2024 , 16-Feb-2025				
Synopsis	This Funding Opportunity Announcement (F bacteriophages, or other non-oncolytic virus interactions between microorganisms, tumo imaging, therapeutics or diagnostics. Project tumor immunity, or as delivery vehicles for t tools and approaches. This FOA will support Applicants are encouraged to address both t microbial-based cancer therapy (including th funding opportunity is part of a broader NCI	ses and their natural product ors, and the immune system, ts can focus on using microon creatment, diagnosis, or image basic mechanistic and precli- the microbial and tumor aspo- nerapies for oral cancer), tun	to study the under and to explore the rganisms as anti-tur ging, complementir inical studies in cell ects of microbial tur nor imaging, tumor	erlying mechanisms ir clinical potential mor agents, as action or synergizing wi culture and animal mor interactions re detection, or diagr	of the complex for cancer vators of anti- th existing models. levant to
108483 Notice of Special Interest (NOSI):	COVID-19 Pandemic Mental Health Research	National Institutes of Health/DHHS	NOT-MH- 22-100 0	17-Sep-2024	Not Specified
Contact Name	Pim Brouwers, Ph.D.				
Contact Telephone	240-627-3863				
Contact Emai	ebrouwer@mail.nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 0	7-Jan-2025			
Synopsis	NIMH is issuing this Notice of Special Interess services research relevant to the COVID-19 p to understand how mental illness contribute COVID-19, and the development of scalable	pandemic. NIMH is especially es to COVID-19 risk and mort	interested in researable ality, how incident	arch to provide an o mental illness deve	evidence base elops with

SPIN ID Program Title	Spe	onsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
	the pandemic both specifically related to the v disruptions, and loss of lives in the pandemic. I treatment and prevention are also of interest to populations based on existing evidence of incr health disparities.	Research addressing the int to NIMH. Research is antici	tersection of COV pated to focus or	ID-19, mental health particularly vulnera	n, and HIV ble
108358 Exploratory/Developmental Bioer	ngineering Research Grants(EBRG) (R21 Clinical	National Institutes of Health/DHHS	PAR-22- 090	16-Oct-2024	275,000 USD
Contact Name	Miguel R. Ossandon, Ph.D.				
Contact Telephone	240-276-5714				
Contact Email	ossandom@mail.nih.gov				
Sponsor Website					
•					
•	Link to program URL				
Program URL		search Grant (EBRG) applic quality, speed, efficacy, ope	ations to demons erability, costs, ar	strate feasibility and dolor accessibility of	potential
Program URL Deadline Dates (ALL) Synopsis Limited Competition: Clinical and	16-Oct-2024 The purpose of this engineering-oriented fund exploratory/developmental Bioengineering Re utility of new capabilities or improvements in o	search Grant (EBRG) applic quality, speed, efficacy, ope	ations to demons erability, costs, ar e delivery, or acce PAR-22-	strate feasibility and dolor accessibility of	potential
Program URL Deadline Dates (ALL) Synopsis Limited Competition: Clinical and Collaborative and Innovative Acce Optional)	16-Oct-2024 The purpose of this engineering-oriented fund exploratory/developmental Bioengineering Re utility of new capabilities or improvements in o problems in basic biomedical, pre-clinical, or cl Translational Science Award (CTSA) Program:	search Grant (EBRG) applic quality, speed, efficacy, ope linical research, clinical care National Institutes of	ations to demons erability, costs, ar e delivery, or acco PAR-22-	strate feasibility and d/or accessibility of essibility	potential solutions to 3,250,000
Program URL Deadline Dates (ALL) Synopsis 10997 <u>Limited Competition: Clinical and</u> <u>Collaborative and Innovative Acceso</u> <u>Optional</u>)	16-Oct-2024 The purpose of this engineering-oriented fund exploratory/developmental Bioengineering Re utility of new capabilities or improvements in o problems in basic biomedical, pre-clinical, or cl <u>Translational Science Award (CTSA) Program:</u> eleration Award (UG3/UH3 Clinical Trial Soju Chang, M.D., M.P.H.	search Grant (EBRG) applic quality, speed, efficacy, ope linical research, clinical care National Institutes of	ations to demons erability, costs, ar e delivery, or acco PAR-22-	strate feasibility and d/or accessibility of essibility	potential solutions to 3,250,000
Program URL Deadline Dates (ALL) Synopsis Limited Competition: Clinical and Collaborative and Innovative Acce Optional) Contact Name Contact Telephone	16-Oct-2024 The purpose of this engineering-oriented fund exploratory/developmental Bioengineering Re utility of new capabilities or improvements in o problems in basic biomedical, pre-clinical, or cl <u>Translational Science Award (CTSA) Program:</u> eleration Award (UG3/UH3 Clinical Trial Soju Chang, M.D., M.P.H.	search Grant (EBRG) applic quality, speed, efficacy, ope linical research, clinical care National Institutes of	ations to demons erability, costs, ar e delivery, or acco PAR-22-	strate feasibility and d/or accessibility of essibility	potential solutions to 3,250,000
Program URL Deadline Dates (ALL) Synopsis Limited Competition: Clinical and Collaborative and Innovative Acce Optional) Contact Name Contact Telephone	16-Oct-2024 The purpose of this engineering-oriented fund exploratory/developmental Bioengineering Re utility of new capabilities or improvements in o problems in basic biomedical, pre-clinical, or cl Translational Science Award (CTSA) Program: eleration Award (UG3/UH3 Clinical Trial Soju Chang, M.D., M.P.H. 301-827-9206 soju.chang@nih.gov	search Grant (EBRG) applic quality, speed, efficacy, ope linical research, clinical care National Institutes of	ations to demons erability, costs, ar e delivery, or acco PAR-22-	strate feasibility and d/or accessibility of essibility	potential solutions to 3,250,000
Program URL Deadline Dates (ALL) Synopsis Limited Competition: Clinical and Collaborative and Innovative Acce Optional) Contact Name Contact Telephone Contact Email Sponsor Website	16-Oct-2024 The purpose of this engineering-oriented fund exploratory/developmental Bioengineering Re utility of new capabilities or improvements in o problems in basic biomedical, pre-clinical, or cl Translational Science Award (CTSA) Program: eleration Award (UG3/UH3 Clinical Trial Soju Chang, M.D., M.P.H. 301-827-9206 soju.chang@nih.gov	search Grant (EBRG) applic quality, speed, efficacy, ope linical research, clinical care National Institutes of	ations to demons erability, costs, ar e delivery, or acco PAR-22-	strate feasibility and d/or accessibility of essibility	potential solutions to 3,250,000
Program URL Deadline Dates (ALL) Synopsis Limited Competition: Clinical and Collaborative and Innovative Acce Optional) Contact Name Contact Telephone Contact Email Sponsor Website	16-Oct-2024 The purpose of this engineering-oriented fund exploratory/developmental Bioengineering Re utility of new capabilities or improvements in o problems in basic biomedical, pre-clinical, or cl Translational Science Award (CTSA) Program: eleration Award (UG3/UH3 Clinical Trial Soju Chang, M.D., M.P.H. 301-827-9206 soju.chang@nih.gov Link to program URL	search Grant (EBRG) applic quality, speed, efficacy, ope linical research, clinical care National Institutes of	ations to demons erability, costs, ar e delivery, or acco PAR-22-	strate feasibility and d/or accessibility of essibility	potential solutions to 3,250,000

SPIN ID Program Title	S	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
	funding opportunity announcement (FOA) in to transform the field of translational science more interventions to all people more quickly Centers, Offices (ICOs), and/or external stake	by addressing the inefficien y through collaborative scier	cies that are comm	non across diseases	and bringing
112346 Notice of Special Interest (NOSI): Minority (SGM)	Research on the Health of Sexual and Gender	National Institutes of Health/DHHS	NOT-MD- 22-012 0	7-Sep-2024	Not Specified
Contact Telephone	Crystal L. Barksdale, PhD MPH 301-827-4228 <u>crystal.barksdale@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 09-Oct-2024 , 12 2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-20		7-Jan-2025 , 05-Fel	o-2025 , 12-Feb-202	25 , 16-Feb-
Synopsis	This Notice calls for research on the health of limited to, individuals who identify as lesbian Individuals with same-sex or -gender attraction included. These populations also encompass orientation, gender identity or expression, or orientation, gender, and/or sex.	, gay, bisexual, asexual, tran ons or behaviors and those v those who do not self-identi	sgender, Two-Spiri vith a difference in fy with one of the	t, queer, and/or int sex development a se terms but whose	ersex. are also sexual
122410 Phased Research to Support Subs Services Studies (R61/R33 Clinical	tance Use Epidemiology, Prevention, and Trials Optional)	National Institutes of Health/DHHS	PAR-24- 062 1	4-Aug-2024	Not Specified
Contact Name	Amy B. Goldstein, PhD				
Contact Telephone	301-827-4124				
Contact Email	amy.goldstein@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	14-Aug-2024 , 11-Oct-2024 , 13-Dec-2024 , 14 2025 , 13-Feb-2026 , 16-Mar-2026 , 15-Jun-20	4-Feb-2025 , 17-Mar-2025 , 1 026 , 14-Aug-2026 , 14-Oct-2	13-Jun-2025 , 14-A 2026 , 14-Dec-2026	ug-2025 , 10-Oct-2	025 , 15-Dec-

PIN ID Program Title	St	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsi	The purpose of this notice of this funding opp addiction services, and prevention to, ultimat encourages research that facilitates rapid tran- supports community/stakeholder engagemen research to practice gap through the rapid tra- study. The goal is to support translational res familial, behavioral, developmental, and socio s with the potential for multi-directional transfi or use disorder; and 3) maximize the efficien to ultimately inform and facilitate real world addiction on the health of the population. Thi available. This NOFO requires a Plan for Enha	tely, reduce the burden of su nslation from one discipline ansition from pilot study to c search improving our ability o-cultural/environmental fac er of knowledge; 2) prevent t delivery of high-quality, pe responses designed to reduc is NOFO invites projects for v ancing Diverse Perspectives (bstance use on p to another (e.g., e it and prevention linical trial, or eff to 1) identify and tors (within the p initiation of subs rsonalized addiction the burden of s which preliminary PEDP), which will	ublic health. This No pidemiology to pre- clinical trials; or rec- ectiveness to impler characterize malles opulation or precise tance use or progre on treatment and r ubstance use, misu- feasibility or pilot of be assessed as part	DFO vention); duces the mentation able individua e subgroups) ession to misu elated service se and/or data are not t of the
	scientific and technical peer review evaluation be withdrawn. Applicants are strongly encour guidance material.	••			•
06848 <u>Notice of Special Interest (NOSI)</u> <u>Craniofacial Health Disparities</u>	be withdrawn. Applicants are strongly encour	••	NOT-DE-		•
Craniofacial Health Disparities	be withdrawn. Applicants are strongly encour guidance material.	National Institutes of	NOT-DE-	and view the availa	ble PEDP Not
Craniofacial Health Disparities	be withdrawn. Applicants are strongly encour guidance material. <u>Biologic Factors Underlying Dental, Oral, and</u> Hiroko Iida, DDS, MPH	National Institutes of	NOT-DE-	and view the availa	ble PEDP Not
Craniofacial Health Disparities Contact Nam Contact Telephon	be withdrawn. Applicants are strongly encour guidance material. <u>Biologic Factors Underlying Dental, Oral, and</u> Hiroko Iida, DDS, MPH	National Institutes of	NOT-DE-	and view the availa	ble PEDP Not
Craniofacial Health Disparities Contact Nam Contact Telephon	be withdrawn. Applicants are strongly encour guidance material. Biologic Factors Underlying Dental, Oral, and Hiroko Iida, DDS, MPH 301-594-7404 <u>hiroko.iida@nih.gov</u>	National Institutes of	NOT-DE-	and view the availa	ble PEDP Not
Craniofacial Health Disparities Contact Nam Contact Telephon Contact Ema Sponsor Websit	be withdrawn. Applicants are strongly encour guidance material. Biologic Factors Underlying Dental, Oral, and Hiroko Iida, DDS, MPH 301-594-7404 <u>hiroko.iida@nih.gov</u>	National Institutes of	NOT-DE-	and view the availa	ble PEDP Not
Craniofacial Health Disparities Contact Nam Contact Telephon Contact Ema Sponsor Websit Program UR	be withdrawn. Applicants are strongly encour guidance material. Biologic Factors Underlying Dental, Oral, and Hiroko Iida, DDS, MPH 301-594-7404 il <u>hiroko.iida@nih.gov</u> e	National Institutes of Health/DHHS	NOT-DE-	and view the availa	ble PEDP Not
Craniofacial Health Disparities Contact Nam Contact Telephon Contact Ema Sponsor Websit Program UR Deadline Dates (ALI	be withdrawn. Applicants are strongly encour guidance material. Biologic Factors Underlying Dental, Oral, and Hiroko lida, DDS, MPH 301-594-7404 il <u>hiroko.iida@nih.gov</u> e L <u>Link to program URL</u>	Aational Institutes of Health/DHHS Y-Jan-2025 cial Research (NIDCR) is issui	ng this Notice of shanisms by which	and view the availa 07-Sep-2024 Special Interest (NO biologic factors (m	Not Specified SI) to icrobial,
Craniofacial Health Disparities Contact Nam Contact Telephon Contact Ema Sponsor Websit Program UR Deadline Dates (ALI Synopsi	be withdrawn. Applicants are strongly encour guidance material. Biologic Factors Underlying Dental, Oral, and Hiroko Iida, DDS, MPH 301-594-7404 <u>hiroko.iida@nih.gov</u> L <u>Link to program URL</u> 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07 The National Institute of Dental and Craniofacts encourage research studies designed to ident	Aational Institutes of Health/DHHS Y-Jan-2025 cial Research (NIDCR) is issui	ng this Notice of shanisms by which disease onset, provide the state of the state o	and view the availa 07-Sep-2024 Special Interest (NO biologic factors (m	SI) to icrobial, sistence.
OB448 Craniofacial Health Disparities Contact Nam Contact Telephon Contact Ema Sponsor Websit Program UR Deadline Dates (ALI Synopsi 0996 Dissemination and Implementat Allowed)	be withdrawn. Applicants are strongly encour guidance material. Biologic Factors Underlying Dental, Oral, and Hiroko Iida, DDS, MPH 301-594-7404 <u>hiroko.iida@nih.gov</u> L Link to program URL 07-Sep-2024, 05-Oct-2024, 16-Oct-2024, 07 The National Institute of Dental and Craniofac s encourage research studies designed to ident immune, genetic) contribute to disparities in	Antional Institutes of Health/DHHS Y-Jan-2025 cial Research (NIDCR) is issuitify and understand the mech dental, oral, and craniofacia	ng this Notice of shanisms by which disease onset, p	and view the availa 07-Sep-2024 Special Interest (NO biologic factors (m ogression, and pers	SI) to icrobial, sistence.

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Email	<u>Gila.Neta@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 1	16-Feb-2025 , 07-May-2025 , 1	.6-Jun-2025 , 07-Se	ep-2025	
Synopsis	The purpose of this Funding Opportunity A strategies for overcoming barriers to the ac interventions, practices, programs, tools, tr and implementation of evidence-based inter there is a benefit in understanding circums that are ineffective, unproven, low-value, o research methods and measures are encou services (e.g. cancer screening) that may ha applications must be within the scope of th	doption, adaptation, integration reatments, guidelines, and poli erventions among underreprese tances that create a need to st or harmful. In addition, studies araged. Applications that focus ave dropped off amidst the on	on, scale-up, and su icies. Studies that p sented communitie cop or reduce ("de- to advance dissen on re-implementa going COVID pande	istainability of evid promote equitable es are encouraged. implement") the u nination and impler tion of evidence-ba emic are encourage	ence-based dissemination Conversely, se of practices nentation ased health
109942 Technology Development Resear Concept (R21 - Clinical Trial Not A	ch for Establishing Feasibility and Proof of Ilowed)	National Institutes of Health/DHHS	PAR-22- 0 126	7-Sep-2024	275,000 USD
Contact Name	Fei Wang, Ph.D.				
Contact Telephone					
Contact Email	wangf@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 1				
	This Funding Opportunity Announcement (technologies for biomedical research that is participating in this FOA. Projects should er potential impact in biomedical research. Ou	s relevant to the NIGMS mission ntail a high degree of risk and/	on or that of other or novelty, which v	NIH Institutes or C vill be offset by a h	enters (ICs) igh future

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	applications should propose development of research. Moreover, feasibility of the propo- preliminary data. Applications that are focu- include unpublished or published data that administratively withdrawn without review	osed technology must not have used on technology developme provide proof of concept are	e already been estai ent to address speci	blished in the liter fic biological ques	ature or with tions and/or
	Research Using Implementation Science To Based Practices in Community-Based Menta ngs	I or Health/DHHS	NOT-MH- 22-170 07	-Sep-2024	Not Specified
Contact Name					
Contact Telephone					
Contact Email					
Sponsor Website					
v	Link to program URL				
	07-Sep-2024, 05-Oct-2024, 16-Oct-2024, This Notice of Special Interest (NOSI) highlig support the adoption and sustainability of e people with mental illness. These settings of (CCBHCs) funded through the Substance Ak Behavioral Health Clinic-Expansion (CCBHC	ghts interest in mental health evidence-based practices (EBP could include, but are not limit buse and Mental Health Servic	services and implen s) in community-ba ed to, Certified Con es Administration (S	nentation science sed settings that d nmunity Behaviora SAMHSA) Certified	leliver care to al Health Clinics
110813 Notice of Special Interest (NOSI): Co-Infection	Towards Developing a Cure for HBV in HIV/H	HBV National Institutes of Health/DHHS	NOT-AI-22- 043	-Sep-2024	Not Specified
Contact Name	Chris Lambros, PhD				
Contact Telephone	240-627-3093				
Contact Email	<u>clambros@niaid.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 2025 , 07-May-2025	16-Oct-2024 , 05-Jan-2025 , 0	7-Jan-2025 , 05-Feb	-2025 , 16-Feb-202	25 , 05-Apr-



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	The purpose of this NOSI is to encourage ap identify and address the unique challenges relating to the following areas will be encou	to achieving HBV cure in the p	presence of HIV. Res	search on HIV/HBV	
107545 Notice of Special Interest (NOSI): Workforce: Focus on Early Stage I	Expanding the Otitis Media Research nvestigators	National Institutes of Health/DHHS	NOT-DC- 22-001 07	-Sep-2024	Not Specified
Contact Name	Bracie Watson, Jr., Ph.D.				
Contact Telephone	301-402-3458				
Contact Email	watsonb@nidcd.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 0 2025 , 07-Sep-2025)7-Jan-2025 , 05-Feb-2025 , 10	6-Feb-2025 <i>,</i> 07-Ma	y-2025 , 05-Jun-20	25 , 16-Jun-
Synopsis	The National Institute on Deafness and Othe basic and clinical scientists who conduct res is to invite Early Stage Investigators (ESIs), a NIH https://grants.nih.gov/grants/new_inve OM—commonly known as ear infections. Th approaches that accelerate the development	earch on otitis media (OM). T s defined by the estigators/index.htm#earlysta nere is a critical need for focu	he purpose of this I ge, to submit resea sed, novel, creative	Notice of Special Ir	nterest (NOSI) nat focus on
	Advanced Postdoctoral-to-Independent Care D Research (K99/R00 Independent Clinical Tri	National Institutos of	RFA-NS- 22-022 11	-Oct-2024	Not Specified
Contact Name	DP Mohapatra, Ph.D.				
Contact Telephone	301-496-9964				
Contact Email	dp.mohapatra@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	11-Oct-2024 , 11-Feb-2025				
Synopsis	The purpose of the NIH HEAL Initiative [®] Pat	hway to Independence Award	d (K99/R00) prograr	n is to support a co	phort of new

PIN ID Program Title		Sponsor Name	Sponsor Number Deadline Da	te Funding Amount
	and well-trainedindependent investigator investigator workforce in research areas transition of eligible postdoctoral research track or equivalent faculty positions. The help awardees establish independent res Opportunity Announcement (FOA) is dest independent clinical trial, a clinical trial fe Experimental Studies with Humans (BESH trial led by a mentor or co-mentor. Those companion FOA (RFA-NS-22-023).	supported by the NIH HEAL Initi hers from their mentored, post program will provide independe earch programs in areas suppor gned specifically for candidates easibility study, an ancillary stud). Applicants to this FOA are pe	ative [®] . This program is designed to doctoral research positions to inde ent NIH research support during th ted by the NIH HEAL Initiative [®] . Th proposing research that does not ly to a clinical trial, or an independ rmitted to propose research exper	o facilitate a time ependent, tenure his transition to his Funding involve leading a ent Basic ience in a clinical
25534 <u>NIH Pathway to Independence Av</u> <u>Required)</u>	ward (Parent K99/R00 Independent Clinica	Trial National Institutes of Health/DHHS	PA-24-193 07-Sep-2024	Not Specified
Contact Name	2			
Contact Telephone				
Contact Emai	l grantinfo@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 2026 , 12-Feb-2026 , 07-May-2026 , 12-Ju			
Synopsis	The purpose of the NIH Pathway to Indep postdoctoral researchers with a research independent, tenure-track or equivalent during this transition in order to help awa Opportunity (NOFO) is designed specifica clinical trial, a clinical trial feasibility study career development. Candidates not plan clinical trial led by another investigator, r	and/or clinical doctorate degre faculty positions. The program ardees to launch competitive, in lly for candidates proposing to y, or a separate ancillary study t ning an independent clinical tri	e from mentored, postdoctoral res will provide independent NIH resea dependent research careers. This serve as the lead investigator of ar to an existing trial, as part of their al, or proposing to gain research e	search positions t arch support Notice of Funding i independent research and
25537 NIH Pathway to Independence Av	ward (Parent K99/R00 Independent Clinica	Trial National Institutes of	DA 24 104 07 San 2024	Not
Not Allowed)		Health/DHHS	PA-24-194 07-Sep-2024	Specified
Contact Name				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone					
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 2 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun				
	Synopsis	The purpose of the NIH Pathway to Indeper postdoctoral researchers with a research and independent, tenure-track or equivalent fact during this transition in order to help award Opportunity (NOFO) is designed specifically clinical trial, a clinical trial feasibility study, a research experience in a clinical trial led b	nd/or clinical doctorate degre culty positions. The program v dees to launch competitive, in r for candidates proposing res or an ancillary clinical trial. Ur	e from mentored, po will provide independ dependent research earch that does not ider this NOFO cand	ostdoctoral resear dent NIH research careers. This Not involve leading an idates are permitt	ch positions to support ice of Funding independent ed to propose
		trial as lead investigator, should apply to th	•			
175516	Mentored Clinical Scientist Resea ndependent Basic Experimental S	trial as lead investigator, should apply to th	e companion NOFO (PA-24-19			Not Specified
175516		trial as lead investigator, should apply to th rch Career Development Award (Parent K08 Studies with Humans Required)	e companion NOFO (PA-24-19 National Institutes of	93).		Not
175516	ndependent Basic Experimental S	trial as lead investigator, should apply to th rch Career Development Award (Parent K08 Studies with Humans Required)	e companion NOFO (PA-24-19 National Institutes of	93).		Not
175516	ndependent Basic Experimental S Contact Name Contact Telephone	trial as lead investigator, should apply to th rch Career Development Award (Parent K08 Studies with Humans Required)	e companion NOFO (PA-24-19 National Institutes of	93).		Not
175516	ndependent Basic Experimental S Contact Name Contact Telephone	trial as lead investigator, should apply to th rch Career Development Award (Parent K08 Studies with Humans Required) 301-496-8580 grantinfo@nih.gov	e companion NOFO (PA-24-19 National Institutes of	93).		Not
175516	ndependent Basic Experimental S Contact Name Contact Telephone Contact Email Sponsor Website	trial as lead investigator, should apply to th rch Career Development Award (Parent K08 Studies with Humans Required) 301-496-8580 grantinfo@nih.gov	e companion NOFO (PA-24-19 National Institutes of	93).		Not
175516	ndependent Basic Experimental S Contact Name Contact Telephone Contact Email Sponsor Website	trial as lead investigator, should apply to th rch Career Development Award (Parent K08 Studies with Humans Required) 301-496-8580 grantinfo@nih.gov	e companion NOFO (PA-24-19 National Institutes of Health/DHHS 12-Feb-2025 , 07-May-2025 , 2	93). PA-24-183 07-	-Sep-2024 2025 , 12-Oct-20	Not Specified 25 , 07-Jan-

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Types of studies that should be submitted u conditions (i.e., experimentally manipulate humans for the purpose of understanding th processes or products in mind. Applicants n or proposing to gain research experience in investigator, must apply to the 'Independen related to the programmatic interests of on scientific missions.	independent variables) and t he fundamental aspects of ph ot planning an independent o a clinical trial or basic experi at Clinical Trial Not Allowed' c	hat assess biomedicates nenomena without specinical trial or basic e mental study with hu ompanion NOFO.	I or behavioral or pecific application experimental stud imans led by anothe he proposed proje	itcomes in towards y with humans, her ect must be
125527 Mentored Research Scientist Dev Basic Experimental Studies with F	elopment Award (Parent K01 Independent Jumans Required)	National Institutes of Health/DHHS	PA-24-177 07-	-Sep-2024	Not Specified
Contact Name					
Contact Telephone					
Contact Email	grantsinfo@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 1 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-	· · · · · · · · · · · · · · · · · · ·			
Synopsis	The purpose of the NIH Mentored Research (three to five years) for an intensive, supervisciences leading to research independence. mechanism to support career development individuals who propose to train in a new five illness or pressing family circumstances. Thi humans, referred to in NOT-OD-18-212 as " within the NIH definition of a clinical trial ar submitted under this NOFO include studies manipulate independent variables) and that understanding the fundamental aspects of p Applicants not planning an independent clir experience in a clinical trial or basic experim 'Independent Clinical Trial Not Allowed' con	vised career development exp Although all participating N experiences that lead to rese eld or for individuals who hav s Parent Announcement is fo prospective basic science stu nd also meet the definition of that prospectively assign hur t assess biomedical or behavi phenomena without specific nical trial or basic experiment nental study with humans led	berience in the biome IH Institutes and Cen earch independence, ve had a hiatus in the r basic science exper dies involving humar basic research. Type nan participants to co oral outcomes in hur application towards p al study with human by another investiga	edical, behavioral, ters (ICs) use this some ICs use the ir research career imental studies ir participants." The s of studies that s onditions (i.e., ex mans for the purp processes or prod s, or proposing to ator, must apply t	or clinical support KO1 award for because of wolving ese studies fall should be berimentally ose of ucts in mind. gain research o the

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		interests of one or more of the participating	NIH Institutes and Centers (I	Cs) based on their s	cientific missions.	
125530	Independent Scientist Award (Pa	rent K02 - Independent Clinical Trial Required	National Institutes of Health/DHHS	PA-24-178 07	-Sep-2024	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Emai	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 1 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-				
	Synopsis	them to expand their potential to make sign five years of salary support and "protected to period of intensive research focus as a mean program must be tailored to meet the indivi- experimental studies involving humans, refe- participants." These studies fall within the N Types of studies that should be submitted u conditions (i.e., experimentally manipulate if humans for the purpose of understanding the processes or products in mind. Applicants ne or proposing to gain research experience in investigator, must apply to the 'Independen related to the programmatic interests of on scientific missions. This Notice of Funding O	time" for newly independent as of enhancing their research idual needs of the candidate. erred to in NOT-OD-18-212 as IIH definition of a clinical trial nder this NOFO include studie independent variables) and th ne fundamental aspects of ph ot planning an independent c a clinical trial or basic experir t Clinical Trial Not Allowed' co e or more of the participating	scientists who can d n careers. Each indep This Parent Annour "prospective basics and also meet the c es that prospectively nat assess biomedica enomena without sp linical trial or basic e mental study with hu ompanion NOFO. Th s NIH Institutes and o	emonstrate the n pendent scientist acement is for bas science studies inv definition of basic v assign human pa al or behavioral ou pecific application experimental stud umans led by anot be proposed proje Centers (ICs) base	eed for a career award ic science volving human research. rticipants to itcomes in towards y with humans, her ct must be

<u>125512</u> Mentored Clinical Scientist Research Career Development Award (Parent K08 –	National Institutes of	DA 24 192 07 Can 2024	Not
125513 Independent Clinical Trial Not Allowed)	Health/DHHS	PA-24-182 07-Sep-2024	Specified

	oonsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Name				
Contact Telephone 301-496-8580				
Contact Email grantinfo@nih.gov				
Sponsor Website				
Program URL Link to program URL				
Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12- 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-20				
prepare qualified individuals for careers that h This program represents the continuation of a individuals with a clinical doctoral degree for a Synopsis biomedical and behavioral research, including specifically for applicants proposing research f feasibility study, or an ancillary clinical trial. U clinical trial led by a mentor or co-mentor. The should apply to the companion NOFO (PA-24-	a long-standing NIH program an intensive, supervised reso g translational research. This that does not involve leadin Inder this NOFO applicants a ose proposing a clinical trial	n that provides supp earch career develo Notice of Funding (g an independent cl re permitted to pro	ort and "protected pment experience Opportunity (NOFC inical trial, a clinic pose a research ex	d time" to in the fields o)) is designed al trial (perience in a
125524 <u>Mentored Research Scientist Development Award (Parent K01 - Independent</u> <u>Clinical Trial Required)</u>	National Institutes of Health/DHHS	PA-24-175 07-	Sep-2024	Not Specified
		PA-24-175 07-	Sep-2024	
Clinical Trial Required)		PA-24-175 07-	Sep-2024	
I25524 Clinical Trial Required) Contact Name		PA-24-175 07-	Sep-2024	
Contact Name Contact Telephone		PA-24-175 07-	Sep-2024	
Clinical Trial Required) Contact Name Contact Telephone Contact Email grantsinfo@nih.gov		PA-24-175 07-	Sep-2024	
Clinical Trial Required) Contact Name Contact Telephone Contact Email grantsinfo@nih.gov Sponsor Website	Health/DHHS -Feb-2025 , 07-May-2025 , 1	2-Jun-2025 , 07-Sep	-2025 , 12-Oct-20	Specified 25 , 07-Jan-

SPIN ID Program Title	s	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
	individuals who propose to train in a new fiel illness or pressing family circumstances. This proposing to serve as the lead investigator of ancillary study to an existing trial, as part of t clinical trial, or proposing to gain research ex NOFO (PA-24-176).	Notice of Funding Opportur f an independent clinical tria heir research and career de	nity (NOFO) is design II, a clinical trial feasi velopment. Applican	ed specifically for ibility study, or a s its not planning a	applicants separate n independent
125532 Independent Scientist Award (Pa Allowed)	rent K02 - Independent Clinical Trial Not	National Institutes of Health/DHHS	PA-24-179 07	-Sep-2024	Not Specified
Contact Name	2				
Contact Telephone	2				
Contact Emai	grantinfo@nih.gov				
Sponsor Website	2				
Program URI	Link to program URL				
Deadline Dates (ALL	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2				
Synopsis	The purpose of the NIH Independent Scienti them to expand their potential to make signi five years of salary support and "protected ti period of intensive research focus as a mean program must be tailored to meet the individ designed specifically for applicants proposing trial feasibility study, or an ancillary clinical tr in a clinical trial led by another investigator. T should apply to the companion NOFO (PA-24 one or more of the participating NIH Institute Opportunity (NOFO) is designed specifically f clinical trial, a clinical trial feasibility study, or career development. Applicants not planning clinical trial led by another investigator, must	ficant contributions to their me" for newly independent s of enhancing their research dual needs of the candidate. g research that does not invo- rial. Under this NOFO applica Those proposing a clinical tri -178). The proposed project es and Centers (ICs) based of or applicants proposing to se a separate ancillary study t g an independent clinical tria	field of research. Th scientists who can d h careers. Each indep This Notice of Fundi olve leading an indep ants are permitted to al or an ancillary clir t must be related to n their scientific miss erve as the lead inve o an existing trial, as il, or proposing to ga	e K02 award prov lemonstrate the n pendent scientist ing Opportunity (f pendent clinical tr propose a resea nical trial as lead in the programmati sions. This Notice estigator of an ind s part of their rese	ides three to eed for a career award NOFO) is ial, a clinical rch experience nvestigator, c interests of of Funding ependent earch and



SPIN ID Program Title	Sp	onsor Name	Sponsor Number	Deadline Date	Funding Amount
Clinical Trial Not Allowed)		Health/DHHS			Specified
Contact Name					
Contact Telephone					
Contact Email	grantsinfo@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12- 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-20	-			
Synopsis	The purpose of the NIH Mentored Research So (three to five years) for an intensive, supervise sciences leading to research independence. Al mechanism to support career development ex individuals who propose to train in a new field illness or pressing family circumstances. Other Funding Opportunity (NOFO) is designed speci independent clinical trial, a clinical trial feasibi permitted to propose research experience in a or an ancillary clinical trial as lead investigator	ed career development exp though all of the participat periences that lead to rese l or for individuals who hav ICs use the K01 to support fically for applicants propo lity study, or a separate an a clinical trial led by a ment	erience in the biom ing NIH Institutes a parch independence e had a hiatus in th career developme sing research that o cillary clinical trial. A or or co-mentor. Ap	edical, behavioral, nd Centers (ICs) us e, some ICs use the eir research career nt in specific fields does not involve le Applicants to this N pplicants proposing	or clinical e this support K01 award for because of This Notice of ading an NOFO are
108327 Research Enhancement Award Pro and Graduate Schools (R15 Clinica	ogram (REAP) for Health Professional Schools al Trial Required)	National Institutes of Health/DHHS	PAR-21- 357 07	7-Sep-2024	375,000 USD
Contact Name	Mahua Mukhopadhyay, Ph.D.				
Contact Telephone	301-435-6886				
Contact Email	mukhopam@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025				
Synopsis	The purpose of the Research Enhancement Av support small scale research grants at instituti providing biomedical research experiences pri	ons that do not receive sub	ostantial funding fro	om the NIH, with a	n emphasis on

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	enhancing the research environment at app science degrees and have received no more costs) in 4 of the last 7 fiscal years. For instit based on the amount of NIH funding receive determining the Organization Funding Level funding opportunity announcement (FOA) s addressing the mission and research interes clinical trials are defined as those that do no low risks to potentially cause physical or psy	e than \$6 million dollars per ye tutions composed of multiple ed by all the schools and colle I can be found here or https:// supports investigator-initiated sts of the participating NIH ins pt require FDA oversight, do n	ear of NIH support (schools and college ges within the insti /grants.nih.gov/gra mechanistic and/o titutes. For purpose	in both direct and es, the \$6 million fu tution as a whole. nts/funding/r15.ht r minimal risk clini es of this FOA, min	F&A/indirect unding limit is Help tm. This REAP cal trials imal risk
	e Discovery/Development Groups (NCDDG) f rs or Alcohol Use Disorder (U01 Clinical Trial	or National Institutes of Health/DHHS	PAR-22- 143	5-Oct-2024	Not Specified
Contact Name	Linda Brady, Ph.D.				
Contact Telephone	301-443-3563				
Contact Email	lbrady@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	25-Oct-2024 , 24-Feb-2025				
Synopsis	The purpose of this Funding Opportunity Ar translation from discovery to early human s neuromodulatory tools for basic and clinical validate tools (pharmacologic or neurostimu for mental disorders or AUD; and support ex pharmacodynamics of promising drug candi agents or Investigational Device Exemption encourages applications to advance the disor rationally based candidate agents and neuro ligands and circuit-engagement devices as t Partnerships between academia and industion multiple projects directed toward a specific multidisciplinary and often long-term appro-	tudies. Studies appropriate for I research on mental health di ulation) in support of experim arly-stage human studies to ra idates/devices and new indica (IDE)-ready devices for the tra covery, preclinical developme ostimulation approaches to tr ools to further characterize ex ry are strongly encouraged. Pr major objective, basic theme	r this FOA will deve sorders or alcohol ental therapeutic s apidly assess the sa tions for novel Inve eatment of mental nt, and proof of con eat mental disorde kisting or to validate ojects seeking sup or program goal, re	elop pharmacologie use disorder (AUD) tudies of innovativ fety, tolerability, a estigational New D disorders or AUD. ncept (PoC) testing rs or AUD, and to c e new drug/device port for a research equiring a broadly	c and); develop and e candidates nd rug (IND)-ready This FOA of new, develop novel targets. program of based,

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		applications proposing preclinical discover including, but not limited to, large biologic (i.e., oligonucleotide- and viral vector-base therapies). This FOA supports a discrete, sp area representing his or her specific intere	macromolecules, (e.g., proteir d), cell therapies, and novel er pecified, circumscribed project	ns, antibodies, and p nerging therapies (e	peptides), gene-ba e.g., microbial and	sed therapies microbiome
126793		cian Training Program (PCTP): Mentored Cli 08 - Basic Experimental Studies with Humar		PAR-24- 12 218 12	-Oct-2024	Not Specified
	Contact Name	Laura D. Wandner				
	Contact Telephone					
	Contact Email	Laura.Wandner@nih.gov				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Oct-2024 , 12-Nov-2024 , 12-Feb-2025 , 2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul- Jul-2027				
	Synopsis	The purpose of this NIH HEAL Initiative Pai Awards (K08) (BESH) is to support the care new and well-trained, independent investi research support during the early-career p supported by the NIH HEAL Initiative's Clin basic science experimental studies involvin involving human participants." These studies basic research. Types of studies that should participants to conditions (i.e., experiment outcomes in humans for the purpose of un towards processes or products in mind. Ap humans, or proposing to gain research exp investigator, must apply to the 'Independe related to the programmatic interests of of scientific missions. This Notice of Funding	er development of individuals gators. This supervised career hase to help awardees establis ical Research in Pain Manager g humans, referred to in NOT- es fall within the NIH definition d be submitted under this NOF ally manipulate independent v derstanding the fundamental plicants not planning an indep erience in a clinical trial or bas nt Clinical Trial Not Allowed' co ne or more of the participating	with clinical doctora development progra h independent rese nent program. This OD-18-212 as "pros n of a clinical trial ar O include studies th ariables) and that a aspects of phenome endent clinical trial ic experimental stud ompanion NOFO.	al degrees to creat am will provide in earch programs in Parent Announce pective basic scien and also meet the d hat prospectively a ssess biomedical of ena without specif or basic experime dy with humans le The proposed pro Centers (ICs) base	te a group of dependent NIH areas ment is for nce studies lefinition of assign human or behavioral ic application ntal study with d by another ject must be d on their

SPIN ID Program Title	5	Sponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
	the lead investigator of an independent clini trial, as part of their research and career dev experimental study with humans, or proposi humans led by another investigator, must ap	velopment. Applicants not pla ing to gain research experien	anning an indepen ce in a clinical tria	ndent clinical trial or al basic experimenta	basic study with
113466 Notice of Special Interest (NOSI): on Interoception Circuits	BRAIN Initiative: Notice of Support for Resear	r <u>ch</u> National Institutes of Health/DHHS	NOT-AT- 23-003	13-Sep-2024	Not Specified
-		ify the research community t	hat NIH welcome	s BRAIN Initiative an	nlications
Synopsis <u>Mentored Career Development F</u> 115095 <u>Nonhuman Primate Research Mo</u> Allowed)	targeting interoceptive processes and circuit Program for Early Stage Investigators Using		s and requiremen		
					opeenee
Contact Name Contact Telephone Contact Emai Sponsor Website	I <u>AITraininghelpdesk@niaid.nih.gov</u>				
Contact Name Contact Telephone Contact Emai Sponsor Website	AITraininghelpdesk@niaid.nih.gov Link to program URL	2-Feb-2025 , 07-May-2025 , 1		Sep-2025 , 12-Oct-20	

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	highly skilled scientists using NHP models to of outcomes into the clinic. The expectation training, awardees will launch independent R01) funding. This Funding Opportunity And does not involve leading an independent cl Applicants to this FOA are permitted to pro	n is that through this sustained research careers and become nouncement (FOA) is designed inical trial, a clinical trial feasil	d period of research e competitive for new d specifically for app pility study, or an an	career developme w research project licants proposing cillary study to a c	ent and grant (e.g., research that linical trial.
125230 Mentored Patient-Oriented Resea Independent Basic Experimental S	arch Career Development Award (Parent K23 Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-186 07	-Sep-2024	Not Specified
Contact Name					
Contact Telephone					
Contact Email	grantinfo@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 2 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-	· · · · · · · · · · · · · · · · · · ·			
Synopsis	The purpose of the NIH Mentored Patient- development of individuals with a clinical d on patient-oriented research. This Parent A to in NOT-OD-18-212 as "prospective basic definition of a clinical trial and also meet th this NOFO include studies that prospectivel independent variables) and that assess bior fundamental aspects of phenomena withou planning an independent clinical trial or basic clinical trial or basic experimental study wit Trial Not Allowed' companion NOFO. The p the participating NIH Institutes and Centers	octoral degree who have mad announcement is for basic scie science studies involving hum e definition of basic research. y assign human participants to medical or behavioral outcom at specific application towards sic experimental study with hu h humans led by another inve proposed project must be relat	le a commitment to ince experimental st ian participants." Th Types of studies that o conditions (i.e., ex es in humans for the processes or produ umans, or proposing estigator, must apply ted to the programn	focus their resear udies involving hu ese studies fall wi at should be subm perimentally mani e purpose of under cts in mind. Applic to gain research e to the 'Independe	ch endeavors mans, referred thin the NIH itted under pulate rstanding the cants not experience in a ent Clinical
125228 Mentored Patient-Oriented Resea Independent Clinical Trial Not Allo	arch Career Development Award (Parent K23 owed)	8 – National Institutes of Health/DHHS	PA-24-185 07	-Sep-2024	Not Specified
Contact Name					

SPIN ID	Program Title	S	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone					
	·	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2				
	Synopsis	The purpose of the NIH Mentored Patient-C development of individuals with a clinical do on patient-oriented research. This Notice of research that does not involve leading an ind trial. Under this NOFO applicants are permitt mentor. Those proposing a clinical trial or an (PA-24-184).	ctoral degree who have mac Funding Opportunity (NOFO lependent clinical trial, a clin red to propose a research ex	le a commitment to) is designed specific ical trial feasibility s perience in a clinical	focus their researd ally for applicants tudy, or an ancilla trial led by a men	ch endeavors proposing ry clinical tor or co-
1 15 1 1 1	Mentored Patient-Oriented Resea Independent Clinical Trial Require	arch Career Development Award (Parent K23 - ed)	 National Institutes of Health/DHHS 	PA-24-184 07-	-Sep-2024	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2	2-Feb-2025 , 07-May-2025 , 2 026 , 07-Sep-2026 , 12-Oct-2	L2-Jun-2025 , 07-Sep 2026 , 07-Jan-2027 ,	-2025 , 12-Oct-20 12-Feb-2027 , 07-	25 , 07-Jan- May-2027
		The purpose of the NIH Mentored Patient-O development of individuals with a clinical do on patient-oriented research. This Notice of serve as the lead investigator of an independ	ctoral degree who have mac Funding Opportunity (NOFO	le a commitment to) is designed specific	focus their resear ally for applicants	ch endeavors proposing to

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125538	NIH Pathway to Independence Av Experimental Studies with Humar	vard (Parent K99/R00 Independent Basic as Required)	National Institutes of Health/DHHS	PA-24-195 07-	-Sep-2024	Not Specified
	Contact Name Contact Telephone Contact Email					
	Sponsor Website					
	Program URL	Link to program URL 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 ,				· · ·
	Deadline Dates (ALL) Synopsis	2026, 12-Feb-2026, 07-May-2026, 12-Jur The purpose of the NIH Pathway to Indeper postdoctoral researchers with a research a independent, tenure-track or equivalent fa during this transition in order to help awar Announcement is for basic science experin basic science studies involving human part meet the definition of basic research. Type prospectively assign human participants to biomedical or behavioral outcomes in hum without specific application towards proce basic experimental study with humans, or with humans led by another investigator, r proposed project must be related to the pu Centers (ICs) based on their scientific missi	n-2026, 07-Sep-2026, 12-Oct- endence Award (K99/R00) pro- and/or clinical doctorate degre aculty positions. The program rdees to launch competitive, in nental studies involving huma icipants." These studies fall w es of studies that should be su o conditions (i.e., experimenta hans for the purpose of unders esses or products in mind. App proposing to gain research ex must apply to the 'Independer rogrammatic interests of one ions.	2026, 07-Jan-2027, ogram is to facilitate a see from mentored, po will provide independ ndependent research ns, referred to in NO ithin the NIH definition bmitted under this N Ily manipulate independ standing the fundame icants not planning a perience in a clinical at Clinical Trial Not Al	12-Feb-2027, 07 a timely transition ostdoctoral researd dent NIH research careers. This Par T-OD-18-212 as " on of a clinical tria OFO include stud endent variables) ental aspects of p an independent c trial or basic expension	-May-2027 of outstanding rch positions to a support ent prospective al and also ies that and that assess henomena linical trial or erimental study n NOFO. The utes and
125559	Midcareer Investigator Award in F Independent Basic Experimental S	Patient-Oriented Research (Parent K24 - Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-189 07-	-Sep-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	grantinfo@nih.gov				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Deadline Dates (ALL)	Link to program URL 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 2 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun				
	Synopsis	The purpose of the NIH Midcareer Investig health-professional doctorates for protecter mentors for junior clinical investigators pur Parent Announcement is for basic science of "prospective basic science studies involving and also meet the definition of basic resear that prospectively assign human participan assess biomedical or behavioral outcomes in phenomena without specific application to clinical trial or basic experimental study with experimental study with humans led by and companion NOFO. The proposed project in NIH Institutes and Centers (ICs) based on the	ator Award in Patient-Orient ed time to devote to patient-orient suing POR research, such as a experimental studies involving human participants." These rch. Types of studies that sho ts to conditions (i.e., experime in humans for the purpose of wards processes or products th humans, or proposing to gat other investigator, must apply nust be related to the progra	ed Research (K24) is priented research (PC clinical residents and g humans, referred to studies fall within th uld be submitted und nentally manipulate in funderstanding the fu in mind. Applicants r ain research experier y to the 'Independen	to provide suppor DR) and to act as r junior clinical fact o in NOT-OD-18-2 e NIH definition o der this NOFO incl ndependent varial undamental aspec not planning an inc nce in a clinical tria t Clinical Trial Not	t to mid-career esearch ulty. This 12 as f a clinical trial ude studies oles) and that cts of dependent al or basic Allowed'
125557	Midcareer Investigator Award in I Independent Clinical Trial Require	Patient-Oriented Research (Parent K24 ed)	National Institutes of Health/DHHS	PA-24-187 07	-Sep-2024	Not Specified
	Contact Name Contact Telephone					
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 2 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun				
	Synopsis	The purpose of the NIH Midcareer Investigate health-professional doctorates for protected mentors for junior clinical investigators pur basic science experimental studies involving involving human participants." These studies	ed time to devote to patient-o suing POR research, such as o g humans, referred to in NOT	oriented research (PC clinical residents. Thi I-OD-18-212 as "pros	DR) and to act as r s Parent Announc pective basic scien	esearch ement is for nce studies

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	basic research. Types of studies that should participants to conditions (i.e., experimental outcomes in humans for the purpose of und towards processes or products in mind. App humans, or proposing to gain research expe investigator, must apply to the 'Independent related to the programmatic interests of one scientific missions. This Notice of Funding Op lead investigator of an independent clinical t trial, as part of their research and career dev gain research experience in a clinical trial lead	Ily manipulate independent w lerstanding the fundamental licants not planning an indep rience in a clinical trial or bas t Clinical Trial Not Allowed' co e or more of the participating pportunity (NOFO) is designe trial, a clinical trial feasibility velopment. Applicants not pla	ariables) and that as aspects of phenome endent clinical trial ic experimental stuc ompanion NOFO. The NIH Institutes and C d specifically for app study, or a separate anning an independe	ssess biomedical of na without specifi or basic experime dy with humans le he proposed projection Centers (ICs) base olicants proposing ancillary study to ent clinical trial, or	or behavioral ic application ntal study with d by another ect must be d on their to serve as the an existing r proposing to
125583 Independent Scientist Award (Par Studies with Humans Required)	ent KO2 Independent Basic Experimental	National Institutes of Health/DHHS	PA-24-180 07-	-Sep-2024	Not Specified
Contact Name					
Contact Telephone					
Contact Email	<u>GrantsInfo@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 1 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2		-		
	The purpose of the NIH Independent Scient them to expand their potential to make sign five years of salary support and "protected t period of intensive research focus as a mean program must be tailored to meet the indivi experimental studies involving humans, refe participants." These studies fall within the N Types of studies that should be submitted un conditions (i.e., experimentally manipulate i humans for the purpose of understanding the processes or products in mind. Applicants no	ificant contributions to their ime" for newly independent as of enhancing their research dual needs of the candidate. erred to in NOT-OD-18-212 as IIH definition of a clinical trial nder this NOFO include studio ndependent variables) and the fundamental aspects of ph	field of research. Th scientists who can d careers. Each indep This Parent Annour "prospective basics and also meet the c es that prospectively nat assess biomedica enomena without sp	e KO2 award prov emonstrate the n pendent scientist of cement is for bas science studies inv definition of basic assign human pa al or behavioral ou pecific application	ides three to eed for a career award ic science volving human research. articipants to itcomes in towards

SPIN ID Program Title	S¢	oonsor Name	Sponsor Number	r Deadline Date	Funding Amount
	or proposing to gain research experience in a investigator, must apply to the 'Independent related to the programmatic interests of one scientific missions.	Clinical Trial Not Allowed' co	ompanion NOFO.	The proposed proj	ect must be
125558 Midcareer Investigator Award in I Independent Clinical Trial Not Allo	Patient-Oriented Research (Parent K24 owed)	National Institutes of Health/DHHS	PA-24-188 (07-Sep-2024	Not Specified
Sponsor Website	g <u>rantinfo@nih.gov</u>				
Deadline Dates (ALL)	07-Sep-2024 12-Oct-2024 07-Jap-2025 12				
Synopsis	The purpose of the NIH Midcareer Investigator health-professional doctorates for protected mentors for junior clinical investigators pursu Notice of Funding Opportunity (NOFO) is design an independent clinical trial, a clinical trial feat permitted to propose a research experience in an ancillary clinical trial as lead investigator, s	time to devote to patient-or ing POR research, such as cl gned specifically for applica asibility study, or an ancillary n a clinical trial led by a mer	riented research (linical residents ar nts proposing reso y clinical trial. Und ntor or co-mentor	POR) and to act as r nd/or junior clinical earch that does not ler this NOFO candio . Those proposing a	esearch aculty. This involve leading lates are
	ent Awards in Implementation Science for eatment (K23 - Clinical Trial Required)	National Institutes of Health/DHHS	PAS-22- 207	12-Oct-2024	Not Specified
	Lori Ducharme, Ph.D.				
Contact Telephone					
Contact Email Sponsor Website	Lori.Ducharme@nih.gov				
FIOGIAIII UKL	Link to program URL				

SPIN ID Program Title			Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
	Synopsis	The purpose of this Mentored Patient-Orien Substance Use Prevention and Treatment (k degree who have made a commitment to for implementation science perspective. These time" (3-5 years) for an intensive, supervise of specialization. Realizing the return on put interventions to address the ongoing overda implementation science, who can help move focuses on identifying modifiable barriers to settings, and developing replicable and scala the past 15 years, there remain a limited nu and implementation science, limiting the fiel deeper bench of clinician researchers who c the substance use field. This Funding Oppor foundational clinical training in substance us support and protected time to acquire train execution of an independent NIH-defined cl in one or more of the four domains of the H treatment; harm reduction; or recovery rese specifically for applicants proposing to serve study, or a separate ancillary study to an exi planning an independent clinical trial, or pro-	(23) is to support the career of ocus their research endeavors awards provide salary and re- d career development experi- olic investment in the develop ose crisis depends on a cadre e these interventions into rou o the uptake and sustained us able strategies to overcome t mber of independent clinicia eld's capacity to address persi- tan be called upon to meet or tunity Announcement (FOA) se prevention or treatment a ing and research experience inical trial applying implement HS Overdose Prevention Strate earch) is required. This Funding as the lead investigator of a isting trial, as part of their res- posing to gain research exper-	development of in son patient-orient search support fo ence leading to re- pment of evidence of skilled clinician utine clinical pract se of evidence-bas hose barriers. Wh n researchers with stent gaps in this ngoing and emerging will support early nd/or co-occurring in implementation tation science me tegy (prevention; ng Opportunity Ar n independent clinical erience in a clinical	dividuals with a clin and research from an r a sustained period search independent e-based treatments researchers with ex- ice. Implementation ed practices in real ile this field has gro n dual expertise in s area. There is a pres- ing implementation career investigators g mental illness, and science. Development ethods to patient-or evidence-based add mouncement (FOA) hical trial, a clinical trial development. Appli	ical doctoral of "protected ce in this area and preventive pertise in a science world clinical wn rapidly ov ubstance use ssing need for challenges in who have a will provide ent and iented resear diction is designed crial feasibility cants not
		and which the test of the second states of the seco	Notional Institutes of			
		ent Awards in Implementation Science for eatment (K01 - Clinical Trial Required)	National Institutes of Health/DHHS	PAS-22- 206	12-Oct-2024	Not Specifie
Substance Use Prevent	tion and Tre				12-Oct-2024	
Substance Use Prevent	tion and Tre	eatment (K01 - Clinical Trial Required)			12-Oct-2024	
Substance Use Prevent Cor Contact	tion and Tre ntact Name Telephone	eatment (K01 - Clinical Trial Required) Lori Ducharme, Ph.D.			12-Oct-2024	
Substance Use Prevent Cor Contact Cor	tion and Tre ntact Name Telephone	eatment (K01 - Clinical Trial Required) Lori Ducharme, Ph.D. 301-827-6331 Lori.Ducharme@nih.gov			12-Oct-2024	

Deadline Dates (ALL) 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	The purpose of this Mentored Research Scie Prevention and Treatment (K01) is to provid development experience leading to research investment in the development of evidence crisis depends on a cadre of skilled research interventions into routine practice. Impleme sustained use of evidence-based practices in overcome those barriers. While this field ha independent researchers with dual expertise capacity to respond to continued calls for re- who can be called upon to meet ongoing an Opportunity Announcement (FOA) will supp prevention or treatment research and will p implementation science. Development and science methods to one of the four domains treatment; harm reduction; or recovery rese specifically for applicants proposing to serve study, or a separate ancillary study to an exi planning an independent clinical trial, or pro- should consult the NIH Research Career Dev	e support and "protected time in independence in this area of based treatments and preven ers with expertise in impleme entation science focuses on id in real world settings and deve s grown rapidly over the past e in addiction research and im search in this area. There is a d emerging implementation of ort early career investigators rovide support and protected execution of an independent s of the HHS Overdose Preven earch) is required. This Funding e as the lead investigator of an sting trial, as part of their rese posing to gain research expendent	e" (3-5 years) for a f specialization. Rea ntive interventions intation science, wh entifying modifiabl loping replicable an 15 years, there rem plementation scien pressing need for a hallenges in the ad who have foundati time to acquire tra NIH-defined clinica tion Strategy (prev g Opportunity Ann independent clinic earch and career de rience in a clinical t	n intensive, super- alizing the return of to address the on- ho can help move e barriers to the u nd scalable strateg nain a limited num nce, constraining t a deeper bench of diction field. This l onal training in su aining and research I trial applying imp ention; evidence-b ouncement (FOA) cal trial, a clinical t evelopment. Appli rial led by another	vised career on public going overdose these ptake and ies to iber of he field's researchers Funding bstance use h experience in plementation pased addiction is designed rial feasibility cants not
112749 Notice of Special Interest (NOSI): Pathways for Individuals with His	HEAL Initiative: Opioid Use Disorder Care tories of Exposure to Violence	National Institutes of Health/DHHS	NOT-DA- 23-007 12	2-Oct-2024	Not Specified
Contact Name	e Carrie Mulford				
Contact Telephone	301-827-6473				
Contact Emai	Carrie.Mulford@nih.gov				
Sponsor Website	2				
Program URI	Link to program URL				
Deadline Dates (ALL	12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025				
Synopsis	The proposed initiative seeks to test innovation of the proposed initiative seeks to test innovation and test innovation and test in test innovation and test innovatio			ance use and ment	al health

SPIN IC	Program Title	2	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
121738	Advancing Research Careers (ARC to Promote Diversity (F99/K00 - C) Predoctoral to Postdoctoral Transition Awa linical Trial Not Allowed)	rd National Institutes of Health/DHHS	PAR-23- 222 07	-Sep-2024	Not Specified
	Contact Name	Laurie Stepanek, Ph.D.				
	Contact Telephone					
	Contact Email	laurie.stepanek@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 11-Oct-2024 , 07-Jan-2025 , 13 2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2				
		The purpose of the Advancing Research Care (F99/K00) program is to support promising, underrepresented groups (see Notice of NIH research positions. It is anticipated that succ advance in impactful careers in the biomedia research and teaching at a range of institution support for late-stage graduate students pur	ate-stage graduate students 's Interest in Diversity), to tr ressful completion of this pha cal research workforce that t on types, industry or governr	from diverse backg ansition into and suc ased award program ypically require post nent research). This	rounds, for examp cceed in mentored will position ARC tdoctoral training two-phase award	le those from I postdoctora scholars to (e.g., academ

12	22207 Ethical, Legal and Social Implication	ons (ELSI) Research (R01 Clinical Trial Optional)	Health/DHHS	PAR-23- 293	21-Oct-2024	Not Specified
	Contact Name	Dave Kaufman				
	Contact Telephone	301-402-4997				
	Contact Email	dave.kaufman@nih.gov				
	Sponsor Website					

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL)	Link to program URL 21-Oct-2024 , 20-Feb-2025 , 17-Jun-2025 , 2 This Notice of Funding Opportunity (NOFO) ethical, legal and social implications (ELSI) of either single or mixed methods. Approache methods, and conceptual, legal, and norma genomics will also be considered responsive encouraged, but not required. Plan for Enha together and capitalizing on innovative idea benefits that flow from a diverse scientific w competitiveness, contributing to robust lea likelihood that underserved populations par best science, the NIH encourages inclusivity but are not limited to: Transdisciplinary rese computational biology, physics, engineering from different types of institutions and orga community-based). Individual applications a Investigators and teams composed of resea backgrounds, including groups traditionally (see NOT-OD-20-031), such as underreprese backgrounds, and women. Opportunities to investigators. This NOFO requires a Plan fo scientific and technical peer review evaluati be withdrawn. Applicants are strongly enco- guidance material.	invites Research Project Gran of human genetic or genomic re- s may include but are not limit tive analyses. Applied research e. Direct engagement with con- ancing Diverse Perspectives The as and distinct perspectives on workforce, including: fostering rning environments, improvin- rticipate in, and benefit from r in research. Examples of stru- earch projects and collaborati g, mathematics, computer and anizations (e.g., research-inte- and partnerships that enhanch- inchers at different career stage underrepresented in the bior ented racial and ethnic groups o enhance the research enviro r Enhancing Diverse Perspecti- ion. Applications that fail to ir	nt (R01) application research. Application ited to empirical qui ch designed to addr mmunities and othe he NIH recognizes to utperform homogen g scientific innovation g the quality of the research, and enha- ictures that promotions among research d data sciences, as we nsive, undergradua e geographic and re- ges. Participation of medical, behavioral s, those with disabi- onment to benefit e- ives (PEDP), which we nclude a PEDP will b	s that propose to sons may propose stalitative and quantess ELSI issues in ger interested group hat diverse teams. There on, enhancing globe research, advanci ncing public trust. Se diverse perspect hers from fields su well as bioethics. E te-focused, minori egional heterogene f individuals from o , and clinical resea findividuals from o arly- and mid-care will be assessed as pe considered income	tudies using titative enetics and os is working e are many bal ng the To support the tives include ch as ngagement ty-serving, eity. liverse rch workforce lisadvantaged er part of the mplete and will
122256 Ethical, Legal and Social Implication Grant (R21 Clinical Trial Optional)	ons (ELSI) Exploratory/Developmental Resea	rch National Institutes of Health/DHHS	PAR-23- 294 2	1-Oct-2024	275,000 USD
Contact Telephone	<u>dave.kaufman@nih.gov</u>				

SPIN ID Program Title	S	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
Program URL	Link to program URL				
Deadline Dates (ALL)	21-Oct-2024 , 20-Feb-2025 , 17-Jun-2025 , 20)-Oct-2025 , 19-Feb-2026 , 1	8-Jun-2026 <i>,</i> 20-Oct	-2026	
Synopsis	This Notice of Funding Opportunity (NOFO) i propose to study the ethical, legal and social propose studies using either single or mixed or develop preliminary data in preparation for qualitative and quantitative methods, and co ELSI issues in genetics and genomics will also stakeholders is encouraged, but not required	implications (ELSI) of humar methods, that break new gro or larger studies. Approaches nceptual, legal, and normati be considered responsive. D	n genetic or genomi ound, extend previc s may include but ar ve analyses. Applie	c research. Applica ous discoveries in r re not limited to er d research designe	ations may new directions, mpirical ed to address
122258 Ethical, Legal and Social Implication	ons (ELSI) Small Research Grant (RO3 Clinical	National Institutes of Health/DHHS	PAR-23- 295 21	-Oct-2024	100,000 USD
Contact Name	Dave Kaufman				
Contact Telephone	301-402-4997				
Contact Email	dave.kaufman@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	21-Oct-2024 , 20-Feb-2025 , 17-Jun-2025 , 20)-Oct-2025 , 19-Feb-2026 , 1	8-Jun-2026 , 20-Oct	-2026	
Synopsis	This Notice of Funding Opportunity (NOFO) i legal and social implications (ELSI) of human contained research projects, such as those th normative or conceptual analyses, including new or emerging issues. This mechanism car existing data. Applications may propose stud ELSI issues in genetics and genomics will also stakeholders is encouraged, but not required	genetic or genomic research nat involve single investigato focused legal, economic, phi also be used for the collecti ies using either single or mix be considered responsive. D	. These applications rs. Of particular inte losophical, anthrop on of preliminary d ed methods. Applie	s should be for sm erest are projects ological, or histori ata and the second ed research design	all, self- that propose cal analyses of dary analysis of ed to address
	al Translational Efforts (IGNITE): Assay Itic Agent Identification (R61/R33 Clinical Tria	National Institutes of Health/DHHS	PAR-21- 21 124 21	-Oct-2024	750,000 USD
Contact Name	Becky Roof, PhD				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	301-496-1779				
		rebecca.roof@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	21-Oct-2024				
	Synopsis	This funding opportunity announcement (F assays and conduct iterative screening effo neuromuscular disorders. This FOA is part of advance projects to the point where they co other translational programs.	rts to identify and characteriz of a suite of Innovation Grants	e potential therapeu to Nurture Initial Tr	utic agents for neu anslational Efforts	rological or 6 (IGNITE) to
114710		Advanced Postdoctoral-to-Independent Care D Research to Promote Diversity (K99/R00 Studies with Humans Required)	National Institutes of Health/DHHS	RFA-NS- 22-024 11	-Oct-2024	Not Specified
	Contact Name	DP Mohapatra, Ph.D.				
	Contact Telephone	301-496-9964				
		dp.mohapatra@nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	11-Oct-2024 , 11-Feb-2025				
	Synopsis	The purpose of this NIH HEAL Initiative® Pa and well-trained, independent investigators Diversity) conducting Pain and/or SUD rese working in research areas supported by the eligible postdoctoral researchers from their equivalent faculty positions. The program w awardees establish independent research p Announcement is for basic science experim basic science studies involving human parti meet the definition of basic research. Types prospectively assign human participants to	s from diverse backgrounds (e arch, in order to promote a di NIH HEAL Initiative [®] . This pro mentored, postdoctoral rese vill provide independent NIH r programs in areas supported b ental studies involving humar cipants." These studies fall wi s of studies that should be sub	e.g. see NOT-OD-20- verse pool of availal ogram is designed to arch positions to inc research support du by the NIH HEAL Initi ns, referred to in NO thin the NIH definition mitted under this F	031, Notice of NIH ole independent in facilitate a timely dependent, tenure ring this transition ative [®] . This Fundii T-OD-18-212 as "p on of a clinical tria OA include studies	's Interest in nvestigators transition of track or to help ng Opportunity prospective I and also that

SPIN ID Pro	gram Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		biomedical or behavioral outcomes in huma without specific application towards process basic experimental study with humans, or p with humans led by another investigator, m proposed project must be related to the pro Centers (ICs) based on their scientific missio	ses or products in mind. Appli roposing to gain research exp ust apply to the 'Independent ogrammatic interests of one o	icants not planning perience in a clinical t Clinical Trial Not A	an independent cl trial or basic expe llowed' companior	inical trial or rimental study n FOA. The
114711 Transi		Advanced Postdoctoral-to-Independent Care <u>D Research to Promote Diversity (K99/R00</u> <u>pwed)</u>	er National Institutes of Health/DHHS	RFA-NS- 22-025 11	-Oct-2024	Not Specified
	Contact Name	DP Mohapatra, Ph.D.				
	Contact Telephone	301-496-9964				
	Contact Email	dp.mohapatra@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Oct-2024 , 11-Feb-2025				
	Synopsis	The purpose of this NIH HEAL Initiative® Pat and well-trained, independent investigators Diversity) conducting Pain and/or SUD resea working in research areas supported by the eligiblepostdoctoral researchers from their r equivalent faculty positions. The program w awardees establish independent research pu Announcement (FOA) is designed specifically clinical trial, a clinical trial feasibility study, a with Humans (BESH). Applicants to this FOA co-mentor. Those proposing an independen	from diverse backgrounds (e arch, in order to promote a dir NIH HEAL Initiative [®] . This pro- mentored, postdoctoral resea ill provide independent NIH r rograms in areas supported b y for candidates proposing re an ancillary study to a clinical are permitted to propose res	.g. see NOT-OD-20- verse pool of availab gram is designed to arch positions to ind esearch support du y the NIH HEAL Initi search that does no trial, or an independ search experience in	031, Notice of NIH ble independent in b facilitate a timely lependent, tenure- ring this transition ative [®] . This Fundir at involve leading a dent Basic Experim a clinical trial led	's Interest in westigators transition of track or to help ng Opportunity n independent ental Studies by a mentor or
114707 Transi		Advanced Postdoctoral-to-Independent Care D Research (Independent Basic Experimental	er National Institutes of Health/DHHS	RFA-NS- 22-023 11	-Oct-2024	Not Specified

Contact Name DP Mohapatra, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Program URL	dp.mohapatra@nih.gov Link to program URL 11-Oct-2024 , 11-Feb-2025 The purpose of the NIH HEAL Initiative® Pat and well-trained independent investigators investigator workforce in research areas su transition of eligible postdoctoral researche track or equivalent faculty positions. The pr help awardees establish independent resea Opportunity Announcement is for basic scie "prospective basic science studies involving	conducting Pain and/or SUD pported by the NIH HEAL Initia ers from their mentored, poste ogram will provide independe inch programs in areas suppor ence experimental studies inve- to the participants." These s ich. Types of studies that show conditions (i.e., experimental ans for the purpose of unders isses or products in mind. Appl proposing to gain research exp nust apply to the 'Independen ogrammatic interests of one of	research, in order to ative [®] . This program doctoral research po- ent NIH research sup ted by the NIH HEA olving humans, refe studies fall within the Id be submitted un- ly manipulate indep tanding the fundam icants not planning perience in a clinical t Clinical Trial Not A	o increase the inden is designed to far ositions to indepen pport during this t L Initiative®. This F rred to in NOT-OD the NIH definition of der this FOA includ thendent variables) thental aspects of p an independent cl trial or basic expending llowed' companio	ependent cilitate a timely ndent, tenure- ransition to funding -18-212 as f a clinical trial de studies that and that assess henomena inical trial or rimental study n FOA. The
	Notice of Special Interest (NOSI): nfection	Pediatric COVID-19 and Respiratory Viral Co-	National Institutes of Health/DHHS	NOT-HL- 22-004 07	2-Sep-2024	Not Specified
	-		07-120-2025 05-Eeb-2025 0	7-May-2025_05-10	n-2025 07-Sen-20	125

SPIN ID	Program Title	s	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
		screen for co-infection, phenotype and collect investigator-initiated applications for basic, t	•	•		•
	Notice of Special Interest (NOSI): Identified Factors Into Models of	Advancing NEI AGI Research on newly Visual System Regeneration	National Institutes of Health/DHHS	NOT-EY- 22-002 05	5-Sep-2024	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email					
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16	5-Oct-2024			
		The National Eye Institute (NEI) is issuing this		-		
	Synopsis	newly identified factors into new or existing r consortium of research teams as part of the r community. Applicants beyond the original co	models of visual system rege Audacious Goal Initiative (AG onsortium are strongly enco	eneration. These fac GI) and are being sh	ctors were identifie	ed by a the research
		newly identified factors into new or existing r consortium of research teams as part of the <i>r</i> community. Applicants beyond the original co Development Award (Parent K25 Independent	models of visual system rege Audacious Goal Initiative (AG onsortium are strongly enco	eneration. These fac GI) and are being sh	ctors were identifie ared broadly with	ed by a
	Mentored Quantitative Research	newly identified factors into new or existing r consortium of research teams as part of the A community. Applicants beyond the original co Development Award (Parent K25 Independent lumans Required)	models of visual system rege Audacious Goal Initiative (AG onsortium are strongly enco t National Institutes of	eneration. These fac GI) and are being sh puraged to apply.	ctors were identifie ared broadly with	ed by a the research Not
	Mentored Quantitative Research Basic Experimental Studies with F	newly identified factors into new or existing r consortium of research teams as part of the A community. Applicants beyond the original co <u>Development Award (Parent K25 Independent</u> <u>lumans Required)</u>	models of visual system rege Audacious Goal Initiative (AG onsortium are strongly enco t National Institutes of	eneration. These fac GI) and are being sh puraged to apply.	ctors were identifie ared broadly with	ed by a the research Not
	Mentored Quantitative Research Basic Experimental Studies with F Contact Name Contact Telephone	newly identified factors into new or existing r consortium of research teams as part of the A community. Applicants beyond the original co <u>Development Award (Parent K25 Independent</u> <u>lumans Required)</u>	models of visual system rege Audacious Goal Initiative (AG onsortium are strongly enco t National Institutes of	eneration. These fac GI) and are being sh puraged to apply.	ctors were identifie ared broadly with	ed by a the research Not
	Mentored Quantitative Research Basic Experimental Studies with F Contact Name Contact Telephone	newly identified factors into new or existing i consortium of research teams as part of the A community. Applicants beyond the original co Development Award (Parent K25 Independent lumans Required)	models of visual system rege Audacious Goal Initiative (AG onsortium are strongly enco t National Institutes of	eneration. These fac GI) and are being sh puraged to apply.	ctors were identifie ared broadly with	ed by a the research Not
	Mentored Quantitative Research Basic Experimental Studies with F Contact Name Contact Telephone Contact Email Sponsor Website	newly identified factors into new or existing i consortium of research teams as part of the A community. Applicants beyond the original co Development Award (Parent K25 Independent lumans Required)	models of visual system rege Audacious Goal Initiative (AG onsortium are strongly enco t National Institutes of	eneration. These fac GI) and are being sh puraged to apply.	ctors were identifie ared broadly with	ed by a the research Not
	Mentored Quantitative Research Basic Experimental Studies with F Contact Name Contact Telephone Contact Email Sponsor Website	newly identified factors into new or existing r consortium of research teams as part of the A community. Applicants beyond the original co <u>Development Award (Parent K25 Independent</u> <u>lumans Required)</u> <u>GrantsInfo@nih.gov</u>	nodels of visual system rege Audacious Goal Initiative (AG onsortium are strongly enco t National Institutes of Health/DHHS	eneration. These fac GI) and are being sh buraged to apply. PA-24-192 07	tors were identifie ared broadly with 7-Sep-2024 p-2025 , 12-Oct-20	ed by a the research Not Specified 25 , 07-Jan-

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	research. This Parent Announcement is for 1 212 as "prospective basic science studies im clinical trial and also meet the definition of studies that prospectively assign human par and that assess biomedical or behavioral ou phenomena without specific application tow clinical trial or basic experimental study with experimental study with humans led by ano companion NOFO. The proposed project m NIH Institutes and Centers (ICs) based on th	volving human participants." basic research. Types of studi ticipants to conditions (i.e., e itcomes in humans for the pu wards processes or products i h humans, or proposing to ga other investigator, must apply nust be related to the program	These studies fall wi ies that should be su experimentally manip rpose of understand n mind. Applicants n in research experien to the 'Independen	thin the NIH defin bmitted under thi pulate independer ling the fundamen not planning an inc ice in a clinical tria t Clinical Trial Not	ition of a s NOFO include nt variables) ital aspects of dependent il or basic Allowed'
125482 Mentored Quantitative Research Clinical Trial Required)	Development Award (Parent K25 Independe	nt National Institutes of Health/DHHS	PA-24-190 07	-Sep-2024	Not Specified
Contact Name					
Contact Telephone					
Contact Email	GrantsInfo@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 1 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-	· · · · · · · · · · · · · · · · · · ·	•		
Synopsis	The purpose of the Mentored Quantitative those investigators whose quantitative scien questions of health and disease. The K25 aw and research for productive professionals w imaging science, informatics, physics, chem research. This Notice of Funding Opportunit investigator of an independent clinical trial, part of their research and career developmer research experience in a clinical trial led by	nce and engineering research vard will provide support and vith quantitative (e.g., mather istry) and engineering backgr cy (NOFO) is designed specific a clinical trial feasibility study ent. Candidates not planning	has thus far not bee "protected time" fo matics, statistics, ecc ounds to integrate the ally for candidates p y, or a separate ancil an independent clini	en focused primar r a period of supe pnomics, compute heir expertise with proposing to serve lary study to an ex ical trial, or proposi	ily on rvised study r science, n NIH-relevant as the lead xisting trial, as sing to gain
125483 Mentored Quantitative Research Clinical Trial Not Allowed)	Development Award (Parent K25 Independe	nt National Institutes of Health/DHHS	PA-24-191 07	-Sep-2024	Not Specified

SPIN ID Program Title	Sponsor Name	Sponsor Number Deadline I	Date Funding Amount
Contact Name			
Contact Telephone			
Contact Email <u>GrantsInfo@nih.gov</u>			
Sponsor Website			
Program URL Link to program URL			
	7-Jan-2025 , 12-Feb-2025 , 07-May-2025 2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oc	· · · · · · · · · · · · · · · · · · ·	
those investigators whose qua questions of health and diseas and research for productive p Synopsis imaging science, informatics, research. This Notice of Fundi involve leading an independer applicants are permitted to pr	Quantitative Research Career Developm antitative science and engineering resear se. The K25 award will provide support an rofessionals with quantitative (e.g., math physics, chemistry) and engineering back ng Opportunity (NOFO) is designed speci- nt clinical trial, a clinical trial feasibility str ropose a research experience in a clinical nical trial as lead investigator, should app	ch has thus far not been focused p nd "protected time" for a period o ematics, statistics, economics, cor grounds to integrate their expertis fically for applicants proposing res udy, or an ancillary clinical trial. Un trial led by a mentor or co-mento	primarily on f supervised study mputer science, se with NIH-relevant search that does not nder this NOFO r. Those proposing a
125512 Mentored Clinical Scientist Research Career Development Award Independent Clinical Trial Required)	d (Parent K08 - National Institutes of Health/DHHS	PA-24-181 07-Sep-2024	Not Specified
Contact Name			
Contact Telephone 301-496-8580			
Contact Telephone 301-496-8580 Contact Email grantinfo@nih.gov			
Contact Email grantinfo@nih.gov			
Contact Email grantinfo@nih.gov Sponsor Website Program URL Link to program URL Doadling Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 0	7-Jan-2025 , 12-Feb-2025 , 07-May-2025 2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oc		

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	biomedical and behavioral research, includi experimental studies involving humans, ref participants." These studies fall within the N Types of studies that should be submitted u conditions (i.e., experimentally manipulate humans for the purpose of understanding t processes or products in mind. Applicants n or proposing to gain research experience in investigator, must apply to the 'Independer related to the programmatic interests of on scientific missions. This Notice of Funding C lead investigator of an independent clinical trial, as part of their research and career de gain research experience in a clinical trial le	erred to in NOT-OD-18-212 as NIH definition of a clinical trial under this NOFO include studie independent variables) and the fundamental aspects of photo planning an independent of a clinical trial or basic experim the Clinical Trial Not Allowed' of the or more of the participating Opportunity (NOFO) is designed trial, a clinical trial feasibility evelopment. Applicants not pla	"prospective basic and also meet the es that prospective nat assess biomedic enomena without s linical trial or basic mental study with h ompanion NOFO. 3 NIH Institutes and d specifically for ap study, or a separate anning an independ	science studies inv definition of basic y assign human pa al or behavioral ou specific application experimental stud umans led by anot The proposed proje Centers (ICs) base plicants proposing e ancillary study to ent clinical trial, ou	volving human research. Inticipants to Itcomes in towards y with humans, ther ect must be d on their to serve as the an existing r proposing to
Notice of Special Interest (NOSI):111464Foster the Careers of Investigatorsyndrome as Part of the INCLUDE		National Institutes of Health/DHHS	NOT-OD- 22-124 07	7-Sep-2024	Not Specified
	Charlene Schramm, PhD				
Contact Telephone	301-402-3793 schrammc@nih.gov				
Sponsor Website					
•	Link to program URL				
-	07-Sep-2024 , 12-Oct-2024				
Synopsis	The NIH INvestigation of Co-occurring cond to improve health and quality-of-life for ind	lividuals with Down syndrome I development of early career training, resources, and ment /ho will lead future research t	e (DS). This Notice o scientists aiming to torship, the NIH inte o improve the unde	f Special Interest (I establish a career ends to support the rstanding of the bi	NOSI) in DS-related e career
094033 NIH Exploratory/Developmental F	Research Grant Program (Parent R21 Clinical	National Institutes of	PA-20-195 07	7-Sep-2024	275,000

Icahn School of Medicine at Mount Sinai

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Trial Not Allowed)		Health/DHHS			USD
Contact Name					
Contact Telephone					
Contact Email	grantsinfo@nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025				
Synopsis	The NIH Exploratory/Developmental Grant for the early and conceptual stages of these breakthrough in a particular area, or to the that could have a major impact on a field of Centers (ICs) participate in Parent Announc announcement and view their respective ar Contact website. ICs that do not participate	e projects. These studies may development of novel techni f biomedical, behavioral, or cl ements. Applicants should ca reas of research interest at th	involve considerable ques, agents, metho inical research. Note refully note which IC e R21 IC-Specific Scie	e risk but may lead odologies, models, e: Not all NIH Insti Cs participate in th entific Interests ar	to a or applications tutes and is
	Research Grant Program (Parent R21 Clinical		PA-20-194 07	-Sep-2024	275,000
Trial Required)	1	Health/DHHS			USD
Contact Name	2				
Contact Telephone	2				
Contact Email	grantsinfo@nih.gov				
Sponsor Website	2				
-	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025				
Synopsis	The NIH Exploratory/Developmental Grant for the early and conceptual stages of these breakthrough in a particular area, or to the that could have a major impact on a field of Announcement requires that at least 1 clini interests of one or more of the participating should note that some ICs (seeRelated Noti	e projects. These studies may development of novel techni f biomedical, behavioral, or cl cal trial be proposed. The pro g NIH Institutes and Centers (involve considerable ques, agents, metho inical research. This posed project must ICs) based on their s	e risk but may lead odologies, models, Parent Funding O be related to the cientific missions.	d to a or applications pportunity programmatic Applicants

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		definition of a clinical trial through this func accept mechanistic studies that meet NIH's of Arthritis and Musculoskeletal and Skin Di Institutes and Centers (ICs) participate in Pa this announcement and view their respectiv Required IC-Specific Scientific Interests and consider applications for funding.	definition of a clinical trial. Se seases (NIAMS) National Inst arent Announcements. Applica ye areas of research interest a	ee Related Notices so itute of Mental Heal ants should carefully at the R21 Basic Expe	ection below. Nati th (NIMH) Note: N y note which ICs pa erimental Studies	onal Institute lot all NIH articipate in with Humans
114/113/1	IIH Exploratory/Developmental F xperimental Studies with Humar	Research Grant Program (Parent R21 Basic ns Required)	National Institutes of Health/DHHS	PA-20-196 07	-Sep-2024	275,000 USD
	Contact Name					
	Contact Telephone	301-496-4000				
	Contact Email	grantsinfo@od.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025				
	Synopsis	The NIH Exploratory/Developmental Grant is for the early and conceptual stages of these breakthrough in a particular area, or to the that could have a major impact on a field of Announcement is for basic science experim science studies involving human participant definition of basic research. Types of studie human participants to conditions (i.e., expe behavioral outcomes in humans for the pur application towards processes or products i products in mind should submit under the a project must be related to the programmat based on their scientific missions. Note: Not Applicants should carefully note which ICs p interest at the R21 Basic Experimental Studi that do not participate in this announcement	e projects. These studies may development of novel technic biomedical, behavioral, or cl ental studies involving humar s." These studies fall within th s that should submit under th rimentally manipulate indeper pose of understanding the fur n mind. Studies conducted w appropriate 'Clinical Trials Rec ic interests of one or more of t all NIH Institutes and Center participate in this announcem ies with Humans Required IC-	involve considerable ques, agents, metho inical research. This hs, referred to inNOT he NIH definition of his FOA include studi endent variables) and ndamental aspects of ith specific application quired' or 'Clinical Tr the participating NI s (ICs) participate in ent and view their re Specific Scientific In	e risk but may lead odologies, models, Parent Funding O T-OD-18-212as "pr a clinical trial and ies that prospectiv d that assess biom of phenomena wit ons toward process ial Optional' FOA. H Institutes and Ce Parent Announce espective areas of	I to a or applications oportunity ospective basic also meet the ely assign hedical or hout specific sses or The proposed enters (ICs) ments. research

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
107449 Notice of Special Interest (NOSI): Service Settings	Reducing Stigma Related to Drug Use in Hur	man National Institutes of Health/DHHS	NOT-DA- 21-060)7-Sep-2024	Not Specified
Contact Name	Richard A. Jenkins PhD				
Contact Telephone	301-443-1923				
Contact Email	jenkinsri@mail.nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 ,	07-Jan-2025			
Synopsis	related to HIV prevention and care. Stigma people who use drugs (PWUD) and insuffic consequences of drug use) among PWUD. associated with providing services to PWUI that create or augment stigma also are of i broaden their services to PWUD. Stigma re cases, implemented on a wide scale, but ge knowledge from this work can inform stign conditions (e.g., cancer, mental illness) whi development of new interventions address	ient uptake of services to pre- Stigmas of interest include: in D, and stigma toward PWUD k nterest here, as well as stigma duction interventions for HIV enerally target sexual transmis na among PWUD. Large literat ich also can provide conceptu	vent, treat, or mitig ternalized stigma a by providers or serv a experienced by p service settings ha ssion as the primar sures on stigma also al and programmat	gate HIV infection (a mong drug users, s vice settings. Policie roviders who might ve been developed y behavioral risk; ho o exist in a variety o tic bases to speed th	and related tigma s and practices otherwise and, in some owever, of other
106966 Notice of Special Interest (NOSI): Improve Transplantation Outcom	Somatic Cell Gene Editing Therapies To les	National Institutes of Health/DHHS	NOT-AI-21- 080)7-Sep-2024	Not Specified
Contact Name	Nasrin Nabavi, Ph.D.				
Contact Telephone	240-627-3538				
Contact Email	nnabavi@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 ,	07-Jan-2025			
Synopsis	The National Institute of Allergy and Infection gene editing (SCGE) approaches to improve				

SPIN ID Program Title	s	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
	islet, or vascularized composite allograft (VC, clinical use.	A) transplants in animal mod	els or human tissue	s or organs exclud	ed from
107248 Notice of Special Interest (NOSI): Related Cardiotoxicity	Improving Outcomes in Cancer Treatment-	National Institutes of Health/DHHS	NOT-CA- 22-001 07	-Sep-2024	Not Specified
	Crystal Wolfrey				opeenieu
Contact Telephone					
	l wolfreyc@mail.nih.gov				
Sponsor Website					
	L Link to program URL				
-) 07-Sep-2024 , 08-Oct-2024				
Synonsi	The purpose of this Notice of Special Interest				-
117692 RFA-MH-23-331 BRAIN Initiativ	s cardiovascular dysfunction while optimizing cardiovascular dysfunction while optimizing cardiotoxicity and translating the findings to <u>re Advanced Postdoctoral Career Transition</u>	cancer outcomes by understa improve risk stratification, e National Institutes of	anding the mechani arly detection, prev RFA-MH-	sms of cancer trea	atment-related gement. Not
117692 RFA-MH-23-331 BRAIN Initiativ Award to Promote Diversity (K99	s cardiovascular dysfunction while optimizing cardiovascular dysfunction while optimizing cardiotoxicity and translating the findings to re Advanced Postdoctoral Career Transition /R00 Independent Clinical Trial Not Allowed)	cancer outcomes by understain improve risk stratification, e	anding the mechani arly detection, prev	sms of cancer trea ention, and mana	atment-related gement.
117692 RFA-MH-23-331 BRAIN Initiativ Award to Promote Diversity (K99 Contact Name	s cardiovascular dysfunction while optimizing of cardiotoxicity and translating the findings to <u>re Advanced Postdoctoral Career Transition</u> <u>(R00 Independent Clinical Trial Not Allowed)</u> James Churchill, Ph.D.	cancer outcomes by understa improve risk stratification, e National Institutes of	anding the mechani arly detection, prev RFA-MH-	sms of cancer trea ention, and mana	atment-related gement. Not
117692 <u>RFA-MH-23-331 BRAIN Initiativ</u> <u>Award to Promote Diversity (K99</u> Contact Name Contact Telephone	s cardiovascular dysfunction while optimizing of cardiotoxicity and translating the findings to re Advanced Postdoctoral Career Transition (/R00 Independent Clinical Trial Not Allowed) James Churchill, Ph.D. 301-326-8800	cancer outcomes by understa improve risk stratification, e National Institutes of	anding the mechani arly detection, prev RFA-MH-	sms of cancer trea ention, and mana	atment-related gement. Not
117692 <u>RFA-MH-23-331 BRAIN Initiativ</u> <u>Award to Promote Diversity (K99</u> Contact Name Contact Telephone Contact Emai	s cardiovascular dysfunction while optimizing of cardiotoxicity and translating the findings to <u>re Advanced Postdoctoral Career Transition</u> <u>(R00 Independent Clinical Trial Not Allowed)</u> James Churchill, Ph.D. James Churchill, Ph.D. BRAINDIVERSITYK99R00@nih.gov	cancer outcomes by understa improve risk stratification, e National Institutes of	anding the mechani arly detection, prev RFA-MH-	sms of cancer trea ention, and mana	atment-related gement. Not
117692 RFA-MH-23-331 BRAIN Initiativ Award to Promote Diversity (K99 Contact Name Contact Telephone Contact Emai Sponsor Website	s cardiovascular dysfunction while optimizing of cardiotoxicity and translating the findings to re Advanced Postdoctoral Career Transition r/ROO Independent Clinical Trial Not Allowed) James Churchill, Ph.D. 301-326-8800 BRAINDIVERSITYK99R00@nih.gov	cancer outcomes by understa improve risk stratification, e National Institutes of	anding the mechani arly detection, prev RFA-MH-	sms of cancer trea ention, and mana	atment-related gement. Not
117692 RFA-MH-23-331 BRAIN Initiativ Award to Promote Diversity (K99 Contact Name Contact Telephone Contact Emai Sponsor Website Program UR	s cardiovascular dysfunction while optimizing of cardiotoxicity and translating the findings to <u>re Advanced Postdoctoral Career Transition</u> <u>(R00 Independent Clinical Trial Not Allowed)</u> James Churchill, Ph.D. James Churchill, Ph.D. BRAINDIVERSITYK99R00@nih.gov	cancer outcomes by understa improve risk stratification, e National Institutes of Health/DHHS	anding the mechani arly detection, prev RFA-MH-	sms of cancer trea ention, and mana	atment-related gement. Not

SPIN ID	Program Title	s	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Notice of Funding Opportunity (NOFO) is de leading an independent clinical trial, a clinica Notice of Funding Opportunity (NOFO) are p mentor. Those proposing a clinical trial or ar (RFA-MH-22-330).	al trial feasibility study, or an permitted to propose researcl	ancillary study to a n experience in a cli	clinical trial. Appli nical trial led by a	cants to this mentor or co-
117690		e Advanced Postdoctoral Career Transition /R00 Independent Clinical Trial Required)	National Institutes of Health/DHHS	RFA-MH- 23-330 11	-Oct-2024	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL	BRAINDIVERSITYK99R00@nih.gov Link to program URL				
	Synopsis	11-Oct-2024 , 13-Feb-2025 , 13-Jun-2025 , 12 The purpose of the NIH BRAIN Initiative Adva program is to enhance diversity in the neuro supported, independent investigators from a biomedical and behavioral sciences, in BRAII transition of outstanding postdoctoral resea postdoctoral research positions to independ independent NIH research support during the Notice of Funding Opportunity is for basic sc "prospective basic science studies involving and also meet the definition of basic research that prospectively assign human participants assess biomedical or behavioral outcomes im phenomena without specific application tow clinical trial or basic experimental study with experimental study with humans led by anot companion NOFO. The proposed project mu NIH Institutes and Centers (ICs) based on the specifically for applicants proposing to serve	anced Postdoctoral Career Tr oscience workforce and maint diverse backgrounds, includir N Initiative research areas. Th orchers with a research and/o dent, tenure-track or equivale his transition to assist awarde cience experimental studies in human participants." These s ch. Types of studies that shou s to conditions (i.e., experime humans for the purpose of u vards processes or products in humans, or proposing to gai ther investigator, must apply list be related to the programme eir scientific missions. This Ne	ain a strong cohort og those from under his program is design r clinical doctorate of nt faculty positions es in launching inder hvolving humans, re tudies fall within th ld be submitted und entally manipulate in understanding the fin n mind. Applicants r in research experier to the 'Independen matic interests of or potice of Funding Op	of new and talent represented ground degree from ment . The program will pendent research ferred to in NOT-C e NIH definition of der this NOFO inclu- ndependent variate undamental aspect not planning an inconce in a clinical triat t Clinical Trial Not me or more of the portunity (NOFO)	ed, NIH- ps in the timely ored, provide careers. This DD-18-212 as a clinical trial ude studies bles) and that ts of lependent I or basic Allowed' participating is designed

SPIN ID Program Title	Sp	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
	study, or a separate ancillary study to an exist planning an independent clinical trial, or prop must apply to companion NOFO (RFA-MH-22-	oosing to gain research expe			
104076 Pilot Health Services and Econom and Tobacco Use Disorders (R34	nic Research on the Treatment of Drug, Alcohol - Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21-180 07	7-Sep-2024	450,000 USD
Contact Nam	Carrie Mulford				
Contact Telephone	e				
Contact Ema	I <u>Carrie.Mulford@nih.gov</u>				
Sponsor Website	e				
Program UR	L Link to program URL				
Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025				
Synopsi	This Funding Opportunity Announcement (FO services research effectiveness trials. Relevan and policies designed to optimize access to, a alcohol use disorder treatments and related s conditions. Relevant approaches may include lack an evidence base. This FOA provides reso in addition to usual trial preparation activities	at trials may test a wide range and the quality, effectiveness services, as well as services f both those that are novel, a purces for assessing the feas	e of approaches, in s, affordability and or comorbid medic and those that are c	cluding interventi utilization of drug, al and mental disc commonly used in	ons, practices, tobacco, or rder practice but
111986 Notice of Special Interest (NOSI): Address Hunger, Food and Nutrit	Stimulating Research to Understand and tion Insecurity	National Institutes of Health/DHHS	NOT-OD- 22-135 07	7-Sep-2024	Not Specified
Contact Nam	Marya Levintova, PhD				
Contact Telephone	e 301-496-9535				
Contact Ema	il <u>marya.levintova@nih.gov</u>				
Sponsor Website	2				
Program UR	L <u>Link to program URL</u>				
Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16	-Oct-2024			
Synopsi	The nurnose of this NOSI is to encourage rese	earch on the efficacy of inter			

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
	nutrition security and assessment of food in Research (ONR) Implementation Working G Centers (ICs) and Offices in support of the go	roup on Nutrition and Health	Disparities in col	laboration with NIH	nstitutes and
	Preventive Interventions to Address opulations that Experience Health Disparities	National Institutes of Health/DHHS	NOT-OD- 22-154	07-Sep-2024	Not Specified
Contact Name	Jennifer Alvidrez, PhD				
Contact Telephone	301-827-0071				
Contact Email	Jennifer.alvidrez@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 1	.6-Oct-2024 , 07-Jan-2025 , 0	5-Feb-2025 <i>,</i> 16-F	eb-2025 <i>,</i> 07-May-20)25
Synopsis	The purpose of this NOSI is to solicit project populations that experience health dispariti		that address car	diometabolic risk fac	tors in
111039 Dissemination and Implementatio	n Research in Health (R21 Clinical Trial	National Institutes of	PAR-22-	07-Sep-2024	275,000
Optional)		Health/DHHS	109	07-369-2024	USD
Contact Name	Gila Neta, Ph.D.				
Contact Telephone	240-276-6785				
Contact Email	gila.neta@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 1	6-Feb-2025 , 07-May-2025			

SPIN ID Program Title	S¢	oonsor Name	Sponsor Number	Deadline Date	Funding Amount
	ervices (e.g. cancer screening) that may have applications must be within the scope of the r	••		-	ed. All
11040 Dissemination and Implementation Allowed)	Research in Health (R03 Clinical Trial Not	National Institutes of Health/DHHS	PAR-22- 106 0	7-Sep-2024	275,000 USD
Contact Name G	Gila Neta, Ph.D.				
Contact Telephone 2	40-276-6785				
Contact Email g	<u>ila.neta@nih.gov</u>				
Sponsor Website					
Program URL L	ink to program URL				
Deadline Dates (ALL) 0	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-	-Feb-2025 , 07-May-2025			
a Synopsis th ti re so	nterventions, practices, programs, tools, trea and implementation of evidence-based interv here is a benefit in understanding circumstar hat are ineffective, unproven, low-value, or h esearch methods and measures are encourage ervices (e.g. cancer screening) that may have applications must be within the scope of the m	ventions among underrepres nces that create a need to st narmful. In addition, studies ged. Applications that focus e dropped off amidst the ong	sented communiti op or reduce ("de to advance dissen on re-implementa going COVID pand	es are encouraged. implement") the u nination and impler ition of evidence-ba emic are encourage	Conversely, se of praction mentation ased health
14123 Engineering Next-Generation Huma Systems (R21 Clinical Trials Not Allo	an Nervous System Microphysiological wed)	National Institutes of Health/DHHS	PAR-23- 047 0	7-Sep-2024	275,000 USD
Contact Name D	David M. Panchision, Ph.D.				
Contact Telephone 3	01-443-5288				
Contact Email p	panchisiond@mail.nih.gov				
Sponsor Website					
Program URL L	ink to program URL				
Deadline Dates (ALL) 0 2	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16- 2026	-Feb-2025 , 07-May-2025 , 1	.6-Jun-2025 , 07-Se	ep-2025 , 16-Oct-20)25 , 07-Jan-

SPIN ID Program Title	S	ponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
Synopsis	This Funding Opportunity Announcement (FC generation human cell-derived microphysiolo architectures and physiology with improved f future studies of complex nervous system der mechanism is intended to encourage explora stages of project development. High risk/high FOA. Applicants with preliminary data may in	ogical systems (MPS) and rel idelity over current capabili- velopment, function and agi tory/developmental researc n reward projects that lack p	ated assays that i ties. Supported p ing in healthy and h by providing su reliminary data n	replicate complex ne rojects will be expec I disease states. The Ipport for the early a nay be most appropr	rvous system ted to enable R21 grant nd conceptual iate for this
114061 Notice of Special Interest (NOSI): and Modulating Neural Circuit Ac	Explainable Artificial Intelligence for Decoding tivity Linked to Behavior	National Institutes of Health/DHHS	NOT-MH- 23-110	07-Sep-2024	Not Specified
Contact Name	Mauricio Rangel-Gomez, Ph.D.				
Contact Telephone	301-435-6908				
Contact Emai	mauricio.rangel-gomez@nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07 2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-20			/lay-2025 , 05-Jun-20	25 , 16-Jun-
Synonsi	This Notice of Special Interest (NOSI) solicits a decoding, and modulation of neural circuits li computationally and experimentally focused that are able to mechanistically explain how e	nked to behavior. This NOSI investigators. This NOSI see	encourages colla ks the developme	aborations between ent of machine learn	ng algorithms
59110251.	humans or animals. Proof-of-concept application provide unbiased, hierarchical explanations of appropriate.				uses XAI to
	humans or animals. Proof-of-concept application provide unbiased, hierarchical explanations of appropriate. es of Gabriella Miller Kids First Pediatric		PAR-23-		uses XAI to
114857 Small Research Grants for Analys Research Data (R03 Clinical Trial I	humans or animals. Proof-of-concept application provide unbiased, hierarchical explanations of appropriate. es of Gabriella Miller Kids First Pediatric	f causal relationships betwee National Institutes of	PAR-23-	al and behavioral da	uses XAI to ta are also 200,000
114857 Small Research Grants for Analys Research Data (R03 Clinical Trial I	humans or animals. Proof-of-concept application provide unbiased, hierarchical explanations of appropriate. es of Gabriella Miller Kids First Pediatric Not Allowed) James N. Coulombe, Ph.D.	f causal relationships betwee National Institutes of	PAR-23-	al and behavioral da	uses XAI to ta are also 200,000
114857 Small Research Grants for Analys Research Data (R03 Clinical Trial I Contact Name Contact Telephone	humans or animals. Proof-of-concept application provide unbiased, hierarchical explanations of appropriate. es of Gabriella Miller Kids First Pediatric Not Allowed) James N. Coulombe, Ph.D.	f causal relationships betwee National Institutes of	PAR-23-	al and behavioral da	uses XAI to ta are also 200,000

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Progra	m URL Link to program URL				
Deadline Date	s (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025	, 16-Oct-2025			
Sy	nopsis nopsis The NIH Common Fund has established the pediatric research data resource populate communities of investigators who study the established and continues to develop a D childhood cancer and structural birth defind to the research community. Access to the leading to more refined diagnostic capab meritorious small research projects focus generated by the Kids First program and/ appropriate for analyzing genomic, pheno-	ed by genome sequence and ph he genetics of childhood cancer ata Resource including a collect ects cohorts and a central porta use data will promote comprehe lities and ultimately more targe ed on analyses of childhood car or associated phenotypic datase	enotypic data that w rs and/or structural ion of curated geno Il where these data ensive and cross-cut eted therapies. This neer and/or structur ets. Development o	will be of high valu birth defects. Kids omic and phenotyp and analysis tools ting research and FOA is intended to ral birth defects ge f approaches, tools	e for the First has ic data from are accessible collaboration o support nomic datasets s, or algorithms
115062 Notice of Special Interest (I Health and Acute and Chro	NOSI): argeting the Endocannabinoid System for nic Diseases	Brain National Institutes of Health/DHHS	NOT-DA- 22-048 07	7-Sep-2024	Not Specified
Contact	Name Yu (Woody) Lin, PhD				
Contact Tele	phone 301-435-1318				
Contact	Email <u>ylin1@mail.nih.gov</u>				
Sponsor W	ebsite				
Progra	m URL Link to program URL				
Deadline Date	o7-Sep-2024 , 25-Sep-2024 , 05-Oct-2024 s (ALL) 2025 , 12-Feb-2025 , 13-Feb-2025 , 16-Fe Sep-2025 , 25-Sep-2025 , 05-Oct-2025 , 1	b-2025 , 07-May-2025 , 25-May	-2025 , 05-Jun-2025		•
Sy	This Notice of Special Interest (NOSI) enco and acute and chronic disease, substance mechanistic understanding of how canna effects as well as the role of cannabinoids	use, and substance use disorde binoids and manipulation of the	er (SUD). The desire ECS can elicit both	d outcomes of res	earch will be a
116487 Translational Research in M (R21 Clinical Trial Optional)	laternal and Pediatric Pharmacology and Therap	eutics National Institutes of Health/DHHS	PAR-23- 16 131 16	5-Oct-2024	275,000 USD
Contact	Name Katie M. Vance. Ph.D.				

Contact Name Katie M. Vance, Ph.D.

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
Contact Telephone	301-435-6640				
Contact Email	Katie.Vance@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 ,	16-Oct-2025 , 16-Feb-2026			
Synopsis	The purpose of this notice of funding oppo precision medicine in pregnant persons, lac other technologies that could have a direct mechanisms of drug action, including the r pregnancy and lactation; and (3) discover a repurposing for safer and more effective m goal is to improve safe and effective precis children, including those with disabilities.	ctating persons, and children t t clinical or health impact; (2) e ole of pediatric ontogeny and and develop novel therapeutics nedications in pregnant and lac	hrough the devel enhance the unde the dynamic physis or enhance the stating persons, n	opment of novel too rstanding of the unc siological changes the usage of existing dru eonates, and childre	ls, models, and lerlying at occur during gs or drug n. The overall
11/360	Research to Address Vaccine Uptake and ons Experiencing Health Disparities	National Institutes of Health/DHHS	NOT-MD- 23-008	05-Oct-2024	Not Specified
Contact Name	Deborah E. Linares, Ph.D., M.A.				
Contact Telephone	301-402-2516				
Contact Email	deborah.linares@nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 2025 , 16-Oct-2025 , 05-Feb-2026 , 16-Feb-		6-Feb-2025 , 05	Jun-2025 , 16-Jun-20	25 , 05-Oct-
Synopsis	This Notice of Special Interest (NOSI) highli uptake and implementation among popula Research is needed to understand and add vaccines (e.g., SARS-CoV-2, pneumococcal, and pertussis [Tdap]) among individuals in and mortality due to long-standing system	tions experiencing health disp ress misinformation, uncertair influenza, hepatitis B, human	arities in the Unit hty, distrust, and papilloma virus (pecially in populat	ed States (U.S.) and hesitancy regarding HPV), varicella, tetar	its territories. uptake of us, diphtheria, k for morbidity

SPIN ID Program Title	S	ponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
	health disparities; 2) evaluate organizational disparities in vaccine access, uptake, and ser reach, address psychosocial barriers, and soc community contexts.	ies completion, and 3) evalu	ate community-ei	ngaged intervention	s (e.g., expand
119755	europsychiatric Symptoms (NPS) in Alzheimer		PAR-23-	16-Oct-2024	275,000
Dementia (R21 Clinical Trial Optic	onal)	Health/DHHS	208	10 000 2021	USD
Contact Name	Laura M. Rowland, Ph.D.				
Contact Telephone	301-480-8335				
	laura.rowland@nih.gov				
Sponsor Website					
-	Link to program URL				
Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16	5-Oct-2025 , 16-Feb-2026 , 1	6-Jun-2026		
Synopsis	The goal of this Notice of Funding Opportuni of mechanisms associated with neuropsychia disease-related dementias (ADRD). The findi and neurobiological pathways leading to NPS advanced into interventions to treat and pre mechanism, while the companion PAR-23-20 projects that lack preliminary data may be m who seek longer-term funding should apply to	atric symptoms (NPS) in pers ngs are expected to advance 5. Findings may also provide vent the development of NP 17 uses the R01 grant mecha lore appropriate for the R21	ons with Alzheim mechanistic und insight into novel S in AD and/or Al nism. Investigator	er's disease (AD) or erstanding of both b therapeutic targets DRD. This NOFO uses rs proposing high ris	Alzheimer's iobehavioral that can be the R21 k/high reward
123347 Pilot and Feasibility Studies in Pre (R34 Clinical Trial Optional)	paration for Substance Use Prevention Trials	National Institutes of Health/DHHS	PAR-24- 060	07-Sep-2024	450,000 USD
Contact Name	Amy B. Goldstein, PhD				
Contact Telephone	301-827-4124				
Contact Email	amy.goldstein@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16 2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2	5-Feb-2025 , 07-May-2025 , 2 2026 , 07-Sep-2026 , 16-Oct-2	16-Jun-2025 , 07-5 2026 , 07-Jan-202	Sep-2025 , 16-Oct-20 7)25 , 07-Jan-

SPIN ID Program Title	Sp	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	The purpose of this notice of funding opportu in the following areas: 1) the development an of substance use and/or the progression from to the prevention of substance use. The latter other service system-based research to addre addition to the prevention of substance use, r through this NOFO include a reduction in neg behavior (e.g., nonfatal and fatal attempts), a hepatitis among diverse populations and sett	nd pilot testing of new or ad n use to misuse or disorder a r may include pilot studies o ess areas such as economics misuse and disorder, other o pative sequalae of use, such and substance-related acquis	apted intervention and 2) services res of strategies or app , funding, service of putcomes of intere as deaths related	ns to prevent or del earch examining qu proaches to interver quality and engager est for the research to impaired driving,	ay the initiation estions specific ntion, and/or nent. In supported suicidal
105756 Investigator Initiated Research in (R21 Clinical Trial Not Allowed)	Computational Genomics and Data Science	National Institutes of Health/DHHS	PAR-21- 255	16-Oct-2024	275,000 USD
Contact Name	Daniel Gilchrist, Ph.D.				
Contact Telephone					
Contact Emai	daniel.gilchrist@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Oct-2024				
Synopsis	The purpose of this funding opportunity anno computational genomics, data science, statist science, and broadly applicable to human hea develops innovative analytical methodologies refinement or hardening of software and tool this FOA should be enabling for genomics and	tics, and bioinformatics relea alth and disease. This FOA su s and approaches, early-stag Is of high value to the biome	vant to one or bot upports fundamen ge development of edical genomics co	h of basic or clinica tal genomics resear tools and software mmunity. Work su	genomic ch that , and pported under
-	alth Research Using Existing Data from the opment (ABCD) Study (R21-Clinical Trial Not	National Institutes of Health/DHHS	PAR-22- 138)7-Sep-2024	275,000 USD
Contact Name	Julia Zehr, Ph.D.				
Contact Telephone	301-443-1617				
Contact Emai	Zehrj@mail.nih.gov				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 1	6-Feb-2025 , 07-May-2025			
	Synopsis	The Adolescent Brain Cognitive Developmer substance use, cultural and environmental f years-old and following them longitudinally through the NIMH Data Archive. The purpos proposing the analysis of this public use dat information about the ABCD Study may be f shorter, higher-risk	actors, and brain structure an to early adulthood. These da se of this Funding Opportunit aset to increase knowledge o	nd function from yo ata will be made av y Announcement (l of adolescent health	outh starting when ailable to the scien FOA) is to encourag and development	they are 9-10 tific community ge applications More
109181 📐	Notice of Special Interest (NOSI):	Public Health Research on Cannabis	National Institutes of Health/DHHS	NOT-DA- 22-003 0	7-Sep-2024	Not Specified
	Contact Name	Marsha Lopez, PhD				
	Contact Telephone	(301) 402-1846				
	Contact Email	<u>(301) 402-1846</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 0	7-Jan-2025 , 05-Feb-2025 , 1	6-Feb-2025		
	Synopsis	The National Institute on Drug Abuse (NIDA cannabis laws and policies in the US and glo		ourage grant applica	ations on the effect	ts of changing
		ogram (REAP) for Health Professional Schools	S National Institutes of	PAR-22-	7-Sep-2024	375,000
<u>a</u>	ind Graduate Schools (R15 Clinica	al Trial Not Allowed)	Health/DHHS	060 0	7-3ep-2024	USD
	Contact Name	Lisa Chadwick				
	Contact Telephone	301-435-7275				
	Contact Email	lisa.chadwick@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	The purpose of the Research Enhancement support small scale research grants at insti- providing biomedical research experiences enhancing the research environment at ap science degrees and have received no mor costs) in 4 of the last 7 fiscal years. For inst based on the amount of NIH funding received determining the Organization Funding Leve	tutions that do not receive sub primarily for health profession plicant institutions. Eligible ins e than \$6 million dollars per ye itutions composed of multiple yed by all the schools and colle	ostantial funding fro nal, undergraduate titutions must awar ear of NIH support (schools and college ges within the instit	m the NIH, with a and graduate stuc d baccalaureate o in both direct and s, the \$6 million f cution as a whole.	n emphasis on lents and r advanced F&A/indirect unding limit is Help
	e Discovery/Development Groups (NCDDG) rs or Alcohol Use Disorder (U19 Clinical Tria		PAR-22- 25 144 25	-Oct-2024	Not Specified
Contact Name	Linda Brady, Ph.D.				
Contact Telephone	301-443-3563				
Contact Email	lbrady@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	25-Oct-2024 , 24-Feb-2025				
Synopsis	The purpose of this Funding Opportunity A translation from discovery to early human neuromodulatory tools for basic and clinica validate tools (pharmacologic or neurostim for mental disorders; and support early-sta of promising drug candidates/devices and Investigational Device Exemption (IDE)-rea applications to advance the discovery, pre- candidate agents and neurostimulation ap- circuit-engagement devices as tools to furt between academia and industry are strong projects directed toward a specific major o and often long-term approach should cons proposing preclinical discovery of biotechn	studies. Studies appropriate for al research on mental health d nulation) in support of experim age human studies to rapidly as new indications for novel Invest dy devices for the treatment of clinical development, and proo proaches to treat mental disor her characterize existing or to gly encouraged. Projects seekin bjective, basic theme or progr ider the companion FOA (PAR-	or this FOA will deve isorders or alcohol u ental therapeutic st ssess the safety, tole stigational New Dru f mental disorders of f of concept (PoC) t ders or or AUD, and validate new drug/o g support for a rese am goal, requiring a 22-143). This FOA v	lop pharmacologi use disorder (AUD cudies of innovativ erability, and phar g (IND)-ready age or AUD. This FOA e esting of new, rati to develop novel device targets. Par earch program of r broadly based, m vill also support ag	c and); develop and ve candidates macodynamics nts or encourages ionally based ligands and therships nultiple ultidisciplinary oplications

SPIN ID Program Title	5	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	but not limited to, large biologic macromole oligonucleotide- and viral vector-based), cel therapies). This FOA supports a discrete, spe area representing his or her specific interest	l therapies, and novel emergi ccified, circumscribed project	ng therapies (e.g., n	nicrobial and micr	obiome
114377 Notice of Special Interest (NOSI): (TBDs)	Advancing Research for Tickborne Diseases	National Institutes of Health/DHHS	NOT-AI-23- 013	-Sep-2024	Not Specified
Contact Name	Samuel Perdue, Ph.D.				
Contact Telephone	240-627-3341				
Contact Emai	sperdue@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 1 2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2 Jan-2026 , 07-Jan-2026		•	-	-
Synopsis	The purpose of this Notice of Special Interest Diseases (NIAID), the National Institute of Ar Mental Health (NIMH), and the National Inst advance research activities relevant to the fi Tickborne Disease Research: Improve fundar and pathogen factors that drive TBD pathog and exploited by TBD pathogens. Advance re approaches, including research for rapid dia pathogens. Accelerate research to improve vector control strategies, and other prevent including studies to develop effective therap infectious TBDs, and new antimicrobials. Sup diagnosing, and treating TBDs, including rep development and assessment of diagnostic,	thritis and Musculoskeletal a titute of Neurological Disorde we strategic priorities identifi mental knowledge of Tickbor enesis and transmission. Eluc esearch to improve the diagn gnostics and multiplex platfo TBD prevention by supporting ion approaches. Promote res- bies to treat symptoms that p oport tools and resources to a ositories, genomic resources,	and Skin Diseases (N ers and Stroke (NIND ed in the recently re ne Diseases (TBDs) t idate the host immu osis of TBDs using be rm approaches that g science to design, earch to improve tre ersist after TBD trea advance research in animal models, and	IAMS), the Nation OS), encourage appeleased NIH Strate to understand the une mechanisms i oth host- and path detect multiple ti develop, and eval eatment for all for utment, therapies understanding, p	al Institute or olications to egic Plan for host, vector, n response to hogen-targeto ckborne uate vaccines rms of TBDs, for non- reventing,
	Developing Academic Research Enhancement Ancement Award Program (REAP) for Institution	t National Institutes of	NOT-OD-	-Sep-2024	Not Specified

SPIN ID Program Title	Sp	oonsor Name	Sponsor Number	Deadline Date	Funding Amount
With an Emphasis On Down Synd	rome Research (R15 Clinical Trial Not Allowed)				
Contact Name	Sujata Barhan, Ph.D.				
Contact Telephone	301-435-0471				
Contact Email	sujata.bardhan@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025				
Synopsis	The NIH INvestigation of Co-occurring condition to improve health and quality-of-life for indivi- announces NIH support for development of A Award Program (REAP) applications to support objectives of the INCLUDE project at institution providing biomedical research experiences pri- environment at applicant institutions. Eligible health professions and have received less that this FOA, a college is a stand-alone entity and pathway of meritorious undergraduate and gr	duals with Down syndrome cademic Research Enhancer t small scale basic and trans ons that do not receive subs- imarily for undergraduate a institutions must award NII n \$6 million per year of NIH not a component of a unive	(DS). This Notice of ment Award (AREA slational research tantial funding fro nd/or graduate str H-relevant baccala support (total cos ersity system. The	of Special Interest (I A) and Research Enh grants that meet pr m the NIH, with an udents and enhanci ureate or advanced its) in 4 of the last 7 goal of this NOSI is	NOSI) nancement ogrammatic emphasis on ng the researcl I degrees in fiscal years. In
	Research on the Impact of Policy Changes and alth Crises on NICHD Populations of Interest	National Institutes of Health/DHHS	NOT-HD- 22-038)7-Sep-2024	Not Specified
Contact Name	Elyse R. Grossman				
Contact Telephone	240-551-3628				
Contact Email	<u>elyse.grossman@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25- 2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-202			b-2025 , 07-May-20)25 , 05-Jun-
Synopsis	This notice informs applicants of an expansion Impact of Policy Changes and Emerging and Ev research priority areas for the National Institu	volving Public Health Crises	on NICHD Populat	tions of Interest" to	include

SPIN ID Program Title	S	sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	this Notice of Special Interest (NOSI) to anno and/or policy changes on the health, develop priority. The NIDA populations of interest inc adults, people using or misusing substances, The NIDA supports research on the impact of the life span. For information on the NIDA St plan/nidas-mission.	oment, and well-being of pop clude neonates, infants, child people with substance use d f policy in understanding and	ulations of inte ren, adolescent isorders, as wel addressing sub	rest to the NIDA is of s, young adults, adult l as the families of the stance use risk and be	high program s, and older ese individuals. ehavior across
114675 Notice of Special Interest (NOSI): the Sequence Read Archive (SRA	Optimization of Data Storage and Utilization f	<u>for</u> National Institutes of Health/DHHS	NOT-GM- 23-015	08-Aug-2024	Not Specified
Contact Name	e				
Contact Telephone	e				
Contact Emai	1				
Sponsor Website	e				
Program UR	L <u>Link to program URL</u>				
Deadline Dates (ALL	08-Aug-2024, 05-Sep-2024, 07-Sep-2024, 0 2025, 07-Jan-2025, 16-Jan-2025, 05-Feb-20 May-2025, 16-May-2025, 05-Jun-2025, 12- , 07-Sep-2025, 05-Oct-2025, 12-Oct-2025, 1)25 , 12-Feb-2025 , 16-Feb-20 Jun-2025 , 16-Jun-2025 , 25-J	25 , 25-Feb-202 un-2025 , 08-Au	25 , 05-Apr-2025 , 12-	Apr-2025 , 07-
Synopsi	The purpose of this Notice of Special Interest ODSS in supporting efficiency optimization a				
	s for Translation of Technologies for Diagnosis	National Institutes of	PAR-21-	05-Oct-2024	2,495,000
and Treatment (R01 - Clinical Tria	al Not Allowed)	Health/DHHS	166	05 000 2024	USD
	-				030
Contact Name	e Miguel Ossandon MS				030
Contact Name Contact Telephone	-				030
Contact Telephone	-				030
Contact Telephone	e 240-276-5714 Il <u>ossandom@mail.nih.gov</u>				
Contact Telephone Contact Emai Sponsor Website	e 240-276-5714 Il <u>ossandom@mail.nih.gov</u>				

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	The purpose of this Funding Opportunity Ar engineering developments into methods or research to assess risk, detect, prevent, diag meet evolving requirements for technologic clinical, clinical and non-clinical settings, do institutes. This FOA specifies a partnership s engaging the strengths of academic, industri inter-disciplinary, multi-institutional researce and translate a solution to their chosen pro suitable for end users. Each partnership sho partnership should plan to transition a tech to a status useful in the chosen setting. Fun translate technologies that address problem of disease status. This FOA defines "innovation	tools that address problems i gnose, treat, and/or manage of es and methods relevant to the mestic or foreign, for condition structure that is expected to he rial, and other investigators. The ch team to work in strategic all blem. They are expected to ploud include at least one acade nology, method, assay, device ding may be requested to enh ms in biology, pathology, risk a	n basic research to disease. The ration e advance of resea ns and diseases w elp bridge gaps in he partners on eac liance to impleme an, design, and va emic and one indu e, and/or system fr nance, adapt, optir ssessment, diagno	o understand disea ale is to deliver new arch and delivery of ithin the missions of knowledge and exp ch application shou nt a coherent strat lidate that the solu strial organization. from a demonstration nize, validate, and osis, treatment, and	se, or in applied w capabilities to f care in pre- of participating perience by Id establish an egy to develop tion will be Each on of possibility otherwise
106119 Small Grants for New Investigator Research (R21 Clinical Trial Option	rs to Promote Diversity in Health-Related nal)	National Institutes of Health/DHHS	PAR-21- 313	17-Sep-2024	375,000 USD
Contact Name	Katrina J. Serrano, Ph.D.				
Contact Telephone	301-480-7855				
Contact Email	katrina.serrano@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025				
	The purpose of this Funding Opportunity Ar backgrounds, including from groups national research, to conduct small research project and Kidney Diseases (NIDDK), the National I Imaging and Bioengineering (NIBIB). New in direct costs of combined research funding (research projects that can be carried out in research independence. The R21 grant med secondary analysis of existing data; small, so	ally underrepresented in biom s in the scientific mission area Human Genome Research Inst westigators at the time of awa excluding NIH training and NIH a short period of time with lin hanism supports different typ	edical, clinical, be s of the National I titute (NHGRI) or t ard under this FOA H career awards). nited resources ar es of projects incl	havioral and social nstitute of Diabete he National Institut will have had less This R21 will suppo d seeks to facilitate uding pilot and feas	sciences s and Digestive te of Biomedical than \$125,000 rt small transition to sibility studies;

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	development of new research technology.				
112904 Notice of Special Interest (NOSI): Bisexual+ People	Research on the Health of Bisexual and	National Institutes of Health/DHHS	NOT-OD- 22-166 07	2-Sep-2024	Not Specified
Contact Name	Christopher Barnhart, PhD				
Contact Telephone	301-594-8983				
Contact Email	christopher.barnhart@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 2025	25-Oct-2024 , 12-Nov-2024 , ()7-Jan-2025 , 05-Feb	o-2025 , 16-Feb-20	25 , 07-May-
Synopsis	This Notice of Special Interest (NOSI) solicit well-being of people who identify as bisexu potential to be attracted, romantically and, time, not necessarily in the same way, and umbrella term that is intended to encompa sexually fluid, and queer.	al or bisexual+. "Bisexual" or /or sexually, to people of mor not necessarily to the same d	"bi" in this NOSI ma e than one sex or ge egree. "Bisexual+" o	y describe those w inder, not necessa or "bi+" in this NOS	vith the rily at the same SI is an
114765 Notice of Special Interest (NOSI): Research	Firearm Injury and Mortality Prevention	National Institutes of Health/DHHS	NOT-OD- 23-039 07	2-Sep-2024	Not Specified
Contact Name	Dara R. Blachman, Ph.D.				
Contact Telephone					
Contact Email	Dara.blachman-demner@nih.gov				
Sponsor Website					
Program URL					
Deadline Dates (ALL)	07-Sep-2024 , 08-Sep-2024 , 05-Oct-2024 , 2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2				25 , 07-May-
Synopsis	The purpose of this Notice is to highlight in the identification of those at risk of firearm injury), the development, piloting, and test	injury (including self- and oth	ner-directed, victims	and perpetrators	, accidental

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		examination of approaches to improve the injury and mortality.	implementation of existing, ev	vidence-based inter	rventions to preve	nt firearm
127139 <mark>(N</mark>		entific and Academic Independent Careers ansition Award to Promote Diversity (K99/R0 ed)	National Institutes of Health/DHHS	PAR-24- 07 226 07	7-Sep-2024	Not Specified
	Contact Name	Lanay M. Mudd, Ph.D., FACSM				
	Contact Telephone	301-594-9346				
	Contact Email	lanay.mudd@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun Jun-2027 , 07-Sep-2027	· · · ·			
	Synopsis	The purpose of the Maximizing Opportunit support a cohort of early career, independe from underrepresented groups) conducting career transition award for postdoctoral so to organizations to provide these scholars of support their transition to and success in in MOSAIC program supports NIH's efforts to perspectives, experiences and backgrounds Transition Award to Promote Diversity (K99 researchers from diverse backgrounds from equivalent research-intensive faculty positi demonstrated meaningful contributions an biomedical research workforce, such as act environments that support the success of t underrepresented groups. This Notice of I proposing to serve as the lead investigator ancillary study to an existing trial, as part of clinical trial, or proposing to gain research	ent investigators from diverse g research in NIH mission areas holars (K99/R00) and a researc with additional mentoring, net dependent, tenure-track or ec develop a biomedical research s needed to advance discovery 9/R00) program is to facilitate a n their mentored postdoctoral ions. The program is designed ad proposed compelling future civities that promote inclusive, trainees and scientists from all Funding Opportunity (NOFO) is of an independent clinical tria f their research and career dev	backgrounds (for e s. The program has ch education coope working and profes quivalent research- n workforce that wi t. The goal of the M a timely transition of research positions to support postdoo plans to promote k supportive, and acc backgrounds, inclu designed specifica I, a clinical trial feas velopment. Candida	xample, individual two components: rative agreement ssional developme intensive faculty ca Il benefit from the OSAIC Postdoctora of promising postd to independent, to croad participation cessible biomedica ding individuals fro lly to support cano sibility study, or a sates not planning a	s an individual (UE5) awarded nt activities to areers. The full range of al Career loctoral enure-track or who have a in the al research om didates separate an independent

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
institutions to apply to companion	NOFO PAR-24-225.			
127245 FCOGroundbreaking Lymphatic Interventions and Drug Exploration	(GLIDE) National Institutes of Health/DHHS	ARPA-H- SOL-24- 3 111	1-Oct-2024	Not Specified
Contact Name				
Contact Telephone				
Contact Email <u>GLIDE@arpa-h.gov</u>				
Sponsor Website				
Program URL Link to program URL				
Deadline Dates (ALL) 31-Oct-2024				
The Advanced Research Projects A	gency for Health (ARPA-H) is posting			
Synopsis The Advanced Research Projects A H-SOL-24-111 for the Groundbreak potential proposers prepare for Pro attachments will be posted at a lat	king Lymphatic Interventions and Dru oposer's Day and plan for solution su ter date.	ug Exploration (GLIDE ummary submission.) Program in order The finalized ISO a	to help
Synopsis The Advanced Research Projects A H-SOL-24-111 for the Groundbreak potential proposers prepare for Pro attachments will be posted at a lat	king Lymphatic Interventions and Dru oposer's Day and plan for solution su ter date.	ug Exploration (GLIDE ummary submission.) Program in order	to help nd related
Synopsis The Advanced Research Projects A H-SOL-24-111 for the Groundbreak potential proposers prepare for Pro attachments will be posted at a lat	king Lymphatic Interventions and Dru oposer's Day and plan for solution su ter date. National Institutes of	ug Exploration (GLIDE ummary submission. PAR-24-) Program in order The finalized ISO a	to help nd related 275,000
The Advanced Research Projects And H-SOL-24-111 for the Groundbreak potential proposers prepare for Product attachments will be posted at a lat .22946 Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Option)	king Lymphatic Interventions and Dru oposer's Day and plan for solution su ter date. National Institutes of	ug Exploration (GLIDE ummary submission. PAR-24-) Program in order The finalized ISO a	to help nd related 275,000
Synopsis The Advanced Research Projects Al H-SOL-24-111 for the Groundbreak potential proposers prepare for Proattachments will be posted at a lat 22946 Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Opt Contact Name	king Lymphatic Interventions and Dru oposer's Day and plan for solution su ter date. National Institutes of	ug Exploration (GLIDE ummary submission. PAR-24-) Program in order The finalized ISO a	to help nd related 275,000
Synopsis The Advanced Research Projects Al H-SOL-24-111 for the Groundbreak potential proposers prepare for Proattachments will be posted at a lat 22946 Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Opt Contact Name Contact Telephone 301-496-6838	king Lymphatic Interventions and Dru oposer's Day and plan for solution su ter date. National Institutes of	ug Exploration (GLIDE ummary submission. PAR-24-) Program in order The finalized ISO a	to help nd related 275,000
SynopsisThe Advanced Research Projects A H-SOL-24-111 for the Groundbreak potential proposers prepare for Pro attachments will be posted at a lat.22946Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Opt Contact Name Contact Telephone Contact EmailAnn Namkung, MPH 301-496-6838 ann.namkung@nih.gov	king Lymphatic Interventions and Dru oposer's Day and plan for solution su ter date. National Institutes of	ug Exploration (GLIDE ummary submission. PAR-24-) Program in order The finalized ISO a	to help nd related 275,000
SynopsisThe Advanced Research Projects A H-SOL-24-111 for the Groundbreak potential proposers prepare for Pro attachments will be posted at a lat122946Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Opt Contact Name Contact TelephoneContact Telephone Sponsor Website Program URL Deadline Dates (AUU)Deadline Dates (AUU)	king Lymphatic Interventions and Dru oposer's Day and plan for solution su ter date. National Institutes of	ug Exploration (GLIDE ummary submission. PAR-24-0 092 0	 Program in order The finalized ISO a 7-Sep-2024 ep-2025 , 16-Oct-20 	to help nd related 275,000 USD

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
	Office of AIDS Research (OAR) as described	in NOT-OD-20-018.			
114250 Trailblazer Award for New and Ea Optional)	arly Stage Investigators (R21 Clinical Trial	National Institutes of Health/DHHS	PAR-24- 022	07-Sep-2024	400,000 USD
Contact Name	e Randy King, Ph.D.				
Contact Telephone	2 301-451-0707				
Contact Emai	l <u>Randy.King@nih.gov</u>				
Sponsor Website	٤				
Program URI	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 16-Nov-2024 , 2025 , 07-Sep-2025 , 16-Oct-2025 , 16-Nov-		16-Mar-2025 , 07-	May-2025 , 16-Jun-2	025 , 16-Jul-
Synopsis	preliminary data. A distinct feature for this	gators/index.htm) to pursue r nces with the life and/or biom ept, or high risk-high impact, a applicants must propose resea	research programs nedical sciences. A and may be techno arch approaches fo	of high interest to t Trailblazer project r blogy design-directed or which there are m	nay be I, discovery-
	if available, minimal preliminary data are al independently produced and not yet publis limited to one-half page, which may include one figure will be considered noncompliant	hed in a peer-reviewed journ e one figure. Applications incl	lefined as materia al.All preliminary o uding data more t	l which the applican data should be clear han one-half page o	has y marked and
125253 Feasibility Trials of the NIH Music of Aging (R34 Clinical Trial Require	independently produced and not yet publis limited to one-half page, which may include one figure will be considered noncompliant c-based Interventions Toolkit for Brain Disord	hed in a peer-reviewed journ e one figure. Applications inclute t with the FOA instructions an	lefined as materia al.All preliminary o uding data more t id will not go forw PAR-24- 168	l which the applican data should be clear han one-half page o	has y marked and
of Aging (R34 Clinical Trial Requir	independently produced and not yet publis limited to one-half page, which may include one figure will be considered noncompliant c-based Interventions Toolkit for Brain Disord	hed in a peer-reviewed journ e one figure. Applications inclu t with the FOA instructions an lers National Institutes of	lefined as materia al.All preliminary o uding data more t id will not go forw PAR-24- 168	l which the applican data should be clear han one-half page of ard to review. 22-Sep-2024 [Optional][LOI/Pre-	has y marked and more than 450,000
of Aging (R34 Clinical Trial Requir	independently produced and not yet publis limited to one-half page, which may include one figure will be considered noncompliant c-based Interventions Toolkit for Brain Disord red)	hed in a peer-reviewed journ e one figure. Applications inclu t with the FOA instructions an lers National Institutes of	lefined as materia al.All preliminary o uding data more t id will not go forw PAR-24- 168	l which the applican data should be clear han one-half page of ard to review. 22-Sep-2024 [Optional][LOI/Pre-	has y marked and more than 450,000
¹²⁵²⁵³ of Aging (R34 Clinical Trial Requir Contact Name Contact Telephone	independently produced and not yet publis limited to one-half page, which may include one figure will be considered noncompliant c-based Interventions Toolkit for Brain Disord red)	hed in a peer-reviewed journ e one figure. Applications inclu t with the FOA instructions an lers National Institutes of	lefined as materia al.All preliminary o uding data more t id will not go forw PAR-24- 168	l which the applican data should be clear han one-half page of ard to review. 22-Sep-2024 [Optional][LOI/Pre-	has y marked and more than 450,000
¹²⁵²⁵³ of Aging (R34 Clinical Trial Requir Contact Name Contact Telephone	independently produced and not yet publis limited to one-half page, which may include one figure will be considered noncompliant c-based Interventions Toolkit for Brain Disord red) e Sekai Chideya, M.D., M.PH a 301-827-1916 I Sekai.Chideya@nih.gov	hed in a peer-reviewed journ e one figure. Applications inclu t with the FOA instructions an lers National Institutes of	lefined as materia al.All preliminary o uding data more t id will not go forw PAR-24- 168	l which the applican data should be clear han one-half page of ard to review. 22-Sep-2024 [Optional][LOI/Pre-	has y marked and more than 450,000
of Aging (R34 Clinical Trial Require Contact Name Contact Telephone Contact Email Sponsor Website	independently produced and not yet publis limited to one-half page, which may include one figure will be considered noncompliant c-based Interventions Toolkit for Brain Disord red) e Sekai Chideya, M.D., M.PH a 301-827-1916 I Sekai.Chideya@nih.gov	hed in a peer-reviewed journ e one figure. Applications inclu t with the FOA instructions an lers National Institutes of	lefined as materia al.All preliminary o uding data more t id will not go forw PAR-24- 168	l which the applican data should be clear han one-half page of ard to review. 22-Sep-2024 [Optional][LOI/Pre-	has y marked and more than 450,000

SPIN ID Program Title	Sr	ponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
Synopsis	The purpose of this Notice of Funding Opport Interventions Toolkit for Brain Disorders of Ag trials guided by the NIH Music-based Interven clinical trials will generate evidence supportin pilot data to design a subsequent clinical effic interventions in the context of brain disorders disease-related dementias, Parkinson's disease order to facilitate development of a competit	ging (R34 Clinical Trial Requintions (MBI) Toolkit for resent of the validity of the NIH ME cacy or effectiveness study (s of aging, including but not se, and stroke. The data coll	red)" in order to arch on brain disc I Toolkit's guidin or pragmatic clini limited to Alzheir	support proof-of-co orders of aging. Thes g principles as well a cal trial) using music mer's disease and A	ncept feasibility se early phase is the necessary c-based zheimer's
112325 Notice of Special Interest (NOSI): Health Outcomes	Research on Addressing Violence to Improve	National Institutes of Health/DHHS	NOT-OD- 22-167	07-Sep-2024	Not Specified
Contact Name	Dara R. Blachman, Ph.D.				
Contact Telephone	301-496-8522				
Contact Email	Dara.blachman-demner@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun- 2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025				
Synopsis	The purpose of this Notice is to highlight interest in addressing the role of violence in health outcomes and integrating violence-related screening and interventions into health care settings. This Notice is to encourage intervention research focused on addressing exposure to violence - including but not limited to child maltreatment, intimate partner violence/teen dating violence, elder mistreatment, peer violence/bullying, and community violence – to improve individual-level health processes and outcomes.				
111641 Notice of Special Interest (NOSI):	Climate Change and Health	National Institutes of Health/DHHS	NOT-ES- 22-006	08-Aug-2024	Not Specified
Contact Name	Claudia L. Thompson				
Contact Telephone	984-287-3330				
Contact Email	thompso1@niehs.nih.gov				
Sponsor Website					
Program URL	Link to program URL				

2-Feb-2025, 1 with Fogarty Ir ennedy Shriver NIMH), Natior of Allergy and of: reducing th ncreased risk f nunities, natio ns that addres	ct-2024 , 12-Nov-2024 , 15-N , 16-Feb-2025 , 19-Feb-2025 r International Center (FIC), er National Institute of Child onal Institute of Nursing Res d Infectious Disease (NIAID) the health threats posed by k from or disparately affecte cions around the world, there ess the impact of climate cha nange in the United States an	25 , 08-), ild esearch D) is by cted by ereby change and
ennedy Shriver NIMH), Natior of Allergy and of: reducing tl ncreased risk f nunities, natio ns that addres	er National Institute of Child onal Institute of Nursing Res d Infectious Disease (NIAID) the health threats posed by k from or disparately affecter cions around the world, there ess the impact of climate cha nange in the United States an	ild esearch D) is by cted by ereby change and
	Not)t
FA-NS- 01- 4-005	1-Oct-2024 Spec	ecified
es for recordin derstanding of have previous for accelerate dissemination	ding and modulation of neur of dynamic signaling in the c busly demonstrated their ated refinement through iter ion and user-friendly incorpo ation hardware and/or devic agnetic, or acoustic	eural e central cerative poration vices
	es for record lerstanding have previo for accelera disseminati instrumenta electrical, m neural activit	6 [Optional][LOI/Pre-App], 20-Jan-2026 es for recording and modulation of ne derstanding of dynamic signaling in the have previously demonstrated their for accelerated refinement through it dissemination and user-friendly incor instrumentation hardware and/or dev electrical, magnetic, or acoustic neural activity, including intracellular s of RFA-NS-21-027, but unlike the prev

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		FOA the focus is narrowed to technologies excludes projects primarily focused on development constructs should consider RFA-R technologies for functional dissection of ne development of molecular reagents, potent BRAIN Initiative announcements including R the proposed technologies should be to reac considerations of cost and ease of access, a function. Technologies should address maj circuit resolution, and should contribute to scales in any region throughout the CNS. Th an expectation that they will be validated w experiments must focus on demonstrating state of biological knowledge as the primar where appropriate, to leverage diverse dom computational modeling, and statistical and will be assessed as part of the scientific and considered incomplete and will be withdraw	elopment of molecular reagen MH-22-245, BRAIN Initiative: E ural circuits (UM1 Clinical Tria tial applicants should consider RFA-MH-21-175 and RFA-EY-2 duce major barriers to conduc and to enable new discoveries or challenges associated with an overall ecosystem of techr he approaches should be comp with in vivo experiments during the capabilities and potential y project goal. Applications ar nains of expertise from biolog alysis. This FOA requires a Pla I technical peer review evalua	nts. Potential applications Engineering and opti- al Not Allowed). For p r the companion FO/ 1-001. For this and t ting neurobiological for understanding n recording and modu- nologies spanning m patible with experim g the course of the p impact of the techno- re encouraged to inte- recouraged to inte- rical, chemical, and p n for Enhancing Dive	ants primarily opti mization of molec projects at an earl A (RFA-NS-24-004) he companion FO experiments, inclu- eural circuit ultiple spatial and ents in behaving a project. Proposed ology, rather than egrate multiple ap thysical sciences, e erse Perspectives (mizing ular ier stage of or alternative A, the aim of uding y, at cellular or temporal animals, with validation advancing the proaches, and engineering, PEDP), which
		: New Technologies and Novel Approaches f Nervous System (R01 Clinical Trial Not Allow		RFA-NS- 24-004 01	-Oct-2024	Not Specified
	Contact Name	Grace M. Hwang, PhD				
	Contact Telephone					
		BRAIN-FOAs@nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	01-Oct-2024 , 03-Apr-2025 [Optional][LOI/F	•••			
		This FOA seeks applications for proof-of-con recording and modulation of neural cells ar of dynamic signaling in the central nervous proposed research may be high-risk, but if research. Applications may propose develo	nd circuits, to address major cl system. Preliminary feasibilit successful could profoundly cl	hallenges and enable y data are not requi hange the course of	e transformative ured, and it is expenses of the second seco	nderstanding cted that the

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		and/or molecular constructs for sensing an optical, electrical, magnetic, or acoustic rec activity, including intracellular signaling and 24-005) is targeted to projects focused on a cycle, where iterative optimization and end focused on development or optimization of this nature are supported by this FOA and a and RFA-EY-21-001. For this and the compa- barriers to conducting neurobiological expe- discoveries for understanding neural circuit recording and modulating CNS activity, at a technologies spanning multiple spatial and compatible with experiments in behaving a during the course of the project. Proposed potential impact of the technology, rather to Applications are encouraged to integrate m expertise from biological, chemical, and phy FOA requires a Plan for Enhancing Diverse F peer review evaluation. Applications that f	cording/manipulation, to targe d engagement of non-neurona optimization of instrumentation d-user testing is needed. The of f molecular constructs for reco other BRAIN Initiative announce anion FOA, the aim of the prop eriments, including consideration t function. Technologies shoul rellular or circuit resolution, an temporal scales in any region inimals, with an expectation the validation experiments must than advancing the state of bio nultiple approaches, and where ysical sciences, engineering, co Perspectives (PEDP), which wil	t neuronal electrica I cells in circuit func- on and devices that a companion FOA doe ording and manipula cements including R posed technologies ons of cost and ease d address major cha d should contribute throughout the CNS nat they will be valid focus on demonstra ological knowledge a e appropriate, to lev omputational model I be assessed as par	I signals or other for tion. A companion are later in the dev s not allow project ting neural activity FA-MH-22-245, RF, should be to reduce of access, and to allenges associated to an overall ecos . The approaches s ated with in vivo e ting the capabilitie as the primary proj rerage diverse dom ling, and statistical t of the scientific a	orms of neural FOA (RFA-NS- velopment s primarily /. Projects of A-MH-21-175, e major enable new d with ystem of should be experiments es and ject goal. nains of analysis. This nd technical
113609	NLM Research Grants in Biomedic Trial Optional)	cal Informatics and Data Science (R01 Clinica	National Library of Medicine/NIH/DHHS	PAR-23- 034 07	-Sep-2024	1,000,000 USD

Contact Name	Meryl Sufian, PhD
Contact Telephone	301-496-4671
Contact Email	<u>sufianm@mail.nih.gov</u>
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	<u>LINK to program URL</u> 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan- 2026
Synopsis	The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	personal wellness. The scope of NLM's inter- methods and approaches to foster data driv independent, scalable, and reusable/reprod of health-related digital objects.	en discovery in the biomedica	al and clinical healt	h sciences as well a	as domain-
115310 Notice of Special Interest (NOSI): Enhance Discovery from Health D	Computational and Statistical Methods to ata	National Library of Medicine/NIH/DHHS	NOT-LM- 23-001	7-Sep-2024	Not Specified
Contact Telephone Contact Email Sponsor Website	<u>sufianm@mail.nih.gov</u>				
Deadline Dates (ALL)	$\begin{bmatrix}$	5-Feb-2025 , 07-May-2025 , 0)5-Jun-2025 , 07-Se	p-2025 , 05-Oct-20	25 , 07-Jan-
Synopsis	The National Library of Medicine is issuing the research that aims to reduce or mitigate gap			ant applications for	cused on
	Administrative Supplements for Validation Dietary Supplement Constituents (Admin Su	Office of Dietary Supplements/NIH/DHHS	NOT-OD- 22-202	5-Oct-2024	Not Specified
Contact Name	Adam J. Kuszak, Ph.D.				
Contact Telephone					
	kuszakaj@mail.nih.gov				
Sponsor Website					
	Link to program URL				
Synopsis	15-Oct-2024 , 15-Jan-2025 , 15-Apr-2025 The NIH Office of Dietary Supplements (ODS and Strategic Initiatives (DPCPSI) announces laboratory validation (SLV) studies of analyti and/or constituents (e.g., active or marker c	the availability of administra cal methods for the identifica	tive supplements fation and/or quanti	or the conduct of f fication of dietary	ormal single- ingredients

SPIN ID	Program Title		Sponsor Name	Sponsor N	umber	Deadline Date	Funding Amount
		supplements, their raw source ma	terials, and/or clinical specimens (e.	g., urine, plasn	na, tissue).	
SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline	Date	Funding Amount
113926	Development of Resources and T Reproducibility, and Translatabili Research (R01)	echnologies for Enhancing Rigor, ty of Animal Models in Biomedical	Office of Research Infrastructure Programs/NIH/DHHS	PAR-23-040	05-Oct-2	024	Not Specified
		Sige Zou, Ph.D.					
	Contact Telephone						
		<u>zous@mail.nih.gov</u>					
	Sponsor Website						
	-	Link to program URL					
		and implementing broadly applica reproducibility, and translatability Announcement (FOA) should be h technologies under this FOA must multiple organ systems, or be app with ORIP's NIH-wide mission and of animal research through the de impact across a broad range of res	ure Programs (ORIP) encourages rese ble technologies, tools, and resource of animal research. Research projec ypothesis driven with strong prelimin either address research interests of licable to diseases and processes that programs. Applications should aim t velopment and implementation of to search areas using animal models. Ap t rigor and reproducibility of animal	es for validatin ts submitted u nary data. Prop multiple NIH In at impact multi to enhance the echnologies, to oplications mus	g animal Inder this posed stu nstitutes ple orgar rigor, rep pols, and	models and enha Funding Opportu Idies, models, resu and Centers (ICs), n systems in order producibility, and resources that ha	ncing rigor, inity ources, or , explore to align translatability ve significant
102835	Development of Animal Models a for Research (R21 Clinical Trial No		Office of Research Infrastructure Programs/NIH/DHHS	PAR-21-167	07-Sep-2	024	275,000 USD
	Contact Name	Sige Zou, Ph.D.					
	Contact Telephone	301-435-0749					
	Contact Email	<u>zous@mail.nih.gov</u>					

Sponsor Website

SPIN ID	Program Title		Sponsor Name	Sponsor N	lumber	Deadline Date	Funding Amount
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jai					
	Synopsis	models, biological materials, and r projects aimed at improving the di proposed project must have broad Infrastructure Programs' (ORIP) tra diseases that impact multiple body	ement (FOA) encourages innovative novel technologies to better underst iagnosis and control of diseases that d application to multiple NIH Institut ans-NIH mission. The proposed stud y systems. Applications that develop primarily relevant to a single NIH IC,	and human he i interfere with es or Centers ies must explo models focus	ealth and n animal (ICs) to a ore multip ed on a s	disease. This FOA use for biomedical lign with the Office ole body systems o specific disease or	also seeks research. The of Research r evaluate area of
113710	RFA-OD-22-028 The Intersectio Health and Disease (R01 Clinical T	n of Sex and Gender Influences on Trial Optional)	Office of Research on Women's Health/NIH/DHHS	RFA-OD-22- 028		2024 al][LOI/Pre-App]	1,400,000 USD
	Contact Name	Chyren Hunter, Ph.D.					
	Contact Telephone	301-496-7849					
	Contact Email	<u>Hunterc@mail.nih.gov</u>					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	23-Oct-2024 [Optional][LOI/Pre-A	pp], 23-Nov-2024				
	Synopsis	of sex and gender in health and dis intersection in understanding heal Goal 1 of the 2019-2023 Trans-NIH Women." The awards under this F	rtunity Announcement (FOA) is to ir sease, including: (1) research applica Ith and disease; and (2) research tha I Strategic Plan for Women's Health OA will be administered by NIH ICs re ealth (ORWH) and the scientific part	ations that exa t addresses or Research "Adv using funds that	imine sex ne of the vancing S at have b	and gender facto five objectives fro cience for the Hea een made availabl	rs and their m Strategic Ilth of



SPIN ID Program Title		Sponsor Name		ponsor lumber	Dea Dat	adline :e	Funding Amount
123333 ECosystem for Leading Innovation	on in Plasma Science and Engineering		National Sc Foundation		D-24- 10Z	13-Aug- 2024	Not Specified
Contact Name	Raymond A. Adomaitis						
Contact Telephone	703-292-7519						
Contact Emai	l <u>eclipse@nsf.gov</u>						
Sponsor Website	Link to sponsor website						
Program URI	Link to program URL						
Deadline Dates (ALL) 13-Aug-2024 , 30-Sep-2024 , 01-Oct-20	024 , 15-Oct-2024 , 31-Oct-202	24 , 18-Nov-2	024			
Synopsis	Plasma science is a transdisciplinary fie physics, plasma chemistry, materials so technological innovation. The primary (ECLIPSE) program is to identify and ca bear on problems of societal and techn s participating NSF programs. The ECLIP engineers, an ecosystem spanning mul fundamental plasma science and techn in supporting multi-disciplinary researd within NSF, and potentially with other struggle to find a natural home within	cience, and space science, con goal of the ECosystem for Lea pitalize on opportunities for b nological need within the scop SE meta-program has been cre ltiple NSF Directorates, in the nological innovation. The ECLI ch in plasma science and engir funding agencies, in consideri	ne together t ding Innovati pringing funda e of science a eated to foste pursuit of tra PSE program neering, and i ng proposals	o advance ki ion in Plasma amental plas and enginee er an inclusiv inslational re builds on th is intended t and suppor	nowled a Scienc ma scie ring sup re comn search e long l o enhar ting pro	ge for disco e and Engi- ence invest oported by nunity of s at the inte- nistory of M nce organiz- jects that	overy and neering igations to the cientists and rface of NSF leadership zational unity may otherwise
1/58/11	Proposals for Centers of Research Excel Computer and Information Science and E		National Sc Foundation		ISF 24- 89	01-Oct- 2024	200,000 USD
Contact Name	Subrata Acharya						
Contact Telephone	703-292-5111						
Contact Emai	l <u>acharyas@nsf.gov</u>						
Sponsor Website	Link to sponsor website						
Program URI	Link to program URL						
Deadline Dates (ALL) 01-Oct-2024						
Synopsis	Consistent with the National Science F	oundation's (NSF) efforts to in	crease instit	utional diver	sity wit	hin science	e, technology,



SPIN ID Program Title		Sponsor Name	Sponsor Number	Dea Dat	adline e	Funding Amount
	engineering and mathematics (STEM), Information Science and Engineering (O proposal with a focus on research in al STEM.	CISE) jointly encourage the sub	omission of planning p	roposals fo	or a future	CREST center
126934 NSF EPSCoR Graduate Fellowship	o Program		National Science Foundation	24-588	02-Oct- 2024	Not Specified
Contact Name	Narcrisha S. Norman					
Contact Telephone	703-292-7965					
Contact Email	nnorman@nsf.gov					
Sponsor Website	Link to sponsor website					
Program URL	Link to program URL					
Deadline Dates (ALL)	02-Oct-2024 , 02-Jun-2025 , 01-Jun-202	26				
Synopsis	The NSF EPSCoR Graduate Fellowship F GRFP Honorable Mention no more tha and obtain financial support for their g the capacity and competitiveness of EF support NSF EPSCoR Graduate Fellows and Office that are participating in the or sub-field of study that the GRFP Hor be made to institutions in EPSCoR juris allowance for each NSF EPSCoR Graduate cost-of-education allowances must be must be budgeted per Fellow. Each Fel awards such that the Fellows receive the during the three years that each Fellow Fellows.	n three years before the prop raduate education at an instit PSCOR jurisdictions by providin as they pursue graduate degr EGFP funding program. Fellow norable Mention recipients pro dictions. Awards will provide to ate Fellow. Stipends must be to budgeted at the level of \$16,0 low must be given up to five y he full stipend amount and the	osal due date to be na ution in an EPSCoR jur g funding to graduate ees in the disciplines s vs may pursue degree eviously listed in their three years of stipend budgeted at the level o 00 per year per Fellow rears to utilize the sup e institution retains th	imed NSF E risdiction. E degree-av specified by s in field th GRFP appl and associ of \$37,000 v. A total o port. Awar e full cost-	PSCoR Gra EGFP aims varding ins y the NSF I hat differ fr ication. EG ated cost- per year p f three yea dees will a of-educati	aduate Fellows to enhance stitutions to Directorates from the field FP awards will of-education er Fellow and ars of support idminister the on allowance
120776 Smart Health and Biomedical Re	search in the Era of Artificial Intelligence	e and Advanced Data Science	National Science Foundation	23-614	03-Oct- 2024	1,200,000 USD
Contact Name	Goli Yamini					



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Telephone	702 202 5267				
•	il <u>sch-correspondence@nsf.gov</u>				
	e Link to sponsor website				
	L Link to program URL				
-) 03-Oct-2024 , 03-Oct-2025				
Synopsi	The purpose of this interagency progra advances in computer and information address pressing questions in the biom s engineering innovations by interdiscip connect, analyze and interpret data fro to these complex biomedical or public address these issues, while advancing	n science, engineering, mathematics, s nedical and public health communities linary teams that develop novel metho om individuals, devices and systems to health problems demand the formation	tatistics, behaviora . Transformations h ods to intuitively an enable discovery a on of interdisciplina	and/or cogniti inge on scienti d intelligently c nd optimize he	ve research to fic and collect, sense, alth. Solutions
122294 <u>Research Experiences for Teach</u>	ers (RET) in Engineering and Computer S	Science Nation Foundation	al Science 24- ation	503 09-Oct- 2024	Not Specified
Contact Name	e Amelia S. Greer				
Contact Telephone	e 703-292-2552				
Contact Emai	il agreer@nsf.gov				
Sponsor Website	e Link to sponsor website				
Program UR	L Link to program URL				
Deadline Dates (ALL) 09-Oct-2024				
Synopsi	The Research Experiences for Teachers research experiences for K-14 educato districts, and industry partners. With t Science and Engineering (CISE) focus o (when applicable) industry mentors. K computer science and translate their r awareness of and participation in com deepen their understanding of classro	rs to foster long-term collaborations the his solicitation, the Directorates for Er n a reciprocal exchange of expertise b -14 educators will enhance their scient esearch experiences into classroom ac puting and engineering pathways. At t	etween universitie gineering (ENG) an etween K-14 educa tific disciplinary kno tivities and curricu he same time, the	s, community c d Computer an tors and resear wledge in engi la to broaden th nosting researc	olleges, school d Information ch faculty and neering or neir students' h faculty will
125690 Mathematical Foundations of A	rtificial Intelligence	Nation	al Science 24-	569 10-Oct-	1,500,000



SPIN ID Program Title		Sponsor Name	Sponsor Number	Dea Dat	adline :e	Funding Amount
			Foundation		2024	USD
Contact Na	me Eyad Abed					
Contact Telepho	ne 703-292-2303					
Contact En	nail <u>eabed@nsf.gov</u>					
Sponsor Webs	ite Link to sponsor website					
Program L	IRL Link to program URL					
Deadline Dates (A	LL) 10-Oct-2024 , 10-Oct-2025 , 09-Oct	t-2026				
Synop	The National Science Foundation D Science and Engineering (CISE), Eng research collaborations consisting of scientists focused on the mathema challenging mathematical and theo properties of AI methods as well as for the current and next generation	gineering (ENG), and Social, Bel of mathematicians, statisticians tical and theoretical foundatio pretical questions aimed at und s the development of novel, an	havioral and Economic Sc s, computer scientists, er ns of AI. Research activiti lerstanding the capabilition	ciences (SBI ngineers, ar ies should f es, limitatio	E) will join nd social a focus on tl ons, and e	tly sponsor nd behavioral he most merging
123645 Campus Cyberinfrastructure			National Science Foundation	24-530	15-Oct- 2024	Not Specified
Contact Na	me Kevin Thompson					
Contact Telepho	ne 703-292-4220					
Contact En	nail <u>kthompso@nsf.gov</u>					
Sponsor Web	ite Link to sponsor website					
Program L	IRL <u>Link to program URL</u>					
Deadline Dates (A	LL) 15-Oct-2024					
Synop	The Campus Cyberinfrastructure (C innovation, integration, and engine overcome disparities in cyber-conn innovation and enable populations engineering, and mathematics (STE the primary motivation for any pro	eering for science applications a lectivity associated with geogra based in these locales to beco EM) research and education are	and distributed research aphic location, and there me more nationally com	projects. P by advance petitive in s	rojects that the geographics the	at help raphy of echnology,

SPIN ID Program Title		Sponsor Name		Sponsor Number	Dea Dat	ndline e	Funding Amount
127027 Graduate Research Fellowship P	Program (GRFP)		National S Foundatio		NSF 24- 591	15-Oct- 2024	Not Specified
Contact Name							
Contact Telephone	866-673-4737						
Contact Emai	l <u>info@nsfgrfp.org</u>						
Sponsor Website							
Program URI	Link to program URL						
Deadline Dates (ALL) 15-Oct-2024 , 16-Oct-2024 , 17-Oct-20	024 , 18-Oct-2024					
Synopsis	the scientific and engineering workfor students who are pursuing full-time re mathematics (STEM) or in STEM educa or STEM education of individuals or STEM education. NSF actively encou has to offer which includes underrepre support individuals who demonstrate applications from undergraduate senio in STEM. First- and second-year gradua	esearch-based master's and do ation. The GRFP provides three who have demonstrated their urages submission of applicatio esented and under-served com the potential to make significa ors and Bachelor's degree-hold	ctoral degree years of su potential fo ons from the nmunities. N nt contribu- lers interest	ees in scien pport over or significan e full spectr NSF GRFP w tions in STE ted in pursu	ce, techno a five-yea t research rum of div as establis M. NSF es uing resea	llogy, engi r fellowsh achievem erse talen shed to ree pecially e rch-based	neering, and ip period for nents in STEM t that society cruit and ncourages graduate study
113761 Expanding AI Innovation through	h Capacity Building and Partnerships		National S Foundatio		23-506	18-Oct- 2024	Not Specified
Contact Name							
Contact Telephone	703-292-5111						
Contact Emai	ExpandAlProgram@nsf.gov						
Sponsor Website	Link to sponsor website						
Program URI	Link to program URL						
Deadline Dates (ALL) 18-Oct-2024 , 10-Mar-2025 , 23-Jun-20	025					
Synopsis	The National Science Foundation and research community for the advancen	its partners support the continent of AI and AI-powered inno	ued growth ovation, pro	of a broad widing a un	and diver	se interdis rtunity to	sciplinary broadly



	Program Title	Sponsor Name	Sponsor	Deadline	Funding
SPINID			Number	Date	Amount

promote the NSF vision and core values, especially inclusion and collaboration. The Expanding AI Innovation through Capacity Building and Partnerships (ExpandAI) program aims to significantly broaden participation in AI research, education, and workforce development through capacity development projects and through partnerships within the National AI Research Institutes ecosystem.



Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Dat	e Fun	ding Amount
115139	Special Emphasis Notice (SEN):R	esearch on Climate Change and Healthcare	Agency for Healthcare Research and Quality/DHHS	NOT-HS-23- 006	08-Aug- 2024	Not Specified
	Contact Name	Brent Sandmeyer, MPH				
	Contact Telephone	301-427-1441				
	Contact Email	Brent.sandmeyer@ahrq.hhs.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Aug-2024 , 12-Aug-2024 , 05-Oct-2024 , 12-Oc 2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , Aug-2025 , 12-Aug-2025 , 25-Sep-2025 , 25-Sep-2 12-Feb-2027	26-Feb-2025, 08-Apr-2025, 12-Apr-	2025 , 25-May	-2025 , 12	-Jun-2025 , 08-
	Synopsis	This Special Emphasis Notice (SEN) announces AH address the intersection of climate change and he	-	ices research ៛	grant appli	cations that
109186	Notice of Special Interest (NOSI) Healthcare Professional Respons	: Health Services Research on Health System and siveness to COVID-19	Agency for Healthcare Research and Quality/DHHS	NOT-HS-22- 010	25-Sep- 2024	Not Specified
	Contact Name	Leeann Comfort, PhD, MPP				
	Contact Telephone					
	Contact Email	Leeann.Comfort@ahrq.hhs.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	25-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Jan	-2025 , 05-Feb-2025			
	Synopsis	This Special Emphasis Notice (SEN) informs the re (AHRQ) is interested in receiving health services re quality, and outcomes of care related to COVID-1	esearch grant applications to develop	models of ca		•
123850	AHRQ Small Health Services Rese	earch Grant Program (R03)	Agency for Healthcare Research and Quality/DHHS	PA-24-155	16-Oct- 2024	100,000 USD
	Contact Name					



Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	e Fun	ding Amount
	Contact Email	kathryn.woolridge@ahrq.hhs.gov				
	Sponsor Website					
	Program URL	Link to program URL				
Deadline Dates (ALL) 16-Oct-2024, 16-Feb-2025, 16-Jun-2025, 16-Oct-2025, 16-Feb-2026, 16-Jun-2026, 16-Oct-2026, 16-Feb-2027, 16-Feb-2027, 16-Feb-2028, 16-Jun-2028, 16-Feb-2029, 16-Jun-2029 The purpose of this Notice of Funding Opportunity (NOFO) is to seek health services research grant applications for AHRQ research priorities, including improving healthcare quality and patient safety, improving healthcare delivery practice improvement, and enhancing whole-person healthcare delivery. AHRQ supports research in all healthcare including the hospital, long-term care, ambulatory care, home healthcare, pharmacy, and care transitions betwee Research may involve many partners and other groups, including patients, families, clinicians, non-clinical healthcare policymakers, payers, healthcare organizations, providers and accreditors, local and State governments, the Fede Government, and others.						27 , 16-Jun-
						very and care settings, veen settings. thcare staff,
123849	AHRQ Health Services Research	Projects (R01)	Agency for Healthcare Research an Quality/DHHS	PA-74-154	05-Oct- 2024	2,000,000 USD
	Contact Name					
	Contact Telephone	301-427-1025				
	Contact Email	kathryn.woolridge@ahrq.hhs.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oc 2027 , 05-Oct-2027 , 05-Feb-2028 , 05-Jun-2028			5-Feb-202	27 , 05-Jun-
	Synopsis	The purpose of this Notice of Funding Opportun AHRQ research priorities, including improving he practice improvement, and enhancing whole-per including the hospital, long-term care, ambulato Research may involve many partners and other a policymakers, payers, healthcare organizations, Government, and others.	valthcare quality and patient safety, in rson healthcare delivery. AHRQ support ry care, home healthcare, pharmacy, groups, including patients, families, cl	mproving health orts research in and care transit inicians, non-cli	all health all health tions betw nical heal	very and care settings, veen settings. thcare staff,
114270	Special Emphasis Notice (SEN): I	nterest in Healthcare Associated Infections and	Agency for Healthcare Research an	d NOT-HS-23-	25-Sep-	Not Specified

Other Federal Funding Opportunities

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Da	ite Fu	nding Amount	
	Combating Antibiotic Resistant E	Bacteria Research		Quality/DHHS	003	2024		
	Contact Name	Leyi Lin, MD						
	Contact Telephone	301-427-1333						
	Contact Email	leyi.lin@ahrq.hhs.	.gov					
	Sponsor Website							
	Program URL	Link to program U	IRL					
	Deadline Dates (ALL)		Oct-2024 , 25-Jan-2025 , 05-Feb 26 , 05-Jun-2026 , 25-Sep-2026	-2025 , 25-May-2025 , 05-Jun-202 05-Oct-2026 , 05-Oct-2026	5,25-Sep-2025	, 25-Jan-2(026 <i>,</i> 05-Feb-	
	Synopsis	The purpose of this Special Emphasis Notice (SEN) is to inform the research community of the Agency for Healthcare Research and Quality (AHRQ) continued interest in, and available funding for, supporting innovative research seeking to reduce the burden of healthcare-associated infections (HAIs) and to address the growing threat posed by antimicrobial resistant organisms. HAIs continue to cause significant patient harm and are also associated with considerable financial consequences for healthcare facilities and for patients. Unfortunately, the COVID-19 pandemic has been associated with observed increases of several types of HAIs as well as increases in antimicrobial resistance, highlighting the importance of developing and studying resilient and adaptable countermeasures.						
107009	Large Research Projects for Com	bating Antibiotic-R	Resistant Bacteria (CARB) (R01)	Agency for Healthcare Research a Quality/DHHS	end PA-22-047	05-Oct- 2024	2,500,000 USD	
	Contact Name	James Cleeman, N	ЛD					
	Contact Telephone	301-427-1330						
	Contact Email	james.cleeman@a	ahrq.hhs.gov					
	Sponsor Website	Link to sponsor we	<u>ebsite</u>					
	Program URL	Link to program U	<u>IRL</u>					
	Deadline Dates (ALL)	05-Oct-2024 , 05-I	Feb-2025 , 05-Jun-2025 , 05-Oct	-2025 , 05-Feb-2026 , 05-Jun-2026	, 05-Oct-2026			
	Agency for Healthcare Research and Quality (AHRQ) invites applications to conduct Large Health Services Research Synopsis Demonstration and Dissemination Projects (R18) focused on Combating Antibiotic-Resistant Bacteria (CARB). This FOA use the R01 Research Project Grant award mechanism.							



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Dessenth in Asselsmin Destinted	- Leitistics on Discusity (DADID)			
043021 Research Grants RAPID Scho	<u>cs Initiative on Diversity (RAPID)</u> lar Awards	Academic Pediatric Association	01-00	t-2024 15,000 USD
Contact Name	3			
Contact Telephone				
Contact Emai				
Sponsor Website	Link to sponsor website			
Program URI	Link to program URL			
Deadline Dates (ALL	01-Oct-2024			
Synopsis	-	et applicants (junior faculty and fellows ir licine (UIM), or disabled. Selected propos	•	
Applicant Types	5			
Funding Limit	15,000.00 maximum			
Limited Submission	No			
070333 Frederick V. Hunt Postdoctoral	Research Fellowship in Acoustics	Acoustical Society of America	07-00	ct-2024 70,000 USD
Contact Name	2			
Contact Telephone	516-576-2360			
Contact Emai	elaine@acousticalsociety.org			
Sponsor Website	Link to sponsor website			
Program URI	Link to program URL			
Deadline Dates (ALL	07-Oct-2024			
Synopsis	The F. V. Hunt Postdoctoral Researc that his estate be used to further the	h Fellowship was established by the Socie e science of and education in acoustics. Fe	ty to carry out Profes ellows receive a stipe	sor Hunt's wish nd, provided jointly



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		by the Hunt estate and a fund establishe at an institution of their choice. One Felle			topic in acoustics
	Applicant Types				
	Funding Limit	70,000.00 see detail			
	Limited Submission	No			
)52818 <u>(</u>	Generic Call for Proposals		Agence Nationale de la Recherche ANR)	15-00	t-2024 Not Specified
	Contact Name				
	Contact Telephone	+33 1 78 09 80 00			
	Contact Email	<u>contact-anr@anr.fr</u>			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Oct-2024			
	Synopsis	The Generic Call for Proposals 2025 (AAP scientific communities and all public and researchers from different scientific field large number of research themes, wheth	private actors involved in French res Is to access, in addition to their recur	earch are concerned	It should allow
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
020306	Grants Program	ŀ	Alpha Foundation	01-00	t-2024 Not Specified

Contact Name Ashley Dyer



SPIN ID Program Title	Sponsor Name	9	Sponsor Number	Deadline Date	Funding Amount
Contact Telephone	256-713-2277				
Contact Email	info@alphafoundationhsv.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Oct-2024				
Synopsis	Since its formation in 1997, the Alpha will select organizations grants to educational, scientific in the discovery and cure of dis	to which grants will be c, and charitable organi	made that further this obj	ective. An emphasi	s will be placed on
Applicant Types					
Funding Limit	0.00 not provided				
Limited Submission	No				
004969 Faculty Development Award			demy of Allergy, munology (AAAAI)	21-Au 2024 [LOI/P App]	300,000
Contact Name	Katie Tetzlaff				
Contact Telephone	414-272-6071				
Contact Email	ktetzlaff@aaaai.org				
Sponsor Website	Link to sponsor website				

Program URL Link to program URL

Deadline Dates (ALL) 21-Aug-2024 [LOI/Pre-App], 24-Oct-2024

Synopsis This mentored award provides up to \$300,000 in funding over a three-year period and is intended to support the development of careers in Allergy and Immunology.



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit	300,000.00 maximum			
	Limited Submission	No			
1/0/5/	AAAAI/ Elliot and Roslyn Jaffe T Research Award at Icahn Schoo	<u>Third-Year Fellowship Food Allergy</u> I of Medicine at Mount Sinai	American Academy of Allergy, Asthma, & Immunology (AAAAI)	25-Oc	t-2024 65,000 USD
	Contact Name	Katie Tetzlaff			
	Contact Telephone	414-272-6071			
	Contact Email	ktetzlaff@aaaai.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Oct-2024			
	Synopsis	allergy/immunology fellow-in-training immunology at Icahn School of Medic	nent of an academic food allergy resear or gastroenterology fellow-in-training i ine at Mount Sinai. Funding is to suppor their research at Icahn School of Medic	n the specialty of foo t education and resea	d allergy and
	Applicant Types				
	Funding Limit	65,000.00 maximum			
	Limited Submission	No			
				14-Au	g-
			American Academy of Allergy	2024	150,000

120002 Drug Hypersensitivity Research Grant	American Academy of Allergy,	2024 150,000	
	Asthma, & Immunology (AAAAI)	[LOI/Pre- USD	
		App]	

Contact Name



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
Contact Telephone	414-272-6071					
Contact Email	info@aaaai.org					
Sponsor Website	Link to sponsor website					
Program URL	Link to program URL					
Deadline Dates (ALL)	14-Aug-2024 [LOI/Pre-App], 17-	-Oct-2024				
Synopsis	This funding opportunity is to support up to three research grants to advance the state of knowledge, develop no techniques, agents, methodologies, models or applications that could have a major impact on drug hypersensitivity research. This funding mechanism is designed to further research in drug allergy/hypersensitivity. For this opportunity, vaccines are not considered drugs and applications that focus on vaccine reactions will not be considered for this award. The awardee must attend the 2025 AAAAI Annual Meeting, in San Diego, CA.					
Applicant Types						
Funding Limit	150,000.00 maximum					
Limited Submission	No					
009566 Potamkin Prize for Research in Diseases	Pick's, Alzheimer's and Related	American Aca	demy of Neurology	31-00	ct-2024 100,000 USD	
Contact Name						
Contact Telephone	612-928-6000					
Contact Email	<u>science@aan.com</u>					
Sponsor Website	Link to sponsor website					
Program URL	Link to program URL					
Deadline Dates (ALL)	31-Oct-2024					
Synopsis	The Potamkin Prize for Researc understanding of the cause, pre diseases.	•	•	• •		



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
	1			
Applicant Types				
Funding Limit	100,000.00 see detail			
Limited Submission	No			
	the ADEA/AAL Institute for Teaching &	American Academy of	07-Oct-20	24 3,500 USD
Learning in the Health Profession	ons	Periodontology Foundation		
Contact Name				
Contact Telephone	312-573-3254			
Contact Email	ariel@perio.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	07-Oct-2024			
Synopsis	-	ble to the Academy for Academic Leade lowships are available to cover full tuitic		-
Applicant Types				
Funding Limit	3,500.00 maximum			
Limited Submission	No			
003686 Strategic Research Grant		American Academy of Sleep Medicine Foundation	21-Oct-20 [LOI/Pre- App]	²⁴ 250,000 USD
Contact Name				
Contact Telephone	630-737-9724			
Contact Email	foundation@aasm.org			



SPIN ID Program Title	Sponsor Na	me	Sponsor Number	Deadline Date	Funding Amount		
Sponsor Website	Link to sponsor website						
Program URL	Link to program URL						
Deadline Dates (ALL)	21-Oct-2024 [LOI/Pre-App], :	10-Mar-2025					
Synopsis	The AASM Foundation is committed to improving patient-centered diagnosis and care for all people with sleep disorders. To ensure that there is a continued advancement in effective diagnosis and care of people with sleep Synopsis disorders, the AASM Foundation provides research funding through the Strategic Research Grant. This grant is investigator-initiated and supports high-impact research projects aimed at addressing gaps in knowledge that i the ability to provide optimal, patient-centered, cost-effective diagnosis and care for people with sleep disorder						
Applicant Types							
Funding Limit	250,000.00 see detail						
Limited Submission	No						
034933 Hench Post-Dissertation Fellow	<u>vship</u>	American A	ntiquarian Society	15-00	ct-2024 Not Specified		
Contact Name	Nan Wolverton						
Contact Telephone	508-471-2119						
Contact Email	nwolverton@mwa.org						
Sponsor Website	Link to sponsor website						
Program URL	Link to program URL						
Deadline Dates (ALL)	15-Oct-2024						
Synopsis	Scholars who are no more th long residential fellowship at relevant to the Society's libra 1876 - is eligible.	t the American Antiqua	rian Society to revise their	dissertation for pub	lication. Any topic		
Applicant Types							



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Funding Amount
	Funding Limit Limited Submission	0.00 maximum No		
1/6/43	Fanconi Cancer Foundation - A/ Cancer Research	ACR NextGen Grant for Transformative	American Association for Cancer Research	02-Oct-2024 450,000 USD
	Sponsor Website	215-440-9300 grants@aacr.org Link to sponsor website Link to program URL 02-Oct-2024 The Fanconi Cancer Foundation-AACR I innovative research from young investi investigators with experience in other a	NextGen Grant for Transformative Canc gators currently working in the Fanconi areas of cancer or biomedical research v \$450,000 over three years for expenses	anemia (FA) field as well as with an interest in studying FA-
	Applicant Types Funding Limit Limited Submission	450,000.00 maximum		
111/15/17	AACR-MPM Oncology Charitabl Research Grants	le Foundation Transformative Cancer	American Association for Cancer Research	01-Oct-2024 400,000 USD
		215-440-9300 grants@aacr.org Link to sponsor website		



SPIN ID Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
Program URL	Link to program	<u>URL</u>					
Deadline Dates (ALL)	01-Oct-2024						
Synopsis	The AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants represents a joint effort t stimulate "high-risk, high-reward" research from early- to mid-career investigators. This novel grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that might not be funded through conventional channels. It is expected that these grants will catalyze significant scientific discoveries that will advance our understanding of cancer and have a potentially transformative impact on future clinical practice.						
Applicant Types							
Funding Limit	400,000.00 max	kimum					
Limited Submission	No						
078944 AACR Immuno-oncology Resea	rch Fellowship		American Asso Research	ociation for Cancer	08-Oc	t-2024 130,000 USD	
Contact Name							
Contact Telephone	215-440-9300						
Contact Email	grants@aacr.or	g					
Sponsor Website	Link to sponsor	<u>website</u>					
Program URL	Link to program	<u>ı URL</u>					
Deadline Dates (ALL)	08-Oct-2024						
Synopsis	benefits of the [.] basic, translatic	fellow while working on	mentored imn	vide two-year grants of \$13 nuno-oncology research. P ated research and must ha December 1, 2024.	roposed research	projects may be	
Applicant Types							
Funding Limit	130,000.00 max	kimum					



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Limited Submission	No			
077402 Kline Peripheral Nerve Researc	h Award	American Association of Neurological Surgeons	14-00	ct-2024 Not Specified
Contact Name	Kristen Jones MD, Chair of Research a	nd Awards Committee		
Contact Telephone				
Contact Email	<u>kristen.jones@duke.edu</u>			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	14-Oct-2024			
Synopsis	promote basic science or clinical resea	Award is awarded to the most outstand arch related to the peripheral nerves, a sal and therefore enhance competitive	nd to provide a mean	s of peer review to
Applicant Types				
Funding Limit	0.00 see detail			
Limited Submission	No			
106678 Clinician Scientist Developmen	t Grant (CSDG)	American Cancer Society, Inc.	15-00	ct-2024 135,000 USD
Contact Name				
Contact Telephone				
Contact Email	grants@cancer.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	15-Oct-2024					
	Synopsis	mentored and p	st Development Grants (C articipate in research tra ors pursue questions rele	ining, thus aid	ing their development a	s independent clini	cian scientists.
	Applicant Types						
	Funding Limit	135,000.00 max	imum				
	Limited Submission	No					
015290	Research and Clinical Research	Professor Grants	<u>A</u>	American Cano	er Society, Inc.	15-00	t-2024 400,000 USD
	Contact Name						
	Contact Telephone	800-227-2345					
	Contact Email	lynne.elmore@c	cancer.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	15-Oct-2024					
The American Cancer Society offers a limited number of grants to investigators who have the rank of full pro- Synopsis Synopsis psychosocial, behavioral, health policy, or epidemiologic cancer research. The award of up to \$80,000 per year budgeted at the recipient's discretion for creative pursuits in cancer research.						linical,	
	Applicant Types						
	Funding Limit	80,000.00 per ye	ear				
	Limited Submission	No					



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
001310 Postdoctoral Fellowships		American Cancer Society, Inc.	15-Oc	t-2024 Not Specified		
Contact Name	2					
Contact Telephone	2 800-227-2345					
Contact Emai	grants@cancer.org					
Sponsor Website	Link to sponsor website					
Program URI	Link to program URL					
Deadline Dates (ALL) 15-Oct-2024					
Synopsis	Synopsis Postdoctoral Fellowships (PF) support new investigators in research training programs to to position them for independent careers in cancer research. As part of their evaluation, peer reviewers consider how well the fellows will broaden the applicant's research training and experience. Awards are for up to 3 years with recently increase progressive stipends of \$66,000, \$68,000, and \$70,000 a year.					
Applicant Types	\$					
Funding Limit	t 0.00 see detail					
Limited Submission	No					
001054 Institutional Research Grants		American Cancer Society, Inc.	15-Oc	t-2024 Not Specified		
Contact Name	٤					
Contact Telephone	800-227-2345					
Contact Emai	grants@cancer.org					
Sponsor Website	Link to sponsor website					
Program URI	Link to program URL					
Deadline Dates (ALL) 15-Oct-2024					



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	Institutional Research Grants are awarded independent investigators to initiate canc cancer research projects so they can obta national research grants.	er research projects. The intent is to	support these junio	r faculty in initiating
Applicant Types				
Funding Limit	0.00 see detail			
Limited Submission	No			
112975 Discovery Boost Grants (DBG)	Ar	merican Cancer Society, Inc.	15-00	t-2024 270,000 USD
Contact Name				
Contact Telephone	404-329-7558			
Contact Email	grants@cancer.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	15-Oct-2024			
Synopsis	Discovery Boost Grants (DBG) support hig continuum. Investigators may focus on de tests. It is expected that preliminary data additional grant funding to further the res Discovery Boost Grants are funded up to s allowable budget is \$297,000 for a 2-year	veloping research methodologies, e generated from a completed DBG w earch and open new and highly inno \$135,000 per year for up to 2 years,	stablishing feasibility ill have the potential ovative areas for inve	r, or leading pilot to secure estigation.
Applicant Types				
Funding Limit	135,000.00 per year			
Limited Submission	No			
	1			



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
116207 AHEAD (Advancing Health Equi	ity and Addressing Cancer Disparities)	American Cancer Society, Inc.	15-Oc	t-2024 270,000 USD
Contact Name	Kimberly Clarke			
Contact Telephone	404-329-7558			
Contact Email	kimberly.clarke@cancer.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	15-Oct-2024			
Synopsis	The American Cancer Society (ACS) is c enhancing access to quality cancer car and survive cancer. Toward this goal, A Disparities) Awards intended to fund p clinical trials—and cancer care closer t	e and ensuring that all people have an ACS is announcing AHEAD (Advancing H ilot, first-in-field, innovative strategies	equal chance to preve ealth Equity and Add	ent, detect, treat, ressing Cancer
Applicant Types	5			
Funding Limit	135,000.00 per year			
Limited Submission	No			
014681 Mentoring Award		American Contact Dermatitis Society	15-Oc	t-2024 3,000 USD
Contact Name				
Contact Telephone	414-918-9805			
Contact Email	info@contactderm.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			



SPIN ID Program Title	Sponsor Nam	ne	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL) 15-Oct-2024				
Synopsi	ACDS Mentoring Awards are g residents, dermatology fellow of contact dermatitis by acqui institutions. Funding may not	vs, or dermatologist up t iring additional academ	to 5 years out of residence ic skills which may not be	y to become leaders	s/experts in the field
Applicant Type	s				
Funding Limi	t 3,000.00 maximum				
Limited Submission	n No				
061455 Mid-Career Development Awa	<u>rd</u>	American Coi Society	ntact Dermatitis	15-0	ct-2024 10,000 USD
Contact Name	e				
Contact Telephone	e 414-918-9805				
Contact Ema	il info@contactderm.org				
Sponsor Website	e <u>Link to sponsor website</u>				
Program UR	L Link to program URL				
Deadline Dates (ALL) 15-Oct-2024				
The ACDS Mid Career Development Award provides financial support for ACDS members to defray the constant of th					of contact
Applicant Type	s				
Funding Limi	t 10,000.00 maximum				
Limited Submission	n No				
	•				



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
041210 Outcomes Research Award		American Contact Dermatitis Society	15-0	ct-2024 50,000 USD
Contact Name	2			
Contact Telephone	414-918-9805			
Contact Ema	info@contactderm.org			
Sponsor Websit	Link to sponsor website			
Program UR	Link to program URL			
Deadline Dates (ALL	15-Oct-2024			
	The American Contact Dermatitis Society			
Synopsi	management. Proposals may include inv value of expert specialist evaluation and centers with availability of extended pat subject to editorial review. Grants of \$10	l management of chronic dermatitis. I management of chronic dermatitis.	Proposals are expected rch will be published	ed from established in Dermatitis
Synopsi Applicant Type	value of expert specialist evaluation and centers with availability of extended path subject to editorial review. Grants of \$10	l management of chronic dermatitis. I management of chronic dermatitis.	Proposals are expected rch will be published	ed from established in Dermatitis
Applicant Type	value of expert specialist evaluation and centers with availability of extended path subject to editorial review. Grants of \$10	l management of chronic dermatitis. I management of chronic dermatitis.	Proposals are expected rch will be published	ed from established in Dermatitis
Applicant Type	value of expert specialist evaluation and centers with availability of extended path subject to editorial review. Grants of \$10 5 50,000.00 maximum	l management of chronic dermatitis. I management of chronic dermatitis.	Proposals are expected rch will be published	ed from established in Dermatitis
Applicant Type Funding Limi Limited Submission	value of expert specialist evaluation and centers with availability of extended path subject to editorial review. Grants of \$10 50,000.00 maximum No <u>ctoral Training in Geroscience (HF-PTG)</u>	l management of chronic dermatitis. I management of chronic dermatitis.	Proposals are expecter rch will be published study interval of up to	ed from established in Dermatitis
Applicant Type Funding Limi Limited Submission 126693 Hevolution Foundation Postdo	value of expert specialist evaluation and centers with availability of extended path subject to editorial review. Grants of \$10 50,000.00 maximum No ctoral Training in Geroscience (HF-PTG)	I management of chronic dermatitis. cch test series. Results from the resea 0,000-\$50,000 will be awarded for a s American Federation for Aging	Proposals are expecter rch will be published study interval of up to	ed from established in Dermatitis o 24 months. ct-2024 ^{Not}
Applicant Type Funding Limi Limited Submission 126693 <u>Hevolution Foundation Postdo</u> <u>Program</u>	value of expert specialist evaluation and centers with availability of extended path subject to editorial review. Grants of \$10 50,000.00 maximum No <u>ctoral Training in Geroscience (HF-PTG)</u>	I management of chronic dermatitis. cch test series. Results from the resea 0,000-\$50,000 will be awarded for a s American Federation for Aging	Proposals are expecter rch will be published study interval of up to	ed from established in Dermatitis o 24 months. ct-2024 ^{Not}
Applicant Type Funding Limi Limited Submission 126693 <u>Hevolution Foundation Postdo</u> <u>Program</u> Contact Name Contact Telephone	value of expert specialist evaluation and centers with availability of extended path subject to editorial review. Grants of \$10 50,000.00 maximum No <u>ctoral Training in Geroscience (HF-PTG)</u>	I management of chronic dermatitis. cch test series. Results from the resea 0,000-\$50,000 will be awarded for a s American Federation for Aging	Proposals are expecter rch will be published study interval of up to	ed from established in Dermatitis o 24 months. ct-2024 ^{Not}
Applicant Type Funding Limi Limited Submission 126693 <u>Hevolution Foundation Postdo</u> <u>Program</u> Contact Name Contact Telephone Contact Emai	value of expert specialist evaluation and centers with availability of extended path subject to editorial review. Grants of \$10 50,000.00 maximum No <u>ctoral Training in Geroscience (HF-PTG)</u>	I management of chronic dermatitis. cch test series. Results from the resea 0,000-\$50,000 will be awarded for a s American Federation for Aging	Proposals are expecter rch will be published study interval of up to	ed from established in Dermatitis o 24 months. ct-2024 ^{Not}



SPIN ID	Program Title	Sponsor Nar	ne	Sponsor Number	Deadline Date	Funding Amour
	Deadline Dates (ALL)	30-Oct-2024				
	Synopsis	Hevolution Foundation Posto MD/PhD students who want Hevolution Foundation will c early 2025. Applicants must b the fellowship (earliest gradu fund individuals for up to 4 y Applicants must be current re projects in any of these coun	to pursue postdoctoral ommit up to \$5M USD o be doctoral students whe lation date: May 2024, la ears including salary and esidents of the United St	research training in the k ver a period of 4 years a o have finished their PhE atest graduation date: M I funds for consumables	biology of aging or ge nd anticipates fundir O or MD/PhD studies larch 2025). The HF-F and a limited annual	eroscience. The ng 12-15 trainees in prior to the start o PTG Program will child allowance.
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
000680 [Established Investigator Award		American He	art Association	02-0 [LOI/ App]	USD
	Contact Name					
	Contact Telephone	214-360-6107, option 1				
	Contact Email	apply@heart.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	02-Oct-2024 [LOI/Pre-App], ()8-Jan-2025			
	Synopsis	The Established Investigator accomplishments and showin cardiovascular or cerebrovas	ng extraordinary promise	e. Candidates will have a	demonstrated comm	nitment to



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit Limited Submission	publication history and scientific accomplish direction that challenges existing paradigms 110,000.00 per year No			
017287		for Excellence in Metabolism Research Am	erican Heart Association	09-0	ct-2024 500 USD
	Contact Name				
	Contact Telephone	214-570-5935			
	Contact Email	professional.help@heart.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	09-Oct-2024			
	Synopsis	The Fellowship Award for Excellence in Met young investigators to the EPI/Lifestyle Scie achieving the highest average scores of all a Lipids/Lipoproteins, Metabolism, and Obesi entries for consideration include broad cate small metabolic studies, small clinical trials, \$500 and a certificate.	ntific Sessions. Up to three awards abstracts submitted in the categorie ty and Adipose Tissue Distribution of gories of study designs, including h	will be given for the es of Diabetes/Meta or Lipids and Lipopr Juman or laboratory	e abstracts bolic Syndrome, oteins. Acceptable r-based research,
	Applicant Types				
	Funding Limit	500.00 see detail			
	Limited Submission	No			
		Am	erican Neurogastroenterology		

030379 ANMS Discovery Grants Program

American Neurogastroenterology and Motility Society

11-Oct-2024 30,000 USD



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
Contact Name	Shanthi Srinivasan						
Contact Telephone							
Contact Emai	ssrini2@emory.edu						
Sponsor Website	Link to sponsor website						
Program URI	Link to program URL						
Deadline Dates (ALL)	11-Oct-2024						
Synopsis	senior GI fellows, postdoctoral re- research careers in the area of ne be awarded in 2023 for qualified a faculty (with no prior or current in	ANMS is accepting grant applications as part of the ANMS Discovery Grants Program. They will provide support for senior GI fellows, postdoctoral research fellows, or Instructor/Assistant Professor-level faculty who are pursuing research careers in the area of neurogastroenterology and GI motility. Up to two grants of up to \$30,000 each will be awarded in 2023 for qualified applicants including senior GI fellows, postdoctoral research fellows, or junior faculty (with no prior or current independent grant funding, i.e. PI status on an R level grant) pursuing projects spanning basic science, translational investigation, and clinical research pertaining to neurogastroenterology and GI motility.					
Applicant Types	5						
Funding Limit	30,000.00 maximum						
Limited Submission	No						
022277 Biotechnology Division Studen	t Excellence Award	American Oil	Chemists' Society	14-00	ct-2024 500 USD		
Sponsor Website	awards@aocs.org Link to sponsor website Link to program URL						



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Biotechnology Division Student Ex poster presentations within the Biotec	dents presenting ou Annual Meeting.	tstanding oral or	
	Applicant Types				
	Funding Limit	500.00 see detail			
	Limited Submission	No			
022295	Health and Nutrition Division St	udent Excellence Award	American Oil Chemists' Society	14-00	ct-2024 500 USD
	Contact Name				
	Contact Telephone				
	Contact Email	awards@aocs.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-Oct-2024			
	Synopsis	The Health and Nutrition Division Stud oral or poster presentation within the	ent Excellence Award recognizes gradua Health and Nutrition technical program	ate students present at the AOCS Annual	ing an outstanding Meeting.
	Applicant Types				
	Funding Limit	500.00 see detail			
	Limited Submission	No			
065572	ARRS Scholarship		American Roentgen Ray Society	07-00	ct-2024 180,000 USD
	Contact Name				
	Contact Telephone	866-940-2777			
	Contact Email	scholarshing @arrs arg			

Contact Email <u>scholarships@arrs.org</u>



SPIN ID	Program Title		Sponsor Name	Sponsor	r Number	Deadline Date	Funding Amoun	nt		
	Sponsor Website	Link to sponsor website								
		Link to program								
	Deadline Dates (ALL)	07-Oct-2024								
Synopsis The ARRS Scholarship supports early-career faculty members in study/research in the radiologic science possibility of changing the way radiology is practiced. The Scholarship is a two-year program, totaling s								e		
	Applicant Types									
	Funding Limit	180,000.00 see	detail							
	Limited Submission	Yes								
058656 (Carl Koller Memorial Research	<u>Grant</u>		erican Society of Re esthesia and Pain M	-	01-Oc [LOI/P App]	t-2024 re- 75,000 US	SD		
	Contact Name									
	Contact Telephone	412-471-2718								
	Contact Email	asraassistant@asra.com								
	Sponsor Website	Link to sponsor	website							
	Program URL	Link to program	<u>ı URL</u>							
	Deadline Dates (ALL)	01-Oct-2024 [LOI/Pre-App], 10-Jan-2025								
	Synopsis	The Carl Koller Memorial Research Grant supports clinical and laboratory studies related to any aspect of regional anesthesia and analgesia and their application to surgery. The amount of the award will not exceed \$75,000.								
	Applicant Types									
	Funding Limit	75,000.00 maxi	mum							
	Limited Submission	No								



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
045646 Research Grants		Aplastic Anemia and MDS International Foundation, Inc.	31-Oct-2	2024 60,000 USE
Contact Nam	ne			
Contact Telephor	ne 800-747-2820			
Contact Ema	ail <u>houk@aamds.org</u>			
Sponsor Websi	te Link to sponsor website			
Program UI	RL Link to program URL			
Deadline Dates (AL	L) 31-Oct-2024			
Superior	The Aplastic Anemia and MDS Interna		-	-
Synop:	marrow disorders in both pediatric an	ilure and advancing the understandin d adult populations.	g, prevention and treatm	ent of bone
Applicant Type	marrow disorders in both pediatric an	-	g, prevention and treatm	ent of bone
Applicant Typ	marrow disorders in both pediatric an	-	g, prevention and treatm	nent of bone
Applicant Typ	marrow disorders in both pediatric an es it 30,000.00 per year	-	g, prevention and treatm	ent of bone
Applicant Type Funding Lim	marrow disorders in both pediatric an es it 30,000.00 per year	-	g, prevention and treatm	100.000
Applicant Type Funding Lim Limited Submissio	marrow disorders in both pediatric an es hit 30,000.00 per year on Yes	d adult populations. Association for Research in Vision		2024 100,000
Applicant Type Funding Lim Limited Submissio 049880 <u>Dr. David L. Epstein Award</u>	marrow disorders in both pediatric an es nit 30,000.00 per year on Yes	d adult populations. Association for Research in Vision		2024 100,000
Applicant Type Funding Lim Limited Submissio 049880 <u>Dr. David L. Epstein Award</u> Contact Nam Contact Telephor	marrow disorders in both pediatric an es nit 30,000.00 per year on Yes	d adult populations. Association for Research in Vision		2024 100,000
Applicant Type Funding Lim Limited Submissio 049880 <u>Dr. David L. Epstein Award</u> Contact Nam Contact Telephor Contact Ema	marrow disorders in both pediatric an es nit 30,000.00 per year on Yes ne 240-221-2900	d adult populations. Association for Research in Vision		2024 100,000
Applicant Type Funding Lim Limited Submissio 049880 <u>Dr. David L. Epstein Award</u> Contact Nam Contact Telephor Contact Ema Sponsor Websi	marrow disorders in both pediatric an es ait 30,000.00 per year on Yes 240-221-2900 ail <u>awards@arvo.org</u>	d adult populations. Association for Research in Vision		2024 100,000



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Synopsis	The Dr. David L. Epstein Award was c scientific understanding and cure of research environments. It is the inter and interest in solving the complex is focused on finding the causes and ne	glaucoma through nt of the donors t ssues of glaucoma	n the support of promisin hat this award further Dr through well-conceived	ng clinician-scientist . Epstein's long-star and executed scien	s in exceptional nding determination tific research
Applicant Types					
	100,000.00 maximum				
Limited Submission	No				
031426 Carl Camras Translational Rese	arch Awards	Association fo and Ophthalm	r Research in Vision ology	01-00	ct-2024 12,000 USD
Contact Name					
Contact Telephone					
Contact Email	arvo@arvo.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Oct-2024				
Synopsis	The Carl Camras Translational Resear research and honors Dr. Carl Camras scientist. An award of \$12,000 will be	, who is highly res		-	
Applicant Types					
Funding Limit	12,000.00 maximum				
Limited Submission	No				
089931 PhD Fellowships		Boehringer Ing	gelheim Fonds	01-00	t-2024 Not Specified



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Name					
	Contact Telephone	+49 (0)6131 2750 80				
	Contact Email	secretariat@bifonds.de				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Oct-2024				
	Synopsis	The Boehringer Ingelheim Fonds (BI worldwide who wish to pursue an ar laboratory.	-			
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
099223 -	National Glaucoma Research Pi Awards	rogram Postdoctoral Fellowship	BrightFocus F	oundation	31-Oct-	2024 150,000 USD
	Contact Name					
	Contact Telephone	1-800-437-2423				
	Contact Email	researchgrants@brightfocus.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	31-Oct-2024				
	Synopsis	BrightFocus provides research funds greater understanding, prevention, a young researchers in their final stage	and treatment of	glaucoma. Postdoctoral fe	llowship awards are	intended for



SPIN ID Program Title	Sponsor Name	•	Sponsor Number	Deadline Date	Funding Amount
	that will serve as the basis for the serve as the basis for the researchers within four years of eligibility period will be conside	f degree conferral or er	nd of residency or fellows		
Applicant Types					
	75,000.00 per year				
Limited Submission					
090492 Travel Awards	1	British Infectio	n Association	31-Oct-2	2024 1,280 USD
Contact Name	Profesor Thushan de Silva				
Contact Telephone					
Contact Email	scientificresearch@britishinfect	tion.org			
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	31-Oct-2024				
Synopsis	The British Infection Association international meetings (either i research, where the abstract is limit.	in person or on-line), in	particular, ASM, ICAAC, II	DSA, and ECCMID to	oresent original
Applicant Types					
Funding Limit	1,000.00 maximum				
Limited Submission	No				
013123 Career Awards for Medical Scie	entists (CAMS)	Burroughs We	llcome Fund	08-Oct-2	2024 700,000 USD
Contact Name					



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	919-991-5115					
	Contact Email	<u>lhaidar@bwfun</u>	d.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>I URL</u>				
	Deadline Dates (ALL)	08-Oct-2024					
	Synopsis	five years for p		who are committed	highly competitive progr d to an academic career, t of faculty service.		00,000 awards over
	Applicant Types						
	Funding Limit	700,000.00 see	detail				
	Limited Submission	No					
045538 [Partnering Opportunity For Clir	nical Trial Stage I	Projects (CLIN2)	California Inst Medicine	titute for Regenerative	30-Au 2024	ug- Not Specified
	Contact Name						
	Contact Telephone	510-340-9101					
	Contact Email	Clinical@cirm.c	a.gov				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>n URL</u>				
	Deadline Dates (ALL)	30-Aug-2024 , 3 30-May-2025 ,		ov-2024 , 30-Dec-20	024 , 31-Jan-2025 , 28-Fe	b-2025 , 31-Mar-202	5 , 30-Apr-2025 ,
	Synopsis	transformative objective of thi	regenerative medic s funding opportun	cine treatments in a triation to the second se	ledicine (CIRM) is to acce an equitable manner to a mpletion of a clinical trial lresses an unmet medica	diverse California an for a regenerative n	nd world. The nedicine-based



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		world-class subject matter experts to	will also devote significant internal resour actively advance the project. The result o both accelerates the program and gives it	of a successful applic	ation will be the
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
045367 <u>P</u>	artnering Opportunity for Late	e Stage Preclinical Projects (CLIN1)	California Institute for Regenerative Medicine	30-Au 2024	ıg- 6,000,000 USD
	Contact Name				
	Contact Telephone	510-340-9101			
	Contact Email	clinical@cirm.ca.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
		30-Aug-2024 , 31-Oct-2024 , 29-Nov-2 30-May-2025 , 30-Jun-2025	2024 , 30-Dec-2024 , 31-Jan-2025 , 28-Feb	o-2025 , 31-Mar-202	5 , 30-Apr-2025 ,
	Synopsis	transformative regenerative medicine objective of this program announcem active IND with the Food and Drug Ac a regenerative medicine therapy (ster funding agency, but will also devote s subject matter experts to actively adv	Regenerative Medicine (CIRM) is to accele e treatments in an equitable manner to a ment is to support late-stage preclinical stu- dministration (FDA) and initiate start-up ac m cell-based or genetic therapy). Under the significant internal resources and leverage vance the project. The result of a successful s the program and gives it the greatest op	diverse California an Idies necessary to fi ctivities to prepare f nis program, CIRM v its external team o ul application will bo	nd world. The le and attain an for a clinical trial for vill act not only as a f world-class e the formation of a
	Applicant Types				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit Limited Submission	6,000,000.00 maximum No			
004422	Research Chairs		Canada Research Chairs	22-0	ct-2024 1,008,000 USD
	Contact Name	Tamara Pyke			
	Contact Telephone	343-571-9650			
	Contact Email	tamara.pyke@chairs-chaires.gc.ca			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-Oct-2024			
	Synopsis	nominate a diverse cadre of outstan strategic research plan and enable training. Eligible postsecondary inst their researchers from the three fe	m (CRCP) offers eligible Canadian degree- nding researchers for professorships in are them to maximize their contributions as co itutions receive a set number of chair allo deral research granting agencies: the Cana gineering Council (NSERC); and the Social	eas that will further t entres of research ar cations based on the dian Institutes for H	he institution's Id research funding received b ealth Research
	Applicant Types				
	Funding Limit	200,000.00 per year			
	Limited Submission	No			
098717	Doctoral Research Award: Vani	er Canada Graduate Scholarships	Canadian Institutes of Health Research	30-0	ct-2024 108,000 USD
	Contact Namo				

Contact Name



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Contact Telephone	613-941-2672				
Contact Email	vanier@cihr-irsc.gc.ca				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	30-Oct-2024				
Synopsis	The Vanier Canada Graduate Scho and helps establish Canada as a g research in four broad themes: 1. Cultural, Environmental and Popu	lobal centre of excel Biomedical Research	llence in research and high n; 2.Clinical Research; 3.He	er learning. CIHR c	ategorizes health
Applicant Types					
Funding Limit	50,000.00 per year				
Limited Submission	No				
072353 Research Grants		CARB-X		04-00	ct-2024 Not Specified
Contact Name	Genevieve Holmes				
Contact Telephone					
Contact Email	<u>carbxpr@bu.edu</u>				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	04-Oct-2024				
Synopsis	The Combating Antibiotic-Resista solicitation with four distinct proc		naceutical Accelerator (CA	RB-X) announced t	oday a funding
Applicant Types					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit Limited Submission	0.00 not provided No			
114X547	Conquer Cancer Foundation Ca Palliative & Supportive Care	reer Development Award (CDA) in	Conquer Cancer Foundation of ASCO	17-00	ct-2024 200,000 USD
	Sponsor Website Program URL Deadline Dates (ALL)	571-483-1700 grants@conquer.org Link to sponsor website Link to program URL 17-Oct-2024 The Conquer Cancer Career Developn investigators who have received their program with a focus on palliative and	nent Award (CDA) in Palliative & Support initial faculty appointment to establish a d supportive care. This is a mentored awa ientific mentor. Applications in all areas o	an independent clinic ard and the research	cal cancer research project is
	Applicant Types Funding Limit Limited Submission	200,000.00 maximum			
003893	Grants Program		Cummings (Frances L. & Edwin L.) Memorial Fund	01-00	ct-2024 Not Specified
	Contact Telephone	Elizabeth H. Costas 212-286-1778 info@cummingsfund.org			



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Sponsor Website	Link to sponsor	website			
Program URL	Link to program	<u>I URL</u>			
Deadline Dates (ALL)	01-Oct-2024				
Synopsis	The primary interest of the Frances L. & Edwin L. Cummings Memorial Fund is to support organizations operati ynopsis New York City and Northeastern New Jersey that provide programs and services in the areas of social welfare, education, and health. The Fund has a special interest in youth programs located in these regions.				
Applicant Types					
Funding Limit	0.00 not provid	ed			
Limited Submission	Yes				
002586 Grants Program		Cure Parkinso	ns Trust	21-Oct	t-2024 320,000 USD
Contact Name	Rosie Fuest, Res	search Manager			
Contact Telephone	0207 487 3892				
Contact Email	Rosie@curepar	<u>kinsons.org.uk</u>			
Sponsor Website	Link to sponsor	website			
Program URL	Link to program	<u>I URL</u>			
Deadline Dates (ALL)					
Synopsis	Parkinson's. For likely to lead to	e primarily funds preclinical and clinica r preclinical research, the sponsor func clinical trials in people with Parkinson tudies of trials in people with Parkinso	ls grants up to £250,000 (G 's within 5 years. For clinica	BP) and prioritise p	projects that are
Applicant Types					
Funding Limit	250,000.00 see	detail			



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Limited Submission	,			
117011 Pathway and Pipeline Grant Prog	am CureP	SP	03-0	ct-2024 100,000 USD
Contact Name J	nnifer Brummet			
Contact Telephone 8	0-457-4777			
Contact Email	ummet@curepsp.org			
Sponsor Website <u>I</u>	<u>k to sponsor website</u>			
Program URL <u>I</u>	k to program URL			
Deadline Dates (ALL) (-Oct-2024			
Synopsis i	rough the Pathway and Pipeline Grant prog novative ideas that need proof of concept of ovides grants to scientists of up to \$100,000	pilot studies in order to qualify		
Applicant Types				
Funding Limit	0,000.00 maximum			
Limited Submission				
024444 Research Fellowship Awards	Cystic	Fibrosis Canada	01-0	ct-2024 64,800 USD
Contact Name				
Contact Telephone				
Contact Email <u>r</u>	search@cysticfibrosis.ca			
Sponsor Website <u>I</u>	<u>k to sponsor website</u>			
Program URL <u>I</u>	k to program URL			
Deadline Dates (ALL)	-Oct-2024			



SPIN ID Program Title	Sponsor Nan	ne Sponsor Nu	mber Deadline Date	Funding Amount
Synopsi Applicant Type Funding Limi	^s fellows who are undertaking	are awarded to build capacity in CF re fulltime research training in areas rele		ng highly qualified
Limited Submission	n No			
020318 DFF-Research Project 2 - Medi	cal Sciences	Danish Agency for Science a Higher Education	and 08-	Oct-2024 602,000 USD
Contact Name	e			
Contact Telephon	e			
Contact Ema	il <u>DFF-opslag@ufm.dk</u>			
Sponsor Website	e Link to sponsor website			
Program UR	L Link to program URL			
Deadline Dates (ALL) 08-Oct-2024			
Synopsi	carried out by multiple resear s duration within a budget fran expenses. DFF Medical Scien	d develop collaboration within Danish rchers (including postdoctoral candida nework of between DKK 2,000,000 to nces offers funding to researchers wh earch in relation to human health and	ites and PhD students) of up DKK 4,300,000, excluding ove o work with all aspects of bas	to 4.5 years in erhead/administration
Applicant Type	s			
Funding Limi	t 4,300,000.00 maximum			
Limited Submission	n No			
020313 Sapere Aude: DFF- Starting Gr	ant	Danish Agency for Science a Higher Education	and 08-	Oct-2024 602,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name				
	Contact Telephone				
	Contact Email	DFF-opslag@ufm.dk			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Oct-2024			
	Synopsis	The Danish Council for Independent Resea outstanding research results in the field of strengthen their research ideas. DFF expect to apply for an ERC Starting Grant/Consoli	Medical Sciences and gives them an ts that a Sapere Aude: DFF–Starting	opportunity to dev Grant will help to er	elop and nable the applicant
	Applicant Types				
	Funding Limit	4,300,000.00 maximum			
	Limited Submission	No			
020349	DFF-Research Project 2 – Huma	nities	nish Agency for Science and gher Education	08-Oc	t-2024 602,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	DFF-opslag@ufm.dk			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Oct-2024			
	Synopsis	To advance the quality of, and develop col research projects carried out by multiple research projects carried out			_



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Funding Amount
	1		
	4.5 years in duration within a budget overhead/administration expenses.	framework of between DKK 2,000,000 to	DKK 4,300,000, excluding
Applicant Types	;		
Funding Limit	4,300,000.00 see detail		
Limited Submission	No		
063107 Sarah K. deCoizart Perpetual Cl	haritable Trust - Grants Program	deCoizart (Sarah K.) Perpetual Charitable Trust	01-Oct-2024 Not Specified
Contact Name	Lindsey Crane, Program Officer		
Contact Telephone			
Contact Email	lindsey.s.crane@jpmorgan.com		
Sponsor Website	Link to sponsor website		
Program URL	Link to program URL		
Deadline Dates (ALL)	01-Oct-2024		
Synopsis	The Sarah K. de Coizart Perpetual Cha blindness. Grants range in size from \$	ritable Trust awards grants focusing on s 20,000 to \$75,000 per year.	pecies conservation and
Applicant Types	;		
Funding Limit	0.00 see detail		
Limited Submission	No		
009823 Research Career Development	Award	Dermatology Foundation	15-Oct-2024 USD
Contact Name			
Contact Telephone	847-328-2256		
Contact Email	DFRAP@dermatologyfoundation.org		



SPIN ID Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Sponsor Website	Link to sponsor	website				
Program UR	L Link to program	<u>ı URL</u>				
Deadline Dates (ALL) 15-Oct-2024					
Synopsi	The Research Ca investigator. It p	areer Development Aw provides career develop	ard (CDA) assist	s an individual in the trans in skin research for a junior	ition from fellowsh ⁻ investigator.	ip to established
Applicant Type	s					
Funding Limi	t 75,000.00 per y	ear				
Limited Submission	n No					
065628 Science of Human Appearance	Career Developr	ment Award	Dermatology I	Foundation	01-Oct	-2024 75,000 USD
Contact Name	e					
Contact Telephone	e 847-328-2256					
Contact Emai	il <u>dfrap@dermatc</u>	ologyfoundation.org				
Sponsor Website	E Link to sponsor	<u>website</u>				
Program UR	L Link to program	<u>URL</u>				
Deadline Dates (ALL) 01-Oct-2024 , 0	1-Nov-2024				
Synopsi	development of s or of therapeut and the paucity	f individuals who wish t ic interventions. This Cl	to understand th DA recognizes th h in the area. Th	nt Award provides annual ne cell and molecular mech ne specialty's sizeable incre nis award is intended to su ntal factors.	nanisms of altered h ease in focus on hur	numan appearance man appearance
Applicant Type	s					
	t 75,000.00 per y	rear				
Limited Submission	n No					



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
020274 Dermatologist Investigator Res	earch Fellowship	Dermatology Foundation	15-Oc	t-2024 35,000 USD		
Contact Name						
Contact Telephone						
Contact Email	dfrap@dermatologyfoundation.org					
Sponsor Website	Link to sponsor website					
Program URL	Link to program URL					
Deadline Dates (ALL)	15-Oct-2024					
Synopsis	The Dermatology Foundation offers a fellowship that is intended to advance the research careers of individuals i early stages of career development. Each awarded fellowship, in the amount of \$35,000, provides an annual sala stipend and is not intended for faculty.					
Applicant Types						
Funding Limit	35,000.00 per year					
Limited Submission	No					
009821 Research Grants Award		Dermatology Foundation	15-Oc	ct-2024 25,000 USD		
Contact Name						
Contact Telephone	847-328-2256					
Contact Email	DFRAP@dermatologyfoundation.org					
Sponsor Website	Link to sponsor website					
Program URL	Link to program URL					
Deadline Dates (ALL)	15-Oct-2024					
Synopsis		vide an annual award of \$25,000 in finantiat benefit the dermatology community a		earch projects in		
Applicant Types						



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit Limited Submission	25,000.00 per year No			
120954	Diversity, Equity, and Inclusion	Career Development Award	Dermatology Foundation	15-0	ct-2024 150,000 USD
	Contact Name				
	Contact Telephone	847-328-2256			
	Contact Email	dfrap@dermatologyfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Oct-2024			
	Synopsis	impacting groups underrepresented minorities; Sexual and gender mino	unces a new Career Development Award t d or underserved in medicine, including, b rities; and Underserved/disadvantaged po U.S. under the sponsorship of a departme rmatology.	ut not limited to: Rac opulations. All Found	ial and ethnic ation-funded
	Applicant Types				
	Funding Limit	75,000.00 per year			
	Limited Submission	No			
084748	Women's Health Career Develo	ppment Award	Dermatology Foundation	15-0	ct-2024 150,000 USD
	Contact Name				
	Contact Telephone	847-328-2256			

Contact Email dfrap@dermatologyfoundation.org



SPIN ID Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Sponsor Website	Link to sponsor	website				
Program URI	Link to program	URL				
Deadline Dates (ALL) 15-Oct-2024					
Synopsis	research is need funding. CDAs of	ed. Career developm	ent awards (CDA stipend of \$75,00	tended to focus on wome s) may be renewed annua 00 that can be supplement n the institution.	lly for up to a total	of two years of
Applicant Type	5					
Funding Limi	t 75,000.00 per ye	ear				
Limited Submissior	No					
069351 Clinical Career Development A	ward in Dermatol	ogic Surgery	Dermatology I	Foundation	15-Oct	t-2024 Not Specified
Contact Name	2					
Contact Telephone	847-328-2256					
Contact Emai	l <u>dfrap@dermato</u>	logyfoundation.org				
Sponsor Website	Link to sponsor v	<u>website</u>				
Program URI	Link to program	URL				
Deadline Dates (ALL) 15-Oct-2024					
	practice of derm surgeons. Projec management, M complications, p	atologic surgery and ts may include but ar lohs micrographic sur	develops the tea e not limited to: gery, Mohs labo	l supports a broad range o ching, research and/or lea study of skin cancers, trea ratory techniques, reconst ery, and noninvasive imagin	dership abilities of atment outcomes, s ruction, wound hea	dermatologic urgical
Applicant Type	5					



SPIN ID	Program Title	Sponsor Name	2	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 see detail				
	Limited Submission	No				
004728	Medical Dermatology Career D	evelopment Award	Dermatology	Foundation	15-0	ct-2024 165,000 USD
	Contact Name					
	Contact Telephone	847-328-2256				
	Contact Email	dfrap@dermatologyfoundatior	n.org			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Oct-2024				
	Synopsis	The Medical Dermatology Care educators, and clinical scholars fosters the careers of young de diagnosing and treating comple	in that aspect of the rmatologists who will	specialty that addresses	severe dermatologic	disease. The award
	Applicant Types					
	Funding Limit	55,000.00 per year				
	Limited Submission	No				
057701	Patient Directed Investigation (<u>Grant</u>	Dermatology	Foundation	15-0	ct-2024 20,000 USD
	Contact Name					
	Contact Telephone	847-328-2256				
	Contact Email	dfrap@dermatologyfoundatior	1.org			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				



SPIN ID Program Title	Sponsor Name	e	Sponsor Number	Deadline Date	Funding Amount	
Deadline Dates (ALL)	15-Oct-2024					
The Dermatology Foundation's Patient Directed Investigation Grant exists to support translational studies that ha Synopsis the potential to benefit patients directly. Such studies may concern medical dermatology, dermatologic surgery, procedural dermatology, pediatric dermatology, or other aspects of the specialty that impact patient care.						
Applicant Types						
Funding Limit	20,000.00 per year					
Limited Submission	No					
084816 Patient Directed Investigation C	<u>Grant</u>	Dermatology F	oundation	15-Oc	t-2024 25,000 USD	
Contact Name						
Contact Telephone	847-328-2256					
Contact Email	dfrap@dermatologyfoundation	n.org				
Sponsor Website	Link to sponsor website					
Program URL	Link to program URL					
Deadline Dates (ALL)	15-Oct-2024					
Synopsis	The Patient Directed Investigat patients directly. Dermatology				tial to benefit	
Applicant Types						
Funding Limit	25,000.00 maximum					
Limited Submission	No					
003290 Physician Scientist Career Deve	lopment Award	Dermatology F	oundation	15-Oc	t-2024 165,000 USD	
Contact Name						
Contact Telephone	847-328-2256					



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Contact Email	dfrap@dermatologyfoundation	.org			
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Oct-2024				
Synopsis	The Physician Scientist CDA sup dermatology, and assists in the academic investigator demonst	transition from fellows	ship to established invest	gator. This award is	
Applicant Types					
Funding Limit	55,000.00 per year				
Limited Submission	No				
042778 Dermatopathology Research Ca	areer Development Award	Dermatology F	Foundation	15-00	t-2024 110,000 USD
Contact Name					
Contact Telephone	847-328-2256				
Contact Email	dfrap@dermatologyfoundation	.org			
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Oct-2024				
Synopsis	The Dermatopathology Career intellectual leaders who demor dermatology through research	strate a strong commi		•	
Applicant Types					
Funding Limit	55,000.00 per year				



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Limited Submission	No			
014221 Public Health Career Developm	ent Award	Dermatology Foundation	15-0	ct-2024 75,000 USD
Contact Name				
Contact Telephone	847-328-2256			
Contact Email	dfrap@dermatologyfoundation.org	g		
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	15-Oct-2024			
Synopsis	health. Research proposals may co	nent Award supports the establishment a incern health care policy, epidemiologica n system development, teledermatology	I research, outcome st	udies, comparative
Applicant Types				
Funding Limit	75,000.00 per year			
Limited Submission	No			
121027 Type 1 Diabetes Research Gran	t Program	Diabetes Research Connection	15-0	ct-2024 75,000 USD
Contact Name				
Contact Telephone	844-484-3372			
Contact Email	research@diabetesresearchconnec	ction.org		
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	15-Oct-2024			



SPIN ID	Program Title	Sponsor Name	Sponsor Numbe	er Deadline	Date Fund	ing Amount
		The Diabetes Research Connection give	es early-career scientists the onr	ortunity to perform	innovative tvn	e 1 diabetes
	Synopsis	research in the broad areas of cure and		forcanity to perform		
	Applicant Types					
	Funding Limit	75,000.00 maximum				
	Limited Submission	No				
175973 -	Mission: A Soil Deal For Europe Healthy Soils	Living Labs in Urban Areas for	European Commission	HORIZON- MISS-2024- SOIL-01-02	08-Oct-2024	13,080,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	See notes for contact information.				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Oct-2024				
	Synopsis	Proposals are invited against the follow Healthy Soils The topic is part of the c of Mission 'A Soil Deal for Europe' The	all: Research and Innovation and	other actions to su	pport the imple	
	Applicant Types					
	Funding Limit	12,000,000.00 on average				
	Limited Submission	No				
1/59/0	<u> Mission: A Soil Deal For Europe</u> n Living Labs	Co-Creating Solutions for Soil Health	European Commission	HORIZON- MISS-2024- SOIL-01-01	08-Oct-2024	13,080,000 USD



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Name					
	Contact Telephone					
	Contact Email	See notes for contact information.				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Oct-2024				
	Synopsis	Proposals are invited against the follo Health in Living Labs The topic is par implementation of Mission 'A Soil De	t of the call: Res	earch and Innovation and	other actions to	support the
	Applicant Types					
	Funding Limit	12,000,000.00 on average				
	Limited Submission	No				
175430	Mission: A Soil Deal For Europe Potential of Soil Biodiversity for	e Harnessing the Multifunctional r Healthy Cropping Systems	European Con	nmission MI	DRIZON- ISS-2024- 08- IIL-01-06	-Oct-2024 8,720,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	See notes for contact information.				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Oct-2024				
	Synopsis	Proposals are invited against the follo Potential of Soil Biodiversity for Healt			-	



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Dat	te Funding Amount
	other actions to support the implementation Mission: A Soil Deal for Europe	on of Mission 'A Soil Deal for Europ	pe' The call contri	butes to the EU
Applicant Types				
Funding Limit	8,000,000.00 on average			
Limited Submission	No			
125926 Mission: A Soil Deal For Europe and Uncertainties in European	e Systems To Quantify Nitrogen Fluxes Landscapes	opean Commission	HORIZON- MISS-2024- 0 SOIL-01-04	8-Oct-2024 12,535,000 USD
Contact Name				
Contact Telephone				
Contact Email	See notes for contact information.			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	08-Oct-2024			
Synopsis	Proposals are invited against the following Fluxes and Uncertainties in European Lands actions to support the implementation of N Soil Deal for Europe	scapes The topic is part of the cal	I: Research and Ir	novation and other
Applicant Types				
Funding Limit	11,500,000.00 on average			
Limited Submission	No			
125869 Mission: A Soil Deal For Europe	e Assessment of Soil Health in Africa Eur	opean Commission	HORIZON- MISS-2024- 0 SOIL-01-09	8-Oct-2024 7,630,000 USD



SPIN ID	Program Title	S	ponsor Name		Sponsor Number	Deadline D	Date	Funding Amount
	Contact Name							
	Contact Telephone							
	Contact Email	See notes for con	tact information.					
	Sponsor Website	Link to sponsor w	<u>ebsite</u>					
	Program URL	Link to program U	<u>JRL</u>					
	Deadline Dates (ALL)	08-Oct-2024						
	Synopsis	Africa The topic	is part of the call: Res	earch and Inno	IZON-MISS-2024-SOIL-01 vation and other actions the EU Mission: A Soil D	to support th	e implen	
	Applicant Types							
	Funding Limit	7,000,000.00 on a	average					
	Limited Submission	No						
1/6665	U4Health Programme (EU4H) iteracy for Cancer Prevention			European Con	nmission	J4H-2024- I-02-2	10-Oct-	2024 1,090,000 USD
	Contact Name							
	Contact Telephone							
	Contact Email	HADEA-HP-CALLS	@ec.europa.eu					
	Sponsor Website							
	Program URL	Link to program L	<u>JRL</u>					
	Deadline Dates (ALL)	10-Oct-2024						
	Synopsis				H-2024-PJ-02-2 Call for c is part of a call for prop			



SPIN ID	Program Title	Sponsor Name	Sponsor Numbe	er Deadline Date	Funding Amount
		health under the EU4Health Programm			4 Work Programme
		and will be managed by the European H	lealth and Digital Executive Age	ncy, (HaDEA).	
	Applicant Types				
	Funding Limit	1,000,000.00 see detail			
	Limited Submission	No			
125928	Aission: A Soil Deal For Europe Cosystem Functions	Soil Health, Pollinators and Key	European Commission	HORIZON- MISS-2024- 08- SOIL-01-05	Oct-2024 8,175,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	See notes for contact information.			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Oct-2024			
	Synopsis	Proposals are invited against the follow Ecosystem Functions The topic is part implementation of Mission 'A Soil Deal	of the call: Research and Innova	ation and other actions to	support the
	Applicant Types				
	Funding Limit	7,500,000.00 on average			
	Limited Submission	No			
26667	U4Health Programme (EU4H) Development of Social Services		European Commission	EU4H-2024- PJ-02-3 10-	Oct-2024 4,033,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor Numbe	er Deadline I	Date Fund	ing Amount
-		ountries Associated to the EU4Health				
	Programme - CR-g-24-43					
	Contact Name					
	Contact Telephone					
	Contact Email	HADEA-HP-CALLS@ec.europa.eu				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Oct-2024				
	Synopsis	Proposals are invited against the follow Social Services for Psychosocial Suppor Clinics in Member States and Countries call for proposals for EU action grants i launched in accordance with the 2024 Executive Agency, (HaDEA).	t and Rehabilitation for Childrer S Associated to the EU4Health Pi n the field of health under the E	n and Their Families ir rogramme - CR-g-24-4 U4Health Programme	n Paediatric O 43 This topic is e (EU4H). The	ncology s part of a call is
	Applicant Types					
	Funding Limit	3,700,000.00 see detail				
	Limited Submission	No				
176661	EU4Health Programme (EU4H) Youth Cancer Survivors - CR-g-2	Call for Proposals on EU Network of 24-45	European Commission	EU4H-2024- PJ-02-4	10-Oct-2024	5,450,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website	HADEA-HP-CALLS@ec.europa.eu				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amou
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Oct-2024				
	Synopsis	Proposals are invited against the follo Cancer Survivors - CR-g-24-45 This top the EU4Health Programme (EU4H). Th managed by the European Health and	pic is part of a call ne call is launche	ll for proposals for EU a d in accordance with th	action grants in the fi	eld of health unde
	Applicant Types					
	Funding Limit	5,000,000.00 see detail				
	Limited Submission	Νο				
126663	EU4Health Programme (EU4H) Integration of Cancer Images In Infrastructure to Foster Screeni	to the Federated Pan-European	European Com	nmission	EU4H-2024- 10-C PJ-02-1 10-C	0ct-2024 4,360,00 USD
	Contact Name					
	Contact Telephone					
	Contact Email	HADEA-HP-CALLS@ec.europa.eu				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Oct-2024				
	Synopsis	Proposals are invited against the follor Cancer Images Into the Federated Par topic is part of a call for proposals for The call is launched in accordance with Digital Executive Agency, (HaDEA).	n-European Infra EU action grants	structure to Foster Scro in the field of health u	eening Programmes - Inder the EU4Health	- CR-g-24-37 This Programme (EU4F
	Applicant Types					



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Funding Limit	4,000,000.00 see detail			
Limited Submission	Νο			
019315 ESCMID Funded Observerships	•	n Society of Clinical plogy and Infectious	16-0	ct-2024 Not Specified
Contact Name				
Contact Telephone				
Contact Emai	info@escmid.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	16-Oct-2024			
Synopsis	ESCMID Funded Observerships provide participa knowledge with colleagues across the fields of C out 100 observerships per year, hosted across o reach up to 2K EUR, financially supports the obs	linical Microbiology (CM) an ur 123 ESCMID Collaborative	d Infectious Diseases	(ID). ESCMID gives
Applicant Types				
Funding Limit	0.00 see detail			
Limited Submission	No			
093882 Max Weber Fellowships	Europea	n University Institute	18-0	ct-2024 Not Specified
Contact Name				
Contact Telephone	+39 055 4685 377			
· · · · · · · · · · · · · · · · · · ·				



SPIN ID Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Sponsor Websi	te Link to sponsor	website				
Program U	RL Link to program	<u>ı URL</u>				
Deadline Dates (AL	L) 18-Oct-2024					
Synops	sis the historical ar	r Programme (MWP) at the nd social sciences in Europe anywhere in the world, reg	e. It is open t	o applicants who are with		
Applicant Typ	es					
Funding Lin	nit 2,500.00 per m	onth				
Limited Submissio	on No					
010638 Central Fund Grants (October	<u>r Round)</u>	Fin	nnish Cultura	l Foundation	31-Oct	-2024 Not Specified
Contact Nan	ne					
Contact Telephor	ne +358 9 612 810					
Contact Ema	ail <u>apurahainfo@s</u>	<u>kr.fi</u>				
Sponsor Websi	te <u>Link to sponsor</u>	website				
-	RL Link to program	<u>i URL</u>				
Deadline Dates (AL	L) 31-Oct-2024					
Synops	sis from the Octob	tural Foundation awards grain er round of applications. In expenditure grant or a spe	the Octobe	r round of applications, it i	• •	•
Applicant Typ	es					
Funding Lin	nit 0.00 see detail					
Limited Submissio	on No					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
014087	Small Research Grant		Fisheries Society of the British Isles	01-00	ct-2024 9,600 USD
	Contact Name				
	Contact Telephone	02039253449			
	Contact Email	<u>theteam@fsbi.org.uk</u>			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024			
	Synopsis		esearch projects each year to support mem ogy and fisheries science that is relevant to ids for up to £7500 per project.	•	
	Applicant Types				
	Funding Limit	7,500.00 maximum			
	Limited Submission	No			
113739	Translational Research Accelera	ation Program (TRAP) Award	Foundation Fighting Blindness	17-00	ct-2024 Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	grants@fightingblindness.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Oct-2024			
	Synopsis	The Foundation Fighting Blindness s The Translational Research Accelera	eeks proposals toward the Translational R ation Program awards will accelerate the m	esearch Acceleration novement of preclini	n Program (TRAP). cal research towarc



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	•	an Investigational New Drug filing and into therapies to fight inherited retinal degene 0.00 see detail	-		potential
	Limited Submission				
025618	Traditional American Students	Awards Ex	oundation for Educational change Between Canada and the nited States of America	01-Oct	t-2024 25,000 USD
	Contact Name				
	Contact Telephone	613-688-5540			
	Contact Email	info@fulbright.ca			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024 , 08-Oct-2024			
	Synopsis	Traditional Fulbright Canada Student Awar graduate students, or promising young pro- research in Canada. Awards may be held a Canada. Explore a wide range of scholarly Canada, the United States, and to the rela- academic year (9 months). Grants begin in	ofessionals who wish to enroll in gradu at any university, research center, thin rissues, including important contempo tionship between the two countries. A	iate-level programs k tank, or governm prary issues that are	or conduct ent agency in e relevant to
	Applicant Types				
	Funding Limit	25,000.00 maximum			
	Limited Submission	No			



SPIN ID Pr	rogram Title	Spo	onsor Name	Sponsor Number	Deadline Date	Funding Amount
030560 <u>Ther</u>	rapeutic Pipeline Program		•	Michael J.) Foundation for nson's Research	03-00	ct-2024 2,000,000 USD
	Contact Name					
	Contact Telephone	212-509-0995				
	Contact Email	grants@michaeljfo	x.org			
	Sponsor Website	Link to sponsor wel	<u>bsite</u>			
	Program URL	Link to program UR	<u>RL</u>			
	Deadline Dates (ALL)	03-Oct-2024				
		The Dre clinical The	ranguties Dingling Dragra		dovolopmont through	nro-clinical and/o
	Synopsis	clinical testing of ap	pproaches addressing unn	n seeks to advance therapeutic let needs of people with Parkin o prevent, stop, or delay disease	son's disease (PD). The	e program is set up
	Synopsis Applicant Types	clinical testing of an to benefit theraped daily symptoms.	pproaches addressing unn	et needs of people with Parkin	son's disease (PD). The	e program is set up
	Applicant Types	clinical testing of an to benefit theraped daily symptoms.	pproaches addressing unn utics with clear potential to	et needs of people with Parkin	son's disease (PD). The	e program is set up
	Applicant Types	clinical testing of ap to benefit theraped daily symptoms. 2,000,000.00 see de	pproaches addressing unn utics with clear potential to	et needs of people with Parkin	son's disease (PD). The	e program is set up
000362 <u>Park</u>	Applicant Types Funding Limit	clinical testing of ap to benefit theraped daily symptoms. 2,000,000.00 see do No	pproaches addressing unn utics with clear potential to etail	et needs of people with Parkin	son's disease (PD). The e progression or to rec	e program is set up
000362 <u>Park</u>	Applicant Types Funding Limit Limited Submission	clinical testing of ap to benefit therapeu daily symptoms. 2,000,000.00 see do No	pproaches addressing unn utics with clear potential to etail	et needs of people with Parkin p prevent, stop, or delay disease	son's disease (PD). The e progression or to rec	e program is set up luce the burden of -t-2024 225,000
000362 <u>Park</u>	Applicant Types Funding Limit Limited Submission Ker B. Francis Fellowship Pro	clinical testing of ap to benefit therapeu daily symptoms. 2,000,000.00 see de No	pproaches addressing unn utics with clear potential to etail	et needs of people with Parkin p prevent, stop, or delay disease	son's disease (PD). The e progression or to rec	e program is set up luce the burden of -t-2024 225,000
000362 <u>Park</u>	Applicant Types Funding Limit Limited Submission Ker B. Francis Fellowship Pro Contact Name Contact Telephone	clinical testing of ap to benefit therapeu daily symptoms. 2,000,000.00 see de No	pproaches addressing unn utics with clear potential to etail Franc	et needs of people with Parkin p prevent, stop, or delay disease	son's disease (PD). The e progression or to rec	e program is set up luce the burden of -t-2024 225,000
000362 <u>Park</u>	Applicant Types Funding Limit Limited Submission Ker B. Francis Fellowship Pro Contact Name Contact Telephone Contact Email	clinical testing of ap to benefit therapeu daily symptoms. 2,000,000.00 see do No ogram 816-531-0077	pproaches addressing unn utics with clear potential to etail Franc	et needs of people with Parkin p prevent, stop, or delay disease	son's disease (PD). The e progression or to rec	e program is set up luce the burden of -t-2024 225,000
000362 <u>Park</u>	Applicant Types Funding Limit Limited Submission Ker B. Francis Fellowship Pro Contact Name Contact Telephone Contact Email Sponsor Website	clinical testing of ap to benefit therapeu daily symptoms. 2,000,000.00 see de No <u>ogram</u> 816-531-0077 <u>PBF@francisfounda</u>	pproaches addressing unn utics with clear potential to etail Franc <u>ation.org</u> <u>bsite</u>	et needs of people with Parkin p prevent, stop, or delay disease	son's disease (PD). The e progression or to rec	e program is set up luce the burden of -t-2024 225,000



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Synopsis	The Parker B. Francis Fellowship in investigators embarking on career are awarded to institutions for the support of qualified post-doctoral	s in pulmonary, crit purpose of provid	tical care and sleep medicining stipends, fringe benefit	ne. Parker B. Francis s, and modest trave	Fellowship grants
Applicant Types	5				
Funding Limit	75,000.00 per year				
Limited Submission	Yes				
113771 Postdoctoral Research Award		Friedreich's A Alliance	taxia Research	15-Aug 2024 [LOI/P App]	200,000
Contact Name	3				
Contact Telephone	484-879-6160				
Contact Email	info@curefa.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Aug-2024 [LOI/Pre-App], 15-Oc	ct-2024			
Synopsis	The Friedreich's Ataxia Research A young investigators in the FA bion year for one or two years.				•
Applicant Types	5				
Funding Limit	. 100,000.00 per year				
Limited Submission	No				



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
			15-Au	•
076236 General Research Grants		riedreich's Ataxia Research	2024	250,000
	А	lliance	[LOI/I App]	Pre- USD
			Abb]	
Contact Name				
Contact Telephone				
	grants@curefa.org			
	Link to sponsor website			
-	Link to program URL			
Deadline Dates (ALL)	15-Aug-2024 [LOI/Pre-App], 15-Oct-2024			
Synopsis	FARA supports research through funding for public-private partnerships that supports forums for leading scientists to share their ataxia. The applicant may request a budge	ort drug discovery, drug developmen r insights, ideas and challenges to ac	t and clinical researc	h and hosting open
Applicant Types				
Funding Limit	125,000.00 per year			
Limited Submission	No			
098050 Ignacio H. de Larramendi Resea	arch Grants Fu	undación MAPFRE	07-00	t-2024 Not Specified
Contact Name				
Contact Telephone	(+34) 91.581.23.45			
Contact Email	becasyayudas@fundacionmapfre.org			
Sponsor Website	Link to sponsor website			
Program URI	Link to program URL			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Deadline Dates (ALL)	07-Oct-2024				
	Synopsis	In 2024, Fundación MAPFRE has annou with the aim of financially supporting re awarded up to a maximum gross value up to a maximum gross value of 15,000	esearch projects in the following area of 30,000 euros each. Insurance and	as: Health Promotion: Social Protection: gra	grants will be	
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
025936	Canada Gairdner International	Awards	Gairdner Foundation	01-0	ct-2024 72,000 USD	
	Contact Name	Sarah Devonshire				
	Contact Telephone					
	Contact Email	sarah@gairdner.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Oct-2024				
	Synopsis	The Canada Gairdner International Award recognizes outstanding biomedical scientists who have made original contributions to medicine with the goal of contributing through research to increased understanding of human biology and disease. The prize is valued at \$100,000 CAD, and is for the personal use of recipients.				
	Applicant Types					
	Funding Limit	100,000.00 see detail				
	Limited Submission	No				



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline D	ate Fun	ding Amount
126746 Call 8 Modelling Regulatory their Deployment to Support E	Sandbox Mechanisms and Enabling reakthrough Innovation	Innovative Hea	-	0RIZON-JU- -2024-08-	10-Oct-202 [LOI/Pre- App]	⁴ 5,668,000 USD
Contact Name	2					
Contact Telephone	+32 (0)2 221 81 81					
Contact Emai	infodesk@ihi.europa.eu					
Sponsor Website	Link to sponsor website					
Program URI	Link to program URL					
Deadline Dates (ALL	10-Oct-2024 [LOI/Pre-App], 23-Apr-20	25				
Synopsis	Proposals are being accepted against the following topic: HORIZON-JU-IHI-2024-08-03 - Modelling Regulatory Sandbox Mechanisms and Enabling their Deployment to Support Breakthrough Innovation This topic is part of the Innovative Health Initiative 8th call for proposals.					•
Applicant Types	3					
Funding Limi	5,200,000.00 maximum					
Limited Submission	No					

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
126740 Call 8 Novel Endpoints for Osteoarthritis (OA) by Applying Big Data Analytics	Innovative Health Initiative (IHI)	HORIZON-JU-IHI- 2024-08-02	10-Oct-2024 [LOI/Pre-App]	15,260,000 USD
Contact Name				
Contact Telephone +32 (0)2 221 81 81				
Contact Email <u>infodesk@ihi.europa.eu</u>				



SPIN ID P	Program Title		Sponsor Name		Sponsor Numb	ber	Deadline	e Date Fun	ding Amount
	Sponsor Website	Link to sponsor	website						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	10-Oct-2024 [L0	DI/Pre-App], 23-Aj	or-2025					
	Proposals are being accepted against the following topic: HORIZON-JU-IHI-2024-08-02 - Novel Endpoints for Synopsis Osteoarthritis (OA) by applying Big Data Analytics This topic is part of the Innovative Health Initiative 8th call for proposals.								
	Applicant Types								
	Funding Limit	14,000,000.00 r	naximum						
	Limited Submission	No							
1/3/185	l 6 Support Healthcare Sys Persistency in the Treatmen			Innovative Health I	nitiative (IHI)	HORIZON- 2024-06-0 stage		10-Oct-2024	12,317,000 USD
	Contact Name								
	Contact Telephone	+32 (0)2 221 81	81						
	Contact Email	<u>infodesk@ihi.eu</u>	uropa.eu						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	10-Oct-2024							
	Synopsis	healthcare syste the Innovative I understand why improvements i	em resilience thro Health Initiative 61 y significant advar n healthcare syste	inst the following to ugh a focus on persis ch call for proposals. ices in technology in ems, which still strug nths. The goal is to do	stency in the tre The main outco recent years ha gle to keep mor	atment of me of this ve not cont e than 50 %	chronic di research c ributed to 6 of peopl	seases This to collaboration is o widespread le on chronic d	pic is part of to better isease



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		leveraging socia	l innovation activities and scalable tecl	hnology to improve the he	alth outcomes of p	eople living with

chronic diseases by supporting treatment persistency with a particular focus on diabetes, obesity, and cardiovascular disease. Persistency is part of drug adherence and is defined as the length of time between starting treatment and the last dose which immediately precedes discontinuation of medication. Although novel treatments are becoming more available with major improvements in convenience and efficacy, poor persistency to treatment is still a major challenge in the healthcare system. Insights from pilots under this topic will be shared with relevant stakeholders of the healthcare ecosystem to improve outcomes for people living with chronic diseases. The pilots should include cardiometabolic diseases, such as diabetes, obesity, and cardiovascular disease. Other chronic diseases may be considered in this collaboration if they contribute to the overall understanding of barriers and opportunities. Moreover, it is not the goal to develop new technologies and/or pharmaceutical drugs during the course of the project, but rather to address how insights and new approaches can be applied in clinical practice and implemented in guidelines and recommendations.

Applicant Types

Funding Limit 11,300,000.00 maximum

Limited Submission No

123482 Call 6 Support Healthcare System on Persistency in the Treatmen	stem Resilience Through a Focus It of Chronic Diseases	Innovative Health Initiative (IHI)	HORIZON-JU-IHI- 2024-06-01-two- stage	10-Oct-2024	12,317,000 USD
Contact Name					
Contact Telephone	+32 (0)2 221 81 81				
Contact Email	infodesk@ihi.europa.eu				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	10-Oct-2024				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

Proposals are being accepted against the following topic: HORIZON-JU-IHI-2024-06-01-two-stage -- Support healthcare system resilience through a focus on persistency in the treatment of chronic diseases This topic is part of the Innovative Health Initiative 6th call for proposals. The main outcome of this research collaboration is to better understand why significant advances in technology in recent years have not contributed to widespread improvements in healthcare systems, which still struggle to keep more than 50 % of people on chronic disease treatment for longer than 12 months. The goal is to develop and pilot innovative and multi-stakeholder approaches leveraging social innovation activities and scalable technology to improve the health outcomes of people living with chronic diseases by supporting treatment persistency with a particular focus on diabetes, obesity, and cardiovascular disease. Persistency is part of drug adherence and is defined as the length of time between starting treatment and Synopsis the last dose which immediately precedes discontinuation of medication. Although novel treatments are becoming more available with major improvements in convenience and efficacy, poor persistency to treatment is still a major challenge in the healthcare system. Insights from pilots under this topic will be shared with relevant stakeholders of the healthcare ecosystem to improve outcomes for people living with chronic diseases. The pilots should include cardiometabolic diseases, such as diabetes, obesity, and cardiovascular disease. Other chronic diseases may be considered in this collaboration if they contribute to the overall understanding of barriers and opportunities. Moreover, it is not the goal to develop new technologies and/or pharmaceutical drugs during the course of the project, but rather to address how insights and new approaches can be applied in clinical practice and implemented in guidelines and recommendations.

Applicant Types

Funding Limit 11,300,000.00 maximum

Limited Submission No

126738 Call 8 Patient-Centred Clinica Digital Health Technologies	I-Study Endpoints Derived Using	Innovative Health Initiative (IHI)	HORIZON-JU-IHI- 2024-08-04	10-Oct-2024 [LOI/Pre-App]	13,734,000 USD
Contact Name					
Contact Telephone	+32 (0)2 221 81 81				
Contact Email	infodesk@ihi.europa.eu				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	10-Oct-2024 [LOI/Pre-App], 23-	Apr-2025				
	Synopsis	Proposals are being accepted a Endpoints Derived Using Digita proposals.	. .			•	
	Applicant Types						
	Funding Limit	12,600,000.00 maximum					
	Limited Submission	No					
1/6/30	Call 8 A City-Based Approach Mortality in Europe	to Reducing Cardiovascular	Innovative Health I	nitiative (IHI) HORIZON 2024-08-0		024 17,167,500 App] USD	
	Contact Name						
	Contact Telephone	+32 (0)2 221 81 81					
	Contact Email	infodesk@ihi.europa.eu					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	10-Oct-2024 [LOI/Pre-App], 23-	Apr-2025				
	Synopsis	Proposals are being accepted against the following topic: HORIZON-JU-IHI-2024-08-01 - A City-Based Approach to Reducing Cardiovascular Mortality in Europe This topic is part of the Innovative Health Initiative 8th call for proposals.					
	Applicant Types						
	Funding Limit	15,750,000.00 maximum					
	Limited Submission	No					



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date F	unding Amount
005262	School of Social Science Visiting	g Scholars		Institute for Advan	ced Study	15-Oct-2024	4 80,000 USD
	Contact Name				,		
	Contact Telephone						
		sssappqueries@	Dias.edu				
	Sponsor Website						
	•	Link to program					
	Deadline Dates (ALL)						
	Synopsis	invited are wor junior and senio Institute fellows	king in the year's o or scholars across s are known) have	designated theme, ha a wide range of field access to campus re	e Institute for residential alf on other projects. The s in the social sciences an sources and facilities, inc "Digital (In)Equality)". Ap	School welcomes appli d related disciplines. N luding offices, libraries	cations from lembers (as subsidized
	Applicant Types						
	Funding Limit	80,000.00 see c	letail				
	Limited Submission	No					
083410	Fulbright Grants - Spain: Englis	n Teaching Assis	tant Award	Institute of Interna Education	tional	08-Oct-2024	Not Specified
	Contact Name						
	Contact Telephone	212-984-5396					
	Contact Email	FBstudent.EUR	@iie.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>URL</u>				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	08-Oct-2024				
	Synopsis	The Fulbright English Teaching Ast language instruction and to provid teaching staff at the early childho to 16 hours per week, with an add assistant-teaching, in English, sub English language. Other activities special programs such as Global C actively engage with their host co	de a native speaker p od, elementary, mid ditional two hours fo jects such as social s include directing cor classrooms (Model U	presence in the classrooms dle school, high school, vo r planning and coordinatio tudies, science and techno nversation groups, in some	5. English Teaching As cational and/or unive on meetings. Respons logy, art, physical ed cases with school st	sistants assist ersity level for up sibilities include ucation, and aff, and leading
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
112144 <mark>F</mark>	ulbright Grants - U.K.: Fulbright	ht/Imperial College London Award	Institute of Internat Education	tional	08-Oct-202	Not Specified
	Contact Name					
	Contact Telephone	312-254-3210				
	Contact Email	FBstudent.EUR@iie.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Oct-2024				
	Synopsis	The Fulbright U.S. Student Progra engineering, science or non-clinic				ny one-year
	Applicant Types					
	Funding Limit	0.00 see detail				



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fur	ding Amount
Limited Submission	No			
096729 Fulbright Grants - Italy: Fulbrig Award at the University of Gas		Institute of International Education	08-Oct-2024	Not Specified
Contact Name				
Contact Telephone	212-984-5396			
Contact Email	bpizzella@fulbright.it			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	08-Oct-2024			
Synopsis	Gastronomic Sciences Pollenzo, It cultures and systems with an emp train students to become holistic	nd the Master of Gastronomy: World Fo taly. The Master's program provides a phasis on issues of food sustainability a gastronomes, i.e. gastronomes who ar od anthropology and ecology; and sens and their attached sociabilities.	n advanced introduction to the nd food sovereignty. The progra e able to understand and critica	world food im intends to Ily reflect
Applicant Types				
Funding Limit	0.00 see detail			
Limited Submission	No			
000405 Christianson Fellowship		InterExchange Foundation	15-Oct-2024	10,000 USD
Contact Name				
Contact Telephone	212-924-0446			
Contact Email	grants@interexchange.org			
Sponsor Website	Link to sponsor website			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amou
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Oct-2024 , 15-Mar-2025			
	Synopsis	The InterExchange Foundation supports ye meaningful projects abroad. Funding is av money to support motivated young Ameri abroad. The volunteer project must be our	ailable for impactful service projec cans who are committed to perfor	ts abroad with up to \$1 m meaningful service p	0,000 in grant projects
	Applicant Types				
	Funding Limit	10,000.00 maximum			
	Limited Submission	No			
049952 <u>I</u>	ADR/AADOCR William J. Gies A	ward	tional Association for Research	01-Oct-20)24 1,000 USI
	Contact Name				
	Contact Telephone				
	Contact Email	awards@iadr.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024			
	Synopsis	The William J. Gies Award is given for the year.	best paper published in the Journa	l of Dental Research du	ring the precedi
	Applicant Types				
	Funding Limit	1,000.00 see detail			
	Limited Submission	No			



SPIN ID	Program Title	S	ponsor Name		Sponsor Number	Deadline Date	Funding Amou
	Contact Name						
	Contact Telephone						
	Contact Email	info@intlfoundat	ion.org				
	Sponsor Website	Link to sponsor w	<u>vebsite</u>				
	Program URL	Link to program U	JRL				
	Deadline Dates (ALL)	31-Oct-2024					
	Synopsis	believe address t	he most pressing need projects with measural	s in the world	cific types of programs, in coday. Eligible organization ne or more of the followi	ons must have substa	antial experience
	Applicant Types						
	Funding Limit	50,000.00 maxim	um				
	Limited Submission	Yes					
007873	ISSLS Prize for Lumbar Researc	<u>h</u>		national Societ y of the Lumba	•	15-Oct-20	024 20,000 US
	Contact Name						
	Contact Telephone	+61 3 8692 2036					
	Contact Email	ISSLS@asnevents	.net.au				
	Sponsor Website	Link to sponsor w	<u>vebsite</u>				
	Program URL	Link to program l	<u>JRL</u>				
	Deadline Dates (ALL)	15-Oct-2024					



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline Date	unding Amount
	Synopsis	competitively on the basi science and clinical science	sponsored by European Spin s of scientific merit in one or ce.	· · ·		
	Applicant Types	20,000.00 see detail				
	Limited Submission					
100174 <u>P</u>	ostdoctoral Junior Leader Fell		la Caixa Foundatio	n	03-Oct-202	4 348,909 USD
	Contact Name					
	Contact Telephone					
	Contact Email	fellowships@contact.fund	daciolacaixa.org			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-Oct-2024				
	Synopsis	carry out their projects at the research areas of Scie Sciences. The call for appl prior to the application de work at the host institution fellowship includes a mixed leadership. Attendance is	n is offering 20 three-year po any university or research o ence, Technology, Engineerin lications is intended for rese eadline and fulfil the require on between 2nd May and 31 ed training programme (face mandatory for all fellows re s, as well as the fellows' account	entre of Spain or Portugal. og and Mathematics (STEM archers who finished their ments for mobility betwee st December 2025. In addi to-face and online) on cros gardless of their discipline	The research must b i), including Bio and H doctoral degree two en countries. The felle tion to the financial s ss-cutting skills, innov . The "la Caixa" Found	e carried out in ealth to seven years ow should start upport, the ration, and
	Applicant Types					



SPIN ID Program Tit	itle	Sponsor Na	ame	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	320,100.00 maximum				
Lir	mited Submission					
100173 Postdoctoral		I	la Caixa Foundati	วท	03-Oct-2	024 348,909 USD
	Contact Name					
Co	Contact Telephone					
	Contact Email	fellowships@contact.funda	ciolacaixa.org			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
Dea	Program URL adline Dates (ALL)					
Dea	adline Dates (ALL)		at universities and resea	rch centres of accredited	d excellence. STEM dis	
Dea	adline Dates (ALL)	03-Oct-2024 "la Caixa" Foundation grant project in a STEM discipline sciences, experimental scien	at universities and resea	rch centres of accredited	d excellence. STEM dis	
Dea	adline Dates (ALL) Synopsis Applicant Types	03-Oct-2024 "la Caixa" Foundation grant project in a STEM discipline sciences, experimental scien	at universities and resea	rch centres of accredited	d excellence. STEM dis	
	adline Dates (ALL) Synopsis Applicant Types	03-Oct-2024 "la Caixa" Foundation grant project in a STEM discipline sciences, experimental scien 320,100.00 maximum	at universities and resea	rch centres of accredited	d excellence. STEM dis	
	adline Dates (ALL) Synopsis Applicant Types Funding Limit mited Submission	03-Oct-2024 "la Caixa" Foundation grant project in a STEM discipline sciences, experimental scien 320,100.00 maximum No	at universities and resea	rch centres of accredited engineering, technology	d excellence. STEM dis and mathematics. 18-Oct-2	ciplines include life
Lir	adline Dates (ALL) Synopsis Applicant Types Funding Limit mited Submission	03-Oct-2024 "la Caixa" Foundation grant project in a STEM discipline sciences, experimental scien 320,100.00 maximum No	at universities and reseances, physics, chemistry,	rch centres of accredited engineering, technology	d excellence. STEM dis and mathematics. 18-Oct-2	ciplines include life
Lir 005575 <u>Career Develo</u>	adline Dates (ALL) Synopsis Applicant Types Funding Limit mited Submission opment Program -	03-Oct-2024 "la Caixa" Foundation grant project in a STEM discipline sciences, experimental scien 320,100.00 maximum No - Scholar	at universities and reseances, physics, chemistry,	rch centres of accredited engineering, technology	d excellence. STEM dis and mathematics. 18-Oct-2	ciplines include life
Lir 005575 <u>Career Develo</u>	adline Dates (ALL) Synopsis Applicant Types Funding Limit mited Submission opment Program - Contact Name	03-Oct-2024 "la Caixa" Foundation grant project in a STEM discipline sciences, experimental scien 320,100.00 maximum No - Scholar	at universities and reseances, physics, chemistry,	rch centres of accredited engineering, technology	d excellence. STEM dis and mathematics. 18-Oct-2	ciplines include life
Lir 005575 <u>Career Develo</u> Co	adline Dates (ALL) Synopsis Applicant Types Funding Limit mited Submission opment Program - Contact Name Contact Telephone Contact Email	03-Oct-2024 "la Caixa" Foundation grant project in a STEM discipline sciences, experimental scien 320,100.00 maximum No - Scholar 888-557-7177	at universities and reseances, physics, chemistry,	rch centres of accredited engineering, technology	d excellence. STEM dis and mathematics. 18-Oct-2	ciplines include life



SPIN ID	Program Title	Sponsor Na	ne	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	18-Oct-2024 [LOI/Pre-App], (01-Nov-2024 [LOI/Pre-Ap	p], 15-Nov-2024		
	Synopsis	The Leukemia & Lymphoma through the Career Develops understanding and diagnosis will ultimately lead to a high translational researchers.	nent Program. CDP contin of blood cancer, as well a	nues to provide a pool of a sthe development of tre	dedicated research atment and prever	ers to advance the ition options that
	Applicant Types					
	Funding Limit	120,000.00 per year				
	Limited Submission	No				
009101 (Career Development Program -	- Fellow	Leukemia and Lym	phoma Society	18-Oct-2 [LOI/Pre	2024 210,000 -App] USD
	Contact Name	Senior Director of Research	Administration			
	Contact Telephone					
	Contact Email	researchprograms@lls.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	18-Oct-2024 [LOI/Pre-App], (01-Nov-2024 [LOI/Pre-Ap	p], 15-Nov-2024		
	Synopsis	The Leukemia & Lymphoma through the Career Develops understanding and diagnosis will ultimately lead to a high awardee pursuing their resea	nent Program. CDP contin of blood cancer, as well a er quality of life for blood	nues to provide a pool of a sthe development of tre	dedicated research atment and prever	ers to advance the ition options that
	Applicant Types					
	Funding Limit	70,000.00 per year				
		-				



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fun	ding Amount
Limited Submission	No			
107290 Postdoctoral Training Award	Life	Science Research Foundation	01-Oct-2024	231,000 USD
Contact Name				
Contact Telephone				
Contact Email	admin@lsrf.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	01-Oct-2024 , 01-Nov-2024			
Synopsis		(LSRF) provides support for exceptiona award provides three (3) years of supp nstitution.		
Applicant Types				
Funding Limit	231,000.00 maximum			
Limited Submission	No			
001875 Postdoctoral Fellowship Progra	m	Sciences Research Indation	01-Oct-2024	231,000 USD
Contact Name				
Contact Telephone				
Contact Email	apply@lsrf.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	01-Oct-2024 , 01-Nov-2024			



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	The LSRF award provides three (3) year research institution. The award is paid their project and is solely for the bene year).	to the university or research institutio	n where the researche	er is carrying out
Applicant Types				
Funding Limit	231,000.00 see detail			
Limited Submission	No			
088576 Research Grants	Lun	nbar Spine Research Society	01-Oct-2 [LOI/Pre-	20,000,1150
Contact Name				
Contact Telephone	608-770-8992			
Contact Email	LSRS@LSRS.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	01-Oct-2024 [LOI/Pre-App]			
Synopsis	The Lumbar Spine Research Society (L innovative projects. These awards are	SRS) is awarding up to two research gra available to qualified principle investig	ants of up to \$20,000 t ators in the field of sp	o fund future, ine.
Applicant Types				
Funding Limit	20,000.00 maximum			
Limited Submission	No			
127250 Young Investigator Research G	r <u>ant</u> Lun	bar Spine Research Society	01-Oct-2 [LOI/Pre-	10 000 USD
Contact Name				



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	unding Amount
Contact Telephone	608-770-8992			
Contact Email	LSRS@LSRS.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	01-Oct-2024 [LOI/Pre-App]			
Synopsis	The Lumbar Spine Research Society (LSRS) is qualified young investigators in the field of s	offering a young investigator resea pine.	arch grants of up to \$10),000 for
Applicant Types				
Funding Limit	10,000.00 maximum			
Limited Submission	No			
				Not
089346 Research Grants Program	Lyme Dise	ease Association, Inc.	31-Oct-2024	Specified
089346 <u>Research Grants Program</u> Contact Name	· · · · · · · · · · · · · · · · · · ·	ease Association, Inc.	31-Oct-2024	1
		ease Association, Inc.	31-Oct-2024	1
Contact Name Contact Telephone		ease Association, Inc.	31-Oct-2024	1
Contact Name Contact Telephone Contact Email	888-366-6611	ease Association, Inc.	31-Oct-2024	1
Contact Name Contact Telephone Contact Email Sponsor Website	888-366-6611 Lymeliter@aol.com	ease Association, Inc.	31-Oct-2024	1
Contact Name Contact Telephone Contact Email Sponsor Website	888-366-6611 <u>Lymeliter@aol.com</u> <u>Link to sponsor website</u> <u>Link to program URL</u>	ease Association, Inc.	31-Oct-2024	1
Contact Name Contact Telephone Contact Email Sponsor Website Program URL	888-366-6611 <u>Lymeliter@aol.com</u> <u>Link to sponsor website</u> <u>Link to program URL</u> 31-Oct-2024 The Lyme Disease Association (LDA) provide			Specified
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	888-366-6611 <u>Lymeliter@aol.com</u> <u>Link to sponsor website</u> <u>Link to program URL</u> 31-Oct-2024 The Lyme Disease Association (LDA) provide other tick-borne diseases.			Specified
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types	888-366-6611 <u>Lymeliter@aol.com</u> <u>Link to sponsor website</u> <u>Link to program URL</u> 31-Oct-2024 The Lyme Disease Association (LDA) provide other tick-borne diseases.			Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
	Grant Program		athers (G.Harold and Leila Y.) oundation	20-Sep-2024	Not Specified
	Contact Name				
	Contact Telephone	2			
	Contact Email	grants@mathersfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Sep-2024 , 04-Oct-2024 [LOI/Pre-/	App], 06-Dec-2024		
	Synopsis	The G. Harold and Leila Y. Mathers For scientific research that will benefit m	oundation's mission is to advance know ankind. Basic scientific research, with I to the Foundation's operating princip	potential translational appli	• •
	Synopsis Applicant Types	The G. Harold and Leila Y. Mathers For scientific research that will benefit m central to this goal, and fundamental	ankind. Basic scientific research, with	potential translational appli	• •
	Applicant Types	The G. Harold and Leila Y. Mathers For scientific research that will benefit m central to this goal, and fundamental	ankind. Basic scientific research, with	potential translational appli	• •
	Applicant Types	The G. Harold and Leila Y. Mathers For scientific research that will benefit m central to this goal, and fundamental 0.00 not provided	ankind. Basic scientific research, with	potential translational appli	• •
012233 4	Applicant Types Funding Limit	The G. Harold and Leila Y. Mathers For scientific research that will benefit m central to this goal, and fundamental 0.00 not provided Yes	ankind. Basic scientific research, with	potential translational appli	
012233 <u>/</u>	Applicant Types Funding Limit Limited Submission	The G. Harold and Leila Y. Mathers For scientific research that will benefit m central to this goal, and fundamental 0.00 not provided Yes <u>av Residency (Minnesota)</u> Man	ankind. Basic scientific research, with I to the Foundation's operating princip ayo Clinic College of Medicine	potential translational appli les.	Not
012233 <u>/</u>	Applicant Types Funding Limit Limited Submission Anatomic and Clinical Patholog	The G. Harold and Leila Y. Mathers For scientific research that will benefit m central to this goal, and fundamental 0.00 not provided Yes <u>av Residency (Minnesota)</u> M an	ankind. Basic scientific research, with I to the Foundation's operating princip ayo Clinic College of Medicine	potential translational appli les.	Not
)12233 <u>/</u>	Applicant Types Funding Limit Limited Submission <u>Anatomic and Clinical Patholog</u> Contact Name Contact Telephone	The G. Harold and Leila Y. Mathers For scientific research that will benefit m central to this goal, and fundamental 0.00 not provided Yes <u>av Residency (Minnesota)</u> M an	ankind. Basic scientific research, with I to the Foundation's operating princip ayo Clinic College of Medicine	potential translational appli les.	Not
)12233 <u>/</u>	Applicant Types Funding Limit Limited Submission <u>Anatomic and Clinical Patholog</u> Contact Name Contact Telephone Contact Email	The G. Harold and Leila Y. Mathers For scientific research that will benefit m central to this goal, and fundamental 0.00 not provided Yes <u>av Residency (Minnesota)</u> 507-284-1196	ankind. Basic scientific research, with I to the Foundation's operating princip ayo Clinic College of Medicine	potential translational appli les.	Not
012233 /	Applicant Types Funding Limit Limited Submission Anatomic and Clinical Patholog Contact Name Contact Telephone Contact Email Sponsor Website	The G. Harold and Leila Y. Mathers For scientific research that will benefit m central to this goal, and fundamental 0.00 not provided Yes <u>av Residency (Minnesota)</u> 507-284-1196 <u>pathologyeducation@mayo.edu</u>	ankind. Basic scientific research, with I to the Foundation's operating princip ayo Clinic College of Medicine	potential translational appli les.	Not



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The mission of the Anatomic and provide outstanding education ar order to prepare graduates to exc and Clinical Pathology Residency Physician Scientist-Research Path	nd practical experient cel in any practice set (AP/CP), the Anatom	ce in every aspect of labor tting. The program include	atory medicine and p es three program trac	athology, in ks: the Anatomic
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
013056	<u>Clinical Neurophysiology, Elect</u> (Minnesota)	roencephalography Fellowship	Mayo Clinic College and Science	of Medicine	01-Oct-202	24 Not Specified
	Contact Name					
	Contact Telephone	507-284-8687				
	Contact Email	Bolduan.Paige@mayo.edu				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Oct-2024				
	Synopsis	The one-year Clinical Neurophysic Minnesota, prepares fellows for a clinical activities. After completing establish and supervise a clinical	in academic career b g their training, fellow	y providing them with exp ws will have the knowledg	perience in teaching, is get and experience needs to be a set of the set of t	research and cessary to
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				



SPIN ID	Program Title	Spo	nsor Name	Sponsor Number	Deadline Date Fu	Inding Amount
012945	Adult Reconstructive Surgery F	ellowship (Arizona)	Mayo C and Scie	linic College of Medicine ence	31-Oct-2024	Not Specified
	Contact Name					
	Contact Telephone	480-342-6202				
	Contact Email	stabler.eric@mayo.e	<u>edu</u>			
	Sponsor Website	Link to sponsor web	<u>site</u>			
	Program URL	Link to program URL	:			
	Deadline Dates (ALL)	31-Oct-2024				
	Synopsis	provides extensive e problems in adolesc on-one with faculty. directly involved in p	exposure to, and exper ents and adults. The fe Fellows perform preo postoperative patient i	y Fellowship at Mayo Clinic's camp ience in, the evaluation and mana ellowship consists of four, three-n perative consultations, participat management. Additionally, fellow leading to presentation and publ	agement of complex hip an nonth rotations in which fe e actively in surgical proced is are active in educational	d knee llows work one- dures and are
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
013125	Obstetrics and Gynecology Res	idency (Minnesota)	Mayo C and Scie	linic College of Medicine ence	01-Oct-2024	Not Specified
	Contact Name					
	Contact Telephone	507-266-3262				
	Contact Email	obgeduc@mayo.edu	<u> </u>			
		obgeduc@mayo.edu Link to sponsor web	-			



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date Fi	unding Amount
Deadline Dates (ALL)					
Synopsis	The Obstetrics and Gynecology F unprecedented experience in a c mentorship coupled with state-c	collegial training setting	ng that emphasizes a uniqu	ue blend of traditional	didactics and
Applicant Types	;				
Funding Limit	0.00 see detail				
Limited Submission	No				
012858 <u>Neurosurgery - Neurologic Sur</u>	gery Residency (Minnesota)	Mayo Clinic College and Science	e of Medicine	31-Oct-2024	Not Specified
Contact Name					
Contact Telephone	507-538-6545				
Contact Email	<u>rstnseduc@mayo.edu</u>				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	31-Oct-2024				
Synopsis	The seven-year Neurologic Surge designed to produce the highest academic neurosurgeons, the Ne academia or private practice. The preparation for both written and clinical research alike, including to clinical and translational researc	caliber academic and eurologic Surgery Resi e program provides re l oral neurosurgery bo the option to pursue a	l clinical neurosurgeons. W idency offers the versatilit esidents with a solid found pard examinations, as well	Vhile the emphasis is o y required for a career lation in basic neurosc l as opportunities for la	n training in either ience and aboratory and
Applicant Types					
Funding Limit	0.00 see detail				



SPIN ID	Program Title	Sponsor Na	ame	Sponsor Number	Deadline Date F	unding Amount
	Limited Submission	No				
013211	General Surgery Residency (Mi	<u>nnesota)</u>	Mayo Clinic Col and Science	lege of Medicine	01-Oct-2024	Not Specified
	Contact Name					
	Contact Telephone	507-284-8240				
	Contact Email	mgsm.roch.mn.surgery@m	<u>ayo.edu</u>			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Oct-2024				
	Synopsis	Mayo Clinic's campus in Roo Residency. The General Sur ACGME and is approved for	gery Residency at May	o Clinic's campus in Roches	, .	
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
013210	General Surgery Residency (Flo	prida)	Mayo Clinic Col and Science	lege of Medicine	01-Oct-2024	Not Specified
	Contact Name					
	Contact Telephone	904-953-0424				
	Contact Email	rodriguez.erin@mayo.edu				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Oct-2024				



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
	The General Su	rgery Residency at Mayo C	linic's campus in Jacksonville, Florid	a, integrates extensive ex	posure to all
Sy	nopsis aspects of curre	• · · ·	firm grounding in underlying scienti		
Applicant	Types				
Fundin	g Limit 0.00 see detail				
Limited Subn	nission No				
013187 Urology Residency (Arizo	ona)	Mayo C and Sci	Clinic College of Medicine ence	01-Oct-2024	Not Specified
Contact	Name				
Contact Tele	phone 480-342-2839				
Contac	Email <u>moore.cassand</u>	ra@mayo.edu			
Sponsor W	ebsite Link to sponsor	website			
Progra	m URL Link to program	<u>I URL</u>			
Deadline Date	s (ALL) 01-Oct-2024				
Sy	nopsis for Graduate M	ence with exposure to all a edical Education. After suc	Clinic's campus in Phoenix, Arizona, aspects of urology. The program is a ccessfully completing the program, r merican Board of Urology.	ccredited by the Accredita	ation Council
Applicant	Types				
Fundin	g Limit 0.00 see detail				
Limited Subn	nission No				
012227 Otolaryngology - Head a	nd Neck Surgery Reside	ency (Arizona) Mayo C and Sci	Clinic College of Medicine ence	31-Oct-2024	Not Specified



SPIN ID Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Contact Name						
Contact Telephone	480-342-2812					
Contact Email	rangel.evangelin	na@mayo.edu				
Sponsor Website	Link to sponsor	<u>website</u>				
Program URL	Link to program	URL				
Deadline Dates (ALL)	31-Oct-2024					
Synopsis	provides superio year residency p with board-cert Neurotology Lar Pediatric otolary apprenticeship	or surgical and medica prepares graduates for ified and fellowship-tr ryngology Rhinology an yngology Facial trauma system in which reside	I training in all a either private p ained staff that t nd endoscopic sk a Microvascular ents are assigned	ey at Mayo Clinic in Phoen reas of otolaryngology an ractice or academic medic reach management conce cull base surgery Facial pl free tissue transfer The Of to one or two Mayo Clini sibility and close supervis	d head and neck surg cine through education pts in: Head and nech astic and reconstruct tolaryngology Reside ic staff consultants for	ery. This five- on and training concology ive surgery ncy uses a unique
Applicant Types						
	0.00 see detail					
Limited Submission	No					
013216 Preliminary Surgery Residency	<u>(Minnesota)</u>		iyo Clinic College d Science	of Medicine	01-Oct-20	24 Not Specified
Contact Name						
Contact Telephone	507-284-4710					
Contact Email	mgsm.roch.mn.	<u>surgery@mayo.edu</u>				
Sponsor Website	Link to sponsor	<u>website</u>				
Program URL	Link to program	URL				



SPIN ID Program Title		Sponsor Name		Sponsor Number	Deadline Date F	unding Amount
Deadline Dates (ALL)	01-Oct-2024					
Synopsis	This residency o subspecialty. Th	ffers a wide variety	<pre>/ of surgical experie s one year of genera</pre>	l preliminary surgery posi nces to residents who hav al surgery training before	ve not yet chosen a su	rgical
Applicant Types	5					
Funding Limit	0.00 see detail					
Limited Submission	No					
013042 Adult Neurology Residency (Ar		Mayo Clinic College and Science	of Medicine	01-Oct-202	4 Not Specified	
Contact Name						
Contact Telephone	480-301-6884					
Contact Email	warfield.linda@	<u>mayo.edu</u>				
Sponsor Website	Link to sponsor	website				
Program URL	Link to program	URL				
Deadline Dates (ALL)	01-Oct-2024					
Synopsis	The Adult Neuro and educators v	blogy Residency at who will be leaders	Mayo Clinic's campu in the field of neurc	us in Arizona provides tra plogy.	ining for excellent clin	ician scientists
Applicant Types	5					
Funding Limit	0.00 see detail					
Limited Submission	No					
013166 Orthopedic Surgery Residency	(Minnesota)		Mayo Clinic College and Science	of Medicine	01-Oct-202	4 Not Specified



SPIN ID Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Contact Name						
Contact Telephone	507-266-4512					
Contact Email	cole.channon@	<u>mayo.edu</u>				
Sponsor Website	Link to sponsor	<u>website</u>				
Program URL	Link to program	URL				
Deadline Dates (ALL)	01-Oct-2024					
Synopsis	The Departmen Surgery Resider	t of Orthopedic Sur acy with rotations ir	gery at Mayo Clinic all subspecialty ar	's campus in Rochester, M eas over a five year period	innesota offers an O	rthopedic
Applicant Types						
Funding Limit	0.00 see detail					
Limited Submission	No					
002648 Geriatric Medicine Fellowship	(Minnesota)		Mayo Clinic College and Science	of Medicine	31-Oct-202	24 Not Specified
Contact Name	Linda Ferrie, Ed	ucation Coordinato	r			
Contact Telephone	507-538-0498					
Contact Email	ferrie.linda@ma	ayo.edu				
Sponsor Website	Link to sponsor	<u>website</u>				
Program URL	Link to program	URL				
Deadline Dates (ALL)	31-Oct-2024					
Synopsis	generation of le		edicine. The fellow	layo Clinic campus in Roch ship offers a robust curric		
Applicant Types						



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
Funding Limit	t 0.00 see detail			
Limited Submission				
013222 Surgery Specialties - Plastic Sur (Arizona)	rgery Integrated Residency	Mayo Clinic College of Medicine and Science	15-Oct-2024	Not Specified
Contact Name	٤			
Contact Telephone	480-342-0584			
Contact Email	l <u>hansalia.rita@mayo.edu</u>			
Sponsor Website	Link to sponsor website			
Program URL	L Link to program URL			
Deadline Dates (ALL)) 15-Oct-2024			
Svnopsis	school graduates interested in s s each year. The program is accred	esidency at Mayo Clinic's campus in Pho pecializing in plastic surgery. The progra dited by the Accreditation Council for Gu	m is six years long and offers or aduate Medical Education. Afte	e position
-,	Plastic Surgery.	nts are eligible to take the written exam	ination offered by the Americar	
Applicant Types	Plastic Surgery.	nts are engible to take the written exam	ination offered by the Americar	
Applicant Types	Plastic Surgery.	nts are engible to take the written exam	ination offered by the Americar	
Applicant Types	Plastic Surgery. s t 0.00 see detail	nts are engible to take the written exam	ination offered by the Americar	-
Applicant Types Funding Limit	Plastic Surgery. s t 0.00 see detail n No	Mayo Clinic College of Medicine and Science	01-Oct-2024	
Applicant Types Funding Limit Limited Submission	Plastic Surgery. s t 0.00 see detail n No <u>nnesota)</u>	Mayo Clinic College of Medicine		Board of
Applicant Types Funding Limit Limited Submission 012164 <u>Anesthesiology Residency (Min</u>	Plastic Surgery. t 0.00 see detail n No nnesota)	Mayo Clinic College of Medicine		Board of



SPIN ID	Program Title		Sponsor Name	Sponsor N	lumber	Deadline Date	Fund	ding Amount
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	01-Oct-2024						
	Synopsis	Mayo Clinic's Anesthesiology Residency in Rochester, Minnesota, aims to craft the next leaders field of anesthesiology and perioperative medicine by providing an outstanding clinical anesthesia experience tailor each individual trainee. Within a three-year program following a transitional internship year, Mayo Clinic anesthesiology residents are immersed in a program comprising two hospitals with more than 109 operating servicing more than 40,000 anesthetics per year in some of the most advanced facilities and cutting-edge m procedures in the world.						
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
003413	Medical Scientist Training Prog	ram	Мауо	Graduate School		01-Oct-2	024	40,000 USD
	Contact Name	Lisa Hurley, Pro	gram Manager					
	Contact Telephone	507-284-4356						
	Contact Email	mayoclinicmdph	nd@mayo.edu					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	01-Oct-2024 , 1	5-Oct-2024					
The Mayo Clinic M.DPh.D. Program educates students to meet the demands of a career as a physician-scie Synopsis combining M.D. and Ph.D. training, we prepare our graduates to be leaders in both clinical medicine and in research to significantly impact the future of medicine and science.						•		
	Applicant Types							
	Funding Limit	40,000.00 see d	etail					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
	Limited Submission	No			
044094	General Research Grants		Govern (Jack) Coats Disease ndation (JMCDF)	01-Oct-2024	35,000 USD
	Contact Name				
	Contact Telephone	888-314-8853			
	Contact Email	deborahmarron@curecoats.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024			
	Synopsis	The General Research Grant is offered specific to Coats' Disease and other re understanding of the pathophysiology	tinal diseases, which may lead to a cure	e or improve treatments a	
	Applicant Types				
	Funding Limit	35,000.00 maximum			
	Limited Submission	No			
057820	Investigator Studies Program (I	MISP) Rotavirus Me	rck	07-Aug-2024	Not Specified
	Contact Name	Lindsay O'Connell			
	Contact Telephone	267-305-9775			
	Contact Email	lindsay.oconnell@msd.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Aug-2024 , 23-Oct-2024			



SPIN ID Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Syno	through the properties implemented, a reviewed public	ovision of drug/vace and sponsored by e	cine and/or total/p xternal investigato rus Investigator Stu	ms to advance science a artial funding, high-quali rs. Results will be genera Idies Program Review Co).	ity research that is init ated and properly diss	iated, designed, eminated in peer-
Applicant Ty	pes					
Funding Li	mit 0.00 not provid	led				
Limited Submiss	ion No					
057824 <u>Investigator Studies Progra</u> <u>& Varicella</u>	m (MISP) Measles	s, Mumps, Rubella	Merck		07-Aug-2	024 Not Specified
Contact Na	me Lindsay O'Conr	nell				
Contact Teleph	one 267-305-9775					
Contact Er	nail <u>lindsay.oconne</u>	ll@msd.com				
Sponsor Web	site <u>Link to sponso</u>	<u>r website</u>				
Program	JRL <u>Link to progran</u>	<u>n URL</u>				
Deadline Dates (A	ALL) 07-Aug-2024 , 1	23-Oct-2024				
Syno	provision of drupsis and sponsored publications. T	ug/vaccine and/or t by external investig	otal/partial fundin gators. Results will s, Rubella & Varicel	ience and improve paties g, high-quality research t be generated and prope lla Investigator Studies P	hat is initiated, design rly disseminated in pe	ned, implemented er-reviewed
Applicant Ty	pes					
Funding Li	mit 0.00 not provid	led				
Limited Submiss	ion No					



SPIN ID	Program Title	Sponsor Nam	ne	Sponsor Number	Deadline Date	Funding Amount
066292	Richard Lounsbery Award		National Academy	y of Sciences	07-Oct-202	4 75,000 USD
	Contact Name					
	Contact Telephone	202-334-2000				
	Contact Email	awards@nas.edu				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Oct-2024				
	Synopsis	The Richard Lounsbery Awarc between the United States an			rage reciprocal scientifi	c exchanges
	Applicant Types					
	Funding Limit	75,000.00 maximum				
	Limited Submission	No				
051065	Center for Regulatory Excellen	ce (CRE) Grant Program	National Council o of Nursing	of State Boards	04-Oct-202	24 300,000 USD
	Contact Name					
	Contact Telephone	312-525-3600				
	Contact Email	CRE@ncsbn.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	04-Oct-2024				
	Synopsis	The Center for Regulatory Exc advance the science of nursin apply for grants up to \$300,00	g policy and regulation		-	•



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
Applicant Types				
Funding Limit	300,000.00 maximum			
Limited Submission	No			
091597 Grants Program		National Operating Committee on Standards for Athletic Equipment	31-Oct-2024	Not Specified
Contact Name	Kim D. Barber Foss, PhD ATC			
Contact Telephone				
Contact Email	Research@nocsae.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	31-Oct-2024			
Synopsis	research in sports medicine and so the intent of the NOCSAE grant pr	ating Committee on Standards for Athlet cience and, where feasible, establish sta rogram is to commission investigator-ini earch and development. The NOCSAE res ogram interests.	ndards for athletic equipmen tiated research and to provide	t. Accordingly, e support for
Applicant Types				
Funding Limit	0.00 see detail			
Limited Submission	No			
075482 Research for Novel Approaches	s in Sustainable Agriculture Grant	Northeast Region Sustainable Agriculture Research and Education Program	06-Aug-2024 [LOI/Pre-App	-
Contact Name				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount			
	Contact Telephone									
	Contact Email	northeastsare@	ouvm.edu							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	<u>URL</u>							
	Deadline Dates (ALL)	06-Aug-2024 [L	ug-2024 [LOI/Pre-App], 29-Oct-2024							
	Synopsis	intended to cor	Research for Novel Approaches in Sustainable Agriculture Grant Program funds "proof of concept" projects nded to confirm the benefit and/or feasibility of new practices and approaches that have high potential for ption by farmers.							
	Applicant Types									
	Funding Limit	200,000.00 see	detail							
	Limited Submission	No								
018771	Department of Medicine - Phys	sician-Scientist T	raining Program	Northwestern Univ School of Medicine		04-Oct-20	24 75,000 USD			
	Contact Name	Benjamin Singe	r, MD, Program Di	rector-Physician Sci	entist Training Program					
	Contact Telephone									
	Contact Email	benjamin-singe	<u>r@northwestern.</u>	<u>edu</u>						
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	URL							
	Deadline Dates (ALL)	04-Oct-2024								
	Synopsis	transition perio position as a ph	d from graduatior ysician-scientist. E	with an MD or com Beyond training in th	ining Program at the Feink bined MD/PhD degree to the Categorical Internal Med lorthwestern University Fe	appointment to a fu dicine Training Progr	ll-time academic am at the McGaw			



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date Fu	unding Amount			
	accepted into the program will be guaranteed a position in the fellowship program of any of the 12 clinical division the Department of Medicine and a minimum of \$75,000 of support during clinical and research training.								
	Applicant Types								
	Funding Limit	75,000.00 minimum							
	Limited Submission	No							
	OREF/RJOS Diversity, Equity, In Orthopaedic Health Care Resea		Orthopaedic Resea Education Foundat		12-Aug-202 [LOI/Pre-Ap	•			
	Contact Name								
	Contact Telephone	847-698-9980							
	Contact Email	grants@oref.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	12-Aug-2024 [LOI/Pre-App], 14-Oct-2024							
The Orthopaedic Research and Education Foundation in collaboration with J. Robert Gladden Society (JR OREF encourage investigators to conduct research in the area of diversity, equity, inclusion, and disparit Orthopaedic Surgery health care. Maximum funding will be a total of \$150,000 over a two -year grant per available.					rities in				
	Applicant Types								
	Funding Limit	150,000.00 maximum							
	Limited Submission	Yes							
038084	Seed Grants		Pablove Foundation	n	08-Oct-2024	Not Specified			
	Contact Namo								

Contact Name



SPIN ID	Program Title	Sponsor Name	e	Sponsor Number	Deadline Date Fu	Inding Amount	
	Contact Telephone	323-657-5557					
	Contact Email	grants@pablove.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)) 08-Oct-2024 The Pablove Foundation invites pediatric cancer researchers to apply for our Powered by Pablove Seed Grant Program, which provides funds to conduct innovative, cutting edge investigations, with preferences going toward less common childhood cancers. In addition, projects that focus on Opsoclonus-Myoclonus Syndrome (OMS) will be considered. The seed grants serve to advance the work of researchers to qualify for larger grants, federal funding and clinical trial.					
	Synopsis						
	Applicant Types						
	Funding Limit	50,000.00 per year					
	Limited Submission	No					
102065 <mark>P</mark>	Medical Education Grant: Loca Program to Increase Awarenes Transthyretin Amyloid Cardiom	s & Understanding of	Pfizer Pharmaceutio	cals	15-Oct-2024	20,000 USD	
	Contact Name	Amanda Stein, Grant Officer					
	Contact Telephone						
	Contact Email	amanda.j.stein@pfizer.com					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	15-Oct-2024					
	Synopsis	Pfizer is issuing this Request fo educational activities focused					



SPIN ID	Program Title	Sponsor Nam	ie	Sponsor Number	Deadline Date	Funding Amount	
		for TTR Amyloidosis. Potential applicants are encouraged to identify and address the educational needs of healthcare professionals to increase awareness of heart failure patients at risk for TTR Amyloidosis and enable appropriate and early patient identification through an evidence-based approach. Individual projects requesting up to \$10,000 will be considered for small local/community programs. Individual projects requesting up to \$20,000 will be considered for large local/community programs.					
	Applicant Types						
	Funding Limit	20,000.00 maximum					
	Limited Submission	No					
1/6/31	American Headache Society & Competitive Grant Program	Pfizer Quality Improvement	Pfizer Pharmaceut	icals	05-Aug-2 [LOI/Pre		
	Contact Name	Angelo Carter, Grant Officer					
	Contact Telephone						
	Contact Email	Angelo.Carter@pfizer.com					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	30-Oct-2024					
	Pfizer and the American Headache Society are issuing this Request for Proposals (RFP) for projects that will ac quality gaps in headache medicine, with a goal of producing information or tools that can be widely used in th and lead to measurable improvements in healthcare services for individuals with headache. Projects should a contribute to the core goal of the American Headache Society (AHS) – improving the lives of people impacted migraine and other headache disorders. Individual projects requesting up to \$375,000 total over two (2) years considered.						
	Applicant Types						
	Funding Limit	375,000.00 maximum					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
	Limited Submission	Νο			
016536	Garite Mini-Sabbatical Grants	Pregnancy F	Pregnancy Foundation		
	Contact Name				
	Contact Telephone	202-517-7068			
	Contact Email	foundation@smfm.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024 , 01-Apr-2025			
	· · · · ·				
	Synopsis	The Garite Mini-Sabbatical Grant allows recipi			
		The Garite Mini-Sabbatical Grant allows recipion guidance of experts in the field of maternal-fet			
	Synopsis Applicant Types	The Garite Mini-Sabbatical Grant allows recipion guidance of experts in the field of maternal-fet			
	Synopsis Applicant Types	The Garite Mini-Sabbatical Grant allows recipion guidance of experts in the field of maternal-fet 0.00 see detail			
076667 [Synopsis Applicant Types Funding Limit	The Garite Mini-Sabbatical Grant allows recipie guidance of experts in the field of maternal-fet 0.00 see detail No			annually.
076667	Synopsis Applicant Types Funding Limit Limited Submission	The Garite Mini-Sabbatical Grant allows recipie guidance of experts in the field of maternal-fer 0.00 see detail No Clinical Research Propionic A	al medicine. Up to \$20,000 in g	rant funds are available	annually. 100,000
076667	Synopsis Applicant Types Funding Limit Limited Submission Research Projects - Basic and C	The Garite Mini-Sabbatical Grant allows recipie guidance of experts in the field of maternal-fet 0.00 see detail No Clinical Research Propionic A	al medicine. Up to \$20,000 in g	rant funds are available	annually. 100,000
076667	Synopsis Applicant Types Funding Limit Limited Submission <u>Research Projects - Basic and C</u> Contact Name Contact Telephone	The Garite Mini-Sabbatical Grant allows recipie guidance of experts in the field of maternal-fet 0.00 see detail No Clinical Research Propionic A	al medicine. Up to \$20,000 in g	rant funds are available	annually. 100,000
076667	Synopsis Applicant Types Funding Limit Limited Submission Research Projects - Basic and C Contact Name Contact Telephone Contact Email	The Garite Mini-Sabbatical Grant allows recipie guidance of experts in the field of maternal-fer 0.00 see detail No Clinical Research 1-877-720-2192	al medicine. Up to \$20,000 in g	rant funds are available	annually. 100,000
076667	Synopsis Applicant Types Funding Limit Limited Submission Research Projects - Basic and C Contact Name Contact Telephone Contact Email Sponsor Website	The Garite Mini-Sabbatical Grant allows recipie guidance of experts in the field of maternal-fee 0.00 see detail No Clinical Research 1-877-720-2192 research@pafoundation.com	al medicine. Up to \$20,000 in g	rant funds are available	annually. 100,000



SPIN ID Program Ti	tle	Sponsor Name	Spo	nsor Number	Deadline Date	Funding Amount
	Synopsis	The Propionic Acidemia Foundati science, supporting projects desig therapeutic avenues for the treat	gned to understand the m			
	Applicant Types					
	Funding Limit	50,000.00 per year				
Li	mited Submission	No				
065095 Fellows Prog	ram		Propionic Acidemia Four	ndation	01-Oct-20	24 50,000 USD
	Contact Name					
C	ontact Telephone	877-720-2192				
	Contact Email	research@pafoundation.com				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
De	adline Dates (ALL)	01-Oct-2024				
	Synopsis	The Propionic Acidemia Foundati year for a metabolic/genetic fello to supplement any existing institu	w working on a research	- ·		•
	Applicant Types					
	Funding Limit	50,000.00 maximum				
Li	mited Submission	No				
		Improving Understanding of Iarmatoma Tumour Syndrome	PTEN Research Foundati	ion	04-Oct-20	281,600 USD
	Contact Name					



SPIN ID	Program Title	Sp	oonsor Name		Sponsor Number	Deadline Date	Fun	ding Amount			
	Contact Telephone										
	Contact Email	research@ptenres	search.org								
	Sponsor Website	Link to sponsor we	<u>ebsite</u>								
	Program URL	Link to program U	to program URL								
	Deadline Dates (ALL)	04-Oct-2024	4-Oct-2024								
	Synopsis	understanding of t development of ne translational pote	rants awarded through this call are intended primarily for non-clinical research projects that aim to directly advance nderstanding of the disease mechanisms underlying PTEN hamartoma tumour syndrome (PHTS) and facilitate the evelopment of new therapeutic options for PHTS. Specifically encouraged are proposals that not only have anslational potential but also incorporate the use of recently generated PHTS patient-derived induced pluripotent em cells (iPSCs) that will be available through a US-based biorepository later in 2024.								
	Applicant Types										
	Funding Limit	220,000.00 maxim	num								
	Limited Submission	No									
001567	Radcliffe Fellowship Program		Rado Stud	cliffe Institute fo ly	or Advanced	12-Sep-2	2024	83,000 USD			
	Contact Name										
	Contact Telephone	617-495-8212									
	Contact Email	fellowships@radc	liffe.harvard.edu								
	Sponsor Website	Link to sponsor we	<u>ebsite</u>								
	Program URL	Link to program URL									
	Deadline Dates (ALL)	12-Sep-2024 , 03-0	Oct-2024								
Synopsis difference in their professional fields and in the larger world. The Radcliffe Fellowship Program awards 50 f											



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date Fi	unding Amount	
	each academic year. Application engineering, and mathematics.	is are accepted in the	disciplines of humanities	s, social sciences, creativ	e arts, science,	
Applicant Types						
Funding Limit	83,000.00 see detail					
Limited Submission	No					
003582 Career Development Bridge Fu	nding Award: K Bridge	Rheumatology Rese Foundation	earch	01-Oct-2024	75,000 USD	
Contact Name	3					
Contact Telephone	404-365-1373					
Contact Email	Foundation@rheumatology.org					
Sponsor Website	Link to sponsor website					
Program URL	Link to program URL					
Deadline Dates (ALL)	01-Oct-2024					
Synopsis	The mission of the Rheumatology Research Foundation is to advance research and training to improve the health of people with rheumatic diseases. The purpose of this award is to provide bridge funding for promising investigators at they are revising outstanding individual career development award applications (i.e., applications for NIH K series					
Applicant Types	5					
Funding Limit	75,000.00 maximum					
Limited Submission	No					
014227 Sir Peter Tizard Research Bursa	ary	Royal College of Pa Child Health	ediatrics and	21-Oct-2024	Not Specified	



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date Fu	Inding Amount
	Contact Name					
	Contact Telephone	020 7092 6174				
	Contact Email	bpsu@rcpch.ac.	<u>uk</u>			
	Sponsor Website	Link to sponsor v	website			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	21-Oct-2024				
	Synopsis		ard Research bursary covers the full ipend for professional development		a study on the Orange	Reporting Card
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
124475 <u> </u>	Individual Investigator Researc	h Grant Awards	RYR-1 Foundation		19-Oct-2024	120,000 USD
	Contact Name	Patricia Raffaele				
	Contact Telephone					
	Contact Email	patricia@ryr1.or	<u>rg</u>			
	Sponsor Website	Link to sponsor v	website			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	19-Oct-2024				
	Synopsis	currently fundin million in resear	dation actively funds research in RYR g almost \$600,000 of RYR-1-RD rese ch. Individual Investigator Research eatest potential to move towards tre	arch, and since their incepti Grant Awards are designed	on, the sponsor has fur to concentrate resear	nded over \$1.5 ch in areas that



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fur	nding Amount
	encouraged to use one or more of RYR-1-RD r academic, and other sources, including recen RYR-1-RD demonstrating moderate-severe m	ly developed animal models. Rece	ntly developed murine	models of
Applicant Types				
Funding Limit	120,000.00 maximum			
Limited Submission	No			
002055 Grants-in-Aid of Research	Sigma Xi		01-Oct-2024	Not Specified
Contact Name				
Contact Telephone	919-549-4691			
Contact Email	giar@sigmaxi.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	01-Oct-2024			
	Sigma Xi, The Scientific Research Honor Socie Sigma Xi Grants in Aid of Research (GIAR) pro- educational experiences. By encouraging clos promotes scientific excellence and achieveme and students in the health professions curren	gram has provided undergraduate e working relationships between si ent through hands-on learning. Und	and graduate students tudents tudents and mentors, the dergraduate and graduate at graduate and graduate at graduate	with valuable ne program
Applicant Types				
Funding Limit	0.00 see detail			
Limited Submission	No			
104938 Dermatology Research Award	Skin of Col	or Society (SOCS)	15-Oct-2024	20,000 USD



SPIN ID	Program Title	Sponsor Nam	ne	Sponsor Number	Deadline Date	Funding Amount				
	Contact Name									
	Contact Telephone	630-578-3991								
	Contact Email	info@skinofcolorsociety.org								
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	15-Oct-2024								
	Synopsis	dermatology research within	he SOCS Dermatology Research Award will provide annual research grants (each up to \$20,000) to promote ermatology research within the field of skin of color. Two of the awards will be given to those applications that focu n inflammatory dermatologic diseases in skin of color.							
	Applicant Types									
	Funding Limit	20,000.00 maximum								
	Limited Submission	No								
104942 🤇	Career Development Award		Skin of Color Societ	y (SOCS)	15-Oct-20	24 100,000 USD				
	Contact Name									
	Contact Telephone	630-578-3991								
	Contact Email	info@skinofcolorsociety.org								
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	15-Oct-2024								
	Synopsis	The Skin of Color Society (SOC year period. This award shoul where further clinical, transla	d have a research focus	on inflammatory dermatol						



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Applicant Types					
	Funding Limit	100,000.00 maximum				
	Limited Submission	No				
UNNX49	Mentored Clinical Scientist Res (K08)	earch Career Development Awar	r Surgery	12-Oct-202	Not Specified	
	Contact Name					
	Contact Telephone	800-258-7188				
	Contact Email	svsfoundation@vascularsociety	v.org			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Oct-2024 , 12-Nov-2024				
	Synopsis	The Mentored Clinical Scientist for careers that have a significan support and protected time for biomedical, behavioral, or clinic	nt impact on the healt an intensive, supervise	h-related research needs c ed research career develop	of the Nation. This pro	ogram provides
	Applicant Types		_			
	Funding Limit	50,000.00 per year				
	Limited Submission	No				
1/11/14	Drotar-Crawford Postdoctoral F Pediatric Psychology	Fellowship Research Grant in	Society of Pediatric	Psychology	15-Oct-202	24 10,000 USD
	Contact Name	Megan Cohen				
	Contact Telephone	202-336-5500				
	Contact Email	Megan.Cohen@nemours.org				



SPIN ID	Program Title	Sponsor Nam	ie	Sponsor Number	Deadline Date	Fund	ding Amount			
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	15-Oct-2024								
	Synopsis	enrolled in a postdoctoral fell advisor in an area of research total for up to two years). Up collaborations, or for presenta	is \$10,000 grant is given to a postdoctoral fellow to support research in pediatric psychology while they are rolled in a postdoctoral fellowship. The research project must be conducted under the supervision of a faculty visor in an area of research specific to pediatric psychology. The budget may span up to two years (e.g. \$10,000 ir tal for up to two years). Up to \$1000 of the award may be allocated for travel related to research training, llaborations, or for presentation of research findings. Funds are not provided for indirect costs, stipends of the llow or costs associated with manuscript preparation.							
	Applicant Types									
	Funding Limit	10,000.00 maximum								
	Limited Submission	No								
120121	Mary Jo Kupst Trainee Grant fo	r Research in Resilience	Society of Pediatri	c Psychology	15-Oct-2	2024	1,000 USD			
	Contact Name	Megan Cohen								
	Contact Telephone	202-336-5500								
	Contact Email	Megan.Cohen@nemours.org								
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	15-Oct-2024								
		This award is designed to help of pediatric psychology specif proposes a research project e The award is available to any a program involving substanti	ically in the area of resil xamining resilience and graduate student, inter	lience. A yearly award of \$ /or family functioning with n or postdoctoral fellow w	1,000 will be made n a pediatric psycho ho is a member of S	to a tr logy p SPP an	ainee who opulation. d involved in			



SPIN ID	Program Title	Sponsor Na	me	Sponsor Number	Deadline Date F	unding Amount
		must be conducted under th	e supervision of a faculty	advisor and may includ	e work leading to a mast	er's or doctoral
		degree or may be an indepen	ndent study.			
	Applicant Types					
	Funding Limit	1,000.00 maximum				
	Limited Submission	No				
016605 <u>N</u>	Marion and Donald Routh Stud	ent Research Grant	Society of Pediatrie	c Psychology	15-Oct-2024	5,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	Megan.Cohen@nemours.org	g			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Oct-2024				
	Synopsis	This grant is designed to ena scholarship. Funding is availa meeting travel. Funds may n associated with manuscript p proposed research.	able up to \$5,000. Up to \$ ot be used for indirect co	5500 of the award amou osts of the University, sti	int can be budgeted for compends of principal invest	onvention and gators or costs
	Applicant Types					
	Funding Limit	5,000.00 maximum				
	Limited Submission	No				
068302 <u>A</u>	Arnold J. Lehman Award		Society of Toxicolo	gy	09-Oct-2024	Not Specified

Contact Name



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone					
	Contact Email	sothq@toxicology.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Oct-2024				
	Synopsis	The Arnold J. Lehman Award is assessment and/or the regulation from the application of sound s influenced the regulatory proce Awards Ceremony and a cash st	on of chemical agents, cientific principles to re ess. This award consists	including pharmaceuticals egulation and/or from res	s. The contribution m earch activities that h	ay have resulted ave significantly
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
016133	Founders Award (for Outstandi	ing Leadership in Toxicology)	Society of Toxicolog	ΣΥ	09-Oct-202	24 Not Specified
	Contact Name					
	Contact Telephone	703-438-3115				
	Contact Email	sothq@toxicology.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Oct-2024				
	Synopsis	The SOT Founders Award is pre demonstrated outstanding lead				



SPIN ID Program Title	Sponso	r Name	Sponsor Number	Deadline Date Fu	nding Amount
	-	r application of state-of-the-a ans between safe and unsafe			
Applicant Types					
Funding Limit	0.00 see detail				
Limited Submission	No				
016141 Perry J. Gehring Student Divers	ity Travel Award	Society of Toxicolo	gy	15-Oct-2024	Not Specified
Contact Name					
Contact Telephone	703-438-3115				
Contact Email	jenna@toxicology.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Oct-2024				
Synopsis	selected to participate in underrepresented in tox who is presenting a pape and travel stipend to ass	ersity Student Award recogniz n the SOT Undergraduate Dive kicology (for example, African er at the upcoming Society of sist in defraying expenses for t tee on Diversity Initiatives and	ersity Program, who is fror American, Hispanic, Native Toxicology Annual Meetin ravel, lodging, and meals	n a racial/ethnic group e American or Pacific Isl g. The recipient will rec at the meeting. The awa	ander), and eive a plaque ird recipient is
Applicant Types					
Funding Limit	0.00 see detail				
Limited Submission	No				
067066 Translational/Bridging Travel A	ward	Society of Toxicolog	gy	09-Oct-2024	2,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
	Contact Name				
	Contact Telephone	703-438-3115			
	Contact Email	sothq@toxicology.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	09-Oct-2024			
	Synopsis	The SOT Awards Committee offers this award, in mid- or senior-level scientist or clinician, with at and who has an active research program, or curr toxicology, disease prevention, or in the applicat	least ten years postdoctoral re ently is active either in the pra	search or clinical pract	ice experience
		toxicology, discuse prevention, or in the applicat	ion of translational toxicology.		
	Applicant Types	toxicology, discuse prevention, of in the applicat	ion of translational toxicology.		
		2,000.00 see detail			
		2,000.00 see detail	ion of translational toxicology.		
001193 [Funding Limit	2,000.00 see detail		22-Oct-202	4 Not Specified
001193	Funding Limit Limited Submission	2,000.00 see detail No		22-Oct-202	4
001193 [Funding Limit Limited Submission E.W. Al Thrasher Awards	2,000.00 see detail No Thrasher Rese		22-Oct-202	4
001193 [Funding Limit Limited Submission E.W. Al Thrasher Awards Contact Name Contact Telephone	2,000.00 see detail No Thrasher Rese		22-Oct-202	4
001193 [Funding Limit Limited Submission E.W. Al Thrasher Awards Contact Name Contact Telephone Contact Email	2,000.00 see detail No Thrasher Rese 801-240-4753		22-Oct-202	4
001193 [Funding Limit Limited Submission E.W. Al Thrasher Awards Contact Name Contact Telephone Contact Email Sponsor Website	2,000.00 see detail No Thrasher Rese 801-240-4753 <u>MartinezAF@ThrasherResearch.org</u>		22-Oct-202	4



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of the E.W. "AI" Thrasher Aw emphasis on projects that have the potent Fund awards grants two times per year, w	tial to translate into clinically mear	ningful results within a	few years. The
	Applicant Types				,
	Funding Limit	0.00 see detail			
	Limited Submission				
091400 [Early Career Awards	Thrashe	er Research Fund	05-Sep- [LOI/Pre	25 000 UN
	Contact Name	Brittni Smith, PhD			
	Contact Telephone	801-240-4720			
	Contact Email	SmithBA@ThrasherResearch.org			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Sep-2024 [LOI/Pre-App], 29-Oct-2024			
	Synopsis	The Fund recognizes that young investigat funding. Therefore, the purpose of this pro by awarding small grants to new researche applicants who will go on to be independe	ogram is to encourage the develop ers, helping them gain a foothold in	ment of medical rese	arch in child health
	Applicant Types				
	Funding Limit	25,000.00 see detail			
	Limited Submission	No			
019127	Hyland R. Johns Grant Program	TREE FU	Ind	15-Sep- [LOI/Pre	25 000 UN



SPIN ID Program Title	Sponsor Name	2	Sponsor Number	Deadline Date	Funding Amount
Contact Name					
Contact Telephone	630-369-8300				
Contact Email	treefund@treefund.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Sep-2024 [LOI/Pre-App], 01	-Oct-2024			
Synopsis	The Hyland R. Johns Grant Propotential of benefiting the every ears, with a maximum award	ryday work of arborists	. Projects are expected to	be completed with	in three to five
Applicant Types					
Funding Limit	25,000.00 maximum				
Limited Submission	No				
020491 John Z. Duling Grant Program		TREE Fund		15-Sep-2 [LOI/Pre	75 (100) (180)
Contact Name					
Contact Telephone	630-369-8300				
Contact Email	treefund@treefund.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Sep-2024 [LOI/Pre-App], 01	-Oct-2024			
Synopsis	The John Z. Duling Grant Progr technology transfer projects the expected to be completed with	at have the potential o	f benefiting the everyday	work of arborists. F	



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date F	unding Amount
	1				
Applicant Types					
-	25,000.00 maximum				
Limited Submission	No				
075116 Dickson Prize in Medicine		University of Pittsb Medicine	urgh School of	25-Oct-2024	\$0,000 USD
Contact Name					
Contact Telephone	412-383-7382				
Contact Email	healthsciences@pitt.edu				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	25-Oct-2024				
Synopsis	The Dickson Prize in Medicine is a paradigm-shifting biomedical reso		a leading American invest	igator who is engaged	in innovative,
Applicant Types					
Funding Limit	50,000.00 see detail				
Limited Submission	No				
059984 VESS/Medtronic Vascular Resid	dent Research Award	Vascular and Endov Surgery Society	ascular	04-Oct-2024	12,500 USD
Contact Name					
Contact Telephone	978-927-7800				
Contact Email	vess@administrare.com.				
Sponsor Website	Link to sponsor website				



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Program URL	Link to program	<u>URL</u>			
Deadline Dates (ALL)	04-Oct-2024				
Synopsis	protected acade basic or clinical	emic development time tha	vard is designed to help residents in tr t will lead to future academic potentia at for basic/translational science, educ nnual winter meeting.	al toward extramura	al funding for
Applicant Types					
Funding Limit	12,500.00 see d	letail			
Limited Submission	No				
003009 Vatican Film Library Mellon Fel	lowship Program	<u>n</u> Vatican	Microfilm Library	01-Oct-20	024 4,500 USD
Contact Name					
Contact Telephone	314-977-3096				
Contact Email	<u>vfl@slu.edu</u>				
Sponsor Website	Link to sponsor	<u>website</u>			
Ŭ	Link to program	<u>I URL</u>			
Deadline Dates (ALL)					
Synopsis	utilizing the coll materials of the	lections of the Vatican Film library. All topics will be co	ble for periods between two and eight Library. Applications must demonstra nsidered that are served by the collec hy, codicology, illumination, text edit	te need to consult t ctions, such as histo	the primary source bry, philosophy,
Applicant Types					
Funding Limit	2,250.00 per m	onth			
Limited Submission	No				



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
059105 E-Team Program	VentureWel	I	02-Oct-202	25,000 USD
Contact Name	3			
Contact Telephone	: 413-587-2172			
Contact Emai	swharmby@venturewell.org			
Sponsor Website	Sponsor Website Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	02-Oct-2024			
Synopsis	The E-Team Program, part of the VentureWell you're likely to take as an innovator and entrep of up to \$25,000 in grant funding, entrepreneu networking with peers and industry experts.	preneur. We help you advance	your invention through	a powerful mix
Applicant Types	;			
Funding Limit	t 25,000.00 see detail			
Limited Submission	ΙΝΟ			
009730 Grants-in-Aid	Whitehall Fo	oundation, Inc.	02-Sep-202	24 30,000 USD
Contact Name	2			
Contact Telephone	561-655-4474			
Contact Emai	email@whitehall.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	02-Sep-2024 , 01-Oct-2024 [LOI/Pre-App]			
Synopsis	The Whitehall Foundation, through its program sciences. It is the Foundation's policy to assist			



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
	supported by Federal Agencies or other for in basic research in neurobiology. The Gra level who experience difficulty in competi Grants-in-Aid can also be made to senior s innovative aspects of the proposal, as well productivity. Grants-in-Aid are awarded for	ints-in-Aid program is designed for rese ng for research funds because they hav scientists. All applications will be judge Il as on past performance and evidence	earchers at the assista ve not yet become fin d on the scientific me of the applicant's co	nt professor mly established. rit and
Applicant Types	5			
Funding Limit	30,000.00 maximum			
Limited Submission	No			
001018 Research Grants	Whiteh	nall Foundation, Inc.	01-Sep-2024	4 300,000 USD
Contact Name				
Contact Telephone	561-655-4474			
Contact Emai	email@whitehall.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	01-Sep-2024 , 01-Oct-2024 [LOI/Pre-App]			
Synopsis	The Whitehall Foundation is focused excluin invertebrate neurobiology. They offer rest institutions in the United States. Research of two years is possible, but it will be awa	earch grants to established scientists o grants of up to three years are availab	f all ages working at a	ccredited
Applicant Types	5			
Funding Limit	100,000.00 per year			
Limited Submission	No			



SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Funding Amour

